"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,GB,A,GB 189524378 A,094-500-443-045-648,1896-11-07,1896,GB 189524378D A,1895-12-19,GB 189524378T A,1895-12-19,Improvements in the Means of and Apparatus for Cleansing and Manipulating the Material Used in Filter Beds and the like.,,CORBETT JOSEPH,CORBETT JOSEPH,,https://lens.org/094-500-443-045-648,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
2,GB,A,GB 190124344 A,185-245-217-080-414,1902-11-27,1902,GB 190124344D A,1901-11-29,GB 190124344T A,1901-11-29,Improvements relating to the Removal of Deposits in Sewers and other Pipes and Conduits,,CORBETT JOSEPH,CORBETT JOSEPH,,https://lens.org/185-245-217-080-414,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
3,US,A,US 5953762 A,067-657-943-890-617,1999-09-21,1999,US 24998399 A,1999-02-11,US 24998399 A,1999-02-11,Sports helmet with protective fincap,"A sports helmet with a protective fincap made up of a sturdy, flexible material and affixed thereto centrally upon the top surface of the helmet such that the fincap extends centrally, upon the helmet, anterioposteriorally from the bottom edge of the frontal brim of the helmet to the backside occipital edge of the helmet. The fincap has minimum breadth and minimum height at the loci of the bottom edge of the frontal brim and the backside occipital edge respectively with breadth and height increasing anteroposteriorly and posteroanteriorly at the same rate to a point of maximum breadth and height at the locus of the intersection of a horizontally inclined line tangent to the uppermost portion of the topside surface of the helmet and positioned perpendicular to the vertically inclined and anteroposteriorally inclined horizontal central axes of symmetry of the helmet. The fincap is coextensive with a centrally positioned fin element made up of the same sturdy, flexible material as the fincap with the fin element being characterized by the presence of a top edge extending from the locus of the bottom edge of the frontal brim of the helmet to the locus of the backside occipital edge of the helmet.",CORBETT; JOSEPH,CORBETT JOSEPH,,https://lens.org/067-657-943-890-617,Granted Patent,yes,13,35,2,2,0,A42B3/065;;A42B3/065;;A42B3/0406;;A42B3/0406;;A42B3/069;;A42B3/069,A42B3/04;;A42B3/06,2/425;;2/422,0,0,,,,EXPIRED
4,GB,A,GB 189420058 A,176-187-987-614-41X,1895-10-19,1895,GB 189420058D A,1894-10-20,GB 189420058T A,1894-10-20,Improvements in and connected with Apparatus for Removing Subaqueous Deposits from Settling Tanks.,,CORBETT JOSEPH,CORBETT JOSEPH,,https://lens.org/176-187-987-614-41X,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
5,CA,A,CA 3590 A,030-960-432-760-764,1874-07-03,1874,CA 3590D A,,CA 3590T A,,REGISTERING TICKET PUNCH,,CORBETT JOSEPH,CORBETT JOSEPH,,https://lens.org/030-960-432-760-764,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
6,CA,A1,CA 2279129 A1,006-670-722-897-894,2000-08-11,2000,CA 2279129 A,1999-07-29,US 24998399 A,1999-02-11,A SPORTS HELMET WITH PROTECTIVE FINCAP,"A sports helmet with a protective fincap made up of a sturdy, flexible material and affixed thereto centrally upon the top surface of the helmet such that the fincap extends centrally, upon the helmet, anteroposteriorly from the bottom edge of the frontal brim of the helmet to the backside occipital edge of the helmet. The fincap has minimum breadth and minimum height at the loci of the bottom edge of the frontal brim and the backside occipital edge respectively with breadth and height increasing anteroposteriorly and posteroanteriorly at the same rate to a point of maximum breadth and height at the locus of the intersection of a horizontally inclined line tangent to the uppermost portion of the topside surface of the helmet and positioned perpendicular to the vertically inclined and anteroposteriorly inclined horizontal central axes of symmetry of the helmet. The fincap is coextensive with a centrally positioned fin element made up of the same sturdy, flexible material as the fincap with the fin element being characterized by the presence of a top edge extending from the locus of the bottom edge of the frontal brim of the helmet to the locus of the backside occipital edge of the helmet.",CORBETT JOSEPH,CORBETT JOSEPH,,https://lens.org/006-670-722-897-894,Patent Application,no,0,0,2,2,0,A42B3/065;;A42B3/065;;A42B3/0406;;A42B3/0406;;A42B3/069;;A42B3/069,A42B3/04;;A42B3/06,,0,0,,,,DISCONTINUED
7,AU,A,AU 1974/073436 A,164-386-937-877-584,1976-03-25,1976,AU 1974/073436 A,1974-09-18,US 41672273 A,1973-11-16,CATHETER,,SHERWOOD MEDICAL IND INC,CORBETT JOSEPH H,,https://lens.org/164-386-937-877-584,Patent Application,no,0,0,11,11,0,A61M25/0009;;A61M25/0014;;A61M25/0009;;A61M25/0014,A61M25/00;;A61M25/16;;B29B7/00;;B29C47/00;;B29C47/86;;B29C48/32,,0,0,,,,DISCONTINUED
8,GB,A,GB 2222429 A,193-954-065-651-370,1990-03-07,1990,GB 8820655 A,1988-09-01,GB 8820655 A,1988-09-01,Mobile scaffold for building or construction work,"In place of extensive scaffolding on a building or construction site, the invention proposes the provision of a mobile scaffold tower 16 mounted on tracks 12 so that the scaffold tower can be moved along the tracks as desired. The tracks are supported at intervals by a series of transom supports 14 which are capable of adjustment to accommodate variations in ground level. <IMAGE>",CORBETT MICHAEL JOSEPH,CORBETT MICHAEL JOSEPH,,https://lens.org/193-954-065-651-370,Patent Application,no,6,6,3,3,0,E04G1/24,E04G1/24,E1S SS            SS,0,0,,,,EXPIRED
9,GB,A,GB 1262229 A,032-427-930-685-733,1972-02-02,1972,GB 3486670 A,1970-07-17,US 84568269 A,1969-07-29,SUCTION CATHETER,"1,262,229. Catheters. SHERWOOD MEDICAL INDUSTRIES Inc. 17 July, 1970 [29 July, 1969], No. 34866/70. Heading A5R. A suction catheter comprises an elongated tube 11 provided with an aperture 16 for admitting air into said tube to vary the suction effect and a resilient member having a first portion 19 carried on said tube adjacent the aperture and a yieldable second portion 18 which in the free state is spaced from the aperture but which is deflectable to progressively close aperture 16. The resilient member may consist of an arcuate strip (20) Figs. 2, 3 and 4, (not shown), curved away from the aperture, or a strip (24) Fig. 5, (not shown) of material folded back upon itself away from aperture 16, or, a flared or cylindrical tubular sleeve (30) Fig. 6, (not shown), spaced from and surrounding tube 10 at the region of aperture 16.",SHERWOOD MEDICAL IND INC,CORBETT JOSEPH HUNTINGTON,,https://lens.org/032-427-930-685-733,Granted Patent,no,0,0,3,3,0,A61M1/7411;;A61M1/7411,A61M1/00,A5R RGV           RGV;;A5R R45           R45,0,0,,,,EXPIRED
10,US,A,US 2374472 A,085-509-942-069-622,1945-04-24,1945,US 51444543 A,1943-12-16,US 51444543 A,1943-12-16,Fingernail drier,,NUTONE INC,RALPH CORBETT JOSEPH,,https://lens.org/085-509-942-069-622,Granted Patent,no,0,11,1,1,0,A45D29/18;;A47K10/48;;A45D29/18;;A47K10/48,A45D29/18;;A47K10/48,,0,0,,,,EXPIRED
11,CA,A,CA 1043970 A,196-318-094-091-191,1978-12-12,1978,CA 209201 A,1974-09-13,US 41672273 A,1973-11-16,METHOD OF MAKING A CATHETER WITH LUER LOCK MEANS,"The method of making a catheter with integral Luer locking means including extruding plastic material to form a tube having a relatively thin-walled portion of relatively small diameter and a relatively thick-walled portion of relatively large diameter. The tube is inserted into a heat forming mold having a Luer lock forming portion, and a mandrel, having a Luer taper, is forced into the portion of large diameter to heat form an integral catheter connector portion with an internal taper and an integral external flange having Luer locking lugs adapted for locking engagement with a complementary Luer lock connector. The catheter can be used in an intravenous catheter or cannula placement unit.",SHERWOOD MEDICAL IND INC,CORBETT JOSEPH H,,https://lens.org/196-318-094-091-191,Granted Patent,no,0,0,11,11,0,A61M25/0009;;A61M25/0014;;A61M25/0009;;A61M25/0014,A61M25/00;;A61M25/16;;B29B7/00;;B29C47/00;;B29C47/86;;B29C48/32,18-113.21,0,0,,,,EXPIRED
12,CA,A,CA 516976 A,075-215-766-599-715,1955-09-27,1955,CA 516976D A,,CA 516976T A,,CEILING HEATER AND VENTILATOR,,NUTONE,CORBETT JOSEPH R,,https://lens.org/075-215-766-599-715,Granted Patent,no,0,1,1,1,0,,,,0,0,,,,EXPIRED
13,US,A,US 6061434 A,003-639-883-206-885,2000-05-09,2000,US 69655496 A,1996-08-14,US 69655496 A,1996-08-14,Video caller identification systems and methods,"Circuits and methods for determining the caller identification for an incoming call and for displaying such caller identification information on a video display device such as a television. A caller identification line modem determines the caller identification information, a control processor translates and/or inputs such caller identification information to a video circuit for displaying the caller identification information. Various methods for so displaying caller identification information are provided, including overlaying such information on an input video signal such as for a predetermined interval of time, generating a separate caller identification video signal, which may be placed, for example, on an unused television channel. The caller identification circuits and methods may be integrated or combined with various advanced television, video and/or telephony functions. An advanced remote control unit may be provided so that the user may determine from the video/television screen the identity of the caller, and then forward the call to a voice messaging system, forward the call to another line, answer the call on a video phone or answer the call on a separate telephone. The caller identification circuit may be provided with programmable intelligence so that incoming calls may not only be displayed on the video/television screen, but also may be desirably processed depending on the identity of the particular caller.",CORBETT JOSEPH C;;FLETCHER WILLIAM I;;LOUDERMILK ALAN R,CORBETT JOSEPH C,CORBETT JOSEPH C (2000-03-02);;LOUDERMILK ALAN R (2000-03-02);;SAMSUNG ELECTRONICS CO. LTD (2006-09-15);;DESIGN ANALYSIS ASSOCIATED INC (1996-09-27);;FLETCHER WILLIAM I (2000-03-02),https://lens.org/003-639-883-206-885,Granted Patent,yes,13,118,2,2,0,H04M1/57;;H04M1/57;;H04M1/6505;;H04M1/6505;;H04M1/663;;H04M1/663;;H04M3/42127;;H04M3/42127;;H04M3/533;;H04M3/533;;H04M3/54;;H04M3/54;;H04M11/06;;H04M11/06;;H04M2203/1016;;H04M2203/1016;;H04N7/147;;H04N7/147,H04M1/57;;H04M1/65;;H04M1/663;;H04M3/42;;H04M3/533;;H04M3/54;;H04M11/06;;H04N7/14,379/93.35;;379/93.23;;379/142,0,0,,,,EXPIRED
14,WO,A1,WO 2003/041873 A1,022-845-428-631-026,2003-05-22,2003,US 0234081 W,2002-10-18,US 771201 A;;US 40245402 P;;US 41608602 P,2001-11-13,IMPROVED SPRINKLER SPACER,"A system for providing a predetermined minimum spacing between a sprinkler head (20) and a sidewalk, curb or the like when installing a sprinkler head (20) in a lawn or other landscaped area. The system includes a spacer or guide (10) which can be attached to the sprinkler head (20) at the time of installation, The spacer includes an inner portion and an outer portion which is intended to be positioned adjacent to (or in close proximity to) the edge of a sidewalk or curb. The width of the spacer determines a minimum distance of spacing between the sprinkler head and the sidewalk or curb. The spacer (10) may include a vertical tab (18) to assure that the spacer (10) is sufficiently far below the ground surface that it will not be contacted by a lawn edging tool. Use of the spacer (10) assures that there will be sufficient spacing between the sprinkler head and the sidewalk, etc, for a lawn edging tool to be used there without damaging the sprinkler head (20).",CORBETT JOSEPH CRAIG,CORBETT JOSEPH CRAIG,,https://lens.org/022-845-428-631-026,Patent Application,yes,9,0,1,5,0,B05B15/622;;B05B15/622;;B05B15/16;;B05B15/74;;B05B15/74,B05B15/00;;B05B15/06;;B05B15/10;;B05B15/16;;B05B15/622,,0,0,,,,PENDING
15,DE,A1,DE 2553100 A1,150-874-894-531-405,1976-06-24,1976,DE 2553100 A,1975-11-26,US 53507774 A,1974-12-20,VERFAHREN ZUM HERSTELLEN EINES MEDIZINISCHEN KATHETERS,,SHERWOOD MEDICAL IND INC,CORBETT JOSEPH H,,https://lens.org/150-874-894-531-405,Patent Application,no,0,5,8,8,0,A61M25/0108;;A61M25/0009,A61M25/00;;A61M25/01;;A61M25/16,,0,0,,,,DISCONTINUED
16,US,A,US 695377 A,061-153-098-334-535,1902-03-11,1902,US 1901/0064142 A,1901-06-11,US 1901/0064142 A,1901-06-11,HERNIAL TRUSS.,,CORBETT JOSEPH A,CORBETT JOSEPH A,,https://lens.org/061-153-098-334-535,Granted Patent,no,0,1,1,1,0,A61F5/24;;A61F5/24,,,0,0,,,,EXPIRED
17,AU,A,AU 1981/069040 A,092-423-276-892-989,1981-10-15,1981,AU 1981/069040 A,1981-04-02,NZ 19339780 A,1980-04-10,ANIMAL FEEDING APPARATUS,,CORBETT TIMOTHY JOSEPH,CORBETT TIMOTHY JOSEPH,,https://lens.org/092-423-276-892-989,Patent Application,no,0,0,2,3,0,,A01K5/02,,0,0,,,,EXPIRED
18,GB,A,GB 190116846 A,184-996-509-142-200,1902-08-14,1902,GB 190116846D A,1901-08-22,GB 190116846T A,1901-08-22,Improvements in Ventilators,"16,846. Henvis, J. C. Aug. 22. Ventilating-shaft tops.-The outlet A is surmounted by a head piece of opposed cones B, D and a larger guard E, both being carried by brackets G of the shape shown.",HENVIS JOSEPH CORBETT,HENVIS JOSEPH CORBETT,,https://lens.org/184-996-509-142-200,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
19,US,A,US 2386738 A,061-605-052-071-914,1945-10-09,1945,US 49353243 A,1943-07-05,US 49353243 A,1943-07-05,Chime signal,,NUTONE INC,RALPH CORBETT JOSEPH,,https://lens.org/061-605-052-071-914,Granted Patent,no,0,5,1,1,0,G10K1/341;;G10K1/341,G10K1/34,,0,0,,,,EXPIRED
20,DE,A1,DE 2447804 A1,174-528-967-388-611,1975-05-22,1975,DE 2447804 A,1974-10-08,US 41672273 A,1973-11-16,VERFAHREN ZUR HERSTELLUNG EINES KATHETERS MIT LUERVERSCHLUSS,,SHERWOOD MEDICAL IND INC,CORBETT JOSEPH H,,https://lens.org/174-528-967-388-611,Patent Application,no,0,2,11,11,0,A61M25/0009;;A61M25/0014;;A61M25/0009;;A61M25/0014,A61M25/00;;A61M25/16;;B29B7/00;;B29C47/00;;B29C47/86;;B29C48/32,,0,0,,,,PENDING
21,US,A,US 3983203 A,013-310-608-369-654,1976-09-28,1976,US 41672273 A,1973-11-16,US 41672273 A,1973-11-16,Method of making a catheter with an integral Luer lock means,"The method of making a catheter with integral Luer locking means including extruding plastic material to form a tube having a relatively thin-walled portion of relatively small diameter and a relatively thick-walled portion of relatively large diameter. The tube is inserted into a heat forming mold having a Luer lock forming portion, and a mandrel, having a Luer taper, is forced into the portion of large diameter to heat form an integral catheter connector portion with an internal taper and an integral external flange having Luer locking lugs adapted for locking engagement with a complementary Luer lock connector. The catheter can be used in a intravenous catheter or cannula placement unit.",SHERWOOD MEDICAL IND INC,CORBETT JOSEPH H,SHERWOOD MEDICAL COMPANY (1982-04-12),https://lens.org/013-310-608-369-654,Granted Patent,yes,12,27,11,11,0,A61M25/0009;;A61M25/0014;;A61M25/0009;;A61M25/0014,A61M25/00;;A61M25/16;;B29B7/00;;B29C47/00;;B29C47/86;;B29C48/32,264/150,0,0,,,,EXPIRED
22,US,A,US 2689906 A,041-890-115-704-177,1954-09-21,1954,US 21042251 A,1951-02-10,US 21042251 A,1951-02-10,Ceiling heater and ventilator,,NU TONE INC,CORBETT JOSEPH R,,https://lens.org/041-890-115-704-177,Granted Patent,no,8,69,1,1,0,F24H3/0411;;F24H3/0411,F24H3/04,,0,0,,,,EXPIRED
23,AU,A,AU 1975/086758 A,113-224-239-380-878,1977-05-26,1977,AU 1975/086758 A,1975-11-19,US 53507774 A,1974-12-20,CATHETER WITH X-RAY OPAQUE MARKINGS,,SHERWOOD MEDICAL IND INC,CORBETT JOSEPH H,,https://lens.org/113-224-239-380-878,Patent Application,no,0,0,8,8,0,A61M25/0108;;A61M25/0009,A61M25/00;;A61M25/01;;A61M25/16,,0,0,,,,DISCONTINUED
24,AU,B2,AU 540622 B2,140-016-543-450-167,1984-11-29,1984,AU 1981/069040 A,1981-04-02,NZ 19339780 A,1980-04-10,ANIMAL FEEDING APPARATUS,,CORBETT TIMOTHY JOSEPH,CORBETT TIMOTHY JOSEPH,,https://lens.org/140-016-543-450-167,Granted Patent,no,0,0,2,3,0,,A01K5/02,,0,0,,,,EXPIRED
25,US,A,US 4655745 A,038-551-402-397-240,1987-04-07,1987,US 76016885 A,1985-07-29,US 76016885 A,1985-07-29,Ventricular catheter,"A catheter for controlling the drainage of fluid from a body cavity, particularly cerebrospinal fluid from the ventricle of human brain in the treatment of hydrocephalus. The catheter is in the form of an elongated, hollow conduit having a plurality of apertures formed at one end in communication with the hollow interior of the conduit. A barrier is mounted on the conduit adjacent the apertures and is located between the apertures and the outflow or opposite end of the conduit. Preferably, the barrier is in the form of a cuff which is inflatable after insertion into the ventricle of the brain to indicate to the surgeon that the inflow end of the catheter has been accurately positioned within the ventricle of the brain and to space the apertures in the inflow end of the catheter a sufficient distance from the surrounding brain tissue and choroid plexus to prevent the growth or adherence of surrounding tissue over the apertures in the conduit.",CORBETT JOSEPH E,CORBETT JOSEPH E,,https://lens.org/038-551-402-397-240,Granted Patent,yes,10,176,1,1,0,A61M25/02;;A61M25/04;;A61M27/006;;A61M2025/0233;;A61M1/84;;A61M25/02;;A61M2025/0233;;A61M27/006;;A61M25/04;;A61M1/84,A61M1/00;;A61M25/02;;A61M25/04;;A61M27/00,604/49;;604/8;;604/96;;604/105,1,0,,,"Garner Balloon Ventricular Catheter Heyer, Schulte Corp. publication, 1971.",EXPIRED
26,US,A,US 3971385 A,078-318-794-994-73X,1976-07-27,1976,US 50420474 A,1974-09-09,US 50420474 A,1974-09-09,Medical tube with cuff,"A medical tube, such as an endotracheal tube, having a balloon cuff filled with silicone gel.",SHERWOOD MEDICAL IND INC,CORBETT JOSEPH H,SHERWOOD MEDICAL COMPANY (1982-04-12);;SMITH KLINE & FRANCH LABORATORIES LIMITED A BRITISH COMPANY (1983-08-12),https://lens.org/078-318-794-994-73X,Granted Patent,yes,7,83,1,1,0,A61M16/04;;Y10S128/21;;A61M2205/32;;A61M16/0425;;A61M16/0438;;A61M16/0484;;A61M16/0445;;A61M16/0436;;A61M16/04;;Y10S128/21;;A61M2205/32;;A61M16/0425;;A61M16/0484;;A61M16/0438,A61M16/04,128/351,0,0,,,,EXPIRED
27,GB,B,GB 2222429 B,092-049-720-079-920,1992-04-08,1992,GB 8820655 A,1988-09-01,GB 8820655 A,1988-09-01,IMPROVEMENT IN OR RELATING TO BUILDING OR CONSTRUCTION WORK,,CORBETT MICHAEL JOSEPH,CORBETT MICHAEL JOSEPH,,https://lens.org/092-049-720-079-920,Granted Patent,no,7,1,3,3,0,E04G1/24,E04G1/24,E1S SS            SS,0,0,,,,EXPIRED
28,US,A,US 3625221 A,165-428-642-457-178,1971-12-07,1971,US 3625221D A,1969-07-29,US 84568269 A,1969-07-29,FLAP-TROL SUCTION CATHETER,,SHERWOOD MEDICAL IND INC,CORBETT JOSEPH H,SHERWOOD MEDICAL COMPANY (1982-04-12),https://lens.org/165-428-642-457-178,Granted Patent,no,4,25,3,3,0,A61M1/7411;;A61M1/7411,A61M1/00,A5R RGV           RGV,0,0,,,,EXPIRED
29,CA,A,CA 1064337 A,178-204-609-530-483,1979-10-16,1979,CA 241549 A,1975-12-11,US 53507774 A,1974-12-20,METHOD OF MAKING A CATHETER WITH X-RAY OPAQUE MARKINGS,"Disclosed is a method of making an elongated medical catheter having an x-ray opaque marking comprising the steps of: extruding an elongated plastic tubular member, then coating a selected surface area of the tubular member with a mixture while leaving other areas free of the mixture, the mixture including an x-ray opaque material and a solution, the solution comprising a plastic material and a solvent therefor, and solidifying the coating in situ to provide an x-ray opaque marking on the tubular member. The marking is formed in its entirety from the mixture and the solution is in liquid form when at room temperature prior to the step of solidifying the coating, and the solvent is also a solvent for the plastic material of the tubular member.",SHERWOOD MEDICAL IND INC,CORBETT JOSEPH H,,https://lens.org/178-204-609-530-483,Granted Patent,no,0,0,8,8,0,A61M25/0108;;A61M25/0009,A61M25/00;;A61M25/01;;A61M25/16,117-61,0,0,,,,EXPIRED
30,WO,A1,WO 2018/075428 A1,173-089-100-356-82X,2018-04-26,2018,US 2017/0056847 W,2017-10-17,US 201662410497 P,2016-10-20,FASTENER AND FASTENING SYSTEM,"A fastening system includes a fastener (10) having a bolt (12) with a pull portion (28) having at least one pull groove (28a), and an outer sleeve (14) having a head (42) with an inner face (46), the bolt (12) being inserted within the sleeve (14). The fastening system includes a fastener installation tool (60) having a puller (62) with at least one tooth (68) and a front face (72). The inner face (46) of the head (42) of the sleeve (14) is angled at an angle measured transverse to a longitudinal axis (X-X) of the fastener (10), while the front face (72) of the puller (62) of the fastener installation tool (60) is angled at an angle measured transverse to a longitudinal axis (Y-Y) of the puller (62). The angles are chosen to match or be substantially the same. The front face (72) of the puller (62) of the fastener installation tool (60) is adapted to engage the inner face (46) of the outer sleeve (14) of the fastener (10) when the fastener installation tool (60) engages the fastener (10), and the inner face (46) of the outer sleeve (14) facilitates the receipt of the front face (72) of the puller (62) and the alignment of the at least one tooth (68) of the puller (62) with the at least one pull groove (70) of the bolt (12) by allowing the puller (62) to shift forward or backward to facilitate such alignment.",ARCONIC INC,CORBETT ROBERT;;LEAVELLE JOSEPH,,https://lens.org/173-089-100-356-82X,Patent Application,yes,5,0,3,3,0,B21J15/022;;F16B19/1054;;B21J15/022;;F16B35/04;;B21J15/045;;F16B19/1054;;F16B2019/1009,F16B19/05;;F16B13/04,,0,0,,,,PENDING
31,US,A,US 3538007 A,038-684-218-975-345,1970-11-03,1970,US 3538007D A,1967-12-04,US 68744267 A,1967-12-04,PAINT STRIPPER FOR ALUMINUM AND MAGNESIUM SURFACES,,GRACE W R & CO,COOPER JOSEPH;;CORBETT WILLIAM J,,https://lens.org/038-684-218-975-345,Granted Patent,no,5,14,1,1,0,C09D9/005;;C09D9/005,C09D9/00,252/144,0,0,,,,EXPIRED
32,US,A,US 3629004 A,102-777-598-699-718,1971-12-21,1971,US 3629004D A,1969-04-17,US 14821371 A;;US 32857473 A;;US 81716069 A,1969-04-17,PAINT-REMOVING METHOD,A method for removing paint from metal surfaces by boiling a solvent or solvent mixture and contacting the painted metal surface with the vapors of the solvent mixture.,GRACE W R & CO,COOPER JOSEPH;;CORBETT WILLIAM JAMES,,https://lens.org/102-777-598-699-718,Granted Patent,no,3,13,5,7,0,C09D9/005;;C11D3/43;;C11D7/24;;C11D7/261;;C11D7/263;;C11D7/265;;C11D7/28;;C11D7/32;;C11D7/34;;C11D7/5009;;C11D7/5013;;C11D7/5018;;C11D7/5022;;C11D2111/16;;C11D7/261;;C11D7/24;;C11D7/5013;;C11D7/263;;C11D7/265;;C11D3/43;;C11D7/34;;C11D7/5018;;C11D7/28;;C11D7/5022;;C09D9/005;;C11D7/5009;;C11D7/32;;C11D2111/16,C09D9/00;;C11D3/43;;C11D7/24;;C11D7/26;;C11D7/28;;C11D7/32;;C11D7/34;;C11D7/50;;C11D11/00,134/31,1,0,,,"Schwartz, Perry, Berch, Surface Active Agents and Detergents, 1958, Interscience Publishers, New York, pp. 109, 110",EXPIRED
33,CA,A1,CA 3162033 A1,178-623-096-952-424,2021-06-24,2021,CA 3162033 A,2020-12-15,US 201916717121 A;;US 2020/0065107 W,2019-12-17,EARTHMOVING FLOW VECTOR GENERATION USING NODE AND CONNECTION INPUT GRAPH,Techniques for generating earthmoving flow vectors for assisting control of a construction machine are disclosed. A design elevation map of an earthmoving site may be obtained. The design elevation map may include a plurality of design elevation points of the earthmoving site. An actual elevation map of the earthmoving site may be obtained. The actual elevation map may include a plurality of actual elevation points of the earthmoving site. A dual-layer input graph may be formed based on the design elevation map and the actual elevation map. The dual-layer input graph may include a plurality of nodes related through a plurality of connections. A flow graph may be generated by solving the dual-layer input graph. The flow graph may include a set of flow vectors indicating movement of the earth within the earthmoving site.,CATERPILLAR TRIMBLE CONTROL TECH LLC,JONES NATHAN;;CORBETT-DAVIES JOSEPH,,https://lens.org/178-623-096-952-424,Patent Application,no,0,0,6,6,0,E02F9/262;;E02F9/2045;;E02F9/268;;E02F9/2054;;E02F3/841;;G05D1/0217;;E02F9/2045;;E02F9/262;;E02F9/265;;G06Q10/047;;G06T17/05;;G01C21/38;;G01C21/3867,E02F9/20;;E02F9/26,,0,0,,,,PENDING
34,WO,A1,WO 2021/126844 A1,036-392-157-222-464,2021-06-24,2021,US 2020/0065107 W,2020-12-15,US 201916717121 A,2019-12-17,EARTHMOVING FLOW VECTOR GENERATION USING NODE AND CONNECTION INPUT GRAPH,Techniques for generating earthmoving flow vectors for assisting control of a construction machine are disclosed. A design elevation map of an earthmoving site may be obtained. The design elevation map may include a plurality of design elevation points of the earthmoving site. An actual elevation map of the earthmoving site may be obtained. The actual elevation map may include a plurality of actual elevation points of the earthmoving site. A dual-layer input graph may be formed based on the design elevation map and the actual elevation map. The dual-layer input graph may include a plurality of nodes related through a plurality of connections. A flow graph may be generated by solving the dual-layer input graph. The flow graph may include a set of flow vectors indicating movement of the earth within the earthmoving site.,CATERPILLAR TRIMBLE CONTROL TECH LLC,JONES NATHAN;;CORBETT-DAVIES JOSEPH,,https://lens.org/036-392-157-222-464,Patent Application,yes,3,0,6,6,0,E02F9/262;;E02F9/2045;;E02F9/268;;E02F9/2054;;E02F3/841;;G05D1/0217;;E02F9/2045;;E02F9/262;;E02F9/265;;G06Q10/047;;G06T17/05;;G01C21/38;;G01C21/3867,E02F9/26;;E02F9/20,,0,0,,,,PENDING
35,US,B2,US 11603646 B2,117-245-387-610-24X,2023-03-14,2023,US 201916717121 A,2019-12-17,US 201916717121 A,2019-12-17,Earthmoving flow vector generation using node and connection input graph,Techniques for generating earthmoving flow vectors for assisting control of a construction machine are disclosed. A design elevation map of an earthmoving site may be obtained. The design elevation map may include a plurality of design elevation points of the earthmoving site. An actual elevation map of the earthmoving site may be obtained. The actual elevation map may include a plurality of actual elevation points of the earthmoving site. A dual-layer input graph may be formed based on the design elevation map and the actual elevation map. The dual-layer input graph may include a plurality of nodes related through a plurality of connections. A flow graph may be generated by solving the dual-layer input graph. The flow graph may include a set of flow vectors indicating movement of the earth within the earthmoving site.,CATERPILLAR TRIMBLE CONTROL TECH LLC,JONES NATHAN;;CORBETT-DAVIES JOSEPH,CATERPILLAR TRIMBLE CONTROL TECHNOLOGIES LLC (2019-12-17),https://lens.org/117-245-387-610-24X,Granted Patent,yes,13,0,6,6,0,E02F9/262;;E02F9/2045;;E02F9/268;;E02F9/2054;;E02F3/841;;G05D1/0217;;E02F9/2045;;E02F9/262;;E02F9/265;;G06Q10/047;;G06T17/05;;G01C21/38;;G01C21/3867,E02F9/26;;E02F9/20;;G01C21/00;;G05D1/02;;G06Q10/04;;G06Q10/047;;G06T17/05,,1,0,,,"International Search Report and Written Opinion for Application No. PCT/US2020/065107, dated May 18, 2021, 18 pages.",ACTIVE
36,EP,A1,EP 4077819 A1,026-216-549-994-660,2022-10-26,2022,EP 20839492 A,2020-12-15,US 201916717121 A;;US 2020/0065107 W,2019-12-17,EARTHMOVING FLOW VECTOR GENERATION USING NODE AND CONNECTION INPUT GRAPH,,CATERPILLAR TRIMBLE CONTROL TECH LLC,JONES NATHAN;;CORBETT-DAVIES JOSEPH,,https://lens.org/026-216-549-994-660,Patent Application,yes,0,0,6,6,0,E02F9/262;;E02F9/2045;;E02F9/268;;E02F9/2054;;E02F3/841;;G05D1/0217;;E02F9/2045;;E02F9/262;;E02F9/265;;G06Q10/047;;G06T17/05;;G01C21/38;;G01C21/3867,E02F9/26;;E02F9/20,,0,0,,,,PENDING
37,US,A1,US 2021/0180295 A1,069-772-546-253-223,2021-06-17,2021,US 201916717121 A,2019-12-17,US 201916717121 A,2019-12-17,EARTHMOVING FLOW VECTOR GENERATION USING NODE AND CONNECTION INPUT GRAPH,Techniques for generating earthmoving flow vectors for assisting control of a construction machine are disclosed. A design elevation map of an earthmoving site may be obtained. The design elevation map may include a plurality of design elevation points of the earthmoving site. An actual elevation map of the earthmoving site may be obtained. The actual elevation map may include a plurality of actual elevation points of the earthmoving site. A dual-layer input graph may be formed based on the design elevation map and the actual elevation map. The dual-layer input graph may include a plurality of nodes related through a plurality of connections. A flow graph may be generated by solving the dual-layer input graph. The flow graph may include a set of flow vectors indicating movement of the earth within the earthmoving site.,CATERPILLAR TRIMBLE CONTROL TECH LLC,JONES NATHAN;;CORBETT-DAVIES JOSEPH,CATERPILLAR TRIMBLE CONTROL TECHNOLOGIES LLC (2019-12-17),https://lens.org/069-772-546-253-223,Patent Application,yes,12,0,6,6,0,E02F9/262;;E02F9/2045;;E02F9/268;;E02F9/2054;;E02F3/841;;G05D1/0217;;E02F9/2045;;E02F9/262;;E02F9/265;;G06Q10/047;;G06T17/05;;G01C21/38;;G01C21/3867,E02F9/26;;E02F9/20;;G05D1/02;;G06Q10/04;;G06T17/05,,0,0,,,,ACTIVE
38,AU,A,AU 1970/012393 A,139-479-833-999-225,1971-09-16,1971,AU 1970/012393 A,1970-03-10,US 81716069 A,1969-04-17,PAINT REMOVING METHOD.,,GRACE W R & CO,COOPER JOSEPH;;CORBETT WILLIAM JAMES,,https://lens.org/139-479-833-999-225,Patent Application,no,0,1,2,7,0,,C09D/;;C23G/,25.4;;25.1,0,0,,,,DISCONTINUED
39,US,A,US 3417025 A,038-320-411-081-530,1968-12-17,1968,US 56646866 A,1966-07-20,US 56646866 A,1966-07-20,Paint stripping composition,,GRACE W R & CO,JOSEPH COOPER;;CORBETT WILLIAM J,,https://lens.org/038-320-411-081-530,Granted Patent,no,2,10,1,1,0,C09D9/00;;C09D9/00,C09D9/00,252/152,0,0,,,,EXPIRED
40,DE,A1,DE 1704861 A1,025-106-603-579-684,1971-10-07,1971,DE 1704861 A,1967-01-03,US 51814866 A;;US 52056966 A,1966-01-03,Strangpresse zur Herstellung einer Mehrzahl von aufeinanderkaschierten rohrfoermigen Kunststoffschichten,,NAT DISTILLERS CHEM CORP,OLIVER CORBETT HERBERT;;JOSEPH QUACKENBUSH JOHN,,https://lens.org/025-106-603-579-684,Patent Application,no,0,1,5,9,0,B29K2105/20;;B29L2031/3462;;B29C48/09;;B29C48/10;;B29C48/151;;B29C48/21;;B29C48/304;;B29C48/335;;B29C48/3363;;B29C48/34;;B29C48/21;;B29C48/34;;B29C48/09;;B29C48/10;;B29C48/151;;B29C48/304;;B29C48/335;;B29C48/3363,B29C48/34;;B29C48/09;;B29C48/10;;B29C48/151;;B29C48/21;;B29C48/335,,0,0,,,,DISCONTINUED
41,DE,A1,DE 1604651 A1,154-917-395-720-722,1970-11-05,1970,DE 1604651 A,1966-06-28,US 46760965 A,1965-06-28,Verfahren und Vorrichtung zum Spritzen von rechteckigem thermoplastischem Material,,NAT DISTILLERS CHEM CORP,JOSEPH QUACKENBUSH JOHN;;OLIVER CORBETT HERBERT,,https://lens.org/154-917-395-720-722,Patent Application,no,0,0,6,7,0,B29C48/03;;B29C48/06;;B29C48/09;;B29C48/12;;B29C48/0018;;B29C48/0019;;B29C48/0022;;B29C48/03;;B29C48/09;;B29C48/0022;;B29C48/06;;B29C48/0019;;B29C48/12;;B29C48/0018,B29C48/03;;B29C48/06;;B29C48/09;;B29C48/12,,0,0,,,,DISCONTINUED
42,EP,B1,EP 0178754 B1,013-862-833-113-482,1988-09-21,1988,EP 85305427 A,1985-07-30,US 66066884 A,1984-10-15,SINGLE STAGE AUTOPHAGE ROCKET,,GRUMMAN AEROSPACE CORPORATION,"CORBETT, MARSHALL J.;;BELISLE, JOSEPH A.",,https://lens.org/013-862-833-113-482,Granted Patent,yes,6,0,10,10,0,B64G1/002;;B64G1/402;;B64G1/404;;F02K7/18;;F02K9/34;;F02K9/60;;F02K9/72;;B64G1/404;;B64G1/002;;F02K7/18;;F02K9/60;;F02K9/34;;B64G1/402;;F02K9/72,B64G1/00;;B64G1/40;;F02K7/18;;F02K9/34;;F02K9/97;;F02K9/60;;F02K9/72,,1,0,,,"PRODUCT ENGINEERING, vol. 41, no. 9, 27th April 1970, pages 18,19, US; ""Hybrid air-gulping rocket enters its final design phase""",EXPIRED
43,US,A,US 3347443 A,054-873-941-492-943,1967-10-17,1967,US 51808566 A,1966-01-03,US 51808566 A,1966-01-03,Container closure,,NAT DISTILLERS CHEM CORP,JOSEPH QUACKENBUSH JOHN;;OLIVER CORBETT HERBERT,,https://lens.org/054-873-941-492-943,Granted Patent,no,9,1,2,2,0,B65D25/42;;B65D25/42;;B65D17/00;;B65D17/00;;Y10S229/927;;Y10S229/927,B65D17/00;;B65D25/42,,0,0,,,,EXPIRED
44,FR,A,FR 1507090 A,179-866-840-626-815,1967-12-22,1967,FR 69048122 A,1966-12-30,US 51828466 A,1966-01-03,Sac d'emballage en matière plastique à triple épaisseur,,NAT DISTILLERS CHEM CORP,QUACKENBUSH JOHN JOSEPH;;CORBETT HERBERT OLIVER,,https://lens.org/179-866-840-626-815,Granted Patent,no,0,1,6,6,0,B32B27/00;;B32B27/00;;B65D31/02;;B65D31/02;;Y10S206/819;;Y10S206/819,B32B27/00;;B65D30/08,,0,0,,,,EXPIRED
45,NO,B,NO 160473 B,062-454-215-339-884,1989-01-09,1989,NO 854066 A,1985-10-14,US 66066884 A,1984-10-15,ETT-TRINNS SELVDESTRUERENDE RAKETT.,,GRUMMAN AEROSPACE CORP,CORBETT MARSHALL J;;BELISLE JOSEPH A,,https://lens.org/062-454-215-339-884,Unknown,no,0,0,10,10,0,B64G1/002;;B64G1/402;;B64G1/404;;F02K7/18;;F02K9/34;;F02K9/60;;F02K9/72;;B64G1/404;;B64G1/002;;F02K7/18;;F02K9/60;;F02K9/34;;B64G1/402;;F02K9/72,B64G1/00;;F02K9/97;;B64G1/40;;F02K7/18;;F02K9/34;;F02K9/60;;F02K9/72,,0,0,,,,EXPIRED
46,FR,A,FR 1485477 A,084-966-369-573-494,1967-06-16,1967,FR 69047476 A,1966-06-27,US 46760965 A,1965-06-28,Procédé de fabrication par extrusion de tubes non circulaires en matière thermoplastique,,NAT DISTILLERS CHEM CORP,QUACKENBUSH JOHN JOSEPH;;CORBETT HERBERT OLIVER,,https://lens.org/084-966-369-573-494,Granted Patent,no,0,0,6,7,0,B29C48/03;;B29C48/06;;B29C48/09;;B29C48/12;;B29C48/0018;;B29C48/0019;;B29C48/0022;;B29C48/03;;B29C48/09;;B29C48/0022;;B29C48/06;;B29C48/0019;;B29C48/12;;B29C48/0018,B29C48/03;;B29C48/06;;B29C48/09;;B29C48/12,,0,0,,,,EXPIRED
47,CA,A1,CA 2945294 A1,128-008-391-389-234,2017-04-13,2017,CA 2945294 A,2016-10-13,US 201562240753 P,2015-10-13,SYSTEMS AND METHODS FOR AUTOMATED ROUTE CALCULATION AND DYNAMIC ROUTE UPDATING,"Systems and methods are provided for automated routing in a facility. A system may comprise at least one processor, and a storage medium comprising executable instructions to configure the processor to receive first data associated with a condition of an individual, search a database in communication with the at least one processor to identify second data for a set of milestones associated with the condition, select, based on the set of milestones, a plurality of locations in the facility corresponding to the set of milestones, receive, from the database, third data associated with performance metrics of the plurality of locations, determine a sequence of the set of milestones and a path through the plurality of locations, the path being determined by correlating the performance metrics to milestones in the set of milestones, and generate for display a graphical user interface illustrating the determined sequence and determined path.",SCHUCK JOSEPH C;;CORBETT CHELSIE M,SCHUCK JOSEPH C;;CORBETT CHELSIE M,,https://lens.org/128-008-391-389-234,Patent Application,no,0,0,2,5,0,G06Q10/0639;;G16H40/20;;G16H40/20;;G06Q10/0639,G06Q10/02;;G16H40/20;;H04W4/04,,0,0,,,,PENDING
48,EP,A1,EP 3156951 A1,149-583-115-184-892,2017-04-19,2017,EP 16193825 A,2016-10-13,US 201562240753 P,2015-10-13,SYSTEMS AND METHODS FOR AUTOMATED ROUTE CALCULATION AND DYNAMIC ROUTE UPDATING,"Systems and methods are provided for automated routing in a facility. A system may comprise at least one processor, and a storage medium comprising executable instructions to configure the processor to receive first data associated with a condition of an individual, search a database in communication with the at least one processor to identify second data for a set of milestones associated with the condition, select, based on the set of milestones, a plurality of locations in the facility corresponding to the set of milestones, receive, from the database, third data associated with performance metrics of the plurality of locations, determine a sequence of the set of milestones and a path through the plurality of locations, the path being determined by correlating the performance metrics to milestones in the set of milestones, and generate for display a graphical user interface illustrating the determined sequence and determined path.
",SCHUCK JOSEPH C;;CORBETT CHELSIE M,SCHUCK JOSEPH C;;CORBETT CHELSIE M,,https://lens.org/149-583-115-184-892,Patent Application,yes,4,3,2,5,0,G06Q10/0639;;G16H40/20;;G16H40/20;;G06Q10/0639,G06Q10/06;;G16H40/20,,0,0,,,,DISCONTINUED
49,DE,A1,DE 1652405 A1,097-476-329-566-986,1969-09-18,1969,DE 1652405 A,1967-01-12,US 54204066 A;;US 55554366 A,1966-04-12,Dispergieren von Plastik-Feinpulvern in Wolkenform,,NAT DISTILLERS CHEM CORP,JOSEPH QUACKENBUSH JOHN;;OLIVER CORBETT HERBERT,,https://lens.org/097-476-329-566-986,Patent Application,no,0,0,7,11,0,B05B7/1404;;B05B7/1463;;B05B7/1472;;B05B7/1477;;B05B13/02;;B05B13/0207;;B05B16/95;;B05C19/02;;B05D1/24;;B05D3/0218;;B05D3/0254;;B05D2252/02;;D21H19/00,B05B7/14;;B05B13/02;;B05B15/12;;B05B16/00;;B05C19/02;;B05D1/24;;D21H19/00,,0,0,,,,DISCONTINUED
50,FR,A,FR 1470221 A,140-621-022-000-684,1967-02-17,1967,FR 69046965 A,1966-02-21,US 43483165 A,1965-02-24,Perfectionnements aux procédés de fabrication de pellicules thermoplastiques et thermodurcissables orientées,,NAT DISTILLERS CHEM CORP,CORBETT HERBERT OLIVER;;QUAKENBUSH JOHN JOSEPH,,https://lens.org/140-621-022-000-684,Granted Patent,no,0,3,4,4,0,B29C55/065;;B29C55/023;;B29C55/085;;B29C55/146,B29C55/02;;B29C55/14,,0,0,,,,EXPIRED
51,US,A,US 2798700 A,043-678-700-980-29X,1957-07-09,1957,US 40937154 A,1954-02-10,US 40937154 A,1954-02-10,Culinary mixer,,NUTONE INC,CORBETT JOSEPH R;;SPRAGUE LINDOL H,,https://lens.org/043-678-700-980-29X,Granted Patent,no,6,17,1,1,0,A47J43/046;;Y10T74/19084;;Y10T74/19679;;B01F27/2324;;B01F27/95;;Y10T74/19084;;Y10T74/19679;;A47J43/046;;B01F27/95;;B01F27/2324,A47J43/046;;B01F7/00;;B01F7/30,,0,0,,,,EXPIRED
52,DE,D1,DE 3565153 D1,070-293-658-391-45X,1988-10-27,1988,DE 3565153 T,1985-07-30,US 66066884 A,1984-10-15,SINGLE STAGE AUTOPHAGE ROCKET,,GRUMMAN AEROSPACE CORP,CORBETT MARSHALL J;;BELISLE JOSEPH A,,https://lens.org/070-293-658-391-45X,Granted Patent,no,0,0,10,10,0,B64G1/002;;B64G1/402;;B64G1/404;;F02K7/18;;F02K9/34;;F02K9/60;;F02K9/72;;B64G1/404;;B64G1/002;;F02K7/18;;F02K9/60;;F02K9/34;;B64G1/402;;F02K9/72,B64G1/00;;B64G1/40;;F02K7/18;;F02K9/34;;F02K9/60;;F02K9/97;;F02K9/72,,0,0,,,,EXPIRED
53,NO,L,NO 854066 L,075-092-615-048-740,1986-04-16,1986,NO 854066 A,1985-10-14,US 66066884 A,1984-10-15,ETT-TRINNS SELVDESTRUERENDE RAKETT.,,GRUMMAN AEROSPACE CORP,CORBETT MARSHALL J;;BELISLE JOSEPH A,,https://lens.org/075-092-615-048-740,Abstract,no,0,0,10,10,0,B64G1/002;;B64G1/402;;B64G1/404;;F02K7/18;;F02K9/34;;F02K9/60;;F02K9/72;;B64G1/404;;B64G1/002;;F02K7/18;;F02K9/60;;F02K9/34;;B64G1/402;;F02K9/72,B64G1/00;;F02K9/97;;B64G1/40;;F02K7/18;;F02K9/34;;F02K9/60;;F02K9/72,,0,0,,,,EXPIRED
54,DE,A1,DE 1569225 A1,123-272-974-429-614,1970-04-02,1970,DE 1569225 A,1965-10-22,US 40601064 A,1964-10-23,Geschichtete Folie,,NAT DISTILLERS CHEM CORP,OLIVER CORBETT HERBERT;;JOSEPH QUACKENBUSH JOHN,,https://lens.org/123-272-974-429-614,Patent Application,no,0,0,4,4,0,B32B27/00,B32B27/00;;B65D65/40,,0,0,,,,DISCONTINUED
55,DE,A1,DE 1629568 A1,028-516-565-609-555,1971-01-28,1971,DE 1629568 A,1966-07-12,US 47101865 A,1965-07-12,Verfahren und Vorrichtung zur Herstellung eines gewellten thermoplastischen Bandes,,NAT DISTILLERS CHEM CORP,JOSEPH QUACKENBUSH JOHN;;OLIVER CORBETT HERBERT,,https://lens.org/028-516-565-609-555,Patent Application,no,0,0,6,6,0,B29L2031/60;;B29C48/08;;B29C48/09;;B29C48/10;;B29C48/11;;B29C48/0015;;B29C48/21;;B29C48/32;;B29C48/335;;B29C48/13;;B29C48/335;;B29L2031/60;;B29C48/08;;B29C48/11;;B29C48/10;;B29C48/09;;B29C48/21;;B29C48/0015;;B29C48/32;;B29C48/13,B29C48/08;;B29C48/10;;B29C48/11;;B29C48/13;;B29C48/32,,0,0,,,,DISCONTINUED
56,DE,A1,DE 1586824 A1,021-112-486-751-697,1970-08-06,1970,DE 1586824 A,1967-01-03,US 51828466 A,1966-01-03,Beutel aus mehrschichtigem thermoplastischem Kunststoff,,NAT DISTILLERS CHEM CORP,JOSEPH QUACKENBUSH JOHN;;OLIVER CORBETT HERBERT,,https://lens.org/021-112-486-751-697,Patent Application,no,0,0,6,6,0,B32B27/00;;B32B27/00;;B65D31/02;;B65D31/02;;Y10S206/819;;Y10S206/819,B32B27/00;;B65D30/08,,0,0,,,,DISCONTINUED
57,GB,A,GB 822247 A,021-849-728-775-090,1959-10-21,1959,GB 2253057 A,1957-07-16,GB 2253057 A,1957-07-16,Culinary mixer,,NUTONE INC,CORBETT JOSEPH R;;SPRAGUE LINDOL H,,https://lens.org/021-849-728-775-090,Granted Patent,no,0,0,1,1,0,A47J43/046,A47J43/046,B1C CABB          CABB;;B1C C104          CABB;;B1C C611          CABB;;B1C C624          CABB;;B1C C642          CABB;;B1C C661          CABB,0,0,,,,EXPIRED
58,NO,C,NO 160473 C,049-152-230-170-891,1989-04-19,1989,NO 854066 A,1985-10-14,US 66066884 A,1984-10-15,ETT-TRINNS SELVDESTRUERENDE RAKETT.,,GRUMMAN AEROSPACE CORP,CORBETT MARSHALL J;;BELISLE JOSEPH A,,https://lens.org/049-152-230-170-891,Granted Patent,no,0,0,10,10,0,B64G1/002;;B64G1/402;;B64G1/404;;F02K7/18;;F02K9/34;;F02K9/60;;F02K9/72;;B64G1/404;;B64G1/002;;F02K7/18;;F02K9/60;;F02K9/34;;B64G1/402;;F02K9/72,B64G1/00;;F02K9/97;;B64G1/40;;F02K7/18;;F02K9/34;;F02K9/60;;F02K9/72,,0,0,,,,EXPIRED
59,DE,A1,DE 1704863 A1,164-265-689-254-765,1971-07-08,1971,DE 1704863 A,1967-02-21,US 52908266 A,1966-02-21,Vorrichtung und Verfahren zur Herstellung eines bedruckten Thermoplastischlauches,,NAT DISTILLERS CHEM CORP,JOSEPH QUACKENBUSH JOHN;;OLIVER CORBETT HERBERT,,https://lens.org/164-265-689-254-765,Patent Application,no,0,0,6,6,0,B32B27/00;;B29C48/09;;B29C48/10;;B29C48/0016;;B29C48/21;;B32B27/00;;B29C48/21;;B29C48/10;;B29C48/09;;B29C48/0016,B29B7/00;;B29C48/09;;B29C48/10;;B29C48/21;;B29C48/32;;B32B27/00,,0,0,,,,DISCONTINUED
60,AU,A,AU 1985/037908 A,051-503-000-640-572,1985-08-01,1985,AU 1985/037908 A,1985-01-18,US 57269684 A,1984-01-20,AIR FLOW CONTROL APPARATUS,,FLANDERS FILTERS,WOOD JOSEPH ARTHUR;;PEEBLES WILLIAM CORBETT,,https://lens.org/051-503-000-640-572,Patent Application,no,0,0,5,5,0,F16K1/165;;F24F13/1406;;F24F13/1413;;F24F13/1426;;F24F2013/1473;;Y10T137/87113;;Y10T137/87434;;Y10T137/87113;;Y10T137/87434;;F24F13/1426;;F16K1/165;;F24F13/1406;;F24F2013/1473;;F24F13/1413,F24F13/15;;F16K1/16;;F24F13/14,,0,0,,,,DISCONTINUED
61,DE,T2,DE 69824137 T2,000-900-589-034-864,2005-05-25,2005,DE 69824137 T,1998-10-01,EP 9806265 W;;US 6085997 P,1997-10-02,EINFÜHRVORRICHTUNG FÜR EINEN TRANSANAL ANASTOMOSE RING,"The invention relates to a device for transanally inserting through the lower bowel one of two unitary members of a Biofragmentable Anastomosis Ring (BAR). The device comprises a curved shaft with a handle and an actuating knob at the proximal end, a nest formed at the distal end of the shaft adapted to mount a BAR carrier assembly, and a second passageway formed through the shaft that terminates at a distal open end formed through the nest. The BAR carrier assembly includes unitary male and female members that collectively comprise the BAR, male and female carriers for mounting the respective unitary member, and a collet for locking in and releasing the BAR from the BAR carrier assembly once both unitary members are secured to respective open ends of the upper and lower bowel section. The BAR Carrier Assembly is actuatable in one of three positions: open, closed, and released. Once secured to the upper bowel section, the surgeon attaches the male carrier with its attached male member to the BAR Carrier Assembly, thus placing the Assembly in the open position. The surgeon then places the BAR Carrier Assembly in the closed position by mating the male member to the female member seated in the nest. Once in the closed position, the surgeon places the BAR Carrier Assembly in the released position by actuating the insertion device and releasing the mated unitary members of the BAR from the BAR Carrier Assembly and withdrawing the insertion device from the lower bowel.",SHERWOOD SERV AG,PHILLIPS JOSEPH;;CORBETT KELLY;;CONNERS A,"COVIDIEN AG, NEUHAUSEN AM RHEINFALL, CH (2007-11-22)",https://lens.org/000-900-589-034-864,Granted Patent,no,0,0,14,14,0,A61B17/1114;;A61B2017/00004,A61B17/00;;A61B17/11,,0,0,,,,EXPIRED
62,FR,A,FR 1508024 A,090-209-072-980-856,1967-12-29,1967,FR 69048162 A,1967-01-13,US 54204066 A;;US 55554366 A,1966-04-12,Perfectionnements à la dispersion de poudres fines de matières plastiques,,NAT DISTILLERS CHEM CORP,QUACKENBUSH JOHN JOSEPH;;CORBETT HERBERT OLIVER,,https://lens.org/090-209-072-980-856,Granted Patent,no,0,1,7,11,0,B05B7/1404;;B05B7/1463;;B05B7/1472;;B05B7/1477;;B05B13/02;;B05B13/0207;;B05B16/95;;B05C19/02;;B05D1/24;;B05D3/0218;;B05D3/0254;;B05D2252/02;;D21H19/00,B05B7/14;;B05B13/02;;B05B15/12;;B05B16/00;;B05C19/02;;B05D1/24;;D21H19/00,,0,0,,,,EXPIRED
63,US,A1,US 2018/0111184 A1,045-759-836-419-757,2018-04-26,2018,US 201715785526 A,2017-10-17,US 201715785526 A;;US 201662410497 P,2016-10-20,FASTENER AND FASTENING SYSTEM,"A fastening system includes a fastener having a bolt with a pull portion having at least one pull groove, and an outer sleeve having a head with an inner face, the bolt being inserted within the sleeve. The fastening system includes a fastener installation tool having a puller with at least one tooth and a front face. The inner face of the head of the sleeve is angled at an included angle measured transverse to a longitudinal axis of the fastener, while the front face of the puller of the fastener installation tool is angled at an included angle measured transverse to a longitudinal axis of the puller. The included angles are chosen to match or be substantially the same. The front face of the puller of the fastener installation tool is adapted to engage the inner face of the outer sleeve of the fastener when the fastener installation tool engages the fastener, and the inner face of the outer sleeve facilitates the receipt of the front face of the puller and the alignment of the at least one tooth of the puller with the at least one pull groove of the bolt by allowing the puller to shift forward or backward to facilitate such alignment.",ARCONIC INC,CORBETT ROBERT J;;LEAVELLE JOSEPH Z,HOWMET AEROSPACE INC (2017-10-09),https://lens.org/045-759-836-419-757,Patent Application,yes,0,1,3,3,0,B21J15/022;;F16B19/1054;;B21J15/022;;F16B35/04;;B21J15/045;;F16B19/1054;;F16B2019/1009,B21J15/04;;F16B19/10,,0,0,,,,ACTIVE
64,EP,A1,EP 0178754 A1,083-090-070-042-090,1986-04-23,1986,EP 85305427 A,1985-07-30,US 66066884 A,1984-10-15,Single stage autophage rocket.,"An autophage rocket has its casing (12), which stores liquid propellant (14), in the form of a single wall of a material which is itself combustible. As the propellant (14) is consumed during flight, the casing (12) is combusted. A plurality of rocket motors (24, 26, 28, 30) are fed with the liquid propellant (14) and combustion products from the liquid propellant (14) and the casing (12) pass through an expansion nozzle (36). The distance between the front (16) of the rocket casing and the motors is progressively reduced as the casing burns.",GRUMMAN AEROSPACE CORP,CORBETT MARSHALL J;;BELISLE JOSEPH A,,https://lens.org/083-090-070-042-090,Patent Application,yes,6,0,10,10,0,B64G1/002;;B64G1/402;;B64G1/404;;F02K7/18;;F02K9/34;;F02K9/60;;F02K9/72;;B64G1/404;;B64G1/002;;F02K7/18;;F02K9/60;;F02K9/34;;B64G1/402;;F02K9/72,B64G1/00;;B64G1/40;;F02K7/18;;F02K9/34;;F02K9/60;;F02K9/97;;F02K9/72,,1,0,,,"PRODUCT ENGINEERING, vol. 41, no. 9, 27th April 1970, pages 18,19, US; ""Hybrid air-gulping rocket enters its final design phase""",EXPIRED
65,US,A,US 2841723 A,101-792-488-064-470,1958-07-01,1958,US 40937254 A,1954-02-10,US 40937254 A,1954-02-10,Motor unit for culinary appliances,,CORBETT,CORBETT JOSEPH R;;SPRAGUE LINDOL H,,https://lens.org/101-792-488-064-470,Granted Patent,no,3,9,1,1,0,H02K7/145;;Y10S366/601;;H02K7/145;;Y10S366/601,H02K7/14,,0,0,,,,EXPIRED
66,FR,A,FR 1487725 A,123-042-952-017-05X,1967-07-07,1967,FR 69047527 A,1966-07-11,US 47101865 A,1965-07-12,Perfectionnements aux articles thermoplastiques ondulés,,NAT DISTILLERS CHEM CORP,CORBETT HERBERT OLIVER;;QUACKENBUSH JOHN JOSEPH,,https://lens.org/123-042-952-017-05X,Granted Patent,no,0,0,6,6,0,B29L2031/60;;B29C48/08;;B29C48/09;;B29C48/10;;B29C48/11;;B29C48/0015;;B29C48/21;;B29C48/32;;B29C48/335;;B29C48/13;;B29C48/335;;B29L2031/60;;B29C48/08;;B29C48/11;;B29C48/10;;B29C48/09;;B29C48/21;;B29C48/0015;;B29C48/32;;B29C48/13,B29C48/08;;B29C48/10;;B29C48/11;;B29C48/13;;B29C48/32,,0,0,,,,EXPIRED
67,CA,A,CA 1247378 A,179-903-347-013-601,1988-12-28,1988,CA 485792 A,1985-06-28,US 66066884 A,1984-10-15,SINGLE STAGE AUTOPHAGE ROCKET,"13 Title of the Invention: SINGLE STAGE AUTOPHAGE ROCKET Inventors: Marshall J. Corbett and Joseph A. Belisle An autophage rocket has its casing constructed from *KEVLAR-epoxy material which is itself combustible and stores liquid propellant. As the propellant is consumed during flight, the casing is combusted so that the pressure within the casing remains constant. A secondary nozzle is mounted to the outlet end of the rocket and cooperates with a ram-rocket construction to achieve additional impulse. A multiplicity of rocket motors are fed from a single stage tank to enable controlled motion of the rocket.",GRUMMAN AEROSPACE CORP,CORBETT MARSHALL J;;BELISLE JOSEPH A,,https://lens.org/179-903-347-013-601,Granted Patent,no,0,0,10,10,0,B64G1/002;;B64G1/402;;B64G1/404;;F02K7/18;;F02K9/34;;F02K9/60;;F02K9/72;;B64G1/404;;B64G1/002;;F02K7/18;;F02K9/60;;F02K9/34;;B64G1/402;;F02K9/72,B64G1/00;;B64G1/40;;F02K7/18;;F02K9/34;;F02K9/97;;F02K9/60;;F02K9/72,60-65,0,0,,,,EXPIRED
68,US,A,US 3321125 A,092-395-236-855-803,1967-05-23,1967,US 51828466 A,1966-01-03,US 51828466 A,1966-01-03,Heavy duty 3-layer thermoplastic shipping bag,,NAT DISTILLERS CHEM CORP,JOSEPH QUACKENBUSH JOHN;;OLIVER CORBETT HERBERT,,https://lens.org/092-395-236-855-803,Granted Patent,no,0,18,6,6,0,B32B27/00;;B32B27/00;;B65D31/02;;B65D31/02;;Y10S206/819;;Y10S206/819,B32B27/00;;B65D30/08,,0,0,,,,EXPIRED
69,GR,B,GR 31990 B,051-855-222-000-270,1967-05-02,1967,GR 670131990 A,1967-01-14,US 54204066 A;;US 55554366 A,1966-04-12,ΔΙΑΣΠΟΡΑ ΥΠΟ ΜΟΡΦΗΝ ΝΕΦΟΥΣ ΛΕΠΤΗΣ ΠΛΑΣΤΙΚΗΣ ΚΟΝΕΩΣ.,ιασπορά υπό μορφή νερούς λεπτής πλαστικής κόνεως.,NAT DISTILLERS CHEM CORP,CORBETT HERBERT OLIVER;;QUACKENBUSH JOHN JOSEPH,,https://lens.org/051-855-222-000-270,Granted Patent,no,0,0,7,11,0,B05B7/1404;;B05B7/1463;;B05B7/1472;;B05B7/1477;;B05B13/02;;B05B13/0207;;B05B16/95;;B05C19/02;;B05D1/24;;B05D3/0218;;B05D3/0254;;B05D2252/02;;D21H19/00,B05B7/14;;B05B13/02;;B05B15/12;;B05B16/00;;B05C19/02;;B05D1/24;;D21H19/00,,0,0,,,,EXPIRED
70,US,A,US 4763858 A,078-761-571-836-028,1988-08-16,1988,US 82651386 A,1986-02-05,US 82651386 A,1986-02-05,Deflectable jet engine inlet,"The inlet of a jet engine is equipped with a pivotally displaceable deflector which becomes deployed when the aircraft is in a stalled, horizontally stabilized condition. As the aircraft undergoes vertical descent, vertically impinging airflow is reflected off the interior surface of the deflector and flows coaxially through the inlet thereby forcing continued rotation of turbine blades. Hydraulic and electronic control devices deriving power from the turbine may be maintained operative even though the aircraft is in a stalled condition, thereby permitting limited horizontal maneuvering of the aircraft as the vertical descent continues.",GRUMMAN AEROSPACE CORP,BELISLE JOSEPH A;;CORBETT MARSHALL J,GRUMMAN AEROSPACE CORPORATION A CORP OF NEW YORK (1986-01-31),https://lens.org/078-761-571-836-028,Granted Patent,yes,23,4,1,1,0,B64D33/02;;B64D2033/026;;Y10T137/0536;;Y10T137/0536;;B64D33/02;;B64D2033/026,B64D33/02,244 53B;;X244 53R;;137/15.1,0,0,,,,EXPIRED
71,DE,D1,DE 69824137 D1,142-963-799-208-065,2004-07-01,2004,DE 69824137 T,1998-10-01,EP 9806265 W;;US 6085997 P,1997-10-02,EINFÜHRVORRICHTUNG FÜR EINEN TRANSANAL ANASTOMOSE RING,"The invention relates to a device for transanally inserting through the lower bowel one of two unitary members of a Biofragmentable Anastomosis Ring (BAR). The device comprises a curved shaft with a handle and an actuating knob at the proximal end, a nest formed at the distal end of the shaft adapted to mount a BAR carrier assembly, and a second passageway formed through the shaft that terminates at a distal open end formed through the nest. The BAR carrier assembly includes unitary male and female members that collectively comprise the BAR, male and female carriers for mounting the respective unitary member, and a collet for locking in and releasing the BAR from the BAR carrier assembly once both unitary members are secured to respective open ends of the upper and lower bowel section. The BAR Carrier Assembly is actuatable in one of three positions: open, closed, and released. Once secured to the upper bowel section, the surgeon attaches the male carrier with its attached male member to the BAR Carrier Assembly, thus placing the Assembly in the open position. The surgeon then places the BAR Carrier Assembly in the closed position by mating the male member to the female member seated in the nest. Once in the closed position, the surgeon places the BAR Carrier Assembly in the released position by actuating the insertion device and releasing the mated unitary members of the BAR from the BAR Carrier Assembly and withdrawing the insertion device from the lower bowel.",SHERWOOD SERV AG,PHILLIPS JOSEPH;;CORBETT KELLY;;CONNERS A,"COVIDIEN AG, NEUHAUSEN AM RHEINFALL, CH (2007-11-22)",https://lens.org/142-963-799-208-065,Granted Patent,no,0,0,14,14,0,A61B17/1114;;A61B2017/00004,A61B17/00;;A61B17/11,,0,0,,,,EXPIRED
72,CA,A,CA 966338 A,197-272-356-310-346,1975-04-22,1975,CA 155281 A,1972-10-31,CA 155281 A,1972-10-31,"BOLT FOR ATTACHING ELEVATOR BUCKETS TO BELTS, AND METHOD OF MAKING SAME",,BELTS BOLTS,CORBETT JOHN M;;SCHENK JOSEPH G,,https://lens.org/197-272-356-310-346,Granted Patent,no,0,0,1,1,0,,,85-6,0,0,,,,EXPIRED
73,US,A,US 3337914 A,056-121-113-277-771,1967-08-29,1967,US 51814866 A,1966-01-03,US 51814866 A,1966-01-03,Stacked extrusion die,,NAT DISTILLERS CHEM CORP,OLIVER CORBETT HERBERT;;JOSEPH QUACKENBUSH JOHN,,https://lens.org/056-121-113-277-771,Granted Patent,no,5,22,2,9,0,B29C2791/007;;B29K2105/20;;B29L2031/3462;;B29C48/09;;B29C48/10;;B29C48/1472;;B29C48/151;;B29C48/21;;B29C48/304;;B29C48/335;;B29C48/3363;;B29C48/34;;B29C48/34;;B29L2031/3462;;B29K2105/20;;B29C2791/007;;B29C48/21;;B29C48/1472;;B29C48/10;;B29C48/151;;B29C48/3363;;B29C48/335;;B29C48/304;;B29C48/09,B29C48/34;;B29C48/09;;B29C48/10;;B29C48/151;;B29C48/21;;B29C48/335,,0,0,,,,EXPIRED
74,FR,A,FR 1507091 A,140-236-108-328-962,1967-12-22,1967,FR 69048123 A,1966-12-30,US 51814866 A;;US 52056966 A,1966-01-03,Dispositif de filière d'extrusion à éléments multiples,,NAT DISTILLERS CHEM CORP,CORBETT HERBERT OLIVER;;QUACKENBUSH JOHN JOSEPH,,https://lens.org/140-236-108-328-962,Granted Patent,no,0,1,5,9,0,B29K2105/20;;B29L2031/3462;;B29C48/09;;B29C48/10;;B29C48/151;;B29C48/21;;B29C48/304;;B29C48/335;;B29C48/3363;;B29C48/34;;B29C48/21;;B29C48/34;;B29C48/09;;B29C48/10;;B29C48/151;;B29C48/304;;B29C48/335;;B29C48/3363,B29C48/34;;B29C48/09;;B29C48/10;;B29C48/151;;B29C48/21;;B29C48/335,,0,0,,,,EXPIRED
75,US,A,US 4703694 A,172-568-086-780-641,1987-11-03,1987,US 66066884 A,1984-10-15,US 66066884 A,1984-10-15,Single stage autophage rocket,"An autophage rocket has its casing constructed from KEVLAR-epoxy material which is itself combustible and stores liquid propellant. As the propellant is consumed during flight, the casing is combusted so that the pressure within the casing remains constant. A secondary nozzle is mounted to the outlet end of the rocket and cooperates with a ram-rocket construction to achieve additional impulse. A multiplicity of rocket motors are fed from a single stage tank to enable controlled motion of the rocket.",GRUMMAN AEROSPACE CORP,CORBETT MARSHALL J;;BELISLE JOSEPH A,GRUMMAN AEROSPACE CORPORATION A NY CORP (1984-09-26),https://lens.org/172-568-086-780-641,Granted Patent,yes,14,6,10,10,0,B64G1/002;;B64G1/402;;B64G1/404;;F02K7/18;;F02K9/34;;F02K9/60;;F02K9/72;;B64G1/404;;B64G1/002;;F02K7/18;;F02K9/60;;F02K9/34;;B64G1/402;;F02K9/72,B64G1/00;;F02K9/97;;B64G1/40;;F02K7/18;;F02K9/34;;F02K9/60;;F02K9/72,102/374;;102/348;;102/364;;102/515;;60/253,1,0,,,"Hybrid Air Gulping Rocket Enters its Final Design Phase, Product Engineering, vol. 41, No. 9, Apr. 27, 1970, pp. 18, 19.",EXPIRED
76,GB,A,GB 1141732 A,192-778-369-007-772,1969-01-29,1969,GB 827267 A,1967-02-21,US 52908266 A,1966-02-21,Tubular extrusion coating process,"1,141,732. Coating by extrusion; laminated tubular films. NATIONAL DISTILLERS & CHEMICAL CORP. 21 Feb., 1967 [21 Feb., 1966], No. 8272/67. Headings B5A and B5B. A process for making a coated tubular film comprises extruding a thermoplastic tube 12 from a die 11, collapsing the tube between rollers 13, printing on the outer surface of the tube in a press 16-21, reinflating the tube after passage through rolls 23 and then extruding a transparent thermoplastic coating from an extrusion head 24 on to the outer surface of the tube 12 to encapsulate the printing thereon. The tube is then cooled by an air ring 26 and rolls 29 and collapsed by plates 27, 28 prior to being stored or formed into bags. The initial tube 12 may be laminated, and the outer surface thereof may be treated at a station 14 prior to the printing stage.",NAT DISTILLERS CHEM CORP,QUACKENBUSH JOHN JOSEPH;;CORBETT HERBERT OLIVER,,https://lens.org/192-778-369-007-772,Granted Patent,no,0,3,6,6,0,B32B27/00;;B29C48/09;;B29C48/10;;B29C48/0016;;B29C48/21;;B32B27/00;;B29C48/21;;B29C48/10;;B29C48/09;;B29C48/0016,B29B7/00;;B29C48/09;;B29C48/10;;B29C48/21;;B29C48/32;;B32B27/00,B5A AA2           AA2;;B5A AB18          AB18F;;B5A AT17P         T17P;;B5A A1G1          T17P;;B5A A1G2          T17P;;B5A A1G3A         T17P;;B5A A1G3B         T17P;;B5A A1G3X         T17P;;B5A A1G7AX        T17P;;B5A A1G7C         T17P;;B5A A1R100        -;;B5A A1R14C1X      -;;B5A A1R214H       AA2;;B5A A1R214H       AB18F;;B5A A1R214H       T17P;;B5A A1R29X        -;;B5A A1R314C1X     AA2;;B5A A1R314C1X     AB18F;;B5A A1R314C1X     T17P;;B5A A1R400        AA2;;B5A A1R420        T17P;;B5A A1R429X       AA2;;B5A A1R429X       T17P;;B5A A2A1          T17P;;B5A A2A3          AA2;;B5A A2A3          T17P;;B5A A2B2          AA2;;B5A A2B2          T17P;;B5A A2D1X         T17P;;B5A A2D2          T17P;;B5A A2H6          T17P;;B5A A2P2          T17P;;B5A A2R           T17P;;B5A A20N2         AA2;;B5A A20N4         AA2;;B5A A20N5         AA2;;B5A A20T10        AB18F;;B5A A20T17        AA2;;B5A A20T17        AB18F;;B5A A6            -;;B5B B231          65;;B5B B25Y          65;;B5B B250          65;;B5B B270          65;;B5B B412          65;;B5B B422          65;;B5B B62Y          65,0,0,,,,EXPIRED
77,US,B1,US 6525579 B1,006-469-606-244-20X,2003-02-25,2003,US 40367054 A,1954-01-12,US 40367054 A,1954-01-12,Pulse translational circuits,"
    In a circuit for producing output pulses which correspond to pre-selected voltage pulses occurring in an input signal train; means connected to derive from said input signal train a succession of unidirectional pulses, at least some of which pulses occur in time coincidence with the leading and trailing edges of said pre-selected voltage pulses; means including a one-shot multi-vibrator connected to receive said unidirectional pulses and produce a first series of pulses having a uniform duration less than the duration of said pre-selected voltage pulses, means including a bi-stable multi-vibrator connected to receive and produce from said first series of pulses a second series of pulses equal to one half the number of pulses in said first series occurring in a given time interval, and means including a discriminator circuit connected to receive said first and second series of pulses and derive a third series of pulses which corresponds to said pre-selected voltage pulses occurring in said input signal train. 
",US ATTORNEY GENERAL,MURDOCK BEN JOSEPH;;CORBETT CHARLES K,,https://lens.org/006-469-606-244-20X,Granted Patent,yes,14,0,1,1,0,H03K5/125;;H03K5/125,H03K5/125,327/165;;375/243;;379/362,0,0,,,,EXPIRED
78,US,B2,US 10710146 B2,089-117-026-961-36X,2020-07-14,2020,US 201715785526 A,2017-10-17,US 201715785526 A;;US 201662410497 P,2016-10-20,Fastener and fastening system,"A fastening system includes a fastener having a bolt with a pull portion having at least one pull groove, and an outer sleeve having a head with an inner face, the bolt being inserted within the sleeve. The fastening system includes a fastener installation tool having a puller with at least one tooth and a front face. The inner face of the head of the sleeve is angled at an included angle measured transverse to a longitudinal axis of the fastener, while the front face of the puller of the fastener installation tool is angled at an included angle measured transverse to a longitudinal axis of the puller. The included angles are chosen to match or be substantially the same. The front face of the puller of the fastener installation tool is adapted to engage the inner face of the outer sleeve of the fastener when the fastener installation tool engages the fastener, and the inner face of the outer sleeve facilitates the receipt of the front face of the puller and the alignment of the at least one tooth of the puller with the at least one pull groove of the bolt by allowing the puller to shift forward or backward to facilitate such alignment.",ARCONIC INC,CORBETT ROBERT J;;LEAVELLE JOSEPH Z,HOWMET AEROSPACE INC (2017-10-09),https://lens.org/089-117-026-961-36X,Granted Patent,yes,78,0,3,3,0,B21J15/022;;F16B19/1054;;B21J15/022;;F16B35/04;;B21J15/045;;F16B19/1054;;F16B2019/1009,F16B35/04;;B21J15/02;;B21J15/04;;F16B19/10,,14,0,,,"International Search Report and Written Opinion dated Dec. 22, 2017, issued by the Korean Intellectual Property Office in International Patent Application No. PCT/US2017/056847 entitled “Fastener and Fastening System” (15 pages).;;International Search Report and Written Opinion dated Jul. 18, 2013, issued by the European Patent Office in International Application No. PCT/US2013/036129.;;International Search Report and Written Opinion dated Apr. 21, 2015, issued by the European Patent Office in International Application No. PCT/US2015/012153.;;International Search Report and Written Opinion dated Apr. 28, 2016, issued by the European Patent Office in International Application No. PCT/US2016/014229.;;International Search Report and Written Opinion dated Nov. 30, 2016, issued by the European Patent Office in International Application No. PCT/US2016/054860.;;Alcoa Fastening Systems, “Blind Bolt Engineering Standard”, UAB130-EU, SK12711.;;Alcoa Fastening Systems, “Blind Bolt Engineering Standard”, UAB130-MV, SK12742.;;Huck Fasteners, “Blind Bolt Engineering Standard”, UABP-EU, SK127856.;;Alcoa Fastening Systems, “Blind Bolt Engineering Standard”, UAB6127-EU, SK12770.;;Huck Fasteners, “Blind Bolt Engineering Standard”, USAB100-EU, SK12771.;;Huck Fasteners, “Blind Bolt Engineering Standard”, UAB100-MV, SK12772.;;Alcoa Fastening Systems, “Blind Bolt Engineering Standard”, OUAB130-EU, SK12801.;;Alcoa Fastening Systems, “Blind Bolt Engineering Standard”, OUAB6127-EU, SK12802.;;Alcoa Fastening Systems, “Blind Bolt Engineering Standard”, OUABP-EU, SK12803.",ACTIVE
79,US,A1,US 2018/0107797 A1,108-581-801-272-95X,2018-04-19,2018,US 201615292797 A,2016-10-13,US 201615292797 A;;US 201562240753 P,2015-10-13,SYSTEMS AND METHODS FOR AUTOMATED ROUTE CALCULATION AND DYNAMIC ROUTE UPDATING,"Systems and methods are provided for automated routing in a facility. A system may comprise at least one processor, and a storage medium comprising executable instructions to configure the processor to receive first data associated with a condition of an individual, search a database in communication with the at least one processor to identify second data for a set of milestones associated with the condition, select, based on the set of milestones, a plurality of locations in the facility corresponding to the set of milestones, receive, from the database, third data associated with performance metrics of the plurality of locations, determine a sequence of the set of milestones and a path through the plurality of locations, the path being determined by correlating the performance metrics to milestones in the set of milestones, and generate for display a graphical user interface illustrating the determined sequence and determined path.",TELETRACKING TECH INC,SCHUCK JOSEPH C;;CORBETT CHELSIE M,,https://lens.org/108-581-801-272-95X,Patent Application,yes,6,4,3,5,0,G16H50/20;;G16H40/20;;G16H40/63;;G16H40/20;;G06F16/245;;G16H50/20,G06F17/30;;G06F19/00,,0,0,,,,ACTIVE
80,DE,A1,DE 2223603 A1,126-584-950-673-147,1972-11-30,1972,DE 2223603 A,1972-05-15,US 14531471 A,1971-05-20,Joining two plastics components of a medical device - - using intermediate metal part between components and then melt form,"Process for joining two separate components of a medical device (e.g. a catheter) consisting of similar plastics material, is characterised by shaping the components to be joined in such a way that they fit in to each other; placing a metal part between the fitted components; placing the whole into an induction heating device; applying heat of induction to the ends of the components and the metal part so as to heat same and soften the overlapping ends; removing the components from the heating device; and cooling so as to effect a medically acceptable joint.",SHERWOOD MEDICAL IND INC,H CORBETT JOSEPH;;I HUGGINS JOHN,,https://lens.org/126-584-950-673-147,Patent Application,no,0,6,1,1,0,A61M39/10;;B29C65/3676;;B29C59/02;;B29C65/362;;B29C66/1222;;B29C66/1224;;B29C66/12441;;B29C66/12469;;B29C66/305;;B29C66/306;;B29C66/5344;;B29C66/612;;B29C66/71;;B29C66/91641;;B29K2023/12;;B29L2031/7542;;B29L2031/7544,A61M39/10;;B29C59/02;;B29C65/00;;B29C65/36,,0,0,,,,DISCONTINUED
81,US,A9,US 2019/0155990 A9,185-963-541-023-135,2019-05-23,2019,US 201615292797 A,2016-10-13,US 201615292797 A;;US 201562240753 P,2015-10-13,SYSTEMS AND METHODS FOR AUTOMATED ROUTE CALCULATION AND DYNAMIC ROUTE UPDATING,"Systems and methods are provided for automated routing in a facility. A system may comprise at least one processor, and a storage medium comprising executable instructions to configure the processor to receive first data associated with a condition of an individual, search a database in communication with the at least one processor to identify second data for a set of milestones associated with the condition, select, based on the set of milestones, a plurality of locations in the facility corresponding to the set of milestones, receive, from the database, third data associated with performance metrics of the plurality of locations, determine a sequence of the set of milestones and a path through the plurality of locations, the path being determined by correlating the performance metrics to milestones in the set of milestones, and generate for display a graphical user interface illustrating the determined sequence and determined path.",TELETRACKING TECH INC,SCHUCK JOSEPH C;;CORBETT CHELSIE M,TELETRACKING TECHNOLOGIES INC (2021-05-05),https://lens.org/185-963-541-023-135,Amended Application,yes,0,0,3,5,0,G16H50/20;;G16H40/20;;G16H40/63;;G16H40/20;;G06F16/245;;G16H50/20,G06F19/00;;G06F17/30,,0,0,,,,ACTIVE
82,US,A1,US 2009/0210313 A1,106-398-970-988-862,2009-08-20,2009,US 7040508 A,2008-02-19,US 7040508 A,2008-02-19,Method for environmentally-friendly shipping,"A method for environmentally-friendly shipping including requesting a shipment of goods, identifying available shipping options, analyzing the available shipping options, presenting the available shipping options, selecting one of the available shipping options and shipping the shipment of goods via the selected available shipping option. The method also includes considering one or more environmental impact measures.",WINEBRAKE JAMES J;;CORBETT JR JAMES JOSEPH,WINEBRAKE JAMES J;;CORBETT JR JAMES JOSEPH,,https://lens.org/106-398-970-988-862,Patent Application,yes,9,16,1,1,0,G06Q10/08;;G06Q30/0601;;G06Q10/08;;G06Q30/0601,G06Q99/00,705/26,0,0,,,,DISCONTINUED
83,EP,A2,EP 0149992 A2,011-601-387-405-849,1985-07-31,1985,EP 85100009 A,1985-01-01,US 57269684 A,1984-01-20,Air flow control apparatus.,"@§ An air flow control apparatus is disclosed which is characterized by essentially zero leakage in its closed position, and by minimal air resistance in its open position. The apparatus includes a housing (12) having an interior framework which defines a plurality of troughs (21) of V-shaped cross section, and with each side of each trough including an opening (34). A closure is associated with each trough, which includes a pair of pivotally mounted plates (39, 40) which are movable between a spread apart position covering and closing the openings in the trough, and a collapsed position wherein the plates are substantially aligned with each other and spaced from the associated openings to permit free air flow therethrough. A continuous upstanding peripheral flange (28, 30, 31, 32) surrounds each opening, and a resilient pad (44) is mounted on each plate of each closure so that the resilient pad mates with the outer edge of the flange when the closure is moved to the spread apart position, and so that the outer edge presses into the resilient pad to effect an air tight seal. The axis (41) of the pivotal plates is adjustable to permit the pressure between the plates and outer edge of the flanges to be uniform about the periphery of each opening.",FLANDERS FILTERS,WOOD JOSEPH ARTHUR;;PEEBLES WILLIAM CORBETT JR,,https://lens.org/011-601-387-405-849,Patent Application,yes,0,4,5,5,0,F16K1/165;;F24F13/1406;;F24F13/1413;;F24F13/1426;;F24F2013/1473;;Y10T137/87113;;Y10T137/87434;;Y10T137/87113;;Y10T137/87434;;F24F13/1426;;F16K1/165;;F24F13/1406;;F24F2013/1473;;F24F13/1413,F16K1/16;;F24F13/14;;F24F13/15,,0,0,,,,DISCONTINUED
84,EP,A3,EP 0149992 A3,096-786-781-231-696,1987-01-21,1987,EP 85100009 A,1985-01-01,US 57269684 A,1984-01-20,AIR FLOW CONTROL APPARATUS,"@§ An air flow control apparatus is disclosed which is characterized by essentially zero leakage in its closed position, and by minimal air resistance in its open position. The apparatus includes a housing (12) having an interior framework which defines a plurality of troughs (21) of V-shaped cross section, and with each side of each trough including an opening (34). A closure is associated with each trough, which includes a pair of pivotally mounted plates (39, 40) which are movable between a spread apart position covering and closing the openings in the trough, and a collapsed position wherein the plates are substantially aligned with each other and spaced from the associated openings to permit free air flow therethrough. A continuous upstanding peripheral flange (28, 30, 31, 32) surrounds each opening, and a resilient pad (44) is mounted on each plate of each closure so that the resilient pad mates with the outer edge of the flange when the closure is moved to the spread apart position, and so that the outer edge presses into the resilient pad to effect an air tight seal. The axis (41) of the pivotal plates is adjustable to permit the pressure between the plates and outer edge of the flanges to be uniform about the periphery of each opening.","FLANDERS FILTERS, INC.","WOOD, JOSEPH ARTHUR;;PEEBLES, WILLIAM CORBETT, JR.",,https://lens.org/096-786-781-231-696,Search Report,yes,2,0,5,5,0,F16K1/165;;F24F13/1406;;F24F13/1413;;F24F13/1426;;F24F2013/1473;;Y10T137/87113;;Y10T137/87434;;Y10T137/87113;;Y10T137/87434;;F24F13/1426;;F16K1/165;;F24F13/1406;;F24F2013/1473;;F24F13/1413,F16K1/16;;F24F13/14;;F24F13/15,,0,0,,,,DISCONTINUED
85,WO,A1,WO 2022/098518 A1,193-307-424-174-588,2022-05-12,2022,US 2021/0056034 W,2021-10-21,US 202017088094 A,2020-11-03,PRETREATED MATERIAL FOR LASER SINTERING,"Disclosed is a composition, in particular to a building material for an additive manufacturing process, wherein the composition is treated by heat. Further, the present invention is directed to a process for the manufacturing of the inventive composition and to a device comprising the inventive composition and the use of the inventive composition.",EOS OF NORTH AMERICA INC,BOOTH RICHARD B;;CORBETT RYAN A;;TUCKER JOSEPH,,https://lens.org/193-307-424-174-588,Patent Application,yes,3,0,4,4,0,C08L23/12;;B33Y70/00;;B29C64/314;;B33Y40/00;;B29C64/153;;B29C64/165;;B33Y10/00;;B29C64/153;;B29C64/268;;B33Y70/00;;C08L23/14;;B29K2995/0097;;B33Y10/00;;B29K2995/004;;B29K2995/0039;;B29K2023/12;;C08L23/12;;B33Y40/00,B29C35/02;;B22F3/105;;B29C35/08;;B32B5/16,,4,4,053-604-343-798-81X;;045-084-537-364-976;;001-217-241-055-533;;117-075-163-468-468,10.1007/bf01184599;;10.1002/pen.760030407;;10.3390/polym10121293;;30961218;;pmc6401993;;10.1016/0032-3861(63)90025-9,"FRONTINI P. M., FAVE A.: ""The effect of annealing temperature on the fracture performance of isotactic polypropylene"", JOURNAL OF MATERIAL SCIENCE, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, vol. 30, no. 9, 1 May 1995 (1995-05-01), Dordrecht , pages 2446 - 2454, XP055939082, ISSN: 0022-2461, DOI: 10.1007/BF01184599;;BECK D L, HILTZ A A, KNOX J R: ""Glass transitions in polypropylene"", SPE TRANSACTIONS, vol. 3, no. 4, 1 October 1963 (1963-10-01), pages 279 - 285, XP055939117;;FLORES ITUARTE IñIGO, WIIKINKOSKI OLLI, JANSSON ANTON: ""Additive Manufacturing of Polypropylene: A Screening Design of Experiment Using Laser-Based Powder Bed Fusion"", POLYMERS, vol. 10, no. 12, pages 1293, XP055831453, DOI: 10.3390/polym10121293;;FARROW, G.: ""Crystallinity, 'crystallite size' and melting point of polypropylene"", POLYMER, ELSEVIER, AMSTERDAM, NL, vol. 4, 1 January 1963 (1963-01-01), AMSTERDAM, NL, pages 191 - 197, XP024115175, ISSN: 0032-3861, DOI: 10.1016/0032-3861(63)90025-9",PENDING
86,WO,A1,WO 2024/017932 A1,145-103-333-108-440,2024-01-25,2024,EP 2023069987 W,2023-07-19,US 202263391068 P;;EP 22189142 A,2022-07-21,A PROCESS FOR CAPTURING CO2 FROM AIR,"The present invention provides a process for capturing carbon dioxide (CO 2 ) from a CO 2 -containing gas stream, in particular air, the process at least comprising the steps of: (a) providing a CO 2 -containing gas stream (10); (b) contacting the CO 2 -containing gas stream (10) provided in step (a) in a contactor (2) with a liquid solvent (30) thereby obtaining a CO 2 -depleted gas stream (20) and a first CO 2 -loaded solvent stream (40); (c) splitting the first CO 2 -loaded solvent stream (40) obtained in step (b), thereby obtaining a second CO 2 -loaded solvent stream (70) and a third CO 2 -loaded solvent stream (50); (d) temporarily storing the second CO 2 -loaded solvent stream (70) obtained in step (c) in a first tank (3); (e) passing CO 2 -loaded solvent (80) from the first tank (3) to an electrochemical device (4); (f) subjecting the CO 2 -loaded solvent (80) in the electrochemical device (4) to an electrochemical reaction thereby obtaining a gas/liquid mixture (100); (g) separating the gas/liquid mixture (100) obtained in step (f) in a gas/liquid separator (5) thereby obtaining a gas stream (130) and a first liquid stream (140); (h) temporarily storing the first liquid stream (140) obtained in step (g) in a second tank (6); (i) recycling first liquid (160) from the second tank (6) to the contactor (2) for use as the liquid solvent (30) in step (b).",SHELL INT RESEARCH;;SHELL USA INC,VERMA SUMIT;;BALAJI SAYEE PRASAAD;;CORBETT PAUL JOSEPH,,https://lens.org/145-103-333-108-440,Patent Application,yes,2,0,1,1,0,B01D53/1425;;B01D53/1475;;B01D2251/304;;B01D2251/306;;B01D2251/604;;B01D2251/606;;B01D2252/10;;B01D2258/06,B01D53/14;;C01B32/50,,8,5,087-616-477-852-043;;045-463-297-323-365;;042-178-298-544-790;;087-616-477-852-043;;180-958-653-817-046,10.1021/acs.iecr.9b05641;;10.1016/j.joule.2018.05.006;;10.1098/rsta.2012.0137;;22869804;;10.1021/acs.iecr.9b05641;;10.1021/acsenergylett.9b00975,"SABATINO FRANCESCO ET AL: ""Evaluation of a Direct Air Capture Process Combining Wet Scrubbing and Bipolar Membrane Electrodialysis"", vol. 59, no. 15, 15 January 2020 (2020-01-15), pages 7007 - 7020, XP093014233, ISSN: 0888-5885, Retrieved from the Internet <URL:http://pubs.acs.org/doi/pdf/10.1021/acs.iecr.9b05641> [retrieved on 20200115], DOI: 10.1021/acs.iecr.9b05641;;M.D. EISAMAN ET AL.: ""Energy-efficient electrochemical CO capture from the atmosphere"", TECHNICAL PROCEEDINGS OF THE 2009 CLEAN TECHNOLOGY CONFERENCE AND TRADE SHOW, May 2009 (2009-05-01), pages 3 - 7;;D.W. KEITH ET AL.: ""A process for capturing CO from the atmosphere"", JOULE, vol. 2, no. 8, 2018, pages 1573 - 1594, XP055611238, DOI: 10.1016/j.joule.2018.05.006;;G. HOLMES ET AL.: ""An air-liquid contactor for large-scale capture of CO from air"", PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY A, vol. 370, 2012, pages 4380 - 4403;;F. SABATINO ET AL.: ""Evaluation of a direct air capture process combining wet scrubbing and bipolar membrane electrodialysis"", INDUSTRIAL ENGINEERING CHEMISTRY RESEARCH, vol. 59, no. 15, 2020, pages 7007 - 7020, XP093014233, DOI: 10.1021/acs.iecr.9b05641;;Y.C. LEE ET AL.: ""CO electroreduction from carbonate electrolyte"", ACS ENERGY LETTERS, vol. 4, no. 6, 2019, pages 1427 - 1431;;M.D. EISAMAN ET AL., TECHNICAL PROCEEDINGS OF THE 2009 CLEAN TECHNOLOGY CONFERENCE AND TRADE SHOW;;Y.C. LEE ET AL., ACS ENERGY LETTERS",PENDING
87,CN,A,CN 116710255 A,052-971-341-102-055,2023-09-05,2023,CN 202180089075 A,2021-10-21,US 202017088094 A;;US 2021/0056034 W,2020-11-03,Pretreated material for laser sintering,"A composition, in particular a building material for use in additive manufacturing processes, is disclosed wherein the composition is treated by heating. Furthermore, the invention relates to a method for manufacturing the composition according to the invention and to a device comprising the composition according to the invention and to the use of the composition according to the invention.",EOS CORP NORTH AMERICA,BOOTH RICHARD B;;CORBETT RYAN A;;TUCKER JOSEPH,,https://lens.org/052-971-341-102-055,Patent Application,no,0,0,4,4,0,C08L23/12;;B33Y70/00;;B29C64/314;;B33Y40/00;;B29C64/153;;B29C64/165;;B33Y10/00;;B29C64/153;;B29C64/268;;B33Y70/00;;C08L23/14;;B29K2995/0097;;B33Y10/00;;B29K2995/004;;B29K2995/0039;;B29K2023/12;;C08L23/12;;B33Y40/00,B29C35/08,,0,0,,,,PENDING
88,WO,A1,WO 2018/231979 A1,180-615-098-465-98X,2018-12-20,2018,US 2018/0037328 W,2018-06-13,US 201715622270 A,2017-06-14,VORTEX RECIRCULATING COMBUSTION BURNER HEAD,"A vortex recirculating combustion head for a burner, including: a housing having a through-bore, an upstream end, and a downstream end, the upstream and downstream ends arranged at opposite sides of the through-bore, the housing configured to receive combustion air; a primary fuel inlet arranged adjacent to the upstream end of the housing configured to introduce a primary fuel stream into the housing; a secondary fuel inlet arranged downstream of the primary fuel inlet configured to introduce a secondary fuel stream into the housing; a flame retention head including a diffuser plate secured to the downstream end of the housing, the diffuser plate including a plurality of openings, a plurality of fins, and a ring; and, an extension member secured to an exterior surface of the flame retention head.",WEBSTER COMBUSTION TECH LLC;;BEARD JUSTIN J;;CORBETT EDWARD;;SONDERVAN JOACHIM P;;VANDERPOOL JOSEPH B,BEARD JUSTIN;;CORBETT EDWARD;;SONDERVAN JOACHIM;;VANDERPOOL JOSEPH,,https://lens.org/180-615-098-465-98X,Patent Application,yes,6,0,15,15,0,F23D14/24;;F23D14/70;;F23D2900/11402;;F23D2900/14241;;F23D14/24;;F23D14/70;;F23D14/24;;F23D14/70,F23C1/00;;F23C9/00;;F23C9/06;;F23D11/40,,1,0,,,See also references of EP 3638950A4,PENDING
89,EP,A1,EP 4217174 A1,135-126-502-793-987,2023-08-02,2023,EP 21889834 A,2021-10-21,US 202017088094 A;;US 2021/0056034 W,2020-11-03,PRETREATED MATERIAL FOR LASER SINTERING,,EOS OF NORTH AMERICA INC,BOOTH RICHARD B;;CORBETT RYAN A;;TUCKER JOSEPH,,https://lens.org/135-126-502-793-987,Patent Application,yes,0,0,4,4,0,C08L23/12;;B33Y70/00;;B29C64/314;;B33Y40/00;;B29C64/153;;B29C64/165;;B33Y10/00;;B29C64/153;;B29C64/268;;B33Y70/00;;C08L23/14;;B29K2995/0097;;B33Y10/00;;B29K2995/004;;B29K2995/0039;;B29K2023/12;;C08L23/12;;B33Y40/00,B29C35/02;;B22F3/105;;B29C35/08;;B32B5/16,,0,0,,,,PENDING
90,US,A1,US 2022/0134642 A1,133-252-800-181-57X,2022-05-05,2022,US 202017088094 A,2020-11-03,US 202017088094 A,2020-11-03,Pretreated Material for Laser Sintering,"Disclosed is a composition, in particular to a building material for an additive manufacturing process, wherein the composition is treated by heat. Further, the present invention is directed to a process for the manufacturing of the inventive composition and to a device comprising the inventive composition and the use of the inventive composition.",EOS OF NORTH AMERICA INC,BOOTH RICHARD B;;CORBETT RYAN A;;TUCKER JOSEPH,EOS OF NORTH AMERICA INC (2020-11-05),https://lens.org/133-252-800-181-57X,Patent Application,yes,20,0,4,4,0,C08L23/12;;B33Y70/00;;B29C64/314;;B33Y40/00;;B29C64/153;;B29C64/165;;B33Y10/00;;B29C64/153;;B29C64/268;;B33Y70/00;;C08L23/14;;B29K2995/0097;;B33Y10/00;;B29K2995/004;;B29K2995/0039;;B29K2023/12;;C08L23/12;;B33Y40/00,B29C64/153;;B29C64/268;;B33Y70/00;;C08L23/12;;C08L23/14,,1,0,,,"CN 107304270 A (October 31, 2017); machine translation. (Year: 2017)",PENDING
91,US,B2,US 6901679 B2,125-697-373-496-041,2005-06-07,2005,US 69693103 A,2003-10-30,US 69693103 A;;US 42378302 P,2002-11-05,Sprinkler spacer system,"A spacer system for attachment to a sprinkler to prevent the positioning of the sprinkler too close to a sidewalk or curb, etc., including a spacer which can be attached to the sprinkler, and an elongated stake having a notch for receiving and holding the spacer. Also described is a tool for use in installing the stake in the ground.",CORBETT JOSEPH CRAIG;;BERSONNET GEORGE B.;;MOHR HARVEY L.;;MOHR KEVIN H.;;CORBETT NATALIE H.,CORBETT JOSEPH CRAIG;;BERSONNET GEORGE B;;MOHR HARVEY L;;MOHR KEVIN H;;CORBETT NATALIE H,CORBETT JOSEPH CRAIG (2003-10-24),https://lens.org/125-697-373-496-041,Granted Patent,yes,20,4,2,2,0,B05B15/16;;B05B15/62;;B05B15/62;;B05B15/16,B05B15/00;;B05B15/06,33/624;;X 33  1 H;;33/645;;239/273,0,0,,,,EXPIRED
92,US,A1,US 2004/0089739 A1,116-462-563-835-224,2004-05-13,2004,US 69693103 A,2003-10-30,US 69693103 A;;US 42378302 P,2002-11-05,Sprinkler spacer system,"
   A spacer system for attachment to a sprinkler to prevent the positioning of the sprinkler too close to a sidewalk or curb, etc., including a spacer which can be attached to the sprinkler, and an elongated stake having a notch for receiving and holding the spacer. Also described is a tool for use in installing the stake in the ground. 
",CORBETT JOSEPH CRAIG;;BERSONNET GEORGE B.;;MOHR HARVEY L.;;MOHR KEVIN H.;;CORBETT NATALIE H.,CORBETT JOSEPH CRAIG;;BERSONNET GEORGE B;;MOHR HARVEY L;;MOHR KEVIN H;;CORBETT NATALIE H,CORBETT JOSEPH CRAIG (2003-10-24),https://lens.org/116-462-563-835-224,Patent Application,yes,23,2,2,2,0,B05B15/16;;B05B15/62;;B05B15/62;;B05B15/16,B05B15/00;;B05B15/06,239/271;;239/272;;239/273,0,0,,,,EXPIRED
93,JP,A,JP 2010253280 A,176-711-745-972-36X,2010-11-11,2010,JP 2010130543 A,2010-06-07,US 6085997 P,1997-10-02,TRANSANAL ANASTOMOSIS RING INSERTION DEVICE,"<P>PROBLEM TO BE SOLVED: To provide an applicator insertion device for surgically inserting a BAR (biofragmentable anastomosis ring). <P>SOLUTION: The device is provided for transanally inserting through the lower bowel one of two biofragmentable anastomosis rings (BARs). The device includes a curved shaft with a handle 13 and an actuating knob 15 at the proximal end, a nest formed at the distal end of the shaft adapted to mount a BAR carrier assembly 11, and a second passageway formed through the shaft that terminates at a distal open end formed through the nest. The BAR carrier assembly includes unitary male and female members that collectively comprise the BAR, male and female carriers for mounting the respective unitary members, and a collet for locking in and releasing the BAR from the BAR carrier assembly once both unitary members are secured to respective open ends of the upper and lower bowel sections. <P>COPYRIGHT: (C)2011,JPO&INPIT",COVIDIEN GROUP SARL,PHILLIPS PAUL JOSEPH;;CORBETT ROBERT KELLY;;CONNERS JOHN A,,https://lens.org/176-711-745-972-36X,Patent Application,no,0,2,14,14,0,A61B17/1114;;A61B2017/00004,A61B17/11;;A61B17/00,,0,0,,,,PENDING
94,US,A1,US 2005/0074105 A1,171-121-750-811-964,2005-04-07,2005,US 82648504 A,2004-04-16,US 82648504 A;;US 37819003 A;;US 16190902 A;;US 87243901 A;;US 56533100 A;;US 69655496 A,1996-08-14,Methods for displaying caller identification information on an integrated display/telephone system capable of displaying images,"Methods for displaying caller identification information on an integrated display/telephone system capable of displaying images are disclosed. One or more signals are received and one or more images are displayed on a display of the integrated display/telephone system. An incoming tclcphone call is received with the integrated display/telephone system, and data corresponding to the incoming telephone call is received by the integrated display/telephone systern. A caller identification display signal is generated, and the caller identification display signal is based on the one or more received signals and the data corresponding to the incoming telephone call received by the integrated display/telephone system. The caller identification display signal includes the one or more received signals and signals from a generator that generates character signals and background display signals. The character signals are generated responsive to the data received with the incoming call, and in response to an incoming telephone call, caller identification information is displayed on. the display along with the displayed one or more images.",CORBETT JOSEPH C.;;FLETCHER WILLIAM I.;;LOUDERMILK ALAN R.,CORBETT JOSEPH C;;FLETCHER WILLIAM I;;LOUDERMILK ALAN R,SAMSUNG ELECTRONICS CO. LTD (2006-09-15),https://lens.org/171-121-750-811-964,Patent Application,yes,15,22,9,9,0,H04L12/66;;H04M1/57;;H04M1/6505;;H04M1/663;;H04M3/42127;;H04M3/533;;H04M3/54;;H04M11/06;;H04M2203/1016;;H04N7/147;;H04M11/06;;H04M3/54;;H04N7/147;;H04M3/42127;;H04M2203/1016;;H04M1/57;;H04M3/533;;H04L12/66;;H04M1/6505;;H04M1/663,H04M1/57;;H04M1/65;;H04M1/663;;H04M3/42;;H04M3/533;;H04M3/54;;H04M11/06;;H04N7/14,379/142.16;;379/142.01;;379/93.23,0,0,,,,EXPIRED
95,CA,C,CA 2275403 C,001-130-813-764-14X,2007-04-10,2007,CA 2275403 A,1998-10-01,EP 9806265 W;;US 6085997 P,1997-10-02,TRANSANAL ANASTOMOSIS RING INSERTION DEVICE,"The invention relates to a device for transanally inserting through the lower bowel one of two unitary members of a Biofragmentable Anastomosis Ring (BAR). The device comprises a curved shaft with a handle and an actuating knob at the proximal end, a nest formed at the distal end of the shaft adapted to mount a BAR carrier assembly, and a second passageway formed through the shaft that terminates at a distal open end formed through the nest. The BAR carrier assembly includes unitary male and female members that collectively comprise the BAR, male and female carriers for mounting the respective unitary member, and a collet for locking in and releasing the BAR from the BAR carrier assembly once both unitary members are secured to respective open ends of the upper and lower bowel section. The BAR Carrier Assembly is actuatable in one of three positions: open, closed, and released.",TYCO GROUP SARL,PHILLIPS PAUL JOSEPH;;CORBETT ROBERT KELLY;;CONNERS JOHN A,,https://lens.org/001-130-813-764-14X,Granted Patent,no,0,0,14,14,0,A61B17/1114;;A61B2017/00004,A61B17/11;;A61B17/00,,0,0,,,,EXPIRED
96,EP,B1,EP 0941034 B1,129-728-431-964-953,2004-05-26,2004,EP 98951487 A,1998-10-01,EP 9806265 W;;US 6085997 P,1997-10-02,TRANSANAL ANASTOMOSIS RING INSERTION DEVICE,"The invention relates to a device for transanally inserting through the lower bowel one of two unitary members of a Biofragmentable Anastomosis Ring (BAR). The device comprises a curved shaft with a handle and an actuating knob at the proximal end, a nest formed at the distal end of the shaft adapted to mount a BAR carrier assembly, and a second passageway formed through the shaft that terminates at a distal open end formed through the nest. The BAR carrier assembly includes unitary male and female members that collectively comprise the BAR, male and female carriers for mounting the respective unitary member, and a collet for locking in and releasing the BAR from the BAR carrier assembly once both unitary members are secured to respective open ends of the upper and lower bowel section. The BAR Carrier Assembly is actuatable in one of three positions: open, closed, and released. Once secured to the upper bowel section, the surgeon attaches the male carrier with its attached male member to the BAR Carrier Assembly, thus placing the Assembly in the open position. The surgeon then places the BAR Carrier Assembly in the closed position by mating the male member to the female member seated in the nest. Once in the closed position, the surgeon places the BAR Carrier Assembly in the released position by actuating the insertion device and releasing the mated unitary members of the BAR from the BAR Carrier Assembly and withdrawing the insertion device from the lower bowel.",SHERWOOD SERV AG,PHILLIPS PAUL JOSEPH;;CORBETT ROBERT KELLY;;CONNERS JOHN A,SHERWOOD SERVICES AG (2004-08-02),https://lens.org/129-728-431-964-953,Granted Patent,yes,4,2,14,14,0,A61B17/1114;;A61B2017/00004,A61B17/00;;A61B17/11,,0,0,,,,EXPIRED
97,US,B2,US 6731727 B2,161-924-708-908-46X,2004-05-04,2004,US 37819003 A,2003-03-03,US 37819003 A;;US 16190902 A;;US 87243901 A;;US 56533100 A;;US 69655496 A,1996-08-14,Methods for displaying caller identification information on an integrated display/telephone system capable of displaying images,"
    Methods for displaying caller identification information on an integrated display/telephone system capable of displaying images are disclosed. One or more signals are received and one or more images are displayed on a display of the integrated display/telephone system. An incoming telephone call is received with the integrated display/telephone system, and data corresponding to the incoming telephone call is received with the incoming telephone call. A caller identification display signal in generated, and the caller identification display signal is based on the one or more received signals and the data received with the incoming telephone call. The caller identification display signal includes the one more received signals and signals from a generator that generates character signals and background display signals. The character signals are generated responsive to the data received with the incoming call, and in response to an incoming telephone call, caller identification is displayed on the display along with the displayed one or more images. 
",CORBETT JOSEPH C;;FLETCHER WILLIAM I;;LOUDERMILK ALAN R,CORBETT JOSEPH C;;FLETCHER WILLIAM I;;LOUDERMILK ALAN R,SAMSUNG ELECTRONICS CO. LTD (2006-09-15),https://lens.org/161-924-708-908-46X,Granted Patent,yes,17,28,9,9,0,H04L12/66;;H04M1/57;;H04M1/6505;;H04M1/663;;H04M3/42127;;H04M3/533;;H04M3/54;;H04M11/06;;H04M2203/1016;;H04N7/147;;H04M11/06;;H04M3/54;;H04N7/147;;H04M3/42127;;H04M2203/1016;;H04M1/57;;H04M3/533;;H04L12/66;;H04M1/6505;;H04M1/663,H04M1/57;;H04M1/65;;H04M1/663;;H04M3/42;;H04M3/533;;H04M3/54;;H04M11/06;;H04N7/14,379/93.35;;379/93.23;;379/142.04;;379/142.17,0,0,,,,EXPIRED
98,US,A1,US 2002/0021790 A1,088-093-283-983-455,2002-02-21,2002,US 87243901 A,2001-06-01,US 87243901 A;;US 56533100 A,2000-05-05,Video caller identification systems and methods,"
   Circuits and methods for determining the caller identification for an incoming call and for displaying such caller identification information on a video display device such as a television. A caller identification line modem determines the caller identification information, a control processor translates and/or inputs such caller identification information to a video circuit for displaying the caller identification information. Various methods for so displaying caller identification information are provided, including overlaying such information on an input video signal such as for a predetermined interval of time, generating a separate caller identification video signal, which may be placed, for example, on an unused television channel. The caller identification circuits and methods may be integrated or combined with various advanced television, video and/or telephony functions. An advanced remote control unit may be provided so that the user may determine from the video/television screen the identity of the caller, and then forward the call to a voice messaging system, forward the call to another line, answer the call on a video phone or answer the call on a separate telephone. The caller identification circuit may be provided with programmable intelligence so that incoming calls may not only be displayed on the video/television screen, but also may be desirably processed depending on the identity of the particular caller. 
",CORBETT JOSEPH C.;;FLETCHER WILLIAM I.;;LOUDERMILK ALAN R.,CORBETT JOSEPH C;;FLETCHER WILLIAM I;;LOUDERMILK ALAN R,SAMSUNG ELECTRONICS CO. LTD (2006-09-15),https://lens.org/088-093-283-983-455,Patent Application,yes,0,23,9,9,0,H04L12/66;;H04M1/57;;H04M1/6505;;H04M1/663;;H04M3/42127;;H04M3/533;;H04M3/54;;H04M11/06;;H04M2203/1016;;H04N7/147;;H04M11/06;;H04M3/54;;H04N7/147;;H04M3/42127;;H04M2203/1016;;H04M1/57;;H04M3/533;;H04L12/66;;H04M1/6505;;H04M1/663,H04M1/57;;H04M1/65;;H04M1/663;;H04M3/42;;H04M3/533;;H04M3/54;;H04M11/06;;H04N7/14,379/93.23,0,0,,,,EXPIRED
99,ES,T3,ES 2218861 T3,007-144-759-756-143,2004-11-16,2004,ES 98951487 T,1998-10-01,US 6085997 P,1997-10-02,DISPOSITIVO DE INSERCION DE UN ANILLO DE ANASTOMOSIS POR VIA ANAL.,"The invention relates to a device for transanally inserting through the lower bowel one of two unitary members of a Biofragmentable Anastomosis Ring (BAR). The device comprises a curved shaft with a handle and an actuating knob at the proximal end, a nest formed at the distal end of the shaft adapted to mount a BAR carrier assembly, and a second passageway formed through the shaft that terminates at a distal open end formed through the nest. The BAR carrier assembly includes unitary male and female members that collectively comprise the BAR, male and female carriers for mounting the respective unitary member, and a collet for locking in and releasing the BAR from the BAR carrier assembly once both unitary members are secured to respective open ends of the upper and lower bowel section. The BAR Carrier Assembly is actuatable in one of three positions: open, closed, and released. Once secured to the upper bowel section, the surgeon attaches the male carrier with its attached male member to the BAR Carrier Assembly, thus placing the Assembly in the open position. The surgeon then places the BAR Carrier Assembly in the closed position by mating the male member to the female member seated in the nest. Once in the closed position, the surgeon places the BAR Carrier Assembly in the released position by actuating the insertion device and releasing the mated unitary members of the BAR from the BAR Carrier Assembly and withdrawing the insertion device from the lower bowel.",SHERWOOD SERV AG,PHILLIPS PAUL JOSEPH;;CORBETT ROBERT KELLY;;CONNERS JOHN A,,https://lens.org/007-144-759-756-143,Granted Patent,no,0,1,14,14,0,A61B17/1114;;A61B2017/00004,A61B17/00;;A61B17/11,,0,0,,,,EXPIRED
100,US,A1,US 2003/0138083 A1,132-917-760-646-367,2003-07-24,2003,US 37819003 A,2003-03-03,US 37819003 A;;US 16190902 A;;US 87243901 A;;US 56533100 A;;US 69655496 A,1996-08-14,Video caller identification systems and methods,"
   Circuits and methods for determining the caller identification for an incoming call and for displaying such caller identification information on a video display device such as a television. A caller identification line modem determines the caller identification information, a control processor translates and/or inputs such caller identification information to a video circuit for displaying the caller identification information. Various methods for so displaying caller identification information are provided, including overlaying such information on an input video signal such as for a predetermined interval of time, generating a separate caller identification video signal, which may be placed, for example, on an unused television channel. The caller identification circuits and methods may be integrated or combined with various advanced television, video and/or telephony functions. An advanced remote control unit may be provided so that the user may determine from the video/television screen the identity of the caller, and then forward the call to a voice messaging system, forward the call to another line, answer the call on a video phone or answer the call on a separate telephone. The caller identification circuit may be provided with programmable intelligence so that incoming calls may not only be displayed on the video/television screen, but also may be desirably processed depending on the identity of the particular caller. 
",CORBETT JOSEPH C.;;FLETCHER WILLIAM I.;;LOUDERMILK ALAN R.,CORBETT JOSEPH C;;FLETCHER WILLIAM I;;LOUDERMILK ALAN R,SAMSUNG ELECTRONICS CO. LTD (2006-09-15),https://lens.org/132-917-760-646-367,Patent Application,yes,0,3,9,9,0,H04L12/66;;H04M1/57;;H04M1/6505;;H04M1/663;;H04M3/42127;;H04M3/533;;H04M3/54;;H04M11/06;;H04M2203/1016;;H04N7/147;;H04M11/06;;H04M3/54;;H04N7/147;;H04M3/42127;;H04M2203/1016;;H04M1/57;;H04M3/533;;H04L12/66;;H04M1/6505;;H04M1/663,H04M1/57;;H04M1/65;;H04M1/663;;H04M3/42;;H04M3/533;;H04M3/54;;H04M11/06;;H04N7/14,379/93.23;;348/14.01;;379/142.01,0,0,,,,EXPIRED
101,EP,A1,EP 0941034 A1,009-019-248-161-180,1999-09-15,1999,EP 98951487 A,1998-10-01,EP 9806265 W;;US 6085997 P,1997-10-02,TRANSANAL ANASTOMOSIS RING INSERTION DEVICE,"The invention relates to a device for transanally inserting through the lower bowel one of two unitary members of a Biofragmentable Anastomosis Ring (BAR). The device comprises a curved shaft with a handle and an actuating knob at the proximal end, a nest formed at the distal end of the shaft adapted to mount a BAR carrier assembly, and a second passageway formed through the shaft that terminates at a distal open end formed through the nest. The BAR carrier assembly includes unitary male and female members that collectively comprise the BAR, male and female carriers for mounting the respective unitary member, and a collet for locking in and releasing the BAR from the BAR carrier assembly once both unitary members are secured to respective open ends of the upper and lower bowel section. The BAR Carrier Assembly is actuatable in one of three positions: open, closed, and released. Once secured to the upper bowel section, the surgeon attaches the male carrier with its attached male member to the BAR Carrier Assembly, thus placing the Assembly in the open position. The surgeon then places the BAR Carrier Assembly in the closed position by mating the male member to the female member seated in the nest. Once in the closed position, the surgeon places the BAR Carrier Assembly in the released position by actuating the insertion device and releasing the mated unitary members of the BAR from the BAR Carrier Assembly and withdrawing the insertion device from the lower bowel.",TYCO GROUP SARL,PHILLIPS PAUL JOSEPH;;CORBETT ROBERT KELLY;;CONNERS JOHN A,SHERWOOD SERVICES AG (2004-08-02),https://lens.org/009-019-248-161-180,Patent Application,yes,0,0,14,14,0,A61B17/1114;;A61B2017/00004,A61B17/00;;A61B17/11,,0,0,,,,EXPIRED
102,US,B2,US 6990181 B2,031-252-186-949-615,2006-01-24,2006,US 82648504 A,2004-04-16,US 82648504 A;;US 37819003 A;;US 16190902 A;;US 87243901 A;;US 56533100 A;;US 69655496 A,1996-08-14,Methods for displaying caller identification information on an integrated display/telephone system capable of displaying images,"Methods for displaying caller identification information on an integrated display/telephone system capable of displaying images are disclosed. One or more signals are received and one or more images are displayed on a display of the integrated display/telephone system. An incoming telephone call is received with the integrated display/telephone system, and data corresponding to the incoming telephone call is received by the integrated display/telephone system. A caller identification display signal is generated, and the caller identification display signal is based on the one or more received signals and the data corresponding to the incoming telephone call received by the integrated display/telephone system. The caller identification display signal includes the one or more received signals and signals from a generator that generates character signals and background display signals. The character signals are generated responsive to the data received with the incoming call, and in response to an incoming telephone call, caller identification information is displayed on the display along with the displayed one or more images.",CORBETT JOSEPH C;;FLETCHER WILLIAM I;;LOUDERMILK ALAN R,CORBETT JOSEPH C;;FLETCHER WILLIAM I;;LOUDERMILK ALAN R,SAMSUNG ELECTRONICS CO. LTD (2006-09-15),https://lens.org/031-252-186-949-615,Granted Patent,yes,18,7,9,9,0,H04L12/66;;H04M1/57;;H04M1/6505;;H04M1/663;;H04M3/42127;;H04M3/533;;H04M3/54;;H04M11/06;;H04M2203/1016;;H04N7/147;;H04M11/06;;H04M3/54;;H04N7/147;;H04M3/42127;;H04M2203/1016;;H04M1/57;;H04M3/533;;H04L12/66;;H04M1/6505;;H04M1/663,H04M11/00;;H04M1/57;;H04M1/65;;H04M1/663;;H04M3/42;;H04M3/533;;H04M3/54;;H04M11/06;;H04N7/14,379/93.35;;379/93.23,0,0,,,,EXPIRED
103,US,A1,US 2002/0146098 A1,013-190-880-391-662,2002-10-10,2002,US 16190902 A,2002-06-03,US 16190902 A;;US 87243901 A;;US 56533100 A;;US 69655496 A,1996-08-14,Video caller identification systems and methods,"
   Circuits and methods for determining the caller identification for an incoming call and for displaying such caller identification information on a video display device such as a television. A caller identification line modem determines the caller identification information, a control processor translates and/or inputs such caller identification information to a video circuit for displaying the caller identification information. Various methods for so displaying caller identification information are provided, including overlaying such information on an input video signal such as for a predetermined interval of time, generating a separate caller identification video signal, which may be placed, for example, on an unused television channel. The caller identification circuits and methods may be integrated or combined with various advanced television, video and/or telephony functions. An advanced remote control unit may be provided so that the user may determine from the video/television screen the identity of the caller, and then forward the call to a voice messaging system, forward the call to another line, answer the call on a video phone or answer the call on a separate telephone. The caller identification circuit may be provided with programmable intelligence so that incoming calls may not only be displayed on the video/television screen, but also may be desirably processed depending on the identity of the particular caller. 
",CORBETT JOSEPH C.;;FLETCHER WILLIAM I.;;LOUDERMILK ALAN R.,CORBETT JOSEPH C;;FLETCHER WILLIAM I;;LOUDERMILK ALAN R,SAMSUNG ELECTRONICS CO. LTD (2006-09-15),https://lens.org/013-190-880-391-662,Patent Application,yes,0,5,9,9,0,H04L12/66;;H04M1/57;;H04M1/6505;;H04M1/663;;H04M3/42127;;H04M3/533;;H04M3/54;;H04M11/06;;H04M2203/1016;;H04N7/147;;H04M11/06;;H04M3/54;;H04N7/147;;H04M3/42127;;H04M2203/1016;;H04M1/57;;H04M3/533;;H04L12/66;;H04M1/6505;;H04M1/663,H04M1/57;;H04M1/65;;H04M1/663;;H04M3/42;;H04M3/533;;H04M3/54;;H04M11/06;;H04N7/14,379/93.23;;379/142.04;;379/142.17,0,0,,,,EXPIRED
104,US,B2,US 6546092 B2,063-478-208-305-195,2003-04-08,2003,US 16190902 A,2002-06-03,US 16190902 A;;US 87243901 A;;US 56533100 A;;US 69655496 A,1996-08-14,Video caller identification systems and methods,"
    Circuits and methods for determining the caller identification for an incoming call and for displaying such caller identification information on a video display device such as a television. A caller identification line modem determines the caller identification information, a control processor translates and/or inputs such caller identification information to a video circuit for displaying the caller identification information. Various methods for so displaying caller identification information are provided, including overlaying such information on an input video signal such as for a predetermined interval of time, generating a separate caller identification video signal, which may be placed, for example, on an unused television channel. The caller identification circuits and methods may be integrated or combined with various advanced television, video and/or telephony functions. An advanced remote control unit may be provided so that the user may determine from the video/television screen the identity of the caller, and then forward the call to a voice messaging system, forward the call to another line, answer the call on a video phone or answer the call on a separate telephone. The caller identification circuit may be provided with programmable intelligence so that incoming calls may not only be displayed on the video/television screen, but also may be desirably processed depending on the identity of the particular caller. 
",CORBETT JOSEPH C;;FLETCHER WILLIAM I;;LOUDERMILK ALAN R,CORBETT JOSEPH C;;FLETCHER WILLIAM I;;LOUDERMILK ALAN R,SAMSUNG ELECTRONICS CO. LTD (2006-09-15),https://lens.org/063-478-208-305-195,Granted Patent,yes,15,44,9,9,0,H04L12/66;;H04M1/57;;H04M1/6505;;H04M1/663;;H04M3/42127;;H04M3/533;;H04M3/54;;H04M11/06;;H04M2203/1016;;H04N7/147;;H04M11/06;;H04M3/54;;H04N7/147;;H04M3/42127;;H04M2203/1016;;H04M1/57;;H04M3/533;;H04L12/66;;H04M1/6505;;H04M1/663,H04M1/57;;H04M1/65;;H04M1/663;;H04M3/42;;H04M3/533;;H04M3/54;;H04M11/06;;H04N7/14,379/93.35;;379/93.23;;379/142.04;;379/142.17,0,0,,,,EXPIRED
105,AU,B2,AU 755390 B2,093-746-419-998-32X,2002-12-12,2002,AU 1998/097481 A,1998-10-01,EP 9806265 W;;US 6085997 P,1997-10-02,Transanal anastomosis ring insertion device,"The invention relates to a device for transanally inserting through the lower bowel one of two unitary members of a Biofragmentable Anastomosis Ring (BAR). The device comprises a curved shaft with a handle and an actuating knob at the proximal end, a nest formed at the distal end of the shaft adapted to mount a BAR carrier assembly, and a second passageway formed through the shaft that terminates at a distal open end formed through the nest. The BAR carrier assembly includes unitary male and female members that collectively comprise the BAR, male and female carriers for mounting the respective unitary member, and a collet for locking in and releasing the BAR from the BAR carrier assembly once both unitary members are secured to respective open ends of the upper and lower bowel section. The BAR Carrier Assembly is actuatable in one of three positions: open, closed, and released. Once secured to the upper bowel section, the surgeon attaches the male carrier with its attached male member to the BAR Carrier Assembly, thus placing the Assembly in the open position. The surgeon then places the BAR Carrier Assembly in the closed position by mating the male member to the female member seated in the nest. Once in the closed position, the surgeon places the BAR Carrier Assembly in the released position by actuating the insertion device and releasing the mated unitary members of the BAR from the BAR Carrier Assembly and withdrawing the insertion device from the lower bowel.",TYCO GROUP SARL,PHILLIPS PAUL JOSEPH;;CORBETT ROBERT KELLY;;CONNERS JOHN A,,https://lens.org/093-746-419-998-32X,Granted Patent,no,0,0,14,14,0,A61B17/1114;;A61B2017/00004,A61B17/00;;A61B17/11,,0,0,,,,EXPIRED
106,WO,A1,WO 1999/017662 A1,143-786-801-219-444,1999-04-15,1999,EP 9806265 W,1998-10-01,US 6085997 P,1997-10-02,TRANSANAL ANASTOMOSIS RING INSERTION DEVICE,"The invention relates to a device for transanally inserting through the lower bowel one of two unitary members of a Biofragmentable Anastomosis Ring (BAR). The device comprises a curved shaft with a handle and an actuating knob at the proximal end, a nest formed at the distal end of the shaft adapted to mount a BAR carrier assembly, and a second passageway formed through the shaft that terminates at a distal open end formed through the nest. The BAR carrier assembly includes unitary male and female members that collectively comprise the BAR, male and female carriers for mounting the respective unitary member, and a collet for locking in and releasing the BAR from the BAR carrier assembly once both unitary members are secured to respective open ends of the upper and lower bowel section. The BAR Carrier Assembly is actuatable in one of three positions: open, closed, and released. Once secured to the upper bowel section, the surgeon attaches the male carrier with its attached male member to the BAR Carrier Assembly, thus placing the Assembly in the open position. The surgeon then places the BAR Carrier Assembly in the closed position by mating the male member to the female member seated in the nest. Once in the closed position, the surgeon places the BAR Carrier Assembly in the released position by actuating the insertion device and releasing the mated unitary members of the BAR from the BAR Carrier Assembly and withdrawing the insertion device from the lower bowel.",TYCO GROUP SARL,PHILLIPS PAUL JOSEPH;;CORBETT ROBERT KELLY;;CONNERS JOHN A,,https://lens.org/143-786-801-219-444,Patent Application,yes,12,14,14,14,0,A61B17/1114;;A61B2017/00004,A61B17/00;;A61B17/11,,0,0,,,,PATENTED
107,CA,A1,CA 2275403 A1,074-250-678-304-240,1999-04-15,1999,CA 2275403 A,1998-10-01,EP 9806265 W;;US 6085997 P,1997-10-02,TRANSANAL ANASTOMOSIS RING INSERTION DEVICE,"The invention relates to a device for transanally inserting through the lower bowel one of two unitary members of a Biofragmentable Anastomosis Ring (BAR). The device comprises a curved shaft with a handle and an actuating knob at the proximal end, a nest formed at the distal end of the shaft adapted to mount a BAR carrier assembly, and a second passageway formed through the shaft that terminates at a distal open end formed through the nest. The BAR carrier assembly includes unitary male and female members that collectively comprise the BAR, male and female carriers for mounting the respective unitary member, and a collet for locking in and releasing the BAR from the BAR carrier assembly once both unitary members are secured to respective open ends of the upper and lower bowel section. The BAR Carrier Assembly is actuatable in one of three positions: open, closed, and released. Once secured to the upper bowel section, the surgeon attaches the male carrier with its attached male member to the BAR Carrier Assembly, thus placing the Assembly in the open position. The surgeon then places the BAR Carrier Assembly in the closed position by mating the male member to the female member seated in the nest. Once in the closed position, the surgeon places the BAR Carrier Assembly in the released position by actuating the insertion device and releasing the mated unitary members of the BAR from the BAR Carrier Assembly and withdrawing the insertion device from the lower bowel.",TYCO GROUP SARL,CORBETT ROBERT KELLY;;PHILLIPS PAUL JOSEPH;;CONNERS JOHN A,,https://lens.org/074-250-678-304-240,Patent Application,no,0,0,14,14,0,A61B17/1114;;A61B2017/00004,A61B17/00;;A61B17/11,,0,0,,,,EXPIRED
108,US,B1,US 6427003 B1,060-845-707-265-995,2002-07-30,2002,US 87243901 A,2001-06-01,US 87243901 A;;US 56533100 A,2000-05-05,Video caller identification systems and methods,"
    Circuits and methods for determining the caller identification for an incoming call and for displaying such caller identification information on a video display device such as a television. A caller identification line modem determines the caller identification information, a control processor translates and/or inputs such caller identification information to a video circuit for displaying the caller identification information. Various methods for so displaying caller identification information are provided, including overlaying such information on an input video signal such as for a predetermined interval of time, generating a separate caller identification video signal, which may be placed, for example, on an unused television channel. The caller identification circuits and methods may be integrated or combined with various advanced television, video and/or telephony functions. An advanced remote control unit may be provided so that the user may determine from the video/television screen the identity of the caller, and then forward the call to a voice messaging system, forward the call to another line, answer the call on a video phone or answer the call on a separate telephone. The caller identification circuit may be provided with programmable intelligence so that incoming calls may not only be displayed on the video/television screen, but also may be desirably processed depending on the identity of the particular caller. 
",CORBETT JOSEPH C;;FLETCHER WILLIAM I;;LOUDERMILK ALAN R,CORBETT JOSEPH C;;FLETCHER WILLIAM I;;LOUDERMILK ALAN R,SAMSUNG ELECTRONICS CO. LTD (2006-09-15),https://lens.org/060-845-707-265-995,Granted Patent,yes,15,28,9,9,0,H04L12/66;;H04M1/57;;H04M1/6505;;H04M1/663;;H04M3/42127;;H04M3/533;;H04M3/54;;H04M11/06;;H04M2203/1016;;H04N7/147;;H04M11/06;;H04M3/54;;H04N7/147;;H04M3/42127;;H04M2203/1016;;H04M1/57;;H04M3/533;;H04L12/66;;H04M1/6505;;H04M1/663,H04M1/57;;H04M1/65;;H04M1/663;;H04M3/42;;H04M3/533;;H04M3/54;;H04M11/06;;H04N7/14,379/93.35;;379/93.23;;379/142.04;;379/142.17,0,0,,,,EXPIRED
109,US,A1,US 2007/0297580 A1,090-482-807-827-244,2007-12-27,2007,US 33923706 A,2006-01-24,US 33923706 A;;US 82648504 A;;US 37819003 A;;US 16190902 A;;US 87243901 A;;US 56533100 A;;US 69655496 A,1996-08-14,Video caller identification systems and methods,"Methods for displaying caller identification information on an integrated display/telephone system capable of displaying images generated with a remote video camera are disclosed. One or more signals are received and one or more images are displayed on a display of the integrated display/telephone system. An incoming telephone call is received with the integrated display/telephone system, and data corresponding to the incoming telephone call is received by the integrated display/telephone system. A caller identification display signal is generated, and the caller identification display signal is based on the one or more received signals and the data corresponding to the incoming telephone call received by the integrated display/telephone system. The caller identification display signal includes the one or more received signals and signals from a generator that generates character signals and background display signals. The character signals are generated responsive to the data received with the incoming call, and in response to an incoming telephone call, caller identification information is displayed on the display along with the displayed one or more images.",CORBETT JOSEPH C;;FLETCHER WILLIAM I;;LOUDERMILK ALAN R,CORBETT JOSEPH C;;FLETCHER WILLIAM I;;LOUDERMILK ALAN R,SAMSUNG ELECTRONICS CO. LTD (2006-09-15),https://lens.org/090-482-807-827-244,Patent Application,yes,21,3,9,9,0,H04L12/66;;H04M1/57;;H04M1/6505;;H04M1/663;;H04M3/42127;;H04M3/533;;H04M3/54;;H04M11/06;;H04M2203/1016;;H04N7/147;;H04M11/06;;H04M3/54;;H04N7/147;;H04M3/42127;;H04M2203/1016;;H04M1/57;;H04M3/533;;H04L12/66;;H04M1/6505;;H04M1/663,H04M1/57;;H04M11/00;;H04M1/65;;H04M1/663;;H04M3/42;;H04M3/533;;H04M3/54;;H04M11/06;;H04N7/14,379/93.23,0,0,,,,DISCONTINUED
110,WO,A1,WO 2003/024541 A1,144-931-954-065-022,2003-03-27,2003,US 0229128 W,2002-09-12,US 31893001 P,2001-09-14,DART FOR THE GAME OF DARTS,"A dart (100) for the game of darts, the dart having a longitudinal axis (135), the dart (100) comprising: a point (105) having a tip and a rear surface, the point (105) slidably, pivotably and removably mounted in a bore (195) in a first end of a barrel (115); a spring (145) mounted inside of the barrel (115) for operatively moving the point with respect to the barrel (115); and a leading edge of a flight (125) operatively attached to a second end of the barrel (115), the second end of the shaft (120) opposite from the first end of the shaft (120).",STURTZ JOSEPH F;;SIMMS FRANK R;;CORBETT STEPHEN D,STURTZ JOSEPH F;;SIMMS FRANK R;;CORBETT STEPHEN D,,https://lens.org/144-931-954-065-022,Patent Application,yes,5,0,1,1,0,F42B6/003,F42B6/00,,0,0,,,,PENDING
111,AT,T1,AT E267553 T1,074-788-678-721-006,2004-06-15,2004,AT 98951487 T,1998-10-01,EP 9806265 W;;US 6085997 P,1997-10-02,EINFÜHRVORRICHTUNG FÜR EINEN TRANSANAL ANASTOMOSE RING,"The invention relates to a device for transanally inserting through the lower bowel one of two unitary members of a Biofragmentable Anastomosis Ring (BAR). The device comprises a curved shaft with a handle and an actuating knob at the proximal end, a nest formed at the distal end of the shaft adapted to mount a BAR carrier assembly, and a second passageway formed through the shaft that terminates at a distal open end formed through the nest. The BAR carrier assembly includes unitary male and female members that collectively comprise the BAR, male and female carriers for mounting the respective unitary member, and a collet for locking in and releasing the BAR from the BAR carrier assembly once both unitary members are secured to respective open ends of the upper and lower bowel section. The BAR Carrier Assembly is actuatable in one of three positions: open, closed, and released. Once secured to the upper bowel section, the surgeon attaches the male carrier with its attached male member to the BAR Carrier Assembly, thus placing the Assembly in the open position. The surgeon then places the BAR Carrier Assembly in the closed position by mating the male member to the female member seated in the nest. Once in the closed position, the surgeon places the BAR Carrier Assembly in the released position by actuating the insertion device and releasing the mated unitary members of the BAR from the BAR Carrier Assembly and withdrawing the insertion device from the lower bowel.",SHERWOOD SERV AG,PHILLIPS PAUL JOSEPH;;CORBETT ROBERT KELLY;;CONNERS JOHN A,,https://lens.org/074-788-678-721-006,Granted Patent,no,0,0,14,14,0,A61B17/1114;;A61B2017/00004,A61B17/00;;A61B17/11,,0,0,,,,DISCONTINUED
112,AU,A,AU 1998/097481 A,077-895-202-787-176,1999-04-27,1999,AU 1998/097481 A,1998-10-01,EP 9806265 W;;US 6085997 P,1997-10-02,Transanal anastomosis ring insertion device,"The invention relates to a device for transanally inserting through the lower bowel one of two unitary members of a Biofragmentable Anastomosis Ring (BAR). The device comprises a curved shaft with a handle and an actuating knob at the proximal end, a nest formed at the distal end of the shaft adapted to mount a BAR carrier assembly, and a second passageway formed through the shaft that terminates at a distal open end formed through the nest. The BAR carrier assembly includes unitary male and female members that collectively comprise the BAR, male and female carriers for mounting the respective unitary member, and a collet for locking in and releasing the BAR from the BAR carrier assembly once both unitary members are secured to respective open ends of the upper and lower bowel section. The BAR Carrier Assembly is actuatable in one of three positions: open, closed, and released. Once secured to the upper bowel section, the surgeon attaches the male carrier with its attached male member to the BAR Carrier Assembly, thus placing the Assembly in the open position. The surgeon then places the BAR Carrier Assembly in the closed position by mating the male member to the female member seated in the nest. Once in the closed position, the surgeon places the BAR Carrier Assembly in the released position by actuating the insertion device and releasing the mated unitary members of the BAR from the BAR Carrier Assembly and withdrawing the insertion device from the lower bowel.",TYCO GROUP SARL,PHILLIPS PAUL JOSEPH;;CORBETT ROBERT KELLY;;CONNERS JOHN A,,https://lens.org/077-895-202-787-176,Patent Application,no,0,0,14,14,0,A61B17/1114;;A61B2017/00004,A61B17/00;;A61B17/11,,0,0,,,,EXPIRED
113,CN,A,CN 1476438 A,035-764-985-349-442,2004-02-18,2004,CN 01819449 A,2001-11-28,US 25163700 P,2000-12-06,Fused heteroaromatic glucokinase activators,化学式I-O的葡萄糖激酶活化化合物或其药用盐：其中M是化学式II或者化学式III；Q是化学式IV或者化学式V；R#+[1]是具有1-3个碳原子的烷基；R#+[2]是氢、卤素、硝基、氰基、或者全氟代甲基；R#+[3]是具有4-7个碳原子的环烷基或者2-丙基；R#+[5]是卤素；R#+[6]是卤素；W是O，S或者NH；每个Y独立为CH或者N；Z是CH#-[2]-CH#-[2]-CH#-[2]-CH#-[2]或者CH＝CR#+[4]-CH＝CH-。其中R#+[4]是氢、卤素、或者具有1-3个碳原子的烷基砜；虚线共同代表杂环结构中的0或者2个另外的双键。化学式I-O的化合物可以作为外消旋物存在或者以所示不对称碳原子处分离的“R”构型存在。,HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMBSY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN,,https://lens.org/035-764-985-349-442,Patent Application,no,0,1,33,35,0,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;A61P3/10;;A61P5/50;;C07D277/82;;C07D215/38;;C07D277/82;;C07D235/30;;C07D263/58,A61K31/4184;;A61K31/423;;A61K31/428;;A61K31/47;;A61P3/10;;C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82,,0,0,,,,EXPIRED
114,GB,A,GB 190207961 A,186-043-303-725-283,1903-03-05,1903,GB 190207961D A,1902-04-05,GB 190207961T A,1902-04-05,"Improvements in Securing Tubs, Corves, Wagons, or the like in Cages or Lifts for Winding Coals in the Shafts or Collieries and for other Purposes.","7961. Corbett, V. C. S. W., Seaman, C. J., and Linday, R. April 5. Lifts. - Consists of means for securing tubs, corves, &c. in mine cages &c. On the inner sides of the cage are two sets of rails or bars B closed or narrowed together at their ends b at both ends of the cage. Between these rails run the ends of a bar D carrying stop blocks adapted to engage the bodies of the tubs &c., or, as shown, their wheels. The tubs, pushed in at one end of the cage, push the bar D before them, and push out the tubs already in the cage until stopped by the bar D reaching the end of the rails B.",CORBETT VINCENT CHARLES STUART;;SEAMAN CHARLES JOSEPH;;LINDAY ROBERT,CORBETT VINCENT CHARLES STUART;;SEAMAN CHARLES JOSEPH;;LINDAY ROBERT,,https://lens.org/186-043-303-725-283,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
115,US,B1,US 6243448 B1,061-138-821-011-36X,2001-06-05,2001,US 56533100 A,2000-05-05,US 56533100 A;;US 69655496 A,1996-08-14,Video caller identification systems and methods,"Circuits and methods for determining the caller identification for an incoming call and for displaying such caller identification information on a video display device such as a television. A caller identification line modem determines the caller identification information, a control processor translates and/or inputs such caller identification information to a video circuit for displaying the caller identification information. Various methods for so displaying caller identification information are provided, including overlaying such information on an input video signal such as for a predetermined interval of time, generating a separate caller identification video signal, which may be placed, for example, on an unused television channel. The caller identification circuits and methods may be integrated or combined with various advanced television, video and/or telephony functions. An advanced remote control unit may be provided so that the user may determine from the video/television screen the identity of the caller, and then forward the call to a voice messaging system, forward the call to another line, answer the call on a video phone or answer the call on a separate telephone. The caller identification circuit may be provided with programmable intelligence so that incoming calls may not only be displayed on the video/television screen, but also may be desirably processed depending on the identity of the particular caller.",CORBETT JOSEPH C;;FLETCHER WILLIAM I;;LOUDERMILK ALAN R,CORBETT JOSEPH C;;FLETCHER WILLIAM I;;LOUDERMILK ALAN R,SAMSUNG ELECTRONICS CO. LTD (2006-09-15),https://lens.org/061-138-821-011-36X,Granted Patent,yes,14,64,2,2,0,H04M1/57;;H04M1/57;;H04M1/6505;;H04M1/6505;;H04M1/663;;H04M1/663;;H04M3/42127;;H04M3/42127;;H04M3/533;;H04M3/533;;H04M3/54;;H04M3/54;;H04M11/06;;H04M11/06;;H04M2203/1016;;H04M2203/1016;;H04N7/147;;H04N7/147,H04M1/57;;H04M1/65;;H04M1/663;;H04M3/42;;H04M3/533;;H04M3/54;;H04M11/06;;H04N7/14,379/93.35;;379/93.23;;379/142,0,0,,,,EXPIRED
116,DE,A1,DE 1504882 A1,136-663-439-314-524,1969-04-17,1969,DE 1504882 A,1965-03-18,DE S0096039 A,1965-03-18,Verfahren und Vorrichtung zur Herstellung von thermoplastischen Artikeln,,MOBIL OIL CORP,OLIVER CORBETT HERBERT;;JOSEPH QUACKENBUSH JOHN;;HERBERT ALLEN CHARLES,,https://lens.org/136-663-439-314-524,Patent Application,no,0,0,1,1,0,B29C48/03;;B29C48/08;;B29C48/10,B29C48/03;;B29C48/08;;B29C48/10,,0,0,,,,DISCONTINUED
117,GT,A,GT 200100243 A,080-848-450-880-608,2002-06-04,2002,GT 200100243 A,2001-12-05,US 25163700 P,2000-12-06,ACTIVADORES HETEROAROMATICOS FUSIONADOS DE LA GLUCOQUINASA,"LA SIGUIENTE INVENCION SE REFIERE A LOS COMPUESTOS ACTIVADORES DE LA GLUCOQUINASA DE FORMULA(I) EN DONDE R1, R2, R3, R4, R5, R6, M, Q, W,Y,Z , SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. LOS COMPUESTOS DE LA PRESENTE INVENCION SIRVEN PARA TRATAMIENTO O PREVENCION DE LA DIABETES TIPO II.",,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN,,https://lens.org/080-848-450-880-608,Amended Application,no,0,0,33,35,0,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;A61P3/10;;A61P5/50;;C07D277/82;;C07D215/38;;C07D277/82;;C07D235/30;;C07D263/58,A61K31/165;;A61K31/4184;;A61K31/423;;A61K31/428;;A61K31/47;;A61P3/10;;C07C233/01;;C07C233/23;;C07C317/14;;C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82,,0,0,,,,PENDING
118,TW,A,TW 200402418 A,178-566-611-084-943,2004-02-16,2004,TW 92109472 A,2003-04-23,US 37616102 P,2002-04-26,Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators,"2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a polar ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type Ⅱ diabetes.",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;KA WANG;;WENDY LEA CORBETT;;JOSEPH SAMUEL GRIMSBY,,https://lens.org/178-566-611-084-943,Patent of Addition,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D277/20;;A61K31/17;;C07D307/16;;A61K31/335;;A61K31/341;;A61K31/351;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,EXPIRED
119,WO,A1,WO 2024/008793 A1,090-499-590-234-114,2024-01-11,2024,EP 2023068544 W,2023-07-05,US 202263359271 P;;EP 22186030 A,2022-07-08,A PROCESS FOR PRODUCING ETHYLENE,"The present invention provides a process for producing ethylene, the process at least comprising the steps of: (a) providing a CO-containing stream (10); (b) converting the CO-containing stream (10) provided in step (a) in an electrolyzer (2) thereby producing an ethylene-containing vapour stream (30) and an ethanol-containing liquid stream (40); (c) subjecting at least a part of the ethylene-containing vapour stream (30) obtained in step (b) to hydration thereby obtaining a first ethanol-enriched stream (90); (d) separating the first ethanol-enriched stream (90) obtained in step (c) thereby obtaining a second ethanol-enriched stream (110) and a water-enriched stream (120); and (e) subjecting the second ethanol-enriched stream (110) to dehydration thereby obtaining ethylene (140).",SHELL INT RESEARCH;;SHELL USA INC,VERMA SUMIT;;OLTHOF TIMOTHÉ JOHANNES;;CORBETT PAUL JOSEPH;;BALAJI SAYEE PRASAAD,,https://lens.org/090-499-590-234-114,Patent Application,yes,7,0,1,1,0,C25B3/03;;C25B3/25;;C25B15/027;;C25B15/081;;C25B15/083,C25B3/03;;C25B3/25;;C25B15/027;;C25B15/08,,4,4,037-906-432-750-993;;092-244-864-240-801;;020-466-410-600-819;;001-505-760-646-868,10.1021/jp970284i;;10.1021/acsenergylett.0c02633;;10.1016/j.pecs.2017.05.005;;10.1016/j.joule.2018.10.007,"YOSHIO HORI ET AL: ""Electrochemical Reduction of CO at a Copper Electrode"", THE JOURNAL OF PHYSICAL CHEMISTRY B, vol. 101, no. 36, 1 September 1997 (1997-09-01), pages 7075 - 7081, XP055046842, ISSN: 1520-6106, DOI: 10.1021/jp970284i;;J. SISLER: ""Ethylene Electrosynthesis: A comparative techno-economic analysis of alkaline vs membrane electrode vs CO -CO-C H tandems"", ACS ENERGY LETT, vol. 6, 2021, pages 997 - 1002;;B. ENDRODI ET AL.: ""Continuous-flow electroreduction of carbon dioxide"", PROGRESS IN ENERGY AND COMBUSTION SCIENCE, vol. 62, September 2017 (2017-09-01), pages 133 - 154, XP085135284, DOI: 10.1016/j.pecs.2017.05.005;;D.S. RIPATTI ET AL.: ""Carbon Monoxide Gas Diffusion Electrolysis that Produces Concentrated C Products with High Single-Pass Conversion"", JOULE, vol. 3, 2019, pages 240 - 256, XP055873184, DOI: 10.1016/j.joule.2018.10.007",PENDING
120,US,B2,US 10982846 B2,078-205-061-777-93X,2021-04-20,2021,US 201715622270 A,2017-06-14,US 201715622270 A,2017-06-14,Vortex recirculating combustion burner head,"A vortex recirculating combustion head for a burner, including: a housing having a through-bore, an upstream end, and a downstream end, the upstream and downstream ends arranged at opposite sides of the through-bore, the housing configured to receive combustion air; a primary fuel inlet arranged adjacent to the upstream end of the housing configured to introduce a primary fuel stream into the housing; a secondary fuel inlet arranged downstream of the primary fuel inlet configured to introduce a secondary fuel stream into the housing; a flame retention head including a diffuser plate secured to the downstream end of the housing, the diffuser plate including a plurality of openings, a plurality of fins, and a ring; and, an extension member secured to an exterior surface of the flame retention head.",WEBSTER COMBUSTION TECH LLC,BEARD JUSTIN J;;CORBETT EDWARD;;SONDERVAN JOACHIM PHILIP;;VANDERPOOL JOSEPH BRANDON,WEBSTER COMBUSTION TECHNOLOGY LLC (2017-06-14),https://lens.org/078-205-061-777-93X,Granted Patent,yes,20,0,15,15,0,F23D14/24;;F23D14/70;;F23D2900/11402;;F23D2900/14241;;F23D14/24;;F23D14/70;;F23D14/24;;F23D14/70,F23M9/00;;F23D14/24;;F23D14/70,,4,0,,,"International Search Report and the Written Opinion of the International Searching Authority, International Application No. PCT/US2018/037328, pp. 1-8, dated Aug. 31, 2018.;;International Preliminary Report on Patentability, International Application No. PCT/US2018/037328, pp. 1-7, dated Dec. 17, 2019.;;Notification of Reasons for Rejection, Japanese Patent Application No. 2019-566645, pp. 1-5, dated Dec. 2, 2020.;;Examination Report, Indian Patent Application No. 201917048872, pp. 1-7, dated Feb. 5, 2021.",ACTIVE
121,CA,A1,CA 3063599 A1,036-949-953-949-993,2018-12-20,2018,CA 3063599 A,2018-06-13,US 201715622270 A;;US 2018/0037328 W,2017-06-14,VORTEX RECIRCULATING COMBUSTION BURNER HEAD,"A vortex recirculating combustion head for a burner, including: a housing having a through-bore, an upstream end, and a downstream end, the upstream and downstream ends arranged at opposite sides of the through-bore, the housing configured to receive combustion air; a primary fuel inlet arranged adjacent to the upstream end of the housing configured to introduce a primary fuel stream into the housing; a secondary fuel inlet arranged downstream of the primary fuel inlet configured to introduce a secondary fuel stream into the housing; a flame retention head including a diffuser plate secured to the downstream end of the housing, the diffuser plate including a plurality of openings, a plurality of fins, and a ring; and, an extension member secured to an exterior surface of the flame retention head.",WEBSTER COMBUSTION TECH LLC,BEARD JUSTIN J;;CORBETT EDWARD;;SONDERVAN JOACHIM P;;VANDERPOOL JOSEPH B,,https://lens.org/036-949-953-949-993,Patent Application,no,0,0,15,15,0,F23D14/24;;F23D14/70;;F23D2900/11402;;F23D2900/14241;;F23D14/24;;F23D14/70;;F23D14/24;;F23D14/70,F23C1/00;;F23C9/00;;F23C9/06;;F23D11/40,,0,0,,,,PENDING
122,BR,A2,BR 112019025315 A2,139-671-271-090-481,2020-06-23,2020,BR 112019025315 A,2018-06-13,US 2018/0037328 W;;US 201715622270 A,2017-06-14,cabeça de combustão de recirculação em vórtice para um queimador,"uma cabeça de combustão de recirculação em vórtice para um queimador, incluindo: um alojamento com um furo atravessante, uma extremidade a montante e uma extremidade a jusante, as extremidades a montante e a jusante arranjadas em lados opostos do furo atravessante, o alojamento configurado para receber ar de combustão; uma entrada de combustível primária arranjada adjacente à extremidade a montante do alojamento configurada para introduzir uma corrente de combustível primária no alojamento; uma entrada de combustível secundária arranjada a jusante da entrada de combustível primária configurada para introduzir uma corrente de combustível secundária no alojamento; uma cabeça de retenção de chama incluindo uma placa difusora presa à extremidade a jusante do alojamento, a placa difusora incluindo uma pluralidade de aberturas, uma pluralidade de aletas, e um anel; e um membro de extensão preso à superfície exterior da cabeça de retenção de chama.",WEBSTER COMBUSTION TECH LLC,EDWARD CORBETT;;JOACHIM P SONDERVAN;;JOSEPH B VANDERPOOL;;JUSTIN J BEARD,,https://lens.org/139-671-271-090-481,Patent Application,no,0,0,15,15,0,F23D14/24;;F23D14/70;;F23D2900/11402;;F23D2900/14241;;F23D14/24;;F23D14/70;;F23D14/24;;F23D14/70,F23D11/40;;F23C1/00;;F23C9/00;;F23C9/06,,0,0,,,,PENDING
123,CA,C,CA 3063599 C,100-482-344-587-264,2022-05-03,2022,CA 3063599 A,2018-06-13,US 201715622270 A;;US 2018/0037328 W,2017-06-14,VORTEX RECIRCULATING COMBUSTION BURNER HEAD,"A vortex recirculating combustion head for a burner, including: a housing having a through-bore, an upstream end, and a downstream end, the upstream and downstream ends arranged at opposite sides of the through-bore, the housing configured to receive combustion air; a primary fuel inlet arranged adjacent to the upstream end of the housing configured to introduce a primary fuel stream into the housing; a secondary fuel inlet arranged downstream of the primary fuel inlet configured to introduce a secondary fuel stream into the housing; a flame retention head including a diffuser plate secured to the downstream end of the housing, the diffuser plate including a plurality of openings, a plurality of fins, and a ring; and, an extension member secured to an exterior surface of the flame retention head.",WEBSTER COMBUSTION TECH LLC,BEARD JUSTIN J;;CORBETT EDWARD;;SONDERVAN JOACHIM P;;VANDERPOOL JOSEPH B,,https://lens.org/100-482-344-587-264,Granted Patent,no,0,0,15,15,0,F23D14/24;;F23D14/70;;F23D2900/11402;;F23D2900/14241;;F23D14/24;;F23D14/70;;F23D14/24;;F23D14/70,F23C1/00;;F23C9/00;;F23C9/06;;F23D11/40,,0,0,,,,PENDING
124,EP,A1,EP 3638950 A1,037-919-221-275-435,2020-04-22,2020,EP 18816538 A,2018-06-13,US 201715622270 A;;US 2018/0037328 W,2017-06-14,VORTEX RECIRCULATING COMBUSTION BURNER HEAD,,WEBSTER COMBUSTION TECH LLC,BEARD JUSTIN J;;CORBETT EDWARD;;SONDERVAN JOACHIM P;;VANDERPOOL JOSEPH B,,https://lens.org/037-919-221-275-435,Patent Application,yes,0,0,15,15,0,F23D14/24;;F23D14/70;;F23D2900/11402;;F23D2900/14241;;F23D14/24;;F23D14/70;;F23D14/24;;F23D14/70,F23C1/00;;F23C9/00;;F23C9/06;;F23D11/40,,0,0,,,,PENDING
125,MX,A,MX 2019014417 A,189-672-763-228-65X,2020-08-03,2020,MX 2019014417 A,2018-06-13,US 201715622270 A;;US 2018/0037328 W,2017-06-14,VORTEX RECIRCULATING COMBUSTION BURNER HEAD.,"A vortex recirculating combustion head for a burner, including: a housing having a through-bore, an upstream end, and a downstream end, the upstream and downstream ends arranged at opposite sides of the through-bore, the housing configured to receive combustion air; a primary fuel inlet arranged adjacent to the upstream end of the housing configured to introduce a primary fuel stream into the housing; a secondary fuel inlet arranged downstream of the primary fuel inlet configured to introduce a secondary fuel stream into the housing; a flame retention head including a diffuser plate secured to the downstream end of the housing, the diffuser plate including a plurality of openings, a plurality of fins, and a ring; and, an extension member secured to an exterior surface of the flame retention head.",WEBSTER COMBUSTION TECH LLC,BEARD JUSTIN J;;CORBETT EDWARD;;SONDERVAN JOACHIM P;;VANDERPOOL JOSEPH B,,https://lens.org/189-672-763-228-65X,Patent Application,no,0,0,15,15,0,F23D14/24;;F23D14/70;;F23D2900/11402;;F23D2900/14241;;F23D14/24;;F23D14/70;;F23D14/24;;F23D14/70,F23C1/00;;F23C9/00;;F23C9/06;;F23D11/40,,0,0,,,,PENDING
126,CN,A,CN 110998184 A,098-021-730-674-081,2020-04-10,2020,CN 201880039055 A,2018-06-13,US 201715622270 A;;US 2018/0037328 W,2017-06-14,VORTEX RECIRCULATING COMBUSTION BURNER HEAD,"A vortex recirculating combustion head for a burner, including: a housing having a through-bore, an upstream end, and a downstream end, the upstream and downstream ends arranged at opposite sides of the through-bore, the housing configured to receive combustion air; a primary fuel inlet arranged adjacent to the upstream end of the housing configured to introduce a primary fuel stream into the housing; a secondary fuel inlet arranged downstream of the primary fuel inlet configured to introduce a secondary fuel stream into the housing; a flame retention head including a diffuser plate secured tothe downstream end of the housing, the diffuser plate including a plurality of openings, a plurality of fins, and a ring; and, an extension member secured to an exterior surface of the flame retention head.",WEBSTER COMB TECH LLC,BEARD JUSTIN J;;CORBETT EDWARD;;SONDERVAN JOACHIM P;;VANDERPOOL JOSEPH B,,https://lens.org/098-021-730-674-081,Patent Application,no,11,0,15,15,0,F23D14/24;;F23D14/70;;F23D2900/11402;;F23D2900/14241;;F23D14/24;;F23D14/70;;F23D14/24;;F23D14/70,F23C1/00;;F23C9/00;;F23C9/06;;F23D11/40,,0,0,,,,ACTIVE
127,KR,A,KR 20200007008 A,128-208-116-498-045,2020-01-21,2020,KR 20197036545 A,2018-06-13,US 201715622270 A;;US 2018/0037328 W,2017-06-14,와류 재순환 연소 버너 헤드,"버너 용 와류 재순환 연소 헤드는, 관통-보어, 상류 단부 및 하류 단부를 가지고, 상기 관통-보어의 대향 측면에 배치된 상류 및 하류 단부를 가지며, 연소 공기를 수용하도록 구성된 하우징; 상기 하우징 내로 1차 연료 스트림을 도입하도록 구성된 하우징의 상류 단부에 인접하게 배치된 1차 연료 유입구; 상기 하우징 내로 2차 연료 스트림을 도입하도록 구성된 1차 연료 유입구의 하류에 배치된 2차 연료 유입구; 디퓨저 플레이트는 복수의 개구, 복수의 핀 및 링을 포함하고, 상기 하우징의 하류 단부에 고정된 상기 디퓨저 플레이트를 포함하는 화염 유지 헤드; 및 상기 화염 유지 헤드의 외부 표면에 고정된 연장 부재를 포함한다.",WEBSTER COMBUSTION TECH LLC,BEARD JUSTIN J;;CORBETT EDWARD;;SONDERVAN JOACHIM P;;VANDERPOOL JOSEPH B,,https://lens.org/128-208-116-498-045,Patent Application,no,3,0,15,15,0,F23D14/24;;F23D14/70;;F23D2900/11402;;F23D2900/14241;;F23D14/24;;F23D14/70;;F23D14/24;;F23D14/70,F23D14/24;;F23D14/70,,0,0,,,,ACTIVE
128,EP,A4,EP 3638950 A4,113-478-008-825-470,2021-05-19,2021,EP 18816538 A,2018-06-13,US 201715622270 A;;US 2018/0037328 W,2017-06-14,VORTEX RECIRCULATING COMBUSTION BURNER HEAD,,WEBSTER COMBUSTION TECH LLC,BEARD JUSTIN J;;CORBETT EDWARD;;SONDERVAN JOACHIM P;;VANDERPOOL JOSEPH B,,https://lens.org/113-478-008-825-470,Search Report,no,5,0,15,15,0,F23D14/24;;F23D14/70;;F23D2900/11402;;F23D2900/14241;;F23D14/24;;F23D14/70;;F23D14/24;;F23D14/70,F23C1/00;;F23C9/00;;F23C9/06;;F23D11/40,,1,0,,,See also references of WO 2018231979A1,PENDING
129,US,A1,US 2018/0363898 A1,157-574-807-222-20X,2018-12-20,2018,US 201715622270 A,2017-06-14,US 201715622270 A,2017-06-14,VORTEX RECIRCULATING COMBUSTION BURNER HEAD,"A vortex recirculating combustion head for a burner, including: a housing having a through-bore, an upstream end, and a downstream end, the upstream and downstream ends arranged at opposite sides of the through-bore, the housing configured to receive combustion air; a primary fuel inlet arranged adjacent to the upstream end of the housing configured to introduce a primary fuel stream into the housing; a secondary fuel inlet arranged downstream of the primary fuel inlet configured to introduce a secondary fuel stream into the housing; a flame retention head including a diffuser plate secured to the downstream end of the housing, the diffuser plate including a plurality of openings, a plurality of fins, and a ring; and, an extension member secured to an exterior surface of the flame retention head.",WEBSTER COMBUSTION TECH LLC,BEARD JUSTIN J;;CORBETT EDWARD;;SONDERVAN JOACHIM PHILIP;;VANDERPOOL JOSEPH BRANDON,WEBSTER COMBUSTION TECHNOLOGY LLC (2017-06-14),https://lens.org/157-574-807-222-20X,Patent Application,yes,6,0,15,15,0,F23D14/24;;F23D14/70;;F23D2900/11402;;F23D2900/14241;;F23D14/24;;F23D14/70;;F23D14/24;;F23D14/70,F23D14/24;;F23D14/64;;F23D14/70,,0,0,,,,ACTIVE
130,DE,D1,DE 69427711 D1,035-862-540-208-216,2001-08-16,2001,DE 69427711 T,1994-08-23,US 11091593 A;;US 9409541 W,1993-08-24,VERFAHREN ZUR HEMMUNG DER STICKSTOFFOXIDBILDUNG,"A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal afflicted with an acute or chronic inflammatory disease which comprises administering to said mammal an effective nitric oxide inhibitory amount of methyl-, or 1,1-dimethyl-, or amino-substituted guanidines.",UNIV ST LOUIS,WILLIAMSON JOSEPH P;;CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G,,https://lens.org/035-862-540-208-216,Granted Patent,no,0,0,15,38,0,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00;;A61K31/195;;A61K31/155,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00,,0,0,,,,EXPIRED
131,AT,T1,AT E191847 T1,133-812-111-329-164,2000-05-15,2000,AT 92121318 T,1992-12-15,US 80791291 A,1991-12-16,VERWENDUNG VON AMINOGUAMIDIN ZUR HERSTELLUNG EINES ARZNEIMITTELS ZUR UNTERDRÜCKUNG DER STICKOXIDBILDUNG,A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal which comprises administering to said mammal an effective nitric oxide inhibitory amount of aminoguanidine.,UNIV WASHINGTON,WILLIAMSON JOSEPH ROBERT;;CORBETT JOHN ANDREW;;MCDANIEL MICHAEL LYNN;;TILTON RONALD GENE,,https://lens.org/133-812-111-329-164,Granted Patent,no,0,0,8,38,0,A61K31/155;;A61K31/195;;A61P13/12;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61P9/12,A61K31/155;;A61K31/195;;A61P3/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61P9/12;;A61P13/12;;A61P25/00;;A61P27/02;;A61P29/00;;A61P37/00;;A61P37/06;;A61P43/00,,0,0,,,,DISCONTINUED
132,EP,B1,EP 0558468 B1,102-326-099-422-973,1996-08-28,1996,EP 93870034 A,1993-02-26,US 84338792 A,1992-02-28,Medicament for inhibiting nitric oxide formation,The use is disclosed of methylguanidine or dimethylguanidine for the manufacture of a medicament particularly suitable for inhibiting nitric oxide formation in a warm blooded mammal. A pharmaceutical composition is disclosed containing methylguanidine or dimethylguanidine or a pharmaceutically acceptable salt thereof which is suitable in the treatment and/or prevention of diabetes-induced vascular dysfunction and complications in humans. <IMAGE> <IMAGE>,UNIV WASHINGTON,CORBETT JOHN ANDREW;;MCDANIEL MICHAEL LYNN;;TILTON RONALD GENE;;WILLIAMSON JOSEPH ROBERT,WASHINGTON UNIVERSITY (2007-10-15),https://lens.org/102-326-099-422-973,Granted Patent,yes,0,0,11,38,0,A61K31/155;;A61K31/195;;A61P3/08;;A61P43/00;;A61P9/00;;A61K31/195;;A61K31/155,A61K31/155;;A61K31/195;;A61P3/08;;A61P43/00,,4,0,,,"CLINICAL SCIENCE, vol. 42, 1972, pages 395-404; P.L. BALESTRI ET AL.: 'Effects of uraemic serum, urea, creatinine and methylguanidine on glucose metabolism';;JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 230, no. 3, 1984, pages 710-717; J.A. HIRSCH: 'Structure-activity relationship between guanidine alkyl derivatives and norephrinerelease: site(s) and mechanism(s) of action';;DIABETES, vol. 40, no. SUP1, 1991, page 210A; K. CHANG ET AL.: 'Aminoguanidine prevents Glucose- and Sorbitol-induced vascular dysfunction in skin chamber granulation tissue';;THE LANCET, vol. 340, no. 8811, 11 July 1992, page 116; N. BENJAMIN: 'Modulators of nitric oxide synthesis'",EXPIRED
133,CA,A1,CA 2169481 A1,136-590-037-159-571,1995-03-02,1995,CA 2169481 A,1994-08-23,US 11091593 A;;US 9409541 W,1993-08-24,Method of Inhibiting Nitric Oxide Formation,"A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal afflicted with an acute or chronic inflammatory disease which comprises administering to said mammal an effective nitric oxide inhibitory amount of methyl-, or 1,1-dimethyl-, or amino-substituted guanidines.",UNIV WASHINGTON,WILLIAMSON JOSEPH P;;CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G,,https://lens.org/136-590-037-159-571,Patent Application,no,0,0,15,38,0,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00;;A61K31/195;;A61K31/155,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00,,0,0,,,,EXPIRED
134,AU,A,AU 1997/024234 A,031-420-220-874-515,1997-10-17,1997,AU 1997/024234 A,1997-03-25,US 62083396 A;;US 9704866 W,1996-03-25,Inhibition of nitric oxide formation in acute and chronic inflammation,,UNIV WASHINGTON,WILLIAMSON JOSEPH R;;CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G,,https://lens.org/031-420-220-874-515,Patent Application,no,0,0,3,3,0,A61K31/155;;A61K31/155,A61K31/155,,0,0,,,,PENDING
135,US,A1,US 2006/0136030 A1,060-988-492-546-586,2006-06-22,2006,US 75679604 A,2004-01-13,US 75679604 A;;US 1223001 A,2001-12-06,Side-top electrode,"A bio-implant having a length and a proximal and a distal end. The bio-implant includes at least two laminae of dielectric material that are joined together, thereby defining a boundary and that also define a side surface that is intersected by the boundary. The laminae also define a nominal top surface that meets the side surface. At least one set of conductors is interposed between the laminae and extends lengthwise from the proximal end toward the distal end, each one of the set of conductors being terminated at the side surface to form a set of conductor terminations. Additionally, a set of electrode contacts, each is constructed on the side surface and extends over a portion of the nominal top surface, each the electrode contact contacting one of the conductor terminations.",KETTERL JOSEPH R;;YARNO JOHN P;;CORBETT SCOTT S;;CLARY THOMAS R,KETTERL JOSEPH R;;YARNO JOHN P;;CORBETT SCOTT S;;CLARY THOMAS R,,https://lens.org/060-988-492-546-586,Patent Application,yes,2,2,7,7,0,A61N1/0541;;Y10T29/49124;;Y10T29/49124;;A61N1/0541,A61N1/05,607/137,0,0,,,,DISCONTINUED
136,US,B2,US 11768364 B2,108-593-325-910-620,2023-09-26,2023,US 202017110409 A,2020-12-03,US 202017110409 A;;US 201962944687 P,2019-12-06,Apparatus and method of estimating values from images,"A method is used to generate a distortion model for a structured illumination microscopy (SIM) optical system. A sliding window is moved in relation to a plurality of images to define a plurality of sub-tiles. Each sub-tile represents a portion of the corresponding image. Parameters are estimated for each sub-tiles. The parameters include two or more parameters selected from the group consisting of modulation, angle, spacing, phase offset, and phase deviation. A full width at half maximum (FWHM) value associated with each sub-tile is estimated. A distortion model is estimated, based at least in part on a combination of the estimated parameters and FWHM values stored in the predetermined format and an estimated center window parameter. A two-dimensional image may be generated, based at least in part on the estimated distortion model. The two-dimensional image may include representations indicating where distortions occur in the optical system.",ILLUMINA INC,LANGLOIS ROBERT;;LU BO;;REN HONGJI;;PINTO JOSEPH;;PRINCE SIMON;;CORBETT AUSTIN,ILLUMINA INC (2020-01-30),https://lens.org/108-593-325-910-620,Granted Patent,yes,19,0,14,14,0,G02B21/367;;G02B21/361;;G02B21/06;;G02B21/367;;G01N21/6458;;G01N21/6458;;G02B21/06;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024;;G02B21/367;;G02B21/06;;G02B21/14;;G02B21/361;;G06T7/0012;;G01N21/6458;;G06T2207/10056;;G06T2207/30024;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024,G06T7/00;;G02B21/14;;G02B21/36,,6,5,069-424-894-171-91X;;060-929-273-435-974;;071-985-290-412-69X;;005-716-544-072-279;;065-431-319-615-131,10810003;;10.1046/j.1365-2818.2000.00710.x;;18326650;;10.1529/biophysj.107.120345;;pmc2397368;;10.1364/oe.21.024692;;24150313;;23389185;;10.1364/oe.21.002032;;pmc5330558;;28270977;;10.1364/boe.8.000695,"Gustafsson, Mats GL. “Surpassing the lateral resolution limit by a factor of two using structured illumination microscopy.” Journal of microscopy 198.2 (2000): 82-87.;;Gustafsson, Mats GL, et al. “Three-dimensional resolution doubling in wide-field fluorescence microscopy by structured illumination.” Biophysical journal 94.12 (2008): 4957-4970.;;Wicker, Kai. “Non-iterative determination of pattern phase in structured illumination microscopy using auto-correlations in Fourier space.” Optics express 21.21 (2013): 24692-24701.;;Wicker, Kai, et al. “Phase optimisation for structured illumination microscopy.” Optics express 21.2 (2013): 2032-2049.;;Yeh, Li-Hao, Lei Tian, and Laura Waller. “Structured illumination microscopy with unknown patterns and a statistical prior.” Biomedical optics express 8.2 (2017): 695-711.;;International Search Report and Written Opinion dated Mar. 23, 2021, for International Application No. PCT/US2020/062970, 14 pages.",ACTIVE
137,AU,A,AU 1994/076369 A,140-541-256-365-504,1995-03-21,1995,AU 1994/076369 A,1994-08-23,US 11091593 A;;US 9409541 W,1993-08-24,Method of inhibiting nitric oxide formation,"A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal afflicted with an acute or chronic inflammatory disease which comprises administering to said mammal an effective nitric oxide inhibitory amount of methyl-, or 1,1-dimethyl-, or amino-substituted guanidines.",UNIV WASHINGTON,WILLIAMSON JOSEPH P;;CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G,,https://lens.org/140-541-256-365-504,Patent Application,no,0,0,15,38,0,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00;;A61K31/195;;A61K31/155,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00,,0,0,,,,EXPIRED
138,US,A1,US 2021/0173196 A1,167-067-230-148-987,2021-06-10,2021,US 202017110409 A,2020-12-03,US 202017110409 A;;US 201962944687 P,2019-12-06,APPARATUS AND METHOD OF ESTIMATING VALUES FROM IMAGES,"A method is used to generate a distortion model for a structured illumination microscopy (SIM) optical system. A sliding window is moved in relation to a plurality of images to define a plurality of sub-tiles. Each sub-tile represents a portion of the corresponding image. Parameters are estimated for each sub-tiles. The parameters include two or more parameters selected from the group consisting of modulation, angle, spacing, phase offset, and phase deviation. A full width at half maximum (FWHM) value associated with each sub-tile is estimated. A distortion model is estimated, based at least in part on a combination of the estimated parameters and FWHM values stored in the predetermined format and an estimated center window parameter. A two-dimensional image may be generated, based at least in part on the estimated distortion model. The two-dimensional image may include representations indicating where distortions occur in the optical system.",ILLUMINA INC,LANGLOIS ROBERT;;LU BO;;REN HONGJI;;PINTO JOSEPH;;PRINCE SIMON;;CORBETT AUSTIN,ILLUMINA INC (2020-01-30),https://lens.org/167-067-230-148-987,Patent Application,yes,11,0,14,14,0,G02B21/367;;G02B21/361;;G02B21/06;;G02B21/367;;G01N21/6458;;G01N21/6458;;G02B21/06;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024;;G02B21/367;;G02B21/06;;G02B21/14;;G02B21/361;;G06T7/0012;;G01N21/6458;;G06T2207/10056;;G06T2207/30024;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024,G02B21/36;;G02B21/14;;G06T7/00,,0,0,,,,ACTIVE
139,EP,B1,EP 0547558 B1,006-698-159-554-829,2000-04-19,2000,EP 92121318 A,1992-12-15,US 80791291 A,1991-12-16,Use of aminoguanidine for the manufacture of a medicament for inhibiting nitric oxide formation,A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal which comprises administering to said mammal an effective nitric oxide inhibitory amount of aminoguanidine.,UNIV WASHINGTON,WILLIAMSON JOSEPH ROBERT;;CORBETT JOHN ANDREW;;MCDANIEL MICHAEL LYNN;;TILTON RONALD GENE,,https://lens.org/006-698-159-554-829,Granted Patent,yes,0,0,8,38,0,A61K31/155;;A61K31/195;;A61P13/12;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61P9/12,A61K31/155;;A61K31/195;;A61P3/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61P9/12;;A61P13/12;;A61P25/00;;A61P27/02;;A61P29/00;;A61P37/00;;A61P37/06;;A61P43/00,,5,1,121-225-904-097-074,7503061;;10.1016/0272-6386(95)90051-9,"Immunology, Wiley-Liss, New York, 1991, pages 5-7 and 204;;Harrison's Principles of Internal Medicine, McGraw-Hill, New York, 13th edition, pages1630-1687;;Immunology, A Synthesis, E.Golub et al. 1991, p.261-269, 545-574;;Am.J.Kidney Dis., vol. 26, no. 6, 1995, pages 875-888;;Diabetes, vol. 42, suppl. 1, page 106A",EXPIRED
140,AU,A,AU 1996/041349 A,002-031-173-600-499,1996-05-15,1996,AU 1996/041349 A,1995-10-25,US 32892594 A;;US 9513788 W,1994-10-25,Method of inhibiting nitric oxide formation,,UNIV WASHINGTON,WILLIAMSON JOSEPH R;;CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G,,https://lens.org/002-031-173-600-499,Patent Application,no,0,6,2,38,0,A61K31/155,A61K31/155,,0,0,,,,PENDING
141,DE,D1,DE 69230928 D1,125-256-863-103-788,2000-05-25,2000,DE 69230928 T,1992-12-15,US 80791291 A,1991-12-16,Verwendung von Aminoguamidin zur Herstellung eines Arzneimittels zur Unterdrückung der Stickoxidbildung,A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal which comprises administering to said mammal an effective nitric oxide inhibitory amount of aminoguanidine.,UNIV ST LOUIS,WILLIAMSON JOSEPH ROBERT;;CORBETT JOHN ANDREW;;MCDANIEL MICHAEL LYNN;;TILTON RONALD GENE,,https://lens.org/125-256-863-103-788,Granted Patent,no,0,0,8,38,0,A61K31/155;;A61K31/195;;A61P13/12;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61P9/12,A61K31/155;;A61K31/195;;A61P3/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61P9/12;;A61P13/12;;A61P25/00;;A61P27/02;;A61P29/00;;A61P37/00;;A61P37/06;;A61P43/00,,0,0,,,,EXPIRED
142,EP,A1,EP 0558468 A1,185-240-170-716-733,1993-09-01,1993,EP 93870034 A,1993-02-26,US 84338792 A,1992-02-28,Medicament for inhibiting nitric oxide formation.,The use is disclosed of methylguanidine or dimethylguanidine for the manufacture of a medicament particularly suitable for inhibiting nitric oxide formation in a warm blooded mammal. A pharmaceutical composition is disclosed containing methylguanidine or dimethylguanidine or a pharmaceutically acceptable salt thereof which is suitable in the treatment and/or prevention of diabetes-induced vascular dysfunction and complications in humans.,UNIV WASHINGTON,CORBETT JOHN ANDREW;;MCDANIEL MICHAEL LYNN;;TILTON RONALD GENE;;WILLIAMSON JOSEPH ROBERT,WASHINGTON UNIVERSITY (2007-10-15),https://lens.org/185-240-170-716-733,Patent Application,yes,0,10,11,38,0,A61K31/155;;A61K31/195;;A61P3/08;;A61P43/00;;A61P9/00;;A61K31/195;;A61K31/155,A61K31/155;;A61K31/195;;A61P3/08;;A61P43/00,,4,3,007-096-178-377-432;;030-609-310-330-143;;090-211-385-323-542,10.1042/cs0420395;;5020280;;6433002;;1377318;;10.1016/0140-6736(92)90439-a,"CLINICAL SCIENCE vol. 42, 1972, pages 395 - 404 P.L. BALESTRI ET AL. 'Effects of uraemic serum, urea, creatinine and methylguanidine on glucose metabolism';;JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS vol. 230, no. 3, 1984, pages 710 - 717 J.A. HIRSCH 'Structure-activity relationship between guanidine alkyl derivatives and norephrinerelease: site(s) and mechanism(s) of action';;DIABETES vol. 40, no. SUP1, 1991, page 210A K. CHANG ET AL. 'Aminoguanidine prevents Glucose- and Sorbitol-induced vascular dysfunction in skin chamber granulation tissue';;THE LANCET vol. 340, no. 8811, 11 July 1992, page 116 N. BENJAMIN 'Modulators of nitric oxide synthesis'",EXPIRED
143,US,A,US 5710181 A,190-865-192-196-24X,1998-01-20,1998,US 62083396 A,1996-03-25,US 62083396 A;;US 32892594 A;;US 11091593 A;;US 84338792 A;;US 90663292 A;;US 80791291 A,1991-12-16,Inhibition of nitric oxide formation in inflammatory bowel disease,A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal afflicted with inflammatory bowel disease which comprises administering to said mammal an effective nitric oxide inhibitory amount of aminoguanidine.,UNIV WASHINGTON,WILLIAMSON JOSEPH R;;CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G,WASHINGTON UNIVERSITY (1996-03-27),https://lens.org/190-865-192-196-24X,Granted Patent,yes,13,4,3,3,0,A61K31/155;;A61K31/155,A61K31/155,514/634,10,8,019-574-203-682-076;;024-391-221-395-133;;001-397-105-172-269;;039-592-591-357-869;;045-769-356-455-053;;088-550-180-516-812;;008-676-084-275-141;;043-828-596-597-08X,10.1016/0006-2952(95)02099-3;;8619882;;7692996;;10.3109/08916939309043889;;10.2337/diacare.13.11.1180;;2261839;;pmc295094;;1991829;;10.1172/jci115014;;3487117;;10.1126/science.3487117;;1378415;;10.2337/diab.41.8.897;;10.2337/diabetes.41.8.897;;1718438;;10.1016/0925-4439(91)90040-g;;10.1073/pnas.87.24.10043;;pmc55311;;1702214,"Southan et al. (1996), Selective Pharmacological Inhibition of Distinct Nitric Oxide Synthase Isoforms, Biochemical Pharmacology 51:383 94.;;Corbett et al. (1993), Nitric Oxide Mediates IL 1 Induced Islet Dysfunction And Destruction: Prevention By Dexamethasone, Autoimmunity 15:145 53.;;Henrich (1990), Diabetes mellitus ein Krankheitssyndrom und seine Behandlung, Pharm. Ztg. 135:1711 24.;;Vlassara (1990), Chronic Diabetic Complications and Tissue Glycosylation Relevant Concern for Diabetes Prone Black Population, Diabetes Care 13:1180 1185.;;Bucala et al. (1991), Advanced Clycosylation Products Quench Nitric Oxide and Mediate Defective Endothelium Dependent Vasodilatation in Experimental Diabetes, J. Clin. Invest. 87:432 438.;;Brownlee et al. (1986), Aminoguanidine Prevents Diabetes Induced Arterial Wall Protein Cross Linking, Science 232:1629 1632.;;Corbett et al. (1992), Does Nitric Oxide Mediate Autoimmune Destruction of Cells , Diabetes 41:897 903.;;Martindale, The Extra Pharmacopoeia, 28th ed., J.E.F. Reynolds, Ed., published by The Pharmaceutical Press (London), pp. 466, 467 and 473 477, 1982.;;O Connor et al., Biochim. Biophys. Acta., 1097(3), pp. 227 231 (Biosis Abs. No. 93030356), 1991.;;Radomski et al., Proc. Natl. Sci USA, 87(24), pp. 10043 10047 (Biosis Abs. No. 91047745), 1990.",EXPIRED
144,US,A1,US 2023/0393379 A1,007-924-144-985-465,2023-12-07,2023,US 202318236088 A,2023-08-21,US 202318236088 A;;US 202017110409 A;;US 201962944687 P,2019-12-06,APPARATUS AND METHOD OF ESTIMATING VALUES FROM IMAGES,"A method is used to generate a distortion model for a structured illumination microscopy (SIM) optical system. A sliding window is moved in relation to a plurality of images to define a plurality of sub-tiles. Each sub-tile represents a portion of the corresponding image. Parameters are estimated for each sub-tiles. The parameters include two or more parameters selected from the group consisting of modulation, angle, spacing, phase offset, and phase deviation. A full width at half maximum (FWHM) value associated with each sub-tile is estimated. A distortion model is estimated, based at least in part on a combination of the estimated parameters and FWHM values stored in the predetermined format and an estimated center window parameter. A two-dimensional image may be generated, based at least in part on the estimated distortion model. The two-dimensional image may include representations indicating where distortions occur in the optical system.",ILLUMINA INC,LANGLOIS ROBERT;;LU BO;;REN HONGJI;;PINTO JOSEPH;;PRINCE SIMON;;CORBETT AUSTIN,ILLUMINA INC (2020-01-30),https://lens.org/007-924-144-985-465,Patent Application,yes,0,0,14,14,0,G02B21/367;;G02B21/361;;G02B21/06;;G02B21/367;;G01N21/6458;;G01N21/6458;;G02B21/06;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024;;G02B21/367;;G02B21/06;;G02B21/14;;G02B21/361;;G06T7/0012;;G01N21/6458;;G06T2207/10056;;G06T2207/30024;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024,G02B21/36;;G02B21/14;;G06T7/00,,0,0,,,,PENDING
145,DE,A1,DE 1443699 A1,048-287-638-790-260,1968-12-05,1968,DE 1443699 A,1963-04-04,US 18493862 A;;US 19539162 A;;US 48618865 A,1962-04-04,Verfahren zur Herstellung von Bis- und Cycloalkyliden-bis-(cycloalkylphenolen) und deren Verwendung zur Stabilisierung von Kunststoffmassen,,DOW CHEMICAL CO,JOSEPH DIETZLER ANDREW;;ALBERT GORDON DAVID;;MARVIN CORBETT JOHN;;DALE MOSS RODNEY,,https://lens.org/048-287-638-790-260,Patent Application,no,0,0,7,11,0,C07C37/14;;C07C37/20;;C07C39/17;;C07C45/69;;C07C321/00;;C07C323/00;;C08K5/13;;C08K5/132;;C08K5/375;;C10M129/16;;C10M129/24;;C10M135/30;;C10M2207/024;;C10M2207/046;;C10M2219/084;;C10M2219/087;;C10M2219/088;;C10M2219/089;;C07C41/30;;C07C2601/14;;C07C2601/18;;C07C321/00;;C07C323/00;;C10M2219/087;;C07C37/20;;C10M2219/084;;C10M135/30;;C08K5/132;;C10M2207/046;;C10M129/16;;C07C39/17;;C07C45/69;;C10M2219/088;;C10M2219/089;;C08K5/13;;C07C37/14;;C10M129/24;;C10M2207/024;;C08K5/375;;C07C41/30;;C07C2601/18;;C07C2601/14,C07C37/14;;C07C37/20;;C07C39/16;;C07C39/17;;C07C45/69;;C08K5/13;;C08K5/132;;C08K5/375;;C08L23/02;;C08L27/00;;C10M129/16;;C10M129/24;;C10M135/30,,0,0,,,,PENDING
146,CA,C,CA 2090574 C,018-106-907-888-722,1999-05-25,1999,CA 2090574 A,1993-02-26,US 84338792 A,1992-02-28,METHOD OF INHIBITING NITRIC OXIDE FORMATION,A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal which comprises administering to said mammal an effective nitric oxide inhibitory amount of methylguanidine or dimethylguanidine.,,WILLIAMSON JOSEPH ROBERT;;CORBETT JOHN ANDREW;;MCDANIEL MICHAEL LYNN;;TILTON RONALD GENE,,https://lens.org/018-106-907-888-722,Granted Patent,no,0,0,11,38,0,A61K31/155;;A61K31/195;;A61P3/08;;A61P43/00;;A61P9/00;;A61K31/195;;A61K31/155,A61K31/155;;A61K31/195;;A61P3/08;;A61P43/00,,0,0,,,,EXPIRED
147,DK,T3,DK 0558468 T3,080-836-782-686-256,1996-09-16,1996,DK 93870034 T,1993-02-26,US 84338792 A,1992-02-28,Lægemiddel til inhibering af nitrogenoxiddannelse,The use is disclosed of methylguanidine or dimethylguanidine for the manufacture of a medicament particularly suitable for inhibiting nitric oxide formation in a warm blooded mammal. A pharmaceutical composition is disclosed containing methylguanidine or dimethylguanidine or a pharmaceutically acceptable salt thereof which is suitable in the treatment and/or prevention of diabetes-induced vascular dysfunction and complications in humans. <IMAGE> <IMAGE>,UNIV WASHINGTON,CORBETT JOHN ANDREW;;MCDANIEL MICHAEL LYNN;;TILTON RONALD GENE;;WILLIAMSON JOSEPH ROBERT,,https://lens.org/080-836-782-686-256,Granted Patent,no,0,0,11,38,0,A61K31/155;;A61K31/195;;A61P3/08;;A61P43/00;;A61P9/00;;A61K31/195;;A61K31/155,A61K31/155;;A61K31/195;;A61P3/08;;A61P43/00,,0,0,,,,EXPIRED
148,US,A,US 5246971 A,072-490-316-981-594,1993-09-21,1993,US 84338792 A,1992-02-28,US 84338792 A;;US 80791291 A,1991-12-16,Method of inhibiting nitric oxide formation,A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal which comprises administering to said mammal an effective nitric oxide inhibitory amount of methylguanidine or dimethylguanidine.,UNIV WASHINGTON,WILLIAMSON JOSEPH R;;CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G,WASHINGTON UNIVERSITY (1992-02-28),https://lens.org/072-490-316-981-594,Granted Patent,yes,3,35,11,38,0,A61K31/155;;A61K31/195;;A61P3/08;;A61P43/00;;A61P9/00;;A61K31/195;;A61K31/155,A61K31/155;;A61K31/195;;A61P3/08;;A61P43/00,514/634;;514/866,9,5,007-464-222-018-08X;;086-732-125-732-349;;045-769-356-455-053;;039-592-591-357-869;;003-137-712-160-069,1712077;;10.1038/351714a0;;1852778;;3487117;;10.1126/science.3487117;;pmc295094;;1991829;;10.1172/jci115014;;1657959;;10.1016/s0021-9258(18)54642-1,"Bredt et al., Nature 351, 714 718 (1991).;;Moncada et al., Pharmacol. Rev. 43, 109 142 (1991).;;Brownlee et al., Science 232, 1629 1632 (1986).;;Bucala et al, J. Clin, Invest. 87, 432 438 (1991).;;Tilton et al. Invest. Ophthalmol. Vis. Sci. 31, 342 (1990).;;Wiliamson et al., Diabetes & Metabolisme 16, 369 370 (1990).;;Chang et al., Diabetes 40 (Supp. 1) 210A (1991).;;Corbett et al., J. Biol. Chem. 266, 21351 21354 (1991).;;Chem. Absts. 115: 248104, Griffith WO 91 04,023 (1991).",EXPIRED
149,DE,D1,DE 69304225 D1,183-598-561-803-715,1996-10-02,1996,DE 69304225 T,1993-02-26,US 84338792 A,1992-02-28,Medikament zur Hemmung der Stickoxid-Bildung,The use is disclosed of methylguanidine or dimethylguanidine for the manufacture of a medicament particularly suitable for inhibiting nitric oxide formation in a warm blooded mammal. A pharmaceutical composition is disclosed containing methylguanidine or dimethylguanidine or a pharmaceutically acceptable salt thereof which is suitable in the treatment and/or prevention of diabetes-induced vascular dysfunction and complications in humans. <IMAGE> <IMAGE>,UNIV WASHINGTON,CORBETT JOHN ANDREW;;MCDANIEL MICHAEL LYNN;;TILTON RONALD GENE;;WILLIAMSON JOSEPH ROBERT,,https://lens.org/183-598-561-803-715,Granted Patent,no,0,0,11,38,0,A61K31/155;;A61K31/195;;A61P3/08;;A61P43/00;;A61P9/00;;A61K31/195;;A61K31/155,A61K31/155;;A61K31/195;;A61P3/08;;A61P43/00,,0,0,,,,EXPIRED
150,US,A,US 5837738 A,079-421-201-490-539,1998-11-17,1998,US 79665497 A,1997-02-05,US 79665497 A;;US 32892594 A;;US 11091593 A;;US 84338792 A;;US 90663292 A;;US 80791291 A,1991-12-16,Method of inhibiting nitric oxide formation,"A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal afflicted with an acute or chronic inflammatory disease which comprises administering to said mammal an effective nitric oxide inhibitory amount of methyl-, or 1,1-dimethyl-, or amino-substituted guanidines.",UNIV WASHINGTON,WILLIAMSON JOSEPH R;;CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G,,https://lens.org/079-421-201-490-539,Granted Patent,yes,14,5,1,38,0,A61K31/155;;A61K31/155,A61K31/155,514/634,22,19,001-397-105-172-269;;060-102-128-283-227;;059-461-666-134-164;;037-676-156-992-484;;023-260-100-962-625;;024-391-221-395-133;;030-625-041-375-799;;036-358-261-658-71X;;039-635-914-583-631;;039-592-591-357-869;;013-769-115-588-268;;037-205-402-886-070;;002-044-961-033-272;;024-347-470-489-765;;045-407-490-756-879;;023-924-729-447-38X;;037-000-258-933-311;;045-769-356-455-053;;092-529-961-785-52X,10.2337/diacare.13.11.1180;;2261839;;373692;;10.1210/edrv-15-4-516;;7988484;;10.1210/er.15.4.516;;8159730;;10.1073/pnas.91.8.3228;;pmc43549;;7514189;;10.1172/jci117185;;pmc294301;;7692996;;10.3109/08916939309043889;;7505613;;10.1021/bi00213a002;;10.1042/bj2870229;;pmc1133148;;1384465;;10.1016/s0021-9258(18)42840-2;;1339449;;pmc295094;;1991829;;10.1172/jci115014;;1612108;;10.1016/0014-2999(92)90526-a;;pmc52031;;2068089;;10.1073/pnas.88.14.6107;;1935535;;10.1002/dmr.5610070106;;1715579;;10.1073/pnas.88.17.7773;;pmc52385;;2265709;;10.1016/0014-5793(90)80502-a;;3283558;;10.1056/nejm198805193182007;;2463214;;10.1007/bf02169204;;3487117;;10.1126/science.3487117;;6519200;;10.1016/0014-4835(84)90065-4,"Henrichs (1990), Pharm. Ztg. 135 :1711 24.;;Vissara (1990), Chronic Diabetic Complications and Tissue Glycosylation Relevant Concern for Diabetes Prone Black Population, Diabetes Care 13 :1180 5.;;Kieronska et al. (1978), The Influence of Aminoguanidine Derivatives on the Process of Humoral and Cellular Immunogenesis, Achivum Immunologiae 26 :959 62.;;Bach, 1994, Endocrine Rev. 15:516 42.;;Masferrer et al., 1994, Proc. Natl. Acad. Sci. USA 91:3228 32.;;Salvemini et al., 1994, J. Clin. Invest. 93:1940 47.;;Corbett et al., 1993, Autoimmunity 15:145 53.;;Corbett et al., 1993, Biochemistry 32:13767 70.;;Corbett et al., 1992, Biochem. J. 287:229 35.;;Fletcher et al., 1992, J. Biol. Chem. 267:4338 44.;;Bucala et al., 1991, J. Clin. Invest. 87:432 38.;;Ialenti et al., 1992, European J. Pharmacol. 211:177 82.;;Kihara et al., 1991, Proc. Natl. Acad. Sci9. USA 88:6107 11.;;Pugliese et al., 1991, Diabetes/Metabolism Rev. 7:35 59.;;Stuehr et al., 1991, Proc. Natl. Acad. Sci. USA 88:7773 77.;;Southern et al., 1990, FEBS. Lett. 276:42 44.;;Hibbs et al., 1990, Nitric Oxide from L Arginine: A Bioregulatory System, Moncada and Higgs, Eds., Elsevier, NY, pp. 189 223.;;Williamson et al., 1990, Diabete & Metab. 16:369 70.;;Brownlee et al., 1988, New Engl. J. Med. 318:1315 21.;;Herbort et al., 1988, Graefe s Arch. Clin. Exp. Ophthalmol. 226:553 58.;;Brownlee et al., 1986, Science 232:1629 32.;;Cousins et al., 1984, Exp. Eye Res. 39:665 26.",EXPIRED
151,AT,T1,AT E202929 T1,079-891-816-767-860,2001-07-15,2001,AT 94926572 T,1994-08-23,US 11091593 A;;US 9409541 W,1993-08-24,VERFAHREN ZUR HEMMUNG DER STICKSTOFFOXIDBILDUNG,"A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal afflicted with an acute or chronic inflammatory disease which comprises administering to said mammal an effective nitric oxide inhibitory amount of methyl-, or 1,1-dimethyl-, or amino-substituted guanidines.",UNIV WASHINGTON,WILLIAMSON JOSEPH P;;CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G,,https://lens.org/079-891-816-767-860,Granted Patent,no,0,0,15,38,0,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00;;A61K31/195;;A61K31/155,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00,,0,0,,,,DISCONTINUED
152,CA,A1,CA 3135207 A1,118-755-790-028-045,2021-06-10,2021,CA 3135207 A,2020-12-03,US 201962944687 P;;US 2020/0062970 W,2019-12-06,APPARATUS AND METHOD OF ESTIMATING VALUES FROM IMAGES,"A method is used to generate a distortion model for a structured illumination microscopy (SIM) optical system. A sliding window is moved in relation to a plurality of images to define a plurality of sub-tiles. Each sub-tile represents a portion of the corresponding image. Parameters are estimated for each sub-tiles. The parameters include two or more parameters selected from the group consisting of modulation, angle, spacing, phase offset, and phase deviation. A full width at half maximum (FWHM) value associated with each sub-tile is estimated. A distortion model is estimated, based at least in part on a combination of the estimated parameters and FWHM values stored in the predetermined format and an estimated center window parameter. A two-dimensional image may be generated, based at least in part on the estimated distortion model. The two-dimensional image may include representations indicating where distortions occur in the optical system.",ILLUMINA INC,LANGLOIS ROBERT;;LU BO;;REN HONGJII;;PINTO JOSEPH;;PRINCE SIMON;;CORBETT AUSTIN,,https://lens.org/118-755-790-028-045,Patent Application,no,0,0,14,14,0,G02B21/367;;G02B21/361;;G02B21/06;;G02B21/367;;G01N21/6458;;G01N21/6458;;G02B21/06;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024;;G02B21/367;;G02B21/06;;G02B21/14;;G02B21/361;;G06T7/0012;;G01N21/6458;;G06T2207/10056;;G06T2207/30024;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024,G02B21/06;;G01N21/63;;G01N21/64;;G02B21/36;;G06T7/00,,0,0,,,,PENDING
153,AT,T1,AT E141790 T1,024-965-379-911-468,1996-09-15,1996,AT 93870034 T,1993-02-26,US 84338792 A,1992-02-28,MEDIKAMENT ZUR HEMMUNG DER STICKOXID-BILDUNG,The use is disclosed of methylguanidine or dimethylguanidine for the manufacture of a medicament particularly suitable for inhibiting nitric oxide formation in a warm blooded mammal. A pharmaceutical composition is disclosed containing methylguanidine or dimethylguanidine or a pharmaceutically acceptable salt thereof which is suitable in the treatment and/or prevention of diabetes-induced vascular dysfunction and complications in humans. <IMAGE> <IMAGE>,UNIV WASHINGTON,CORBETT JOHN ANDREW;;MCDANIEL MICHAEL LYNN;;TILTON RONALD GENE;;WILLIAMSON JOSEPH ROBERT,,https://lens.org/024-965-379-911-468,Granted Patent,no,0,0,11,38,0,A61K31/155;;A61K31/195;;A61P3/08;;A61P43/00;;A61P9/00;;A61K31/195;;A61K31/155,A61K31/155;;A61K31/195;;A61P3/08;;A61P43/00,,0,0,,,,DISCONTINUED
154,AU,A1,AU 2020/396959 A1,039-507-840-725-943,2021-09-23,2021,AU 2020/396959 A,2020-12-03,US 201962944687 P;;US 2020/0062970 W,2019-12-06,Apparatus and method of estimating values from images,"A method is used to generate a distortion model for a structured illumination microscopy (SIM) optical system. A sliding window is moved in relation to a plurality of images to define a plurality of sub-tiles. Each sub-tile represents a portion of the corresponding image. Parameters are estimated for each sub-tiles. The parameters include two or more parameters selected from the group consisting of modulation, angle, spacing, phase offset, and phase deviation. A full width at half maximum (FWHM) value associated with each sub-tile is estimated. A distortion model is estimated, based at least in part on a combination of the estimated parameters and FWHM values stored in the predetermined format and an estimated center window parameter. A two-dimensional image may be generated, based at least in part on the estimated distortion model. The two-dimensional image may include representations indicating where distortions occur in the optical system.",ILLUMINA INC,LANGLOIS ROBERT;;LU BO;;REN HONGJII;;PINTO JOSEPH;;PRINCE SIMON;;CORBETT AUSTIN,,https://lens.org/039-507-840-725-943,Patent Application,no,0,0,14,14,0,G02B21/367;;G02B21/361;;G02B21/06;;G02B21/367;;G01N21/6458;;G01N21/6458;;G02B21/06;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024;;G02B21/367;;G02B21/06;;G02B21/14;;G02B21/361;;G06T7/0012;;G01N21/6458;;G06T2207/10056;;G06T2207/30024;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024,G02B21/06;;G01N21/64;;G01N21/65;;G02B21/36,,0,0,,,,PENDING
155,EP,A1,EP 3931618 A1,172-740-509-228-835,2022-01-05,2022,EP 20828481 A,2020-12-03,US 201962944687 P;;US 2020/0062970 W,2019-12-06,APPARATUS AND METHOD OF ESTIMATING VALUES FROM IMAGES,,ILLUMINA INC,LANGLOIS ROBERT;;LU BO;;REN HONGJII;;PINTO JOSEPH;;PRINCE SIMON;;CORBETT AUSTIN,,https://lens.org/172-740-509-228-835,Patent Application,yes,0,0,14,14,0,G02B21/367;;G02B21/361;;G02B21/06;;G02B21/367;;G01N21/6458;;G01N21/6458;;G02B21/06;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024;;G02B21/367;;G02B21/06;;G02B21/14;;G02B21/361;;G06T7/0012;;G01N21/6458;;G06T2207/10056;;G06T2207/30024;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024,G02B21/06;;G01N21/64;;G01N21/65;;G02B21/36,,0,0,,,,PENDING
156,US,A,US 5358969 A,009-166-653-117-36X,1994-10-25,1994,US 11091593 A,1993-08-24,US 11091593 A;;US 80791291 A;;US 84338792 A;;US 90663292 A,1991-12-16,Method of inhibiting nitric oxide formation,"A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal afflicted with an acute or chronic inflammatory disease which comprises administering to said mammal an effective nitric oxide inhibitory amount of methyl-, or 1,1-dimethyl-, or amino-substituted guanidines.",UNIV WASHINGTON,WILLIAMSON JOSEPH R;;CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G,WASHINGTON UNIVERSITY (1993-08-24),https://lens.org/009-166-653-117-36X,Granted Patent,yes,7,20,15,38,0,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00;;A61K31/195;;A61K31/155,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00,514/632;;514/634,9,5,007-464-222-018-08X;;086-732-125-732-349;;045-769-356-455-053;;039-592-591-357-869;;003-137-712-160-069,1712077;;10.1038/351714a0;;1852778;;3487117;;10.1126/science.3487117;;pmc295094;;1991829;;10.1172/jci115014;;1657959;;10.1016/s0021-9258(18)54642-1,"Bredt et al., Nature 351, 714 718 (1991).;;Moncada et al., Pharmacol. Rev. 43, 109 142 (1991).;;Brownlee et al., Science 232, 1629 1632 (1986).;;Bucala et al., J. Clin. Invest. 87, 432 438 (1991).;;Tilton et al., Invest. Ophthalmol. Vis. Sci. 31, 342 (1990).;;Williamson et al., Diabetes & Metabolisme 16, 369 370 (1990).;;Chang et al., Diabetes 40 (Supp. 1) 210A (1991).;;Corbett et al., J. Biol. Chem. 266, 21351 21354 (1991).;;Chem. Absts. 115: 248104, of Griffith WO 91 04,023 (1989).",EXPIRED
157,MX,A,MX 2021010497 A,042-291-469-596-427,2022-01-18,2022,MX 2021010497 A,2020-12-03,US 201962944687 P;;US 2020/0062970 W,2019-12-06,APPARATUS AND METHOD OF ESTIMATING VALUES FROM IMAGES.,"A method is used to generate a distortion model for a structured illumination microscopy (SIM) optical system. A sliding window is moved in relation to a plurality of images to define a plurality of sub-tiles. Each sub-tile represents a portion of the corresponding image. Parameters are estimated for each sub-tiles. The parameters include two or more parameters selected from the group consisting of modulation, angle, spacing, phase offset, and phase deviation. A full width at half maximum (FWHM) value associated with each sub-tile is estimated. A distortion model is estimated, based at least in part on a combination of the estimated parameters and FWHM values stored in the predetermined format and an estimated center window parameter. A two-dimensional image may be generated, based at least in part on the estimated distortion model. The two-dimensional image may include representations indicating where distortions occur in the optical system.",ILLUMINA INC,LANGLOIS ROBERT;;CORBETT AUSTIN;;LU BO;;PINTO JOSEPH;;PRINCE SIMON;;REN HONGJI,,https://lens.org/042-291-469-596-427,Patent Application,no,0,0,14,14,0,G02B21/367;;G02B21/361;;G02B21/06;;G02B21/367;;G01N21/6458;;G01N21/6458;;G02B21/06;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024;;G02B21/367;;G02B21/06;;G02B21/14;;G02B21/361;;G06T7/0012;;G01N21/6458;;G06T2207/10056;;G06T2207/30024;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024,G02B21/06;;G01N21/64;;G01N21/65;;G02B21/36,,0,0,,,,PENDING
158,EP,B1,EP 0771195 B1,113-968-313-702-479,2001-07-11,2001,EP 94926572 A,1994-08-23,US 9409541 W;;US 11091593 A,1993-08-24,METHOD OF INHIBITING NITRIC OXIDE FORMATION,"A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal afflicted with an acute or chronic inflammatory disease which comprises administering to said mammal an effective nitric oxide inhibitory amount of methyl-, or 1,1-dimethyl-, or amino-substituted guanidines.",UNIV WASHINGTON,WILLIAMSON JOSEPH P;;CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G,,https://lens.org/113-968-313-702-479,Granted Patent,yes,3,0,15,38,0,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00;;A61K31/195;;A61K31/155,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00,,1,0,,,"INVEST. OPHTHALMOL. VIS. SCI., vol. 35, no. 8, 1994, pages 3278-3288, XP000673017 R.G. TILTON ET AL.: ""Endotoxin-induced uveitis in the rat is attenuated""",EXPIRED
159,US,A,US 5246970 A,134-020-068-967-048,1993-09-21,1993,US 90663292 A,1992-06-30,US 90663292 A;;US 80791291 A,1991-12-16,Method of inhibiting nitric oxide formation,A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal which comprises administering to said mammal an effective nitric oxide inhibitory amount of aminoguanidine.,UNIV WASHINGTON,WILLIAMSON JOSEPH R;;CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G,WASHINGTON UNIVERSITY A CORP. OF MO (1992-06-30),https://lens.org/134-020-068-967-048,Granted Patent,yes,4,52,1,38,0,A61K31/155;;A61K31/195;;A61K31/195;;A61K31/155,A61K31/155;;A61K31/195,514/632;;514/903,9,5,007-464-222-018-08X;;086-732-125-732-349;;045-769-356-455-053;;039-592-591-357-869;;003-137-712-160-069,1712077;;10.1038/351714a0;;1852778;;3487117;;10.1126/science.3487117;;pmc295094;;1991829;;10.1172/jci115014;;1657959;;10.1016/s0021-9258(18)54642-1,"Bredt et al., Nature 351, 714 718 (1991).;;Moncada et al., Pharmacol. Rev. 43, 109 142 (1991).;;Brownlee et al., Science 232, 1629 1632 (1986).;;Bucala et al., J. Clin. Invest. 87, 432 438 (1991).;;Tilton et al., Invest. Ophthalmol. Vis. Sci. 31, 342 (1990).;;Williamson et al., Diabetes & Metabolisme 16, 369 370 (1990).;;Chang et al., Diabetes 40 (Supp. 1) 210A (1991).;;Corbett et al., J. Biol. Chem. 266, 21351 21354 (1991).;;Chem. Absts. 115:248104, Griffith WO 91 04,023 (1991).",EXPIRED
160,DE,T2,DE 69230928 T2,139-849-459-710-844,2001-01-11,2001,DE 69230928 T,1992-12-15,US 80791291 A,1991-12-16,Verwendung von Aminoguamidin zur Herstellung eines Arzneimittels zur Unterdrückung der Stickoxidbildung,A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal which comprises administering to said mammal an effective nitric oxide inhibitory amount of aminoguanidine.,UNIV ST LOUIS,WILLIAMSON JOSEPH ROBERT;;CORBETT JOHN ANDREW;;MCDANIEL MICHAEL LYNN;;TILTON RONALD GENE,,https://lens.org/139-849-459-710-844,Granted Patent,no,0,0,8,38,0,A61K31/155;;A61K31/195;;A61P13/12;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61P9/12,A61K31/155;;A61K31/195;;A61P3/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61P9/12;;A61P13/12;;A61P25/00;;A61P27/02;;A61P29/00;;A61P37/00;;A61P37/06;;A61P43/00,,0,0,,,,EXPIRED
161,AU,B2,AU 688370 B2,011-215-727-472-074,1998-03-12,1998,AU 1994/076369 A,1994-08-23,US 11091593 A;;US 9409541 W,1993-08-24,Method of inhibiting nitric oxide formation,"A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal afflicted with an acute or chronic inflammatory disease which comprises administering to said mammal an effective nitric oxide inhibitory amount of methyl-, or 1,1-dimethyl-, or amino-substituted guanidines.",UNIV WASHINGTON,WILLIAMSON JOSEPH P;;CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G,,https://lens.org/011-215-727-472-074,Granted Patent,no,1,0,15,38,0,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00;;A61K31/195;;A61K31/155,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00,,0,0,,,,EXPIRED
162,EP,A4,EP 0771195 A4,003-781-229-851-158,1997-12-29,1997,EP 94926572 A,1994-08-23,US 9409541 W;;US 11091593 A,1993-08-24,METHOD OF INHIBITING NITRIC OXIDE FORMATION,"A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal afflicted with an acute or chronic inflammatory disease which comprises administering to said mammal an effective nitric oxide inhibitory amount of methyl-, or 1,1-dimethyl-, or amino-substituted guanidines.",UNIV WASHINGTON,WILLIAMSON JOSEPH P;;CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G,,https://lens.org/003-781-229-851-158,Search Report,no,1,0,15,38,0,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00;;A61K31/195;;A61K31/155,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00,,1,1,016-165-286-617-803,7519183,"R.G. TILTON ET AL.: ""Endotoxin-induced uveitis in the rat is attenuated"", INVEST. OPHTHALMOL. VIS. SCI., vol. 35, no. 8, 1994, pages 3278 - 3288, XP000673017",EXPIRED
163,EP,A1,EP 0547558 A1,030-713-119-947-292,1993-06-23,1993,EP 92121318 A,1992-12-15,US 80791291 A,1991-12-16,Use of aminoguanidine for the manufacture of a medicament for inhibiting nitric oxide formation.,A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal which comprises administering to said mammal an effective nitric oxide inhibitory amount of aminoguanidine.,UNIV WASHINGTON,WILLIAMSON JOSEPH ROBERT;;CORBETT JOHN ANDREW;;MCDANIEL MICHAEL LYNN;;TILTON RONALD GENE,,https://lens.org/030-713-119-947-292,Patent Application,yes,3,15,8,38,0,A61K31/155;;A61K31/195;;A61P13/12;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61P9/12,A61K31/155;;A61K31/195;;A61P3/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61P9/12;;A61P13/12;;A61P25/00;;A61P27/02;;A61P29/00;;A61P37/00;;A61P37/06;;A61P43/00,,5,4,045-769-356-455-053;;001-397-105-172-269;;039-592-591-357-869;;088-550-180-516-812,3487117;;10.1126/science.3487117;;10.2337/diacare.13.11.1180;;2261839;;pmc295094;;1991829;;10.1172/jci115014;;1378415;;10.2337/diab.41.8.897;;10.2337/diabetes.41.8.897,"PHARM. ZTG. vol. 135, no. 26, 28 June 1990, pages 9 - 22; HELMUT R. HENRICHS: 'Diabetes mellitus - ein Krankheitssyndrom und seine Behandlung';;SCIENCE vol. 232, no. 4758, June 1986, pages 1629 - 1632; M.BROWNLEE ET AL.: 'Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking';;DIABETES CARE vol. 13, no. 11, November 1990, pages 1180 - 1185; HELEN VLASSARA: 'Chronic diabetic complications and tissue glycosylation';;J.CLIN.INVEST. vol. 87, no. 2, 1991, pages 432 - 438; RICHARD BUCALA ET AL.: 'Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes';;DIABETES vol. 41, no. 8, 1992, pages 897 - 903; JOHN A. CORBETT ET AL.: 'Does nitric oxide mediate autoimmune destruction of beta-cells?'",EXPIRED
164,TW,A,TW 202138866 A,040-882-966-311-332,2021-10-16,2021,TW 109142219 A,2020-12-01,US 201962944687 P,2019-12-06,Apparatus and method of estimating values from images,"A method is used to generate a distortion model for a structured illumination microscopy (SIM) optical system. A sliding window is moved in relation to a plurality of images to define a plurality of sub-tiles. Each sub-tile represents a portion of the corresponding image. Parameters are estimated for each sub-tiles. The parameters include two or more parameters selected from the group consisting of modulation, angle, spacing, phase offset, and phase deviation. A full width at half maximum (FWHM) value associated with each sub-tile is estimated. A distortion model is estimated, based at least in part on a combination of the estimated parameters and FWHM values stored in the predetermined format and an estimated center window parameter. A two-dimensional image may be generated, based at least in part on the estimated distortion model. The two-dimensional image may include representations indicating where distortions occur in the optical system.",ILLUMINA INC,LANGLOIS ROBERT;;LU BO;;REN HONGJI;;PINTO JOSEPH;;PRINCE SIMON;;CORBETT AUSTIN,,https://lens.org/040-882-966-311-332,Patent of Addition,no,0,0,14,14,0,G02B21/367;;G02B21/361;;G02B21/06;;G02B21/367;;G01N21/6458;;G01N21/6458;;G02B21/06;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024;;G02B21/367;;G02B21/06;;G02B21/14;;G02B21/361;;G06T7/0012;;G01N21/6458;;G06T2207/10056;;G06T2207/30024;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024,G02B21/06;;G01N21/64;;G01N21/65;;G02B21/36,,0,0,,,,PENDING
165,ES,T3,ES 2161782 T3,169-450-944-088-095,2001-12-16,2001,ES 94926572 T,1994-08-23,US 11091593 A,1993-08-24,METODO DE INHIBICION DE FORMACION DE OXIDO NITRICO.,"A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal afflicted with an acute or chronic inflammatory disease which comprises administering to said mammal an effective nitric oxide inhibitory amount of methyl-, or 1,1-dimethyl-, or amino-substituted guanidines.",UNIV WASHINGTON,WILLIAMSON JOSEPH P;;CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G,,https://lens.org/169-450-944-088-095,Granted Patent,no,0,0,15,38,0,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00;;A61K31/195;;A61K31/155,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00,,0,0,,,,EXPIRED
166,CN,A,CN 112925091 A,071-075-894-637-037,2021-06-08,2021,CN 202011429023 A,2020-12-07,US 201962944687 P,2019-12-06,APPARATUS AND METHOD OF ESTIMATING VALUES FROM IMAGES,"The invention relates to an apparatus and a method of estimating values from images. A method is used to generate a distortion model for a structured illumination microscopy (SIM) optical system. A sliding window is moved in relation to a plurality of images to define a plurality of sub-tiles. Each sub-tile represents a portion of the corresponding image. Parameters are estimated for each sub-tiles. The parameters include two or more parameters selected from the group consisting of modulation, angle, spacing, phase offset, and phase deviation. A full width at half maximum (FWHM) value associated with each sub-tile is estimated. A distortion model is estimated, based at least in part on a combination of the estimated parameters and FWHM values stored in the predetermined format and an estimated center window parameter. A two-dimensional image may be generated, based at least in part on the estimated distortion model. The two-dimensional image may include representations indicating where distortions occur in the optical system.",ILLUMINA INC,LANGLOIS ROBERT;;LU BO;;REN HONGJI;;PINTO JOSEPH;;PRINCE SIMON;;CORBETT AUSTIN,,https://lens.org/071-075-894-637-037,Patent Application,no,0,1,14,14,0,G02B21/367;;G02B21/361;;G02B21/06;;G02B21/367;;G01N21/6458;;G01N21/6458;;G02B21/06;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024;;G02B21/367;;G02B21/06;;G02B21/14;;G02B21/361;;G06T7/0012;;G01N21/6458;;G06T2207/10056;;G06T2207/30024;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024,G02B21/36,,0,0,,,,PENDING
167,WO,A1,WO 1995/005811 A1,132-175-522-324-899,1995-03-02,1995,US 9409541 W,1994-08-23,US 11091593 A,1993-08-24,METHOD OF INHIBITING NITRIC OXIDE FORMATION,"A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal afflicted with an acute or chronic inflammatory disease which comprises administering to said mammal an effective nitric oxide inhibitory amount of methyl-, or 1,1-dimethyl-, or amino-substituted guanidines.",UNIV WASHINGTON,WILLIAMSON JOSEPH P;;CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G,,https://lens.org/132-175-522-324-899,Patent Application,yes,2,2,15,38,0,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00;;A61K31/195;;A61K31/155,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00,,0,0,,,,PATENTED
168,CA,A1,CA 2090574 A1,031-762-321-571-919,1993-08-29,1993,CA 2090574 A,1993-02-26,US 84338792 A,1992-02-28,METHOD OF INHIBITING NITRIC OXIDE FORMATION,The use is disclosed of methylguanidine or dimethylguanidine for the manufacture of a medicament particularly suitable for inhibiting nitric oxide formation in a warm blooded mammal. A pharmaceutical composition is disclosed containing methylguanidine or dimethylguanidine or a pharmaceutically acceptable salt thereof which is suitable in the treatment and/or prevention of diabetes-induced vascular dysfunction and complications in humans. <IMAGE> <IMAGE>,UNIV WASHINGTON,CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G;;WILLIAMSON JOSEPH R,,https://lens.org/031-762-321-571-919,Patent Application,no,0,0,11,38,0,A61K31/155;;A61K31/195;;A61P3/08;;A61P43/00;;A61P9/00;;A61K31/195;;A61K31/155,A61K31/155;;A61K31/195;;A61P3/08;;A61P43/00,,0,0,,,,EXPIRED
169,US,A1,US 2003/0109913 A1,008-915-510-689-458,2003-06-12,2003,US 1223001 A,2001-12-06,US 1223001 A,2001-12-06,Bio-implant and method of making the same,"
   A bio-implant having a length and a proximal and a distal end. The bio-implant has at least two lamina of dielectric material joined together, thereby defining a boundary and also defining a side surface that is intersected by this boundary. In addition, at least one set of conductors is interposed between the two lamina and extend lengthwise from the proximal end toward the distal end, each one of the set of conductors being terminated adjacent to the side surface to form a set of conductor terminations. Further, a set of electrode contact points are constructed on the side surface, with each electrode contact point contacting one of said conductor terminations. 
",KETTERL JOSEPH P.;;YARNO JOHN P.;;CORBETT SCOTT S.;;CLARY THOMAS R.,KETTERL JOSEPH P;;YARNO JOHN P;;CORBETT SCOTT S;;CLARY THOMAS R,MICROCONNEX CORPORATION (2002-03-05);;ADVANCED COCHLEAR SYSTEMS INC (2002-03-05),https://lens.org/008-915-510-689-458,Patent Application,yes,0,3,7,7,0,A61N1/0541;;Y10T29/49124;;Y10T29/49124;;A61N1/0541,A61N1/05,607/116,0,0,,,,EXPIRED
170,WO,A1,WO 1997/035566 A1,019-206-784-069-157,1997-10-02,1997,US 9704866 W,1997-03-25,US 62083396 A,1996-03-25,INHIBITION OF NITRIC OXIDE FORMATION IN ACUTE AND CHRONIC INFLAMMATION,A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal afflicted with a pathophysiologic condition manifested by acute and chronic inflammation which comprises administering to said mammal an effective nitric oxide inhibitory amount of aminoguanidine.,UNIV WASHINGTON,WILLIAMSON JOSEPH R;;CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G,,https://lens.org/019-206-784-069-157,Patent Application,yes,2,2,3,3,0,A61K31/155;;A61K31/155,A61K31/155,,0,0,,,,PENDING
171,BR,A2,BR 112021019628 A2,028-734-332-851-231,2022-06-21,2022,BR 112021019628 A,2020-12-03,US 2020/0062970 W;;US 201962944687 P,2019-12-06,"Método, mídia legível por processador e aparelho","método, mídia legível por processador e aparelho. a presente invenção se refere a um método que é utilizado para gerar um modelo de distorção para um sistema óptico de microscopia de iluminação estruturada (sim). uma janela deslizante é movida em relação a uma pluralidade de imagens para definir uma pluralidade de sub-blocos. cada sub-bloco representa uma porção da imagem correspondente. os parâmetros são estimados para cada sub-bloco. os parâmetros incluem dois ou mais parâmetros selecionados do grupo que consiste em modulação, ângulo, espaçamento, deslocamento de fase e desvio de fase. um valor de largura total a meia altura (fwhm) associado a cada sub-bloco é estimado. um modelo de distorção é estimado, com base, ao menos em parte, em uma combinação dos parâmetros estimados e valores de fwhm armazenados no formato predeterminado e em um parâmetro estimado da janela central. uma imagem bidimensional pode ser gerada, com base, ao menos em parte, no modelo de distorção estimado. a imagem bidimensional pode incluir representações que indicam onde ocorrem distorções no sistema óptico.",ILLUMINA INC,CORBETT AUSTIN;;LU BO;;REN HONGJI;;PINTO JOSEPH;;LANGLOIS ROBERT;;PRINCE SIMON,,https://lens.org/028-734-332-851-231,Patent Application,no,0,0,14,14,0,G02B21/367;;G02B21/361;;G02B21/06;;G02B21/367;;G01N21/6458;;G01N21/6458;;G02B21/06;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024;;G02B21/367;;G02B21/06;;G02B21/14;;G02B21/361;;G06T7/0012;;G01N21/6458;;G06T2207/10056;;G06T2207/30024;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024,G01N21/64;;G01N21/65;;G02B21/06;;G02B21/36,,0,0,,,,PENDING
172,CA,C,CA 2169481 C,036-912-636-846-406,1999-11-16,1999,CA 2169481 A,1994-08-23,US 11091593 A;;US 9409541 W,1993-08-24,METHOD OF INHIBITING NITRIC OXIDE FORMATION,"A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal afflicted with an acute or chronic inflammatory disease which comprises administering to said mammal an effective nitric oxide inhibitory amount of methyl-, or 1,1 dimethyl-, or amino-substituted guanidines.",,WILLIAMSON JOSEPH R;;CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G,,https://lens.org/036-912-636-846-406,Granted Patent,no,0,0,15,38,0,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00;;A61K31/195;;A61K31/155,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00,,0,0,,,,EXPIRED
173,WO,A1,WO 1996/012483 A1,053-979-575-375-841,1996-05-02,1996,US 9513788 W,1995-10-25,US 32892594 A,1994-10-25,METHOD OF INHIBITING NITRIC OXIDE FORMATION,"A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal afflicted with an acute or chronic inflammatory disease which comprises administering to said mammal an effective nitric oxide inhibitory amount of methyl-, or 1,1-dimethyl-, or amino-substituted guanidines.",UNIV WASHINGTON;;WILLIAMSON JOSEPH R;;CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G,WILLIAMSON JOSEPH R;;CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G,,https://lens.org/053-979-575-375-841,Patent Application,yes,2,23,2,38,0,A61K31/155,A61K31/155,,0,0,,,,PENDING
174,WO,A1,WO 2021/113421 A1,120-207-264-624-36X,2021-06-10,2021,US 2020/0062970 W,2020-12-03,US 201962944687 P,2019-12-06,APPARATUS AND METHOD OF ESTIMATING VALUES FROM IMAGES,"A method is used to generate a distortion model for a structured illumination microscopy (SIM) optical system. A sliding window is moved in relation to a plurality of images to define a plurality of sub-tiles. Each sub-tile represents a portion of the corresponding image. Parameters are estimated for each sub-tiles. The parameters include two or more parameters selected from the group consisting of modulation, angle, spacing, phase offset, and phase deviation. A full width at half maximum (FWHM) value associated with each sub-tile is estimated. A distortion model is estimated, based at least in part on a combination of the estimated parameters and FWHM values stored in the predetermined format and an estimated center window parameter. A two-dimensional image may be generated, based at least in part on the estimated distortion model. The two-dimensional image may include representations indicating where distortions occur in the optical system.",ILLUMINA INC,LANGLOIS ROBERT;;LU BO;;REN HONGJII;;PINTO JOSEPH;;PRINCE SIMON;;CORBETT AUSTIN,,https://lens.org/120-207-264-624-36X,Patent Application,yes,4,0,14,14,0,G02B21/367;;G02B21/361;;G02B21/06;;G02B21/367;;G01N21/6458;;G01N21/6458;;G02B21/06;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024;;G02B21/367;;G02B21/06;;G02B21/14;;G02B21/361;;G06T7/0012;;G01N21/6458;;G06T2207/10056;;G06T2207/30024;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024,G02B21/06;;G01N21/64;;G01N21/65;;G02B21/36,,3,2,005-716-544-072-279;;010-656-014-403-973,23389185;;10.1364/oe.21.002032;;10.1109/jstqe.2016.2521542,"WICKER ET AL., PHASE OPTIMISATION FOR STRUCTURED ILLUMINATION MICROSCOPY, 2013;;LAL ET AL., STRUCTURED ILLUMINATION MICROSCOPY IMAGE RECONSTRUCTION ALGORITHM, 2015;;WICKER, HELP EXPLAIN WICKER PHASE ESTIMATION, 2013",PENDING
175,DE,T2,DE 69427711 T2,126-863-993-942-281,2002-05-08,2002,DE 69427711 T,1994-08-23,US 11091593 A;;US 9409541 W,1993-08-24,VERFAHREN ZUR HEMMUNG DER STICKSTOFFOXIDBILDUNG,"A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal afflicted with an acute or chronic inflammatory disease which comprises administering to said mammal an effective nitric oxide inhibitory amount of methyl-, or 1,1-dimethyl-, or amino-substituted guanidines.",UNIV ST LOUIS,WILLIAMSON JOSEPH P;;CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G,,https://lens.org/126-863-993-942-281,Granted Patent,no,0,0,15,38,0,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00;;A61K31/195;;A61K31/155,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00,,0,0,,,,EXPIRED
176,CA,A1,CA 2085399 A1,141-630-021-665-191,1993-06-17,1993,CA 2085399 A,1992-12-15,US 80791291 A,1991-12-16,METHOD FOR INHIBITING NITRIC OXIDE FORMATION,07-24(836)A METHOD OF INHIBITING NITRIC OXIDE FORMATION Abstract of the Disclosure A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal which comprises administering to said mammal an effective nitric oxide inhibitory amount of aminoguanidine.,UNIV WASHINGTON,WILLIAMSON JOSEPH R;;CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G,,https://lens.org/141-630-021-665-191,Patent Application,no,0,0,8,38,0,A61K31/155;;A61K31/195;;A61P13/12;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61P9/12,A61K31/155;;A61K31/195;;A61P3/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61P9/12;;A61P13/12;;A61P25/00;;A61P27/02;;A61P29/00;;A61P37/00;;A61P37/06;;A61P43/00,,0,0,,,,DISCONTINUED
177,NZ,A,NZ 273167 A,139-438-899-027-735,1999-08-30,1999,NZ 27316794 A,1994-08-23,US 11091593 A;;US 9409541 W,1993-08-24,"INHIBITING NITRIC OXIDE PRODUCTION IN WARM-BLOODED MAMMAL BY ADMINISTRATION OF AMINO-, DIAMINO-, METHYL- OR DIMETHYLGUANIDINE","A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal afflicted with an acute or chronic inflammatory disease which comprises administering to said mammal an effective nitric oxide inhibitory amount of methyl-, or 1,1-dimethyl-, or amino-substituted guanidines.",UNIV WASHINGTON,WILLIAMSON JOSEPH P;;CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G,,https://lens.org/139-438-899-027-735,Patent Application,no,0,0,15,38,0,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00;;A61K31/195;;A61K31/155,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00,,0,0,,,,DISCONTINUED
178,EP,A1,EP 0771195 A1,129-954-486-702-956,1997-05-07,1997,EP 94926572 A,1994-08-23,US 9409541 W;;US 11091593 A,1993-08-24,METHOD OF INHIBITING NITRIC OXIDE FORMATION,"A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal afflicted with an acute or chronic inflammatory disease which comprises administering to said mammal an effective nitric oxide inhibitory amount of methyl-, or 1,1-dimethyl-, or amino-substituted guanidines.",UNIV WASHINGTON,WILLIAMSON JOSEPH P;;CORBETT JOHN A;;MCDANIEL MICHAEL L;;TILTON RONALD G,,https://lens.org/129-954-486-702-956,Patent Application,yes,0,0,15,38,0,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00;;A61K31/195;;A61K31/155,A61K31/155;;A61K31/195;;A61P27/02;;A61P29/00,,0,0,,,,EXPIRED
179,KR,A,KR 20220110661 A,158-000-976-512-527,2022-08-09,2022,KR 20217030528 A,2020-12-03,US 201962944687 P;;US 2020/0062970 W,2019-12-06,이미지들로부터 값들을 추정하는 장치 및 방법,"방법은 구조화된 조명 현미경(structured illumination microscopy, SIM) 광학 시스템에 대한 왜곡 모델을 생성하는 데 사용된다. 복수의 서브-타일들을 한정하기 위해 복수의 이미지들에 대해 슬라이딩 윈도우가 이동된다. 각각의 서브-타일은 대응하는 이미지의 일부분을 나타낸다. 파라미터들이 각각의 서브-타일들에 대해 추정된다. 파라미터들은 변조, 각도, 간격, 위상 오프셋, 및 위상 편차로 이루어진 군으로부터 선택되는 2개 이상의 파라미터들을 포함한다. 각각의 서브-타일과 연관된 반치전폭(FWHM) 값이 추정된다. 왜곡 모델은 미리결정된 포맷으로 저장된 추정된 파라미터들 및 FWHM 값들과 추정된 중심 윈도우 파라미터의 조합에 적어도 부분적으로 기초하여 추정된다. 추정된 왜곡 모델에 적어도 부분적으로 기초하여 2차원 이미지가 생성될 수 있다. 2차원 이미지는 왜곡들이 광학 시스템에서 발생하는 곳을 나타내는 표현들을 포함할 수 있다.",ILLUMINA INC,LANGLOIS ROBERT;;LU BO;;REN HONGJI;;PINTO JOSEPH;;PRINCE SIMON;;CORBETT AUSTIN,,https://lens.org/158-000-976-512-527,Patent Application,no,0,0,14,14,0,G02B21/367;;G02B21/361;;G02B21/06;;G02B21/367;;G01N21/6458;;G01N21/6458;;G02B21/06;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024;;G02B21/367;;G02B21/06;;G02B21/14;;G02B21/361;;G06T7/0012;;G01N21/6458;;G06T2207/10056;;G06T2207/30024;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024,G02B21/36;;G01N21/64;;G02B21/06;;G02B21/14;;G06T7/00,,0,0,,,,PENDING
180,DE,T2,DE 69304225 T2,094-966-234-624-859,1997-01-30,1997,DE 69304225 T,1993-02-26,US 84338792 A,1992-02-28,Medikament zur Hemmung der Stickoxid-Bildung,The use is disclosed of methylguanidine or dimethylguanidine for the manufacture of a medicament particularly suitable for inhibiting nitric oxide formation in a warm blooded mammal. A pharmaceutical composition is disclosed containing methylguanidine or dimethylguanidine or a pharmaceutically acceptable salt thereof which is suitable in the treatment and/or prevention of diabetes-induced vascular dysfunction and complications in humans. <IMAGE> <IMAGE>,UNIV WASHINGTON,CORBETT JOHN ANDREW;;MCDANIEL MICHAEL LYNN;;TILTON RONALD GENE;;WILLIAMSON JOSEPH ROBERT,,https://lens.org/094-966-234-624-859,Granted Patent,no,0,0,11,38,0,A61K31/155;;A61K31/195;;A61P3/08;;A61P43/00;;A61P9/00;;A61K31/195;;A61K31/155,A61K31/155;;A61K31/195;;A61P3/08;;A61P43/00,,0,0,,,,EXPIRED
181,AU,A8,AU 2002/364528 A8,065-928-283-314-786,2003-06-23,2003,AU 2002/364528 A,2002-12-05,US 1223001 A;;US 0238889 W,2001-12-06,Bio-implant and method of making the same,,MICROCONNEX CORP;;KETTERL JOSEPH R;;CLARY THOMAS R;;CORBETT SCOTT S III;;YARNO JOHN P;;ADVANCED COCHLEAR SYS INC,CORBETT SCOTT S III;;YARNO JOHN P;;KETTERL JOSEPH R;;CLARY THOMAS R,,https://lens.org/065-928-283-314-786,Patent Application,no,0,0,7,7,0,A61N1/0541;;Y10T29/49124;;Y10T29/49124;;A61N1/0541,A61N1/05,,0,0,,,,DISCONTINUED
182,WO,A2,WO 2003/049638 A2,048-557-121-975-358,2003-06-19,2003,US 0238889 W,2002-12-05,US 1223001 A,2001-12-06,BIO-IMPLANT AND METHOD OF MAKING THE SAME,"A bio-implant (10) having a length and a proximal (16) and a distal end (18). The bio-implant has at least two lamina (12, 13) of dielectric material joined together, thereby defining a boundary therebetween and also defining a side surface (20) that is intersected by this boundary. In addition, at least one set of conductors (14) is interposed between the two lamina (12, 13) and extend lengthwise from the proximal (16) end toward the distal end (18), each one of the set of conductors being terminated adjacent to the side surface (20) to form a set of conductor terminations. Further, a set of electrode contact points (22) are constructed on the side surface (20), with each electrode contact point (22) contacting one of said conductor (14) terminations.",ADVANCED COCHLEAR SYS INC;;MICROCONNEX CORP;;KETTERL JOSEPH R;;YARNO JOHN P;;CORBETT SCOTT S III;;CLARY THOMAS R,KETTERL JOSEPH R;;YARNO JOHN P;;CORBETT SCOTT S III;;CLARY THOMAS R,,https://lens.org/048-557-121-975-358,Patent Application,yes,0,0,7,7,0,A61N1/0541;;Y10T29/49124;;Y10T29/49124;;A61N1/0541,A61N1/05,,0,0,,,,PENDING
183,US,B2,US 6678564 B2,143-734-609-524-671,2004-01-13,2004,US 1223001 A,2001-12-06,US 1223001 A,2001-12-06,Bio-implant and method of making the same,"
    A bio-implant having a length and a proximal and a distal end. The bio-implant has at least two lamina of dielectric material joined together, thereby defining a boundary and also defining a side surface that is intersected by this boundary. In addition, at least one set of conductors is interposed between the two lamina and extend lengthwise from the proximal end toward the distal end, each one of the set of conductors being terminated adjacent to the side surface to form a set of conductor terminations. Further, a set of electrode contact points are constructed on the side surface, with each electrode contact point contacting one of said conductor terminations. 
",ADVANCED COCHLEAR SYS INC;;MICROCONNEX CORP,KETTERL JOSEPH R;;YARNO JOHN P;;CORBETT III SCOTT S;;CLARY THOMAS R,MICROCONNEX CORPORATION (2002-03-05);;ADVANCED COCHLEAR SYSTEMS INC (2002-03-05),https://lens.org/143-734-609-524-671,Granted Patent,yes,4,103,7,7,0,A61N1/0541;;Y10T29/49124;;Y10T29/49124;;A61N1/0541,A61N1/05,607/137;;29/829,0,0,,,,EXPIRED
184,IL,A,IL 286665 A,039-346-550-521-796,2021-10-31,2021,IL 28666521 A,2021-09-24,US 201962944687 P;;US 2020/0062970 W,2019-12-06,Apparatus and method of estimating values from images,,ILLUMINA INC;;LANGLOIS ROBERT;;LU BO;;REN HONGJI;;PINTO JOSEPH FRANCIS;;PRINCE SIMON;;CORBETT AUSTIN,LANGLOIS ROBERT;;LU BO;;REN HONGJI;;PINTO JOSEPH FRANCIS;;PRINCE SIMON;;CORBETT AUSTIN,,https://lens.org/039-346-550-521-796,Patent Application,no,0,0,14,14,0,G02B21/367;;G02B21/361;;G02B21/06;;G02B21/367;;G01N21/6458;;G01N21/6458;;G02B21/06;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024;;G02B21/367;;G02B21/06;;G02B21/14;;G02B21/361;;G06T7/0012;;G01N21/6458;;G06T2207/10056;;G06T2207/30024;;G02B21/14;;G02B21/367;;G06T7/0012;;G06T2207/10056;;G06T2207/30024,,,0,0,,,,PENDING
185,AU,A1,AU 2002/364528 A1,122-255-010-109-105,2003-06-23,2003,AU 2002/364528 A,2002-12-05,US 1223001 A;;US 0238889 W,2001-12-06,BIO-IMPLANT AND METHOD OF MAKING THE SAME,,MICROCONNEX CORP;;KETTERL JOSEPH R;;YARNO JOHN P;;CORBETT SCOTT S III;;CLARY THOMAS R;;ADVANCED COCHLEAR SYS INC,KETTERL JOSEPH R;;YARNO JOHN P;;CORBETT SCOTT S III;;CLARY THOMAS R,,https://lens.org/122-255-010-109-105,Patent Application,no,0,0,7,7,0,A61N1/0541;;Y10T29/49124;;Y10T29/49124;;A61N1/0541,A61N1/05,,0,0,,,,DISCONTINUED
186,WO,A3,WO 2003/049638 A3,126-063-144-106-769,2004-04-22,2004,US 0238889 W,2002-12-05,US 1223001 A,2001-12-06,BIO-IMPLANT AND METHOD OF MAKING THE SAME,"A bio-implant (10) having a length and a proximal (16) and a distal end (18). The bio-implant has at least two lamina (12, 13) of dielectric material joined together, thereby defining a boundary therebetween and also defining a side surface (20) that is intersected by this boundary. In addition, at least one set of conductors (14) is interposed between the two lamina (12, 13) and extend lengthwise from the proximal (16) end toward the distal end (18), each one of the set of conductors being terminated adjacent to the side surface (20) to form a set of conductor terminations. Further, a set of electrode contact points (22) are constructed on the side surface (20), with each electrode contact point (22) contacting one of said conductor (14) terminations.",ADVANCED COCHLEAR SYS INC;;MICROCONNEX CORP;;KETTERL JOSEPH R;;YARNO JOHN P;;CORBETT SCOTT S III;;CLARY THOMAS R,KETTERL JOSEPH R;;YARNO JOHN P;;CORBETT SCOTT S III;;CLARY THOMAS R,,https://lens.org/126-063-144-106-769,Search Report,yes,2,0,7,7,0,A61N1/0541;;Y10T29/49124;;Y10T29/49124;;A61N1/0541,A61N1/05,,0,0,,,,PENDING
187,US,A1,US 2022/0113532 A1,020-030-613-370-809,2022-04-14,2022,US 202117558829 A,2021-12-22,US 202117558829 A;;US 202017110406 A;;US 201962944692 P,2019-12-06,APPARATUS AND METHOD OF PROVIDING PARAMETER ESTIMATION,"A method is used to generate a report presenting parameter values corresponding to a structured illumination microscopy (SIM) optical system. The parameter values are based at least in part on the performed modulation calculation corresponding to an image set captured with the SIM optical system. A minimum FWHM slice is identified, based at least in part on an average FWHM value across the images in the first image set. Parameter estimation is performed on the identified minimum FWHM slice. Best in-focus parameters are identified based at least in part on the performed estimation. A phase estimate is performed for each image in the set. A modulation calculation is performed based at least in part on the identified best in-focus parameters. The report is based at least in part on the performed modulation calculation.",ILLUMINA INC,CORBETT AUSTIN;;LU BO;;LANGLOIS ROBERT;;PINTO JOSEPH;;CHEN YU;;NEWMAN PETER;;REN HONGJI,ILLUMINA INC (2020-02-05),https://lens.org/020-030-613-370-809,Patent Application,yes,4,0,22,22,0,G02B21/367;;G02B21/361;;G02B21/0032;;G02B21/0076;;G02B21/365;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/082;;G02B21/365;;G02B21/367;;G02B26/06;;G06T7/0014;;G06T7/80;;G06T2207/10056;;G06T2207/30168;;G02B21/06;;G02B21/361;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/361;;G02B21/06;;G06T7/0014;;G06T7/80;;G02B21/082;;G06T2207/10056;;G06T2207/30168;;H04N23/56;;G06T7/80;;G02B21/082;;G02B21/365;;G02B26/06;;G06T7/0014;;G06T2207/10056;;G06T2207/30168;;H04N23/56,G02B21/36;;G02B26/06;;G06T7/00;;G06T7/80;;H04N5/225,,0,0,,,,ACTIVE
188,SA,B1,SA 521430479 B1,061-244-806-991-864,2023-01-10,2023,SA 521430479 A,2021-09-30,US 201962944692 P;;US 2020/0062971 W,2019-12-06,APPARATUS AND METHOD OF PROVIDING PARAMETER ESTIMATION,"A method is used to generate a report presenting parameter values corresponding to a SIM optical system (100). The parameter values are based at least in part on the performed modulation calculation corresponding to an image set (410) captured with the SIM optical system (100). A minimum FWHM slice is identified, based at least in part on an average FWHM value across the images in the first image set. Parameter estimation is performed on the identified minimum FWHM slice. Best in-focus parameters are identified based at least in part on the performed estimation (418). A phase estimate is performed for each image in the set. A modulation calculation is performed based at least in part on the identified best in-focus parameters. The report is based at least in part on the performed modulation calculation. [Figure 7]",ILLUMINA INC,AUSTIN CORBETT;;BO LU;;PETER NEWMAN;;JOSEPH PINTO;;ROBERT LANGLOIS;;HONGJI REN;;YU CHEN,,https://lens.org/061-244-806-991-864,Granted Patent,no,0,0,22,22,0,G02B21/367;;G02B21/361;;G02B21/0032;;G02B21/0076;;G02B21/365;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/082;;G02B21/365;;G02B21/367;;G02B26/06;;G06T7/0014;;G06T7/80;;G06T2207/10056;;G06T2207/30168;;G02B21/06;;G02B21/361;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/361;;G02B21/06;;G06T7/0014;;G06T7/80;;G02B21/082;;G06T2207/10056;;G06T2207/30168;;H04N23/56;;G06T7/80;;G02B21/082;;G02B21/365;;G02B26/06;;G06T7/0014;;G06T2207/10056;;G06T2207/30168;;H04N23/56,,,0,0,,,,ACTIVE
189,EP,A1,EP 4070145 A1,182-772-447-447-117,2022-10-12,2022,EP 20829106 A,2020-12-03,US 201962944692 P;;US 2020/0062971 W,2019-12-06,APPARATUS AND METHOD OF PROVIDING PARAMETER ESTIMATION,,ILLUMINA INC,CORBETT AUSTIN;;LU BO;;LANGLOIS ROBERT;;PINTO JOSEPH;;CHEN YU;;NEWMAN PETER;;REN HONGJI,,https://lens.org/182-772-447-447-117,Patent Application,yes,0,0,22,22,0,G02B21/367;;G02B21/361;;G02B21/0032;;G02B21/0076;;G02B21/365;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/082;;G02B21/365;;G02B21/367;;G02B26/06;;G06T7/0014;;G06T7/80;;G06T2207/10056;;G06T2207/30168;;G02B21/06;;G02B21/361;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/361;;G02B21/06;;G06T7/0014;;G06T7/80;;G02B21/082;;G06T2207/10056;;G06T2207/30168;;H04N23/56;;G06T7/80;;G02B21/082;;G02B21/365;;G02B26/06;;G06T7/0014;;G06T2207/10056;;G06T2207/30168;;H04N23/56,G02B21/00;;G02B21/36,,0,0,,,,PENDING
190,US,A1,US 2021/0173194 A1,071-924-299-468-471,2021-06-10,2021,US 202017110406 A,2020-12-03,US 202017110406 A;;US 201962944692 P,2019-12-06,APPARATUS AND METHOD OF PROVIDING PARAMETER ESTIMATION,"A method is used to generate a report presenting parameter values corresponding to a structured illumination microscopy (SIM) optical system. The parameter values are based at least in part on the performed modulation calculation corresponding to an image set captured with the SIM optical system. A minimum FWHM slice is identified, based at least in part on an average FWHM value across the images in the first image set. Parameter estimation is performed on the identified minimum FWHM slice. Best in-focus parameters are identified based at least in part on the performed estimation. A phase estimate is performed for each image in the set. A modulation calculation is performed based at least in part on the identified best in-focus parameters. The report is based at least in part on the performed modulation calculation.",ILLUMINA INC,CORBETT AUSTIN;;LU BO;;LANGLOIS ROBERT;;PINTO JOSEPH;;CHEN YU;;NEWMAN PETER;;REN HONGJI,ILLUMINA INC (2020-02-05),https://lens.org/071-924-299-468-471,Patent Application,yes,0,1,22,22,0,G02B21/367;;G02B21/361;;G02B21/0032;;G02B21/0076;;G02B21/365;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/082;;G02B21/365;;G02B21/367;;G02B26/06;;G06T7/0014;;G06T7/80;;G06T2207/10056;;G06T2207/30168;;G02B21/06;;G02B21/361;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/361;;G02B21/06;;G06T7/0014;;G06T7/80;;G02B21/082;;G06T2207/10056;;G06T2207/30168;;H04N23/56;;G06T7/80;;G02B21/082;;G02B21/365;;G02B26/06;;G06T7/0014;;G06T2207/10056;;G06T2207/30168;;H04N23/56,G02B21/36;;G02B26/06;;G06T7/00;;G06T7/80;;H04N5/225,,0,0,,,,ACTIVE
191,KR,A,KR 20220112175 A,093-185-177-842-72X,2022-08-10,2022,KR 20217030510 A,2020-12-03,US 201962944692 P;;US 2020/0062971 W,2019-12-06,파라미터 추정을 제공하는 장치 및 방법,"방법은 구조화된 조명 현미경(structured illumination microscopy, SIM) 광학 시스템에 대응하는 파라미터 값들을 제시하는 보고서를 생성하는 데 사용된다. 파라미터 값들은 SIM 광학 시스템으로 캡처된 이미지 세트에 대응하는 수행된 변조 계산에 적어도 부분적으로 기초한다. 제1 이미지 세트의 이미지들에 걸친 평균 FWHM 값에 적어도 부분적으로 기초하여, 최소 FWHM 슬라이스가 식별된다. 식별된 최소 FWHM 슬라이스에 대해 파라미터 추정이 수행된다. 수행된 추정에 적어도 부분적으로 기초하여 최상의 인-포커스 파라미터들이 식별된다. 세트의 각각의 이미지에 대해 위상 추정이 수행된다. 식별된 최상의 인-포커스 파라미터들에 적어도 부분적으로 기초하여 변조 계산이 수행된다. 보고서는 수행된 변조 계산에 적어도 부분적으로 기초한다.",ILLUMINA INC,CORBETT AUSTIN;;LU BO;;LANGLOIS ROBERT;;PINTO JOSEPH;;CHEN YU;;NEWMAN PETER;;REN HONGJI,,https://lens.org/093-185-177-842-72X,Patent Application,no,0,0,22,22,0,G02B21/367;;G02B21/361;;G02B21/0032;;G02B21/0076;;G02B21/365;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/082;;G02B21/365;;G02B21/367;;G02B26/06;;G06T7/0014;;G06T7/80;;G06T2207/10056;;G06T2207/30168;;G02B21/06;;G02B21/361;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/361;;G02B21/06;;G06T7/0014;;G06T7/80;;G02B21/082;;G06T2207/10056;;G06T2207/30168;;H04N23/56;;G06T7/80;;G02B21/082;;G02B21/365;;G02B26/06;;G06T7/0014;;G06T2207/10056;;G06T2207/30168;;H04N23/56,G02B21/36;;G02B21/00;;G02B21/06;;G02B21/08;;G06T7/00;;G06T7/80;;H04N5/225,,0,0,,,,PENDING
192,CA,A1,CA 3134978 A1,101-333-802-700-808,2021-06-10,2021,CA 3134978 A,2020-12-03,US 201962944692 P;;US 2020/0062971 W,2019-12-06,APPARATUS AND METHOD OF PROVIDING PARAMETER ESTIMATION,"A method is used to generate a report presenting parameter values corresponding to a structured illumination microscopy (SIM) optical system. The parameter values are based at least in part on the performed modulation calculation corresponding to an image set captured with the SIM optical system. A minimum FWHM slice is identified, based at least in part on an average FWHM value across the images in the first image set. Parameter estimation is performed on the identified minimum FWHM slice. Best in-focus parameters are identified based at least in part on the performed estimation. A phase estimate is performed for each image in the set. A modulation calculation is performed based at least in part on the identified best in-focus parameters. The report is based at least in part on the performed modulation calculation.",ILLUMINA INC,CORBETT AUSTIN;;LU BO;;LANGLOIS ROBERT;;PINTO JOSEPH;;CHEN YU;;NEWMAN PETER;;REN HONGJI,,https://lens.org/101-333-802-700-808,Patent Application,no,0,0,22,22,0,G02B21/367;;G02B21/361;;G02B21/0032;;G02B21/0076;;G02B21/365;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/082;;G02B21/365;;G02B21/367;;G02B26/06;;G06T7/0014;;G06T7/80;;G06T2207/10056;;G06T2207/30168;;G02B21/06;;G02B21/361;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/361;;G02B21/06;;G06T7/0014;;G06T7/80;;G02B21/082;;G06T2207/10056;;G06T2207/30168;;H04N23/56;;G06T7/80;;G02B21/082;;G02B21/365;;G02B26/06;;G06T7/0014;;G06T2207/10056;;G06T2207/30168;;H04N23/56,G02B21/06;;G02B21/36;;G06T7/80,,0,0,,,,PENDING
193,US,B2,US 11243390 B2,036-603-011-425-67X,2022-02-08,2022,US 202017110406 A,2020-12-03,US 202017110406 A;;US 201962944692 P,2019-12-06,Apparatus and method of providing parameter estimation,"A method is used to generate a report presenting parameter values corresponding to a structured illumination microscopy (SIM) optical system. The parameter values are based at least in part on the performed modulation calculation corresponding to an image set captured with the SIM optical system. A minimum FWHM slice is identified, based at least in part on an average FWHM value across the images in the first image set. Parameter estimation is performed on the identified minimum FWHM slice. Best in-focus parameters are identified based at least in part on the performed estimation. A phase estimate is performed for each image in the set. A modulation calculation is performed based at least in part on the identified best in-focus parameters. The report is based at least in part on the performed modulation calculation.",ILLUMINA INC,CORBETT AUSTIN;;LU BO;;LANGLOIS ROBERT;;PINTO JOSEPH;;CHEN YU;;NEWMAN PETER;;REN HONGJI,ILLUMINA INC (2020-02-05),https://lens.org/036-603-011-425-67X,Granted Patent,yes,12,3,22,22,0,G02B21/367;;G02B21/361;;G02B21/0032;;G02B21/0076;;G02B21/365;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/082;;G02B21/365;;G02B21/367;;G02B26/06;;G06T7/0014;;G06T7/80;;G06T2207/10056;;G06T2207/30168;;G02B21/06;;G02B21/361;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/361;;G02B21/06;;G06T7/0014;;G06T7/80;;G02B21/082;;G06T2207/10056;;G06T2207/30168;;H04N23/56;;G06T7/80;;G02B21/082;;G02B21/365;;G02B26/06;;G06T7/0014;;G06T2207/10056;;G06T2207/30168;;H04N23/56,G06K9/00;;G02B21/08;;G02B21/36;;G02B26/06;;G06T7/00;;G06T7/80;;H04N5/225,,11,10,125-808-963-554-634;;004-265-334-389-212;;010-656-014-403-973;;174-909-913-327-708;;065-431-319-615-131;;069-424-894-171-91X;;060-929-273-435-974;;009-768-775-840-781;;071-985-290-412-69X;;005-716-544-072-279,10.1117/12.2251183;;28406496;;10.1038/nprot.2017.019;;10.1109/jstqe.2016.2521542;;10.3390/photonics4020033;;pmc5330558;;28270977;;10.1364/boe.8.000695;;10810003;;10.1046/j.1365-2818.2000.00710.x;;18326650;;10.1529/biophysj.107.120345;;pmc2397368;;10.1101/pdb.top066936;;22135661;;10.1364/oe.21.024692;;24150313;;23389185;;10.1364/oe.21.002032,"International Search Report and Written Opinion dated Mar. 29, 2021, for International Application No. PCT/US2020/062971, 17 pages.;;Chang, Chia-Yuan, and Shean-Jen Chen. “Improvement of axial excitation confinement in temporal focusing-based multiphoton microscopy via spatially modulated illumination.” Emerging Digital Micromirror Device Based Systems and Applications IX. vol. 10117. International Society for Optics and Photonics, 2017.;;Demmerle, Justin, et al. “Strategic and practical guidelines for successful structured illumination microscopy.” Nature protocols 12.5 (2017): 988-1010.;;Lal, Amit, Chunyan Shan, and Peng Xi. “Structured illumination microscopy image reconstruction algorithm.” IEEE Journal of Selected Topics in Quantum Electronics 22.4 (2016): 50-63.;;Schropp, Martin, Christian Seebacher, and Rainer Uhl. “XL-SIM: Extending superresolution into deeper layers.” Photonics. vol. 4. No. 2. Multidisciplinary Digital Publishing Institute, 2017.;;Yeh, Li-Hao, Lei Tian, and Laura Waller. “Structured illumination microscopy with unknown patterns and a statistical prior.” Biomedical optics express 8.2 (2017): 695-711.;;Gustafsson, Mats GL. “Surpassing the lateral resolution limit by a factor of two using structured illumination microscopy.” Journal of microscopy 198.2 (2000): 82-87.;;Gustafsson, Mats GL, et al. “Three-dimensional resolution doubling in wide-field fluorescence microscopy by structured illumination.” Biophysical journal 94.12 (2008): 4957-4970.;;Murray, John M. “Methods for imaging thick specimens: confocal microscopy, deconvolution, and structured illumination.” Cold Spring Harbor Protocols 2011.12 (2011):pdb-top066936.;;Wicker, Kai. “Non-iterative determination of pattern phase in structured illumination microscopy using auto-correlations in Fourier space.” Optics express 21.21 (2013): 24692-24701.;;Wicker, Kai, et al. “Phase optimisation for structured illumination microscopy.” Optics express 21.2 (2013): 2032-2049.",ACTIVE
194,AU,A1,AU 2020/398201 A1,058-630-104-983-250,2021-09-23,2021,AU 2020/398201 A,2020-12-03,US 201962944692 P;;US 2020/0062971 W,2019-12-06,Apparatus and method of providing parameter estimation,"A method is used to generate a report presenting parameter values corresponding to a structured illumination microscopy (SIM) optical system. The parameter values are based at least in part on the performed modulation calculation corresponding to an image set captured with the SIM optical system. A minimum FWHM slice is identified, based at least in part on an average FWHM value across the images in the first image set. Parameter estimation is performed on the identified minimum FWHM slice. Best in-focus parameters are identified based at least in part on the performed estimation. A phase estimate is performed for each image in the set. A modulation calculation is performed based at least in part on the identified best in-focus parameters. The report is based at least in part on the performed modulation calculation.",ILLUMINA INC,CORBETT AUSTIN;;LU BO;;LANGLOIS ROBERT;;PINTO JOSEPH;;CHEN YU;;NEWMAN PETER;;REN HONGJI,,https://lens.org/058-630-104-983-250,Patent Application,no,0,0,22,22,0,G02B21/367;;G02B21/361;;G02B21/0032;;G02B21/0076;;G02B21/365;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/082;;G02B21/365;;G02B21/367;;G02B26/06;;G06T7/0014;;G06T7/80;;G06T2207/10056;;G06T2207/30168;;G02B21/06;;G02B21/361;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/361;;G02B21/06;;G06T7/0014;;G06T7/80;;G02B21/082;;G06T2207/10056;;G06T2207/30168;;H04N23/56;;G06T7/80;;G02B21/082;;G02B21/365;;G02B26/06;;G06T7/0014;;G06T2207/10056;;G06T2207/30168;;H04N23/56,G02B21/00;;G02B21/36,,0,0,,,,PENDING
195,WO,A1,WO 2021/113422 A1,047-439-760-427-936,2021-06-10,2021,US 2020/0062971 W,2020-12-03,US 201962944692 P,2019-12-06,APPARATUS AND METHOD OF PROVIDING PARAMETER ESTIMATION,"A method is used to generate a report presenting parameter values corresponding to a structured illumination microscopy (SIM) optical system. The parameter values are based at least in part on the performed modulation calculation corresponding to an image set captured with the SIM optical system. A minimum FWHM slice is identified, based at least in part on an average FWHM value across the images in the first image set. Parameter estimation is performed on the identified minimum FWHM slice. Best in-focus parameters are identified based at least in part on the performed estimation. A phase estimate is performed for each image in the set. A modulation calculation is performed based at least in part on the identified best in-focus parameters. The report is based at least in part on the performed modulation calculation.",ILLUMINA INC,CORBETT AUSTIN;;LU BO;;LANGLOIS ROBERT;;PINTO JOSEPH;;CHEN YU;;NEWMAN PETE;;REN HONGJII,,https://lens.org/047-439-760-427-936,Patent Application,yes,2,0,22,22,0,G02B21/367;;G02B21/361;;G02B21/0032;;G02B21/0076;;G02B21/365;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/082;;G02B21/365;;G02B21/367;;G02B26/06;;G06T7/0014;;G06T7/80;;G06T2207/10056;;G06T2207/30168;;G02B21/06;;G02B21/361;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/361;;G02B21/06;;G06T7/0014;;G06T7/80;;G02B21/082;;G06T2207/10056;;G06T2207/30168;;H04N23/56;;G06T7/80;;G02B21/082;;G02B21/365;;G02B26/06;;G06T7/0014;;G06T2207/10056;;G06T2207/30168;;H04N23/56,G02B21/00;;G02B21/36,,7,6,004-265-334-389-212;;174-909-913-327-708;;065-431-319-615-131;;125-808-963-554-634;;005-716-544-072-279;;010-656-014-403-973,28406496;;10.1038/nprot.2017.019;;10.3390/photonics4020033;;pmc5330558;;28270977;;10.1364/boe.8.000695;;10.1117/12.2251183;;23389185;;10.1364/oe.21.002032;;10.1109/jstqe.2016.2521542,"AMIT LAL ET AL: ""Structured illumination microscopy image reconstruction algorithm"", ARXIV.ORG, CORNELL UNIVERSITY LIBRARY, 201 OLIN LIBRARY CORNELL UNIVERSITY ITHACA, NY 14853, 19 February 2016 (2016-02-19), XP080685256, DOI: 10.1109/JSTQE.2016.2521542;;JUSTIN DEMMERLE ET AL: ""Strategic and practical guidelines for successful structured illumination microscopy"", NATURE PROTOCOLS, vol. 12, no. 5, 13 April 2017 (2017-04-13), GB, pages 988 - 1010, XP055502082, ISSN: 1754-2189, DOI: 10.1038/nprot.2017.019;;SCHROPP MARTIN ET AL: ""XL-SIM: Extending Superresolution into Deeper Layers"", PHOTONICS, vol. 4, no. 4, 20 December 2017 (2017-12-20), pages 33, XP055780675, DOI: 10.3390/photonics4020033;;LI-HAO YEH ET AL: ""Structured illumination microscopy with unknown patterns and a statistical prior"", BIOMEDICAL OPTICS EXPRESS, vol. 8, no. 2, 1 February 2017 (2017-02-01), United States, pages 695, XP055498241, ISSN: 2156-7085, DOI: 10.1364/BOE.8.000695;;CHANG CHIA-YUAN ET AL: ""Improvement of axial excitation confinement in temporal focusing-based multiphoton microscopy via spatially modulated illumination"", PROCEEDINGS OF SPIE; [PROCEEDINGS OF SPIE ISSN 0277-786X VOLUME 10524], SPIE, US, vol. 10117, 20 February 2017 (2017-02-20), pages 101170F - 101170F, XP060083353, ISBN: 978-1-5106-1533-5, DOI: 10.1117/12.2251183;;WICKER ET AL., PHASE OPTIMISATION FOR STRUCTURED ILLUMINATION MICROSCOPY, 2013;;LAL ET AL., STRUCTURED ILLUMINATION MICROSCOPY IMAGE RECONSTRUCTION ALGORITHM, 2015",PENDING
196,WO,A8,WO 2021/113422 A8,134-075-297-879-744,2021-10-21,2021,US 2020/0062971 W,2020-12-03,US 201962944692 P,2019-12-06,APPARATUS AND METHOD OF PROVIDING PARAMETER ESTIMATION,"A method is used to generate a report presenting parameter values corresponding to a structured illumination microscopy (SIM) optical system. The parameter values are based at least in part on the performed modulation calculation corresponding to an image set captured with the SIM optical system. A minimum FWHM slice is identified, based at least in part on an average FWHM value across the images in the first image set. Parameter estimation is performed on the identified minimum FWHM slice. Best in-focus parameters are identified based at least in part on the performed estimation. A phase estimate is performed for each image in the set. A modulation calculation is performed based at least in part on the identified best in-focus parameters. The report is based at least in part on the performed modulation calculation.",ILLUMINA INC,CORBETT AUSTIN;;LU BO;;LANGLOIS ROBERT;;PINTO JOSEPH;;CHEN YU;;NEWMAN PETER;;REN HONGJI,,https://lens.org/134-075-297-879-744,Amended Application,yes,0,0,22,22,0,G02B21/367;;G02B21/361;;G02B21/0032;;G02B21/0076;;G02B21/365;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/082;;G02B21/365;;G02B21/367;;G02B26/06;;G06T7/0014;;G06T7/80;;G06T2207/10056;;G06T2207/30168;;G02B21/06;;G02B21/361;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/361;;G02B21/06;;G06T7/0014;;G06T7/80;;G02B21/082;;G06T2207/10056;;G06T2207/30168;;H04N23/56;;G06T7/80;;G02B21/082;;G02B21/365;;G02B26/06;;G06T7/0014;;G06T2207/10056;;G06T2207/30168;;H04N23/56,G02B21/00;;G02B21/36,,0,0,,,,PENDING
197,CN,A,CN 115576094 A,029-303-522-583-460,2023-01-06,2023,CN 202211279924 A,2020-12-04,US 201962944692 P;;CN 202011415877 A,2019-12-06,APPARATUS AND METHOD FOR PROVIDING PARAMETER ESTIMATION,The invention relates to an apparatus and a method for providing parameter estimation. A method for generating a report presenting parameter values corresponding to a structured illumination microscopy (SIM) optical system. The parameter value is based at least in part on a performed modulation calculation corresponding to a group of images captured with the SIM optical system. A minimum FWHM slice is identified based at least in part on an average FWHM value for all images in the first group of images. And performing parameter estimation on the identified minimum FWHM slice. Optimal focus alignment parameters are identified based at least in part on the performed estimates. Phase estimation is performed on each image in the group. A modulation calculation is performed based at least in part on the identified optimal focus alignment parameter. The reporting is based at least in part on the performed modulation calculation.,ILLUMINA INC,CORBETT AUSTIN;;LU BO;;LANGLOIS ROBERT;;PINTO JOSEPH;;CHEN YU;;NEWMAN PETER;;REN HONGJI,,https://lens.org/029-303-522-583-460,Patent Application,no,0,1,22,22,0,G02B21/367;;G02B21/361;;G02B21/0032;;G02B21/0076;;G02B21/365;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/082;;G02B21/365;;G02B21/367;;G02B26/06;;G06T7/0014;;G06T7/80;;G06T2207/10056;;G06T2207/30168;;G02B21/06;;G02B21/361;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/361;;G02B21/06;;G06T7/0014;;G06T7/80;;G02B21/082;;G06T2207/10056;;G06T2207/30168;;H04N23/56;;G06T7/80;;G02B21/082;;G02B21/365;;G02B26/06;;G06T7/0014;;G06T2207/10056;;G06T2207/30168;;H04N23/56,G02B21/36,,0,0,,,,PENDING
198,TW,A,TW 202138867 A,108-584-392-744-373,2021-10-16,2021,TW 109142218 A,2020-12-01,US 201962944692 P,2019-12-06,Apparatus and method of providing parameter estimation,"A method is used to generate a report presenting parameter values corresponding to a structured illumination microscopy (SIM) optical system. The parameter values are based at least in part on the performed modulation calculation corresponding to an image set captured with the SIM optical system. A minimum FWHM slice is identified, based at least in part on an average FWHM value across the images in the first image set. Parameter estimation is performed on the identified minimum FWHM slice. Best in-focus parameters are identified based at least in part on the performed estimation. A phase estimate is performed for each image in the set. A modulation calculation is performed based at least in part on the identified best in-focus parameters. The report is based at least in part on the performed modulation calculation.",ILLUMINA INC,CORBETT AUSTIN;;LU BO;;LANGLOIS ROBERT;;PINTO JOSEPH;;CHEN YU;;NEWMAN PETER;;REN HONGJI,,https://lens.org/108-584-392-744-373,Patent of Addition,no,0,0,22,22,0,G02B21/367;;G02B21/361;;G02B21/0032;;G02B21/0076;;G02B21/365;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/082;;G02B21/365;;G02B21/367;;G02B26/06;;G06T7/0014;;G06T7/80;;G06T2207/10056;;G06T2207/30168;;G02B21/06;;G02B21/361;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/361;;G02B21/06;;G06T7/0014;;G06T7/80;;G02B21/082;;G06T2207/10056;;G06T2207/30168;;H04N23/56;;G06T7/80;;G02B21/082;;G02B21/365;;G02B26/06;;G06T7/0014;;G06T2207/10056;;G06T2207/30168;;H04N23/56,G02B21/36,,0,0,,,,PENDING
199,TW,B,TW I229078 B,019-407-094-376-994,2005-03-11,2005,TW 89105714 A,2000-03-28,US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,Glucokinase activators,"The present invention relates to compounds of the formula I, wherein R1, R2, R3 and R4 are as defined in claim 1 and pharmaceutically acceptable salts thereof. The compounds are glucokinase activators which increase insulin secretion in the treatment of type II diabetes.",HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN,,https://lens.org/019-407-094-376-994,Granted Patent,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
200,US,B2,US 11885953 B2,114-761-257-606-826,2024-01-30,2024,US 202117558829 A,2021-12-22,US 202117558829 A;;US 202017110406 A;;US 201962944692 P,2019-12-06,Apparatus and method of providing parameter estimation,"A method is used to generate a report presenting parameter values corresponding to a structured illumination microscopy (SIM) optical system. The parameter values are based at least in part on the performed modulation calculation corresponding to an image set captured with the SIM optical system. A minimum FWHM slice is identified, based at least in part on an average FWHM value across the images in the first image set. Parameter estimation is performed on the identified minimum FWHM slice. Best in-focus parameters are identified based at least in part on the performed estimation. A phase estimate is performed for each image in the set. A modulation calculation is performed based at least in part on the identified best in-focus parameters. The report is based at least in part on the performed modulation calculation.",ILLUMINA INC,CORBETT AUSTIN;;LU BO;;LANGLOIS ROBERT;;PINTO JOSEPH;;CHEN YU;;NEWMAN PETER;;REN HONGJI,ILLUMINA INC (2020-02-05),https://lens.org/114-761-257-606-826,Granted Patent,yes,17,0,22,22,0,G02B21/367;;G02B21/361;;G02B21/0032;;G02B21/0076;;G02B21/365;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/082;;G02B21/365;;G02B21/367;;G02B26/06;;G06T7/0014;;G06T7/80;;G06T2207/10056;;G06T2207/30168;;G02B21/06;;G02B21/361;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/361;;G02B21/06;;G06T7/0014;;G06T7/80;;G02B21/082;;G06T2207/10056;;G06T2207/30168;;H04N23/56;;G06T7/80;;G02B21/082;;G02B21/365;;G02B26/06;;G06T7/0014;;G06T2207/10056;;G06T2207/30168;;H04N23/56,G02B21/08;;G02B21/36;;G02B26/06;;G06T7/00;;G06T7/80;;H04N23/56,,11,10,125-808-963-554-634;;004-265-334-389-212;;069-424-894-171-91X;;060-929-273-435-974;;010-656-014-403-973;;009-768-775-840-781;;174-909-913-327-708;;071-985-290-412-69X;;005-716-544-072-279;;065-431-319-615-131,10.1117/12.2251183;;28406496;;10.1038/nprot.2017.019;;10810003;;10.1046/j.1365-2818.2000.00710.x;;18326650;;10.1529/biophysj.107.120345;;pmc2397368;;10.1109/jstqe.2016.2521542;;10.1101/pdb.top066936;;22135661;;10.3390/photonics4020033;;10.1364/oe.21.024692;;24150313;;23389185;;10.1364/oe.21.002032;;pmc5330558;;28270977;;10.1364/boe.8.000695,"Chang, Chia-Yuan, and Shean-Jen Chen. “Improvement of axial excitation confinement in temporal focusing-based multiphoton microscopy via spatially modulated illumination.” Emerging Digital Micromirror Device Based Systems and Applications IX. vol. 10117. International Society for Optics and Photonics, 2017.;;Demmerle, Justin, et al. “Strategic and practical guidelines for successful structured illumination microscopy.” Nature protocols 12.5 (2017): 988-1010.;;Gustafsson, Mats GL. “Surpassing the lateral resolution limit by a factor of two using structured illumination microscopy.” Journal of microscopy 198.2 (2000): 82-87.;;Gustafsson, Mats GL, et al. “Three-dimensional resolution doubling in wide-field fluorescence microscopy by structured illumination.” Biophysical journal 94.12 (2008): 4957-4970.;;Lal, Amit, Chunyan Shan, and Peng Xi. “Structured illumination microscopy image reconstruction algorithm.” IEEE Journal of Selected Topics in Quantum Electronics 22.4 (2016): 50-63.;;Murray, John M. “Methods for imaging thick specimens: confocal microscopy, deconvolution, and structured illumination.” Cold Spring Harbor Protocols 2011.12 (2011): pdb-top066936.;;Schropp, Martin, Christian Seebacher, and Rainer Uhl. “XL-SIM: Extending superresolution into deeper layers.” Photonics. vol. 4. No. 2. Multidisciplinary Digital Publishing Institute, 2017.;;Wicker, Kai. “Non-iterative determination of pattern phase in structured illumination microscopy using auto-correlations in Fourier space.” Optics express 21.21 (2013): 24692-24701.;;Wicker, Kai, et al. “Phase optimisation for structured illumination microscopy.” Optics express 21.2 (2013): 2032-2049.;;Yeh, Li-Hao, Lei Tian, and Laura Waller. “Structured illumination microscopy with unknown patterns and a statistical prior.” Biomedical optics express 8.2 (2017): 695-711.;;International Search Report and Written Opinion dated Mar. 29, 2021, for International Application No. PCT/US2020/062971, 17 pages.",ACTIVE
201,WO,A8,WO 2021/113422 A8,129-035-145-051-430,2021-09-10,2021,US 2020/0062971 W,2020-12-03,US 201962944692 P,2019-12-06,APPARATUS AND METHOD OF PROVIDING PARAMETER ESTIMATION,"A method is used to generate a report presenting parameter values corresponding to a structured illumination microscopy (SIM) optical system. The parameter values are based at least in part on the performed modulation calculation corresponding to an image set captured with the SIM optical system. A minimum FWHM slice is identified, based at least in part on an average FWHM value across the images in the first image set. Parameter estimation is performed on the identified minimum FWHM slice. Best in-focus parameters are identified based at least in part on the performed estimation. A phase estimate is performed for each image in the set. A modulation calculation is performed based at least in part on the identified best in-focus parameters. The report is based at least in part on the performed modulation calculation.",ILLUMINA INC,CORBETT AUSTIN;;LU BO;;LANGLOIS ROBERT;;PINTO JOSEPH;;CHEN YU;;NEWMAN PETER;;REN HONGII,,https://lens.org/129-035-145-051-430,Amended Application,yes,0,0,22,22,0,G02B21/367;;G02B21/361;;G02B21/0032;;G02B21/0076;;G02B21/365;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/082;;G02B21/365;;G02B21/367;;G02B26/06;;G06T7/0014;;G06T7/80;;G06T2207/10056;;G06T2207/30168;;G02B21/06;;G02B21/361;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/361;;G02B21/06;;G06T7/0014;;G06T7/80;;G02B21/082;;G06T2207/10056;;G06T2207/30168;;H04N23/56;;G06T7/80;;G02B21/082;;G02B21/365;;G02B26/06;;G06T7/0014;;G06T2207/10056;;G06T2207/30168;;H04N23/56,G02B21/00;;G02B21/36,,0,0,,,,PENDING
202,MX,A,MX 2021010437 A,198-098-784-763-152,2022-01-11,2022,MX 2021010437 A,2020-12-03,US 201962944692 P;;US 2020/0062971 W,2019-12-06,APPARATUS AND METHOD OF PROVIDING PARAMETER ESTIMATION.,"A method is used to generate a report presenting parameter values corresponding to a structured illumination microscopy (SIM) optical system. The parameter values are based at least in part on the performed modulation calculation corresponding to an image set captured with the SIM optical system. A minimum FWHM slice is identified, based at least in part on an average FWHM value across the images in the first image set. Parameter estimation is performed on the identified minimum FWHM slice. Best in-focus parameters are identified based at least in part on the performed estimation. A phase estimate is performed for each image in the set. A modulation calculation is performed based at least in part on the identified best in-focus parameters. The report is based at least in part on the performed modulation calculation.",ILLUMINA INC,CHEN YU;;LANGLOIS ROBERT;;CORBETT AUSTIN;;LU BO;;PINTO JOSEPH;;NEWMAN PETER;;REN HONGJI,,https://lens.org/198-098-784-763-152,Patent Application,no,0,0,22,22,0,G02B21/367;;G02B21/361;;G02B21/0032;;G02B21/0076;;G02B21/365;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/082;;G02B21/365;;G02B21/367;;G02B26/06;;G06T7/0014;;G06T7/80;;G06T2207/10056;;G06T2207/30168;;G02B21/06;;G02B21/361;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/361;;G02B21/06;;G06T7/0014;;G06T7/80;;G02B21/082;;G06T2207/10056;;G06T2207/30168;;H04N23/56;;G06T7/80;;G02B21/082;;G02B21/365;;G02B26/06;;G06T7/0014;;G06T2207/10056;;G06T2207/30168;;H04N23/56,G02B21/00;;G02B21/36,,0,0,,,,PENDING
203,CN,A,CN 112925090 A,187-270-859-685-498,2021-06-08,2021,CN 202011415877 A,2020-12-04,US 201962944692 P,2019-12-06,APPARATUS AND METHOD OF PROVIDING PARAMETER ESTIMATION,"The invention relates to an apparatus and a method of providing parameter estimation. A method is used to generate a report presenting parameter values corresponding to a structured illumination microscopy (SIM) optical system. The parameter values are based at least in part on the performed modulation calculation corresponding to an image set captured with the SIM optical system. A minimum FWHM slice is identified, based at least in part on an average FWHM value across the images in the first image set. Parameter estimation is performed on the identified minimum FWHM slice. Best in-focus parameters are identified based at least in part on the performed estimation. A phase estimate is performed for each image in the set. A modulation calculation is performed based at least in part on the identified best in-focus parameters. The report is based at least in part on the performed modulation calculation.",ILLUMINA INC,CORBETT AUSTIN;;LU BO;;LANGLOIS ROBERT;;PINTO JOSEPH;;CHEN YU;;NEWMAN PETER;;REN HONGJI,,https://lens.org/187-270-859-685-498,Patent Application,no,5,0,22,22,0,G02B21/367;;G02B21/361;;G02B21/0032;;G02B21/0076;;G02B21/365;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/082;;G02B21/365;;G02B21/367;;G02B26/06;;G06T7/0014;;G06T7/80;;G06T2207/10056;;G06T2207/30168;;G02B21/06;;G02B21/361;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/361;;G02B21/06;;G06T7/0014;;G06T7/80;;G02B21/082;;G06T2207/10056;;G06T2207/30168;;H04N23/56;;G06T7/80;;G02B21/082;;G02B21/365;;G02B26/06;;G06T7/0014;;G06T2207/10056;;G06T2207/30168;;H04N23/56,G02B21/36,,5,5,004-265-334-389-212;;125-808-963-554-634;;065-431-319-615-131;;010-656-014-403-973;;174-909-913-327-708,28406496;;10.1038/nprot.2017.019;;10.1117/12.2251183;;pmc5330558;;28270977;;10.1364/boe.8.000695;;10.1109/jstqe.2016.2521542;;10.3390/photonics4020033,"JUSTIN DEMMERLE ET AL: ""Strategic and practical guidelines for successful structured illumination microscopy"", 《 NATURE PROTOCOLS 》;;CHIA-YUAN CHANG ET AL: ""Improvement of axial excitation confinement in temporal focusing-based multiphoton microscopy via spatially modulated illumination"", 《 PROCEEDINGS OF SPIE 》;;LI-HAO YEH ET AL: ""Structured illumination microscopy with unknown patterns and a statistical prior"", 《 BIOMEDICAL OPTICS EXPRESS 》;;AMIT LAL ET AL: ""Structured illumination microscopy image reconstruction algorithm"", 《IEEE JOURNAL OF SELECTED TOPICS IN QUANTURN》;;MARTIN SCHROPP ET AL: ""XL-SIM: Extending Superresolution into Deeper Layers"", 《PHOTONICS》",ACTIVE
204,US,B2,US 9017000 B2,143-456-975-600-083,2015-04-28,2015,US 44488707 A,2007-07-06,US 44488707 A;;US 82876806 P;;US 2007/0072938 W,2006-10-09,Automatic parking structure,"The present invention as disclosed herein is an improved vehicle parking structure and method for using the same. The vehicle parking structure provides for the automated storage and retrieval of vehicles in response to user inputs. In one aspect, the vehicle parking structure comprises one or more transfer rooms in which a vehicle operator may deposit and later retrieve a vehicle, a plurality of parking spaces of either fixed or variable dimensions, and one or more vehicle transporters used to move vehicles from the one or more transfer rooms to the plurality of parking spaces. The one or more vehicle transporters are in turn each preferably comprised of one or more vertical stabilizers, one or more tractors, one or more lifts, a lifting platform, and a dolly. The vehicle transporters move the lifting platform and dolly so that the dolly may be positioned to access a vehicle located in a transfer room or parking space.",MCDOWELL JR JOSEPH COLEMAN;;STORY MICHAEL CORBETT;;STORY JAMES BOWMER;;FRITTS CHARLES JEFFERSON;;ACEVEDO JUAN CARLOS;;TROTTER VICTOR DALE;;AVERYT LEN KEITH;;STORY CHRISTOPHER CORBETT;;SAFE PARKING LTD,MCDOWELL JR JOSEPH COLEMAN;;STORY MICHAEL CORBETT;;STORY JAMES BOWMER;;FRITTS CHARLES JEFFERSON;;ACEVEDO JUAN CARLOS;;TROTTER VICTOR DALE;;AVERYT LEN KEITH;;STORY CHRISTOPHER CORBETT,PV PATENTS LLC (2007-07-20);;SAFE PARKING LIMITED (2012-02-22),https://lens.org/143-456-975-600-083,Granted Patent,yes,10,2,4,4,0,E04H6/183;;E04H6/183;;E04H6/225;;E04H6/225;;E04H6/282,E04H6/22;;E04H6/18,414/256;;414/283,1,0,,,"PCT International Search Report mailed Dec. 26, 2007 for PCT/US07/72938.",ACTIVE
205,EP,A1,EP 2115245 A1,167-642-640-586-515,2009-11-11,2009,EP 07812680 A,2007-07-06,US 2007/0072938 W;;US 82876806 P,2006-10-09,AUTOMATIC PARKING STRUCTURE,,PV PATENTS L L C,MCDOWELL JOSEPH COLEMAN JR;;STORY MICHAEL CORBETT;;STORY JAMES BOWMER;;FRITTS CHARLES JEFFERSON;;ACEVEDO JUAN CARLOS;;TROTTER VICTOR DALE;;AVERYT LEN KEITH;;STORY CHRISTOPHER CORBETT,,https://lens.org/167-642-640-586-515,Patent Application,yes,0,0,4,4,0,E04H6/183;;E04H6/183;;E04H6/225;;E04H6/225;;E04H6/282,E04H6/00,,1,0,,,See references of WO 2008045606A1,DISCONTINUED
206,US,A1,US 2011/0082588 A1,040-134-147-613-827,2011-04-07,2011,US 44488707 A,2007-07-06,US 44488707 A;;US 82876806 P;;US 2007/0072938 W,2006-10-09,AUTOMATIC PARKING STRUCTURE,"The present invention as disclosed herein is an improved vehicle parking structure and method for using the same. The vehicle parking structure provides for the automated storage and retrieval of vehicles in response to user inputs. In one aspect, the vehicle parking structure comprises one or more transfer rooms in which a vehicle operator may deposit and later retrieve a vehicle, a plurality of parking spaces of either fixed or variable dimensions, and one or more vehicle transporters used to move vehicles from the one or more transfer rooms to the plurality of parking spaces. The one or more vehicle transporters are in turn each preferably comprised of one or more vertical stabilizers, one or more tractors, one or more lifts, a lifting platform, and a dolly. The vehicle transporters move the lifting platform and dolly so that the dolly may be positioned to access a vehicle located in a transfer room or parking space.",MCDOWELL JR JOSEPH COLEMAN;;STORY MICHAEL CORBETT;;STORY JAMES BOWMER;;FRITTS CHARLES JEFFERSON;;ACEVEDO JUAN CARLOS;;TROTTER VICTOR DALE;;AVERYT LEN KEITH;;STORY CHRISTOPHER CORBETT,MCDOWELL JR JOSEPH COLEMAN;;STORY MICHAEL CORBETT;;STORY JAMES BOWMER;;FRITTS CHARLES JEFFERSON;;ACEVEDO JUAN CARLOS;;TROTTER VICTOR DALE;;AVERYT LEN KEITH;;STORY CHRISTOPHER CORBETT,PV PATENTS LLC (2007-07-20);;SAFE PARKING LIMITED (2012-02-22),https://lens.org/040-134-147-613-827,Patent Application,yes,8,26,4,4,0,E04H6/183;;E04H6/183;;E04H6/225;;E04H6/225;;E04H6/282,E04H6/12;;G05B15/02,700/275;;414/256;;414/814,0,0,,,,ACTIVE
207,WO,A1,WO 2008/045606 A1,192-835-897-917-970,2008-04-17,2008,US 2007/0072938 W,2007-07-06,US 82876806 P,2006-10-09,AUTOMATIC PARKING STRUCTURE,"The present invention as disclosed herein is an improved vehicle parking structure (10) and method for using the same. The vehicle parking structure (10) provides for the automated storage and retrieval of vehicles(14) in response to user inputs. In one aspect, the vehicle parking structure (10) comprises one or more transfer rooms (12) in which a vehicle operator may deposit and later retrieve a vehicle (14), a plurality of parking spaces (16) of either fixed or variable dimensions, and one or more vehicle transporters (18) used to move vehicles (14) from the one or more transfer rooms (12) to the plurality of parking spaces (16). The one or more vehicle transporters (18)are in turn each preferably comprised of one or more vertical stabilizers 20), one or more tractors (22), one or more lifts (26), a lifting platform (26), and a dolly (30). The vehicle transporters (18) move the lifting platform (26) and dolly (30) so that the dolly (30) may be positioned to access a vehicle (14) located in a transfer room (12) or parking space (16).",PV PATENTS L L C;;MCDOWELL JOSEPH COLEMAN JR;;STORY MICHAEL CORBETT;;STORY JAMES BOWMER;;FRITTS CHARLES JEFFERSON;;ACEVEDO JUAN CARLOS;;TROTTER VICTOR DALED;;AVERYT LEN KEITH;;STORY CHRISTOPHER CORBETT,MCDOWELL JOSEPH COLEMAN JR;;STORY MICHAEL CORBETT;;STORY JAMES BOWMER;;FRITTS CHARLES JEFFERSON;;ACEVEDO JUAN CARLOS;;TROTTER VICTOR DALED;;AVERYT LEN KEITH;;STORY CHRISTOPHER CORBETT,,https://lens.org/192-835-897-917-970,Patent Application,yes,2,8,4,4,0,E04H6/183;;E04H6/183;;E04H6/225;;E04H6/225;;E04H6/282,E04H6/00,,0,0,,,,PENDING
208,US,A,US 5850803 A,194-170-294-460-376,1998-12-22,1998,US 86129097 A,1997-05-21,US 86129097 A,1997-05-21,Personal watercraft having daytime running headlight,"A personal watercraft has a daytime running headlight that illuminates continuously or stroboscopically when the personal watercraft is operating. The daytime running headlight makes the watercraft more noticeable to other boaters. Several embodiments are shown in which one or more daytime running headlights are mounted to the personal watercraft above the deckline of the watercraft and forward of the handlebars of the watercraft. Such positioning renders the daytime running headlight easily noticeable to other boaters even in relatively choppy water. The daytime running headlights should not only illuminate light forward of the watercraft, but should also illuminate peripherally from the watercraft. A linkage mechanism can be used to turn the one or more headlights in the direction in which the watercraft is turning.",BRUNSWICK CORP,JONES CORBETT B;;HATCH EDWIN B;;GONRING STEVEN J;;JONES DAVID D;;POMEROY JOSEPH H,BRUNSWICK CORPORATION (1997-04-25),https://lens.org/194-170-294-460-376,Granted Patent,yes,7,9,1,1,0,B63B45/02;;B63B45/04;;B63B2201/08;;F02B61/045;;B63B34/10;;F02B61/045;;B63B2201/08;;B63B45/04;;B63B45/02;;B63B34/10,B63B35/73;;B63B45/02;;B63B45/04;;F02B61/04,114/343;;362/61;;114/270,1,0,,,"Enhancing the Conspicuity of Personal Watercraft, Marine Technology Society, Milligan et al., pp. 1 11, Sep., 1996.",EXPIRED
209,US,A,US 6149224 A,040-264-835-480-963,2000-11-21,2000,US 33057599 A,1999-06-11,US 33057599 A,1999-06-11,Break away trim panel assembly,"A break away trim panel assembly for a panel in an occupant compartment of a vehicle includes a trim panel having an inner side and an outer side and a reinforcement attached to the outer side of the trim panel. The reinforcement includes a channel. The break away trim panel assembly also includes a fastener disposed within the channel for attaching the trim panel to the panel, such that application of a force from a predetermined angle pushes the fastener through the channel to break away the trim panel from the panel in a predetermined direction.",DELPHI TECH INC,TIBERIA JOSEPH WILLIAM;;MORRIS ALETHEA KEESIA;;CORBETT THOMAS JAY;;STRNAD GEORGE JIRI;;GAREAU PETER J,,https://lens.org/040-264-835-480-963,Granted Patent,yes,14,39,1,1,0,B60R13/0243;;B60R13/0243;;B60R21/0428;;B60R21/0428;;B60R2013/0287;;B60R2013/0287,B60R13/02;;B60R21/04,296/146.7;;296/189;;296/39.1;;49/502;;280/751,0,0,,,,EXPIRED
210,TW,B,TW I281917 B,132-857-721-754-46X,2007-06-01,2007,TW 92109472 A,2003-04-23,US 37616102 P,2002-04-26,Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators,"2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a polar ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN+,,https://lens.org/132-857-721-754-46X,Granted Patent,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D277/20;;A61K31/17;;A61K31/341;;A61K31/351;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D309/06;;C07D409/12,,0,0,,,,EXPIRED
211,NO,D0,NO 922273 D0,138-381-336-430-415,1992-06-10,1992,NO 922273 A,1992-06-10,US 71317391 A;;US 83515992 A,1991-06-10,TIOXANTENON-ANTITUMORMIDLER,"1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones having the formula <CHEM> wherein n is 2 or 3; R<1> and R<2> are independently lower-alkyl; Q is a residue chosen from the group consisting of CH2NHR<3>, CH2N(R<4>)SO2R<7>, CH2NHCHO, CH=N-Ar, C(O)NR<5>R<6>, CH2N(R<4>)C(O)R<7>, CH2N(C2H5)CHO, and CH2N(R<4>)P(O)(O-lower-alkyl)2; R<3> is hydrogen or lower-alkyl; R<4> is hydrogen or lower-alkyl; R<5> is hydrogen, lower-alkyl or Ar; R<6> is hydrogen or lower-alkyl; R<7> is lower-alkyl, or Ar; R<8> is hydrogen, lower-alkyl, lower-alkoxy, or halogen; and Ar is phenyl or phenyl substituted with methyl, methoxyl, halogen or nitro; or a pharmaceutically acceptable acid-addition salt or solvate thereof, are disclosed as antitumor agents. Compositions containing the thioxanthenones and the method of use of thioxanthenones for treating tumors and cancer in mammals are also disclosed.",STERLING WINTHROP INC,MILLER THEODORE CHARLES;;COLLINS JOSEPH CHARLES;;MATTES KENNETH CHARLES;;PERNI ROBERT BRUNO;;CORBETT THOMAS HUGHES,,https://lens.org/138-381-336-430-415,Patent Application,no,0,0,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/382;;A61K31/38;;A61K31/39;;A61K31/67;;A61P35/00;;C07D335/16;;C07F9/6553,,0,0,,,,EXPIRED
212,HU,A9,HU 211706 A9,106-302-504-539-18X,1995-12-28,1995,HU 9500615 P,1995-06-30,HU 9500615 P,1995-06-30,THIOXANTHENONE ANTITUMOR AGENTS,,STERLING WINTHROP INC,MILLER THEODORE CHARLES;;COLLINS JOSEPH CHARLES;;MATTES KENNETH CHARLES;;WENTLAND MARK PHILIP;;CORBETT THOMAS HUGHES;;GUILES JOSEPH WILLIAM;;PERNI ROBERT B,"SANOFI-SYNTHELABO, FR (2000-05-29)",https://lens.org/106-302-504-539-18X,Unknown,no,0,0,1,1,0,,A61K31/38;;C07C261/00;;C07D311/82;;C07D335/12,,0,0,,,,PENDING
213,US,A,US 5346917 A,144-604-079-900-377,1994-09-13,1994,US 4484393 A,1993-04-08,US 4484393 A;;US 71317391 A;;US 83515992 A,1991-06-10,Thioxanthenone antitumor agents,1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones are disclosed as antitumor agents. Compositions containing the thioxanthenones and methods of treating tumors and cancer in mammals with the thioxanthenones are also disclosed.,STERLING WINTHROP INC,MILLER THEODORE C;;COLLINS JOSEPH C;;MATTES KENNETH C;;WENTLAND MARK P;;PERNI ROBERT B;;CORBETT THOMAS H;;GUILES JOSEPH W,STERLING WINTHROP INC (1993-07-01);;SANOFI-SYTHELABO (2000-02-11);;SANOFI S.A (1996-02-27),https://lens.org/144-604-079-900-377,Granted Patent,yes,4,6,52,52,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07F9/655372;;C07D335/16,A61K31/382;;A61K31/39;;A61K31/38;;A61K31/67;;A61P35/00;;C07D335/12;;C07D335/16;;C07F9/24;;C07F9/6553,514/437;;514/455;;514/908;;549/27;;549/392,5,4,056-974-461-762-970;;035-713-471-451-298;;023-200-016-376-16X;;135-473-461-855-438,10.1002/jps.2600541126;;10.1021/jm00338a022;;14188792;;3351846;;10.1021/jm00399a003;;3336024;;10.1021/jm00396a040,"I. Nabih & M. Elsheikh, Chlorination and Condensation Reactions at the 4 Methyl Group of Lucanthone and Oxalucanthone , J. Pharm. Sci. 54, 1672 1673 (1965).;;E. J. Blanz and F. A. French, A Systematic Investigation of Thioxanthen 9 ones and Analogs as Potential Antitumor Agents , J. Med. Chem. 6, 185 191 (1963).;;A. Yarinsky & H. Freele, A Comparison of Molluscicidal and Mollusc Inhibitory Activity of Hycanthone and Lucanthone and the Effect of the Drugs on the Development of Schistosoma mansoni in the Snail Intermediate Host, Australorbis glabratus , J. Tropical Med. Hyg. 73, 23 27 (1970).;;B. Palmer et al, Potential Antitumor Agents. 54. Chromophore Requirements for in Vivo Antitumor Activity among the General Class of Linear Tricyclic Carboxamides , J. Med. Chem. 31, 707 712 (1988).;;Archer et al., J. Med. Chem. 31, 254 260 (1988). (II).",EXPIRED
214,SG,A1,SG 52765 A1,093-417-271-169-21X,1998-09-28,1998,SG 1996009160 A,1995-03-31,US 4484393 A,1993-04-08,Thioxanthenone antitumor agents,"Compounds having anti-tumour activity are disclosed having the formula <CHEM> wherein: (1) n is 2 or 3; R<1> and R<2> are independently lower-alkyl; Q is a residue chosen from the group consisting of CH2NHR<3>, CH2N(R<4>)SO2R<7>, CH2NHCHO, CH=N-Ar, C(O)NR<5>R<6>, CH2N(R<4>)C(O)R<7>, CH2N(C2H5)CHO, CH2N(R<4>)P(O)(O-lower-alkyl)2, CH2N=CH-N(R<9>)(R<10>), CH2N(R<4>)C(O)CF3 and CH2N(R<4>)C(O)OR<7>; R<3> is hydrogen or lower-alkyl; R<4> is hydrogen, lower-alkyl or Ar; R<5> is hydrogen, lower-alkyl or Ar; R<6> is hydrogen or lower-alkyl; R<7> is lower-alkyl, or Ar; R<8> is hydroxy; Ar is phenyl or phenyl substituted with methyl, methoxy, hydroxy, halogen or nitro; and R<9> and R<10> are independently lower-alkyl; or (2) Q is a residue chosen from the group consisting of CH2N(R<4>)SO2R<7>, CH=N-Ar, C(O)NR<5>R<6>, CH2N(R<4>)C(O)R<7>, CH2N(R<4>)P(O)(O-lower-alkyl)2, CH2N(R<4>)C(O)CF3 and CH2N(R<4>)C(O)OR<7>; R<8> is hydrogen, lower-alkyl, lower-alkoxy, or hydroxy; Ar is phenyl substituted by hydroxy; and n, R<1>, R<2>, R<4>, R<5>, R<6>, and R<7> are as defined hereinabove in part (1) with the proviso that one or more of R<4>, R<5>, or R<7> is Ar; or (3) Q is a residue chosen from the group consisting of CH2N=CH-N(R<9>)(R<10>) and CH2N(R<4>)C(O)CF3 ; R<8> is hydrogen, lower-alkyl, lower-alkoxy, or hydroxy; and n, R<1>, R<2>, R<4>, R<7>, Ar, R<9> and R<10> are as defined hereinabove in part (1), or a pharmaceutically acceptable acid-addition salt or solvate thereof . Compositions containing the thioxanthenones and methods of treating tumors and cancer in mammals with the thioxanthenones are also disclosed.",STERLING WINTHROP INC,COLLINS JOSEPH CHARLES;;GUILES JOSEPH WILLIAM;;MATTES KENNETH CHARLES;;WENTLAND MARK PHILIP;;PERNI ROBERT BRUNO;;MILLER THEODORE CHARLES;;CORBETT THOMAS HUGHES,,https://lens.org/093-417-271-169-21X,Patent Application,no,0,0,52,52,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07F9/655372;;C07D335/16,A61K31/382;;A61K31/39;;A61K31/67;;A61K31/38;;A61P35/00;;C07D335/12;;C07D335/16;;C07F9/24;;C07F9/6553,,0,0,,,,PENDING
215,US,A,US 5380749 A,038-626-186-682-736,1995-01-10,1995,US 21698994 A,1994-03-23,US 21698994 A;;US 4484393 A;;US 83515992 A;;US 71317391 A,1991-06-10,Thioxanthenone antitumor agents,1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones are disclosed as antitumor agents. Compositions containing the thioxanthenones and methods of treating tumors and cancer in mammals with the thioxanthenones are also disclosed.,STERLING WINTHROP INC,MILLER THEODORE C;;COLLINS JOSEPH C;;MATTES KENNETH C;;WENTLAND MARK P;;PERNI ROBERT B;;CORBETT THOMAS H;;GUILES JOSEPH W,SANOFI-SYTHELABO (2000-02-11);;SANOFI S.A (1996-02-27),https://lens.org/038-626-186-682-736,Granted Patent,yes,5,8,52,52,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07F9/655372;;C07D335/16,A61K31/382;;A61K31/39;;A61K31/67;;A61P35/00;;A61K31/38;;C07D335/12;;C07D335/16;;C07F9/24;;C07F9/6553,514/437;;514/455;;560/24;;549/26;;549/27;;549/392,5,4,056-974-461-762-970;;035-713-471-451-298;;023-200-016-376-16X;;135-473-461-855-438,10.1002/jps.2600541126;;10.1021/jm00338a022;;14188792;;3351846;;10.1021/jm00399a003;;3336024;;10.1021/jm00396a040,"I. Nabih & M. Elsheikh, Chlorination and Condensation Reactions at the 4 Methyl Group of Lucanthone and Oxalucanthone , J. Pharm. Sci. 54, 1672 1673 (1965).;;E. J. Blanz and F. A. French, A Systematic Investigation of Thioxanthen 9 Ones and Apalogs as Potential Antitumor Agents , J. Med. Chem. 6, 185 191 (1963).;;A. Yarinsky & H. Freele, A Comparison of Molluscicidal and Mollusc Inhibitory Activity of Hycanthone and Lucanthone and the Effect of the Drugs on the Development of Schistosoma mansoni in the Snail Intermediate Host, Australorbis glabratus , J. Tropical Med. Hyg. 73, 23 27 (1970).;;B. Palmer et al., Potential Antitumor Agents. 54. Chromophore Requirements for in Vivo Antitumor Activity among the General Class of Linear Tricyclic Carboxamides , J. Med. Chem. 31, 707 712 (1988).;;Archer et al., J. Med. Chem. 31, 254 260 (1988).",EXPIRED
216,HU,A9,HU 211613 A9,086-550-545-658-715,1995-12-28,1995,HU 9500613 P,1995-06-30,HU 9500613 P,1995-06-30,THIOXANTHENONE ANTITUMOR AGENTS,,STERLING WINTHROP INC,MILLER THEODORE C;;COLLINS JOSEPH C;;MATTES KENNETH C;;WENTLAND MARK P;;PERNI ROBERT B;;CORBETT THOMAS H;;GUILES JOSEPH W,"SANOFI, FR (1997-04-28);;SANOFI-SYNTHELABO, FR (2000-06-28)",https://lens.org/086-550-545-658-715,Unknown,no,0,0,1,1,0,,A01N43/18;;A61K31/38;;C07D335/12,,0,0,,,,PENDING
217,BR,B1,BR 102014027364 B1,072-197-303-700-914,2021-01-12,2021,BR 102014027364 A,2014-10-31,US 201361898600 P;;US 201414527152 A,2013-11-01,"sistema de controle e de medição da altura de corte para uma ceifeira de base, método, e, colheitadeira","sistema de controle e de medição da altura de corte para uma ceifeira de base, método, e, colheitadeira. um sistema é fornecido de forma que pode incluir um sensor 3d. o sensor 3d pode ser configurado para detectar uma área de um elevador em uma colheitadeira. o sensor 3d pode ainda ser configurado para transmitir um primeiro sinal associado com a área. o sistema também inclui um dispositivo de processamento na comunicação com o sensor 3d. o sistema pode ainda incluir um dispositivo de memória no qual são armazenadas instruções executáveis pelo dispositivo de processamento para fazer com que o dispositivo de processamento receba o primeiro sinal e determine um volume de um material no elevador com base no primeiro sinal.",UNIV CARNEGIE MELLON;;DEERE & CO;;UNIV IOWA STATE RES FOUND INC,BRYAN E DUGAS;;CARLOS VALLESPI-GONZALEZ;;DANIEL JOSEPH CORBETT;;HERMAN BADINO;;HERMAN HERMAN;;MATTHEW J DARR,,https://lens.org/072-197-303-700-914,Granted Patent,no,0,0,9,9,0,G01F25/0084;;G01F25/0084;;G01F22/00;;G01F22/00,G01F22/00;;G01F25/00,,0,0,,,,ACTIVE
218,AU,A1,AU 2014/256411 A1,103-706-124-444-279,2015-05-21,2015,AU 2014/256411 A,2014-10-31,US 201414527152 A;;US 201361898600 P,2013-11-01,Yield measurement and base cutter height control systems for a harvester,Abstract A system is provided that can include a 3D sensor. The 3D sensor can be configured to detect an area of an elevator on a harvester. The 3D sensor can further be configured to transmit a first signal associated with the area. The system can also include a processing device in communication with the 3D sensor. The system can further include a memory device in which instructions executable by the processing device are stored for causing the processing device to receive the first signal and determine a volume of a material on the elevator based on the first signal.,UNIV CARNEGIE MELLON;;UNIV IOWA STATE RES FOUND INC;;DEERE & CO,DARR MATTHEW J;;CORBETT DANIEL JOSEPH;;HERMAN HERMAN;;VALLESPI-GONZALEZ CARLOS;;DUGAS BRYAN E;;BADINO HERNAN,,https://lens.org/103-706-124-444-279,Patent Application,no,0,0,9,9,0,G01F25/0084;;G01F25/0084;;G01F22/00;;G01F22/00,A01D31/02,,0,0,,,,ACTIVE
219,IL,B1,IL 286661 B1,153-606-526-256-559,2023-06-01,2023,IL 28666121 A,2021-09-24,US 201962944692 P;;US 2020/0062971 W,2019-12-06,Apparatus and method of providing parameter estimation,,ILLUMINA INC;;CORBETT AUSTIN;;LU BO;;LANGLOIS ROBERT;;PINTO JOSEPH FRANCIS;;CHEN YU;;NEWMAN PETER CLARKE;;REN HONGJI,CORBETT AUSTIN;;LU BO;;LANGLOIS ROBERT;;PINTO JOSEPH FRANCIS;;CHEN YU;;NEWMAN PETER CLARKE;;REN HONGJI,,https://lens.org/153-606-526-256-559,Unknown,no,0,0,22,22,0,G02B21/367;;G02B21/361;;G02B21/0032;;G02B21/0076;;G02B21/365;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/082;;G02B21/365;;G02B21/367;;G02B26/06;;G06T7/0014;;G06T7/80;;G06T2207/10056;;G06T2207/30168;;G02B21/06;;G02B21/361;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/361;;G02B21/06;;G06T7/0014;;G06T7/80;;G02B21/082;;G06T2207/10056;;G06T2207/30168;;H04N23/56;;G06T7/80;;G02B21/082;;G02B21/365;;G02B26/06;;G06T7/0014;;G06T2207/10056;;G06T2207/30168;;H04N23/56,G02B21/00;;G02B21/06;;G02B21/08;;G02B21/36;;G02B26/06,,0,0,,,,PENDING
220,IL,A,IL 286661 A,050-166-509-532-872,2021-10-31,2021,IL 28666121 A,2021-09-24,US 201962944692 P;;US 2020/0062971 W,2019-12-06,Apparatus and method of providing parameter estimation,,ILLUMINA INC;;CORBETT AUSTIN;;LU BO;;LANGLOIS ROBERT;;PINTO JOSEPH FRANCIS;;CHEN YU;;NEWMAN PETER CLARKE;;REN HONGJI,CORBETT AUSTIN;;LU BO;;LANGLOIS ROBERT;;PINTO JOSEPH FRANCIS;;CHEN YU;;NEWMAN PETER CLARKE;;REN HONGJI,,https://lens.org/050-166-509-532-872,Patent Application,no,0,0,22,22,0,G02B21/367;;G02B21/361;;G02B21/0032;;G02B21/0076;;G02B21/365;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/082;;G02B21/365;;G02B21/367;;G02B26/06;;G06T7/0014;;G06T7/80;;G06T2207/10056;;G06T2207/30168;;G02B21/06;;G02B21/361;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/361;;G02B21/06;;G06T7/0014;;G06T7/80;;G02B21/082;;G06T2207/10056;;G06T2207/30168;;H04N23/56;;G06T7/80;;G02B21/082;;G02B21/365;;G02B26/06;;G06T7/0014;;G06T2207/10056;;G06T2207/30168;;H04N23/56,,,0,0,,,,PENDING
221,WO,A1,WO 2023/192435 A1,081-118-674-847-93X,2023-10-05,2023,US 2023/0016826 W,2023-03-30,US 202263325236 P,2022-03-30,HETEROSTRUCTURES WITH NANOSTRUCTURES OF LAYERED MATERIAL,"A method of fabricating a heterostructure includes forming a layered material structure such that the layered material structure has an edge, and growing epitaxially a nanostructure of layered material laterally from the edge of the layered material structure such that an inplane interface between the layered material structure and the nanostructure is defined. Growing the nanostructure is implemented at a growth temperature sufficiently near a decomposition temperature of the layered material such that a nucleation interface of the nanostructure has a single atomic configuration.",UNIV MICHIGAN REGENTS;;OHIO STATE INNOVATION FOUNDATION,WANG PING;;LEE WONCHEOL;;CORBETT JOSEPH P;;WANG DING;;GUPTA JAY A;;KIOUPAKIS EMMANOUIL;;MI ZETIAN,,https://lens.org/081-118-674-847-93X,Patent Application,yes,2,0,1,1,0,C30B29/403;;C30B29/60;;C30B23/02;;H01L33/32;;H01L21/02527;;H01L21/02458;;H01L21/02488;;H01L21/02502;;H01L21/0259;;B82Y10/00;;B82Y40/00;;H01L29/518;;H01L29/1606;;H01L29/20;;H01L29/267;;H01L29/24;;H01L29/778;;H01L29/7783;;H01L29/7606;;H01L29/42356;;H01L29/42364,C30B29/68;;C30B25/04;;C30B25/18;;H01L21/02,,3,3,041-788-297-110-490;;057-362-446-114-544;;010-170-037-240-265,24458370;;10.1038/ncomms4193;;10.1038/srep43644;;pmc5327397;;28240323;;35355349;;10.1002/adma.202201387,"GONG YONGJI, SHI GANG, ZHANG ZHUHUA, ZHOU WU, JUNG JEIL, GAO WEILU, MA LULU, YANG YANG, YANG SHUBIN, YOU GE, VAJTAI ROBERT, XU QIA: ""Direct chemical conversion of graphene to boron- and nitrogen- and carbon-containing atomic layers"", NATURE COMMUNICATIONS, vol. 5, no. 1, XP093099297, DOI: 10.1038/ncomms4193;;WOFFORD JOSEPH M., NAKHAIE SIAMAK, KRAUSE THILO, LIU XIANJIE, RAMSTEINER MANFRED, HANKE MICHAEL, RIECHERT HENNING, J. LOPES J. MAR: ""A hybrid MBE-based growth method for large-area synthesis of stacked hexagonal boron nitride/graphene heterostructures"", SCIENTIFIC REPORTS, vol. 7, no. 1, XP093099305, DOI: 10.1038/srep43644;;WANG PING, LEE WONCHEOL, CORBETT JOSEPH P., KOLL WILLIAM H., VU NGUYEN M., LALEYAN DAVID ARTO, WEN QIANNAN, WU YUANPENG, PANDEY AY: ""Scalable Synthesis of Monolayer Hexagonal Boron Nitride on Graphene with Giant Bandgap Renormalization"", ADVANCED MATERIALS, VCH PUBLISHERS, DE, vol. 34, no. 21, 1 May 2022 (2022-05-01), DE , XP093099307, ISSN: 0935-9648, DOI: 10.1002/adma.202201387",PENDING
222,AU,B2,AU 2014/256411 B2,133-900-895-704-347,2018-09-27,2018,AU 2014/256411 A,2014-10-31,US 201414527152 A;;US 201361898600 P,2013-11-01,Yield measurement and base cutter height control systems for a harvester,Abstract A system is provided that can include a 3D sensor. The 3D sensor can be configured to detect an area of an elevator on a harvester. The 3D sensor can further be configured to transmit a first signal associated with the area. The system can also include a processing device in communication with the 3D sensor. The system can further include a memory device in which instructions executable by the processing device are stored for causing the processing device to receive the first signal and determine a volume of a material on the elevator based on the first signal.,UNIV CARNEGIE MELLON;;DEERE & CO;;UNIV IOWA STATE RES FOUND INC,DARR MATTHEW J;;CORBETT DANIEL JOSEPH;;HERMAN HERMAN;;VALLESPI-GONZALEZ CARLOS;;DUGAS BRYAN E;;BADINO HERNAN,,https://lens.org/133-900-895-704-347,Granted Patent,no,7,0,9,9,0,G01F22/00;;G01F25/0084;;G01F25/0084;;G01F22/00,A01D31/02,,0,0,,,,ACTIVE
223,CN,A,CN 104718874 A,083-401-922-968-164,2015-06-24,2015,CN 201410602449 A,2014-10-31,US 201361898600 P;;US 201414527152 A,2013-11-01,Yield measurement and base cutter height control systems for a harvester,A system is provided that can include a 3D sensor. The 3D sensor can be configured to detect an area of an elevator on a harvester. The 3D sensor can further be configured to transmit a first signal associated with the area. The system can also include a processing device in communication with the 3D sensor. The system can further include a memory device in which instructions executable by the processing device are stored for causing the processing device to receive the first signal and determine a volume of a material on the elevator based on the first signal.,UNIV IOWA STATE RES FOUND;;DEERE & CO;;UNIV CARNEGIE MELLON,HERMAN HERMAN;;MATTHEW J DARR;;CARLOS VALLESPI-GONZALEZ;;BRYAN E DUGAS;;HERNAN BADINO;;DANIEL JOSEPH CORBETT,,https://lens.org/083-401-922-968-164,Patent Application,no,9,6,9,9,0,G01F25/0084;;G01F25/0084;;G01F22/00;;G01F22/00,A01D41/127,,0,0,,,,ACTIVE
224,US,B2,US 10371561 B2,007-588-272-058-383,2019-08-06,2019,US 201414527152 A,2014-10-29,US 201414527152 A;;US 201361898600 P,2013-11-01,Yield measurement and base cutter height control systems for a harvester,A system is provided that can include a 3D sensor. The 3D sensor can be configured to detect an area of an elevator on a harvester. The 3D sensor can further be configured to transmit a first signal associated with the area. The system can also include a processing device in communication with the 3D sensor. The system can further include a memory device in which instructions executable by the processing device are stored for causing the processing device to receive the first signal and determine a volume of a material on the elevator based on the first signal.,UNIV IOWA STATE RES FOUND INC;;DEERE & CO;;UNIV CARNEGIE MELLON,DARR MATTHEW J;;CORBETT DANIEL JOSEPH;;HERMAN HERMAN;;VALLESPI-GONZALEZ CARLOS;;DUGAS BRYAN E;;BADINO HERNAN,DEERE & COMPANY (2014-11-18);;IOWA STATE UNIVERSITY RESEARCH FOUNDATION INC (2014-11-03);;CARNEGIE MELLON UNIVERSITY (2014-12-18),https://lens.org/007-588-272-058-383,Granted Patent,yes,19,5,9,9,0,G01F25/0084;;G01F25/0084;;G01F22/00;;G01F22/00,G01F25/00;;G01F22/00,,2,0,,,"Office Action issued in Chinese Application No. 201410602449.5 dated Sep. 22, 2017 along with an English translation.;;Office Action issued for Chinese Application No. 201410602449.5 dated Jun. 19, 2018 along with an English translation (16 pages).",ACTIVE
225,US,A1,US 2015/0124054 A1,103-990-968-020-135,2015-05-07,2015,US 201414527152 A,2014-10-29,US 201414527152 A;;US 201361898600 P,2013-11-01,YIELD MEASUREMENT AND BASE CUTTER HEIGHT CONTROL SYSTEMS FOR A HARVESTER,A system is provided that can include a 3D sensor. The 3D sensor can be configured to detect an area of an elevator on a harvester. The 3D sensor can further be configured to transmit a first signal associated with the area. The system can also include a processing device in communication with the 3D sensor. The system can further include a memory device in which instructions executable by the processing device are stored for causing the processing device to receive the first signal and determine a volume of a material on the elevator based on the first signal.,UNIV IOWA STATE RES FOUND INC;;DEERE & CO;;UNIV CARNEGIE MELLON,DARR MATTHEW J;;CORBETT DANIEL JOSEPH;;HERMAN HERMAN;;VALLESPI-GONZALEZ CARLOS;;DUGAS BRYAN E;;BADINO HERNAN,DEERE & COMPANY (2014-11-18);;IOWA STATE UNIVERSITY RESEARCH FOUNDATION INC (2014-11-03);;CARNEGIE MELLON UNIVERSITY (2014-12-18),https://lens.org/103-990-968-020-135,Patent Application,yes,27,62,9,9,0,G01F25/0084;;G01F25/0084;;G01F22/00;;G01F22/00,G01F25/00,348/46,0,0,,,,ACTIVE
226,IL,A,IL 302506 A,182-907-562-585-676,2023-06-01,2023,IL 30250623 A,2023-04-28,US 201962944692 P;;US 2020/0062971 W,2019-12-06,Apparatus and method of providing parameter estimation,,ILLUMINA INC;;CORBETT AUSTIN;;LU BO;;LANGLOIS ROBERT;;PINTO JOSEPH FRANCIS;;CHEN YU;;NEWMAN PETER CLARKE;;REN HONGJI,CORBETT AUSTIN;;LU BO;;LANGLOIS ROBERT;;PINTO JOSEPH FRANCIS;;CHEN YU;;NEWMAN PETER CLARKE;;REN HONGJI,,https://lens.org/182-907-562-585-676,Patent Application,no,0,0,22,22,0,G02B21/367;;G02B21/361;;G02B21/0032;;G02B21/0076;;G02B21/365;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/082;;G02B21/365;;G02B21/367;;G02B26/06;;G06T7/0014;;G06T7/80;;G06T2207/10056;;G06T2207/30168;;G02B21/06;;G02B21/361;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/361;;G02B21/06;;G06T7/0014;;G06T7/80;;G02B21/082;;G06T2207/10056;;G06T2207/30168;;H04N23/56;;G06T7/80;;G02B21/082;;G02B21/365;;G02B26/06;;G06T7/0014;;G06T2207/10056;;G06T2207/30168;;H04N23/56,G02B21/00;;G02B21/08;;G02B21/36;;G02B26/06;;H04N23/56,,0,0,,,,PENDING
227,IN,A,IN 3130DE2014 A,014-326-245-032-528,2015-07-03,2015,IN 3130DE2014 A,2014-10-31,US 201361898600 P;;US 201414527152 A,2013-11-01,“YIELD MEASUREMENT AND BASE CUTTER HEIGHT CONTROL FOR HARVESTER”,A system is provided that can include a 3D sensor. The 3D sensor can be configured to detect an area of an elevator on a harvester. The 3D sensor can further be configured to transmit a first signal associated with the area. The system can also include a processing device in communication with the 3D sensor. The system can further include a memory device in which instructions executable by the processing device are stored for causing the processing device to receive the first signal and determine a volume of a material on the elevator based on the first signal.,UNIV IOWA STATE RES FOUND;;DEERE & CO;;UNIV CARNEGIE MELLON,DARR MATTHEW J;;CORBETT DANIEL JOSEPH;;HERMAN HERMAN;;VALLESPI-GONZALEZ CARLOS;;DUGAS BRYAN E;;BADINO HERNAN,,https://lens.org/014-326-245-032-528,Patent Application,no,0,0,9,9,0,G01F25/0084;;G01F25/0084;;G01F22/00;;G01F22/00,A01D93/00,,0,0,,,,PENDING
228,BR,A2,BR 102014027364 A2,057-407-827-755-165,2016-08-09,2016,BR 102014027364 A,2014-10-31,US 201361898600 P;;US 201414527152 A,2013-11-01,"sistema de controle e de medição da altura de corte para uma ceifeira de base, método, e, colheitadeira","sistema de controle e de medição da altura de corte para uma ceifeira de base, método, e, colheitadeira"" um sistema é fornecido de forma que pode incluir um sensor 3d. o sensor 3d pode ser configurado para detectar uma área de um elevador em uma colheitadeira. o sensor 3d pode ainda ser configurado para transmitir um primeiro sinal associado com a área. o sistema também inclui um dispositivo de processamento na comunicação com o sensor 3d. o sistema pode ainda incluir um dispositivo de memória no qual são armazenadas instruções executáveis pelo dispositivo de processamento para fazer com que o dispositivo de processamento receba o primeiro sinal e determine um volume de um material no elevador com base no primeiro sinal.",UNIV CARNEGIE MELLON;;DEERE & CO;;UNIV IOWA STATE RES FOUND,DUGAS BRYAN E;;VALLESPI-GONZALEZ CARLOS;;CORBETT DANIEL JOSEPH;;BADINO HERMAN;;HERMAN HERMAN;;DARR MATTHEW J,,https://lens.org/057-407-827-755-165,Patent Application,no,0,0,9,9,0,G01F25/0084;;G01F25/0084;;G01F22/00;;G01F22/00,G01F22/00;;G01F25/00,,0,0,,,,ACTIVE
229,IL,B2,IL 286661 B2,070-946-860-695-815,2023-10-01,2023,IL 28666121 A,2021-09-24,US 201962944692 P;;US 2020/0062971 W,2019-12-06,Apparatus and method of providing parameter estimation,,ILLUMINA INC;;CORBETT AUSTIN;;LU BO;;LANGLOIS ROBERT;;PINTO JOSEPH FRANCIS;;CHEN YU;;NEWMAN PETER CLARKE;;REN HONGJI,CORBETT AUSTIN;;LU BO;;LANGLOIS ROBERT;;PINTO JOSEPH FRANCIS;;CHEN YU;;NEWMAN PETER CLARKE;;REN HONGJI,,https://lens.org/070-946-860-695-815,Unknown,no,0,0,22,22,0,G02B21/367;;G02B21/361;;G02B21/0032;;G02B21/0076;;G02B21/365;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/082;;G02B21/365;;G02B21/367;;G02B26/06;;G06T7/0014;;G06T7/80;;G06T2207/10056;;G06T2207/30168;;G02B21/06;;G02B21/361;;G02B21/367;;G02B21/0032;;G02B21/0076;;G02B21/361;;G02B21/06;;G06T7/0014;;G06T7/80;;G02B21/082;;G06T2207/10056;;G06T2207/30168;;H04N23/56;;G06T7/80;;G02B21/082;;G02B21/365;;G02B26/06;;G06T7/0014;;G06T2207/10056;;G06T2207/30168;;H04N23/56,G02B21/00;;G02B21/06;;G02B21/08;;G02B21/36;;G02B26/06,,0,0,,,,PENDING
230,AU,B2,AU 2002/221902 B2,040-687-940-689-704,2006-11-23,2006,AU 2002/221902 A,2001-11-28,US 25163700 P;;EP 0113870 W,2000-12-06,Fused heteroaromatic glucokinase activators,,HOFFMANN LA ROCHE,MAHANEY PAIGE ERIN;;CORBETT WENDY LEA;;GRIMBSY JOSEPH SAMUEL;;KESTER ROBERT FRANCIS;;SARABU RAMAKANTH;;HAYNES NANCY-ELLEN,,https://lens.org/040-687-940-689-704,Granted Patent,no,0,0,33,35,0,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;A61P3/10;;A61P5/50;;C07D277/82;;C07D215/38;;C07D277/82;;C07D235/30;;C07D263/58,C07D263/58;;A61K31/4184;;A61K31/423;;A61K31/428;;A61K31/47;;A61P3/10;;C07D215/38;;C07D235/30;;C07D277/82,,0,0,,,,EXPIRED
231,US,A1,US 2002/0103199 A1,141-447-581-814-794,2002-08-01,2002,US 617001 A,2001-12-04,US 617001 A;;US 25163700 P,2000-12-06,Fused heteroaromatic glucokinase activators,"
   Glucokinase activating amides are useful for increasing insulin secretion in the treatment of type II diabetes. 
",CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH,,https://lens.org/141-447-581-814-794,Patent Application,yes,0,30,33,35,0,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;A61P3/10;;A61P5/50;;C07D277/82;;C07D215/38;;C07D277/82;;C07D235/30;;C07D263/58,A61K31/4184;;A61K31/423;;A61K31/428;;A61K31/47;;A61P3/10;;C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82,514/243;;514/249;;514/266.4;;514/314;;544/183;;544/292;;544/356;;546/159,0,0,,,,EXPIRED
232,PT,E,PT 1341774 E,053-339-736-968-387,2006-05-31,2006,PT 01999565 T,2001-11-28,US 25163700 P,2000-12-06,"ACTIVADORES HETEROAROMATICOS, FUNDIDOS DE GLICOCINASE",,HOFFMANN LA ROCHE,CORBETT WENDY LEA;;SAMUEL GRIMBSY JOSEPH;;NANCY-ELLEN HAYNES;;FRANCIS KESTER ROBERT;;ERIN MAHANEY PAIGE;;RAMAKANTH SARABU,,https://lens.org/053-339-736-968-387,Granted Patent,no,0,0,33,35,0,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;A61P3/10;;A61P5/50;;C07D277/82;;C07D215/38;;C07D277/82;;C07D235/30;;C07D263/58,A61K31/4184;;A61K31/423;;A61K31/428;;A61K31/47;;A61P3/10;;C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82,,0,0,,,,EXPIRED
233,BR,A,BR 0115999 A,046-505-013-297-097,2003-09-30,2003,BR 0115999 A,2001-11-28,EP 0113870 W;;US 25163700 P,2000-12-06,"Composto, composição farmacêutica que compreende o mesmo, sua utilização, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto","""COMPOSTO, COMPOSIçãO FARMACêUTICA QUE COMPREENDE O MESMO, SUA UTILIZAçãO, PROCESSO PARA O TRATAMENTO PROFILáTICO OU TERAPêUTICO DE DIABETES DO TIPO II E PROCESSO PARA A PREPARAçãO DO COMPOSTO"". Expõem-se compostos da Fórmula I-O de estimulação de glicoquinase ou seus sais farmaceuticamente aceitáveis: em que M é a Fórmula II ou Fórmula III; Q é a Fórmula IV ou a Fórmula V; R^ 1^ é uma alquila que tem de 1 a 3 átomos de carbono; R^ 2^ é hidrogênio, halo, nitro, ciano, ou perfluoro-metilo; R^ 3^ é cicloalquila que tem de 4 a 7 átomos de carbono ou 2-propilo; R^ 5^ é halogênio; R^ 6^ é halogênio; W é O, S ou NH; cada Y é independentemente CH ou N; Z é CH~ 2~-CH~ 2~-CH~ 2~-CH~ 2~ ou CH=CR^ 4^-CH=CH-, em que R^ 4^ é hidrogênio, halo, ou uma alquil sulfona que tem de 1 a 3 átomos de carbono; e as linhas tracejadas representam coletivamente O ou 2 aglutinações duplas adicionais na estrutura de anel heterocíclica. Os compostos da Fórmula I-O podem estar presentes seja como um racemato ou na configuração ""R"" isolada no carbono assimétrico ilustrado.",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMBSY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH,,https://lens.org/046-505-013-297-097,Patent Application,no,0,0,33,35,0,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;A61P3/10;;A61P5/50;;C07D277/82;;C07D215/38;;C07D277/82;;C07D235/30;;C07D263/58,A61K31/4184;;A61K31/423;;A61K31/428;;A61K31/47;;A61P3/10;;C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82,,0,0,,,,DISCONTINUED
234,PA,A1,PA 8534301 A1,028-044-181-470-862,2002-08-26,2002,PA 8534301 A,2001-12-04,US 25163700 P,2000-12-06,ACTIVADORES HETEROAROMÁTICOS FUSINADOS DE LA GLUCOQUINASA,"LOS COMPUESTOS DE LA GLUCOQUINASA O LAS SALES FARMACEUTICAMENTE ACEPTABLES DE FORMULA I-0: EN DONDE M ES Q ES R1 ES UN ALQUILO CON DE 1 A 3 ATOMOS DE CARBONO; R2 ES HIDROGENO, HALO, NITRO, CIANO, O PERFLUORURO-METIL; R3 ES UN CICLOALQUILO CON DE 4 A 7 ATOMOS DE CARBONO P 2-PROPILO; R5 ES HALOGENO; R6 ES HALOGENO; W ES O, S O NH; CADA Y ES INDEPENDIENTEMENTE CH O N; Z ES -CH2-CH2-CH2-CH2- O -CH=CH4-CH=CH-, EN DONDE R4 ES HIDROGENO, HALO, O UNA ALQUIL SULFONA CON DE 1 A 3 ATOMOS DE CARBONO; Y LAS LINEAS DE PUNTOS COLECTIVAMENTE REPRESENTAN 0 O 2 DOBLES ENLACES ADICIONALES EN LA ESTRUCTURA DEL ANILLO HETEROCICLICO. LOS COMPUESTOS DE FORMULA I-0 TAMBIEN SE PUEDEN PRESENTAR EN FORMA DE RACEMATO O EN LA CONFIGURACION ""R"" AISLADA EN EL CARBONO ASIMETRICO MOSTRADO.",HOFFMANN LA ROCHE,SARABU RAMAKANTH;;CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN,,https://lens.org/028-044-181-470-862,Patent Application,no,0,0,33,35,0,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;A61P3/10;;A61P5/50;;C07D277/82;;C07D215/38;;C07D277/82;;C07D235/30;;C07D263/58,A61K31/4184;;A61K31/423;;A61K31/428;;A61K31/47;;A61P3/10;;C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;C07H15/00,,0,0,,,,PENDING
235,EP,B1,EP 1341774 B1,015-142-288-850-168,2006-02-01,2006,EP 01999565 A,2001-11-28,EP 0113870 W;;US 25163700 P,2000-12-06,FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS,,HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMBSY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH,,https://lens.org/015-142-288-850-168,Granted Patent,yes,1,0,33,35,0,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;A61P3/10;;A61P5/50;;C07D277/82;;C07D215/38;;C07D277/82;;C07D235/30;;C07D263/58,C07D263/58;;A61K31/4184;;A61K31/423;;A61K31/428;;A61K31/47;;A61P3/10;;C07D215/38;;C07D235/30;;C07D277/82,,0,0,,,,EXPIRED
236,US,B1,US 6448399 B1,078-961-183-479-133,2002-09-10,2002,US 709101 A,2001-12-04,US 709101 A;;US 25163700 P,2000-12-06,Fused heteroaromatic glucokinase activators,"
    Glucokinase activating amides are useful for increasing insulin secretion in the treatment of type II diabetes. 
",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH,,https://lens.org/078-961-183-479-133,Granted Patent,yes,2,88,33,35,0,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;A61P3/10;;A61P5/50;;C07D277/82;;C07D215/38;;C07D277/82;;C07D235/30;;C07D263/58,A61K31/4184;;A61K31/423;;A61K31/428;;A61K31/47;;A61P3/10;;C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82,544/183;;544/283;;544/353;;546/152;;564/155,21,15,061-893-046-790-102;;040-526-770-522-399;;098-019-860-572-873;;002-463-604-557-082;;047-763-655-227-523;;032-877-568-180-983;;065-414-058-876-944;;127-807-720-503-216;;063-903-680-107-744;;054-215-992-897-022;;028-044-206-918-302;;035-153-689-789-141;;073-561-881-544-866;;128-989-144-955-885;;032-079-103-893-493,6364828;;10.1152/ajpendo.1984.246.1.e1;;7553875;;10.1016/0092-8674(95)90235-x;;10.1096/fasebj.10.10.8751724;;8751724;;pmc1135815;;7619052;;10.1042/bj3090167;;9435328;;10.1056/nejm199801223380404;;10.1021/jo00125a055;;10.1021/jo00143a035;;10.1021/jo01069a523;;10.1021/jm00131a012;;2509709;;10.1021/jo00339a019;;10.1021/jo00280a045;;5069770;;10.1021/jm00280a009;;10.1080/00397919208021079;;10.1016/s0022-1139(00)80301-2;;10.1016/s0040-4039(01)93421-5,"Colowick, S.P., The Enzymes, vol. 9 (P. Boyer, ed.) Academic Press, New York, New York, pp. 1-48 (1973).;;Chipkin et al., Joslin's Diabetes Mellitus (C. R. Kahn and G.C. Wier, eds.) Lea & Febiger, Philiadelphia, PA, pp. 97-115 (1994).;;Printz et al., Ann. Rev. Nutrition, vol. 13 (R.E. Olson, D. M. Bier and D.B. McCormick, eds.) Annual Review, Inc., Palo Alto, CA, pp. 463-496 (1993).;;Meglasson et al., Amer. J. Physiol., 246, E1-E13 (1984).;;Grupe et al., Cell, 83, pp. 69-78 (1995).;;Ferre et al., FASEB J., 10, pp. 1213-1218 (1996).;;Liang et al., Biochem. J., 309, pp. 167-173 (1995).;;Glaser et al., New England J. Med., 338, pp. 226-230 (1998).;;Skeean et al., Synthesis, pp. 628-630 (1990).;;Boswell et al., J. Org. Chem., 60, pp. 6592-6594 (1995).;;Sheikh et al., J. Org. Chem., 47, pp. 4341-4344 (1982).;;Brown et al., J. Org. Chem., pp. 4707-4708 (1961).;;Wrobel et al., J. Med. Chem., 32, pp. 2493-2500 (1989).;;Greenlee et al., J. Org. Chem., 46 pp. 5351-5353 (1981).;;Testaferri et al., Synthesis, pp. 751-757 (1983).;;Ulman et al., J. Org. Chem., 54, pp. 4691-4692 (1989).;;Levine et al., J. Med. Chem., pp. 1029-1032 (1972).;;D.J. milner, Synthetic Commun., 22, pp. 73-82 (1992).;;Fukuhara et al., J. Fluorine Chem., pp. 299-304 (1991).;;Myers et al., J. Am. Chem. Soc., pp. 6496-6511 (1997).;;Ahmar et al., Tetradron Lett., pp. 7053-7056 (1989).",EXPIRED
237,CA,A1,CA 2429642 A1,137-332-237-245-452,2002-06-13,2002,CA 2429642 A,2001-11-28,EP 0113870 W;;US 25163700 P,2000-12-06,FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS,"Glucokinase activating compounds or pharmaceutically acceptable salts of Formula I-0: wherein M is Formula II or Formula III; Q is Formula IV or Formula V; R1 is an alkyl having from 1 to 3 carbon atoms; R2 is hydrogen, halo, nitro, cyano, or perfluoro-methyl; R3 is a cycloalkyl having from 4 to 7 carbon atoms or 2-propyl; R5 is halogen; R6 is halogen; W is O, S or NH; each Y is independently CH or N; Z is CH2-CH2-CH2-CH2 or CH=CR4-CH=CH-, wherein R4 is hydrogen, halo, or an alkyl sulfone having from 1 to 3 carbon atoms; and dotted lines collectively represent O or 2 additional double bonds in the heterocyclic ring structure. Compounds of Formula 1-0 may be present either as a racemate or in the isolated ""R"" configuration at the asymmetric carbon shown.",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMBSY JOSEPH SAMUEL;;SARABU RAMAKANTH;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN,,https://lens.org/137-332-237-245-452,Patent Application,no,0,0,33,35,0,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;A61P3/10;;A61P5/50;;C07D277/82;;C07D215/38;;C07D277/82;;C07D235/30;;C07D263/58,A61K31/4184;;A61K31/423;;A61K31/428;;A61K31/47;;A61P3/10;;C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82,,0,0,,,,EXPIRED
238,US,A1,US 2002/0111372 A1,155-137-429-488-060,2002-08-15,2002,US 600501 A,2001-12-04,US 600501 A;;US 25163700 P,2000-12-06,FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS,"
   Glucokinase activating amides are useful for increasing insulin secretion in the treatment of type II diabetes. 
",CORBETT WENDY L.;;GRIMSBY JOSEPH S.;;HAYNES NANCY-ELLEN;;KESTER ROBERT F.;;MAHANEY PAIGE E.;;SARABU RAMAKANTH,CORBETT WENDY L;;GRIMSBY JOSEPH S;;HAYNES NANCY-ELLEN;;KESTER ROBERT F;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/155-137-429-488-060,Patent Application,yes,0,22,2,35,0,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82,514/367;;514/375;;514/395;;548/161;;548/222;;548/309.7,0,0,,,,EXPIRED
239,US,B1,US 6433188 B1,193-264-718-474-378,2002-08-13,2002,US 600501 A,2001-12-04,US 600501 A;;US 25163700 P,2000-12-06,Fused heteroaromatic glucokinase activators,"
    Glucokinase activating amides as herein disclosed are useful for increasing insulin secretion in the treatment of type II diabetes. 
",CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH,,https://lens.org/193-264-718-474-378,Granted Patent,yes,1,42,2,35,0,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82,549/32;;549/467;;548/330,22,15,061-893-046-790-102;;040-526-770-522-399;;098-019-860-572-873;;002-463-604-557-082;;047-763-655-227-523;;032-877-568-180-983;;065-414-058-876-944;;127-807-720-503-216;;063-903-680-107-744;;054-215-992-897-022;;028-044-206-918-302;;035-153-689-789-141;;073-561-881-544-866;;128-989-144-955-885;;032-079-103-893-493,6364828;;10.1152/ajpendo.1984.246.1.e1;;7553875;;10.1016/0092-8674(95)90235-x;;10.1096/fasebj.10.10.8751724;;8751724;;pmc1135815;;7619052;;10.1042/bj3090167;;9435328;;10.1056/nejm199801223380404;;10.1021/jo00125a055;;10.1021/jo00143a035;;10.1021/jo01069a523;;10.1021/jm00131a012;;2509709;;10.1021/jo00339a019;;10.1021/jo00280a045;;5069770;;10.1021/jm00280a009;;10.1080/00397919208021079;;10.1016/s0022-1139(00)80301-2;;10.1016/s0040-4039(01)93421-5,"Yuan et al., Beijing Saxue Xuebao, 24(4), 504-6 (1988) (abstract).*;;Colowick, S.P., The Enzymes, vol. 9 (P. Boyer, ed.) Academic Press, New York, New York, pp. 1-48 (1973).;;Chipkin et al., Joslin's Diabetes Mellitus (C.R. Kahn and G.C. Wier, eds.) Lea & Febiger, Philadelphia, PA, pp. 97-115 (1994).;;Printz et al., Ann. Rev. Nutrition, vol. 13 (R.E. Olson, D.M. Bier and D.B. McCormick, eds.) Annual Review, Inc., Palo Alto, CA, pp. 463-496 (1993).;;Meglasson et al., Amer. J. Physiol., 246, E1-E13 (1984).;;Grupe et al., Cell, 83, pp. 69-78 (1995).;;Ferre et al., FASEB J., 10, pp. 1213-1218 (1996).;;Liang et al., Biochem. J., 309, pp. 167-173 (1995).;;Glaser et al., New England J. Med., 338, pp. 226-230 (1998).;;Skeean et al., Synthesis, pp. 628-630 (1990).;;Boswell et al., J. Org. Chem., 60, pp. 6592-6594 (1995).;;Sheikh et al., J. Org. Chem., 47, pp. 4341-4344 (1982).;;Brown et al., J. Org. Chem., pp. 4707-4708 (1961).;;Wrobel et al., J. Med. Chem., 32, pp. 2493-2500 (1989).;;Greenlee et al., J. Org. Chem., 46, pp. 5351-5353 (1981).;;Testaferri et al., Synthesis, pp. 751-757 (1983).;;Ulman et al., J. Org. Chem., 54, pp. 4691-4692 (1989).;;Levine et al., J. Med. Chem., pp. 1029-1032 (1972).;;D.J. Milner, Synthetic Commun., 22, pp. 73-82 (1992).;;Fukuhara et al., J. Fluorine Chem., pp. 299-304 (1991).;;Myers et al., J. Am. Chem. Soc., pp. 6496-6511 (1997).;;Ahmar et al., Tetrahedron Lett., pp. 7053-7056 (1989).",EXPIRED
240,ZA,B,ZA 200303748 B,042-151-316-085-568,2004-08-16,2004,ZA 200303748 A,2003-05-14,US 25163700 P,2000-12-06,Fused heteroaromatic glucokinase activators.,,HOFFMANN LA ROCHE,CORBETT WENDY LEA;;HAYNES NANCY-ELLEN;;MAHANEY PAIGE ERIN;;GRIMSBY JOSEPH SAMUEL;;KESTER ROBERT FRANCIS;;SARABU RAMAKANTH,,https://lens.org/042-151-316-085-568,Granted Patent,no,0,0,33,35,0,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;A61P3/10;;A61P5/50;;C07D277/82;;C07D215/38;;C07D277/82;;C07D235/30;;C07D263/58,A61K31/4184;;A61K31/423;;A61K31/428;;A61K31/47;;A61P3/10;;C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82,,0,0,,,,EXPIRED
241,PE,A1,PE 20020753 A1,030-748-902-506-210,2002-08-27,2002,PE 2001001217 A,2001-12-04,US 25163700 P,2000-12-06,HETEROAROMATICOS FUSIONADOS COMO ACTIVADORES DE LA GLUCOQUINASA,"SE REFIERE A AMIDAS DE COMPUESTOS HETEROAROMATICOS FUSIONADOS DE FORMULA R3-CH2-C*H(M)-C(=O)-NH-Q DONDE: M ES ALQUILSULFONILFENIL, FENIL SUSTITUIDO CON R5 Y R6; Q ES UN GRUPO a, b; R1 ES ALQUILO C1-C3; R2 ES H, HALO, NITRO, CIANO, PERFLUOROMETILO; R3 ES CICLOALQUILO C4-C7, 2-PROPILO; R5 Y R6 SON HALOGENO; W ES O, S, NH; Y ES CH, N; Z ES -(CH2)4-, HC=CR4-CH=CH-; R4 ES H, HALO, ALQUILSULFONA C1-C3. SON COMPUESTOS PREFERIDOS N-BENZOTIAZOL-2-IL-2(R)-(3-CLORO-4-METANOSULFONIL-FENIL)-3-CICLOPENTILPROPIONAMIDA; N-(1H-BENZOIMIDAZOL-2-IL)-2-(3-CLORO-4-METANOSULFONIL-FENIL)-3-CICLOPENTILPROPIONAMIDA. 2-(3-CLORO-4-METANOSULFONIL-FENIL)-3-CICLOPENTIL-N-QUINOLIN-2-IL-PROPIONAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS SON ACTIVADORES DE LA GLUCOQUINASA Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE DIABETES",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH;;KESTER ROBERT FRANCIS,,https://lens.org/030-748-902-506-210,Patent Application,no,0,0,33,35,0,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;A61P3/10;;A61P5/50;;C07D277/82;;C07D215/38;;C07D277/82;;C07D235/30;;C07D263/58,A61K31/4184;;A61K31/423;;A61K31/428;;A61K31/47;;A61P3/10;;C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82,,0,0,,,,DISCONTINUED
242,ES,T3,ES 2256340 T3,168-665-205-054-141,2006-07-16,2006,ES 01999565 T,2001-11-28,US 25163700 P,2000-12-06,ACTIVADORES HETEROAROMATICOS FUSIONADOS DE LA GLUCOQUINASA.,"Un compuesto seleccionado del grupo consistente en una amida de fórmula I-0: en donde M es o Q es o R1 es un alquilo con de 1 a 3 átomos de carbono; R2 es hidrógeno, halo, nitro, ciano, o perfluoro-metilo; R3 es un cicloalquilo con de 4 a 7 átomos de carbono o 2- propilo; R5 es halógeno; R6 es halógeno; W es O, S o NH; Cada Y es independientemente CH o N; Z es -CH2-CH2-CH2-CH2- o -CH=CR4-CH=CH-, en donde R4 es hidrógeno, halo, o una alquil sulfona con de 1 a 3 átomos de carbono; las línias de puntos colectivamente representan 0 ó 2 dobles enlaces adicionales en la estructura del anillo heterocíclico; y * denota un átomo de carbono asimétrico; o una sal farmacéuticamente aceptable del mismo.",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMBSY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH,,https://lens.org/168-665-205-054-141,Granted Patent,no,0,0,33,35,0,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;A61P3/10;;A61P5/50;;C07D277/82;;C07D215/38;;C07D277/82;;C07D235/30;;C07D263/58,A61K31/4184;;A61K31/423;;A61K31/428;;A61K31/47;;A61P3/10;;C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82,,0,0,,,,EXPIRED
243,US,B2,US 6545155 B2,178-052-838-704-520,2003-04-08,2003,US 617001 A,2001-12-04,US 617001 A;;US 25163700 P,2000-12-06,Fused heteroaromatic glucokinase activators,"
    Glucokinase activating amides useful for increasing insulin secretion in the treatment of type II diabetes are disclosed. 
",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH,,https://lens.org/178-052-838-704-520,Granted Patent,yes,1,77,33,35,0,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;A61P3/10;;A61P5/50;;C07D277/82;;C07D215/38;;C07D277/82;;C07D235/30;;C07D263/58,A61K31/4184;;A61K31/423;;A61K31/428;;A61K31/47;;A61P3/10;;C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82,546/159;;546/162;;544/183;;544/253;;544/292;;544/356,21,15,061-893-046-790-102;;040-526-770-522-399;;098-019-860-572-873;;002-463-604-557-082;;047-763-655-227-523;;032-877-568-180-983;;065-414-058-876-944;;127-807-720-503-216;;063-903-680-107-744;;054-215-992-897-022;;028-044-206-918-302;;035-153-689-789-141;;073-561-881-544-866;;128-989-144-955-885;;032-079-103-893-493,6364828;;10.1152/ajpendo.1984.246.1.e1;;7553875;;10.1016/0092-8674(95)90235-x;;10.1096/fasebj.10.10.8751724;;8751724;;pmc1135815;;7619052;;10.1042/bj3090167;;9435328;;10.1056/nejm199801223380404;;10.1021/jo00125a055;;10.1021/jo00143a035;;10.1021/jo01069a523;;10.1021/jm00131a012;;2509709;;10.1021/jo00339a019;;10.1021/jo00280a045;;5069770;;10.1021/jm00280a009;;10.1080/00397919208021079;;10.1016/s0022-1139(00)80301-2;;10.1016/s0040-4039(01)93421-5,"Colowick, S.P., The Enzymes, vol. 9 (P. Boyer, ed.) Academic Press, New York, New York, pp. 1-48 (1973).;;Chipkin et al., Joslin's Diabetes Mellitus (C. R. Kahn and G. C. Wier, eds.) Lea & Febiger, Philadelphia, PA, pp. 97-115 (1994).;;Printz et al., Ann. Rev. Nutrition, vol. 13 (R. E. Olson, D. M. Bier and D. B. McCormick, eds.) Annual Review, Inc., Palo Alto, CA, pp. 463-496 (1993).;;Meglasson et al., Amer. J. Physiol., 246, E1-E13 (1984).;;Grupe et al., Cell, 83, pp. 69-78 (1995).;;Ferre et al., FASEB J., 10, pp. 1213-1218 (1996).;;Liang et al., Biochem. J., 309, pp. 167-173 (1995).;;Glaser et al., New England J. Med., 338, pp. 226-230 (1998).;;Skeean et al., Synthesis, pp. 628-630 (1990).;;Boswell et al., J. Org. Chem., 60, pp. 6592-6594 (1995).;;Sheikh et al., J. Org. Chem., 47, pp. 4341-4344 (1982).;;Brown et al., J. Org. Chem., pp. 4707-4708 (1961).;;Wrobel et al., J. Med. Chem., 32, pp. 2493-2500 (1989).;;Greenlee et al., J. Org. Chem., 46, pp. 5351-5353 (1981).;;Testaferri et al., Synthesis, pp. 751-757 (1983).;;Ulman et al., J. Org. Chem., 54, pp. 4691-4692 (1989).;;Stiller et al., J. Med. Chem., pp. 1029-1032 (1972).;;D. J. Milner, Synthetic Commun., 22, pp. 73-82 (1992).;;Fukuhara et al., J. Fluorine Chem., pp. 299-304 (1991).;;Myers et al., J. Am. Chem. Soc., pp. 6496-6511 (1997).;;Ahmar et al., Tetrahedron Lett., pp. 7053-7056 (1989).",EXPIRED
244,AU,A,AU 2002/021902 A,001-564-267-429-480,2002-06-18,2002,AU 2002/021902 A,2001-11-28,EP 0113870 W;;US 25163700 P,2000-12-06,Fused heteroaromatic glucokinase activators,,HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMBSY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH,,https://lens.org/001-564-267-429-480,Patent Application,no,0,0,33,35,0,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;A61P3/10;;A61P5/50;;C07D277/82;;C07D215/38;;C07D277/82;;C07D235/30;;C07D263/58,A61K31/4184;;A61K31/423;;A61K31/428;;A61K31/47;;A61P3/10;;C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82,,0,0,,,,PENDING
245,AT,T1,AT E316965 T1,187-272-780-348-367,2006-02-15,2006,AT 01999565 T,2001-11-28,US 25163700 P,2000-12-06,KONDENSIERTE HETEROAROMATISCHE GLUCOKINASEAKTIVATOREN,,HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMBSY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH,,https://lens.org/187-272-780-348-367,Granted Patent,no,0,0,33,35,0,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;A61P3/10;;A61P5/50;;C07D277/82;;C07D215/38;;C07D277/82;;C07D235/30;;C07D263/58,A61K31/4184;;A61K31/423;;A61K31/428;;A61K31/47;;A61P3/10;;C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82,,0,0,,,,EXPIRED
246,US,A1,US 2002/0107396 A1,025-432-429-644-105,2002-08-08,2002,US 709101 A,2001-12-04,US 709101 A;;US 25163700 P,2000-12-06,FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS,"
   Glucokinase activating amides are useful for increasing insulin secretion in the treatment of type II diabetes. 
",CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH,,https://lens.org/025-432-429-644-105,Patent Application,yes,0,32,33,35,0,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;A61P3/10;;A61P5/50;;C07D277/82;;C07D215/38;;C07D277/82;;C07D235/30;;C07D263/58,A61K31/4184;;A61K31/423;;A61K31/428;;A61K31/47;;A61P3/10;;C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82,546/159;;544/183;;544/292;;544/356,0,0,,,,EXPIRED
247,WO,A1,WO 2002/046173 A1,190-974-287-057-325,2002-06-13,2002,EP 0113870 W,2001-11-28,US 25163700 P,2000-12-06,FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS,"Glucokinase activating compounds or pharmaceutically acceptable salts of Formula I-0: wherein M is Formula II or Formula III; Q is Formula IV or Formula V; R1 is an alkyl having from 1 to 3 carbon atoms; R2 is hydrogen, halo, nitro, cyano, or perfluoro-methyl; R3 is a cycloalkyl having from 4 to 7 carbon atoms or 2-propyl; R5 is halogen; R6 is halogen; W is O, S or NH; each Y is independently CH or N; Z is CH¿2?-CH2-CH2-CH2 or CH=CR?4¿-CH=CH-, wherein R4 is hydrogen, halo, or an alkyl sulfone having from 1 to 3 carbon atoms; and dotted lines collectively represent O or 2 additional double bonds in the heterocyclic ring structure. Compounds of Formula 1-0 may be present either as a racemate or in the isolated 'R' configuration at the asymmetric carbon shown.",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMBSY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH,,https://lens.org/190-974-287-057-325,Patent Application,yes,1,79,33,35,0,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;A61P3/10;;A61P5/50;;C07D277/82;;C07D215/38;;C07D277/82;;C07D235/30;;C07D263/58,A61K31/4184;;A61K31/423;;A61K31/428;;A61K31/47;;A61P3/10;;C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82,,0,0,,,,PATENTED
248,DK,T3,DK 1341774 T3,032-151-920-771-959,2006-06-12,2006,DK 01999565 T,2001-11-28,US 25163700 P,2000-12-06,Kondenserede heteroaromatiske glucokinase-aktivatorer,,HOFFMANN LA ROCHE,CORBETT WENDY LEA;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH;;GRIMBSY JOSEPH SAMUEL,,https://lens.org/032-151-920-771-959,Granted Patent,no,0,0,33,35,0,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;A61P3/10;;A61P5/50;;C07D277/82;;C07D215/38;;C07D277/82;;C07D235/30;;C07D263/58,C07D263/58;;A61K31/4184;;A61K31/423;;A61K31/428;;A61K31/47;;A61P3/10;;C07D215/38;;C07D235/30;;C07D277/82,,0,0,,,,EXPIRED
249,ES,T3,ES 2226811 T3,176-913-504-672-003,2005-04-01,2005,ES 00918816 T,2000-03-20,US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,ACTIVADORES DE GLUCOQUINASA.,"Un compuesto que comprende una amida de la fórmula I: en donde el * indica un átomo de carbono asimétrico; R1 y R2 son independientemente hidrógeno, halo, amino, hidroxiamino, nitro, ciano, sulfonamido, alquilo inferior, -OR5, -C(O)OR5, perfluoro-alquilo inferior, alquilo inferior tio, perfluoro-alquilo inferior tio, alquilo inferior sulfonilo, perfluoro-alquilo inferior sulfonilo o alquilo inferior sulfinilo; R3 es cicloalquilo que presenta de 3 a 7 átomos de carbono; R4 es -C(O)NHR40; o un anillo heteroaromático de cinco o seis miembros no sustituídos o monosustituídos unido por un átomo de carbono del anillo al grupo amina mostrado, el anillo heteroaromático de cinco o seis miembros contiene de 1 a 3 heteroátomos de azufre, oxígeno o nitrógeno, con un heteroátomo que es nitrógeno el cual se encuentra junto al átomo de carbono que conecta el anillo; dicho anillo heteroaromático monosustituído se encuentra monosustituído en una posición de átomo de carbono del anillo diferente que no sea adyacente a dicho átomo de carbono de conexión con un sustituyente seleccionado del grupo que consiste de alquilo inferior, halo, nitro, ciano, -(CH2)n-0R6, -(CH2)n- C(O)OR7, -(CH2)n-C(O)NHR6, -C(O)-C(O)0R8, -(CH2)n-NHR6; R40 es hidrógeno, alquilo inferior, alquenilo inferior, hidroxi alquilo inferior, halo alquilo inferior, -(CH2)n-C (O)OR5 ó -C(O)-(CH2)n-C(O)OR6; R5 es hidrógeno, alquilo inferior o perfluoro-alquilo inferior; R6, R7 y R8 son independientemente hidrógeno o alquilo inferior; y n es 0, 1, 2, 3 ó 4; ""alquilo inferior"" y ""alcoxilo inferior"" indican grupos con 1 a 7 átomos de carbono; y ""alquenilo inferior"" indica grupos con 2 a 6 átomos de carbono; ó una sal respectiva farmacéuticamente aceptable.",HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM,,https://lens.org/176-913-504-672-003,Granted Patent,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
250,US,B1,US 6441184 B1,071-844-436-353-911,2002-08-27,2002,US 616801 A,2001-12-04,US 616801 A;;US 25163700 P,2000-12-06,Fused heteroaromatic glucokinase activators,"
    Glucokinase activating amides are useful for increasing insulin secretion in the treatment of type II diabetes. 
",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH,,https://lens.org/071-844-436-353-911,Granted Patent,yes,2,39,33,35,0,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;A61P3/10;;A61P5/50;;C07D277/82;;C07D215/38;;C07D277/82;;C07D235/30;;C07D263/58,A61K31/4184;;A61K31/423;;A61K31/428;;A61K31/47;;A61P3/10;;C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82,548/161;;548/222;;548/307.4,21,15,061-893-046-790-102;;040-526-770-522-399;;098-019-860-572-873;;002-463-604-557-082;;047-763-655-227-523;;032-877-568-180-983;;065-414-058-876-944;;127-807-720-503-216;;063-903-680-107-744;;054-215-992-897-022;;028-044-206-918-302;;035-153-689-789-141;;073-561-881-544-866;;128-989-144-955-885;;032-079-103-893-493,6364828;;10.1152/ajpendo.1984.246.1.e1;;7553875;;10.1016/0092-8674(95)90235-x;;10.1096/fasebj.10.10.8751724;;8751724;;pmc1135815;;7619052;;10.1042/bj3090167;;9435328;;10.1056/nejm199801223380404;;10.1021/jo00125a055;;10.1021/jo00143a035;;10.1021/jo01069a523;;10.1021/jm00131a012;;2509709;;10.1021/jo00339a019;;10.1021/jo00280a045;;5069770;;10.1021/jm00280a009;;10.1080/00397919208021079;;10.1016/s0022-1139(00)80301-2;;10.1016/s0040-4039(01)93421-5,"Colowick, S.P., The Enzymes, vol. 9 (P. Boyer, ed.) Academic Press, New York, New York, pp. 1-48 (1973).;;Chipkin et al., Joslin's Diabetes Mellitus (C. R. Kahn and G. C. Wier, eds.) Lea & Febiger, Philadelphia, PA, pp. 97-115 (1994).;;Printz et al., Ann. Rev. Nutrition, vol. 13 (R. E. Olson, D. M. Bier and D. B. McCormick, eds.) Annual Review, Inc., Palo Alto, CA, pp. 463-496 (1993).;;Meglasson et al., Amer. J. Physiol., 246, E1-E13 (1984).;;Grupe et al., Cell, 83, pp. 69-78 (1995).;;Ferre et al., FASEB J., 10, pp. 1213-1218 (1996).;;Liang et al., Biochem. J., 309, pp. 167-173 (1995).;;Glaser et al., New England J. Med., 338, pp. 226-230 (1998).;;Skeean et al., Synthesis, pp. 628-630 (1990).;;Boswell et al., J. Org. Chem., 60, pp. 6592-6594 (1995).;;Sheikh et al., J. Org. Chem., 47, pp. 4341-4344 (1982).;;Brown et al., J. Org. Chem., pp. 4707-4708 (1961).;;Wrobel et al., J. Med. Chem., 32, pp. 2493-2500 (1989).;;Greenlee et al., J. Org. Chem., 46, pp. 5351-5353 (1981).;;Testaferri et al., Synthesis, pp. 751-757 (1983).;;Ulman et al., J. Org. Chem., 54, pp. 4691-4692 (1989).;;Levine et al., J. Med. Chem., pp. 1029-1032 (1972).;;D. J. Milner, Synthetic Commun., 22, pp. 73-82 (1992).;;Fukuhara et al., J. Fluorine Chem., pp. 299-304 (1991).;;Myers et al., J. Am. Chem. Soc., pp. 6496-6511 (1997).;;Ahmar et al., Tetrahedron Lett., pp. 7053-7056 (1989).",EXPIRED
251,EP,A1,EP 1341774 A1,142-497-988-170-718,2003-09-10,2003,EP 01999565 A,2001-11-28,EP 0113870 W;;US 25163700 P,2000-12-06,FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS,,HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMBSY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH,,https://lens.org/142-497-988-170-718,Patent Application,yes,0,0,33,35,0,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;A61P3/10;;A61P5/50;;C07D277/82;;C07D215/38;;C07D277/82;;C07D235/30;;C07D263/58,A61K31/4184;;A61K31/423;;A61K31/428;;A61K31/47;;A61P3/10;;C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82,,0,0,,,,EXPIRED
252,CA,C,CA 2429642 C,152-388-983-872-403,2007-11-20,2007,CA 2429642 A,2001-11-28,EP 0113870 W;;US 25163700 P,2000-12-06,FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS,"Glucokinase activating compounds or pharmaceutically acceptable salts of Formula I-0: (See formula I-0) wherein M is (See formula I) or (See formula II) Q is (See formula III) or (See formula IV) R1 is an alkyl having from 1 to 3 carbon atoms; R2 is hydrogen, halo, nitro, cyano, or perfluoro-methyl; R3 is a cycloalkyl having from 4 to 7 carbon atoms or 2- propyl; R5 is halogen; R6 is halogen; W is O, S or NH; each Y is independently CH or N; Z is CH2-CH2-CH2-CH2 or CH=CR4-CH=CH-, wherein R4 is hydrogen, halo, or an alkyl sulfone having from 1 to 3 carbon atoms; and dotted lines collectively represent O or 2 additional double bonds in the heterocyclic ring structure. Compounds of Formula 1-0 may be present either as a racemate or in the isolated ""R"" configuration at the asymmetric carbon shown.",HOFFMANN LA ROCHE,SARABU RAMAKANTH;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;CORBETT WENDY LEA;;HAYNES NANCY-ELLEN;;GRIMSBY JOSEPH SAMUEL,,https://lens.org/152-388-983-872-403,Granted Patent,no,0,0,33,35,0,C07D215/38;;C07D235/30;;C07D263/58;;C07D277/82;;A61P3/10;;A61P5/50;;C07D277/82;;C07D215/38;;C07D277/82;;C07D235/30;;C07D263/58,C07D263/58;;A61K31/4184;;A61K31/423;;A61K31/428;;A61K31/47;;A61P3/10;;C07D215/38;;C07D235/30;;C07D277/82,,0,0,,,,EXPIRED
253,EP,A1,EP 0518414 A1,079-133-979-606-516,1992-12-16,1992,EP 92201587 A,1992-06-03,US 71317391 A;;US 83515992 A,1991-06-10,Thioxanthenone antitumor agents.,"1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones having the formula
  
 wherein n is 2 or 3; 
   R¹ and R² are independently lower-alkyl; 
   Q is a residue chosen from the group consisting of CH₂NHR³, CH₂N(R⁴)SO₂R⁷, CH₂NHCHO, CH=N-Ar, C(O)NR⁵R⁶, CH₂N(R⁴)C(O)R⁷, CH₂N(C₂H₅)CHO, and CH₂N(R⁴)P(O)(O-lower-alkyl)₂; 
   R³ is hydrogen or lower-alkyl; 
   R⁴ is hydrogen or lower-alkyl; 
   R⁵ is hydrogen, lower-alkyl or Ar; 
   R⁶ is hydrogen or lower-alkyl; 
   R⁷ is lower-alkyl, or Ar; 
   R⁸ is hydrogen, lower-alkyl, lower-alkoxy, or halogen; and 
   Ar is phenyl or phenyl substituted with methyl, methoxyl, halogen or nitro; 
or a pharmaceutically acceptable acid-addition salt or solvate thereof, are disclosed as antitumor agents. Compositions containing the thioxanthenones and the method of use of thioxanthenones for treating tumors and cancer in mammals are also disclosed.",STERLING WINTHROP INC,MILLER THEODORE CHARLES;;COLLINS JOSEPH CHARLES;;WENTLAND MARK PHILIP;;PERNI ROBERT BRUNO;;CORBETT THOMAS HUGHES;;MATTES KENNETH CHARLES,SANOFI-AVENTIS (2004-11-15);;SANOFI-SYNTHELABO (2000-06-05);;SANOFI (1998-02-02);;SANOFI TRANSFER- SANOFI-SYNTHELABO (2000-05-31);;STERLING WINTHROP INC. TRANSFER- SANOFI (1997-06-30),https://lens.org/079-133-979-606-516,Patent Application,yes,2,9,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/382;;A61K31/39;;A61K31/67;;A61K31/38;;A61P35/00;;C07D335/16;;C07F9/6553,,3,3,035-713-471-451-298;;023-200-016-376-16X;;056-974-461-762-970,10.1021/jm00338a022;;14188792;;3351846;;10.1021/jm00399a003;;10.1002/jps.2600541126,"JOURNAL OF MEDICINAL CHEMISTRY, vol. 6, no. 2, March 1963, Washington, DC, US, pages 185 - 191; E.J. BLANZ ET AL.: 'A systematic investigation of thioxanthen-9-ones and analogues as potential antitumour agents';;JOURNAL OF MEDICINAL CHEMISTRY. vol. 31, no. 4, April 1988, Washington, DC, US, pages 707 - 712; B.D. PALMER ET AL.: 'Potential antitumour agents. 54. Chromophore requirements for in vivo antitumour activity among the general class of linear tricyclic carboxamides';;JOURNAL OF PHARMACEUTICAL SCIENCES. vol. 54, no. 11, November 1965, Washington, DC, US, pages 1672 - 1673; I. NABIH ET AL.: 'Chlorination and condensation reactions at the 4-methyl group of lucanthone and oxalucanthone'",EXPIRED
254,PE,A1,PE 20080689 A1,133-314-713-383-473,2008-06-14,2008,PE 2007000962 A,2007-07-25,US 82044106 P,2006-07-26,DERIVADOS DE AMINA INHIBIDORES DE QUINASA,"REFERIDA A UN DERIVADO DE AMINA DE FORMULA (I), DONDE A ES UN BICICLO FUSIONADO; u ES UN ENTERO DE 0 A 3; V ES N O CR7; W Y X SON N O CR8; Y ES CH, N O NH; Z ES CH O N; D Y E SON C O N; L ES -(CR3R4)m- O C(O); m ES UN ENTERO DE 1 A 6; R1 Y R2 SON H, ALQUILO C1-C6, CICLOALQUILO C3-C10, CICLOALQUENILO C5-C10, ENTRE OTROS; R3 Y R4 SON H, ALQUILO C1-C6, CF3; R5 ES OR13, NR14R15, NR11C(O)R10, ENTRE OTROS; R6 ES ALQUILO C1-C6 O CICLOALQUILO C3-C10; R7 ES HALOGENO, OH, CF3, ENTRE OTROS; R8 ES H, HALO, CN, OH O ALQUILO C1-C6; R10 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; R11 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; R13 ES ALQUILO C1-C6, CICLOALQUILO C3-C10, CICLOALQUENILO C5-C10, ENTRE OTROS; R14 ES H, CF3, ALQUILO C1-C6, ENTRE OTROS; R15 ES ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (3S)-3-{[(4-CLOROFENIL9AMINO]METIL}-1-(5-METIL-7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)PIRROLIDIN-3-AMINA, 3-({[2-FLUORO-3-(TRIFLUOROMETIL)FENIL]AMINO}METIL)-1-(5-METIL-7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)PIRROLIDIN-3-AMINA, (3S)-1-(5-METIL-7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-3-{[3-(TRIFLUOROMETIL)FENIL]AMINO}METIL)PIRROLIDIN-3-AMINA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE QUINASA AKT Y/O P70S6K1 Y SON UTILES EN EL TRATAMIENTO DE CELULAS CANCEROSAS",PFIZER PROD INC,CORBETT MATTHEW STEPHEN;;KAUFFMAN GOSS STRYKER;;FREEMAN-COOK KEVIN DANIEL;;LIPPA BLAISE SCOTT;;LUZZIO MICHAEL JOSEPH;;MORRIS JOEL,,https://lens.org/133-314-713-383-473,Patent Application,no,0,0,8,9,0,A61P35/00;;C07D487/04;;C07D471/04;;C07D473/00,A61K31/519;;A61K31/535;;C07D471/04;;C07D487/04,,0,0,,,,DISCONTINUED
255,DE,D1,DE 69200179 D1,190-114-473-012-008,1994-07-14,1994,DE 69200179 T,1992-06-03,US 71317391 A;;US 83515992 A,1991-06-10,Thioxanthenon-Antitumormittel.,"1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones having the formula <CHEM> wherein n is 2 or 3; R<1> and R<2> are independently lower-alkyl; Q is a residue chosen from the group consisting of CH2NHR<3>, CH2N(R<4>)SO2R<7>, CH2NHCHO, CH=N-Ar, C(O)NR<5>R<6>, CH2N(R<4>)C(O)R<7>, CH2N(C2H5)CHO, and CH2N(R<4>)P(O)(O-lower-alkyl)2; R<3> is hydrogen or lower-alkyl; R<4> is hydrogen or lower-alkyl; R<5> is hydrogen, lower-alkyl or Ar; R<6> is hydrogen or lower-alkyl; R<7> is lower-alkyl, or Ar; R<8> is hydrogen, lower-alkyl, lower-alkoxy, or halogen; and Ar is phenyl or phenyl substituted with methyl, methoxyl, halogen or nitro; or a pharmaceutically acceptable acid-addition salt or solvate thereof, are disclosed as antitumor agents. Compositions containing the thioxanthenones and the method of use of thioxanthenones for treating tumors and cancer in mammals are also disclosed.",STERLING WINTHROP INC,MILLER THEODORE CHARLES;;COLLINS JOSEPH CHARLES;;WENTLAND MARK PHILIP;;PERNI ROBERT BRUNO;;CORBETT THOMAS HUGHES;;MATTES KENNETH CHARLES,"SANOFI-SYNTHELABO, PARIS, FR (2001-07-19);;SANOFI, PARIS, FR (1998-08-06)",https://lens.org/190-114-473-012-008,Granted Patent,no,0,0,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/382;;A61K31/39;;A61K31/67;;A61K31/38;;A61P35/00;;C07D335/16;;C07F9/6553,,0,0,,,,EXPIRED
256,SG,A1,SG 50625 A1,197-913-001-490-728,1998-07-20,1998,SG 1996007125 A,1992-06-03,US 71317391 A;;US 83515992 A,1991-06-10,Thioxanthenone antitumor agents,"1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones having the formula <CHEM> wherein n is 2 or 3; R<1> and R<2> are independently lower-alkyl; Q is a residue chosen from the group consisting of CH2NHR<3>, CH2N(R<4>)SO2R<7>, CH2NHCHO, CH=N-Ar, C(O)NR<5>R<6>, CH2N(R<4>)C(O)R<7>, CH2N(C2H5)CHO, and CH2N(R<4>)P(O)(O-lower-alkyl)2; R<3> is hydrogen or lower-alkyl; R<4> is hydrogen or lower-alkyl; R<5> is hydrogen, lower-alkyl or Ar; R<6> is hydrogen or lower-alkyl; R<7> is lower-alkyl, or Ar; R<8> is hydrogen, lower-alkyl, lower-alkoxy, or halogen; and Ar is phenyl or phenyl substituted with methyl, methoxyl, halogen or nitro; or a pharmaceutically acceptable acid-addition salt or solvate thereof, are disclosed as antitumor agents. Compositions containing the thioxanthenones and the method of use of thioxanthenones for treating tumors and cancer in mammals are also disclosed.",STERLING WINTHROP INC,COLLINS JOSEPH CHARLES;;MATTES KENNETH CHARLES;;WANTLAND MARK PHILIP;;PERNI ROBERT BRUNO;;MILLER THEODORE CHARLES;;CORBETT THOMAS HUGHES,,https://lens.org/197-913-001-490-728,Patent Application,no,0,0,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/382;;A61K31/39;;A61K31/67;;A61K31/38;;A61P35/00;;C07D335/16;;C07F9/6553,,0,0,,,,PENDING
257,WO,A1,WO 2010/054335 A1,108-605-069-826-600,2010-05-14,2010,US 2009/0063757 W,2009-11-09,US 11243208 P,2008-11-07,AUTOMATIC PARKING STRUCTURE,"A mechanism for moving vehicles within a vehicle parking structure comprises a lift platform which can be moved vertically and laterally to positions in register with one or more transfer rooms through which vehicles enter and leave the structure and a selected parking space of the structure. A vehicle transfer mechanism is carried on the platform and includes four self-powered tractors carrying lift arms that can be driven off the platform to engage the tires of a vehicle and to transfer that vehicle onto the platform for transportation between a transfer room and a parking space. The tractors, when deployed, pass outside the vehicle tires with the lift arms folded and can then be operated to extend the arms in a way that engages the tires and lifts the vehicle.",HOF MAN LLC;;MCDOWELL JOSEPH COLEMAN;;STORY MICHAEL CORBETT;;STORY JAMES BOWMER;;MILLER DWAYNE DAVID;;LANEY SEAN PATRICK;;REECE DANIEL JORDAN,MCDOWELL JOSEPH COLEMAN;;STORY MICHAEL CORBETT;;STORY JAMES BOWMER;;MILLER DWAYNE DAVID;;LANEY SEAN PATRICK;;REECE DANIEL JORDAN,,https://lens.org/108-605-069-826-600,Patent Application,yes,6,3,3,3,0,E04H6/183;;E04H6/183;;E04H6/305,E04H6/00,,0,0,,,,PENDING
258,DE,T2,DE 69200179 T2,023-875-112-633-475,1995-01-19,1995,DE 69200179 T,1992-06-03,US 71317391 A;;US 83515992 A,1991-06-10,Thioxanthenon-Antitumormittel.,"1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones having the formula <CHEM> wherein n is 2 or 3; R<1> and R<2> are independently lower-alkyl; Q is a residue chosen from the group consisting of CH2NHR<3>, CH2N(R<4>)SO2R<7>, CH2NHCHO, CH=N-Ar, C(O)NR<5>R<6>, CH2N(R<4>)C(O)R<7>, CH2N(C2H5)CHO, and CH2N(R<4>)P(O)(O-lower-alkyl)2; R<3> is hydrogen or lower-alkyl; R<4> is hydrogen or lower-alkyl; R<5> is hydrogen, lower-alkyl or Ar; R<6> is hydrogen or lower-alkyl; R<7> is lower-alkyl, or Ar; R<8> is hydrogen, lower-alkyl, lower-alkoxy, or halogen; and Ar is phenyl or phenyl substituted with methyl, methoxyl, halogen or nitro; or a pharmaceutically acceptable acid-addition salt or solvate thereof, are disclosed as antitumor agents. Compositions containing the thioxanthenones and the method of use of thioxanthenones for treating tumors and cancer in mammals are also disclosed.",STERLING WINTHROP INC,MILLER THEODORE CHARLES;;COLLINS JOSEPH CHARLES;;WENTLAND MARK PHILIP;;PERNI ROBERT BRUNO;;CORBETT THOMAS HUGHES;;MATTES KENNETH CHARLES,"SANOFI-SYNTHELABO, PARIS, FR (2001-07-19);;SANOFI, PARIS, FR (1998-08-06)",https://lens.org/023-875-112-633-475,Granted Patent,no,0,0,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/382;;A61K31/39;;A61K31/67;;A61K31/38;;A61P35/00;;C07D335/16;;C07F9/6553,,0,0,,,,EXPIRED
259,WO,A3,WO 2008/012635 A3,175-940-978-446-611,2008-05-08,2008,IB 2007002065 W,2007-07-13,US 82044106 P,2006-07-26,AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS,"The invention relates to compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein: A is a moiety of formula (II), and to pharmaceutically acceptable salts and solvates thereof. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula I to a patient in need thereof, and to compositions for treating such disorders which contain the compounds of formula (I). The invention also relates to methods of making the compounds of formula (I).",PFIZER PROD INC;;CORBETT MATTHEW STEPHEN;;KAUFFMAN GOSS STRYKER;;FREEMAN-COOK KEVIN DANIEL;;LIPPA BLAISE SCOTT;;LUZZIO MICHAEL JOSEPH;;MORRIS JOEL,CORBETT MATTHEW STEPHEN;;KAUFFMAN GOSS STRYKER;;FREEMAN-COOK KEVIN DANIEL;;LIPPA BLAISE SCOTT;;LUZZIO MICHAEL JOSEPH;;MORRIS JOEL,,https://lens.org/175-940-978-446-611,Search Report,yes,2,0,8,9,0,A61P35/00;;C07D487/04;;C07D471/04;;C07D473/00,C07D487/04;;A61K31/519;;A61K31/535;;C07D471/04,,0,0,,,,PENDING
260,DK,T3,DK 0518414 T3,036-922-204-456-606,1994-08-15,1994,DK 92201587 T,1992-06-03,US 71317391 A;;US 83515992 A,1991-06-10,Thioxanthenon-antitumormidler,"1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones having the formula <CHEM> wherein n is 2 or 3; R<1> and R<2> are independently lower-alkyl; Q is a residue chosen from the group consisting of CH2NHR<3>, CH2N(R<4>)SO2R<7>, CH2NHCHO, CH=N-Ar, C(O)NR<5>R<6>, CH2N(R<4>)C(O)R<7>, CH2N(C2H5)CHO, and CH2N(R<4>)P(O)(O-lower-alkyl)2; R<3> is hydrogen or lower-alkyl; R<4> is hydrogen or lower-alkyl; R<5> is hydrogen, lower-alkyl or Ar; R<6> is hydrogen or lower-alkyl; R<7> is lower-alkyl, or Ar; R<8> is hydrogen, lower-alkyl, lower-alkoxy, or halogen; and Ar is phenyl or phenyl substituted with methyl, methoxyl, halogen or nitro; or a pharmaceutically acceptable acid-addition salt or solvate thereof, are disclosed as antitumor agents. Compositions containing the thioxanthenones and the method of use of thioxanthenones for treating tumors and cancer in mammals are also disclosed.",STERLING WINTHROP INC,MILLER THEODORE CHARLES;;COLLINS JOSEPH CHARLES;;WENTLAND MARK PHILIP;;PERNI ROBERT BRUNO;;CORBETT THOMAS HUGHES;;MATTES KENNETH CHARLES,,https://lens.org/036-922-204-456-606,Granted Patent,no,0,0,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/382;;A61K31/39;;A61K31/67;;A61K31/38;;A61P35/00;;C07D335/16;;C07F9/6553,,0,0,,,,EXPIRED
261,IE,A1,IE 921871 A1,033-546-328-837-982,1992-12-16,1992,IE 921871 A,1992-07-01,US 71317391 A;;US 83515992 A,1991-06-10,Thioxanthenone antitumor agents,"1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones having the formula <CHEM> wherein n is 2 or 3; R<1> and R<2> are independently lower-alkyl; Q is a residue chosen from the group consisting of CH2NHR<3>, CH2N(R<4>)SO2R<7>, CH2NHCHO, CH=N-Ar, C(O)NR<5>R<6>, CH2N(R<4>)C(O)R<7>, CH2N(C2H5)CHO, and CH2N(R<4>)P(O)(O-lower-alkyl)2; R<3> is hydrogen or lower-alkyl; R<4> is hydrogen or lower-alkyl; R<5> is hydrogen, lower-alkyl or Ar; R<6> is hydrogen or lower-alkyl; R<7> is lower-alkyl, or Ar; R<8> is hydrogen, lower-alkyl, lower-alkoxy, or halogen; and Ar is phenyl or phenyl substituted with methyl, methoxyl, halogen or nitro; or a pharmaceutically acceptable acid-addition salt or solvate thereof, are disclosed as antitumor agents. Compositions containing the thioxanthenones and the method of use of thioxanthenones for treating tumors and cancer in mammals are also disclosed.",SANOFI SA,MILLER THEODORE CHARLES;;COLLINS JOSEPH CHARLES;;MATTES KENNETH CHARLES;;WENTLAND MARK PHILIP;;PERNI ROBERT BRUNO;;CORBETT THOMAS HUGHES,,https://lens.org/033-546-328-837-982,Patent Application,no,0,0,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/382;;A61K31/39;;A61K31/67;;A61K31/38;;A61P35/00;;C07D335/16;;C07F9/6553,,0,0,,,,EXPIRED
262,CA,C,CA 2070120 C,105-852-284-393-421,2005-11-15,2005,CA 2070120 A,1992-06-01,US 71317391 A;;US 83515992 A,1991-06-10,THIOXANTHENONE ANTITUMOR AGENTS,"1-[[(Dialkylamino)alkyl]amino]-4-substituted- thioxanthen-9-ones of the formula: (see above formula) (wherein n is 2 or 3; R1 and R2 are each alkyl; Q is -CH2NHR3, -CH2NR4SO2R7, -CH2NHCHO, -CH=N-Ar, -CO-NR5R6, -CH2NR4COR7, -CH2N(C2H5) CHO or -CH2NR4PO(O-alkyl)2; R3, R4 and R6 are each H or alkyl; R5 is H, alkyl or Ar; R7 is alkyl or Ar; R8 is H, alkyl, alkoxy or halogen; and Ar is phenyl optionally substituted by methyl, methoxy, halogen or nitro) are disclosed as antitumor agents. Compositions containing the thioxanthenones and methods of treating tumors and cancer in mammals with the thioxanthenones are also disclosed.",STERLING WINTHROP INC,MILLER THEODORE C;;COLLINS JOSEPH C;;MATTES KENNETH C;;WENTLAND MARK P;;PERNI ROBERT B;;CORBETT THOMAS H,,https://lens.org/105-852-284-393-421,Granted Patent,no,0,0,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/38;;A61K31/382;;A61K31/39;;A61K31/67;;A61P35/00;;C07D335/16;;C07F9/6553,,0,0,,,,EXPIRED
263,NZ,A,NZ 242862 A,112-037-578-600-468,1993-09-27,1993,NZ 24286292 A,1992-05-22,US 71317391 A;;US 83515992 A,1991-06-10,THIOXANTHENONE ANTITUMOR COMPOUNDS AND COMPOSITIONS THEREOF,"1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones having the formula <CHEM> wherein n is 2 or 3; R<1> and R<2> are independently lower-alkyl; Q is a residue chosen from the group consisting of CH2NHR<3>, CH2N(R<4>)SO2R<7>, CH2NHCHO, CH=N-Ar, C(O)NR<5>R<6>, CH2N(R<4>)C(O)R<7>, CH2N(C2H5)CHO, and CH2N(R<4>)P(O)(O-lower-alkyl)2; R<3> is hydrogen or lower-alkyl; R<4> is hydrogen or lower-alkyl; R<5> is hydrogen, lower-alkyl or Ar; R<6> is hydrogen or lower-alkyl; R<7> is lower-alkyl, or Ar; R<8> is hydrogen, lower-alkyl, lower-alkoxy, or halogen; and Ar is phenyl or phenyl substituted with methyl, methoxyl, halogen or nitro; or a pharmaceutically acceptable acid-addition salt or solvate thereof, are disclosed as antitumor agents. Compositions containing the thioxanthenones and the method of use of thioxanthenones for treating tumors and cancer in mammals are also disclosed.",STERLING WINTHROP INC,COLLINS JOSEPH CHARLES;;MATTES KENNETH CHARLES;;WENTLAND MARK PHILIP;;PERNI ROBERT BRUNO;;CORBETT THOMAS HUGHES;;ROSS MICHAEL ELLIOT,,https://lens.org/112-037-578-600-468,Patent Application,no,0,0,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/382;;A61K31/39;;A61K31/67;;A61P35/00;;C07D335/16;;A61K31/38;;C07F9/6553,,0,0,,,,DISCONTINUED
264,AU,A,AU 1992/017046 A,188-996-652-966-005,1992-12-17,1992,AU 1992/017046 A,1992-05-21,US 71317391 A;;US 83515992 A,1991-06-10,THIOXANTHENONE ANTITUMOR AGENTS,"1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones having the formula <CHEM> wherein n is 2 or 3; R<1> and R<2> are independently lower-alkyl; Q is a residue chosen from the group consisting of CH2NHR<3>, CH2N(R<4>)SO2R<7>, CH2NHCHO, CH=N-Ar, C(O)NR<5>R<6>, CH2N(R<4>)C(O)R<7>, CH2N(C2H5)CHO, and CH2N(R<4>)P(O)(O-lower-alkyl)2; R<3> is hydrogen or lower-alkyl; R<4> is hydrogen or lower-alkyl; R<5> is hydrogen, lower-alkyl or Ar; R<6> is hydrogen or lower-alkyl; R<7> is lower-alkyl, or Ar; R<8> is hydrogen, lower-alkyl, lower-alkoxy, or halogen; and Ar is phenyl or phenyl substituted with methyl, methoxyl, halogen or nitro; or a pharmaceutically acceptable acid-addition salt or solvate thereof, are disclosed as antitumor agents. Compositions containing the thioxanthenones and the method of use of thioxanthenones for treating tumors and cancer in mammals are also disclosed.",SANOFI SYNTHELABO,THEODORE CHARLES MILLER;;KENNETH CHARLES MATTES;;JOSEPH CHARLES COLLINS;;MARK PHILIP WENTLAND;;ROBERT BRUNO PERNI;;THOMAS HUGHES CORBETT,SANOFI-SYNTHELABO (2000-04-13),https://lens.org/188-996-652-966-005,Patent Application,no,0,1,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/38;;A61K31/382;;A61K31/39;;A61K31/67;;A61P35/00;;C07D335/16;;C07F9/6553,,0,0,,,,EXPIRED
265,IE,B1,IE 66828 B1,094-195-170-797-271,1996-02-07,1996,IE 921871 A,1992-07-01,US 71317391 A;;US 83515992 A,1991-06-10,Thioxanthenone antitumor agents,"1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones having the formula <CHEM> wherein n is 2 or 3; R<1> and R<2> are independently lower-alkyl; Q is a residue chosen from the group consisting of CH2NHR<3>, CH2N(R<4>)SO2R<7>, CH2NHCHO, CH=N-Ar, C(O)NR<5>R<6>, CH2N(R<4>)C(O)R<7>, CH2N(C2H5)CHO, and CH2N(R<4>)P(O)(O-lower-alkyl)2; R<3> is hydrogen or lower-alkyl; R<4> is hydrogen or lower-alkyl; R<5> is hydrogen, lower-alkyl or Ar; R<6> is hydrogen or lower-alkyl; R<7> is lower-alkyl, or Ar; R<8> is hydrogen, lower-alkyl, lower-alkoxy, or halogen; and Ar is phenyl or phenyl substituted with methyl, methoxyl, halogen or nitro; or a pharmaceutically acceptable acid-addition salt or solvate thereof, are disclosed as antitumor agents. Compositions containing the thioxanthenones and the method of use of thioxanthenones for treating tumors and cancer in mammals are also disclosed.",STERLING WINTHROP INC,MILLER THEODORE CHARLES;;COLLINS JOSEPH CHARLES;;MATTES KENNETH CHARLES;;WENTLAND MARK PHILIP;;PERNI ROBERT BRUNO;;CORBETT THOMAS HUGHES,,https://lens.org/094-195-170-797-271,Granted Patent,no,0,0,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/382;;A61K31/39;;A61K31/67;;A61K31/38;;A61P35/00;;C07D335/16;;C07F9/6553,,0,0,,,,EXPIRED
266,UY,A1,UY 30499 A1,135-749-035-268-753,2008-02-29,2008,UY 30499 A,2007-07-24,US 82044106 P,2006-07-26,DERIVADOS DE AMINA UTILES COMO AGENTES ANTICANCERIGENOS,"Compuestos de formula I: o una sal farmacéuticamente aceptable de los mismos, donde: A es un resto de formula: y sales farmacéuticamente aceptables y solvatos de los mismos, en los que X, Z, D, E, V, W, Y, R1, R2, R5 y R6, L y u son como se definen en el presente documento. Composiciones conteniéndolos, procesos de preparacion y aplicaciones.",PFIZER PROD INC,MORRIS JOEL;;LUZZIO MICHAEL JOSEPH;;LIPPA BLAISE SCOTT;;FREEMAN-COOK KEVIN DANIEL;;KAUFFMAN GOSS STRYKER;;CORBETT MATTHEW STEPHEN,,https://lens.org/135-749-035-268-753,Patent Application,no,0,0,8,9,0,A61P35/00;;C07D487/04;;C07D471/04;;C07D473/00,C07D207/14;;A61K31/519;;A61K31/53;;A61P35/00,,0,0,,,,DISCONTINUED
267,FI,A0,FI 922694 A0,168-810-136-023-47X,1992-06-10,1992,FI 922694 A,1992-06-10,US 71317391 A;;US 83515992 A,1991-06-10,TIOXANTENONDERIVAT MED ANTITUMOER- EFFEKT.,"1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones having the formula <CHEM> wherein n is 2 or 3; R<1> and R<2> are independently lower-alkyl; Q is a residue chosen from the group consisting of CH2NHR<3>, CH2N(R<4>)SO2R<7>, CH2NHCHO, CH=N-Ar, C(O)NR<5>R<6>, CH2N(R<4>)C(O)R<7>, CH2N(C2H5)CHO, and CH2N(R<4>)P(O)(O-lower-alkyl)2; R<3> is hydrogen or lower-alkyl; R<4> is hydrogen or lower-alkyl; R<5> is hydrogen, lower-alkyl or Ar; R<6> is hydrogen or lower-alkyl; R<7> is lower-alkyl, or Ar; R<8> is hydrogen, lower-alkyl, lower-alkoxy, or halogen; and Ar is phenyl or phenyl substituted with methyl, methoxyl, halogen or nitro; or a pharmaceutically acceptable acid-addition salt or solvate thereof, are disclosed as antitumor agents. Compositions containing the thioxanthenones and the method of use of thioxanthenones for treating tumors and cancer in mammals are also disclosed.",STERLING WINTHROP INC,MILLER THEODORE CHARLES;;COLLINS JOSEPH CHARLES;;MATTES KENNETH CHARLES;;WENTLAND MARK PHILIP;;PERNI ROBERT BRUNO;;CORBETT THOMAS HUGHES,SANOFI (1997-07-07),https://lens.org/168-810-136-023-47X,Patent Application,no,0,0,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/382;;A61K31/38;;A61K31/39;;A61K31/67;;A61P35/00;;C07D335/16;;C07F9/6553,,0,0,,,,DISCONTINUED
268,NO,L,NO 922273 L,027-861-052-131-198,1992-12-11,1992,NO 922273 A,1992-06-10,US 71317391 A;;US 83515992 A,1991-06-10,TIOXANTENON-ANTITUMORMIDLER,"1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones having the formula <CHEM> wherein n is 2 or 3; R<1> and R<2> are independently lower-alkyl; Q is a residue chosen from the group consisting of CH2NHR<3>, CH2N(R<4>)SO2R<7>, CH2NHCHO, CH=N-Ar, C(O)NR<5>R<6>, CH2N(R<4>)C(O)R<7>, CH2N(C2H5)CHO, and CH2N(R<4>)P(O)(O-lower-alkyl)2; R<3> is hydrogen or lower-alkyl; R<4> is hydrogen or lower-alkyl; R<5> is hydrogen, lower-alkyl or Ar; R<6> is hydrogen or lower-alkyl; R<7> is lower-alkyl, or Ar; R<8> is hydrogen, lower-alkyl, lower-alkoxy, or halogen; and Ar is phenyl or phenyl substituted with methyl, methoxyl, halogen or nitro; or a pharmaceutically acceptable acid-addition salt or solvate thereof, are disclosed as antitumor agents. Compositions containing the thioxanthenones and the method of use of thioxanthenones for treating tumors and cancer in mammals are also disclosed.",STERLING WINTHROP INC,MILLER THEODORE CHARLES;;COLLINS JOSEPH CHARLES;;MATTES KENNETH CHARLES;;PERNI ROBERT BRUNO;;CORBETT THOMAS HUGHES;;WENTLAND MARK PHILIP,,https://lens.org/027-861-052-131-198,Abstract,no,0,0,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/382;;A61K31/38;;A61K31/39;;A61K31/67;;A61P35/00;;C07D335/16;;C07F9/6553,,0,0,,,,EXPIRED
269,KR,B1,KR 100209826 B1,176-587-526-047-742,1999-07-15,1999,KR 920009956 A,1992-06-09,US 71317391 A;;US 83515992 A,1991-06-10,THIOXETHANONE-ANTITUMOR AGENTS,"1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones having the formula <CHEM> wherein n is 2 or 3; R<1> and R<2> are independently lower-alkyl; Q is a residue chosen from the group consisting of CH2NHR<3>, CH2N(R<4>)SO2R<7>, CH2NHCHO, CH=N-Ar, C(O)NR<5>R<6>, CH2N(R<4>)C(O)R<7>, CH2N(C2H5)CHO, and CH2N(R<4>)P(O)(O-lower-alkyl)2; R<3> is hydrogen or lower-alkyl; R<4> is hydrogen or lower-alkyl; R<5> is hydrogen, lower-alkyl or Ar; R<6> is hydrogen or lower-alkyl; R<7> is lower-alkyl, or Ar; R<8> is hydrogen, lower-alkyl, lower-alkoxy, or halogen; and Ar is phenyl or phenyl substituted with methyl, methoxyl, halogen or nitro; or a pharmaceutically acceptable acid-addition salt or solvate thereof, are disclosed as antitumor agents. Compositions containing the thioxanthenones and the method of use of thioxanthenones for treating tumors and cancer in mammals are also disclosed.",SANOFI SA,MILLER THEODORE C;;COLLINS JOSEPH C;;MATTES KENNETH C;;WENTLAND MARK P;;PERNI ROBERT B;;CORBETT THOMAS H,,https://lens.org/176-587-526-047-742,Granted Patent,no,0,0,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/382;;A61K31/38;;A61K31/39;;A61K31/67;;A61P35/00;;C07D335/16;;C07F9/6553,,0,0,,,,EXPIRED
270,FI,B,FI 114024 B,025-022-791-225-18X,2004-07-30,2004,FI 922694 A,1992-06-10,US 71317391 A;;US 83515992 A,1991-06-10,Menetelmä terapeuttisesti käyttökelpoisten tioksantenonijohdannaisten valmistamiseksi,"1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones having the formula <CHEM> wherein n is 2 or 3; R<1> and R<2> are independently lower-alkyl; Q is a residue chosen from the group consisting of CH2NHR<3>, CH2N(R<4>)SO2R<7>, CH2NHCHO, CH=N-Ar, C(O)NR<5>R<6>, CH2N(R<4>)C(O)R<7>, CH2N(C2H5)CHO, and CH2N(R<4>)P(O)(O-lower-alkyl)2; R<3> is hydrogen or lower-alkyl; R<4> is hydrogen or lower-alkyl; R<5> is hydrogen, lower-alkyl or Ar; R<6> is hydrogen or lower-alkyl; R<7> is lower-alkyl, or Ar; R<8> is hydrogen, lower-alkyl, lower-alkoxy, or halogen; and Ar is phenyl or phenyl substituted with methyl, methoxyl, halogen or nitro; or a pharmaceutically acceptable acid-addition salt or solvate thereof, are disclosed as antitumor agents. Compositions containing the thioxanthenones and the method of use of thioxanthenones for treating tumors and cancer in mammals are also disclosed.",SANOFI SYNTHELABO,MILLER THEODORE CHARLES;;COLLINS JOSEPH CHARLES;;MATTES KENNETH CHARLES;;WENTLAND MARK PHILIP;;PERNI ROBERT BRUNO;;CORBETT THOMAS HUGHES,SANOFI (1997-07-07),https://lens.org/025-022-791-225-18X,Patent Application,no,0,0,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/382;;A61K31/38;;A61K31/39;;A61K31/67;;A61P35/00;;C07D335/16;;C07F9/6553,,0,0,,,,DISCONTINUED
271,GT,A,GT 200700062 A,169-899-888-222-113,2008-08-08,2008,GT 200700062 A,2007-07-24,US 82044106 P,2006-07-26,DERIVADOS DE AMINA UTILES COMO AGENTES ANTICANCERIGENOS,"LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE FORMULA GENERAL I EN LA QUE A,L,R1,R2,R5,R6,U, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS DERIVADOS DE AMINA IMPIDEN LA TRANSFORMACION DE UNA PARTE DEL ADN DE UNA CELULA EN UN ONCOGEN QUE PUEDE LLEGAR A SER CANCEROSA A NIVEL DE LAS QUINASAS ABERRANTES CAPACES DE CAUSAR TRANSFORMACION CELULAR POR LO QUE SON DE UTILIDAD EN TRASTORNOS HIPERPROLIFERATIVOS TALES COMO EL CANCER. T2007",,CORBETT MATTHEW STEPHEN;;KAUFFMAN GOSS STRYKER;;FREEMAN-COOK KEVIN DANIEL;;LIPPA BLAISE SCOTT;;LUZZIO MICHAEL JOSEPH;;MORRIS JOEL,,https://lens.org/169-899-888-222-113,Amended Application,no,0,0,8,9,0,A61P35/00;;C07D487/04;;C07D471/04;;C07D473/00,A61P35/00;;C07C211/35;;C07D207/04;;C07D403/04,,0,0,,,,PENDING
272,HU,A,HU T61992 A,195-997-382-412-640,1993-03-29,1993,HU 9201926 A,1992-06-10,US 71317391 A;;US 83515992 A,1991-06-10,PROCESS FOR PRODUCING ANTITUMORAL THIOXANTHENONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS ACTIVE INGREDIENT,"1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones having the formula <CHEM> wherein n is 2 or 3; R<1> and R<2> are independently lower-alkyl; Q is a residue chosen from the group consisting of CH2NHR<3>, CH2N(R<4>)SO2R<7>, CH2NHCHO, CH=N-Ar, C(O)NR<5>R<6>, CH2N(R<4>)C(O)R<7>, CH2N(C2H5)CHO, and CH2N(R<4>)P(O)(O-lower-alkyl)2; R<3> is hydrogen or lower-alkyl; R<4> is hydrogen or lower-alkyl; R<5> is hydrogen, lower-alkyl or Ar; R<6> is hydrogen or lower-alkyl; R<7> is lower-alkyl, or Ar; R<8> is hydrogen, lower-alkyl, lower-alkoxy, or halogen; and Ar is phenyl or phenyl substituted with methyl, methoxyl, halogen or nitro; or a pharmaceutically acceptable acid-addition salt or solvate thereof, are disclosed as antitumor agents. Compositions containing the thioxanthenones and the method of use of thioxanthenones for treating tumors and cancer in mammals are also disclosed.",STERLING WINTHROP INC,MILLER THEODORE CHARLES;;COLLINS JOSEPH CHARLES;;MATTES KENNETH CHARLES;;WENTLAND MARK PHILIP;;PERNI ROBERT BRUNO;;CORBETT THOMAS HUGHES,,https://lens.org/195-997-382-412-640,Unknown,no,0,0,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/382;;A61K31/39;;A61K31/38;;A61K31/67;;A61P35/00;;C07D335/16;;C07F9/6553,,0,0,,,,EXPIRED
273,AU,B2,AU 642596 B2,083-251-460-916-747,1993-10-21,1993,AU 1992/017046 A,1992-05-21,US 71317391 A;;US 83515992 A,1991-06-10,Thioxanthenone antitumor agents,"1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones having the formula <CHEM> wherein n is 2 or 3; R<1> and R<2> are independently lower-alkyl; Q is a residue chosen from the group consisting of CH2NHR<3>, CH2N(R<4>)SO2R<7>, CH2NHCHO, CH=N-Ar, C(O)NR<5>R<6>, CH2N(R<4>)C(O)R<7>, CH2N(C2H5)CHO, and CH2N(R<4>)P(O)(O-lower-alkyl)2; R<3> is hydrogen or lower-alkyl; R<4> is hydrogen or lower-alkyl; R<5> is hydrogen, lower-alkyl or Ar; R<6> is hydrogen or lower-alkyl; R<7> is lower-alkyl, or Ar; R<8> is hydrogen, lower-alkyl, lower-alkoxy, or halogen; and Ar is phenyl or phenyl substituted with methyl, methoxyl, halogen or nitro; or a pharmaceutically acceptable acid-addition salt or solvate thereof, are disclosed as antitumor agents. Compositions containing the thioxanthenones and the method of use of thioxanthenones for treating tumors and cancer in mammals are also disclosed.",STERLING WINTHROP INC,MILLER THEODORE CHARLES;;MATTES KENNETH CHARLES;;COLLINS JOSEPH CHARLES;;WENTLAND MARK PHILIP;;PERNI ROBERT BRUNO;;CORBETT THOMAS HUGHES,SANOFI-SYNTHELABO (2000-04-13),https://lens.org/083-251-460-916-747,Granted Patent,no,1,0,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/38;;A61K31/382;;A61K31/39;;A61K31/67;;A61P35/00;;C07D335/16;;C07F9/6553,,0,0,,,,EXPIRED
274,ES,T3,ES 2276097 T3,163-662-108-295-079,2007-06-16,2007,ES 03749855 T,2003-04-14,US 37616102 P,2002-04-26,FENILACETAMIDAS SUSTITUIDAS Y SU EMPLEO0 COMO ACTIVADORES DE GLUCOQUINASA.,"Un compuesto de fórmula: I en donde R1 y R2 son independientemente hidrógeno, halo, amino, hidroxiamino, ciano, nitro, alquilo inferior, -OR5, perfluoro-alquilo inferior, tioalquilo inferior, perfluoro-tioalquilo inferior, sulfonil alquilo inferior, perfluoro-sulfonilalquilo inferior, sulfinil alquilo inferior, o sulfonamido; R3 es una cadena de alquilo no ramificada de 4-5 átomos de carbono o una cadena de heteroalquilo no ramificada de 3-4 átomos de carbono más un átomo de oxígeno o de azufre, en donde la cadena, en combinación con el átomo de carbono al que está unida, forma un anillo de cinco o seis miembros, y cuando la cadena no contiene heteroátomos, un carbono miembro de la cadena está sustituido con una fracción seleccionadoa del grupo consistente en hidroxi, oxo, hidroxiimino, metoxiimino, halo, metoxilo, y acetoxilo, o un carbono miembro de la cadena está disustituido con un hidroxilo y un alquilo inferior o está disustituido con halógeno cuando la cadena contiene un heteroátomoO, la cadena no está sustituida, y cuando la cadena contiene un heteroátomo S, la cadena no está sustituida o el heteroátomo S miembro de la cadena está sustituido por un grupo oxo; R4 es un anillo heteroaromático de cinco o seis miembros no sustituido o mono-sustituido unido por un átomo de carbono del anillo al grupo amina mostrado, cuyo anillo heteroaromático de cinco o seis miembros contiene de 1 a 3 heteroátomos seleccionados de azufre, oxígeno o nitrógeno, siendo un heteroátomo nitrógeno que es adyacente a dicho átomo de carbono enlazante del anillo; dicho anillo heteroaromático mono-sustituido estando mono-sustituido en una posición diferente al átomo de carbono del anillo adyacente a dicho átomo de carbono enlazante con un sustituyente seleccionado del grupo consistente en alquilo inferior, halo, nitro, ciano, perfluoro-alquilo inferior, amidooxima, o n es 0, 1, 2, 3 ó 4; R5 es hidrógeno, alquilo inferior, o perfluoro-alquilo inferior; R6 es alquilo inferior; y R7 es hidrógeno o alquilo inferior; * denota un átomo de carbono que es asimétrico en todos o la mayoría de los compuestos de fórmula I; y en donde ""inferior"" significa 1 a 7 átomos de carbono; o una sal farmacéuticamente aceptable del mismo.",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;RACHA JAGDISH KUMAR,,https://lens.org/163-662-108-295-079,Granted Patent,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D277/20;;C07D307/16;;A61K31/17;;A61K31/335;;A61K31/341;;A61K31/351;;A61K31/38;;A61K31/425;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07C275/52;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,EXPIRED
275,MX,A,MX 9202753 A,094-182-298-205-359,1993-01-01,1993,MX 9202753 A,1992-06-09,US 71317391 A;;US 83515992 A,1991-06-10,AGENTES ANTITUMOR DE TIOXANTENONA.,"1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones having the formula <CHEM> wherein n is 2 or 3; R<1> and R<2> are independently lower-alkyl; Q is a residue chosen from the group consisting of CH2NHR<3>, CH2N(R<4>)SO2R<7>, CH2NHCHO, CH=N-Ar, C(O)NR<5>R<6>, CH2N(R<4>)C(O)R<7>, CH2N(C2H5)CHO, and CH2N(R<4>)P(O)(O-lower-alkyl)2; R<3> is hydrogen or lower-alkyl; R<4> is hydrogen or lower-alkyl; R<5> is hydrogen, lower-alkyl or Ar; R<6> is hydrogen or lower-alkyl; R<7> is lower-alkyl, or Ar; R<8> is hydrogen, lower-alkyl, lower-alkoxy, or halogen; and Ar is phenyl or phenyl substituted with methyl, methoxyl, halogen or nitro; or a pharmaceutically acceptable acid-addition salt or solvate thereof, are disclosed as antitumor agents. Compositions containing the thioxanthenones and the method of use of thioxanthenones for treating tumors and cancer in mammals are also disclosed.",STERLING WINTHROP INC,MILLER THEODORE CHARLES;;COLLINS JOSEPH CHARLES;;MATTES KENNETH CHARLES;;WENTLAND MARK PHILIP;;PERNI ROBERT BRUNO;;CORBETT THOMAS HUGHES,,https://lens.org/094-182-298-205-359,Patent Application,no,0,0,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/382;;A61K31/38;;A61K31/39;;A61K31/67;;A61P35/00;;C07D335/16;;C07F9/6553,,0,0,,,,EXPIRED
276,WO,A2,WO 2008/012635 A2,076-068-938-533-202,2008-01-31,2008,IB 2007002065 W,2007-07-13,US 82044106 P,2006-07-26,AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS,"The invention relates to compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein: A is a moiety of formula (Il) and to pharmaceutically acceptable salts and solvates thereof, wherein X, Z, D, E, V, W, Y, R 1 , R 2 , R 5 , R 6 , L, and u are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula I to a patient in need thereof, and to compositions for treating such disorders which contain the compounds of formula (I). The invention also relates to methods of making the compounds of formula (I).",PFIZER PROD INC;;CORBETT MATTHEW STEPHEN;;KAUFFMAN GOSS STRYKER;;FREEMAN-COOK KEVIN DANIEL;;LIPPA BLAISE SCOTT;;LUZZIO MICHAEL JOSEPH;;MORRIS JOEL,CORBETT MATTHEW STEPHEN;;KAUFFMAN GOSS STRYKER;;FREEMAN-COOK KEVIN DANIEL;;LIPPA BLAISE SCOTT;;LUZZIO MICHAEL JOSEPH;;MORRIS JOEL,,https://lens.org/076-068-938-533-202,Patent Application,yes,0,74,8,9,0,A61P35/00;;C07D487/04;;C07D471/04;;C07D473/00,C07D487/04;;A61K31/519;;A61K31/535;;C07D471/04,,0,0,,,,PENDING
277,TW,A,TW 200817408 A,128-146-188-405-556,2008-04-16,2008,TW 96127409 A,2007-07-25,US 82044106 P,2006-07-26,Amine derivatives useful as anticancer agents,"The invention relates to compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein: A is a moiety of formula: and to pharmaceutically acceptable salts and solvates thereof, wherein X, Z, D, E, V, W, Y, R1, R2, R5, R6, L, and u are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula I to a patient in need thereof, and to compositions for treating such disorders which contain the compounds of formula I. The invention also relates to methods of making the compounds of formula I.",PFIZER PROD INC,CORBETT MATTHEW STEPHEN;;KAUFFMAN GOSS STRYKER;;FREEMAN-COOK KEVIN DANIEL;;LIPPA BLAISE SCOTT;;LUZZIO MICHAEL JOSEPH;;MORRIS JOEL,,https://lens.org/128-146-188-405-556,Patent of Addition,no,0,0,8,9,0,A61P35/00;;C07D487/04;;C07D471/04;;C07D473/00,C07D487/04;;A61K31/519;;A61P35/00;;C07D471/04,,0,0,,,,PENDING
278,FI,A,FI 922694 A,163-752-519-570-855,1992-12-11,1992,FI 922694 A,1992-06-10,US 71317391 A;;US 83515992 A,1991-06-10,TIOXANTENONDERIVAT MED ANTITUMOEREFFEKT,"1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones having the formula <CHEM> wherein n is 2 or 3; R<1> and R<2> are independently lower-alkyl; Q is a residue chosen from the group consisting of CH2NHR<3>, CH2N(R<4>)SO2R<7>, CH2NHCHO, CH=N-Ar, C(O)NR<5>R<6>, CH2N(R<4>)C(O)R<7>, CH2N(C2H5)CHO, and CH2N(R<4>)P(O)(O-lower-alkyl)2; R<3> is hydrogen or lower-alkyl; R<4> is hydrogen or lower-alkyl; R<5> is hydrogen, lower-alkyl or Ar; R<6> is hydrogen or lower-alkyl; R<7> is lower-alkyl, or Ar; R<8> is hydrogen, lower-alkyl, lower-alkoxy, or halogen; and Ar is phenyl or phenyl substituted with methyl, methoxyl, halogen or nitro; or a pharmaceutically acceptable acid-addition salt or solvate thereof, are disclosed as antitumor agents. Compositions containing the thioxanthenones and the method of use of thioxanthenones for treating tumors and cancer in mammals are also disclosed.",STERLING WINTHROP INC,MILLER THEODORE CHARLES;;COLLINS JOSEPH CHARLES;;MATTES KENNETH CHARLES;;WENTLAND MARK PHILIP;;PERNI ROBERT BRUNO;;CORBETT THOMAS HUGHES,SANOFI (1997-07-07),https://lens.org/163-752-519-570-855,Patent Application,no,0,0,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/38;;A61K31/382;;A61K31/39;;A61K31/67;;A61P35/00;;C07D335/16;;C07F9/6553,,0,0,,,,DISCONTINUED
279,HU,B,HU 218655 B,012-932-978-186-660,2000-10-28,2000,HU 9201926 A,1992-06-10,US 71317391 A;;US 83515992 A,1991-06-10,"ANTITUMORAL THIOXANTHENONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS ACTIVE INGREDIENT AND PROCESS FOR PRODUCING THEM","1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones having the formula <CHEM> wherein n is 2 or 3; R<1> and R<2> are independently lower-alkyl; Q is a residue chosen from the group consisting of CH2NHR<3>, CH2N(R<4>)SO2R<7>, CH2NHCHO, CH=N-Ar, C(O)NR<5>R<6>, CH2N(R<4>)C(O)R<7>, CH2N(C2H5)CHO, and CH2N(R<4>)P(O)(O-lower-alkyl)2; R<3> is hydrogen or lower-alkyl; R<4> is hydrogen or lower-alkyl; R<5> is hydrogen, lower-alkyl or Ar; R<6> is hydrogen or lower-alkyl; R<7> is lower-alkyl, or Ar; R<8> is hydrogen, lower-alkyl, lower-alkoxy, or halogen; and Ar is phenyl or phenyl substituted with methyl, methoxyl, halogen or nitro; or a pharmaceutically acceptable acid-addition salt or solvate thereof, are disclosed as antitumor agents. Compositions containing the thioxanthenones and the method of use of thioxanthenones for treating tumors and cancer in mammals are also disclosed.",SANOFI-SYNTHELABO,COLLINS JOSEPH CHARLES;;CORBETT THOMAS HUGHES;;MATTES KENNETH CHARLES;;MILLER THEODORE CHARLES;;PERNI ROBERT BRUNO;;WENTLAND MARK PHILIP,,https://lens.org/012-932-978-186-660,Granted Patent,no,0,0,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/382;;A61K31/39;;A61K31/67;;A61K31/38;;A61P35/00;;C07D335/16;;C07F9/6553,,0,0,,,,EXPIRED
280,CA,A1,CA 2070120 A1,112-920-864-120-994,1992-12-11,1992,CA 2070120 A,1992-06-01,US 71317391 A;;US 83515992 A,1991-06-10,THIOXANTHENONE ANTITUMOR AGENTS,D.N. 2528A 1-¢¢(Dialkylamino)alkyl!amino!-4-substituted-thioxanthen-9-ones are disclosed as antitumor agents. Compositions containing the thioxanthenones and methods of treating tumors and cancer in mammals with the thioxanthenones are also disclosed.,STERLING WINTHROP INC,MILLER THEODORE C;;COLLINS JOSEPH C;;MATTES KENNETH C;;WENTLAND MARK P;;PERNI ROBERT B;;CORBETT THOMAS H,,https://lens.org/112-920-864-120-994,Patent Application,no,0,0,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/38;;A61K31/382;;A61K31/39;;A61K31/67;;A61P35/00;;C07D335/16;;C07F9/6553,,0,0,,,,EXPIRED
281,NO,B1,NO 302364 B1,148-223-503-833-342,1998-02-23,1998,NO 922273 A,1992-06-10,US 71317391 A;;US 83515992 A,1991-06-10,"Tioksantenon-forbindelser, farmasöytisk preparat inneholdende slike og deres anvendelse","1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones having the formula <CHEM> wherein n is 2 or 3; R<1> and R<2> are independently lower-alkyl; Q is a residue chosen from the group consisting of CH2NHR<3>, CH2N(R<4>)SO2R<7>, CH2NHCHO, CH=N-Ar, C(O)NR<5>R<6>, CH2N(R<4>)C(O)R<7>, CH2N(C2H5)CHO, and CH2N(R<4>)P(O)(O-lower-alkyl)2; R<3> is hydrogen or lower-alkyl; R<4> is hydrogen or lower-alkyl; R<5> is hydrogen, lower-alkyl or Ar; R<6> is hydrogen or lower-alkyl; R<7> is lower-alkyl, or Ar; R<8> is hydrogen, lower-alkyl, lower-alkoxy, or halogen; and Ar is phenyl or phenyl substituted with methyl, methoxyl, halogen or nitro; or a pharmaceutically acceptable acid-addition salt or solvate thereof, are disclosed as antitumor agents. Compositions containing the thioxanthenones and the method of use of thioxanthenones for treating tumors and cancer in mammals are also disclosed.",SANOFI SA,MILLER THEODORE CHARLES;;COLLINS JOSEPH CHARLES;;MATTES KENNETH CHARLES;;PERNI ROBERT BRUNO;;CORBETT THOMAS HUGHES;;WENTLAND MARK PHILIP,,https://lens.org/148-223-503-833-342,Granted Patent,no,0,0,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/382;;A61K31/39;;A61K31/38;;A61K31/67;;A61P35/00;;C07D335/16;;C07F9/6553,,0,0,,,,EXPIRED
282,US,A1,US 2013/0167243 A1,117-606-838-882-756,2013-06-27,2013,US 201113212996 A,2011-08-18,US 201113212996 A;;US 201161488687 P,2011-05-20,Secure User Interface Content,"Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for handing secure user interface content. In one aspect, a method includes receiving, at a data processing apparatus, content over a communication network from a computing system separate from the data processing apparatus; determining that the received content is authentic secure content; retrieving information stored at the data processing apparatus and previously selected by a user for purposes of securing user interface content; rendering the received content, to a display of the data processing apparatus, as a user interface with a visual wrapper, where the visual wrapper includes the retrieved information, visually separates the user interface from other visual elements on the display, and includes an indication that the user interface is secure; and processing input received through the user interface.",CORBETT JIM D;;GOLDMAN OLIVER;;GWALANI RAJESH K;;KWON ROBERT O;;MOYER JOHN JOSEPH;;ORR MICHAEL BRIAN;;UHLEY PELEUS;;ADOBE SYSTEMS INC,CORBETT JIM D;;GOLDMAN OLIVER;;GWALANI RAJESH K;;KWON ROBERT O;;MOYER JOHN JOSEPH;;ORR MICHAEL BRIAN;;UHLEY PELEUS,ADOBE INC (2011-08-04),https://lens.org/117-606-838-882-756,Patent Application,yes,0,4,2,2,0,G06F21/53;;G06F2221/032;;G06F21/53;;G06F2221/032,G06F21/00,726/26,0,0,,,,ACTIVE
283,US,A1,US 2013/0142599 A1,055-205-505-544-113,2013-06-06,2013,US 200913127671 A,2009-11-09,US 200913127671 A;;US 11243208 P;;US 2009/0063757 W,2008-11-07,AUTOMATIC PARKING STRUCTURE,"A mechanism for moving vehicles within a vehicle parking structure comprises a lift platform which can be moved vertically and laterally to positions in register with one or more transfer rooms through which vehicles enter and leave the structure and a selected parking space of the structure. A vehicle transfer mechanism is carried on the platform and includes four self-powered tractors carrying lift arms that can be driven off the platform to engage the tires of a vehicle and to transfer that vehicle onto the platform for transportation between a transfer room and a parking space. The tractors, when deployed, pass outside the vehicle tires with the lift arms folded and can then be operated to extend the arms in a way that engages the tires and lifts the vehicle.",MCDOWELL JR JOSEPH COLEMAN;;STORY MICHAEL CORBETT;;STORY JAMES BOWMER;;MILLER DWAYNE DAVID;;LANEY SEAN PATRICK;;REECE DANIEL JORDAN,MCDOWELL JR JOSEPH COLEMAN;;STORY MICHAEL CORBETT;;STORY JAMES BOWMER;;MILLER DWAYNE DAVID;;LANEY SEAN PATRICK;;REECE DANIEL JORDAN,PV PATENTS LLC (2014-09-02);;SAFE PARKING LIMITED (2012-02-22);;SAFE PARKING LTD (2020-11-11),https://lens.org/055-205-505-544-113,Patent Application,yes,1,21,3,3,0,E04H6/183;;E04H6/183;;E04H6/305,E04H6/30,414/256,0,0,,,,ACTIVE
284,US,B2,US 6782619 B2,196-122-084-693-725,2004-08-31,2004,US 93226601 A,2001-08-17,US 93226601 A,2001-08-17,Method of making high contact density electrode array,"
    A laminated multi-electrode biocompatible implant, comprising a first layer of flexible, biocompatible dielectric material having a first, exposed surface. A second layer of flexible biocompatible dielectric material, is adhered to the first layer. Further, a third layer of flexible biocompatible dielectric material is adhered to the second layer. Additionally, a first conductive trace is interposed between the first layer and the second layer and a second conductive trace interposed between said second layer and said third layer. Finally, a first conductor, which breaches said first layer, conductively connects the first conductive trace to the exposed surface of the first layer, thereby forming a first electrode and a second conductor, which breaches the first layer and the second layer, conductively connects the second conductive trace to the exposed surface of the first layer, thereby forming a second electrode. 
",ADVANCED COCHLEAR SYS INC,CORBETT III SCOTT S;;JOHNSON TIMOTHY J;;CLOPTON BEN M;;SPELMAN FRANCIS A;;STROLE JEFFERY A;;KETTERL JOSEPH R,MICROCONNEX (2006-03-02);;ADVANCED COCHLEAR SYSTEMS INC (2011-04-19),https://lens.org/196-122-084-693-725,Granted Patent,yes,6,21,5,5,0,A61N1/0541;;Y10T29/49176;;Y10T29/49176;;A61N1/0541,A61N1/05,29/858;;264/295;;264/372;;264/263;;607/137,0,0,,,,EXPIRED
285,US,B2,US 8561208 B2,065-775-488-095-025,2013-10-15,2013,US 201113212996 A,2011-08-18,US 201113212996 A;;US 201161488687 P,2011-05-20,Secure user interface content,"Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for handling secure user interface content. In one aspect, a method includes receiving, at a data processing apparatus, content over a communication network from a computing system separate from the data processing apparatus; determining that the received content is authentic secure content; retrieving information stored at the data processing apparatus and previously selected by a user for purposes of securing user interface content; rendering the received content, to a display of the data processing apparatus, as a user interface with a visual wrapper, where the visual wrapper includes the retrieved information, visually separates the user interface from other visual elements on the display, and includes an indication that the user interface is secure; and processing input received through the user interface.",CORBETT JIM D;;GOLDMAN OLIVER;;GWALANI RAJESH K;;KWON ROBERT O;;MOYER JOHN JOSEPH;;ORR MICHAEL BRIAN;;UHLEY PELEUS;;ADOBE SYSTEMS INC,CORBETT JIM D;;GOLDMAN OLIVER;;GWALANI RAJESH K;;KWON ROBERT O;;MOYER JOHN JOSEPH;;ORR MICHAEL BRIAN;;UHLEY PELEUS,ADOBE INC (2011-08-04),https://lens.org/065-775-488-095-025,Granted Patent,yes,4,14,2,2,0,G06F21/53;;G06F2221/032;;G06F21/53;;G06F2221/032,G06F21/20;;G06F21/22,726/27;;726/26;;726/28;;726/29;;726/30;;713/189;;713/193,7,1,099-694-186-263-002,10.1109/vlhcc.2004.45,"Unknown Author, ""HTTPS,"" definition of HTTPS in the Free Online Encyclopedia, downloaded from the Internet at: http://encyclopedia2.thefreedictionary.com/HTTPS, on May 13, 2011, 2 pages.;;Unknown Author, ""SiteKey,"" definition of SiteKey in the Wikipedia, downloaded from the Internet at: http://en.wikipedia.org/wiki/SiteKey, on May 13, 2011, 2 pages.;;Unknown Author, ""SSL,"" definition of SSL in the Free Online Encyclopedia, downloaded from the Internet at: http://encyclopedia2.thefreedictionary.com/SSL, 3 pages.;;Youll, Jim, ""Fraud Vulnerabilities in SiteKey Security at Bank of America,"" Jul. 18, 2006, Review draft to Bank of America/RSA, 15 pages.;;Cannella et al., ""Secure Visualization of Authentication Information: A Case Study,"" 2004, Proceedings of the IEEE Symposium on Visual Languages and Human Centric Computing, 3 pages.;;Ross et al., ""Stronger Password Authentication Using Browser Extensions,"" 2005, 14th USENIX Security Symposium, 15 pages.;;Smetters et al., ""Breaking out of the Browser to Defend Against Phishing Attacks,"" 2008, downloaded from the Internet at: http://www.ceas.cc/2008/papers/ceas2008-paper-58.pdf, 10 pages.",ACTIVE
286,US,B2,US 9464450 B2,170-856-624-124-89X,2016-10-11,2016,US 200913127671 A,2009-11-09,US 200913127671 A;;US 11243208 P;;US 2009/0063757 W,2008-11-07,Automatic parking structure,"A mechanism for moving vehicles within a vehicle parking structure comprises a lift platform which can be moved vertically and laterally to positions in register with one or more transfer rooms through which vehicles enter and leave the structure and a selected parking space of the structure. A vehicle transfer mechanism is carried on the platform and includes four self-powered tractors carrying lift arms that can be driven off the platform to engage the tires of a vehicle and to transfer that vehicle onto the platform for transportation between a transfer room and a parking space. The tractors, when deployed, pass outside the vehicle tires with the lift arms folded and can then be operated to extend the arms in a way that engages the tires and lifts the vehicle.",MCDOWELL JR JOSEPH COLEMAN;;STORY MICHAEL CORBETT;;STORY JAMES BOWMER;;MILLER DWAYNE DAVID;;LANEY SEAN PATRICK;;REECE DANIEL JORDAN;;SAFE PARKING LTD,MCDOWELL JR JOSEPH COLEMAN;;STORY MICHAEL CORBETT;;STORY JAMES BOWMER;;MILLER DWAYNE DAVID;;LANEY SEAN PATRICK;;REECE DANIEL JORDAN,PV PATENTS LLC (2014-09-02);;SAFE PARKING LIMITED (2012-02-22);;SAFE PARKING LTD (2020-11-11),https://lens.org/170-856-624-124-89X,Granted Patent,yes,7,0,3,3,0,E04H6/183;;E04H6/183;;E04H6/305,E04H6/00;;E04H6/18;;E04H6/30,,1,0,,,"PCT International Search Report mailed on Dec. 29, 2009 for PCT/US2009/063757.",ACTIVE
287,MA,A1,MA 27113 A1,174-467-630-844-822,2004-12-20,2004,MA 27915 A,2004-10-26,US 37616102 P,2002-04-26,ACTIVATEURS DE GLUCOKINASE OXYGENES CYCLOALKYLE OU SUBSTITUES CYCLOALKYLE,"PHENYLACETAMIDES SUBSTITUES ET LEUR UTILISATION EN TANT QU'ACTIVATEURS DE LA GLUCOKINASE Les composés de formule I; dans laquelle la formule II représente un groupe substitué, un groupe oxa-cycloalkyle ou un groupe thia-cycloalkyle, sont des activateurs de la glucokinase utiles dans le traitement du diabète de type II.",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;RACHA JAGDISH KUMAR;;SARABU RAMAKANTH;;HAYNES NANCY-ELLEN,,https://lens.org/174-467-630-844-822,Granted Patent,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,A61K31/17;;A61K31/341;;A61K31/351;;A61K31/426;;A61K31/427;;C07D277/20;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,ACTIVE
288,US,A1,US 2001/0039344 A1,042-203-148-869-436,2001-11-08,2001,US 52614300 A,2000-03-15,US 52614300 A;;US 12670799 P;;US 16594499 P,1999-03-29,Heteroaromatic glucokinase activators,"
   2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes. 
",BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;SARABU RAMAKANTH,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;SARABU RAMAKANTH,HOFFMANN-LA ROCHE INC (2000-02-24),https://lens.org/042-203-148-869-436,Patent Application,yes,0,30,3,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07D241/20;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/10;;C07D213/75;;C07D233/88;;C07D277/46;;C07D237/22;;C07D277/58;;C07C323/62;;C07D263/48;;C07C317/44;;C07D213/80;;C07D239/42;;C07D213/82;;C07D261/14;;C07D277/56;;C07D241/20;;C07D253/07;;C07C275/50;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/10,A61K31/42;;A61K31/426;;A61P3/10;;C07C275/50;;C07C317/44;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,544/332,0,0,,,,EXPIRED
289,US,B1,US 6320050 B1,024-533-039-402-537,2001-11-20,2001,US 52614300 A,2000-03-15,US 52614300 A;;US 12670799 P;;US 16594499 P,1999-03-29,Heteroaromatic glucokinase activators,"2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.",HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;SARABU RAMAKANTH,HOFFMANN-LA ROCHE INC (2000-02-24),https://lens.org/024-533-039-402-537,Granted Patent,yes,9,103,3,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07D241/20;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/10;;C07D213/75;;C07D233/88;;C07D277/46;;C07D237/22;;C07D277/58;;C07C323/62;;C07D263/48;;C07C317/44;;C07D213/80;;C07D239/42;;C07D213/82;;C07D261/14;;C07D277/56;;C07D241/20;;C07D253/07;;C07C275/50;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/10,A61K31/42;;A61K31/426;;A61P3/10;;C07C275/50;;C07C317/44;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,544/332;;544/329;;546/309;;548/127;;548/128;;548/134;;548/139;;548/195;;548/214,6,2,007-968-011-469-541;;013-432-036-690-340,10.1021/ja01192a063;;18105968;;10.1107/s0108270189009492,"Mndzhoyan, A. L. et al., Effect of Organic Acids of Pyridyl and Thiazolylamides on Certain Members of Coli-Typhosal, Staphylococcal, Streptococcal Groups and on Acid-Resistant Mycobacteria, Biol. Svoistva Khim. Soedin., Akad. Nauk Arm. SSR, Inst. Tonkoi O, 1962.*;;Speilman et al., Journal of American Chemical Society, vol. 70, pp. 4189-4191 (1948).;;Rodier et al., Acta Crystallogr., C46, pp. 154-156 (1990).;;Robert et al., Eur. J. Med. Chem., 29, pp. 841-854 (1994).;;Spickett et al., Eur. J. Med. Chem. -Chimica Therapeutica, 11(1), pp. 7-12 (1976).;;Bhat et al., J. Inst. Chemists (India), 61, pp. 134-136 (1989).",EXPIRED
290,ES,T3,ES 2055635 T3,033-496-456-153-881,1994-08-16,1994,ES 92201587 T,1992-06-03,US 71317391 A;;US 83515992 A,1991-06-10,AGENTES ANTITUMORALES DE TIOXANTENONA.,"1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones having the formula <CHEM> wherein n is 2 or 3; R<1> and R<2> are independently lower-alkyl; Q is a residue chosen from the group consisting of CH2NHR<3>, CH2N(R<4>)SO2R<7>, CH2NHCHO, CH=N-Ar, C(O)NR<5>R<6>, CH2N(R<4>)C(O)R<7>, CH2N(C2H5)CHO, and CH2N(R<4>)P(O)(O-lower-alkyl)2; R<3> is hydrogen or lower-alkyl; R<4> is hydrogen or lower-alkyl; R<5> is hydrogen, lower-alkyl or Ar; R<6> is hydrogen or lower-alkyl; R<7> is lower-alkyl, or Ar; R<8> is hydrogen, lower-alkyl, lower-alkoxy, or halogen; and Ar is phenyl or phenyl substituted with methyl, methoxyl, halogen or nitro; or a pharmaceutically acceptable acid-addition salt or solvate thereof, are disclosed as antitumor agents. Compositions containing the thioxanthenones and the method of use of thioxanthenones for treating tumors and cancer in mammals are also disclosed.",STERLING WINTHROP INC,MILLER THEODORE CHARLES;;COLLINS JOSEPH CHARLES;;WENTLAND MARK PHILIP;;PERNI ROBERT BRUNO;;CORBETT THOMAS HUGHES;;MATTES KENNETH CHARLES C O EAS,,https://lens.org/033-496-456-153-881,Granted Patent,no,0,0,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/382;;A61K31/39;;A61K31/67;;A61K31/38;;A61P35/00;;C07D335/16;;C07F9/6553,,0,0,,,,EXPIRED
291,EP,B1,EP 0518414 B1,158-279-420-205-717,1994-06-08,1994,EP 92201587 A,1992-06-03,US 71317391 A;;US 83515992 A,1991-06-10,Thioxanthenone antitumor agents.,"1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones having the formula <CHEM> wherein n is 2 or 3; R<1> and R<2> are independently lower-alkyl; Q is a residue chosen from the group consisting of CH2NHR<3>, CH2N(R<4>)SO2R<7>, CH2NHCHO, CH=N-Ar, C(O)NR<5>R<6>, CH2N(R<4>)C(O)R<7>, CH2N(C2H5)CHO, and CH2N(R<4>)P(O)(O-lower-alkyl)2; R<3> is hydrogen or lower-alkyl; R<4> is hydrogen or lower-alkyl; R<5> is hydrogen, lower-alkyl or Ar; R<6> is hydrogen or lower-alkyl; R<7> is lower-alkyl, or Ar; R<8> is hydrogen, lower-alkyl, lower-alkoxy, or halogen; and Ar is phenyl or phenyl substituted with methyl, methoxyl, halogen or nitro; or a pharmaceutically acceptable acid-addition salt or solvate thereof, are disclosed as antitumor agents. Compositions containing the thioxanthenones and the method of use of thioxanthenones for treating tumors and cancer in mammals are also disclosed.",STERLING WINTHROP INC,MILLER THEODORE CHARLES;;COLLINS JOSEPH CHARLES;;WENTLAND MARK PHILIP;;PERNI ROBERT BRUNO;;CORBETT THOMAS HUGHES;;MATTES KENNETH CHARLES C O EAS,SANOFI-AVENTIS (2004-11-15);;SANOFI-SYNTHELABO (2000-06-05);;SANOFI (1998-02-02);;SANOFI TRANSFER- SANOFI-SYNTHELABO (2000-05-31);;STERLING WINTHROP INC. TRANSFER- SANOFI (1997-06-30),https://lens.org/158-279-420-205-717,Granted Patent,yes,0,1,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/382;;A61K31/39;;A61K31/67;;A61K31/38;;A61P35/00;;C07D335/16;;C07F9/6553,,1,0,,,"patent abstracts, vol. 21, february 1993, derwent publications, London, GB",EXPIRED
292,EP,A1,EP 2513103 A1,029-368-087-381-916,2012-10-24,2012,EP 10792890 A,2010-12-13,US 28611609 P;;EP 2010069455 W,2009-12-14,AZAINDOLE GLUCOKINASE ACTIVATORS,,HOFFMANN LA ROCHE,BERTHEL STEVEN JOSEPH;;CHEN LI;;CORBETT WENDY LEA;;FENG LICHUN;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;SO SUNG-SAU;;TILLEY JEFFERSON WRIGHT,,https://lens.org/029-368-087-381-916,Patent Application,yes,0,1,16,16,0,C07D471/04;;C07D401/06;;C07D403/10;;C07D405/06;;C07C2601/04;;C07C2601/06;;A61P3/00;;A61P43/00;;A61P3/10;;A61K31/437;;C07D471/04;;C07C2601/06;;C07C2601/04;;C07D471/04;;C07D401/06;;C07D405/06;;C07D403/10;;C07C2601/04;;C07C2601/06,C07D401/06;;C07D403/10;;C07D405/06;;C07D471/04,,0,0,,,,DISCONTINUED
293,US,A1,US 2003/0225283 A1,063-658-006-253-495,2003-12-04,2003,US 42110903 A,2003-04-23,US 42110903 A;;US 37616102 P,2002-04-26,Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators,"
   2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a polar ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes. 
",CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;RACHA JAGDISH KUMAR;;SARABU RAMAKANTH;;WANG KA,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;RACHA JAGDISH KUMAR;;SARABU RAMAKANTH;;WANG KA,,https://lens.org/063-658-006-253-495,Patent Application,yes,5,32,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,A61K31/17;;A61K31/341;;A61K31/351;;C07D277/20;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,544/405;;549/65;;549/491;;548/204;;564/47;;564/161,0,0,,,,EXPIRED
294,EP,A1,EP 1501815 A1,017-713-458-792-992,2005-02-02,2005,EP 03749855 A,2003-04-14,EP 0303844 W;;US 37616102 P,2002-04-26,SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS,,HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;RACHA JAGDISH KUMAR;;SARABU RAMAKANTH;;WANG KA,,https://lens.org/017-713-458-792-992,Patent Application,yes,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D277/20;;A61K31/17;;A61K31/341;;A61K31/351;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,EXPIRED
295,UY,A1,UY 27787 A1,085-823-338-351-467,2003-10-31,2003,UY 27787 A,2003-04-28,US 37616102 P,2002-04-26,ACTIVADORES CICLOALQUIL SUSTITUIDOS Y CICLOALQUIL OXIGENADOS DE GLUCOQUINASA.,"Las 2,3- Di-sustituidas N-heteroaromática propionamidas siendo dicha sustitución en la posición 2 un grupo fenilo sustituido y en la posición 3 un anillo polar, dichas propionamidas son activadores de la glucoquinasa que aumenta la secreción de insulina en el tratamiento de la diabetes tipo II.",HOFFMANN LA ROCHE,RACHA JAGDISH K;;GRIMSBY JOSEPH S;;WANG KA;;HAYNES NANCY-ELLEN;;MAHENEY PAIGE E;;SARABU RAMAKANTH;;KESTER ROBERT F;;CORBETT WENDY L,,https://lens.org/085-823-338-351-467,Patent Application,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D277/20;;A61K31/17;;A61K31/341;;A61K31/351;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,DISCONTINUED
296,WO,A1,WO 2011/073117 A1,125-800-565-716-734,2011-06-23,2011,EP 2010069455 W,2010-12-13,US 28611609 P,2009-12-14,AZAINDOLE GLUCOKINASE ACTIVATORS,"Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.",HOFFMANN LA ROCHE;;BERTHEL STEVEN JOSEPH;;CHEN LI;;CORBETT WENDY LEA;;FENG LICHUN;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;SO SUNG-SAU;;TILLEY JEFFERSON WRIGHT,BERTHEL STEVEN JOSEPH;;CHEN LI;;CORBETT WENDY LEA;;FENG LICHUN;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;SO SUNG-SAU;;TILLEY JEFFERSON WRIGHT,,https://lens.org/125-800-565-716-734,Patent Application,yes,5,2,16,16,0,C07D471/04;;C07D401/06;;C07D403/10;;C07D405/06;;C07C2601/04;;C07C2601/06;;A61P3/00;;A61P43/00;;A61P3/10;;A61K31/437;;C07D471/04;;C07C2601/06;;C07C2601/04;;C07D471/04;;C07D401/06;;C07D405/06;;C07D403/10;;C07C2601/04;;C07C2601/06,A61K31/437;;C07D471/04,,16,14,056-206-411-978-675;;106-170-725-806-657;;061-893-046-790-102;;040-526-770-522-399;;098-019-860-572-873;;002-463-604-557-082;;047-763-655-227-523;;074-121-168-885-806;;016-865-549-924-168;;081-609-796-032-196;;060-895-089-314-256;;041-561-940-793-141;;002-463-604-557-082;;041-656-638-510-229,10.1016/s1874-6047(08)60113-4;;10.1146/annurev.nutr.13.1.463;;10.1146/annurev.nu.13.070193.002335;;8369155;;6364828;;10.1152/ajpendo.1984.246.1.e1;;7553875;;10.1016/0092-8674(95)90235-x;;10.1096/fasebj.10.10.8751724;;8751724;;pmc1135815;;7619052;;10.1042/bj3090167;;9435328;;10.1056/nejm199801223380404;;17987520;;10.1021/cr068006f;;17973536;;10.1002/ejoc.200700391;;10.1021/cr050992x;;17305399;;17212474;;10.1021/cr0505674;;pmc1135815;;7619052;;10.1042/bj3090167;;2337595;;10.1021/bi00455a026,"COLOWICK, S.P.: ""The Enzymes"", vol. 9, 1973, ACADEMIC PRESS, pages: 1 - 48;;CHIPKIN, S.R.; KELLY, K.L.; RUDERMAN, N.B.: ""Joslin's Diabetes"", 1994, LEA AND FEBIGER, pages: 97 - 115;;PRINTZ, R.G.; MAGNUSON, M.A.; GRANNER, D.K.: ""Ann. Rev. Nutrition"", vol. 13, 1993, ANNUAL REVIEW, INC., pages: 463 - 496;;MEGLASSON, M.D.; MATSCHINSKY, F.M., AMER. J. PHYSIOL., vol. 246, 1984, pages E1 - E13;;GRUPE, A.; HULTGREN, B.; RYAN, A. ET AL., CELL, vol. 83, 1995, pages 69 - 78;;FERRIE, T.; RIU, E.; BOSCH, F. ET AL., FASEB J., vol. 10, 1996, pages 1213 - 1218;;LIANG, Y.; KESAVAN, P.; WANG, L. ET AL., BIOCHEM. J., vol. 309, 1995, pages 167 - 173;;GLASER, B.; KESAVAN, P.; HEYMAN, M. ET AL., NEW ENGLAND J. MED., vol. 338, 1998, pages 226 - 230;;GREENE, T. W.: ""Protective Groups in Organic Synthesis"", 1991, JOHN WILEY & SONS, INC.;;DOUCET, H.; HIERSO, J.-C., CURR. OPIN. DRUG DISCOVERY DEV., vol. 10, 2007, pages 672 - 690;;BECCALLI, E. M.; BROGGINI, G.; MARTINELLI, M.; OTTOCORNOLA, S., CHEM. REV., vol. 107, 2007, pages 5318 - 5365;;KIENLE, M.; DUBBAKA, S. R.; BRADE, K.; KNOCHEL, P., EUR. J. ORG. CHEM., 2007, pages 4166 - 4176;;CHINCHILLA, R.; NAJERA, C., CHEM. REV, vol. 107, 2007, pages 874 - 922;;YIN, L.; LIEBSCHER, J., CHEM. REV., vol. 107, 2007, pages 133 - 173;;LIANG, Y.; KESAVAN, P.; WANG, L.; NISWENDER, K.; TANIZAWA, Y.; PERMUT, M. A.; MAGNUSON, M.; MATSCHINSKY, F. M.: ""Variable effects ofmaturity-onset-diabetes-of- youth (MODY)-associated glucokinase mutations on the substrate interactions and stability of the enzyme"", BIOCHEM. J., vol. 309, 1995, pages 167 - 173;;NEET, K.; KEENAN, R. P.; TIPPETT, P.S.: ""Observation of a kinetic slow transition in monomeric glucokinase"", BIOCHEMISTRY, vol. 29, 1990, pages 770 - 777",PENDING
297,PT,E,PT 1501815 E,025-892-251-117-806,2007-01-31,2007,PT 03749855 T,2003-04-14,US 37616102 P,2002-04-26,SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS,,HOFFMANN LA ROCHE,KESTER ROBERT FRANCIS;;SARABU RAMAKANTH;;MAHANEY PAIGE ERIN;;CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;RACHA JAGDISH KUMAR;;WANG KA,,https://lens.org/025-892-251-117-806,Granted Patent,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D277/20;;A61K31/17;;C07D307/16;;A61K31/335;;A61K31/341;;A61K31/351;;A61K31/38;;A61K31/425;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07C275/52;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,EXPIRED
298,BR,A2,BR 112012014463 A2,170-429-627-662-232,2017-03-14,2017,BR 112012014463 A,2010-12-13,EP 2010069455 W;;US 28611609 P,2009-12-14,ativadores de glucoquinase azaindol,"ativadores de glucoquinase azaindol. são providos aquim compostos da fórmula (i): bem como os sais farmceuticamente aceitáveis dos mesmos, em que os substituintes são como aqueles revelados no relatório descritivo. estes compostos, e as composições farmacêuticas que os contêm, são úteis para o tratamento de doenças ou de distúrbios do metabolismo tais como, por exemplo, diabete mellitus do tipo ii.",F HOFFMANN-LA ROCHE AG (T),JEFFERSON WRIGHT TILLEY;;LI CHEN;;LICHUN FENG;;NANCY-ELLEN HAYNES;;ROBERT FRANCIS KESTER;;STEVEN JOSEPH BERTHEL;;SUNG-SAU SO;;WENDY LEA CORBETT,,https://lens.org/170-429-627-662-232,Patent Application,no,0,0,16,16,0,C07D471/04;;C07D401/06;;C07D403/10;;C07D405/06;;C07C2601/04;;C07C2601/06;;A61P3/00;;A61P43/00;;A61P3/10;;A61K31/437;;C07D471/04;;C07C2601/06;;C07C2601/04;;C07D471/04;;C07D401/06;;C07D405/06;;C07D403/10;;C07C2601/04;;C07C2601/06,C07D471/04;;A61K31/437,,0,0,,,,DISCONTINUED
299,HK,A1,HK 1078088 A1,085-125-831-306-653,2006-03-03,2006,HK 06100724 A,2006-01-17,US 37616102 P;;EP 0303844 W,2002-04-26,Substituted phenylacetamides and their use as glucokinase activators,,HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;RACHA JAGDISH KUMAR;;SARABU RAMAKANTH;;WANG KA,,https://lens.org/085-125-831-306-653,Patent Application,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D/;;C07D277/20;;A61K/;;A61K31/17;;A61K31/341;;A61K31/351;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P/;;A61P3/10;;C07C/;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,DISCONTINUED
300,NO,L,NO 20044534 L,142-425-204-825-681,2004-12-22,2004,NO 20044534 A,2004-10-21,US 37616102 P;;EP 0303844 W,2002-04-26,Substituerte fenylacetamider og deres anvendelse som glukokinaseaktivatorer,"Legemiddel Forbindelser med formel (I); hvori formel (U) representerer en substituert gmppe, en oksa-cykloalkylgruppe eller en tia-cykloalkylgmppe, er glukokinase-aktivatorer som er anvendelig ved behandling av type II diabetes.",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH;;GRIMSBY JOSEPH SAMUEL;;RACHA JAGDISH KUMAR;;WANG KA,,https://lens.org/142-425-204-825-681,Abstract,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,A61K31/17;;A61K31/341;;A61K31/351;;C07D277/20;;A61K31/426;;C07D417/12;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12,,0,0,,,,DISCONTINUED
301,US,A1,US 2006/0178429 A1,108-723-437-083-95X,2006-08-10,2006,US 40216706 A,2006-04-10,US 40216706 A;;US 42110903 A;;US 37616102 P,2002-04-26,Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators,"2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a polar ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.",CORBETT WENDY L;;GRIMSBY JOSEPH S;;HAYNES NANCY-ELLEN;;KESTER ROBERT F;;MAHANEY PAIGE E;;RACHA JAGDISH K;;SARABU RAMAKANTH;;WANG KA,CORBETT WENDY L;;GRIMSBY JOSEPH S;;HAYNES NANCY-ELLEN;;KESTER ROBERT F;;MAHANEY PAIGE E;;RACHA JAGDISH K;;SARABU RAMAKANTH;;WANG KA,,https://lens.org/108-723-437-083-95X,Patent Application,yes,5,12,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D277/20;;A61K31/17;;C07D307/02;;A61K31/34;;A61K31/341;;A61K31/35;;A61K31/351;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,514/459;;514/471;;549/419;;549/475,0,0,,,,EXPIRED
302,CN,A,CN 102686587 A,140-008-675-240-268,2012-09-19,2012,CN 201080056772 A,2010-12-13,EP 2010069455 W;;US 28611609 P,2009-12-14,Azaindole glucokinase activators,"Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.",HOFFMANN LA ROCHE,JOSEPH BERTHEL STEVEN;;LI CHEN;;LEA CORBETT WENDY;;LICHUN FENG;;NANCY-ELLEN HAYNES;;FRANCIS KESTER ROBERT;;SUNG-SAU SO;;WRIGHT TILLEY JEFFERSON,,https://lens.org/140-008-675-240-268,Patent Application,no,2,1,16,16,0,C07D471/04;;C07D401/06;;C07D403/10;;C07D405/06;;C07C2601/04;;C07C2601/06;;A61P3/00;;A61P43/00;;A61P3/10;;A61K31/437;;C07D471/04;;C07C2601/06;;C07C2601/04;;C07D471/04;;C07D401/06;;C07D405/06;;C07D403/10;;C07C2601/04;;C07C2601/06,C07D471/04;;A61K31/437,,0,0,,,,INACTIVE
303,PE,A1,PE 20040451 A1,007-130-859-731-27X,2004-07-21,2004,PE 2003000409 A,2003-04-24,US 37616102 P,2002-04-26,ACTIVADORES CICLOALQUIL SUSTITUIDOS Y CICLOALQUIL OXIGENADOS DE GLUCOQUINASA,"SE REFIERE A UN COMPUESTO DE FORMULA I DONDE R1 Y R2 SON INDEPENDIENTEMENTE H, HALO, HIDROXIAMINO, CIANO, NITRO, ALQUILO INFERIOR, -OR5, PERFLUOROALQUILO ENTRE OTROS; R3 ES UNA CADENA DE ALQUILO NO RAMIFICADO DE 4-5 CARBONOS O HETEROALQUILO NO RAMIFICADO DE 3-4 CARBONOS MAS UN O o S DONDE LA CADENA EN COMBINACION CON UN C AL QUE ESTA UNIDO FORMA UN ANILLO DE 5-6 MIEMBROS Y SI LA CADENA NO TIENE HETEROATOMOS UN C PUEDE ESTAR SUSTITUIDO POR -OH, OXO, HIDROXIIMINO, ENTRE OTROS, SI TIENE UN HETEROATOMO DE O o S LA CADENA NO ESTA SUSTITUIDA, O EL S ESTE SUSTITUIDO POR UN OXO; R4 ES -CONHR6 O UN HETEROAROMATICO DE 5-6 MIEMBROS NO SUSTITUIDO O MONO-SUSTITUIDO UNIDO CON UN C AL GRUPO AMINO, ESTE ANILLO PUEDE TENER DE 1 A 3 HETEROATOMOS DE S, O o N, DICHO ANILLO PUEDE ESTAR SUSTITUIDO POR ALQUILO INFERIOR, HALO, NITRO, CIANO, NITRO, PERFLUOROALQUILO, AMIDOOXIMA, -(CH2)n-OR7, -(CH2)n-CO-OR7, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1-[2-(3,4-DICLORO-FENIL)-3-(TETRAHIDRO-FURAN-2-IL)-PROPIONIL]-3-METIL-UREA.1-[2-(3,4-DICLORO-FENIL)-3-(2-HIDROXI-CICLOPENTIL)-PROPIONIL]-3-METIL-UREA, 2(R)-(3-CLORO-4-METANOSULFONIL-FENIL)-3-((R)-3-OXO-CICLOPENTIL)-N-PIRAZIN-2-IL-PROPIONAMIDA.TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON ACTIVADORES DE LA GLUCOQUINASA Y SON UTILES EN EL TRATAMIENTO DE LA DIABETES TIPO II",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;RACHA JAGDISH KUMAR;;WANG KA;;GRIMSBY JOSEPH SAMUEL;;SARABU RAMAKANTH,,https://lens.org/007-130-859-731-27X,Patent Application,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,A61K31/17;;A61K31/341;;A61K31/351;;A61K31/38;;A61K31/426;;C07D277/20;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,EXPIRED
304,PA,A1,PA 8572301 A1,036-256-520-616-147,2004-05-26,2004,PA 8572301 A,2003-04-24,US 37616102 P,2002-04-26,ACTIVADORES CICLOALQUIL SUSTITUIIDOS Y CICLOALQUIL OXIGENADOS DE GLUCOQUINASA,"LAS 2,3-DI-SUSTITUIDAS N-HETEROAROMATICO PROPIONAMIDAS SIENDO DICHA SUSTITUCION EN LA POSICION 2 UN GRUPO FENILO SUSTITUIDO Y EN LA POSICION 3 UN ANILLO POLAR, DICHAS PROPIONAMIDAS SON ACTIVADORES DE LA GLUCOQUINASA QUE AUMENTA LA SECRECION DE INSULINA EN EL TRATAMIENTO DE LA DIABETES TIPO II.",HOFFMANN LA ROCHE,RAMAKANTH SARABU;;CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;RACHA JAGDISH KUMAR;;WANG KA,,https://lens.org/036-256-520-616-147,Patent Application,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,A61K31/17;;A61K31/335;;A61K31/341;;A61K31/351;;A61K31/38;;A61K31/426;;A61K31/427;;A61K31/44;;C07D277/20;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07C275/52;;C07D213/75;;C07D213/80;;C07D241/20;;C07D277/44;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,PENDING
305,HK,A1,HK 1171226 A1,134-077-870-013-337,2013-03-22,2013,HK 12112005 A,2012-11-23,EP 2010069455 W;;US 28611609 P,2009-12-14,AZAINDOLE GLUCOKINASE ACTIVATORS,,HOFFMANN LA ROCHE,BERTHEL STEVEN JOSEPH;;CHEN LI;;CORBETT WENDY LEA;;FENG LICHUN;;NANCY-ELLEN HAYNES;;KESTER ROBERT FRANCIS;;SO SUNG-SAU;;TILLEY JEFFERSON WRIGHT,,https://lens.org/134-077-870-013-337,Patent Application,no,0,0,16,16,0,C07D471/04;;C07D401/06;;C07D403/10;;C07D405/06;;C07C2601/04;;C07C2601/06;;A61P3/00;;A61P43/00;;A61P3/10;;A61K31/437;;C07D471/04;;C07C2601/06;;C07C2601/04;;C07D471/04;;C07D401/06;;C07D405/06;;C07D403/10;;C07C2601/04;;C07C2601/06,A61K/;;C07D/,,0,0,,,,DISCONTINUED
306,GT,A,GT 200300096 A,135-850-982-913-286,2004-01-15,2004,GT 200300096 A,2003-04-24,US 37616102 P,2002-04-26,ACTIVADORES DE CICLOALQUIL SUSTITUIDOS Y CICLOALQUIL OXIGENADOS DE GLUCOQUINASA,"LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA GENERAL I EN DONDE R1,R2,R3,R4,C, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON ACTIVADORES DE LA GLUCOQUINASA QUE AUMENTAN LA SECRECION DE INSULINA POR LO QUE SON DE UTILIDAD EN CASOS DE DIABETES TIPO II.",,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;RACHA JAGDISH KUMAR;;SARUBU RAMAKANTH;;WANG KA,,https://lens.org/135-850-982-913-286,Amended Application,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D277/20;;A61K31/17;;A61K31/341;;A61K31/351;;A61K31/41;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C233/91;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D257/04;;C07D277/44;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,PENDING
307,DK,T3,DK 1501815 T3,177-941-441-353-738,2007-04-02,2007,DK 03749855 T,2003-04-14,US 37616102 P;;EP 0303844 W,2002-04-26,Substituerede phenylacetamider og anvendelse deraf som glucokinaseaktivatorer,,HOFFMANN LA ROCHE,GRIMSBY JOSEPH SAMUEL;;MAHANEY PAIGE ERIN;;RACHA JAGDISH KUMAR;;WANG KA;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;SARABU RAMAKANTH;;CORBETT WENDY LEA,,https://lens.org/177-941-441-353-738,Granted Patent,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D277/20;;C07D307/16;;A61K31/17;;A61K31/335;;A61K31/341;;A61K31/351;;A61K31/38;;A61K31/425;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07C275/52;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,EXPIRED
308,AT,T1,AT E346056 T1,004-800-090-325-053,2006-12-15,2006,AT 03749855 T,2003-04-14,US 37616102 P,2002-04-26,SUBSTITUIERTE PHENYLACETAMIDE UND DEREN VERWENDUNG ALS GLUCOKINASEAKTIVATOREN,,HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;RACHA JAGDISH KUMAR;;SARABU RAMAKANTH;;WANG KA,,https://lens.org/004-800-090-325-053,Granted Patent,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D277/20;;A61K31/17;;A61K31/341;;A61K31/351;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,EXPIRED
309,WO,A9,WO 2003/095438 A9,030-864-622-349-829,2004-12-23,2004,EP 0303844 W,2003-04-14,US 37616102 P,2002-04-26,SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS,"Compounds of the formula (I); wherein formula (II) represents a substituted group, an oxa-cycloalkyl group or a thia-cycloalkyl group, are glucokinase activators useful in the treatment of type II diabetes.",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;RACHA JAGDISH KUMAR;;SARABU RAMAKANTH;;WANG KA,,https://lens.org/030-864-622-349-829,Patent Application,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,A61K31/17;;A61K31/341;;A61K31/351;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,PATENTED
310,MX,A,MX 2012006287 A,035-075-495-162-657,2012-07-03,2012,MX 2012006287 A,2010-12-13,US 28611609 P;;EP 2010069455 W,2009-12-14,AZAINDOLE GLUCOKINASE ACTIVATORS.,"Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;TILLEY JEFFERSON WRIGHT;;KESTER ROBERT FRANCIS;;CHEN LI;;HAYNES NANCY-ELLEN;;BERTHEL STEVEN JOSEPH;;FENG LICHUN;;SO SUNG-SAU,,https://lens.org/035-075-495-162-657,Patent Application,no,0,0,16,16,0,C07D471/04;;C07D401/06;;C07D403/10;;C07D405/06;;C07C2601/04;;C07C2601/06;;A61P3/00;;A61P43/00;;A61P3/10;;A61K31/437;;C07D471/04;;C07C2601/06;;C07C2601/04;;C07D471/04;;C07D401/06;;C07D405/06;;C07D403/10;;C07C2601/04;;C07C2601/06,A61K31/437;;C07D471/04,,0,0,,,,ACTIVE
311,BR,A,BR 0309546 A,135-854-250-003-04X,2005-02-15,2005,BR 0309546 A,2003-04-14,EP 0303844 W;;US 37616102 P,2002-04-26,"Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii","""COMPOSTO, COMPOSIçãO FARMACêUTICA QUE COMPREENDE O MESMO, PROCESSO PARA A SUA PREPARAçãO E UTILIZAçãO E MéTODO PARA TRATAMENTO PROFILáTICO OU TERAPêUTICO DE DIABETES DO TIPO II"". Os compostos da fórmula (II), em que a fórmula (II) representa um grupo substituído, um grupo oxa-cicloalquila ou um grupo tio-cicloalquila, são ativadores de glicoquinase de utilidade no tratamento de diabetes do tipo II.",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;RACHA JAGDISH KUMAR;;SARABU RAMAKANTH;;WANG KA,,https://lens.org/135-854-250-003-04X,Patent Application,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D277/20;;A61K31/17;;A61K31/341;;A61K31/351;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,DISCONTINUED
312,CN,B,CN 102686587 B,040-366-356-077-189,2015-05-27,2015,CN 201080056772 A,2010-12-13,EP 2010069455 W;;US 28611609 P,2009-12-14,Azaindole glucokinase activators,,HOFFMANN LA ROCHE,BERTHEL STEVEN JOSEPH;;CHEN LI;;CORBETT WENDY LEA;;FENG LICHUN;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;SO SUNG-SAU;;TILLEY JEFFERSON WRIGHT,,https://lens.org/040-366-356-077-189,Granted Patent,no,0,0,16,16,0,C07D471/04;;C07D401/06;;C07D403/10;;C07D405/06;;C07C2601/04;;C07C2601/06;;A61P3/00;;A61P43/00;;A61P3/10;;A61K31/437;;C07D471/04;;C07C2601/06;;C07C2601/04;;C07D471/04;;C07D401/06;;C07D405/06;;C07D403/10;;C07C2601/04;;C07C2601/06,C07D471/04;;A61K31/437,,0,0,,,,INACTIVE
313,US,B2,US 7105671 B2,081-600-404-095-657,2006-09-12,2006,US 42110903 A,2003-04-23,US 42110903 A;;US 37616102 P,2002-04-26,Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators,"2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a polar ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;RACHA JAGDISH KUMAR;;SARABU RAMAKANTH;;WANG KA,,https://lens.org/081-600-404-095-657,Granted Patent,yes,11,7,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D241/20;;A61K31/17;;C07D277/20;;A61K31/341;;A61K31/351;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D277/44;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,544/336;;546/309;;548/195;;549/155;;549/158,13,7,061-893-046-790-102;;040-526-770-522-399;;098-019-860-572-873;;002-463-604-557-082;;047-763-655-227-523;;013-432-036-690-340;;007-968-011-469-541,6364828;;10.1152/ajpendo.1984.246.1.e1;;7553875;;10.1016/0092-8674(95)90235-x;;10.1096/fasebj.10.10.8751724;;8751724;;pmc1135815;;7619052;;10.1042/bj3090167;;9435328;;10.1056/nejm199801223380404;;10.1107/s0108270189009492;;10.1021/ja01192a063;;18105968,"Colowick, S.P., The Enzymes, vol. 9 (P. Boyer, ed.) Academic Press, New York, NY, p. 1-48 (1973).;;Chipkin, et. al., in Joslin's Diabetes (C.R. Kahn and G.C. Wier, eds.), Lea and Febiger, Philadelphia, PA, p. 97-115 (1994).;;Printz, et. al., Ann. Rev. Nutrition, vol. 13 (R.E. Olson, D.M. Bier, and D.B. McCormick, eds.) Annual Review Inc, Palo Alto, CA pp. 463-496 (1993).;;Meglasson, et. al., Amer. J. Physiol., 246, E1-E13 (1984).;;Grupe, et. al., Cell 83, 69-78, (1995).;;Ferre, et al., FASEB J., 10, 1213-1218 (1996).;;Liang, et al., Biochem. J. 309, 167-173 (1995).;;Glaser, et. al. New England J. Med. 338, 226-230 (1998).;;Rodier, et. al., Acta Crystallogr., C46 (1990) pp. 154-156.;;Robert, J. M. H., et. al., Eur J. Med. Chem. vol. 29, (1994), pp. 841-854.;;Spickett, et. al., Eur. J. Med. Chem.-Chimica Therapeutica, vol. 11(1), (1976), pp. 7-12.;;Bhat, A. R., et. al., J. Inst. Chemists (India), vol. 61, 1989, pp. 134-136.;;Spielman, M.A., et. al., J. Am. Chem. Soc., 70 (1948), pp. 4189-4191.",EXPIRED
314,BR,A8,BR 112012014463 A8,136-080-608-780-346,2017-12-26,2017,BR 112012014463 A,2010-12-13,EP 2010069455 W;;US 28611609 P,2009-12-14,ativadores de glucoquinase azaindol,"ativadores de glucoquinase azaindol. são providos aquim compostos da fórmula (i): bem como os sais farmceuticamente aceitáveis dos mesmos, em que os substituintes são como aqueles revelados no relatório descritivo. estes compostos, e as composições farmacêuticas que os contêm, são úteis para o tratamento de doenças ou de distúrbios do metabolismo tais como, por exemplo, diabete mellitus do tipo ii.",F HOFFMANN LA ROCHE AG T,JEFFERSON WRIGHT TILLEY;;LI CHEN;;LICHUN FENG;;NANCY-ELLEN HAYNES;;ROBERT FRANCIS KESTER;;STEVEN JOSEPH BERTHEL;;SUNG-SAU SO;;WENDY LEA CORBETT,,https://lens.org/136-080-608-780-346,Patent Application,no,0,0,16,16,0,C07D471/04;;C07D401/06;;C07D403/10;;C07D405/06;;C07C2601/04;;C07C2601/06;;A61P3/00;;A61P43/00;;A61P3/10;;A61K31/437;;C07D471/04;;C07C2601/06;;C07C2601/04;;C07D471/04;;C07D401/06;;C07D405/06;;C07D403/10;;C07C2601/04;;C07C2601/06,C07D471/04;;A61K31/437,,0,0,,,,DISCONTINUED
315,HR,A2,HR P20040953 A2,162-946-052-648-16X,2005-06-30,2005,HR P20040953 A,2004-10-12,US 37616102 P;;EP 0303844 W,2002-04-26,SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS,,HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSB SAMUEL JOSEPH;;HAYNES NANCY-ELLEN;;KESTER FRANCIS ROBERT;;MAHANEY ERIN PAIGE;;RACHA KUMAR JAGDISH;;SARABU REMAKANTH;;WANG KA,,https://lens.org/162-946-052-648-16X,Patent Application,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D277/20;;A61K31/17;;A61K31/341;;A61K31/351;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,DISCONTINUED
316,HR,B1,HR P20010688 B1,011-340-150-788-551,2008-10-31,2008,HR P20010688 A,2001-09-19,EP 0002450 W;;US 12670799 P;;US 16594499 P;;US 16594899 P,1999-03-29,GLUCOKINASE ACTIVATORS,"Spoj naznačen time, da obuhvaća amid formule I: pri čemu* označava asimetrični atom ugljika; R1 i R2 su međusobno neovisno vodik, halo, amino, hidroksiamino, nitro, cijano, sulfonamido, niži alkil, -OR5, -C(O)OR5, perfluoro-niži alkil, niži alkil tio, perfluoro-niži alkil tio, niži alkil sulfonil, perfluoro-niži alkil sulfonil ili niži alkil sulfinil; R3 je cikloalkil s 3 do 7 ugljikova atoma; R4je -C(O)NHR40; ili nesupstituirani ili mono-supstituirani petero- ili šesteročlani heteroaromatski prsten koji je povezan preko ugljikova atoma iz prstena s prikazanom aminskom skupinom, a koji petero- ili šesteročlani heteroaromatski prsten sadrži od 1 do 3 heteroatoma koji se biraju između sumpora, kisika ili dušika, pri čemu je jedan heteroatomdušik koji ima susjedni položaj u odnosu na povezni ugljikov atom iz prstena; pritom je spomenuti monosupstituirani heteroaromatski prsten monosupstituiran na mjestu ugljikova atoma u prstenu različitom od susjednog s obzirom na spomenuti povezni ugljikov atom, a supstituent se bira iz skupine kojučine niži alkil, halo, nitro, cijano, -(CH2)n-OR6, - (CH2)n-C(O)OR7, - (CH2)n-C(O)NHR6, -C(O)-C(O)OR8, -(CH2)n-NHR6;R40 je vodik, niži alkil, niži alkenil, hidroksi niži alkil, halo niži alkil, -(CH2)n-C(O)OR5 ili -C(O)-(CH2)n-C(O)OR6;R5 je vodik, niži alkil ili perfluoro-niži alkil; R6, R7 i R8 sumeđusobno neovisno vodik ili niži alkil; in je 0,1, 2, 3 ili 4; ""niži alkil"" i ""niži alkoksi"" označavaju grupe s 1 do 7 ugljikovih atoma; i ""niži alkenil"" označava grupe od 2 do 6 ugljikova atoma; ili njihovu farmaceutski prihvatljivu sol. Patent sadrži još 21 patentni zahtjev.",HOFFMANN LA ROCHE,BIZZARO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;SARABU RAMAKATH,,https://lens.org/011-340-150-788-551,Granted Patent,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,C07D277/46;;A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
317,MY,A,MY 135222 A,190-575-113-588-793,2008-02-29,2008,MY PI20031564 A,2003-04-24,US 37616102 P,2002-04-26,SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS,"THIS INVENTION PROVIDES PROPIONAMIDES OF THE FORMULA: WHEREIN R1, R2 AND R3 ARE AS DEFINED IN THE SPECIFICATION. THE COMPOUNDS ARE GLUCOKINASE ACTIVATORS WHICH INCREASE INSULIN SECRETION AND ARE THUS USEFUL IN THE TREATMENT OF TYPE II DIABETES.",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;RACHA JAGDISH KUMAR;;SARABU RAMAKANTH;;WANG KA,,https://lens.org/190-575-113-588-793,Granted Patent,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D277/20;;A61K31/17;;A61K31/341;;A61K31/351;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,EXPIRED
318,PL,A1,PL 373701 A1,047-725-979-815-121,2005-09-05,2005,PL 37370103 A,2003-04-14,US 37616102 P,2002-04-26,SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS,,HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;RACHA JAGDISH KUMAR;;SARABU RAMAKANTH;;WANG KA,,https://lens.org/047-725-979-815-121,Patent Application,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,A61K31/17;;A61K31/341;;A61K31/351;;A61K31/426;;A61K31/427;;A61K31/44;;C07D277/20;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,DISCONTINUED
319,AU,B8,AU 2003/232204 B8,049-900-152-635-593,2009-07-30,2009,AU 2003/232204 A,2003-04-14,EP 0303844 W;;US 37616102 P,2002-04-26,Substituted phenylacetamides and their use as glucokinase activators,,HOFFMANN LA ROCHE,HAYNES NANCY-ELLEN;;GRIMSBY JOSEPH SAMUEL;;SARABU RAMAKANTH;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;CORBETT WENDY LEA;;WANG KA;;RACHA JAGDISH KUMAR,,https://lens.org/049-900-152-635-593,Amended Patent,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D277/20;;A61K31/17;;A61K31/341;;A61K31/351;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,EXPIRED
320,CA,C,CA 2482346 C,110-444-114-525-629,2010-03-09,2010,CA 2482346 A,2003-04-14,EP 0303844 W;;US 37616102 P,2002-04-26,SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS,"Compounds of the formula (I); wherein formula (II) represents a substituted group, an oxa-cycloalkyl group or a thia-cycloalkyl group, are glucokinase activators useful in the treatment of type II diabetes.",HOFFMANN LA ROCHE,SARABU RAMAKANTH;;CORBETT WENDY LEA;;WANG KA;;RACHA JAGDISH KUMAR;;MAHANEY PAIGE ERIN;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;GRIMSBY JOSEPH SAMUEL,,https://lens.org/110-444-114-525-629,Granted Patent,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D277/20;;C07D307/16;;A61K31/17;;A61K31/335;;A61K31/341;;A61K31/351;;A61K31/38;;A61K31/425;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07C275/52;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,EXPIRED
321,NZ,A,NZ 535706 A,177-073-379-698-374,2007-08-31,2007,NZ 53570603 A,2003-04-14,US 37616102 P;;EP 0303844 W,2002-04-26,Substituted phenylacetamides and their use as glucokinase activators,"Disclosed are compounds of formula I and processes for preparing them wherein R1 and R2 are independently H, halo, amino, hydroxyamino, cyano, nitro, alkyl, -OR5, -COOR6, perfluoro-alkyl, alkyl-thio, perfluoro-alkylthio, alkyl sulfonyl, perfluoro-alkyl sulfonyl, alkyl sulfinyl, or sulfonamido; R3 is an unbranched alkyl chain of 4-5 carbon atoms or an unbranched heteroalkyl chain of 3-4 carbon atoms plus one oxygen or sulphur atom, wherein the chain, in combination with the carbon atom it is bonded to, forms a five- or six- membered ring, and when the chain contains no heteroatoms, one carbon member o the chain is substituted with one moiety selected from the group consisting of hydroxyl, oxo, hydroxyimino, methoxyimino, halo, methoxy, and acetoxy, or one member of the chain is disubstituted with one hydroxyl and one lower alkyl or is disubstituted with halogen, when the chain contains an O heteroatom, the chain is unsubstituted, and when the chain contains an S heteroatom the chain is unsubstituted or the S heteroatom member of the chain is substituted by an oxo group; R4 is C(O)NHR6, or an unsubstituted or mono-substituted five or six membered heteroaromatic ring connected by a ring carbon atom to the amine group shown, which five, or six membered heteroaromatic ring contains from 1-3 heteroations selected from S, O or N, with one heteroatom being N which is adjacent to the connecting ring C atom and is substituted as defined; N is 0-4; R5 is H, alkyl, or perfluro-alkyl; R6 is alkyl; and R7 is H or alkyl. Compounds of the type disclosed are useful for the treatment or prophylaxis of type II diabetes.",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;RACHA JAGDISH KUMAR;;SARABU RAMAKANTH;;WANG KA,,https://lens.org/177-073-379-698-374,Patent Application,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,A61K31/17;;A61K31/341;;A61K31/351;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,PENDING
322,SI,T1,SI 1501815 T1,190-511-811-040-925,2007-02-28,2007,SI 200330566 T,2003-04-14,US 37616102 P;;EP 0303844 W;;EP 03749855 A,2002-04-26,SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS,,HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;RACHA JAGDISH KUMAR;;SARABU RAMAKANTH;;WANG KA,,https://lens.org/190-511-811-040-925,Granted Patent,no,0,0,1,51,0,,C07D307/00;;A61K31/00;;A61P3/00;;C07C275/00;;C07D213/00;;C07D241/00;;C07D277/00;;C07D309/00;;C07D405/00;;C07D409/00;;C07D417/00,,0,0,,,,EXPIRED
323,CN,A,CN 1649859 A,041-796-973-799-255,2005-08-03,2005,CN 03809383 A,2003-04-14,US 37616102 P,2002-04-26,Substituted phenylacetamides and their use as glucokinase activators,,HOFFMANN LA ROCHE,LEA CORBETT WENDY;;SAMUEL GRIMSBY JOSEPH;;NANCY-ELLEN HAYNES;;FRANCIS KESTER ROBERT;;ERIN MAHANEY PAIGE;;KUMAR RACHA JAGDISH;;RAMAKANTH SARABU;;KA WANG,,https://lens.org/041-796-973-799-255,Patent Application,no,0,3,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D277/20;;A61K31/17;;A61K31/341;;A61K31/351;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,EXPIRED
324,US,B2,US 8222416 B2,080-526-956-888-891,2012-07-17,2012,US 94353910 A,2010-11-10,US 94353910 A;;US 28611609 P,2009-12-14,Azaindole glucokinase activators,"Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.",BERTHEL STEVEN JOSEPH;;CHEN LI;;CORBETT WENDY LEA;;FENG LICHUN;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;SO SUNG-SAU;;TILLEY JEFFERSON WRIGHT;;HOFFMANN LA ROCHE,BERTHEL STEVEN JOSEPH;;CHEN LI;;CORBETT WENDY LEA;;FENG LICHUN;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;SO SUNG-SAU;;TILLEY JEFFERSON WRIGHT,,https://lens.org/080-526-956-888-891,Granted Patent,yes,45,0,16,16,0,C07D471/04;;C07D401/06;;C07D403/10;;C07D405/06;;C07C2601/04;;C07C2601/06;;A61P3/00;;A61P43/00;;A61P3/10;;A61K31/437;;C07D471/04;;C07C2601/06;;C07C2601/04;;C07D471/04;;C07D401/06;;C07D405/06;;C07D403/10;;C07C2601/04;;C07C2601/06,C07D471/02;;A61K31/545,546/113;;514/200,1,0,,,"International Search Report for PCT/EP2010/069455 dated Mar. 15, 2011.",INACTIVE
325,US,B2,US 7259166 B2,146-638-848-746-879,2007-08-21,2007,US 40216706 A,2006-04-10,US 40216706 A;;US 42110903 A;;US 37616102 P,2002-04-26,Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators,"2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a polar ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;RACHA JAGDISH KUMAR;;SARABU RAMAKANTH;;WANG KA,,https://lens.org/146-638-848-746-879,Granted Patent,yes,11,4,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D241/20;;A61K31/17;;C07D277/20;;A61K31/341;;A61K31/351;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D277/44;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,514/255.05;;514/336;;514/371;;514/459;;514/460;;514/471;;544/336;;546/282.1;;548/195;;549/419;;549/493;;549/494;;549/495;;549/496,13,7,061-893-046-790-102;;040-526-770-522-399;;098-019-860-572-873;;002-463-604-557-082;;047-763-655-227-523;;013-432-036-690-340;;007-968-011-469-541,6364828;;10.1152/ajpendo.1984.246.1.e1;;7553875;;10.1016/0092-8674(95)90235-x;;10.1096/fasebj.10.10.8751724;;8751724;;pmc1135815;;7619052;;10.1042/bj3090167;;9435328;;10.1056/nejm199801223380404;;10.1107/s0108270189009492;;10.1021/ja01192a063;;18105968,"Colowick, S.P., The Enzymes, vol. 9 (P. Boyer, ed.) Academic Press, New York, NY, p. 1-48 (1973).;;Chipkin, et. al., in Joslin's Diabetes (C.R. Kahn and G.C. Wier, eds.), Lea and Febiger, Philadelphia, PA, p. 97-115 (1994).;;Printz, et. al., Ann. Rev. Nutrition, vol. 13 (R.E. Olson, D.M. Bier, and D.B. McCormick, eds.) Annual Review Inc, Palo Alto, CA pp. 463-496 (1993).;;Meglasson, et al., Amer. J. Physiol., 246, E1-E13 (1984).;;Grupe, et al., Cell 83, 69-78, (1995).;;Ferre, et al., FASEB J., 10, 1213-1218 (1996).;;Liang, et al., Biochem. J. 309, 167-173 (1995).;;Glaser, et al. New England J. Med. 338, 226-230 (1998).;;Rodier, et. al., Acta Crystallogr., C46 (1990) pp. 154-156.;;Robert, J. M. H., et. al., Eur J. Med. Chem. vol. 29, (1994), pp. 841-854.;;Spickett, et. al., Eur. J. Med. Chem.-Chimica Therapeutica, vol. 11(1), (1976), pp. 7-12.;;Bhat, A. R., et. al., J. Inst. Chemists (India), vol. 61, 1989, pp. 134-136.;;Spielman, M.A., et. al., J. Am. Chem. Soc., 70 (1948), pp. 4189-4191.",EXPIRED
326,US,A1,US 2011/0144105 A1,192-871-183-843-939,2011-06-16,2011,US 94353910 A,2010-11-10,US 94353910 A;;US 28611609 P,2009-12-14,AZAINDOLE GLUCOKINASE ACTIVATORS,"Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.",BERTHEL STEVEN JOSEPH;;CHEN LI;;CORBETT WENDY LEA;;FENG LICHUN;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;SO SUNG-SAU;;TILLEY JEFFERSON WRIGHT,BERTHEL STEVEN JOSEPH;;CHEN LI;;CORBETT WENDY LEA;;FENG LICHUN;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;SO SUNG-SAU;;TILLEY JEFFERSON WRIGHT,,https://lens.org/192-871-183-843-939,Patent Application,yes,3,2,16,16,0,C07D471/04;;C07D401/06;;C07D403/10;;C07D405/06;;C07C2601/04;;C07C2601/06;;A61P3/00;;A61P43/00;;A61P3/10;;A61K31/437;;C07D471/04;;C07C2601/06;;C07C2601/04;;C07D471/04;;C07D401/06;;C07D405/06;;C07D403/10;;C07C2601/04;;C07C2601/06,A61K31/437;;A61K31/5377;;A61P3/00;;A61P3/10;;C07D471/04,514/234.5;;514/300;;544/127;;546/113,0,0,,,,INACTIVE
327,EA,B1,EA 011297 B1,010-865-810-713-391,2009-02-27,2009,EA 200401398 A,2003-04-14,US 37616102 P;;EP 0303844 W,2002-04-26,SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS,"Compounds of the formula (I), wherein formula (II) represents a substituted group, an oxa-cycloalkyl group or a thia-cycloalkyl group, are glucokinase activators useful in the treatment of type II diabetes.",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEV PAIGE ERIN;;RACHA JAGDISH KUMAR;;SARABU RAMAKANTH;;WANG KA,,https://lens.org/010-865-810-713-391,Granted Patent,no,2,1,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D277/20;;C07D307/16;;A61K31/17;;A61K31/335;;A61K31/341;;A61K31/351;;A61K31/38;;A61K31/425;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07C275/52;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,EXPIRED
328,AU,A1,AU 2003/232204 A1,028-641-777-524-644,2003-11-11,2003,AU 2003/232204 A,2003-04-14,EP 0303844 W;;US 37616102 P,2002-04-26,SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS,,HOFFMANN LA ROCHE,GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;RACHA JAGDISH KUMAR;;SARABU RAMAKANTH;;WANG KA;;CORBETT WENDY LEA,,https://lens.org/028-641-777-524-644,Patent Application,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D277/20;;A61K31/17;;A61K31/341;;A61K31/351;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,EXPIRED
329,KR,A,KR 20120104357 A,033-530-766-464-454,2012-09-20,2012,KR 20127018375 A,2010-12-13,US 28611609 P,2009-12-14,AZAINDOLE GLUCOKINASE ACTIVATORS,,HOFFMANN LA ROCHE,BERTHEL STEVEN JOSEPH;;CHEN LI;;CORBETT WENDY LEA;;FENG LICHUN;;HAYNES NANCY ELLEN;;KESTER ROBERT FRANCIS;;SO SUNG SAU;;TILLEY JEFFERSON WRIGHT,,https://lens.org/033-530-766-464-454,Patent Application,no,0,0,16,16,0,C07D471/04;;C07D401/06;;C07D403/10;;C07D405/06;;C07C2601/04;;C07C2601/06;;A61P3/00;;A61P43/00;;A61P3/10;;A61K31/437;;C07D471/04;;C07C2601/06;;C07C2601/04;;C07D471/04;;C07D401/06;;C07D405/06;;C07D403/10;;C07C2601/04;;C07C2601/06,A61K31/437;;A61P3/10,,0,0,,,,DISCONTINUED
330,AU,B2,AU 2003/232204 B2,171-480-186-159-294,2006-09-14,2006,AU 2003/232204 A,2003-04-14,EP 0303844 W;;US 37616102 P,2002-04-26,Substituted phenylacetamides and their use as glucokinase activators,,HOFFMANN LA ROCHE,HAYNES NANCY-ELLEN;;GRIMSBY JOSEPH SAMUEL;;SARABU RAMAKANTH;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;CORBETT WENDY LEA;;WANG KA;;RACHA JAGDISH KUMAR,,https://lens.org/171-480-186-159-294,Granted Patent,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D277/20;;C07D307/16;;A61K31/17;;A61K31/341;;A61K31/351;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,EXPIRED
331,CA,A1,CA 2482346 A1,192-569-090-737-769,2003-11-20,2003,CA 2482346 A,2003-04-14,EP 0303844 W;;US 37616102 P,2002-04-26,SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS,"Compounds of the formula (I); wherein formula (II) represents a substituted group, an oxa-cycloalkyl group or a thia-cycloalkyl group, are glucokinase activators useful in the treatment of type II diabetes.",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;WANG KA;;GRIMSBY JOSEPH SAMUEL;;RACHA JAGDISH KUMAR;;SARABU RAMAKANTH;;MAHANEY PAIGE ERIN;;KESTER ROBERT FRANCIS;;HAYNES NANCY-ELLEN,,https://lens.org/192-569-090-737-769,Patent Application,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D277/20;;A61K31/17;;A61K31/341;;A61K31/351;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,EXPIRED
332,EP,B1,EP 1501815 B1,132-094-438-167-603,2006-11-22,2006,EP 03749855 A,2003-04-14,EP 0303844 W;;US 37616102 P,2002-04-26,SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS,,HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;RACHA JAGDISH KUMAR;;SARABU RAMAKANTH;;WANG KA,,https://lens.org/132-094-438-167-603,Granted Patent,yes,2,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D277/20;;C07D307/16;;A61K31/17;;A61K31/335;;A61K31/341;;A61K31/351;;A61K31/38;;A61K31/425;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07C275/52;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,EXPIRED
333,WO,A1,WO 2003/095438 A1,182-674-039-208-353,2003-11-20,2003,EP 0303844 W,2003-04-14,US 37616102 P,2002-04-26,SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS,"Compounds of the formula (I); wherein formula (II) represents a substituted group, an oxa-cycloalkyl group or a thia-cycloalkyl group, are glucokinase activators useful in the treatment of type II diabetes.",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;RACHA JAGDISH KUMAR;;SARABU RAMAKANTH;;WANG KA,,https://lens.org/182-674-039-208-353,Patent Application,yes,2,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,A61K31/17;;A61K31/341;;A61K31/351;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,PATENTED
334,JO,B1,JO 2406 B1,109-795-907-047-486,2007-06-17,2007,JO P20030046 A,2003-04-23,US 16137602 P,2002-04-26,SUBSTITUTED -CUCLOALKYL AND OXYGENATED-CYCLOALKYL GLUCOKINASE ACTIVATORS,"2.3 Di- Substituted N- Heteroaromatic propionamides with said substitution at the 2- position being a substituted phenyl group and at the 3- position being a polar ring, said propionamides being a polar ring, said propionamides being glucokinase activators which increase insulin secreation in the treatment of type II diabetes.",HOFFMANN LA ROCHE,RAMAKANTH SATABU;;NANCY-ELLEN HAYNES;;WENDY LEA CORBETT;;JOSEPH SAMUEL GRIMSBY;;ROBERT FRANCIS KESTER;;PAIGE ERIN MAHANEY;;JAGDISH KUMAR RACHA;;KA WANG,,https://lens.org/109-795-907-047-486,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
335,RS,A,RS 93604 A,118-891-585-462-826,2007-02-05,2007,YU P93604 A,2003-04-14,US 37616102 P;;EP 0303844 W,2002-04-26,SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS,"Compounds of the formula (I); wherein formula (II) represents a substituted group, an oxa-cycloalkyl group or a thia-cycloalkyl group, are glucokinase activators useful in the treatment of type II diabetes.",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;RACHA JAGDISH KUMAR;;SARABU RAMAKANTH;;WANG KA,,https://lens.org/118-891-585-462-826,Patent Application,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07D277/20;;A61K31/17;;C07D307/16;;A61K31/335;;A61K31/341;;A61K31/351;;A61K31/38;;A61K31/425;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07C275/52;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,PENDING
336,CA,A1,CA 2782172 A1,071-231-712-530-004,2011-06-23,2011,CA 2782172 A,2010-12-13,US 28611609 P;;EP 2010069455 W,2009-12-14,AZAINDOLE GLUCOKINASE ACTIVATORS,"Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.",HOFFMANN LA ROCHE,BERTHEL STEVEN JOSEPH;;CHEN LI;;CORBETT WENDY LEA;;FENG LICHUN;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;SO SUNG-SAU;;TILLEY JEFFERSON WRIGHT,,https://lens.org/071-231-712-530-004,Patent Application,no,0,0,16,16,0,C07D471/04;;C07D401/06;;C07D403/10;;C07D405/06;;C07C2601/04;;C07C2601/06;;A61P3/00;;A61P43/00;;A61P3/10;;A61K31/437;;C07D471/04;;C07C2601/06;;C07C2601/04;;C07D471/04;;C07D401/06;;C07D405/06;;C07D403/10;;C07C2601/04;;C07C2601/06,C07D471/04;;A61K31/437,,0,0,,,,DISCONTINUED
337,TN,A1,TN SN04211 A1,072-080-010-606-351,2007-03-12,2007,TN SN04211 A,2004-10-20,EP 0303844 W;;US 37616102 P,2002-04-26,PHENYLACETAMIDES SUBSTITUES ET LEURS UTILISATION EN TANT QU'ACTIVATEURS DE LA GLUCOKINASE,Les composés de formule I; dans laquelle la formule II représente un groupe substitué; un groupe oxa-cycloalkyle ou un groupe thia-cycloalkyle; sont des activateurs de la glucokinase utiles dans le traitement du diabète de type II.,HOFFMANN LA ROCHE,CORBETT WENDY LEA;;GRIMSBY JOSEPH SAMUEL;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;RACHA JAGDISH KUMAR;;SARABU RAMAKANTH;;WANG KA,,https://lens.org/072-080-010-606-351,Patent Application,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,C07C275/50;;A61K31/17;;C07D277/20;;A61K31/341;;A61K31/351;;A61K31/426;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,PENDING
338,US,B1,US 6610846 B1,158-832-499-655-956,2003-08-26,2003,US 67578100 A,2000-09-28,US 67578100 A;;US 52614300 A;;US 12670799 P;;US 16594499 P,1999-03-29,Heteroaromatic glucokinase activators,"
    2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 3-position being a substituted phenyl group and at the 2-position being a methyl cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes. 
",HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH,HOFFMANN-LA ROCHE INC (2000-12-27),https://lens.org/158-832-499-655-956,Granted Patent,yes,7,93,6,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D239/47;;C07D241/20;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;C07D213/75;;C07D237/22;;C07D239/47;;C07D285/135;;C07D263/48;;C07C275/50;;C07C317/44;;C07D233/88;;C07D213/82;;C07D277/46;;C07D277/56;;C07D253/07;;C07D213/80;;C07D261/14;;C07C323/62;;C07D237/20;;C07D239/42;;C07D241/20;;C07D277/58;;C07C2601/02;;C07C2601/10;;C07C2601/08;;C07C2601/14;;C07C2601/04,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D241/20;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/18;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,544/182;;544/211;;544/224;;544/238;;544/329;;544/336,5,2,013-432-036-690-340;;007-968-011-469-541,10.1107/s0108270189009492;;10.1021/ja01192a063;;18105968,"Rodier et al., Acta Crystallogr., C46, p. 154-156 (1990).;;Robert et al., Eur. J. Med. Chem., vol. 29, pp. 841-854 (1994).;;Spickett et al., Eur. J. Med. Chem.-Chimica Therapeutica, vol. 11(1), pp. 7-12 (1976).;;Bhat et al., Inst. Chemists (India), vol. 61, pp. 134-136 (1989).;;Spielman, M.A., et al., J. Am. Chem. Soc., 70, pp. 4189-4191 (1948).",EXPIRED
339,US,B2,US 7223868 B2,171-466-234-274-326,2007-05-29,2007,US 9871705 A,2005-04-04,US 9871705 A;;US 61635903 A;;US 67578100 A;;US 52614300 A;;US 12670799 P;;US 16594499 P,1999-03-29,Heteroaromatic glucokinase activators,"2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 3-position being a substituted phenyl group and at the 2-position being a methyl cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.",HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH,,https://lens.org/171-466-234-274-326,Granted Patent,yes,14,0,6,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D239/47;;C07D241/20;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;C07D213/75;;C07D237/22;;C07D239/47;;C07D285/135;;C07D263/48;;C07C275/50;;C07C317/44;;C07D233/88;;C07D213/82;;C07D277/46;;C07D277/56;;C07D253/07;;C07D213/80;;C07D261/14;;C07C323/62;;C07D237/20;;C07D239/42;;C07D241/20;;C07D277/58;;C07C2601/02;;C07C2601/10;;C07C2601/08;;C07C2601/14;;C07C2601/04,C07D213/75;;C07C275/50;;C07C317/44;;C07C323/62;;C07D213/80;;C07D213/82;;C07D213/84;;C07D233/88;;C07D237/22;;C07D239/42;;C07D241/20;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/18;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,546/289;;546/297;;546/309;;546/310,1,0,,,"Mann et al., STN International (2005), HCAPLUS Database, Columbus, OH, Accession No. 80:82694, Registry No. 51505-04-5.",EXPIRED
340,US,A1,US 2004/0014968 A1,072-124-477-396-839,2004-01-22,2004,US 61635903 A,2003-07-09,US 61635903 A;;US 67578100 A;;US 52614300 A;;US 12670799 P;;US 16594499 P,1999-03-29,Heteroaromatic glucokinase activators,"
   2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 3-position being a substituted phenyl group and at the 2-position being a methyl cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes. 
",BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH,,https://lens.org/072-124-477-396-839,Patent Application,yes,9,100,6,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D239/47;;C07D241/20;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;C07D213/75;;C07D237/22;;C07D239/47;;C07D285/135;;C07D263/48;;C07C275/50;;C07C317/44;;C07D233/88;;C07D213/82;;C07D277/46;;C07D277/56;;C07D253/07;;C07D213/80;;C07D261/14;;C07C323/62;;C07D237/20;;C07D239/42;;C07D241/20;;C07D277/58;;C07C2601/02;;C07C2601/10;;C07C2601/08;;C07C2601/14;;C07C2601/04,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D241/20;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/18;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,544/59;;544/162;;544/382;;546/308;;548/192;;548/233;;548/326.5;;548/557,0,0,,,,EXPIRED
341,AU,A,AU 1998/071420 A,032-019-398-674-532,1998-12-30,1998,AU 1998/071420 A,1998-04-22,US 86600597 A;;US 9807993 W,1997-05-30,Method and apparatus for drop weight impact testing,,PHILLIPS PETROLEUM CO,BURWELL FRED JOE;;JONES RONALD DE WAYNE;;CROSS JOSEPH B;;MILLARD ARTHUR WAYNE;;SPRAGUE DENNIS CORBETT;;PINNICK HERBERT ROBERT JR;;DORSEY GEORGE LEONARD,,https://lens.org/032-019-398-674-532,Patent Application,no,0,0,3,3,0,G01N3/303;;G01N3/303,G01N3/30,,0,0,,,,DISCONTINUED
342,ZA,B,ZA 200407986 B,140-636-021-559-488,2005-10-18,2005,ZA 200407986 A,2004-10-04,US 37616102 P,2002-04-26,Substituted phenylacetamides and their use as glucokinase activators.,,HOFFMANN LA ROCHE,CORBETT WENDY LEA;;HAYNES NANCY-ELLEN;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH;;GRIMSBY JOSEPH SAMUEL;;KESTER ROBERT FRANCIS;;FRANCIS RACHA;;JAGDISH KUMAR;;WANG KA,,https://lens.org/140-636-021-559-488,Granted Patent,no,0,0,50,51,0,C07C275/50;;C07D213/75;;C07D241/20;;C07D277/46;;C07D307/16;;C07D309/04;;C07D405/12;;C07D409/12;;C07D417/12;;C07C2601/08;;A61P3/10;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D213/75;;C07D417/12;;C07D309/04;;C07D307/16;;C07D405/12;;C07D409/12;;C07C275/50;;C07D241/20;;C07D277/46;;C07C2601/08,A61K31/17;;A61K31/341;;A61K31/351;;A61K31/426;;C07D277/20;;A61K31/427;;A61K31/44;;A61K31/4433;;A61K31/4965;;A61K31/497;;A61P3/10;;C07C273/18;;C07C275/50;;C07D213/75;;C07D241/20;;C07D277/44;;C07D277/46;;C07D307/16;;C07D309/04;;C07D309/06;;C07D405/12;;C07D409/12;;C07D417/12,,0,0,,,,ACTIVE
343,US,B2,US 6951945 B2,151-146-059-806-103,2005-10-04,2005,US 61635903 A,2003-07-09,US 61635903 A;;US 67578100 A;;US 52614300 A;;US 12670799 P;;US 16594499 P,1999-03-29,Heteroaromatic glucokinase activators,"2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 3-position being a substituted phenyl group and at the 2-position being a methyl cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.",HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH,,https://lens.org/151-146-059-806-103,Granted Patent,yes,8,3,6,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D239/47;;C07D241/20;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;C07D213/75;;C07D237/22;;C07D239/47;;C07D285/135;;C07D263/48;;C07C275/50;;C07C317/44;;C07D233/88;;C07D213/82;;C07D277/46;;C07D277/56;;C07D253/07;;C07D213/80;;C07D261/14;;C07C323/62;;C07D237/20;;C07D239/42;;C07D241/20;;C07D277/58;;C07C2601/02;;C07C2601/10;;C07C2601/08;;C07C2601/14;;C07C2601/04,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D241/20;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/18;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,548/127;;548/128;;548/134;;548/139;;548/195;;548/214,5,2,013-432-036-690-340;;007-968-011-469-541,10.1107/s0108270189009492;;10.1021/ja01192a063;;18105968,"Rodier et al., Acta Crystallogr., C46, p. 154-156 (1990).;;Robert et al., Eur. J. Med. Chem., vol. 29, pp. 841-854 (1994).;;Spickett et al., Eur. J. Med. Chem.-Chimica Therapeutica, vol. 11(1), pp. 7-12 (1976).;;Bhat et al., Inst. Chemists (India), vol. 61, pp. 134-136 (1989).;;Spielman, M.A., et. al. J. Am. Chem. Soc., 70, pp. 4189-4191 (1948).",EXPIRED
344,WO,A1,WO 1998/054558 A1,114-144-128-087-069,1998-12-03,1998,US 9807993 W,1998-04-22,US 86600597 A,1997-05-30,METHOD AND APPARATUS FOR DROP WEIGHT IMPACT TESTING,"A test fixture (10) of the type that requires repeated manual lifting of weights in a drop-tube (16) for performing an ASTM drop weight test, is provided with a computer (100) automated pneumatically powered lift mechanism. The lift mechanism (32) for the weights responds to a series of computer generated signals that are applied to a set of electropneumatic actuators for driving pistons to lift and drop the weight. Associated with the lift mechanism is a set opto-interrupter devices (101) that generate a position signal representative of the position of the weight to be dropped as it ascends in the drop tube. In use the computer is provided with a desired drop height and essentially continuously compares the position signal with the desired drop height and releases the weight in the drop tube to impact a sample material (22) when the position signal equals the desired drop height.",PHILLIPS PETROLEUM CO,BURWELL FRED JOE;;JONES RONALD DE WAYNE;;CROSS JOSEPH B;;MILLARD ARTHUR WAYNE;;SPRAGUE DENNIS CORBETT;;PINNICK HERBERT ROBERT JR;;DORSEY GEORGE LEONARD,,https://lens.org/114-144-128-087-069,Patent Application,yes,4,2,3,3,0,G01N3/303;;G01N3/303,G01N3/30,,0,0,,,,PENDING
345,US,A1,US 2007/0203207 A1,169-269-019-775-860,2007-08-30,2007,US 78910507 A,2007-04-23,US 78910507 A;;US 9871705 A;;US 61635903 A;;US 67578100 A;;US 52614300 A;;US 12670799 P;;US 16594499 P,1999-03-29,Heteroaromatic glucokinase activators,"2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 3-position being a substituted phenyl group and at the 2-position being a methyl cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.",BIZZARRO FRED T;;CORBETT WENDY L;;GRIPPO JOSEPH F;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE W;;KESTER ROBERT F;;MAHANEY PAIGE E;;SARABU RAMAKANTH,BIZZARRO FRED T;;CORBETT WENDY L;;GRIPPO JOSEPH F;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE W;;KESTER ROBERT F;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/169-269-019-775-860,Patent Application,yes,8,0,6,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D239/47;;C07D241/20;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;C07D213/75;;C07D237/22;;C07D239/47;;C07D285/135;;C07D263/48;;C07C275/50;;C07C317/44;;C07D233/88;;C07D213/82;;C07D277/46;;C07D277/56;;C07D253/07;;C07D213/80;;C07D261/14;;C07C323/62;;C07D237/20;;C07D239/42;;C07D241/20;;C07D277/58;;C07C2601/02;;C07C2601/10;;C07C2601/08;;C07C2601/14;;C07C2601/04,A61K31/425;;C07C211/00;;C07C211/01;;C07C275/50;;C07C311/00;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D241/20;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/00;;C07D277/18;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,514/365;;548/199;;562/837;;564/1;;564/366,0,0,,,,DISCONTINUED
346,US,A1,US 2005/0261503 A1,035-469-322-801-782,2005-11-24,2005,US 9871705 A,2005-04-04,US 9871705 A;;US 61635903 A;;US 67578100 A;;US 52614300 A;;US 12670799 P;;US 16594499 P,1999-03-29,Heteroaromatic glucokinase activators,"2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 3-position being a substituted phenyl group and at the 2-position being a methyl cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.",BIZZARO FRED T;;CORBETT WENDY L;;GRIPPO JOSEPH F;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE W;;KESTER ROBERT F;;MAHANEY PAIGE E;;SARABU RAMAKANTH,BIZZARO FRED T;;CORBETT WENDY L;;GRIPPO JOSEPH F;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE W;;KESTER ROBERT F;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/035-469-322-801-782,Patent Application,yes,8,0,6,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D239/47;;C07D241/20;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;C07D213/75;;C07D237/22;;C07D239/47;;C07D285/135;;C07D263/48;;C07C275/50;;C07C317/44;;C07D233/88;;C07D213/82;;C07D277/46;;C07D277/56;;C07D253/07;;C07D213/80;;C07D261/14;;C07C323/62;;C07D237/20;;C07D239/42;;C07D241/20;;C07D277/58;;C07C2601/02;;C07C2601/10;;C07C2601/08;;C07C2601/14;;C07C2601/04,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D241/20;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/18;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,548/192,0,0,,,,EXPIRED
347,AT,T1,AT E106882 T1,074-389-206-976-395,1994-06-15,1994,AT 92201587 T,1992-06-03,US 71317391 A;;US 83515992 A,1991-06-10,THIOXANTHENON-ANTITUMORMITTEL.,"1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones having the formula <CHEM> wherein n is 2 or 3; R<1> and R<2> are independently lower-alkyl; Q is a residue chosen from the group consisting of CH2NHR<3>, CH2N(R<4>)SO2R<7>, CH2NHCHO, CH=N-Ar, C(O)NR<5>R<6>, CH2N(R<4>)C(O)R<7>, CH2N(C2H5)CHO, and CH2N(R<4>)P(O)(O-lower-alkyl)2; R<3> is hydrogen or lower-alkyl; R<4> is hydrogen or lower-alkyl; R<5> is hydrogen, lower-alkyl or Ar; R<6> is hydrogen or lower-alkyl; R<7> is lower-alkyl, or Ar; R<8> is hydrogen, lower-alkyl, lower-alkoxy, or halogen; and Ar is phenyl or phenyl substituted with methyl, methoxyl, halogen or nitro; or a pharmaceutically acceptable acid-addition salt or solvate thereof, are disclosed as antitumor agents. Compositions containing the thioxanthenones and the method of use of thioxanthenones for treating tumors and cancer in mammals are also disclosed.",STERLING WINTHROP INC,MILLER THEODORE CHARLES;;COLLINS JOSEPH CHARLES;;WENTLAND MARK PHILIP;;PERNI ROBERT BRUNO;;CORBETT THOMAS HUGHES;;MATTES KENNETH CHARLES C O EAS;;DEPARTMENT STATE STREET,,https://lens.org/074-389-206-976-395,Granted Patent,no,0,0,34,34,0,C07D335/16;;C07F9/655372;;A61P35/00;;C07D335/16,A61K31/38;;A61K31/382;;A61K31/39;;A61K31/67;;A61P35/00;;C07D335/16;;C07F9/6553,,0,0,,,,DISCONTINUED
348,JO,B1,JO 2475 B1,065-272-456-067-201,2009-01-20,2009,JO P20000301 A,2000-03-27,US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,Glucokinase Activators,"The present invention relates to compounds of the formula I: Wherein R1, R2, R3 and R4 are as defined in claim 1 and pharmaceutically acceptable salts thereof. The compounds are glucokinase activators which increase insulin secretion in the treatment of type II diabetes.",HOFFMANN LA ROCHE,ANTONINO FOCELLA;;FRED THOMAS BIZZARRO;;GEORGE WILLIAM HOLLAND;;JOSEPH FRANCIS GRIPPO;;NANCY-ELLEN HAYNES;;PAIGE E MAHANEY;;RAMAKANTH SATABU;;WENDY LEA CORBETT;;ROBERT FRANCIS KESTER,,https://lens.org/065-272-456-067-201,Granted Patent,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
349,NO,B1,NO 320697 B1,010-513-144-480-119,2006-01-16,2006,NO 20014671 A,2001-09-26,EP 0002450 W;;US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,"Glucokinase-aktivatorer, fremstilling av disse, og anvendelse til fremstilling av medikamenter samt anvendelse av disse til forebygging og behandling av diabetes.","Foreliggende oppfinnelse angår forbindelser med formel (I) hvori, R, Rog R 4 er som definert i krav I og farmasøytisk akseptable salter derav. Forbindelsene er glucokinase-aktivatorer som øker insulin-sekresjon ved behandling av type II diabetes.",HOFFMANN LA ROCHE,HOLLAND GEORGE WILLIAM;;BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONIO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH,,https://lens.org/010-513-144-480-119,Granted Patent,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,C07D277/46;;A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
350,RS,B,RS 50045 B,087-356-249-423-716,2008-11-28,2008,YU P69501 A,2000-03-20,US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,AKTIVATORI GLUKOKINAZE,"Jedinjenje koje obuhvata amid formule I:u kojoj znak * označava asimetričan atom R1 i R2ugljenika, nezavisno jedan od drugog označavaju vodonik, halogen, amino, hidroksiamino, nitro, cijan, sulfonamido, niži alkil, -OR5 , -C(O)OR5, perfluorniži alkil, niži alkil-tio, perfluor-niži alkil-tio, niži alkil-sulfonil, perfluor-niži alkil-sulfonil ili niži alkil-sulfinil, R3 označava cikloalkil koji ima 3-7 atoma ugljenika, R4 označava -C (O) NHR40 ili nesupstituisan ili monosupstituisan petočlani ili šestočlani heteroaromatični prsten koji je pomoću atoma ugljenika iz prstena vezan za prikazanu aminsku grupu, pri čemu ovaj petočlani ili šestočlani heteroaromatični prsten sadrži 1-3 heteroatoma odabrana od sumpora, kiseonika ili azota, pri čemu je jedan heteroatom ustvari azot koji je susedan vezivnom atomu ugljenika iz prstena, pri čemu je pomenuti mono-supstituisani heteroaromatični prsten monosupstituisan u položaju na atomu ugljenika iz prstena različitom od susednog položaja u odnosu na pomenuti vezivni atom ugljenika iz prstena sa supstituentom odabranim iz grupe koja se sastoji od nižeg alkila, halogena, nitro-grupe, cijan-grupe, - (CH2) n-OR6, - (CH2) n-C (O) OR7, - (CH2) n-C (O) NHR6, -C(O)-C(O)ORB, -(CH2)n-NHR6, R40 označava vodonik, niži alkil, niži alkenil, hidroksi-niži alkil, halogen-niži alkil, - (CH2) n-C (O) OR5 ili -C (O) - (CH2) n-C (O) OR6, R5 označava vodonik, niži alkil ili perfluor-niži alkil, R6, R7 i R8 nezavisno jedan od drugog>označavaju vodonik ili niži alkil i n je 0, 1, 2, 3 ili 4; ""niži alkil"" i ""niži alkoksi"" označavaju grupe sa 1 do 7 atoma ugljenika, a ""niži alkenil"" označava grupe sa 2 do 6 atoma ugljenika, ili njegovu farmaceutski prihvatljivu so. Prijava sadrži još 19 zahteva.",HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/087-356-249-423-716,Granted Patent,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4164;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/00;;A61P3/10;;A61P43/00;;C07C275/00;;C07C275/50;;C07C317/00;;C07C317/44;;C07C323/00;;C07C323/60;;C07C323/62;;C07D/;;C07D213/00;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/00;;C07D233/88;;C07D237/00;;C07D237/20;;C07D237/22;;C07D239/00;;C07D239/42;;C07D241/28;;C07D253/00;;C07D253/07;;C07D261/00;;C07D261/14;;C07D263/00;;C07D263/34;;C07D263/48;;C07D277/00;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/00;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
351,GC,A,GC 0000333 A,147-375-616-976-493,2007-03-31,2007,GC P2000590 A,2000-03-29,US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,Glucokinase activators,,HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/147-375-616-976-493,Granted Patent,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/00;;A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
352,HU,A2,HU P0200396 A2,149-438-744-808-636,2002-07-29,2002,HU P0200396 A,2000-03-20,US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,"GLUCKOKINASE ACTIVATORS, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE",,HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONIO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/149-438-744-808-636,Patent Application,no,0,12,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,DISCONTINUED
353,TR,T2,TR 200102805 T2,182-453-216-857-145,2002-04-22,2002,TR 200102805 T,2000-03-20,US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,Glikokinaz aktivatörleri,"Mevcut bulus, formül (I)'in R1,R2,R3, ve R4'ün istem 1 'de tanimlandigi gibi oldugu bilesikleri ve bunlarin farmasötik açidan kabul edilebilir tuzlari ile ilgilidir. Bilesikler, tip II diyabetin tedavisinde ensülin salgisini arttiran glikokinaz aktivatörleridir.",HOFFMANN LA ROCHE,BIZZARRO THOMAS FRED;;CORBETT LEA WENDY;;FOCELLA ANTONINO;;GRIPPO FRANCIS JOSEPH;;HAYNES NANCY-ELLEN;;HOLLAND WILLIAM GEORGE;;KESTER FRANCIS ROBERT;;MAHANEY E PAIGE;;SARABU RAMAKANTH,,https://lens.org/182-453-216-857-145,Patent Application,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,PENDING
354,BR,B1,BR 0009486 B1,179-768-923-362-561,2011-03-09,2011,BR 0009486 A,2000-03-20,EP 0002450 W;;US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,"composto que compreende uma amida, composição farmacêutica que compreende esse composto, seu uso e processo para a preparação do mesmo.",,,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/179-768-923-362-561,Granted Patent,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,C07D277/46;;A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D213/85;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/20;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
355,HR,A2,HR P20010688 A2,103-985-103-090-939,2003-06-30,2003,HR P20010688 A,2001-09-19,EP 0002450 W;;US 12670799 P;;US 16594499 P;;US 16594899 P,1999-03-29,GLUCOKINASE ACTIVATORS,,HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/103-985-103-090-939,Patent Application,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
356,NO,D0,NO 20014671 D0,093-988-366-098-169,2001-09-26,2001,NO 20014671 A,2001-09-26,EP 0002450 W;;US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,Glucokinase-aktivatorer,,HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONIO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/093-988-366-098-169,Patent Application,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
357,CZ,A3,CZ 20013490 A3,166-135-074-092-664,2002-04-17,2002,CZ 20013490 A,2000-03-20,US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,Glucokinase activators,,HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/166-135-074-092-664,Patent Application,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
358,DE,D1,DE 60014610 D1,032-876-912-098-643,2004-11-11,2004,DE 60014610 T,2000-03-20,US 12670799 P;;US 16594899 P;;US 16594499 P;;EP 0002450 W,1999-03-29,GLUKOKINASE AKTIVATOREN,,HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/032-876-912-098-643,Granted Patent,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
359,EP,B1,EP 1169312 B1,090-070-824-129-762,2004-10-06,2004,EP 00918816 A,2000-03-20,EP 0002450 W;;US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,GLUCOKINASE ACTIVATORS,,HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/090-070-824-129-762,Granted Patent,yes,2,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,1,0,,,"SPIELMAN M. A. ET AL.: ""Anticonvulsant Drugs. II. Some Acylureas"" JOURNAL OF AMERICAN CHEMICAL SOCIETY, vol. 70, 1948, pages 4189-4191, XP000940775",EXPIRED
360,SI,T1,SI 1169312 T1,094-263-048-209-247,2005-02-28,2005,SI 200030538 T,2000-03-20,EP 0002450 W;;EP 00918816 A;;US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,GLUCOKINASE ACTIVATORS,,HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/094-263-048-209-247,Granted Patent,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
361,AU,B2,AU 767830 B2,182-051-169-557-163,2003-11-27,2003,AU 2000/039630 A,2000-03-20,EP 0002450 W;;US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,Glucokinase activators,,HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/182-051-169-557-163,Granted Patent,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
362,AT,T1,AT E278680 T1,157-102-413-871-64X,2004-10-15,2004,AT 00918816 T,2000-03-20,EP 0002450 W;;US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,GLUKOKINASE AKTIVATOREN,,HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/157-102-413-871-64X,Granted Patent,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,PENDING
363,US,B1,US 6528543 B1,102-699-193-125-117,2003-03-04,2003,US 53250600 A,2000-03-21,US 53250600 A;;US 16594899 P;;US 12670799 P,1999-03-29,Urea derivatives,"
    Glucokinase activating compounds of the formula 

    wherein R ^{ 1 } and R ^{ 2 } are independently hydrogen, halo, amino, nitro, cyano, sulfonamido, lower alkyl, perfluoro-lower alkyl, lower alkyl thio, perfluoro-lower alkyl thio, lower alkyl sulfonyl, or perfluoro-lower alkyl sulfonyl; R ^{ 3 } is cycloalkyl having from 3 to 7 carbon atoms or lower alkyl having from 2 to 4 carbon atoms; R ^{ 4 } is hydrogen, lower alkyl, lower alkenyl, hydroxy lower alkyl, halo lower alkyl, 

    R ^{ 5 } and R ^{ 6 } are hydrogen or lower alkyl; and n is 0, 1, 2, 3 or 4; or a pharmaceutically acceptable salt thereof 
",HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONIO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH,HOFFMANN-LA ROCHE INC (2000-02-24),https://lens.org/102-699-193-125-117,Granted Patent,yes,5,86,2,62,0,A61P3/10;;C07C275/50;;C07C275/50;;C07C317/44;;C07C317/44;;C07C323/62;;C07C323/62;;C07C2601/02;;C07C2601/02;;C07C2601/04;;C07C2601/04;;C07C2601/08;;C07C2601/08;;C07C2601/10;;C07C2601/10;;C07C2601/14;;C07C2601/14;;C07D213/75;;C07D213/75;;C07D213/80;;C07D213/80;;C07D213/82;;C07D213/82;;C07D233/88;;C07D233/88;;C07D237/22;;C07D237/22;;C07D239/42;;C07D239/42;;C07D253/07;;C07D253/07;;C07D261/14;;C07D261/14;;C07D263/48;;C07D263/48;;C07D277/46;;C07D277/46;;C07D277/56;;C07D277/56;;C07D277/58;;C07D277/58;;C07D285/135;;C07D285/135,C07D277/46;;A61K31/426;;A61P3/10;;C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,514/594;;514/522;;514/530;;514/542;;514/595;;558/413;;558/417;;560/9;;560/13;;564/47;;564/56,10,4,007-968-011-469-541;;061-048-461-766-064;;004-179-238-162-885;;118-365-266-853-766,10.1021/ja01192a063;;18105968;;6797442;;10.1016/0304-4165(84)90141-7;;6435683;;10.1016/s0040-4039(97)01403-2,"Speilman et al., Journal of American Chemical Society, vol. 70, pps. 4189-4191 (1948).;;Ribalta et al., Arzneim.-Forsch, 31(10A), p. 1782-1786 (1981).;;Spickett et al., Eur. J. Med. Chem.-Chim. Ther., 11(1), p. 7-12 (1976).;;Ruettinger et al., Biochimica et Biophysica Acta, 801, p. 372-380 (1984).;;M. Rautio, Farm. Aikak, 84(4), p. 143-153 (1975).;;Jimenez et al., J. Indian Chem. Soc., 65, p. 725-728 (1988).;;Selvi et al., Tetrahedron Lett., 38, p. 6263-6266 (1997).;;Kitagawa et al., Kuromatogurafi, 15, p. 17-20 (1994).;;Chemical Abstract for B2 (1981) 95:1329162.;;Abstract for B1 (1978) WPI (Derwent) Acc. No. 1980-09606C/198006.",EXPIRED
364,MY,A,MY 136926 A,145-068-130-157-460,2008-11-28,2008,MY PI20001212 A,2000-03-27,US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,GLUCOKINASE ACTIVATORS,"THE PRESENT INVENTION RELATES TO COMPOUNDS OF THE FORMULA I;@@@@@(I)@@WHEREIN R1, R2, R3 AND R4 ARE AS DEFINED IN CLAIM 1 AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF. THE COMPOUNDS ARE GLUCOKINASE ACTIVATORS WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES.",HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/145-068-130-157-460,Granted Patent,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,C07D277/56;;A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
365,HK,A1,HK 1046139 A1,101-241-792-839-348,2002-12-27,2002,HK 02107692 A,2002-10-23,EP 0002450 W;;US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,Glucokinase activators.,,HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/101-241-792-839-348,Patent Application,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
366,CO,A1,CO 5170534 A1,133-451-631-445-993,2002-06-27,2002,CO 00022164 A,2000-03-28,US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,DERIVADOS DE FENIL PROPIONAMIDA COMO ACTIVADORES DE LA GLUCOQUINASA,"Un compuesto que comprende una amida de la fórmula: <EMI FILE=""00022164_1"" ID=""1"" IMF=JPEG >en donde el * indica un átomo de carbono asimétrico; R1 y R2 son independientemente hidrógeno, halo, amino, hidroxiamino, nitro, ciano, sulfonamido, alquilo C1-C7, -OR5, -C(O)OR5, perfluoro-alquilo C1-C7, alquilo C1-C7, tio, perfluoro-alquilo C1-C7, tio, alquilo C1-C7 sulfonilo, perfluoro-alquilo C1-C7, sulfonilo o alquilo C1-C7, sulfinilo; R3 es cicloalquilo que presenta de 3 a 7 átomos de carbono o alquilo C1-C7 que presenta de 2 a 4 átomos de carbono;R4 es -C(O)NHR40; o un anillo heteroaromático de cinco o seis miembros no sustituidos o monosustituídos unido por un átomo de carbono del anillo al grupo amina mostrado, el anillo heteroaromático de cinco o seis miembros contiene de 1 a 3 heteroátomos de azufre, oxígeno o nitrógeno, con un heteroátomo que es nitrógeno el cual se encuentra junto al átomo de carbono que conecta el anillo; dicho anillo heteroaromático monosustituído se encuentra monosustituido en la posición de átomo de carbono del anillo diferente que no sea adyacente a dicho átomo de carbono de conexión con un sustituyente seleccionado del grupo que consiste de alquilo C1-C7, halo, nitro, ciano, -(CH2)nOR6, -(CH2)n-C(O)OR7, -(CH2)n-C(O)NHR6, -C(O)-C(O)OR8, -(CH2)n- NHR6;R40 es hidrógeno, alquilo C1-C7, alquenilo C2-C6, hidroxi alquilo C1-C7, halo alquilo C1-C7, -(CH2)n-C(O)OR5 ó -C(O)-(CH2)n-C(O)OR6;R5 es hidrógeno, alquilo C1-C7 o perfluoro-alquilo C1-C7;R6, R7 y R8 son independientemente hidrógeno o alquilo C1-C7; y n es 0, 1, 2, 3 ó 4;o una sal derivada farmacéuticamente aceptable.",HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE ERIN;;SARABU RAMAKANTH,,https://lens.org/133-451-631-445-993,Patent Application,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/16;;A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
367,NZ,A,NZ 514038 A,173-824-306-299-064,2004-01-30,2004,NZ 51403800 A,2000-03-20,EP 0002450 W;;US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,Glucokinase activators,"Described are compounds of formula (I), wherein; R1 and R2 are H, halo, amino, hydroxyamino, nitro, cyano, sulfamido, alkyl, -OR5-, OC(O)OR5-, perfluoro-lower alkyl, lower alkylthio, perfluoro-lower alkylthio, lower alkyl sulfonyl, perfluoro-lower alkyl sulfonyl or lower alkyl sulfinyl; R3 is cycloalkyl and R4 is -C(O)NHR40 or an unsubstituted or monosubstituted five or six membered heteroaromatic ring. Alsod escribed is their use in pharmaceuticals for the treatment and prophylaxis of type II diabetes and a process for their preparation.",HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/173-824-306-299-064,Patent Application,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,DISCONTINUED
368,DK,T3,DK 1169312 T3,194-557-443-631-797,2005-01-31,2005,DK 00918816 T,2000-03-20,EP 00918816 A;;EP 0002450 W;;US 12670799 P;;US 16594499 P;;US 16594899 P,1999-03-29,Glucokinaseaktivatorer,,HOFFMANN LA ROCHE,CORBETT WENDY LEA;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;SARABU RAMAKANTH;;BIZZARRO FRED THOMAS;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HOLLAND GEORGE WILLIAM;;MAHANEY PAIGE E,,https://lens.org/194-557-443-631-797,Granted Patent,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
369,PT,E,PT 1169312 E,153-008-010-865-935,2005-01-31,2005,PT 00918816 T,2000-03-20,US 12670799 P;;US 16594499 P;;US 16594899 P,1999-03-29,ACTIVADORES DE GLICOCINASE,,HOFFMANN LA ROCHE,CORBETT WENDY LEA;;THOMAS BIZZARRO FRED;;ANTONINO FOCELLA;;FRANCIS GRIPPO JOSEPH;;NANCY-ELLEN HAYNES;;WILLIAM HOLLAND GEORGE;;FRANCIS KESTER ROBERT;;MAHANEY PAIGE E;;RAMAKANTH SARABU,,https://lens.org/153-008-010-865-935,Granted Patent,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
370,HK,B,HK 1046139 B,155-884-644-806-024,2004-12-10,2004,HK 02107692 A,2002-10-23,EP 0002450 W;;US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,GLUCOKINASE ACTIVATORS,,HOFFMANN LA ROCHE,FRED THOMAS BIZZARRO;;WENDY LEA CORBETT;;ANTONINO FOCELLA;;JOSEPH FRANCIS GRIPPO;;NANCY-ELLEN HAYNES;;GEORGE WILLIAM HOLLAND;;ROBERT FRANCIS KESTER;;PAIGE E MAHANEY;;RAMAKANTH SARABU,,https://lens.org/155-884-644-806-024,Granted Patent,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,C07D/;;A61K/;;A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P/;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
371,CA,A1,CA 2368347 A1,168-441-698-368-188,2000-10-05,2000,CA 2368347 A,2000-03-20,EP 0002450 W;;US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,GLUCOKINASE ACTIVATORS,"The present invention relates to compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in claim 1 and pharmaceutically acceptable salts thereof. The compounds are glucokinase activators which increase insulin secretion in the treatment of type II diabetes.",HOFFMANN LA ROCHE,FOCELLA ANTONINO;;MAHANEY PAIGE E;;KESTER ROBERT FRANCIS;;CORBETT WENDY LEA;;BIZZARRO FRED THOMAS;;HAYNES NANCY-ELLEN;;SARABU RAMAKANTH;;HOLLAND GEORGE WILLIAM;;GRIPPO JOSEPH FRANCIS,,https://lens.org/168-441-698-368-188,Patent Application,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
372,CA,C,CA 2368347 C,182-107-190-530-379,2007-05-22,2007,CA 2368347 A,2000-03-20,EP 0002450 W;;US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,GLUCOKINASE ACTIVATORS,"The present invention relates to compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in claim 1 and pharmaceutically acceptable salts thereof. The compounds are glucokinase activators which increase insulin secretion in the treatment of type II diabetes.",HOFFMANN LA ROCHE,HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;HAYNES NANCY-ELLEN;;FOCELLA ANTONINO;;BIZZARRO FRED THOMAS;;GRIPPO JOSEPH FRANCIS;;SARABU RAMAKANTH;;CORBETT WENDY LEA;;MAHANEY PAIGE E,,https://lens.org/182-107-190-530-379,Granted Patent,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,C07D277/46;;A61K31/17;;A61K31/4164;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/4965;;A61K31/50;;A61K31/501;;A61K31/505;;A61K31/53;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D213/85;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/20;;C07D241/28;;C07D253/06;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
373,NO,L,NO 20014671 L,007-055-608-558-217,2001-09-26,2001,NO 20014671 A,2001-09-26,EP 0002450 W;;US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,Glucokinase-aktivatorer,,HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONIO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/007-055-608-558-217,Abstract,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
374,WO,A3,WO 2000/058293 A3,081-640-275-837-576,2001-01-25,2001,EP 0002450 W,2000-03-20,US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,GLUCOKINASE ACTIVATORS,"The present invention relates to compounds of formula (I) wherein R?1, R2, R3 and R4¿ are as defined in claim 1 and pharmaceutically acceptable salts thereof. The compounds are glucokinase activators which increase insulin secretion in the treatment of type II diabetes.",HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/081-640-275-837-576,Search Report,yes,2,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,1,1,007-968-011-469-541,10.1021/ja01192a063;;18105968,"SPIELMAN M. A. ET AL.: ""Anticonvulsant Drugs. II. Some Acylureas"", JOURNAL OF AMERICAN CHEMICAL SOCIETY, vol. 70, 1948, pages 4189 - 4191, XP000940775",PATENTED
375,MA,A1,MA 26780 A1,150-980-042-281-951,2004-12-20,2004,MA 26343 A,2001-09-28,US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,ACTIVATEURS DE LA GLUCOKINASE.,,HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/150-980-042-281-951,Granted Patent,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
376,BR,A,BR 0009486 A,029-332-615-930-962,2002-01-02,2002,BR 0009486 A,2000-03-20,EP 0002450 W;;US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,"Compostos que contêm uma amida, utilização desses compostos, composição farmacêutica, processo para o tratamento profilático ou terapêutico de, diabetes do tipo ii e processo para a preparação dos compostos","""<UM>COMPOSTOS QUE CONTêM UMA AMIDA, UTILIZAçãO DESSES COMPOSTOS, COMPOSIçãO FARMACêUTICA, PROCESSO PARA O TRATAMENTO PROFILáTICO OU TERAPêUTICO DE DIABETES DO TIPO II 5 E PROCESSO PARA A PREPARAçãO DOS COMPOSTOS<MV>"". A presente invenção refere-se a compostos da fórmula (I), em que R^ 1^, R^ 2^, R^ 3^ e R^ 4^ são conforme definidos na reivindicação 1, e aos seus sais farmacologicamente aceitáveis. Os compostos são estimuladores de glicoquinase que aumenta a secreção de insulina no tratamento de diabetes do tipo II.",HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/029-332-615-930-962,Patent Application,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
377,EP,A2,EP 1169312 A2,099-451-383-804-166,2002-01-09,2002,EP 00918816 A,2000-03-20,EP 0002450 W;;US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,GLUCOKINASE ACTIVATORS,,HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/099-451-383-804-166,Patent Application,yes,0,15,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
378,PE,A1,PE 20001584 A1,157-380-917-662-243,2001-01-15,2001,PE 0002552000 A,2000-03-24,US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,ACTIVADORES DE LA GLUCOQUINASA,"SE REFIERE A UN COMPUESTO QUE COMPRENDE UNA AMIDA DE FORMULA I, DONDE: R1 Y R2 SON H, HALO, AMINO, HIDROXIAMINO, NITRO, CIANO, SULFONAMIDO, OR5, C(O)OR5, ENTRE OTROS; R3 ES CICLOALQUILO C3-C7, ALQUILO C2-C4; R4 ES C(O)NHR40, ANILLO HETEROAROMATICO DE 5-6 MIEMBROS CON 1-3 S, O, N; N ESTA JUNTO AL CARBONO DEL ANILLO EL QUE SE ENCUENTRA MONOSUSTITUIDO; EN UNA POSICION DIFERENTE AL C ADYACENTE AL N; CON UN SUSTITUYENTE TAL COMO ALQUILO, HALO, NITRO, CIANO, -(CH2)n-OR6, -(CH2)n-C(O)OR7, (CH2)n-C(O)NHR6, -C(O)-C(O)OR8, -(CH2)n-NHR6; R40 ES H, ALQUILO, ALQUENILO, HIDROXIALQUILO, ENTRE OTROS; n ES 0-4; R5 ES H, ALQUILO, PERFLUROALQUILO; R6, R7 Y R8 SON H, ALQUILO. SON COMPUESTOS PREFERIDOS 2-(3-CLORO-FENIL)-3-CICLOPENTIL-N-TIAZOL-2-IL-PROPIONAMIDA, 2-(4-BROMO-FENIL)-3-CICLOPENTIL-N-TIAZOL-2-IL-PROPIONAMIDA, 2-(4-CLORO-FENIL)-3-CICLOOPENTIL-N-TIAZOL-2-IL-PROPIONAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES UN ACTIVADOR DE LA GLUCOQUINASA INCREMENTANDO LA SECRECION DE INSULINA Y PUEDE SER UTIL PARA EL TRATAMIENTO DE LA DIABETES",HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;SARABU RAMAKANTH;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;HAYNES NANCY-ELLEN,,https://lens.org/157-380-917-662-243,Patent Application,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/425;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
379,PL,A1,PL 350669 A1,018-249-954-656-295,2003-01-27,2003,PL 35066900 A,2000-03-20,US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,GLUCOKINASE ACTIVATORS,,HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/018-249-954-656-295,Patent Application,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,DISCONTINUED
380,YU,A,YU 69501 A,135-320-443-778-339,2005-07-19,2005,YU P69501 A,2000-03-20,US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,GLUCOKINASE ACTIVATORS,"The present invention relates to compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in claim 1 and pharmaceutically acceptable salts thereof. The compounds are glucokinase activators which increase insulin secretion in the treatment of type II diabetes.",HOFFMANN LA ROCHE,BIZZARO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONIO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/135-320-443-778-339,Patent Application,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
381,WO,A2,WO 2000/058293 A2,055-746-706-257-251,2000-10-05,2000,EP 0002450 W,2000-03-20,US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,GLUCOKINASE ACTIVATORS,"The present invention relates to compounds of formula (I) wherein R?1, R2, R3 and R4¿ are as defined in claim 1 and pharmaceutically acceptable salts thereof. The compounds are glucokinase activators which increase insulin secretion in the treatment of type II diabetes.",HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/055-746-706-257-251,Patent Application,yes,0,163,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,PATENTED
382,AU,A,AU 2000/039630 A,111-748-376-353-061,2000-10-16,2000,AU 2000/039630 A,2000-03-20,EP 0002450 W;;US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,Glucokinase activators,,HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/111-748-376-353-061,Patent Application,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
383,DE,T2,DE 60014610 T2,192-720-399-729-926,2006-03-09,2006,DE 60014610 T,2000-03-20,US 12670799 P;;US 16594899 P;;US 16594499 P;;EP 0002450 W,1999-03-29,GLUKOKINASE AKTIVATOREN,,HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/192-720-399-729-926,Granted Patent,no,0,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/38;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,0,0,,,,EXPIRED
384,CZ,B6,CZ 301366 B6,121-595-020-437-924,2010-02-03,2010,CZ 20013490 A,2000-03-20,US 12670799 P;;US 16594899 P;;US 16594499 P,1999-03-29,"2-Phenyl-3-cycloalkyl propionamide compound, process for its preparation and pharmaceutical composition in which the compound is comprised","In the present invention, there is disclosed a 2-phenyl-3-cycloalkyl propionamide compound of the general formula I and pharmaceutically acceptable salts thereof. The compounds are glucokinase activators, which increase insulin secretion in the treatment of type II diabetes. There is also disclosed a pharmaceutical composition containing the above indicated compounds as well as its use when treating type II diabetes.",HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;CORBETT WENDY LEA;;FOCELLA ANTONINO;;GRIPPO JOSEPH FRANCIS;;HAYNES NANCY-ELLEN;;HOLLAND GEORGE WILLIAM;;KESTER ROBERT FRANCIS;;MAHANEY PAIGE E;;SARABU RAMAKANTH,,https://lens.org/121-595-020-437-924,Granted Patent,no,2,0,50,62,0,C07C275/50;;C07C317/44;;C07C323/62;;C07D213/75;;C07D213/80;;C07D213/82;;C07D233/88;;C07D237/22;;C07D239/42;;C07D253/07;;C07D261/14;;C07D263/48;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/135;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/10;;C07C2601/14;;A61P3/00;;A61P3/10;;A61P43/00;;C07D277/56,C07D277/38;;A61K31/17;;A61K31/4168;;A61K31/42;;A61K31/421;;A61K31/426;;A61K31/433;;A61K31/4402;;A61K31/455;;A61K31/50;;A61K31/505;;A61P3/10;;A61P43/00;;C07C275/50;;C07C317/44;;C07C323/60;;C07C323/62;;C07D/;;C07D213/75;;C07D213/80;;C07D213/803;;C07D213/82;;C07D233/88;;C07D237/20;;C07D237/22;;C07D239/42;;C07D241/28;;C07D253/07;;C07D261/14;;C07D263/34;;C07D263/48;;C07D277/20;;C07D277/46;;C07D277/56;;C07D277/58;;C07D285/12;;C07D285/135,,1,0,,,"Spielman M.A. et al.: Journal of American Chemical Society 1948, 70, str. 4190 (tab. I)",EXPIRED
385,ZA,B,ZA 200107833 B,183-207-709-924-409,2002-12-23,2002,ZA 200107833 A,2001-09-21,US 12670799 P,1999-03-29,Glucokinase activators.,,HOFFMANN LA ROCHE,BIZZARRO FRED THOMAS;;FOCELLA ANTONINO;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;SARABU RAMAKANTH;;CORBETT WENDY LEA;;GRIPPO JOSEPH FRANCIS;;HOLLARD GEORGE WILLIAM;;MAHANEY PAIGE E,,https://lens.org/183-207-709-924-409,Granted Patent,no,0,0,1,62,0,,A61K/;;A61P/;;C07C/;;C07D/,,0,0,,,,EXPIRED
386,US,A1,US 2015/0105474 A1,097-302-242-892-279,2015-04-16,2015,US 201314054135 A,2013-10-15,US 201314054135 A,2013-10-15,ISOAMYL NITRITE FORMULATIONS,"The present invention is directed at isoamyl nitrite formulations suitable for use in medicinal applications. The formulations include a composition of isoamyl nitrite in combination with an epoxidized vegetable oil, identified as stabilized isoamyl nitrite. The isoamyl nitrite may also be combined with petrolatum. Methods of treatment of the formulations are applicable to cyanide poisoning, H 2 S poisoning as well as treatment for elevated blood pressure.",SOUTHWEST RES INST,ZWIENER ALBERT M;;CARSON KENNETH H;;MCDONOUGH JOSEPH A;;CABELL LARRY A;;CANTU NORMA L;;DRABIK SANDRA J;;CLARK ANDREW P-Z;;THOMPSON PAUL M;;CORBETT RICHARD MICHAEL,SOUTHWEST RESEARCH INSTITUTE (2013-10-22),https://lens.org/097-302-242-892-279,Patent Application,yes,2,0,2,2,0,A61K47/06;;A61K47/06;;A61K9/0043;;A61K9/0043;;A61K31/04;;A61K31/04;;A61K47/44;;A61K47/44,A61K47/46;;A61K31/04;;A61K47/02;;A61K47/06,514/740,0,0,,,,ACTIVE
387,US,B2,US 9216222 B2,020-994-520-798-490,2015-12-22,2015,US 201314054135 A,2013-10-15,US 201314054135 A,2013-10-15,Isoamyl nitrite formulations,"The present invention is directed at isoamyl nitrite formulations suitable for use in medicinal applications. The formulations include a composition of isoamyl nitrite in combination with an epoxidized vegetable oil, identified as stabilized isoamyl nitrite. The isoamyl nitrite may also be combined with petrolatum. Methods of treatment of the formulations are applicable to cyanide poisoning, H 2 S poisoning as well as treatment for elevated blood pressure.",SOUTHWEST RES INST,ZWIENER ALBERT M;;CARSON KENNETH H;;MCDONOUGH JOSEPH A;;CABELL LARRY A;;CANTU NORMA L;;DRABIK SANDRA J;;CLARK ANDREW P-Z;;THOMPSON PAUL M;;CORBETT RICHARD MICHAEL,SOUTHWEST RESEARCH INSTITUTE (2013-10-22),https://lens.org/020-994-520-798-490,Granted Patent,yes,7,1,2,2,0,A61K47/06;;A61K47/06;;A61K9/0043;;A61K9/0043;;A61K31/04;;A61K31/04;;A61K47/44;;A61K47/44,A61K47/06;;A61K9/00;;A61K31/04;;A61K47/44,,2,0,,,"S.I. Baskin, et al, ""Cyanide Poisoning"", Medical Aspects of Chemical and Biological Warfare, Walter Reed Army Medical Center, Washington, D.C., 1997, Chapter 10, pp. 271-286.;;K. Mathes, et al, ""The Determination of Methaemoblobin and Cyanomethaemoglobin in Circulating Blood"", Naunyn-Schmiedebergs Arch. Exp. Pathol. Pharmakol., 1939, 191; pp. 706-714 (English translation not available).",ACTIVE
388,EP,B1,EP 1817233 B1,121-443-379-897-182,2011-03-23,2011,EP 05816178 A,2005-11-02,US 2005/0039446 W;;US 62434804 P,2004-11-02,AUTOMATED FLOWABLE DUNNAGE DISPENSING SYSTEM AND METHOD,"A system (10) for dispensing dunnage material includes a chute (30) connectable to a supply (20, 40) of flowable dunnage. A container (12) or a bottom of the chute (30) is moved into a dispensing position where the bottom of the chute (30) is proximate the fill plane of the container (12). A controller (16) selectively opens a shutter (50) at the bottom of the chute (30) to dispense dunnage and then closes the shutter (50) to separate the dispensed dunnage from the dunnage in the chute (30) while also removing the dunnage above the fill plane of the container (12). The chute (30) includes at least one substantially horizontal plate member (54) that is openable to selectively vary the size of an aperture (52) created thereby at the bottom of the chute (30) for dispensing dunnage material therethrough.",RANPAK CORP,CORBETT JAMES J;;HARDING JOSEPH J;;MOLITOR CHARLES D;;PINTZ MICHAEL A;;WILLIAMS SCOTT J;;STILL RAPHEAL R;;SULL TIMOTHY E;;RICH RONALD;;PIERSON DAVID A;;GILLES PAUL C,,https://lens.org/121-443-379-897-182,Granted Patent,yes,8,0,14,14,0,B65B55/20;;B65B55/20;;B65B55/20,B65B55/20,,0,0,,,,ACTIVE
389,AT,T1,AT E502857 T1,081-851-979-699-618,2011-04-15,2011,AT 05816178 T,2005-11-02,US 62434804 P;;US 2005/0039446 W,2004-11-02,AUTOMATISIERTES SYSTEM UND VERFAHREN ZUR ABGABE VON RIESELFÄHIGEN POLSTERELEMENTEN,"A system (10) for dispensing dunnage material includes a chute (30) connectable to a supply (20, 40) of flowable dunnage. A container (12) or a bottom of the chute (30) is moved into a dispensing position where the bottom of the chute (30) is proximate the fill plane of the container (12). A controller (16) selectively opens a shutter (50) at the bottom of the chute (30) to dispense dunnage and then closes the shutter (50) to separate the dispensed dunnage from the dunnage in the chute (30) while also removing the dunnage above the fill plane of the container (12). The chute (30) includes at least one substantially horizontal plate member (54) that is openable to selectively vary the size of an aperture (52) created thereby at the bottom of the chute (30) for dispensing dunnage material therethrough.",RANPAK CORP,CORBETT JAMES J;;HARDING JOSEPH J;;MOLITOR CHARLES D;;PINTZ MICHAEL A;;WILLIAMS SCOTT J;;STILL RAPHEAL R;;SULL TIMOTHY E;;RICH RONALD;;PIERSON DAVID A;;GILLES PAUL C,,https://lens.org/081-851-979-699-618,Granted Patent,no,0,0,14,14,0,B65B55/20;;B65B55/20;;B65B55/20,,,0,0,,,,INACTIVE
390,US,B2,US 7849664 B2,063-513-136-673-810,2010-12-14,2010,US 71840805 A,2005-11-02,US 71840805 A;;US 62434804 P;;US 2005/0039446 W,2004-11-02,Automated flowable dunnage dispensing system and method,"A system ( 10 ) for dispensing dunnage material includes a chute ( 30 ) connectable to a supply ( 20, 40 ) of flowable dunnage. A container ( 12 ) or a bottom of the chute ( 30 ) is moved into a dispensing position where the bottom of the chute ( 30 ) is proximate the fill plane of the container ( 12 ). A controller ( 16 ) selectively opens a shutter ( 50 ) at the bottom of the chute ( 30 ) to dispense dunnage and then closes the shutter ( 50 ) to separate the dispensed dunnage from the dunnage in the chute ( 30 ) while also removing the dunnage above the fill plane of the container ( 12 ). The chute ( 30 ) includes at least one substantially horizontal plate member ( 54 ) that is openable to selectively vary the size of an aperture ( 52 ) created thereby at the bottom of the chute ( 30 ) for dispensing dunnage material therethrough.",RANPAK CORP,CORBETT JAMES J;;HARDING JOSEPH J;;MOLITOR CHARLES D;;PINTZ MICHAEL A;;WILLIAMS SCOTT J;;STILL RAPHEAL R;;SULL TIMOTHY E;;RICH RONALD;;PIERSON DAVID A;;GILLES PAUL C,RANPAK CORP (2006-01-03),https://lens.org/063-513-136-673-810,Granted Patent,yes,29,7,14,14,0,B65B55/20;;B65B55/20;;B65B55/20,B65B57/00;;B65B23/00,53/472;;53/55;;53/267,0,0,,,,ACTIVE
391,AU,B2,AU 2005/302282 B2,104-918-105-410-111,2012-05-03,2012,AU 2005/302282 A,2005-11-02,US 62434804 P;;US 2005/0039446 W,2004-11-02,Automated flowable dunnage dispensing system and method,"A system (10) for dispensing dunnage material includes a chute (30) connectable to a supply (20, 40) of flowable dunnage. A container (12) or a bottom of the chute (30) is moved into a dispensing position where the bottom of the chute (30) is proximate the fill plane of the container (12). A controller (16) selectively opens a shutter (50) at the bottom of the chute (30) to dispense dunnage and then closes the shutter (50) to separate the dispensed dunnage from the dunnage in the chute (30) while also removing the dunnage above the fill plane of the container (12). The chute (30) includes at least one substantially horizontal plate member (54) that is openable to selectively vary the size of an aperture (52) created thereby at the bottom of the chute (30) for dispensing dunnage material therethrough.",RANPAK CORP,SULL TIMOTHY E;;PINTZ MICHAEL A;;HARDING JOSEPH J;;GILLES PAUL C;;CORBETT JAMES J;;PIERSON DAVID A;;MOLITOR CHARLES D;;STILL RAPHEAL R;;RICH RONALD;;WILLIAMS SCOTT J,,https://lens.org/104-918-105-410-111,Granted Patent,no,5,0,14,14,0,B65B55/20;;B65B55/20;;B65B55/20,B65B55/20,,0,0,,,,INACTIVE
392,AU,A1,AU 2005/302282 A1,144-869-339-460-640,2006-05-11,2006,AU 2005/302282 A,2005-11-02,US 62434804 P;;US 2005/0039446 W,2004-11-02,Automated flowable dunnage dispensing system and method,"A system (10) for dispensing dunnage material includes a chute (30) connectable to a supply (20, 40) of flowable dunnage. A container (12) or a bottom of the chute (30) is moved into a dispensing position where the bottom of the chute (30) is proximate the fill plane of the container (12). A controller (16) selectively opens a shutter (50) at the bottom of the chute (30) to dispense dunnage and then closes the shutter (50) to separate the dispensed dunnage from the dunnage in the chute (30) while also removing the dunnage above the fill plane of the container (12). The chute (30) includes at least one substantially horizontal plate member (54) that is openable to selectively vary the size of an aperture (52) created thereby at the bottom of the chute (30) for dispensing dunnage material therethrough.",RANPAK CORP,SULL TIMOTHY E;;PINTZ MICHAEL A;;HARDING JOSEPH J;;GILLES PAUL C;;CORBETT JAMES J;;PIERSON DAVID A;;MOLITOR CHARLES D;;STILL RAPHEAL R;;RICH RONALD;;WILLIAMS SCOTT J,,https://lens.org/144-869-339-460-640,Patent Application,no,0,0,14,14,0,B65B55/20;;B65B55/20;;B65B55/20,B65B55/20,,0,0,,,,INACTIVE
393,KR,A,KR 20070085621 A,096-320-553-039-462,2007-08-27,2007,KR 20077012399 A,2007-06-01,US 62434804 P,2004-11-02,AUTOMATED FLOWABLE DUNNAGE DISPENSING SYSTEM AND METHOD,"A system (10) for dispensing dunnage material includes a chute (30) connectable to a supply (20, 40) of flowable dunnage. A container (12) or a bottom of the chute (30) is moved into a dispensing position where the bottom of the chute (30) is proximate the fill plane of the container (12). A controller (16) selectively opens a shutter (50) at the bottom of the chute (30) to dispense dunnage and then closes the shutter (50) to separate the dispensed dunnage from the dunnage in the chute (30) while also removing the dunnage above the fill plane of the container (12). The chute (30) includes at least one substantially horizontal plate member (54) that is openable to selectively vary the size of an aperture (52) created thereby at the bottom of the chute (30) for dispensing dunnage material therethrough.",RANPAK CORP,CORBETT JAMES J;;HARDING JOSEPH J;;MOLITOR CHARLES D;;PINTZ MICHAEL A;;WILLIAMS SCOTT J;;STILL RAPHEAL R;;SULL TIMOTHY E;;RICH RONALD;;PIERSON DAVID A;;GILLES PAUL C,,https://lens.org/096-320-553-039-462,Patent Application,no,0,7,14,14,0,B65B55/20;;B65B55/20;;B65B55/20,B65B55/20,,0,0,,,,DISCONTINUED
394,WO,A2,WO 2006/050354 A2,149-984-224-594-169,2006-05-11,2006,US 2005/0039446 W,2005-11-02,US 62434804 P,2004-11-02,AUTOMATED FLOWABLE DUNNAGE DISPENSING SYSTEM AND METHOD,"A system (10) for dispensing dunnage material includes a chute (30) connectable to a supply (20, 40) of flowable dunnage. A container (12) or a bottom of the chute (30) is moved into a dispensing position where the bottom of the chute (30) is proximate the fill plane of the container (12). A controller (16) selectively opens a shutter (50) at the bottom of the chute (30) to dispense dunnage and then closes the shutter (50) to separate the dispensed dunnage from the dunnage in the chute (30) while also removing the dunnage above the fill plane of the container (12). The chute (30) includes at least one substantially horizontal plate member (54) that is openable to selectively vary the size of an aperture (52) created thereby at the bottom of the chute (30) for dispensing dunnage material therethrough.",RANPAK CORP;;CORBETT JAMES J;;HARDING JOSEPH J;;MOLITOR CHARLES D;;PINTZ MICHAEL A;;WILLIAMS SCOTT J;;STILL RAPHEAL R;;SULL TIMOTHY E;;RICH RONALD;;PIERSON DAVID A;;GILLES PAUL C,CORBETT JAMES J;;HARDING JOSEPH J;;MOLITOR CHARLES D;;PINTZ MICHAEL A;;WILLIAMS SCOTT J;;STILL RAPHEAL R;;SULL TIMOTHY E;;RICH RONALD;;PIERSON DAVID A;;GILLES PAUL C,,https://lens.org/149-984-224-594-169,Patent Application,yes,0,10,14,14,0,B65B55/20;;B65B55/20;;B65B55/20,B65B55/20,,0,0,,,,PENDING
395,CA,A1,CA 2585883 A1,189-281-305-687-359,2006-05-11,2006,CA 2585883 A,2005-11-02,US 62434804 P;;US 2005/0039446 W,2004-11-02,AUTOMATED FLOWABLE DUNNAGE DISPENSING SYSTEM AND METHOD,"A system (10) for dispensing dunnage material includes a chute (30) connectable to a supply (20, 40) of flowable dunnage. A container (12) or a bottom of the chute (30) is moved into a dispensing position where the bottom of the chute (30) is proximate the fill plane of the container (12). A controller (16) selectively opens a shutter (50) at the bottom of the chute (30) to dispense dunnage and then closes the shutter (50) to separate the dispensed dunnage from the dunnage in the chute (30) while also removing the dunnage above the fill plane of the container (12). The chute (30) includes at least one substantially horizontal plate member (54) that is openable to selectively vary the size of an aperture (52) created thereby at the bottom of the chute (30) for dispensing dunnage material therethrough.",RANPAK CORP,PIERSON DAVID A;;WILLIAMS SCOTT J;;HARDING JOSEPH J;;PINTZ MICHAEL A;;GILLES PAUL C;;MOLITOR CHARLES D;;CORBETT JAMES J;;RICH RONALD;;STILL RAPHEAL R;;SULL TIMOTHY E,,https://lens.org/189-281-305-687-359,Patent Application,no,0,1,14,14,0,B65B55/20;;B65B55/20;;B65B55/20,B65B55/20,,0,0,,,,ACTIVE
396,WO,A3,WO 2006/050354 A3,083-517-638-237-238,2006-08-17,2006,US 2005/0039446 W,2005-11-02,US 62434804 P,2004-11-02,AUTOMATED FLOWABLE DUNNAGE DISPENSING SYSTEM AND METHOD,"A system (10) for dispensing dunnage material includes a chute (30) connectable to a supply (20, 40) of flowable dunnage. A container (12) or a bottom of the chute (30) is moved into a dispensing position where the bottom of the chute (30) is proximate the fill plane of the container (12). A controller (16) selectively opens a shutter (50) at the bottom of the chute (30) to dispense dunnage and then closes the shutter (50) to separate the dispensed dunnage from the dunnage in the chute (30) while also removing the dunnage above the fill plane of the container (12). The chute (30) includes at least one substantially horizontal plate member (54) that is openable to selectively vary the size of an aperture (52) created thereby at the bottom of the chute (30) for dispensing dunnage material therethrough.",RANPAK CORP;;CORBETT JAMES J;;HARDING JOSEPH J;;MOLITOR CHARLES D;;PINTZ MICHAEL A;;WILLIAMS SCOTT J;;STILL RAPHEAL R;;SULL TIMOTHY E;;RICH RONALD;;PIERSON DAVID A;;GILLES PAUL C,CORBETT JAMES J;;HARDING JOSEPH J;;MOLITOR CHARLES D;;PINTZ MICHAEL A;;WILLIAMS SCOTT J;;STILL RAPHEAL R;;SULL TIMOTHY E;;RICH RONALD;;PIERSON DAVID A;;GILLES PAUL C,,https://lens.org/083-517-638-237-238,Search Report,yes,8,0,14,14,0,B65B55/20;;B65B55/20;;B65B55/20,B65B55/20,,0,0,,,,PENDING
397,US,A1,US 2009/0064638 A1,178-448-430-925-507,2009-03-12,2009,US 71840805 A,2005-11-02,US 71840805 A;;US 62434804 P;;US 2005/0039446 W,2004-11-02,AUTOMATED FLOWABLE DUNNAGE DISPENSING SYSTEM AND METHOD,"A system ( 10 ) for dispensing dunnage material includes a chute ( 30 ) connectable to a supply ( 20, 40 ) of flowable dunnage. A container ( 12 ) or a bottom of the chute ( 30 ) is moved into a dispensing position where the bottom of the chute ( 30 ) is proximate the fill plane of the container ( 12 ). A controller ( 16 ) selectively opens a shutter ( 50 ) at the bottom of the chute ( 30 ) to dispense dunnage and then closes the shutter ( 50 ) to separate the dispensed dunnage from the dunnage in the chute ( 30 ) while also removing the dunnage above the fill plane of the container ( 12 ). The chute ( 30 ) includes at least one substantially horizontal plate member ( 54 ) that is openable to selectively vary the size of an aperture ( 52 ) created thereby at the bottom of the chute ( 30 ) for dispensing dunnage material therethrough.",RANPAK CORP,CORBETT JAMES J;;HARDING JOSEPH J;;MOLITOR CHARLES D;;PINTZ MICHAEL A;;WILLIAMS SCOTT J;;STILL RAPHEAL R;;SULL TIMOTHY E;;RICH RONALD;;PIERSON DAVID A;;GILLES PAUL C,RANPAK CORP (2006-01-03),https://lens.org/178-448-430-925-507,Patent Application,yes,28,21,14,14,0,B65B55/20;;B65B55/20;;B65B55/20,B65B57/00;;B65B55/20,53/472;;53/52;;53/115;;53/55;;53/474,0,0,,,,ACTIVE
398,EP,A2,EP 1817233 A2,024-695-637-112-988,2007-08-15,2007,EP 05816178 A,2005-11-02,US 2005/0039446 W;;US 62434804 P,2004-11-02,AUTOMATED FLOWABLE DUNNAGE DISPENSING SYSTEM AND METHOD,"A system (10) for dispensing dunnage material includes a chute (30) connectable to a supply (20, 40) of flowable dunnage. A container (12) or a bottom of the chute (30) is moved into a dispensing position where the bottom of the chute (30) is proximate the fill plane of the container (12). A controller (16) selectively opens a shutter (50) at the bottom of the chute (30) to dispense dunnage and then closes the shutter (50) to separate the dispensed dunnage from the dunnage in the chute (30) while also removing the dunnage above the fill plane of the container (12). The chute (30) includes at least one substantially horizontal plate member (54) that is openable to selectively vary the size of an aperture (52) created thereby at the bottom of the chute (30) for dispensing dunnage material therethrough.",RANPAK CORP,CORBETT JAMES J;;HARDING JOSEPH J;;MOLITOR CHARLES D;;PINTZ MICHAEL A;;WILLIAMS SCOTT J;;STILL RAPHEAL R;;SULL TIMOTHY E;;RICH RONALD;;PIERSON DAVID A;;GILLES PAUL C,,https://lens.org/024-695-637-112-988,Patent Application,yes,0,0,14,14,0,B65B55/20;;B65B55/20;;B65B55/20,B65B55/20,,0,0,,,,ACTIVE
399,CA,C,CA 2585883 C,141-683-810-393-714,2016-01-05,2016,CA 2585883 A,2005-11-02,US 62434804 P;;US 2005/0039446 W,2004-11-02,AUTOMATED FLOWABLE DUNNAGE DISPENSING SYSTEM AND METHOD,A system for dispensing dunnage material includes a chute connectable to a supply of flowable dunnage. A container or a bottom of the chute is moved into a dispensing position where the bottom of the chute is proximate the fill plane of the container. A controller selectively opens a shutter at the bottom of the chute to dispense dunnage and then closes the shutter to separate the dispensed dunnage from the dunnage in the chute while also removing the dunnage above the fill plane of the container. The chute includes at least one substantially horizontal plate member that is openable to selectively vary the size of an aperture created thereby at the bottom of the chute for dispensing dunnage material therethrough.,RANPAK CORP,CORBETT JAMES J;;HARDING JOSEPH J;;MOLITOR CHARLES D;;PINTZ MICHAEL A;;WILLIAMS SCOTT J;;STILL RAPHEAL R;;SULL TIMOTHY E;;RICH RONALD;;PIERSON DAVID A;;GILLES PAUL C,,https://lens.org/141-683-810-393-714,Granted Patent,no,0,0,14,14,0,B65B55/20;;B65B55/20;;B65B55/20,B65B55/20,,0,0,,,,ACTIVE
400,DE,D1,DE 602005027106 D1,126-978-083-589-44X,2011-05-05,2011,DE 602005027106 T,2005-11-02,US 62434804 P;;US 2005/0039446 W,2004-11-02,AUTOMATISIERTES SYSTEM UND VERFAHREN ZUR ABGABE VON RIESELFÄHIGEN POLSTERELEMENTEN,"A system (10) for dispensing dunnage material includes a chute (30) connectable to a supply (20, 40) of flowable dunnage. A container (12) or a bottom of the chute (30) is moved into a dispensing position where the bottom of the chute (30) is proximate the fill plane of the container (12). A controller (16) selectively opens a shutter (50) at the bottom of the chute (30) to dispense dunnage and then closes the shutter (50) to separate the dispensed dunnage from the dunnage in the chute (30) while also removing the dunnage above the fill plane of the container (12). The chute (30) includes at least one substantially horizontal plate member (54) that is openable to selectively vary the size of an aperture (52) created thereby at the bottom of the chute (30) for dispensing dunnage material therethrough.",RANPAK CORP,CORBETT JAMES J;;HARDING JOSEPH J;;MOLITOR CHARLES D;;PINTZ MICHAEL A;;WILLIAMS SCOTT J;;STILL RAPHEAL R;;SULL TIMOTHY E;;RICH RONALD;;PIERSON DAVID A;;GILLES PAUL C,,https://lens.org/126-978-083-589-44X,Granted Patent,no,0,0,14,14,0,B65B55/20;;B65B55/20;;B65B55/20,B65B55/20,,0,0,,,,ACTIVE
401,EP,A1,EP 3474893 A1,080-464-493-635-44X,2019-05-01,2019,EP 17758969 A,2017-06-27,US 201662355212 P;;US 2017/0039595 W,2016-06-27,SELF-ASSEMBLING INSECT FERRITIN NANOPARTICLES FOR DISPLAY OF CO-ASSEMBLED TRIMERIC ANTIGENS,,US HEALTH,KWONG PETER;;GEORGIEV IVELIN;;JOYCE MICHAEL GORDON;;KANEKIYO MASARU;;DRUZ ALIAKSANDR;;BAXA ULRICH;;VAN GALEN JOSEPH;;CHEN RITA;;CHENG CHENG;;MASCOLA JOHN;;TSYBOVSKY YAROSLAV;;YANG YONGPING;;THOMAS PAUL;;GRAHAM BARNEY;;MOIN SYED MOHAMMAD;;BOYINGTON JEFFREY;;CORBETT KIZZMEKIA,,https://lens.org/080-464-493-635-44X,Patent Application,yes,0,0,5,5,0,A61K39/12;;A61K39/295;;C07K14/11;;C07K14/162;;C07K14/43563;;A61K2039/55555;;A61K2039/6031;;C07K2319/00;;C07K2319/735;;C12N2740/16134;;C12N2760/16134;;C12N2760/16234;;A61K39/21;;A61K2039/55555;;C07K14/082;;C07K14/11;;C07K14/162;;C07K14/165;;C07K14/43563;;C07K2319/735;;C12N7/00;;C12N2740/16134;;C12N2760/16134;;C12N2770/20034,A61K39/295;;A61K39/12;;C07K14/11;;C07K14/16;;C07K14/435,,0,0,,,,PENDING
402,US,A1,US 2019/0330279 A1,144-319-948-771-915,2019-10-31,2019,US 201716312166 A,2017-06-27,US 201716312166 A;;US 201662355212 P;;US 2017/0039595 W,2016-06-27,SELF-ASSEMBLING INSECT FERRITIN NANOPARTICLES FOR DISPLAY OF CO-ASSEMBLED TRIMERIC ANTIGENS,Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.,THE US SECRETARY DEPT OF HEALTH AND HUMAN SERVICE,KWONG PETER;;GEORGIEV IVELIN;;JOYCE MICHAEL GORDON;;KANEKIYO MASARU;;DRUZ ALIAKSANDR;;BAXA ULRICH;;VAN GALEN JOSEPH;;CHEN RITA;;CHENG CHENG;;MASCOLA JOHN;;TSYBOVSKY YAROSLAV;;YANG YONGPING;;THOMAS PAUL;;GRAHAM BARNEY;;MOIN SYED MOHAMMAD;;BOYINGTON JEFFREY;;CORBETT KIZZMEKIA,THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (2017-08-30),https://lens.org/144-319-948-771-915,Patent Application,yes,0,9,5,5,186,A61K39/12;;A61K39/21;;A61K39/295;;A61K2039/55555;;A61K2039/55555;;A61K2039/6031;;C07K14/11;;C07K14/082;;C07K14/11;;C07K14/162;;C07K14/162;;C07K14/165;;C07K14/43563;;C07K14/43563;;C07K2319/00;;C07K2319/735;;C07K2319/735;;C12N7/00;;C12N2740/16134;;C12N2740/16134;;C12N2760/16134;;C12N2760/16134;;C12N2760/16234;;C12N2770/20034,C07K14/11;;A61K39/21;;C07K14/08;;C07K14/16;;C07K14/165;;C07K14/435;;C12N7/00,,0,0,,,,ACTIVE
403,SG,A,SG 10201913004U A,116-349-366-417-176,2020-03-30,2020,SG 10201913004U A,2015-11-19,US 201462083056 P,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN;;BARNHART BRYAN C;;YAMNIUK AARON;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN;;MYERS JOSEPH;;SCHWEIZER LIANG;;HATCHER SANDRA;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/116-349-366-417-176,Unknown,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,,,0,0,,,,PENDING
404,TW,A,TW 201625693 A,086-590-432-990-523,2016-07-16,2016,TW 104138281 A,2015-11-19,US 201462083056 P,2014-11-21,Antibodies against CD73 and uses thereof,"The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN;;MYERS JOSEPH E JR;;SCHWEIZER LIANG;;HATCHER SANDRA V,,https://lens.org/086-590-432-990-523,Patent of Addition,no,0,1,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/395;;A61K47/48;;A61P35/00,,0,0,,,,ACTIVE
405,AR,A1,AR 102698 A1,049-047-081-013-125,2017-03-15,2017,AR P150103765 A,2015-11-19,US 201462083056 P,2014-11-21,ANTICUERPOS CONTRA CD73 Y SUS USOS,"Anticuerpos monoclonales aislados, en particular, anticuerpos humanos, que se fijan al Cúmulo de Diferenciación 73 (CD73) humano con gran afinidad, inhiben la actividad de CD73 y median opcionalmente la internalización de CD73 dependiente de anticuerpo. También moléculas de ácido nucleico que codifican los anticuerpos de la presente, vectores de expresión, células huésped y métodos para expresar los anticuerpos de la presente. También inmunoconjugados, moléculas biespecíficas y composiciones farmacéuticas que comprenden los anticuerpos de la presente. También métodos para inhibir el crecimiento de una célula tumoral que expresa CD73 usando los anticuerpos de la presente, lo cual incluye métodos para tratar distintos tipos de cáncer. Reivindicación 11: El anticuerpo, o la porción de fijación al antígeno de este, de acuerdo con la reivindicación 10, caracterizado porque el anticuerpo comprende secuencias de CDR1, CDR2 y CDR3 de la cadena pesada que comprenden. SEQ ID Nº 5, 6 y 7, respectivamente, y/o las secuencias de CDR1, CDR2 y CDR3 de la cadena liviana que comprenden SEQ ID Nº 9, 10 y 11, respectivamente.",BRISTOL MYERS SQUIBB CO,SANDRA V HATCHER;;LIANG SCHWEIZER;;JOSEPH E MYERS JR;;MARTIN CORBETT;;RICHARD HUANG;;JOHN SACK;;GUODONG CHEN;;MARIA N JURE-KUNKEL;;ANGELA GOODENOUGH;;EMANUELA SEGA;;MING LEI;;KARLA HENNING;;MOHAN SRINIVASAN;;AARON P YAMNIUK;;BRYAN BARNHART;;ALAN J KORMAN;;NILS LONBERG,,https://lens.org/049-047-081-013-125,Patent Application,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;C12N15/13;;C12N15/16;;C12N15/22,,0,0,,,,PENDING
406,MA,A1,MA 40309 A1,018-010-642-084-975,2018-01-31,2018,MA 40309 A,2015-11-19,US 201462083056 P;;US 2015/0061639 W,2014-11-21,Anticorps anti-cd73 et leurs utilisations,"La présente invention concerne des anticorps monoclonaux isolés, en particulier des anticorps humains, qui se lient au marqueur de différenciation 73 (cd73) humain avec une grande affinité et inhibent l'activité du cd73, et éventuellement gèrent l'internalisation du cd73 dépendant des anticorps. L'invention concerne également des molécules d'acide nucléique codant pour les anticorps selon l'invention, des vecteurs d'expression, des cellules hôtes et des procédés pour exprimer les anticorps selon l'inventi",BRISTOL MYERS SQUIBB CO,HUANG RICHARD;;YAMNIUK AARON;;CORBETT MARTIN;;LONBERG NILS;;SRINIVASAN MOHAN;;CHEN GUODONG;;HUANG HAICHUN;;HENNING KARLA A;;LEI MING;;KORMAN ALAN;;BARNHART BRYAN C;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA;;SACK JOHN;;MYERS JOSEPH;;SCHWEIZER LIANG;;HATCHER SANDRA;;ZHANG PINGPING,,https://lens.org/018-010-642-084-975,Patent Application,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/395;;A61P35/00;;C07K16/30;;C07K16/40,,0,0,,,,PENDING
407,TN,A1,TN 2017000203 A1,022-931-318-149-125,2018-10-19,2018,TN 2017000203 A,2015-11-19,US 201462083056 P;;US 2015/0061639 W,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,"The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.",BRISTOL MYERS SQUIBB CO,BARNHART BRYAN C;;CHEN GUODONG;;CORBETT MARTIN;;GOODENOUGH ANGELA;;HATCHER SANDRA;;HENNING KARLA A;;HUANG HAICHUN;;HUANG RICHARD;;JURE-KUNKEL MARIA;;KORMAN ALAN;;LEI MING;;LONBERG NILS;;MYERS JOSEPH;;SACK JOHN;;SCHWEIZER LIANG;;SEGA EMANUELA;;SRINIVASAN MOHAN;;YAMNIUK AARON;;ZHANG PINGPING,,https://lens.org/022-931-318-149-125,Patent Application,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,A61K39/395;;A61P35/00;;C07K16/28;;C07K16/30;;C07K16/40,,0,0,,,,PENDING
408,NZ,A,NZ 731633 A,194-165-008-354-884,2022-01-28,2022,NZ 73163315 A,2015-11-19,US 2015/0061639 W;;US 201462083056 P,2014-11-21,Antibodies against cd73 and uses thereof,"The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers. In a particular embodiment the CD73-binding antibody comprises the heavy chain CDRs NYGMH, VILYDGSNKYYPDSVKG and GGSSWYPDSFDI; and light chain CDRs RASQGISSWLA, AASSLQS and QQYNSYPLT; and comprise a heavy chain constant region comprises an IgG2 hinge and IgG2 CH1 domain.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;SRINIVASAN MOHAN;;CHEN GUODONG;;HUANG RICHARD;;BARNHART BRYAN C;;YAMNIUK AARON;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA;;SACK JOHN;;CORBETT MARTIN;;MYERS JOSEPH;;SCHWEIZER LIANG;;HATCHER SANDRA;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/194-165-008-354-884,Patent Application,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/395;;A61P35/00;;C07K16/30;;C07K16/40,,0,0,,,,PENDING
409,WO,A8,WO 2017/152085 A8,073-597-504-309-240,2020-04-16,2020,US 2017/0020714 W,2017-03-03,US 201662363703 P;;US 201662431987 P;;US 201662303985 P;;US 201662305378 P;;US 201662341220 P,2016-03-04,COMBINATION THERAPY WITH ANTI-CD73 ANTIBODIES,"Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-CD73 antibody in combination with an immuno-oncology agent, such as an anti-PD- 1 antibody.",BRISTOL MYERS SQUIBB CO,BARNHART BRYAN;;KORMAN ALAN;;LONBERG NILS;;YAMNIUK AARON;;SRINIVASAN MOHAN;;HENNING KARLA;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN;;MYERS JOSEPH;;SCHWEIZER LIANG;;HATCHER SANDRA;;ALTURA RACHEL;;HUANG HAICHUN;;ZHANG PINGPING;;HILT EDWARD;;HEDRICK MICHAEL,,https://lens.org/073-597-504-309-240,Amended Application,yes,0,0,21,21,0,A61K9/0019;;A61K2039/507;;A61P1/04;;A61P1/18;;A61P5/00;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/2818;;C07K16/2896;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;C07K16/2818;;C07K16/2896;;A61K2039/507;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;A61P1/04;;A61P1/18;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;A61P5/00;;C07K16/2896;;C07K2317/52;;C07K2317/92;;C07K2317/94;;C07K2317/55;;C07K2317/34;;C07K2299/00;;C07K2317/21;;C07K2317/77;;C07K2317/76;;C07K2317/56;;A61P5/00;;C07K2317/54;;A61P43/00;;A61P1/18;;A61K9/0019;;C07K2317/90;;A61P1/04;;A61P35/00;;A61K2039/507;;C07K16/2818;;A61P15/00;;A61P11/00;;A61P35/00;;C07K16/2818;;C07K16/2896;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/56;;C07K2317/77;;C07K2317/76;;C07K2317/90;;C07K2317/94;;C07K2317/92;;A61K2039/507;;A61P35/00;;A61K9/0019;;C07K16/2818;;C07K16/2896;;C07K2317/76;;C07K2317/55;;C07K2299/00;;C07K2317/54;;C07K2317/34;;A61K2039/507;;C07K2317/92;;C07K2317/90;;C07K2317/52;;C07K2317/56;;C07K2317/21;;C07K2317/94;;C07K2317/77,C07K16/28;;A61K39/00,,0,0,,,,PENDING
410,SG,A,SG 10201913033U A,174-230-559-361-995,2020-03-30,2020,SG 10201913033U A,2017-03-03,US 201662303985 P;;US 201662305378 P;;US 201662341220 P;;US 201662363703 P;;US 201662431987 P,2016-03-04,COMBINATION THERAPY WITH ANTI-CD73 ANTIBODIES,,BRISTOL MYERS SQUIBB CO,BARNHART BRYAN;;KORMAN ALAN;;LONBERG NILS;;YAMNIUK AARON;;SRINIVASAN MOHAN;;HENNING KARLA;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN;;MYERS JOSEPH;;SCHWEIZER LIANG;;HATCHER SANDRA;;ALTURA RACHEL;;HUANG HAICHUN;;ZHANG PINGPING;;HILT EDWARD;;HEDRICK MICHAEL,,https://lens.org/174-230-559-361-995,Unknown,no,0,0,21,21,0,A61K9/0019;;A61K2039/507;;A61P1/04;;A61P1/18;;A61P5/00;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/2818;;C07K16/2896;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;C07K16/2818;;C07K16/2896;;A61K2039/507;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;A61P1/04;;A61P1/18;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;A61P5/00;;C07K16/2896;;C07K2317/52;;C07K2317/92;;C07K2317/94;;C07K2317/55;;C07K2317/34;;C07K2299/00;;C07K2317/21;;C07K2317/77;;C07K2317/76;;C07K2317/56;;A61P5/00;;C07K2317/54;;A61P43/00;;A61P1/18;;A61K9/0019;;C07K2317/90;;A61P1/04;;A61P35/00;;A61K2039/507;;C07K16/2818;;A61P15/00;;A61P11/00;;A61P35/00;;C07K16/2818;;C07K16/2896;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/56;;C07K2317/77;;C07K2317/76;;C07K2317/90;;C07K2317/94;;C07K2317/92;;A61K2039/507;;A61P35/00;;A61K9/0019;;C07K16/2818;;C07K16/2896;;C07K2317/76;;C07K2317/55;;C07K2299/00;;C07K2317/54;;C07K2317/34;;A61K2039/507;;C07K2317/92;;C07K2317/90;;C07K2317/52;;C07K2317/56;;C07K2317/21;;C07K2317/94;;C07K2317/77,,,0,0,,,,PENDING
411,TW,B,TW I758928 B,086-809-658-819-693,2022-03-21,2022,TW 109137987 A,2015-11-19,US 201462083056 P,2014-11-21,Antibodies against cd73 and uses thereof,,BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN;;MYERS JOSEPH E JR;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/086-809-658-819-693,Granted Patent,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,,,2,2,094-218-297-204-09X;;048-700-652-556-098,23406016;;10.1186/1476-4598-12-11;;pmc3582597;;24043904;;10.4049/jimmunol.1301274,"Rust, Steven, et al. ""Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’breast cancer cell type."" Molecular cancer 12.1 (2013): 11.;;Terp, Mikkel G., et al. ""Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells."" The Journal of Immunology 191.8 (2013): 4165-4173.",ACTIVE
412,US,A1,US 2016/0145350 A1,096-596-220-818-81X,2016-05-26,2016,US 201614994828 A,2016-01-13,US 201614994828 A;;US 2015/0061639 W;;US 201462083056 P,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,"The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN S;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JR JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V,BRISTOL-MYERS SQUIBB COMPANY (2016-01-14),https://lens.org/096-596-220-818-81X,Patent Application,yes,0,57,66,66,380,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/40;;A61K39/395;;A61K45/06;;A61K47/48;;C07K16/30;;G01N33/573,,2,2,002-007-578-507-698;;048-700-652-556-098,10458776;;10.1002/(sici)1521-4141(199908)29:08<2613::aid-immu2613>3.0.co;2-j;;24043904;;10.4049/jimmunol.1301274,"Armour, K.L. et al. Recombinant human IgG molecules lacking Fc gamma receptor I binding and monocyte triggering activities. Eur. J. Immunol., vol. 29, p. 2613-2624 (1999);;Terp, M.G. et al. Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells. J. Immunol., vol. 191(8):4165-4173 (2013).",ACTIVE
413,TW,A,TW 202124451 A,020-064-962-597-572,2021-07-01,2021,TW 109137987 A,2015-11-19,US 201462083056 P,2014-11-21,Antibodies against CD73 and uses thereof,"The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN;;MYERS JOSEPH E JR;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/020-064-962-597-572,Patent of Addition,no,0,1,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/395;;A61K47/50;;A61P35/00,,0,0,,,,ACTIVE
414,TW,B,TW I711630 B,018-457-811-824-147,2020-12-01,2020,TW 104138281 A,2015-11-19,US 201462083056 P,2014-11-21,Antibodies against cd73 and uses thereof,,BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN;;MYERS JOSEPH E JR;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/018-457-811-824-147,Granted Patent,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,,,1,1,048-700-652-556-098,24043904;;10.4049/jimmunol.1301274,"Rust, Steven, et al. ""Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’breast cancer cell type."" Molecular cancer 12.1 (2013): 11. Terp, Mikkel G., et al. ""Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells."" The Journal of Immunology 191.8 (2013): 4165-4173.",ACTIVE
415,SG,A,SG 11201806861S A,170-512-662-451-841,2018-09-27,2018,SG 11201806861S A,2017-03-03,US 201662303985 P;;US 201662305378 P;;US 201662341220 P;;US 201662363703 P;;US 201662431987 P;;US 2017/0020714 W,2016-03-04,COMBINATION THERAPY WITH ANTI-CD73 ANTIBODIES,,BRISTOL MYERS SQUIBB CO,BARNHART BRYAN;;KORMAN ALAN;;LONBERG NILS;;YAMNIUK AARON;;SRIVISAN MOHAN;;HENNING KARLA;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN;;MYERS JOSEPH;;SCHWEIZER LIANG;;HATCHER SANDRA;;ALTURA RACHEL;;HUANG HAICHUN;;ZHANG PINGPING;;HILT EDWARD;;HEDRICK MICHAEL,,https://lens.org/170-512-662-451-841,Unknown,no,0,0,21,21,0,A61K9/0019;;A61K2039/507;;A61P1/04;;A61P1/18;;A61P5/00;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/2818;;C07K16/2896;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;C07K16/2818;;C07K16/2896;;A61K2039/507;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;A61P1/04;;A61P1/18;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;A61P5/00;;C07K16/2896;;C07K2317/52;;C07K2317/92;;C07K2317/94;;C07K2317/55;;C07K2317/34;;C07K2299/00;;C07K2317/21;;C07K2317/77;;C07K2317/76;;C07K2317/56;;A61P5/00;;C07K2317/54;;A61P43/00;;A61P1/18;;A61K9/0019;;C07K2317/90;;A61P1/04;;A61P35/00;;A61K2039/507;;C07K16/2818;;A61P15/00;;A61P11/00;;A61P35/00;;C07K16/2818;;C07K16/2896;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/56;;C07K2317/77;;C07K2317/76;;C07K2317/90;;C07K2317/94;;C07K2317/92;;A61K2039/507;;A61P35/00;;A61K9/0019;;C07K16/2818;;C07K16/2896;;C07K2317/76;;C07K2317/55;;C07K2299/00;;C07K2317/54;;C07K2317/34;;A61K2039/507;;C07K2317/92;;C07K2317/90;;C07K2317/52;;C07K2317/56;;C07K2317/21;;C07K2317/94;;C07K2317/77,C07K16/28;;A61K39/00,,0,0,,,,PENDING
416,UY,A,UY 36404 A,185-824-291-944-811,2016-06-01,2016,UY 36404 A,2015-11-19,US 201462083056 P,2014-11-21,"ANTICUERPOS MONOCLONALES (Ab) COMO DETECTORES DE CD73 E INHIBIDORES DE SU ACTIVIDAD ENZIMÁTICA, Y COMPOSICIONES QUE LOS CONTIENEN","Se divulgan anticuerpos monoclonales aislados que se fijan al Cúmulo de Diferenciación 73 (CD73) humano, inhiben la actividad de CD73 y median la internalización de CD73 dependiente de anticuerpo. Se proporcionan moléculas de ácido nucleico que codifican los anticuerpos de la invención, vectores de expresión,células huésped y métodos para expresar dichos anticuerpos. Se proporcionan inmunoconjugados, moléculas biespecíficas y composiciones farmacéuticas que comprenden los anticuerpos de la invención, asi como métodos para inhibir el crecimiento de una célula tumoral que expresa CD73 usando los anticuerpos de la invención, ymétodos para tratar distintos tipos de cáncer.",BRISTOL MYERS SQUIBB COMPANY UNA CORPORACIÓN DEL ESTADO DE DELAWARE,KORMAN ALAN J;;KARLA HENNING;;GUODONG CHEN;;RICHARD HUANG;;HAICHUN HUANG;;NILS LONBERG;;BRYAN BARNHART;;YAMNIUK AARON P;;MOHAN SRINIVASAN;;MING LEI;;EMANUELA SEGA;;ANGELA GOODENOUGH;;JURE-KUNKEL MARIA N;;JOHN SACK;;MARTIN CORBETT;;JR JOSEPH E MYERS;;LIEN SCHWEIZER;;HATCHER SANDRA V;;PINGPING ZHANG,,https://lens.org/185-824-291-944-811,Patent Application,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,A61P35/00;;A61K39/395;;C07K16/30;;C07K19/00;;C12N5/10;;C12N15/13;;C12N15/85;;C12P21/08,,0,0,,,,PENDING
417,EP,A1,EP 3725808 A1,055-266-504-241-486,2020-10-21,2020,EP 20164125 A,2015-11-19,US 201462083056 P;;EP 15816276 A;;US 2015/0061639 W,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,"The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/055-266-504-241-486,Patent Application,yes,233,0,66,66,394,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/395;;A61P35/00;;C07K16/30;;C07K16/40,,208,174,094-218-297-204-09X;;048-700-652-556-098;;039-889-533-551-521;;005-126-168-767-527;;004-922-729-065-965;;140-815-540-810-121;;002-699-487-824-639;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;033-955-564-406-161;;040-577-067-037-463;;104-212-297-137-759;;010-953-281-569-514;;039-889-533-551-521;;013-795-151-218-458;;038-613-711-274-229;;023-676-781-371-861;;068-238-957-669-243;;014-277-808-472-992;;061-754-151-573-898;;113-327-994-370-771;;006-553-734-546-212;;105-316-874-895-908;;032-728-154-591-070;;056-201-471-905-934;;028-862-168-091-90X;;067-078-099-297-810;;040-701-579-915-050;;018-694-084-068-187;;104-557-841-648-936;;034-441-292-442-799;;038-895-768-831-047;;132-281-029-747-299;;087-667-912-261-011;;001-835-514-097-551;;002-377-881-851-166;;022-179-293-052-569;;038-595-729-934-153;;007-709-585-201-038;;006-574-964-805-278;;030-323-674-660-051;;092-023-577-402-127;;019-381-122-709-352;;059-687-023-079-503;;111-914-031-290-975;;043-234-476-479-208;;054-706-628-377-190;;056-584-393-786-220;;026-126-853-260-259;;071-305-244-060-783;;075-247-958-346-33X;;040-833-896-641-924;;088-086-720-613-343;;002-007-578-507-698;;020-576-792-007-611;;120-925-618-376-989;;007-454-016-910-916;;066-149-708-871-507;;135-761-430-417-685;;004-473-514-471-578;;039-055-633-551-472;;005-537-680-968-965;;066-081-654-645-396;;004-458-031-333-650;;053-392-328-406-863;;076-774-944-138-418;;008-328-268-697-591;;057-218-939-320-948;;094-082-569-858-098;;014-023-664-920-775;;130-038-918-195-153;;005-827-013-023-322;;025-344-156-370-62X;;059-062-592-770-898;;015-462-197-604-87X;;051-727-807-844-974;;019-159-298-022-100;;042-646-734-745-105;;010-488-381-022-259;;082-210-673-349-152;;004-458-031-333-650;;041-909-244-299-232;;078-432-639-041-575;;042-740-484-382-110;;040-307-220-582-194;;020-126-213-879-311;;078-432-639-041-575;;030-100-991-545-155;;042-740-484-382-110;;113-845-646-947-618;;060-497-589-543-959;;004-204-680-158-661;;081-343-876-706-909;;005-638-542-147-993;;070-318-112-524-781;;061-519-730-880-032;;057-945-343-734-358;;005-642-729-451-09X;;003-752-183-823-430;;002-348-443-531-16X;;048-438-498-956-024;;024-929-137-199-30X;;124-805-115-929-413;;003-752-183-823-430;;015-466-204-116-873;;125-012-690-966-647;;071-163-081-597-04X;;035-135-729-507-737;;094-685-907-794-422;;062-029-719-290-327;;070-624-200-848-669;;012-746-915-512-650;;038-478-749-169-986;;035-554-935-107-802;;099-647-105-451-350;;009-621-637-014-514;;100-985-030-110-978;;030-630-100-818-462;;106-753-778-592-300;;032-820-729-763-323;;060-375-551-951-388;;043-108-278-056-872;;050-836-464-727-069;;071-707-020-428-907;;023-468-000-960-289;;077-525-954-203-403;;028-969-172-280-017;;020-753-772-581-741;;047-951-914-695-080;;062-485-301-455-912;;026-744-100-669-883;;117-663-803-983-152;;051-940-176-386-905;;029-667-686-534-996;;071-441-220-740-553;;013-417-878-440-713;;028-742-425-129-686;;012-300-595-074-789;;031-815-870-004-331;;040-841-912-862-912;;011-583-491-184-648;;126-659-091-098-052;;038-166-075-279-931;;083-079-509-375-354;;002-905-645-585-384;;007-364-858-655-289;;056-942-841-068-650;;107-302-749-967-437;;039-238-464-990-600;;036-564-551-324-053;;020-123-860-433-320;;011-516-147-270-264;;020-986-423-793-233;;029-750-154-523-855;;087-879-787-031-413;;027-326-505-837-755;;061-757-907-136-641;;090-774-193-364-453;;053-703-232-770-99X;;041-157-943-929-732;;007-470-431-271-066;;112-179-955-215-674;;056-422-417-058-69X;;005-022-447-377-963;;127-416-339-660-812;;001-467-559-709-949;;008-213-515-306-640;;053-703-232-770-99X;;033-109-855-318-388;;030-249-121-435-10X;;015-467-638-461-61X;;015-821-816-269-604;;040-363-636-264-022,23406016;;10.1186/1476-4598-12-11;;pmc3582597;;24043904;;10.4049/jimmunol.1301274;;1827828;;10.1084/jem.173.6.1483;;pmc2190830;;10.1111/j.1600-065x.1998.tb01574.x;;9553767;;pmc2883609;;10.1158/0008-5472.can-09-3109;;20179192;;10.1073/pnas.0908801107;;20080644;;pmc2824381;;10.1016/s0163-7258(00)00053-x;;11007998;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;10.1038/nri2761;;20414204;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;10.4049/jimmunol.148.5.1547;;1531669;;10.1038/nbt1135;;16151405;;1827828;;10.1084/jem.173.6.1483;;pmc2190830;;9780179;;10.4049/jimmunol.161.8.4083;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;10.1126/science.3929380;;3929380;;10556249;;10.1093/protein/12.10.879;;10.4049/jimmunol.137.11.3614;;2431039;;10.1016/0042-6822(90)90025-m;;1693247;;1697100;;10.1111/j.1365-3083.1990.tb02896.x;;8424945;;10.1021/bi00055a024;;pmc19525;;9012796;;10.1073/pnas.94.2.412;;10.1016/0022-2836(70)90057-4;;5420325;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;10.1021/ja00245a050;;7521646;;10.1038/nbt0994-899;;10.1126/science.2471267;;2471267;;16263307;;10.1016/j.jasms.2005.09.008;;10.1021/bi00161a011;;1332755;;10.1021/bi00078a011;;7687462;;15299382;;10.1107/s0907444994001344;;2185018;;10.1111/j.1432-1033.1990.tb15454.x;;9351804;;10.1016/s0969-2126(97)00279-7;;977570;;10.1016/s0021-9258(20)81858-4;;10.1002/eji.1830240409;;8149953;;15299544;;10.1107/s0907444992010400;;9624003;;10.1038/30989;;10.1038/321522a0;;3713831;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;1404388;;10.1016/0022-2836(92)90223-7;;10.1038/nbt1344;;17989688;;19018092;;10.1182/blood-2008-09-179754;;10.1016/0161-5890(92)90200-h;;1533898;;10.4049/jimmunol.1003412;;21357255;;10.1016/j.molimm.2008.06.027;;18691763;;10.3410/f.1001160.6701;;11520463;;10.1016/s1074-7613(01)00183-2;;8340761;;pmc2191116;;10.1084/jem.178.2.661;;2965792;;10.1038/332563a0;;pmc52646;;10.1073/pnas.88.20.9036;;1833770;;10917521;;10.1038/35018508;;19896358;;10.1016/j.copbio.2009.10.011;;10458776;;10.1002/(sici)1521-4141(199908)29:08<2613::aid-immu2613>3.0.co;2-j;;10.1097/00007890-199457110-00001;;10.1097/00007890-199406150-00001;;8009586;;9317161;;10.4049/jimmunol.159.7.3613;;pmc2467532;;10.2210/pdb3c2s/pdb;;18560159;;10.1107/s0907444908007877;;20503261;;10.1002/dmrr.1080;;pmc40279;;10.1073/pnas.92.26.11980;;8618827;;10.1182/blood-2006-07-034017;;17038522;;10.1016/j.ymeth.2013.06.035;;23872058;;10.1158/1535-7163.mct-08-0201;;18723496;;10.4161/mabs.2.2.11158;;pmc2840237;;20150767;;11096108;;10.1074/jbc.m009483200;;11160318;;10.4049/jimmunol.166.4.2571;;pmc1389705;;10.1073/pnas.0508123103;;16537476;;10.1182/blood-2009-06-225979;;10.3410/f.4252956.4109054;;pmc2881503;;20194898;;10.1016/j.yexcr.2011.03.018;;21459085;;17875730;;10.1158/0008-5472.can-07-0696;;10.1186/bcr3069;;22129105;;pmc3326565;;3138110;;pmc454472;;10.1002/j.1460-2075.1988.tb03037.x;;10.1158/0008-5472.can-07-6297;;18483271;;10.1111/j.1365-3083.2009.02338.x;;19906198;;10.1046/j.1365-2567.1998.00472.x;;pmc1364140;;9659234;;16622479;;10.1038/nri1837;;21852502;;10.1126/science.1206954;;pmc3164589;;10.1073/pnas.1208698109;;pmc3390832;;22723355;;23744091;;10.1093/protein/gzt022;;pmc3785249;;14699147;;10.1074/jbc.c300470200;;10.4049/jimmunol.176.1.346;;16365427;;11096108;;10.1074/jbc.m009483200;;12391234;;10.4049/jimmunol.169.9.5171;;10.1074/jbc.m604292200;;16793771;;10.4049/jimmunol.0804182;;19494290;;10.1038/nbt.1601;;pmc2855492;;20081867;;17077181;;10.1093/intimm/dxl110;;10.1074/jbc.m604292200;;16793771;;10.1038/nbt1143;;16186811;;10.4049/jimmunol.0804182;;19494290;;10688122;;15695407;;10.1158/0008-5472.622.65.2;;pmc4154799;;10429243;;10.1038/11717;;pmc48562;;10.1073/pnas.89.5.1904;;1542690;;19915550;;10.1038/nbt.1588;;10.1038/6179;;10052355;;10.1002/eji.1830230216;;8436176;;2507634;;10.4049/jimmunol.143.8.2595;;10.1073/pnas.0908590107;;20080725;;pmc2818909;;11986321;;10.1074/jbc.m202069200;;16219319;;10.1016/j.jim.2005.08.009;;10.1158/1078-0432.ccr-08-3222;;19401346;;10.1002/bit.20151;;15352059;;10.1038/nbt1178;;16429149;;11986321;;10.1074/jbc.m202069200;;12427744;;10.1074/jbc.m210665200;;10.1146/annurev.immunol.26.021607.090232;;18370923;;10.1146/annurev.bi.41.070172.003325;;4563441;;10.4049/jimmunol.172.9.5489;;15100290;;2459288;;pmc2189025;;10.1084/jem.168.3.1099;;12042244;;10.1093/glycob/12.4.43r;;10.1038/316452a0;;3927174;;11275255;;10.1016/s0161-5890(00)00105-x;;10.2174/1389201023378229;;12463418;;10.1023/b:pham.0000008042.15988.c0;;14725359;;10397155;;10.1016/s0165-2478(99)00029-2;;10.1093/chromsci/40.6.343;;12137207;;8644915;;10.1021/ac00116a002;;10.1038/348552a0;;2247164;;1172191;;10.1038/256495a0;;8159246;;10.1038/368856a0;;8144892;;7494109;;10.3109/08830189509061738;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;10.1093/intimm/5.6.647;;8347558;;8348148;;10.1038/ng0693-117;;8458340;;10.1002/j.1460-2075.1993.tb05722.x;;pmc413279;;10.1093/intimm/6.4.579;;8018598;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;10.1038/nbt727;;12172556;;pmc363152;;10.1128/mcb.8.1.466-472.1988;;2827008;;10.1128/mcb.8.1.466;;25291200;;10.1016/0167-5699(85)90161-6;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;18553400;;10.1002/bit.21855;;17099914;;10.1002/bit.21260;;pmc3064176;;21282104;;10.1074/jbc.m110.185041;;10.1016/j.cbpa.2009.03.023;;19414278;;10.1002/anie.200801313;;19072788;;10.1039/b908687k;;19675886;;10.1002/cbic.200800801;;19130455;;10.1016/j.chembiol.2008.01.007;;18291317;;19924746;;pmc4878437;;10.1002/anie.200903627;;10.1021/bc800294a;;19191567;;16424916;;10.1038/nrd1957;;10.1002/jps.2600660104;;833720;;2674208;;10.1002/j.1552-4604.1989.tb03403.x;;3390170;;10.1016/s0006-291x(88)81333-0;;10.1128/aac.39.1.180;;pmc162506;;7695303;;7907597;;10.1016/s0021-9258(17)37081-3;;10.1016/0014-5793(94)00313-0;;8206150;;7820457;;10.1006/immu.1994.1029;;15470033;;10.4049/jimmunol.173.8.4919;;10700237;;10.1038/73193;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1126/science.7545313;;7545313;;9500607;;10.1038/nm0398-328;;9850053;;2871125;;pmc2188095;;10.1084/jem.163.5.1037;;10.1016/0167-5699(92)90153-x;;1385707;;8910274;;10.1126/science.274.5291.1363;;10657670;;10.4049/jimmunol.164.4.2160;;9176498;;10.1038/nm0697-682;;9930702;;10.1038/16717;;10.1016/s0969-2126(94)00113-8;;7704521;;9707601;;pmc21462;;10.1073/pnas.95.17.10067;;9850053;;10.1038/nm735;;12118245;;10.3410/f.1008846.113460;;15930300;;10.1158/0008-5472.can-04-3319;;27754618;;27799103;;10.1016/s0076-6879(97)76066-x;;22997138;;10.1002/cbic.201200426;;10.2210/pdb4h1s/pdb;;19461840;;pmc2483472;;10.1107/s0021889807021206,"STEVEN RUST ET AL: ""Combining phenotypic and proteomic approaches to identify membrane targets in a 'triple negative' breast cancer breast cancer cell type"", MOLECULAR CANCER, BIOMED CENTRAL, LONDON, GB, vol. 12, no. 1, 13 February 2013 (2013-02-13), pages 11, XP021139556, ISSN: 1476-4598, DOI: 10.1186/1476-4598-12-11;;M. G. TERP ET AL: ""Anti-Human CD73 Monoclonal Antibody Inhibits Metastasis Formation in Human Breast Cancer by Inducing Clustering and Internalization of CD73 Expressed on the Surface of Cancer Cells"", THE JOURNAL OF IMMUNOLOGY, vol. 191, no. 8, 16 September 2013 (2013-09-16), US, pages 4165 - 4173, XP055245512, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1301274;;CANFIELD S M ET AL: ""THE BINDING AFFINITY OF HUMAN IGG FOR ITS HIGH AFFINITY FC RECEPTOR IS DETERMINED BY MULTIPLE AMINO ACIDS IN THE CH2 DOMAIN AND IS MODULATED BY THE HINGE REGION"", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 173, no. 6, 1 June 1991 (1991-06-01), pages 1483 - 1491, XP001181027, ISSN: 0022-1007, DOI: 10.1084/JEM.173.6.1483;;RESTA ET AL., IMMUNOL REV, vol. 161, 1998, pages 95 - 109;;COLGAN ET AL., PRINERGIC SIGNAL, vol. 2, 2006, pages 351 - 60;;ZHANG ET AL., CANCER RES, vol. 70, 2010, pages 2245 - 55;;STAGG ET AL., PNAS, vol. 107, 2010, pages 1547 - 52;;SPYCHALA ET AL., PHARMACOL THER, vol. 3000, no. 87, pages 161 - 73;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;CHANCARTER, NAT. REV. IMMUNOL., vol. 10, 2010, pages 301;;SONGSIVILAILACHMANN, CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;LONBERG, NATURE BIOTECH., vol. 23, no. 9, 2005, pages 1117 - 1125;;JEFFERIS ET AL., MABS, vol. 1, 2009, pages 1;;CANFIELDMORRISON, J. EXP. MED., vol. 173, 1991, pages 1483;;ROUX ET AL., J. IMMUNOL., vol. 161, 1998, pages 4083;;ROUX ET AL., J IMMUNOL, vol. 161, 1998, pages 4083;;ALLEN ET AL., BIOCHEMISTRY, vol. 48, 2009, pages 3755;;FISHWILD, D. ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;CUNNINGHAMWELLS, SCIENCE, vol. 229, 1985, pages 1202;;KOBAYASHI ET AL., PROTEIN ENG., vol. 12, no. 10, 1999, pages 879 - 884;;STAHLI ET AL., METHODS IN ENZYMOLOGY, vol. 9, 1983, pages 242;;KIRKLAND ET AL., J. IMMUNOL., vol. 137, 1986, pages 3614;;MOREL ET AL., MOL. IMMUNOL., vol. 25, no. 1, 1988, pages 7;;CHEUNG ET AL., VIROLOGY, vol. 176, 1990, pages 546;;MOLDENHAUER ET AL., SCAND. J. IMMUNOL., vol. 32, 1990, pages 77;;BRUMMELL ET AL., BIOCHEM., vol. 32, 1993, pages 1180 - 1187;;BURKS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 412 - 417;;E. MEYERSW. MILLER, CABIOS, vol. 4, 1989, pages 11 - 17;;NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 444 - 453;;ALTSCHUL ET AL.: ""Basic local alignment search tool"", J. MOL. BIOL., vol. 215, 1990, pages 403 - 410, XP002949123, DOI: 10.1006/jmbi.1990.9999;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3389 - 3402;;LEE ET AL., J. AM. CHEM. SOC., vol. 109, 1987, pages 3464,3466;;JESPERS ET AL., BIOTECHNOLOGY, vol. 12, 1994, pages 899;;CUNNINGHAMWELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085;;HAMBLEYGROSS, J. AMERICAN SOC. MASS SPECTROMETRY, vol. 16, 2005, pages 2057;;ZINN-JUSTIN ET AL., BIOCHEMISTRY, vol. 31, 1992, pages 11335 - 11347;;ZINN-JUSTIN ET AL., BIOCHEMISTRY, vol. 32, 1993, pages 6884 - 6891;;GIEGE ET AL., ACTA CRYSTALLOGR., vol. D50, 1994, pages 339 - 350;;MCPHERSON, EUR. J. BIOCHEM., vol. 189, 1990, pages 1 - 23;;CHAYEN, STRUCTURE, vol. 5, 1997, pages 1269 - 1274;;MCPHERSON, J. BIOL. CHEM., vol. 251, 1976, pages 6300 - 6303;;COX, J. P. L. ET AL.: ""A Directory of Human Germ-line V Segments Reveals a Strong Bias in their Usage"", EUR. J. IMMUNOL., vol. 24, 1994, pages 827 - 836, XP003004702, DOI: 10.1002/eji.1830240409;;MUELLER ET AL., MOL. IMMUNOL., vol. 114, 115, 1997, pages 441 - 423;;BRICOGNE, ACTA CRYST., vol. D49, 1993, pages 37 - 60;;ROVERSI ET AL., ACTA CRYST., vol. D56, 2000, pages 1313 - 1323;;RIECHMANN, L. ET AL., NATURE, vol. 393, 1998, pages 474 - 478;;JONES, P. ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;QUEEN, C. ET AL., PROC. NATL. ACAD. SEE. U.S.A., vol. 86, 1989, pages 10029 - 10033;;TOMLINSON, I. M. ET AL.: ""The Repertoire of Human Germline V Sequences Reveals about Fifty Groups of V Segments with Different Hypervariable Loops"", J. MOL. BIOL., vol. 227, 1992, pages 776 - 798, XP024020607, DOI: 10.1016/0022-2836(92)90223-7;;ROTHER ET AL., NAT. BIOTECHNOL., vol. 25, 2007, pages 1256;;BRUHNS ET AL., BLOOD, vol. 113, 2009, pages 3716;;SARMAY ET AL., MOLEC. IMMUNOL., vol. 29, no. 5, 1992, pages 633 - 9;;HORTON ET AL., J. IMMUNOL., vol. 186, 2011, pages 4223;;CHU ET AL., MOL. IMMUNOL., vol. 45, 2008, pages 3926;;GROSS ET AL., IMMUNITY, vol. 15, 2001, pages 289;;IDUSOGIE ET AL., J. IMMUNOL., vol. 164, 2000, pages 1925;;TAO ET AL., J. EXP. MED., vol. 178, 1993, pages 661;;LABRIJN ET AL., CURR. OP. IMMUNOL., vol. 20, 2008, pages 460;;DUNCANWINTER, NATURE, vol. 332, 1988, pages 563;;CHAPPEL ET AL., PROC. NAT'L ACAD. SCI. (USA), vol. 88, 1991, pages 9036;;SONDERMANN ET AL., NATURE, vol. 406, 2000, pages 267;;STROHL, CURRENT OPINION IN BIOTECHNOLOGY, vol. 20, 2009, pages 685 - 691;;ARMOUR ET AL., EUR. J. IMMUNOL., vol. 29, 1999, pages 2613;;ALEGRE ET AL., TRANSPLANTATION, vol. 57, 1994, pages 1537;;COLE ET AL., J. IMMUNOL., vol. 159, 1997, pages 3613;;OGANESYAN ET AL., ACTA CRYSTALLOGR. D. BIOL. CRYSTALLOGR., vol. 64, 2008, pages 700;;DAVIS ET AL., J. IMMUNOL., vol. 34, 2007, pages 2204;;GLAESNER ET AL., DIABETES METAB. RES. REV., vol. 26, 2010, pages 287;;HUTCHINS ET AL., PROC. NAT'L ACAD. SCI. (USA), vol. 92, 1995, pages 11980;;AN ET AL., MABS, vol. 1, 2009, pages 572;;MCEARCHERN ET AL., BLOOD, vol. 109, 2007, pages 1185;;VAFA ET AL., METHODS, vol. 65, 2014, pages 114;;RICHARDS ET AL., MOL. CANCER THERAP., vol. 7, 2008, pages 2517;;MOORE ET AL., MABS, vol. 2, 2010, pages 181;;SHIELDS ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604;;IDUSOGIE ET AL., J. IMMUNOL., vol. 166, 2001, pages 2571;;LAZAR ET AL., PROC. NAT'L ACAD SCI. (USA), vol. 103, 2006, pages 4005;;MOSSNER ET AL., BLOOD, vol. 115, 2010, pages 4393;;DESJARLAISLAZAR, EXP. CELL RES., vol. 317, 2011, pages 1278;;STAVENHAGEN ET AL., CANCER RES., vol. 67, 2007, pages 8882;;NORDSTROM ET AL., BREAST CANCER RES., vol. 13, 2011, pages R123;;DANGL ET AL., EMBO J., vol. 7, 1988, pages 1989;;NATSUME ET AL., CANCER RES., vol. 68, 2008, pages 3863;;MICHAELSEN ET AL., SCAND. J. IMMUNOL., vol. 70, 2009, pages 553;;REDPATH ET AL., IMMUNOLOGY, vol. 93, 1998, pages 595;;DALL'ACQUA ET AL., J. IMMUNOL., vol. 177, 2006, pages 1129;;CARTER, NAT. REV. IMMUNOL., vol. 6, 2006, pages 343;;LIRAVETCH, SCIENCE, vol. 333, 2011, pages 1030;;LIRAVETCH, PROC. NAT'L ACAD. SCI (USA), vol. 109, 2012, pages 10966;;MIMOTO ET AL., PROTEIN. ENG. DES. & SELECTION, vol. 26, 2013, pages 589;;HINTON ET AL., J. BIOL. CHEM., vol. 279, no. 8, 2004, pages 6213 - 6216;;HINTON ET AL., JOURNAL OF IMMUNOLOGY, vol. 176, 2006, pages 346 - 356;;SHIELDS ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 9, 2001, pages 6591 - 6604;;DALL ACQUA ET AL., JOURNAL OF IMMUNOLOGY, vol. 169, 2002, pages 5171 - 5180;;DALL'ACQUA ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, 2006, pages 23514 - 23524;;YEUNG ET AL., J. IMMUNOL., vol. 182, 2009, pages 7663;;ZALEVSKY ET AL., NAT. BIOTECHNOL., vol. 28, 2010, pages 157;;PETKOVA ET AL., INT. IMMUNOL., vol. 18, 2006, pages 1759;;DALL'ACQUA ET AL., J. BIOL. CHEM., vol. 281, 2006, pages 23514;;VACCARO ET AL., NAT. BIOTECHNOL., vol. 23, 2005, pages 1283;;YEUNG ET AL., J. IMMUNOL., vol. 182, 2010, pages 7663 - 7671;;HORNICK ET AL., J. NUCL. MED., vol. 41, 2000, pages 355;;KIM ET AL., EUR. J. IMMUNOL., vol. 29, 2000, pages 2819;;KENANOVA ET AL., CANCER RES., vol. 65, 2005, pages 622;;CHAPMAN ET AL., NAT. BIOTECHNOL., vol. 17, 1999, pages 780;;YEH ET AL., PROC. NAT'L ACAD. SCI., vol. 89, 1992, pages 1904;;SCHELLENBERGER ET AL., NAT. BIOTECHNOL., vol. 27, 2009, pages 1186;;UMANA ET AL., NAT. BIOTECH., vol. 17, 1999, pages 176 - 180;;BOLT ET AL., EUR. J. IMMUNOL., vol. 23, 1993, pages 403;;TAOMORRISON, J. IMMUNOL., vol. 143, 1989, pages 2595;;JUNG ET AL., PROC. NAT'L ACAD. SCI (USA), vol. 107, 2010, pages 604;;SHIELDS ET AL., JBC, vol. 277, 2002, pages 26733;;NIWA ET AL., J. IMMUNOL. METHODS, vol. 306, 2005, pages 151;;CARDARELLI ET AL., CLIN. CANCER RES., vol. 15, 2009, pages 3376;;CARDARELLI ET AL., CANCER IMMUNOL. IMMUNOTHERAP., vol. 59, 2010, pages 257;;YAMANE-OHNUKI ET AL., BIOTECHNOL. BIOENG., vol. 87, 2004, pages 614;;ZHANG ET AL., MABS, vol. 3, 2011, pages 289;;LI ET AL., NAT. BIOTECHNOL., vol. 24, 2006, pages 210;;SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740;;SHINKAWA ET AL., J. BIOL. CHEM., vol. 278, 2003, pages 3466;;NIMMERJAHN ET AL., ANN. REV. IMMUNOL., vol. 26, 2008, pages 513;;MARSHALL ET AL., ANNU REV BIOCHEM, vol. 41, 1972, pages 673 - 702;;GALAMORRISON, J. IMMUNOL, vol. 172, 2004, pages 5489 - 94;;WALLICK ET AL., J EXP MED, vol. 168, 1988, pages 1099 - 109;;SPIRO, GLYCOBIOLOGY, vol. 12, 2002, pages 43R - 56R;;PAREKH ET AL., NATURE, vol. 316, 1985, pages 452 - 7;;MIMURA ET AL., MOL IMMUNOL, vol. 37, 2000, pages 697 - 706;;KRISHNAMURTHY RMANNING M C, CURR PHARM BIOTECHNOL, vol. 3, 2002, pages 361 - 71;;CHEN ET AL., PHARM RES, vol. 20, 2003, pages 1952 - 60;;GHIRLANDO ET AL., IMMUNOL LETT, vol. 68, 1999, pages 47 - 52;;MURRAY ET AL., J. CHROMATOGR SCI, vol. 40, 2002, pages 343 - 9;;ALEXANDER A JHUGHES D E, ANAL CHEM, vol. 67, 1995, pages 3626 - 32;;KABAT, E. A.: ""Sequences of Proteins of Immunological Interest"", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, NIH;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 495;;LONBERG ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;TUAILLON ET AL., J. IMMUNOL., vol. 152, 1994, pages 2912 - 2920;;LONBERG, N.HUSZAR, D., INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93;;HARDING, F.LONBERG, N., ANN. N.Y. ACAD. SCI., vol. 764, 1995, pages 536 - 546;;TAYLOR, L. ET AL., NUCLEIC ACIDS RESEARCH, vol. 20, 1992, pages 6287 - 6295;;CHEN, J. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 5, 1993, pages 647 - 656;;TUAILLON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;CHOI ET AL., NATURE GENETICS, vol. 4, 1993, pages 117 - 123;;CHEN, J. ET AL., EMBO J., vol. 12, 1993, pages 821 - 830;;TAYLOR, L. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 6, 1994, pages 579 - 591;;TOMIZUKA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 722 - 727;;KUROIWA ET AL., NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 889 - 894;;GOEDDEL: ""Gene Expression Technology. Methods in Enzymology"", vol. 185, 1990, ACADEMIC PRESS;;TAKEBE, Y. ET AL., MOL. CELL. BIOL., vol. 8, 1988, pages 466 - 472;;BOSS, M. A.WOOD, C. R., IMMUNOLOGY TODAY, vol. 6, 1985, pages 12 - 13;;URLAUBCHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R. J. KAUFMANP. A. SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621;;DICK ET AL., BIOTECHNOL. BIOENG., vol. 100, 2008, pages 1132;;DICK ET AL., BIOTECHNOL. BIOENG., vol. 97, 2007, pages 544;;LIU ET AL., JBC, 2011;;LIU ET AL., J. BIOL. CHEM., vol. 286, 2011, pages 11211;;SENTER, P. D., CURR. OPIN. CHEM. BIOL., vol. 13, 2009, pages 235 - 244;;HACKENBERGER, C. P. R.SCHWARZER, D., ANGEW. CHEM. INT. ED. ENGL., vol. 47, 2008, pages 10030 - 10074;;SUNBUL, M.YIN, J., ORG. BIOMOL. CHEM., vol. 7, 2009, pages 3361 - 3371;;FRESE, M. A.DIERKS, T., CHEMBIOCHEM., vol. 10, 2009, pages 425 - 427;;TAKI, M. ET AL., PROT. ENG. DES. SEL., vol. 17, 2004, pages 119 - 126;;GAUTIER, A. ET AL., CHEM. BIOL., vol. 15, 2008, pages 128 - 136;;BORDUSA, F., HIGHLIGHTS IN BIOORGANIC CHEMISTRY, 2004, pages 389 - 403;;REN, H. ET AL., ANGEW. CHEM. INT. ED. ENGL., vol. 48, 2009, pages 9658 - 9662;;TAYLOR, E. VOGELIMPERIALI, B: ""Protein Engineering"", NUCLEIC ACIDS AND MOLECULAR BIOLOGY, vol. 22, 2009, pages 65 - 96;;DE GRAAF, A. J. ET AL., BIOCONJUG. CHEM., vol. 20, 2009, pages 1281 - 1295;;SCHRAMA ET AL., NATURE REV. DRUG DISC., vol. 5, 2006, pages 147;;BERGE, S.M. ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;V.V. RANADE, J. CLIN. PHARMACOL., vol. 29, 1989, pages 685;;UMEZAWA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 153, 1988, pages 1038;;P.G. BLOEMAN ET AL., FEBS LETT., vol. 357, 1995, pages 140;;M. OWAIS ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 39, 1995, pages 180;;BRISCOE ET AL., AM. J. PHYSIOL., vol. 1233, 1995, pages 134;;SCHREIER ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 9090;;K. KEINANENM.L. LAUKKANEN, FEBS LETT., vol. 346, 1994, pages 123;;J.J. KILLIONI.J. FIDLER, IMMUNOMETHODS, vol. 4, 1994, pages 273;;HE ET AL., J. IMMUNOL., vol. 173, 2004, pages 4919 - 28;;KUGLER ET AL., NATURE MEDICINE, vol. 60-62, 2000, pages 332 - 336;;TAMURA ET AL., SCIENCE, vol. 278, 1997, pages 3023 - 3043;;DRANOFF ET AL., PROC. NATL. ACAD. SCI U.S.A., vol. 90, 1993, pages 3539 - 43;;ROSENBERG, S A, IMMUNITY, vol. 10, 1999, pages 281 - 7;;KIM ET AL., SCIENCE, vol. 266, 1994, pages 2011 - 2013;;SUOTSRIVASTAVA, SCIENCE, vol. 269, 1995, pages 1585 - 1588;;NESTLE ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 - 332;;MOKYR ET AL., CANCER RESEARCH, vol. 58, 1998, pages 5301 - 5304;;KEHRL ET AL., J. EXP. MED., vol. 163, 1986, pages 1037 - 1050;;HOWARDO'GARRA, IMMUNOLOGY TODAY, vol. 13, 1992, pages 198 - 200;;HAHNE ET AL., SCIENCE, vol. 274, 1996, pages 1363 - 1365;;WEINBERG ET AL., IMMUNOL, vol. 164, 2000, pages 2160 - 2169;;MELERO ET AL., NATURE MEDICINE, vol. 3, 1997, pages 682 - 685;;HUTLOFF ET AL., NATURE, vol. 397, 1999, pages 262 - 266;;POLJAK, STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;TANSEY, DRUG DISCOVERY TODAY, vol. 00, 2009, pages 1;;ROSENBLATT ET AL., J. IMMUNOTHERAPY, vol. 34, 2011, pages 409;;HURWITZ ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, no. 17, 1998, pages 10067 - 10071;;CAMACHO ET AL., J. CLIN. ONCOLOGY, vol. 22, 2004, pages 145;;MOKYR ET AL., CANCER RES., vol. 58, 1998, pages 5301 - 5304;;""PDR"", 2004, pages: 608 - 610;;FULDA ET AL., NAT MED, vol. 8, 2002, pages 808 - 15;;HYER ET AL., CANCER RESEARCH, vol. 65, 2005, pages 4799 - 808;;OTWINOWSKI Z.MINOR W., METHODS IN ENZYMOLOGY, vol. 276, 1997, pages 307 - 326;;HEUTS ET AL., CHEMBIOCHEM., vol. 13, no. 16, 5 November 2012 (2012-11-05), pages 2384 - 91;;MCCOY ET AL., J. APPL. CRYST., vol. 40, 2007, pages 658 - 674;;BRICOGNE ET AL.: ""BUSTER"", 2011, GLOBAL PHASING LTD",PENDING
418,CN,A,CN 113773388 A,012-489-444-130-239,2021-12-10,2021,CN 202111102059 A,2015-11-19,US 201462083056 P;;CN 201580063448 A,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,"The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON PAUL;;SRINIVASAN MOHAN;;HENNING KARLA ANN;;RAY MIRANDA;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;CHEUNG PATRICK,,https://lens.org/012-489-444-130-239,Patent Application,no,3,1,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/395;;A61K45/06;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/30;;C07K16/40,,1,0,,,"陈景等: ""CD73在肿瘤免疫治疗中的研究进展"", 《癌症进展》, no. 06, pages 72 - 75",PENDING
419,HU,T2,HU E050596 T2,063-445-045-170-087,2020-12-28,2020,HU E15816276 A,2015-11-19,US 201462083056 P,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/063-445-045-170-087,Amended Patent,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61P35/00;;C07K16/30;;C07K16/40,,0,0,,,,PENDING
420,JP,A,JP 2021061837 A,080-232-841-482-185,2021-04-22,2021,JP 2020200743 A,2020-12-03,US 201462083056 P,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,"To provide methods of regulating tumor progression through multiple mechanisms, as well as methods for regulating CD73 activity and related therapeutic agents.SOLUTION: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.SELECTED DRAWING: None",BRISTOL MYERS SQUIBB CO,NILS LONBERG;;ALAN J KORMAN;;BRYAN C BARNHART;;AARON P YAMNIUK;;MOHAN SRINIVASAN;;KARLA HENNING;;LEI MING;;EMANUELA SEGA;;ANGELA GOODENOUGH;;MARIA N JURE-KUNKEL;;CHEN GUODONG;;JOHN SACK;;RICHARD HUANG;;MARTIN J CORBETT;;JOSEPH E MYERS JR;;LIANG SCHWEIZER;;SANDRA V HATCHER;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/080-232-841-482-185,Patent Application,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C12N15/13;;A61K39/395;;A61K45/00;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P5/14;;A61P7/00;;A61P11/00;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P17/00;;A61P19/08;;A61P21/00;;A61P25/00;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/04;;A61P43/00;;C07K16/28;;C07K16/46;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/62;;C12N15/63;;C12P21/08;;G01N33/543;;G01N33/574,,4,0,,,"J. IMMUNOL., vol. 191, JPN6019029852, 2013, pages 4165 - 4173, ISSN: 0004834535;;PROC. NATL. ACAD. SCI. U.S.A., vol. 107, no. 4, JPN6019029846, 2010, pages 1547 - 1552, ISSN: 0004834536;;CLIN. CANCER RES., vol. 19, no. 20, JPN6019029848, 2013, pages 5626 - 5635, ISSN: 0004834537;;MOL. CANCER, vol. 12:11, JPN6019029850, 2013, ISSN: 0004834538",ACTIVE
421,CN,A,CN 107001474 A,151-898-331-911-984,2017-08-01,2017,CN 201580063448 A,2015-11-19,US 201462083056 P;;US 2015/0061639 W,2014-11-21,Antibodies against CD73 and uses thereof,"The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/151-898-331-911-984,Patent Application,no,4,36,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/395;;A61P35/00;;C07K16/30;;C07K16/40;;G01N33/573;;G01N33/68,,1,1,094-218-297-204-09X,23406016;;10.1186/1476-4598-12-11;;pmc3582597,"STEVEN RUST ET AL: ""Combining phenotypic and proteomic approaches to identify membrane targets in a ""triple negative"" breast cancer breast cancer cell type"", 《MOLECULAR CANCER》",ACTIVE
422,SI,T1,SI 3221363 T1,042-851-439-145-417,2020-09-30,2020,SI 201531307 T,2015-11-19,US 201462083056 P;;US 2015/0061639 W;;EP 15816276 A,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/042-851-439-145-417,Granted Patent,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/00;;A61K39/00;;A61P35/00,,0,0,,,,ACTIVE
423,MX,A,MX 2018007072 A,055-712-403-025-036,2018-12-12,2018,MX 2018007072 A,2016-12-08,US 201562265611 P;;US 201662324428 P;;US 201662365543 P;;US 201615355836 A;;US 2016/0065570 W,2015-12-10,END EFFECTOR FOR INSTRUMENT WITH ULTRASONIC AND ELECTROSURGICAL FEATURES.,"An apparatus includes a body, a shaft assembly, and an end effector. The end effector includes an ultrasonic blade and a clamp arm assembly. The ultrasonic blade is in acoustic communication with an acoustic waveguide of the shaft assembly. The clamp arm assembly is pivotable toward and away from the ultrasonic blade. The clamp arm assembly includes a clamp pad and an electrode. The clamp pad is configured to compress tissue against the ultrasonic blade. The clamp pad has a proximal end, a distal end, and a pair of lateral sides extending from the proximal end to the distal end. The electrode is operable to apply RF energy to tissue. The electrode extends along both lateral sides of the clamp pad. The electrode further extends around the distal end of the clamp pad.",ETHICON LLC,BOUDREAUX CHAD P;;WIENER EITAN T;;DAVISON MARK A;;JOHNSON GREGORY W;;MILLER MATTHEW C;;MESSERLY JEFFREY D;;LESKO JASON R;;FREDERICK L ESTERA;;BARRY C WORRELL;;AMY M KRUMM (PORTER);;CATHERINE A CORBETT;;JOHN A HIBNER;;JOSEPH ISOSAKI;;SHAN WAN;;CANDICE OTREMBIAK;;WILLIAM B II WEISENBURGH,,https://lens.org/055-712-403-025-036,Patent Application,no,0,0,12,22,0,A61B18/1445;;A61B18/1492;;A61B2017/00389;;A61B2018/00404;;A61B2018/00595;;A61B2018/00607;;A61B2018/00619;;A61B2018/0063;;A61B2018/00791;;A61B2018/00922;;A61B2018/00994;;A61B2017/320094;;A61B2017/320095;;A61B17/320092;;A61B2017/2825;;A61B2017/320094;;A61B2017/320095;;A61B18/1445;;A61B2018/00595;;A61B2018/00607;;A61B2018/00404;;A61B2018/00619;;A61B18/1492;;A61B2017/00389;;A61B2018/00791;;A61B2018/00922;;A61B2018/0063;;A61B2018/00994;;A61B18/1206;;A61B2018/00077;;A61B2018/00083;;A61B2018/126;;A61B2018/142;;A61B2018/1455;;A61B17/320092,A61B18/14;;A61B17/00;;A61B17/29;;A61B17/32,,0,0,,,,PENDING
424,LT,T,LT 3221363 T,133-062-481-595-072,2020-08-10,2020,LT 15816276 T,2015-11-19,US 201462083056 P;;US 2015/0061639 W,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/133-062-481-595-072,Unknown,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/395;;A61P35/00;;C07K16/30;;C07K16/40,,0,0,,,,PENDING
425,MY,A,MY 189836 A,046-168-856-506-032,2022-03-11,2022,MY PI2017701826 A,2015-11-19,US 2015/0061639 W;;US 201462083056 P,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,"The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/046-168-856-506-032,Granted Patent,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;C07K16/30;;C07K16/40,,0,0,,,,ACTIVE
426,EA,B1,EA 035766 B1,122-438-492-300-755,2020-08-07,2020,EA 201790986 A,2015-11-19,US 201462083056 P;;US 2015/0061639 W,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,"The present invention provides an isolated human antibody that bind to human Cluster of Differentiation 73 (CD73) and comprises heavy chain CDR1, CDR2 and CDR3 sequences comprising SEQ ID NOs: 5, 6 and 7, respectively, and light chain CDRl, CDR2 and CDR3 sequences comprising SEQ ID NOs: 12, 14, and 15, respectively, wherein the antibody comprises a heavy chain constant region comprising an IgG2 hinge and an IgG1 CH1 domain. The present invention provides a method of treating cancer expressing CD73 using the antibody of the invention.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/122-438-492-300-755,Granted Patent,no,3,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/395;;A61P35/00;;C07K16/30;;C07K16/40,,3,3,094-218-297-204-09X;;048-700-652-556-098;;039-889-533-551-521,23406016;;10.1186/1476-4598-12-11;;pmc3582597;;24043904;;10.4049/jimmunol.1301274;;1827828;;10.1084/jem.173.6.1483;;pmc2190830,"STEVEN RUST;SANDRINE GUILLARD;KRIS SACHSENMEIER;CARL HAY;MAX DAVIDSON;ANDERS KARLSSON;ROGER KARLSSON;ERIN BRAND;DAVID LOWNE;JOHN E: ""Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer c"", MOLECULAR CANCER, BIOMED CENTRAL, LONDON, GB, vol. 12, no. 1, 13 February 2013 (2013-02-13), GB, pages 11, XP021139556, ISSN: 1476-4598, DOI: 10.1186/1476-4598-12-11;;M. G. TERP, K. A. OLESEN, E. C. ARNSPANG, R. R. LUND, B. C. LAGERHOLM, H. J. DITZEL, R. LETH-LARSEN: ""Anti-Human CD73 Monoclonal Antibody Inhibits Metastasis Formation in Human Breast Cancer by Inducing Clustering and Internalization of CD73 Expressed on the Surface of Cancer Cells"", THE JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 191, no. 8, 15 October 2013 (2013-10-15), US, pages 4165 - 4173, XP055245512, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1301274;;CANFIELD S M, MORRISON S L: ""THE BINDING AFFINITY OF HUMAN IGG FOR ITS HIGH AFFINITY FC RECEPTOR IS DETERMINED BY MULTIPLE AMINO ACIDS IN THE CH2 DOMAIN AND IS MODULATED BY THE HINGE REGION"", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 173, no. 06, 1 June 1991 (1991-06-01), US, pages 1483 - 1491, XP001181027, ISSN: 0022-1007, DOI: 10.1084/jem.173.6.1483",ACTIVE
427,ES,T3,ES 2807182 T3,173-701-401-026-574,2021-02-22,2021,ES 15816276 T,2015-11-19,US 201462083056 P;;US 2015/0061639 W,2014-11-21,Anticuerpos frente a CD73 y sus usos,"Un anticuerpo aislado que se une a Grupo de Diferenciación 73 (CD73) humano y que comprende las secuencias CDR1, CDR2 y CDR3 de la cadena pesada que comprenden las SEQ ID NO: 5, 6 y 7, respectivamente, y las secuencias CDR1, CDR2 y CDR3 de la cadena ligera que comprenden las SEQ ID NO: 13, 14 y 15, respectivamente, en donde el anticuerpo comprende una región constante de la cadena pesada que comprende una bisagra de IgG2 y dominio CH1 de IgG2.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/173-701-401-026-574,Granted Patent,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/395;;A61P35/00;;C07K16/30;;C07K16/40,,0,0,,,,ACTIVE
428,RS,B1,RS 60631 B1,073-978-051-895-396,2020-09-30,2020,RS P20200915 A,2015-11-19,US 201462083056 P;;US 2015/0061639 W;;EP 15816276 A,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/073-978-051-895-396,Granted Patent,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/395;;A61P35/00;;C07K16/30;;C07K16/40,,0,0,,,,ACTIVE
429,CA,A1,CA 2968357 A1,015-432-883-733-404,2016-05-26,2016,CA 2968357 A,2015-11-19,US 201462083056 P;;US 2015/0061639 W,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,"The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/015-432-883-733-404,Patent Application,no,0,0,66,66,380,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/395;;A61P35/00;;C07K16/30;;C07K16/40,,0,0,,,,PENDING
430,PL,T3,PL 3221363 T3,081-680-787-785-454,2021-01-11,2021,PL 15816276 T,2015-11-19,US 201462083056 P;;EP 15816276 A;;US 2015/0061639 W,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/081-680-787-785-454,Patent Application,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/395;;A61P35/00;;C07K16/30;;C07K16/40,,0,0,,,,PENDING
431,WO,A2,WO 2017/100423 A2,143-200-893-462-829,2017-06-15,2017,US 2016/0065570 W,2016-12-08,US 201562265611 P;;US 201662324428 P;;US 201662365543 P;;US 201615355836 A,2015-12-10,END EFFECTOR FOR INSTRUMENT WITH ULTRASONIC AND ELECTROSURGICAL FEATURES,"An apparatus includes a body, a shaft assembly, and an end effector. The end effector includes an ultrasonic blade and a clamp arm assembly. The ultrasonic blade is in acoustic communication with an acoustic waveguide of the shaft assembly. The clamp arm assembly is pivotable toward and away from the ultrasonic blade. The clamp arm assembly includes a clamp pad and an electrode. The clamp pad is configured to compress tissue against the ultrasonic blade. The clamp pad has a proximal end, a distal end, and a pair of lateral sides extending from the proximal end to the distal end. The electrode is operable to apply RF energy to tissue. The electrode extends along both lateral sides of the clamp pad. The electrode further extends around the distal end of the clamp pad.",ETHICON ENDO SURGERY LLC,JOHNSON GREGORY W;;LESKO JASON R;;ESTERA FREDERICK L;;KRUMM (PORTER) AMY M;;CORBETT CATHERINE A;;WEISENBURGH II WILLIAM B;;WORRELL BARRY C;;DAVISON MARK A;;BOUDREAUX CHAD P;;HIBNER JOHN A;;ISOSAKI JOSEPH;;WAN SHAN;;OTREMBIAK CANDICE;;WIENER EITAN T;;MESSERLY JEFFREY D;;MILLER MATTHEW C,,https://lens.org/143-200-893-462-829,Patent Application,yes,42,10,12,22,0,A61B18/1445;;A61B18/1492;;A61B2017/00389;;A61B2018/00404;;A61B2018/00595;;A61B2018/00607;;A61B2018/00619;;A61B2018/0063;;A61B2018/00791;;A61B2018/00922;;A61B2018/00994;;A61B2017/320094;;A61B2017/320095;;A61B17/320092;;A61B2017/2825;;A61B2017/320094;;A61B2017/320095;;A61B18/1445;;A61B2018/00595;;A61B2018/00607;;A61B2018/00404;;A61B2018/00619;;A61B18/1492;;A61B2017/00389;;A61B2018/00791;;A61B2018/00922;;A61B2018/0063;;A61B2018/00994;;A61B18/1206;;A61B2018/00077;;A61B2018/00083;;A61B2018/126;;A61B2018/142;;A61B2018/1455;;A61B17/320092,A61B18/14,,0,0,,,,PENDING
432,AU,A1,AU 2021/215286 A1,155-352-118-722-237,2021-09-09,2021,AU 2021/215286 A,2021-08-13,AU 2021/215286 A;;AU 2015/349878 A;;US 201462083056 P;;US 2015/0061639 W,2014-11-21,Antibodies against CD73 and uses thereof,"The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/155-352-118-722-237,Patent Application,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/395;;A61P35/00;;C07K16/30;;C07K16/40,,0,0,,,,PENDING
433,CO,A2,CO 2017005845 A2,002-253-949-821-883,2017-09-11,2017,CO 2017005845 A,2017-06-14,US 2015/0061639 W;;US 201462083056 P,2014-11-21,Anticuerpos monoclonales aislados contra cd73,"La presente invención proporciona anticuerpos monoclonales aislados, en particular, anticuerpos humanos, que se fijan al Cúmulo de Diferenciación 73 (CD73) humano con gran afinidad, inhiben la actividad de CD73 y median opcionalmente la internalización de CD73 dependiente de anticuerpo. También se proporcionan moléculas de ácido nucleico que codifican los anticuerpos de la invención, vectores de expresión, células huésped y métodos para expresar los anticuerpos de la invención. También se proporcionan inmunoconjugados, moléculas biespecíficas y composiciones farmacéuticas que comprenden los anticuerpos de la invención. La invención también proporciona métodos para inhibir el crecimiento de una célula tumoral que expresa CD73 usando los anticuerpos de la invención, lo cual incluye métodos para tratar distintos tipos de cáncer.",BRISTOL MYERS SQUIBB CO,CORBETT MARTIN J;;LONBERG NILS;;SRINIVASAN MOHAN;;CHEN GUODONG;;HUANG RICHARD;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;SACK JOHN;;SCHWEIZER LIANG;;HUANG HAICHUN;;ZHANG PINGPING;;JURE-KUNKEL MARIA N;;MYERS JOSEPH E;;HATCHER SANDRA V,,https://lens.org/002-253-949-821-883,Patent Application,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/395;;A61P35/00;;C07K16/30;;C07K16/40,,0,0,,,,PENDING
434,EP,A2,EP 3221363 A2,058-597-671-757-389,2017-09-27,2017,EP 15816276 A,2015-11-19,US 201462083056 P;;US 2015/0061639 W,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/058-597-671-757-389,Patent Application,yes,0,1,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/395;;A61P35/00;;C07K16/30;;C07K16/40,,0,0,,,,ACTIVE
435,SG,A,SG 11201703192S A,057-898-488-798-636,2017-05-30,2017,SG 11201703192S A,2015-11-19,US 201462083056 P;;US 2015/0061639 W,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/057-898-488-798-636,Unknown,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/395;;A61P35/00;;C07K16/30;;C07K16/40,,0,0,,,,PENDING
436,PH,A1,PH 12017500918 A1,158-828-685-824-82X,2017-11-20,2017,PH 12017500918 A,2017-05-18,US 201462083056 P;;US 2015/0061639 W,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,"The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/158-828-685-824-82X,Patent Application,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,A61P35/00;;A61K39/395;;C07K16/28;;C07K16/30;;C07K16/40,,0,0,,,,PENDING
437,DK,T3,DK 3221363 T3,150-763-963-665-940,2020-08-10,2020,DK 15816276 T,2015-11-19,US 201462083056 P;;US 2015/0061639 W,2014-11-21,ANTISTOFFER MOD CD73 OG ANVENDELSER DERAF,,BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/150-763-963-665-940,Granted Patent,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/395;;A61P35/00;;C07K16/30;;C07K16/40,,0,0,,,,ACTIVE
438,WO,A2,WO 2016/081748 A2,027-777-690-604-824,2016-05-26,2016,US 2015/0061639 W,2015-11-19,US 201462083056 P,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,"The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/027-777-690-604-824,Patent Application,yes,227,78,66,66,380,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,A61K39/395;;C07K16/28;;A61P35/00;;C07K16/30;;C07K16/40,,234,185,005-126-168-767-527;;051-427-852-498-113;;087-153-613-664-816;;004-922-729-065-965;;140-815-540-810-121;;002-699-487-824-639;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;033-955-564-406-161;;040-577-067-037-463;;104-212-297-137-759;;010-953-281-569-514;;013-795-151-218-458;;018-694-084-068-187;;014-277-808-472-992;;061-754-151-573-898;;113-327-994-370-771;;006-553-734-546-212;;068-238-957-669-243;;105-316-874-895-908;;056-201-471-905-934;;028-862-168-091-90X;;040-701-579-915-050;;018-694-084-068-187;;104-557-841-648-936;;034-441-292-442-799;;038-895-768-831-047;;132-281-029-747-299;;087-667-912-261-011;;001-835-514-097-551;;002-377-881-851-166;;038-595-729-934-153;;065-102-359-566-736;;042-204-626-457-327;;006-574-964-805-278;;030-323-674-660-051;;092-023-577-402-127;;022-179-293-052-569;;075-221-862-753-349;;059-687-023-079-503;;111-914-031-290-975;;043-234-476-479-208;;054-706-628-377-190;;056-584-393-786-220;;054-717-629-774-351;;026-126-853-260-259;;039-889-533-551-521;;019-381-122-709-352;;009-326-889-091-346;;071-305-244-060-783;;075-247-958-346-33X;;040-833-896-641-924;;002-007-578-507-698;;020-576-792-007-611;;120-925-618-376-989;;026-221-045-144-327;;007-454-016-910-916;;013-977-769-158-191;;066-149-708-871-507;;135-761-430-417-685;;004-473-514-471-578;;005-537-680-968-965;;066-081-654-645-396;;088-086-720-613-343;;004-458-031-333-650;;053-392-328-406-863;;004-458-031-333-650;;076-774-944-138-418;;053-665-670-663-452;;057-218-939-320-948;;094-082-569-858-098;;014-023-664-920-775;;130-038-918-195-153;;005-827-013-023-322;;025-344-156-370-62X;;059-062-592-770-898;;015-462-197-604-87X;;051-727-807-844-974;;019-159-298-022-100;;042-646-734-745-105;;010-488-381-022-259;;082-210-673-349-152;;004-458-031-333-650;;041-909-244-299-232;;078-432-639-041-575;;042-740-484-382-110;;040-307-220-582-194;;020-126-213-879-311;;078-432-639-041-575;;030-100-991-545-155;;042-740-484-382-110;;113-845-646-947-618;;060-497-589-543-959;;004-204-680-158-661;;081-343-876-706-909;;005-638-542-147-993;;043-239-734-190-347;;061-519-730-880-032;;057-945-343-734-358;;005-642-729-451-09X;;003-752-183-823-430;;002-348-443-531-16X;;048-438-498-956-024;;024-929-137-199-30X;;124-805-115-929-413;;008-328-268-697-591;;003-752-183-823-430;;015-466-204-116-873;;003-752-183-823-430;;070-318-112-524-781;;071-163-081-597-04X;;035-135-729-507-737;;094-685-907-794-422;;062-029-719-290-327;;070-624-200-848-669;;012-746-915-512-650;;035-554-935-107-802;;099-647-105-451-350;;009-621-637-014-514;;100-985-030-110-978;;030-630-100-818-462;;032-820-729-763-323;;083-549-078-331-651;;043-108-278-056-872;;050-836-464-727-069;;071-707-020-428-907;;023-468-000-960-289;;033-754-369-798-314;;077-525-954-203-403;;028-969-172-280-017;;060-375-551-951-388;;020-753-772-581-741;;038-613-711-274-229;;047-951-914-695-080;;062-485-301-455-912;;038-613-711-274-229;;023-676-781-371-861;;026-744-100-669-883;;117-663-803-983-152;;051-940-176-386-905;;029-667-686-534-996;;071-441-220-740-553;;013-417-878-440-713;;028-742-425-129-686;;012-300-595-074-789;;031-815-870-004-331;;040-841-912-862-912;;011-583-491-184-648;;126-659-091-098-052;;038-166-075-279-931;;083-079-509-375-354;;067-078-099-297-810;;007-364-858-655-289;;056-942-841-068-650;;107-302-749-967-437;;039-238-464-990-600;;036-564-551-324-053;;020-123-860-433-320;;011-516-147-270-264;;020-986-423-793-233;;087-879-787-031-413;;027-326-505-837-755;;061-757-907-136-641;;030-049-949-326-687;;090-774-193-364-453;;029-750-154-523-855;;053-703-232-770-99X;;041-157-943-929-732;;007-470-431-271-066;;112-179-955-215-674;;007-709-585-201-038;;056-422-417-058-69X;;005-022-447-377-963;;127-416-339-660-812;;066-749-017-721-197;;001-467-559-709-949;;008-213-515-306-640;;053-703-232-770-99X;;033-109-855-318-388;;030-249-121-435-10X;;015-467-638-461-61X;;056-201-471-905-934;;015-821-816-269-604;;040-363-636-264-022,10.1111/j.1600-065x.1998.tb01574.x;;9553767;;pmc2254482;;10.1007/s11302-005-5302-5;;18404475;;10.1158/0008-5472.can-10-1544;;pmc2922475;;20682793;;pmc2883609;;10.1158/0008-5472.can-09-3109;;20179192;;10.1073/pnas.0908801107;;20080644;;pmc2824381;;10.1016/s0163-7258(00)00053-x;;11007998;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;10.1038/nri2761;;20414204;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;10.4049/jimmunol.148.5.1547;;1531669;;10.1038/nbt1135;;16151405;;9780179;;10.4049/jimmunol.161.8.4083;;10.1126/science.2471267;;2471267;;10.4049/jimmunol.137.11.3614;;2431039;;10.1016/0042-6822(90)90025-m;;1693247;;1697100;;10.1111/j.1365-3083.1990.tb02896.x;;8424945;;10.1021/bi00055a024;;10556249;;10.1093/protein/12.10.879;;pmc19525;;9012796;;10.1073/pnas.94.2.412;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;7521646;;10.1038/nbt0994-899;;10.1126/science.2471267;;2471267;;16263307;;10.1016/j.jasms.2005.09.008;;10.1021/bi00161a011;;1332755;;10.1021/bi00078a011;;7687462;;15299382;;10.1107/s0907444994001344;;2185018;;10.1111/j.1432-1033.1990.tb15454.x;;9351804;;10.1016/s0969-2126(97)00279-7;;977570;;10.1016/s0021-9258(20)81858-4;;15299544;;10.1107/s0907444992010400;;27799107;;10.1016/s0076-6879(97)76070-1;;3127726;;10.1038/332323a0;;10.1038/321522a0;;3713831;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;1404388;;10.1016/0022-2836(92)90223-7;;10.1002/eji.1830240409;;8149953;;18066027;;10.1038/nbt1207-1369;;19018092;;10.1182/blood-2008-09-179754;;10.1016/0161-5890(92)90200-h;;1533898;;10.4049/jimmunol.1003412;;21357255;;10.1016/j.molimm.2008.06.027;;18691763;;10.3410/f.1001160.6701;;11520463;;10.1016/s1074-7613(01)00183-2;;10.4049/jimmunol.164.8.4178;;10754313;;8340761;;pmc2191116;;10.1084/jem.178.2.661;;1827828;;10.1084/jem.173.6.1483;;pmc2190830;;10.1038/nbt1344;;17989688;;9307060;;10.1016/s0161-5890(97)00042-4;;2965792;;10.1038/332563a0;;pmc52646;;10.1073/pnas.88.20.9036;;1833770;;10917521;;10.1038/35018508;;10458776;;10.1002/(sici)1521-4141(199908)29:08<2613::aid-immu2613>3.0.co;2-j;;10.1097/00007890-199457110-00001;;10.1097/00007890-199406150-00001;;8009586;;9317161;;10.4049/jimmunol.159.7.3613;;10657642;;10.4049/jimmunol.164.4.1925;;pmc2467532;;10.2210/pdb3c2s/pdb;;18560159;;10.1107/s0907444908007877;;18577454;;10.1016/j.coi.2008.05.010;;20503261;;10.1002/dmrr.1080;;pmc40279;;10.1073/pnas.92.26.11980;;8618827;;10.1182/blood-2006-07-034017;;17038522;;10.1158/1535-7163.mct-08-0201;;18723496;;10.4161/mabs.2.2.11158;;pmc2840237;;20150767;;19896358;;10.1016/j.copbio.2009.10.011;;11096108;;10.1074/jbc.m009483200;;11160318;;10.4049/jimmunol.166.4.2571;;11096108;;10.1074/jbc.m009483200;;pmc1389705;;10.1073/pnas.0508123103;;16537476;;pmc2826232;;19965644;;10.1182/blood-2009-06-229039;;10.1016/j.yexcr.2011.03.018;;21459085;;17875730;;10.1158/0008-5472.can-07-0696;;10.1186/bcr3069;;22129105;;pmc3326565;;3138110;;pmc454472;;10.1002/j.1460-2075.1988.tb03037.x;;10.1158/0008-5472.can-07-6297;;18483271;;10.1111/j.1365-3083.2009.02338.x;;19906198;;10.1046/j.1365-2567.1998.00472.x;;pmc1364140;;9659234;;16622479;;10.1038/nri1837;;21852502;;10.1126/science.1206954;;pmc3164589;;10.1073/pnas.1208698109;;pmc3390832;;22723355;;23744091;;10.1093/protein/gzt022;;pmc3785249;;14699147;;10.1074/jbc.c300470200;;10.4049/jimmunol.176.1.346;;16365427;;11096108;;10.1074/jbc.m009483200;;12391234;;10.4049/jimmunol.169.9.5171;;10.1074/jbc.m604292200;;16793771;;10.4049/jimmunol.0804182;;19494290;;10.1038/nbt.1601;;pmc2855492;;20081867;;17077181;;10.1093/intimm/dxl110;;10.1074/jbc.m604292200;;16793771;;10.1038/nbt1143;;16186811;;10.4049/jimmunol.0804182;;19494290;;10688122;;15695407;;10.1158/0008-5472.622.65.2;;pmc4154799;;10429243;;10.1038/11717;;pmc48562;;10.1073/pnas.89.5.1904;;1542690;;19915550;;10.1038/nbt.1588;;10.1038/nbt.1553;;19620983;;10.1002/eji.1830230216;;8436176;;2507634;;10.4049/jimmunol.143.8.2595;;10.1073/pnas.0908590107;;20080725;;pmc2818909;;11986321;;10.1074/jbc.m202069200;;16219319;;10.1016/j.jim.2005.08.009;;10.1158/1078-0432.ccr-08-3222;;19401346;;10.1002/bit.20151;;15352059;;10.1038/nbt1178;;16429149;;10.1182/blood-2009-06-225979;;10.3410/f.4252956.4109054;;pmc2881503;;20194898;;11986321;;10.1074/jbc.m202069200;;12427744;;10.1074/jbc.m210665200;;11986321;;10.1074/jbc.m202069200;;10.1038/6179;;10052355;;10.1146/annurev.bi.41.070172.003325;;4563441;;10.4049/jimmunol.172.9.5489;;15100290;;2459288;;pmc2189025;;10.1084/jem.168.3.1099;;12042244;;10.1093/glycob/12.4.43r;;10.1038/316452a0;;3927174;;11275255;;10.1016/s0161-5890(00)00105-x;;10.1023/b:pham.0000008042.15988.c0;;14725359;;10397155;;10.1016/s0165-2478(99)00029-2;;10.1093/chromsci/40.6.343;;12137207;;8644915;;10.1021/ac00116a002;;10.1038/348552a0;;2247164;;8159246;;10.1038/368856a0;;10.1007/978-3-642-78432-3_3;;7494109;;10.3109/08830189509061738;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;10.1093/intimm/5.6.647;;8347558;;8475122;;10.1073/pnas.90.8.3720;;pmc46373;;8348148;;10.1038/ng0693-117;;8458340;;10.1002/j.1460-2075.1993.tb05722.x;;pmc413279;;8144892;;10.1093/intimm/6.4.579;;8018598;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;10.1038/nbt727;;12172556;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;10.1126/science.3929380;;3929380;;pmc363152;;10.1128/mcb.8.1.466-472.1988;;2827008;;10.1128/mcb.8.1.466;;25291200;;10.1016/0167-5699(85)90161-6;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;18553400;;10.1002/bit.21855;;17099914;;10.1002/bit.21260;;pmc3064176;;21282104;;10.1074/jbc.m110.185041;;10.1016/j.cbpa.2009.03.023;;19414278;;10.1002/anie.200801313;;19072788;;10.1039/b908687k;;19675886;;10.1002/cbic.200800801;;19130455;;10.1016/j.chembiol.2008.01.007;;18291317;;19924746;;pmc4878437;;10.1002/anie.200903627;;10.1021/bc800294a;;19191567;;10.1021/ja00245a050;;10.1002/jps.2600660104;;833720;;2674208;;10.1002/j.1552-4604.1989.tb03403.x;;3390170;;10.1016/s0006-291x(88)81333-0;;10.1128/aac.39.1.180;;pmc162506;;7695303;;7907597;;10.1016/s0021-9258(17)37081-3;;10.1016/0014-5793(94)00313-0;;8206150;;7820457;;10.1006/immu.1994.1029;;15470033;;10.4049/jimmunol.173.8.4919;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1126/science.7545313;;7545313;;9311915;;10.1126/science.278.5335.117;;9500607;;10.1038/nm0398-328;;10700237;;10.1038/73193;;9850053;;2871125;;pmc2188095;;10.1084/jem.163.5.1037;;10.1016/0167-5699(92)90153-x;;1385707;;8910274;;10.1126/science.274.5291.1363;;9624003;;10.1038/30989;;10657670;;10.4049/jimmunol.164.4.2160;;9176498;;10.1038/nm0697-682;;9930702;;10.1038/16717;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0969-2126(94)00113-8;;7704521;;9707601;;pmc21462;;10.1073/pnas.95.17.10067;;9850053;;10.1038/nm735;;12118245;;10.3410/f.1008846.113460;;15930300;;10.1158/0008-5472.can-04-3319;;27754618;;27799103;;10.1016/s0076-6879(97)76066-x;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;22997138;;10.1002/cbic.201200426;;10.2210/pdb4h1s/pdb;;19461840;;pmc2483472;;10.1107/s0021889807021206,"RESTA ET AL., IMMUNOL REV, vol. 161, 1998, pages 95 - 109;;COLGAN ET AL., PRINERGIC SIGNAL, vol. 2, 2006, pages 351 - 360;;ZHANG ET AL., CANCER RES, vol. 70, 2010, pages 6407 - 6411;;JIN ET AL., CANCER RES, vol. 70, 2010, pages 2245 - 2255;;STAGG ET AL., PNAS, vol. 107, 2010, pages 1547 - 1552;;SPYCHALA ET AL., PHARMACOL THER, vol. 87, pages 161 - 173;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;CHAN; CARTER, NAT. REV. IMMUNOL., vol. 10, 2010, pages 301;;SONGSIVILAI; LACHMANN, CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;LONBERG, NATURE BIOTECH, vol. 23, no. 9, 2005, pages 1117 - 1125;;JEFFERIS ET AL., MABS, vol. 1, 2009, pages 1;;KABAT, E. A. ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, NIH PUBLICATION NO. 91-3242;;ROUX ET AL., J IMMUNOL, vol. 161, 1998, pages 4083;;ALLEN ET AL., BIOCHEMISTRY, vol. 48, 2009, pages 3755;;JEFFERIS ET AL., MABS, vol. 1, no. 1, 2009;;""Epitope Mapping Protocols in Methods in Molecular Biology"", vol. 66, 1996;;CUNNINGHAM; WELLS, SCIENCE, vol. 244, 1985, pages 1081;;ED HARLOW; DAVID LANE: ""Cold Spring Harb Protoc"", 2006, article ""Chapter 11"";;ED HARLOW; DAVID LANE: ""Using Antibodies"", 1999, COLD SPRING HARBOR LABORATORY PRESS;;STAHLI ET AL., METHODS IN ENZYMOLOGY, vol. 9, 1983, pages 242;;KIRKLAND ET AL., J. IMMUNOL., vol. 137, 1986, pages 3614;;HARLOW; LANE: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR PRESS;;MOREL ET AL., MOL. IMMUNOL., vol. 25, no. 1, 1988, pages 7;;CHEUNG ET AL., VIROLOGY, vol. 176, 1990, pages 546;;MOLDENHAUER ET AL., SCAND. J. IMMUNOL., vol. 32, 1990, pages 77;;BRUMMELL ET AL., BIOCHEM, vol. 32, 1993, pages 1180 - 1187;;KOBAYASHI ET AL., PROTEIN ENG., vol. 12, no. 10, 1999, pages 879 - 884;;BURKS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 412 - 417;;E. MEYERS; W. MILLER, CABIOS, vol. 4, 1989, pages 11 - 17;;NEEDLEMAN; WUNSCH, J. MOL. BIOL., 1970, pages 444 - 453;;ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3389 - 3402;;""Current Protocols in Molecular Biology"", 1987, GREENE PUBLISHING AND WILEY INTERSCIENCE;;JESPERS ET AL., BIOTECHNOLOGY, vol. 12, 1994, pages 899;;CUNNINGHAM; WELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085;;WEI ET AL., DRUG DISCOVERY TODAY, vol. 19, 2014, pages 95;;HAMBLEY; GROSS, J. AMERICAN SOC. MASS SPECTROMETRY, vol. 16, 2005, pages 2057;;ZINN-JUSTIN ET AL., BIOCHEMISTRY, vol. 31, 1992, pages 11335 - 11347;;ZINN-JUSTIN ET AL., BIOCHEMISTRY, vol. 32, 1993, pages 6884 - 6891;;GIEGE ET AL., ACTA CRYSTALLOGR, vol. D50, 1994, pages 339 - 350;;MCPHERSON, EUR. J. BIOCHEM., vol. 189, 1990, pages 1 - 23;;CHAYEN, STRUCTURE, vol. 5, 1997, pages 1269 - 1274;;MCPHERSON, J. BIOL. CHEM., vol. 251, 1976, pages 6300 - 6303;;SCOPES: ""Protein Purification: Principles and Practice"", 1994, SPRINGER-VERLAG;;BLUNDELL; JOHNSON ET AL.: ""Meth. Enzymol."", vol. 114, 115, 1985, ACADEMIC PRESS;;BRICOGNE, ACTA CRYST., vol. D49, 1993, pages 37 - 60;;BRICOGNE: ""Meth. Enzymol."", vol. 276A, 1997, pages: 361 - 423;;ROVERSI ET AL., ACTA CRYST., vol. D56, 2000, pages 1313 - 1323;;RIECHMANN, L. ET AL., NATURE, vol. 332, 1998, pages 323 - 327;;JONES, P. ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;QUEEN, C. ET AL., PROC. NATL. ACAD. SEE. U.S.A., vol. 86, 1989, pages 10029 - 10033;;TOMLINSON, I. M. ET AL.: ""The Repertoire of Human Germline V Sequences Reveals about Fifty Groups of V Segments with Different Hypervariable Loops"", J. MOL. BIOL., vol. 227, 1992, pages 776 - 798;;COX, J. P. L. ET AL.: ""A Directory of Human Germ-line V Segments Reveals a Strong Bias in their Usage"", EUR. J. IMMUNOL., vol. 24, 1994, pages 827 - 836;;SALFELD, NAT. BIOTECHNOL., vol. 25, 2007, pages 1369;;BRUHNS ET AL., BLOOD, vol. 113, 2009, pages 3716;;SARMAY ET AL., MOLEC. IMMUNOL., vol. 29, no. 5, 1992, pages 633 - 639;;HORTON ET AL., J. IMMUNOL., vol. 186, 2011, pages 4223;;CHU ET AL., MOL. IMMUNOL., vol. 45, 2008, pages 3926;;GROSS ET AL., IMMUNITY, vol. 15, 2001, pages 289;;IDUSOGIE ET AL., J. IMMUNOL., vol. 164, 2000, pages 4178;;TAO ET AL., J. EXP. MED., vol. 178, 1993, pages 661;;CANFIELD; MORRISON, J. EXP. MED., vol. 173, 1991, pages 1483;;ROTHER ET AL., NAT. BIOTECHNOL., vol. 25, 2007, pages 1256;;MUELLER ET AL., MOL. IMMUNOL., vol. 34, 1997, pages 441;;LABRIJN ET AL., CURR. OP. IMMUNOL., vol. 20, 2008, pages 479;;DUNCAN; WINTER, NATURE, vol. 332, 1988, pages 563;;CHAPPEL ET AL., PROC. NAT'L ACAD. SCI. (USA), vol. 88, 1991, pages 9036;;SONDERMANN ET AL., NATURE, vol. 406, 2000, pages 267;;ARMOUR ET AL., EUR. J. IMMUNOL., vol. 29, 1999, pages 2613;;ALEGRE ET AL., TRANSPLANTATION, vol. 57, 1994, pages 1537;;COLE ET AL., J. IMMUNOL., vol. 159, 1997, pages 3613;;REDDY ET AL., J. IMMUNOL., vol. 164, 2000, pages 1925;;OGANESYAN ET AL., ACTA CRYSTALLOGR. D. BIOL. CRYSTALLOGR., vol. 64, 2008, pages 700;;LABRIJN, CURR. OP. IMMUNOL., vol. 20, 2008, pages 479;;DAVIS ET AL., J. IMMUNOL., vol. 34, 2007, pages 2204;;GLAESNER ET AL., DIABETES METAB. RES. REV., vol. 26, 2010, pages 287;;HUTCHINS ET AL., PROC. NAT'L ACAD. SCI. (USA), vol. 92, 1995, pages 11980;;AN ET AL., MABS, vol. 1, 2009, pages 572;;MCEARCHERN ET AL., BLOOD, vol. 109, 2007, pages 1185;;METHODS, vol. 65, 2014, pages 114;;RICHARDS ET AL., MOL. CANCER THERAP., vol. 7, 2008, pages 2517;;MOORE ET AL., MABS, vol. 2, 2010, pages 181;;STROHL, CURRENT OPINION IN BIOTECHNOLOGY, vol. 20, 2009, pages 685 - 691;;SHIELDS, J. BIOL. CHEM., vol. 276, 2001, pages 6591;;IDUSOGIE ET AL., J. IMMUNOL., vol. 166, 2001, pages 2571;;SHIELDS ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604;;LAZAR ET AL., PROC. NAT'L ACAD SCI. (USA), vol. 103, 2006, pages 4005;;AWAN ET AL., BLOOD, vol. 115, 2010, pages 1204;;DESJARLAIS; LAZAR, EXP. CELL RES., vol. 317, 2011, pages 1278;;LAZAR ET AL., PROC. NAT'L ACAD SCI. (USA, vol. 103, 2006, pages 4005;;STAVENHAGEN ET AL., CANCER RES., vol. 67, 2007, pages 8882;;NORDSTROM ET AL., BREAST CANCER RES., vol. 13, 2011, pages R123;;DANGL ET AL., EMBO J., vol. 7, 1988, pages 1989;;NATSUME ET AL., CANCER RES., vol. 68, 2008, pages 3863;;MICHAELSEN ET AL., SCAND. J. IMMUNOL., vol. 70, 2009, pages 553;;REDPATH ET AL., IMMUNOLOGY, vol. 93, 1998, pages 595;;DALL'ACQUA ET AL., J. IMMUNOL., vol. 177, 2006, pages 1129;;CARTER, NAT. REV. IMMUNOL, vol. 6, 2006, pages 343;;PRESTA, CURR. OP. IMMUNOL., vol. 20, 2008, pages 460;;LI; RAVETCH, SCIENCE, vol. 333, 2011, pages 1030;;LI; RAVETCH, PROC. NAT'L ACAD. SCI (USA), vol. 109, 2012, pages 10966;;MIMOTO ET AL., PROTEIN. ENG. DES. & SELECTION, vol. 26, 2013, pages 589;;HINTON ET AL., J. BIOL. CHEM., vol. 279, no. 8, 2004, pages 6213 - 6216;;HINTON ET AL., JOURNAL OF IMMUNOLOGY, vol. 176, 2006, pages 346 - 356;;SHIELDS ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 9, 2001, pages 6591 - 6604;;DALL ACQUA ET AL., JOURNAL OF IMMUNOLOGY, vol. 169, 2002, pages 5171 - 5180;;DALL'ACQUA ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, 2006, pages 23514 - 23524;;YEUNG ET AL., J. IMMUNOL., vol. 182, 2009, pages 7663;;ZALEVSKY ET AL., NAT. BIOTECHNOL., vol. 28, 2010, pages 157;;PETKOVA ET AL., INT. IMMUNOL., vol. 18, 2006, pages 1759;;DALL'ACQUA ET AL., J. BIOL. CHEM., vol. 281, 2006, pages 23514;;VACCARO ET AL., NAT. BIOTECHNOL., vol. 23, 2005, pages 1283;;YEUNG ET AL., J. IMMUNOL., vol. 182, 2010, pages 7663 - 7671;;HORNICK ET AL., J. NUCL. MED., vol. 41, 2000, pages 355;;KIM ET AL., EUR. J. IMMUNOL., vol. 29, 2000, pages 2819;;KENANOVA ET AL., CANCER RES., vol. 65, 2005, pages 622;;CHAPMAN ET AL., NAT. BIOTECHNOL., vol. 17, 1999, pages 780;;YEH ET AL., PROC. NAT'L ACAD. SCI., vol. 89, 1992, pages 1904;;SCHELLENBERGER ET AL., NAT. BIOTECHNOL., vol. 27, 2009, pages 1186;;LABRIJN ET AL., NAT. BIOTECHNOL., vol. 27, 2009, pages 767;;""Fundamental Immunology. 4th ed."", 1999, LIPPINCOTT-RAVEN;;BOLT ET AL., EUR. J. IMMUNOL., vol. 23, 1993, pages 403;;TAO; MORRISON, J. IMMUNOL., vol. 143, 1989, pages 2595;;JUNG ET AL., PROC. NAT'L ACAD. SCI (USA), vol. 107, 2010, pages 604;;SHIELDS ET AL., JBC, vol. 277, 2002, pages 26733;;NIWA ET AL., J. IMMUNOL. METHODS, vol. 306, 2005, pages 151;;CARDARELLI ET AL., CLIN. CANCER RES., vol. 15, 2009, pages 3376;;CARDARELLI ET AL., CANCER IMMUNOL. IMMUNOTHERAP., vol. 59, 2010, pages 257;;YAMANE-OHNUKI ET AL., BIOTECHNOL. BIOENG., vol. 87, 2004, pages 614;;ZHANG ET AL., MABS, vol. 3, 2011, pages 289;;LI ET AL., NAT. BIOTECHNOL., vol. 24, 2006, pages 210;;MOSSNER ET AL., BLOOD, vol. 115, 2010, pages 4393;;SHIELDS ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733;;SHINKAWA ET AL., J. BIOL. CHEM., vol. 278, 2003, pages 3466;;SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740;;UMANA ET AL., NAT. BIOTECH., vol. 17, 1999, pages 176 - 180;;MARSHALL ET AL., ANNU REV BIOCHEM, vol. 41, 1972, pages 673 - 702;;GALA; MORRISON, J. IMMUNOL, vol. 172, 2004, pages 5489 - 5494;;WALLICK ET AL., J EXP MED, vol. 168, 1988, pages 1099 - 1109;;SPIRO, GLYCOBIOLOGY, vol. 12, 2002, pages 43R - 56R;;PAREKH ET AL., NATURE, vol. 316, 1985, pages 452 - 457;;MIMURA ET AL., MOL IMMUNOL, vol. 37, 2000, pages 697 - 706;;CURR PHARM BIOTECHNOL, vol. 3, 2002, pages 361 - 371;;CHEN ET AL., PHARM RES, vol. 20, 2003, pages 1952 - 1960;;GHIRLANDO ET AL., IMMUNOL LETT, vol. 68, 1999, pages 47 - 52;;MURRAY ET AL., J. CHROMATOGR SCI, vol. 40, 2002, pages 343 - 349;;ALEXANDER A J; HUGHES D E, ANAL CHEM, vol. 67, 1995, pages 3626 - 3632;;KABAT, E. A.: ""Sequences of Proteins of Immunological Interest"", 1991, NIH PUBLICATION NO. 91-3242;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;LONBERG ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;LONBERG, N.: ""Handbook of Experimental Pharmacology"", vol. 113, 1994, pages: 49 - 101;;LONBERG, N; HUSZAR, D., INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93;;HARDING, F.; LONBERG, N., ANN. N.Y. ACAD. SCI., vol. 764, 1995, pages 536 - 546;;TAYLOR, L ET AL., NUCLEIC ACIDS RESEARCH, vol. 20, 1992, pages 6287 - 6295;;CHEN, J. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 5, 1993, pages 647 - 656;;TUAILLON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 3720 - 3724;;CHOI ET AL., NATURE GENETICS, vol. 4, 1993, pages 117 - 123;;CHEN, J. ET AL., EMBO J., vol. 12, 1993, pages 821 - 830;;TUAILLON ET AL., J. IMMUNOL., vol. 152, 1994, pages 2912 - 2920;;TAYLOR, L. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 6, 1994, pages 579 - 591;;FISHWILD, D ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;TOMIZUKA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 722 - 727;;KUROIWA ET AL., NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 889 - 894;;FISHWILD ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;MORRISON, S., SCIENCE, vol. 229, 1985, pages 1202;;""Gene Expression Technology. Methods in Enzymology"", vol. 185, 1990, ACADEMIC PRESS;;TAKEBE, Y. ET AL., MOL. CELL. BIOL., vol. 8, 1988, pages 466 - 472;;BOSS, M. A.; WOOD, C. R., IMMUNOLOGY TODAY, vol. 6, 1985, pages 12 - 13;;URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R. J. KAUFMAN; P. A. SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621;;DICK ET AL., BIOTECHNOL. BIOENG., vol. 100, 2008, pages 1132;;DICK ET AL., BIOTECHNOL. BIOENG., vol. 97, 2007, pages 544;;LIU ET AL., JBC, 2011, pages 28611211;;LIU ET AL., J. BIOL. CHEM., vol. 286, 2011, pages 11211;;SENTER, P. D., CURR. OPIN. CHEM. BIOL., vol. 13, 2009, pages 235 - 244;;HACKENBERGER, C. P. R.; SCHWARZER, D., ANGEW. CHEM. INT. ED. ENGL., vol. 47, 2008, pages 10030 - 10074;;SUNBUL, M.; YIN, J., ORG. BIOMOL. CHEM., vol. 7, 2009, pages 3361 - 3371;;FRESE, M. A.; DIERKS, T., CHEMBIOCHEM., vol. 10, 2009, pages 425 - 427;;TAKI, M. ET AL., PROT. ENG. DES. SEL., vol. 17, 2004, pages 119 - 126;;GAUTIER, A. ET AL., CHEM. BIOL., vol. 15, 2008, pages 128 - 136;;BORDUSA, F., HIGHLIGHTS IN BIOORGANIC CHEMISTRY, 2004, pages 389 - 403;;REN, H. ET AL., ANGEW. CHEM. INT. ED. ENGL., vol. 48, 2009, pages 9658 - 9662;;TAYLOR, E. VOGEL; IMPERIALI, B, NUCLEIC ACIDS AND MOLECULAR BIOLOGY, vol. 22, 2009, pages 65 - 96;;DE GRAAF, A. J. ET AL., BIOCONJUG. CHEM., vol. 20, 2009, pages 1281 - 1295;;LEE ET AL., J. AM. CHEM. SOC., vol. 109, 1987, pages 3464,3466;;BERGE, S.M. ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;V.V. RANADE, J. CLIN. PHARMACOL., vol. 29, 1989, pages 685;;UMEZAWA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN, vol. 153, 1988, pages 1038;;P.G. BLOEMAN ET AL., FEBS LETT., vol. 357, 1995, pages 140;;M. OWAIS ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 39, 1995, pages 180;;BRISCOE ET AL., AM. J. PHYSIOL., vol. 1233, 1995, pages 134;;SCHREIER ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 9090;;M.L. LAUKKANEN, FEBS LETT., vol. 346, 1994, pages 123;;J.J. KILLION; I.J. FIDLER, IMMUNOMETHODS, vol. 4, 1994, pages 273;;HE ET AL., J. IMMUNOL., vol. 173, 2004, pages 4919 - 4928;;ROSENBERG, S.: ""ASCO Educational Book Spring"", 2000, article ""Development of Cancer Vaccines"", pages: 60 - 62;;LOGOTHETIS, C.: ""ASCO Educational Book Spring"", 2000, pages: 300 - 302;;KHAYAT, D.: ""ASCO Educational Book Spring"", 2000, pages: 414 - 428;;FOON, K.: ""ASCO Educational Book Spring"", 2000, pages: 730 - 738;;RESTIFO, N; SZNOL, M. ET AL.: ""Cancer Vaccines"", 1997, article ""Cancer: Principles and Practice of Oncology"", pages: 3023 - 3043;;DRANOFF ET AL., PROC. NATL. ACAD. SCI U.S.A., vol. 90, 1993, pages 3539 - 3543;;ROSENBERG, S A, IMMUNITY, vol. 10, 1999, pages 281 - 287;;KIM ET AL., SCIENCE, vol. 266, 1994, pages 2011 - 2013;;SUOT; SRIVASTAVA, SCIENCE, vol. 269, 1995, pages 1585 - 1588;;TAMURA ET AL., SCIENCE, vol. 278, 1997, pages 117 - 120;;NESTLE ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 - 332;;KUGLER ET AL., NATURE MEDICINE, vol. 6, 2000, pages 332 - 336;;MOKYR ET AL., CANCER RESEARCH, vol. 58, 1998, pages 5301 - 5304;;KEHRL ET AL., J. EXP. MED., vol. 163, 1986, pages 1037 - 1050;;HOWARD; O'GARRA, IMMUNOLOGY TODAY, vol. 13, 1992, pages 198 - 200;;HAHNE ET AL., SCIENCE, vol. 274, 1996, pages 1363 - 1365;;RIDGE ET AL., NATURE, vol. 393, 1998, pages 474 - 478;;WEINBERG ET AL., IMMUNOL, vol. 164, 2000, pages 2160 - 2169;;MELERO ET AL., NATURE MEDICINE, vol. 3, 1997, pages 682 - 685;;HUTLOFF ET AL., NATURE, vol. 397, 1999, pages 262 - 266;;HOLLIGER, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;POLJAK, STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;TANSEY, DRUG DISCOVERY TODAY, 2009, pages 1;;HURWITZ ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, no. 17, 1998, pages 10067 - 10071;;CAMACHO ET AL., J. CLIN. ONCOLOGY, vol. 22, no. 145, 2004;;MOKYR ET AL., CANCER RES., vol. 58, 1998, pages 5301 - 5304;;""PDR"", 2004, pages: 608 - 610;;FULDA ET AL., NAT MED, vol. 8, 2002, pages 808 - 815;;HYER ET AL., CANCER RESEARCH, vol. 65, 2005, pages 4799 - 4808;;""Physicians' Desk Reference"", 1996, MEDICAL ECONOMICS COMPANY;;OTWINOWSKI Z; MINOR W., METHODS IN ENZYMOLOGY, vol. 276, 1997, pages 307 - 326;;ALTSCHUL ET AL.: ""Basic local alignment search tool"", J. MOL. BIOL., vol. 215, 1990, pages 403 - 410;;HEUTS ET AL., CHEMBIOCHEM., vol. 13, no. 16, 5 November 2012 (2012-11-05), pages 2384 - 2391;;MCCOY ET AL., J. APPL. CRYST, vol. 40, 2007, pages 658 - 674;;BRICOGNE ET AL.: ""BUSTER version 2.11.6"", 2011, UNITED KINGDOM: GLOBAL PHASING LTD",PENDING
439,HR,T1,HR P20201176 T1,064-903-279-913-48X,2020-11-13,2020,HR P20201176 T,2020-07-28,US 201462083056 P;;EP 15816276 A;;US 2015/0061639 W,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/064-903-279-913-48X,Granted Patent,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/395;;A61P35/00;;C07K16/30;;C07K16/40,,0,0,,,,ACTIVE
440,PE,A1,PE 20170782 A1,059-147-746-945-033,2017-07-04,2017,PE 2017000897 A,2015-11-19,US 201462083056 P,2014-11-21,ANTICUERPOS FRENTE A CD73 Y USOS DE LOS MISMOS,"Se refiere a un anticuerpo aislado o porcion de union a antigeno del mismo que se une al grupo de diferenciacion 73 (CD73) humano y presenta una o mas de las siguientes propiedades: a) se une a CD73 humano con una KD de 10 nM o menos, b) inhibe la actividad enzimatica de CD73, c) internaliza CD73 mediante internalizacion de CD73 mediada por anticuerpos en celulas, por ejemplo, celulas tumorales y d) se une a un epitopo conformacional que comprende los aminoacidos 65-83 y 157-172 de CD73 humano. Tambien se refiere a una molecula biespecifica, un acido nucleico, un vector de expresion, una composicion, un kit y a un metodo de preparacion. Dicho anticuerpo es util en la inhibicion del crecimiento de tumores, inhibicion de metastasis, entre otros",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/059-147-746-945-033,Patent Application,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/395;;A61P35/00;;C07K16/30;;C07K16/40,,0,0,,,,PENDING
441,WO,A3,WO 2017/100423 A3,093-940-601-979-423,2017-11-16,2017,US 2016/0065570 W,2016-12-08,US 201562265611 P;;US 201662324428 P;;US 201662365543 P;;US 201615355836 A,2015-12-10,END EFFECTOR FOR INSTRUMENT WITH ULTRASONIC AND ELECTROSURGICAL FEATURES,"An apparatus includes a body, a shaft assembly, and an end effector. The end effector includes an ultrasonic blade and a clamp arm assembly. The ultrasonic blade is in acoustic communication with an acoustic waveguide of the shaft assembly. The clamp arm assembly is pivotable toward and away from the ultrasonic blade. The clamp arm assembly includes a clamp pad and an electrode. The clamp pad is configured to compress tissue against the ultrasonic blade. The clamp pad has a proximal end, a distal end, and a pair of lateral sides extending from the proximal end to the distal end. The electrode is operable to apply RF energy to tissue. The electrode extends along both lateral sides of the clamp pad. The electrode further extends around the distal end of the clamp pad.",ETHICON ENDO SURGERY LLC,JOHNSON GREGORY W;;LESKO JASON R;;ESTERA FREDERICK L;;KRUMM (PORTER) AMY M;;CORBETT CATHERINE A;;WEISENBURGH II WILLIAM B;;WORRELL BARRY C;;DAVISON MARK A;;BOUDREAUX CHAD P;;HIBNER JOHN A;;ISOSAKI JOSEPH;;WAN SHAN;;OTREMBIAK CANDICE;;WIENER EITAN T;;MESSERLY JEFFREY D;;MILLER MATTHEW C,,https://lens.org/093-940-601-979-423,Search Report,yes,5,0,12,22,0,A61B18/1445;;A61B18/1492;;A61B2017/00389;;A61B2018/00404;;A61B2018/00595;;A61B2018/00607;;A61B2018/00619;;A61B2018/0063;;A61B2018/00791;;A61B2018/00922;;A61B2018/00994;;A61B2017/320094;;A61B2017/320095;;A61B17/320092;;A61B2017/2825;;A61B2017/320094;;A61B2017/320095;;A61B18/1445;;A61B2018/00595;;A61B2018/00607;;A61B2018/00404;;A61B2018/00619;;A61B18/1492;;A61B2017/00389;;A61B2018/00791;;A61B2018/00922;;A61B2018/0063;;A61B2018/00994;;A61B18/1206;;A61B2018/00077;;A61B2018/00083;;A61B2018/126;;A61B2018/142;;A61B2018/1455;;A61B17/320092,A61B17/00;;A61B18/14;;A61B17/29;;A61B17/32,,0,0,,,,PENDING
442,BR,A2,BR 112018011660 A2,131-654-380-481-160,2018-12-04,2018,BR 112018011660 A,2016-12-08,US 2016/0065570 W;;US 201562265611 P;;US 201662324428 P;;US 201662365543 P;;US 201615355836 A,2015-12-10,atuador de extremidade para instrumento com recursos ultrassônicos e eletrocirúrgicos,"a presente invenção se refere a um aparelho que inclui um corpo, um conjunto de eixo de acionamento e um atuador de extremidade. o atuador de extremidade inclui uma lâmina ultrassônica e um conjunto de braço de aperto. a lâmina ultrassônica está em comunicação acústica com um guia de ondas acústicas do conjunto de eixo de acionamento. o conjunto de braço de aperto é pivotante em direção à, e na direção oposta à lâmina ultrassônica. o conjunto de braço de aperto inclui uma almofada de aperto e um eletrodo. o braço de aperto é configurado para comprimir o tecido contra a lâmina ultrassônica. a almofada de aperto tem uma extremidade proximal, uma extremidade distal e um par de paredes laterais que se estende entre a extremidade proximal e a extremidade distal. o eletrodo é operável para aplicar energia de rf ao tecido. o eletrodo se estende ao longo de ambos os lados laterais da almofada de aperto. o eletrodo se estende adicionalmente ao redor da extremidade distal da almofada de aperto.",ETHICON LLC,AMY M KRUMM (PORTER);;BARRY C WORRELL;;CANDICE OTREMBIAK;;CATHERINE A CORBETT;;CHAD P BOUDREAUX;;EITAN T WIENER;;FREDERICK L ESTERA;;GREGORY W JOHNSON;;JASON R LESKO;;JEFFREY D MESSERLY;;JOHN A HIBNER;;JOSEPH ISOSAKI;;MARK A DAVISON;;MATTHEW C MILLER;;SHAN WAN;;WILLIAM B WEISENBURGH II,,https://lens.org/131-654-380-481-160,Patent Application,no,0,0,12,22,0,A61B18/1445;;A61B18/1492;;A61B2017/00389;;A61B2018/00404;;A61B2018/00595;;A61B2018/00607;;A61B2018/00619;;A61B2018/0063;;A61B2018/00791;;A61B2018/00922;;A61B2018/00994;;A61B2017/320094;;A61B2017/320095;;A61B17/320092;;A61B2017/2825;;A61B2017/320094;;A61B2017/320095;;A61B18/1445;;A61B2018/00595;;A61B2018/00607;;A61B2018/00404;;A61B2018/00619;;A61B18/1492;;A61B2017/00389;;A61B2018/00791;;A61B2018/00922;;A61B2018/0063;;A61B2018/00994;;A61B18/1206;;A61B2018/00077;;A61B2018/00083;;A61B2018/126;;A61B2018/142;;A61B2018/1455;;A61B17/320092,A61B18/14;;A61B17/00;;A61B17/29;;A61B17/32,,0,0,,,,ACTIVE
443,EP,A2,EP 3621540 A2,132-321-323-733-844,2020-03-18,2020,EP 16820077 A,2016-12-08,US 201562265611 P;;US 201662324428 P;;US 201662365543 P;;US 201615355836 A;;US 2016/0065570 W,2015-12-10,END EFFECTOR FOR INSTRUMENT WITH ULTRASONIC AND ELECTROSURGICAL FEATURES,,ETHICON LLC,JOHNSON GREGORY W;;LESKO JASON R;;ESTERA FREDERICK L;;KRUMM (PORTER) AMY M;;CORBETT CATHERINE A;;WEISENBURGH II WILLIAM B;;WORRELL BARRY C;;DAVISON MARK A;;BOUDREAUX CHAD P;;HIBNER JOHN A;;ISOSAKI JOSEPH;;WAN SHAN;;OTREMBIAK CANDICE;;WIENER EITAN T;;MESSERLY JEFFREY D;;MILLER MATTHEW C,,https://lens.org/132-321-323-733-844,Patent Application,yes,0,0,12,22,0,A61B18/1445;;A61B18/1492;;A61B2017/00389;;A61B2018/00404;;A61B2018/00595;;A61B2018/00607;;A61B2018/00619;;A61B2018/0063;;A61B2018/00791;;A61B2018/00922;;A61B2018/00994;;A61B2017/320094;;A61B2017/320095;;A61B17/320092;;A61B2017/2825;;A61B2017/320094;;A61B2017/320095;;A61B18/1445;;A61B2018/00595;;A61B2018/00607;;A61B2018/00404;;A61B2018/00619;;A61B18/1492;;A61B2017/00389;;A61B2018/00791;;A61B2018/00922;;A61B2018/0063;;A61B2018/00994;;A61B18/1206;;A61B2018/00077;;A61B2018/00083;;A61B2018/126;;A61B2018/142;;A61B2018/1455;;A61B17/320092,A61B18/14;;A61B17/00;;A61B17/29;;A61B17/32,,0,0,,,,DISCONTINUED
444,MX,A,MX 2017006624 A,007-918-022-649-665,2017-08-21,2017,MX 2017006624 A,2015-11-19,US 201462083056 P;;US 2015/0061639 W,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF.,"The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.",BRISTOL MYERS SQUIBB CO,HAICHUN HUANG;;NILS LONBERG;;AARON P YAMNIUK;;MARTIN J CORBETT;;ALAN J KORMAN;;MOHAN SRINIVASAN;;GUODONG CHEN;;RICHARD HUANG;;BRYAN C BARNHART;;KARLA A HENNING;;MING LEI;;LIANG SCHWEIZER;;SANDRA V HATCHER;;EMANUELA SEGA;;ANGELA GOODENOUGH;;MARIA N JUREKUNKEL;;JOHN SACK;;JOSEPH E MYERS;;PINGPING ZHANG,,https://lens.org/007-918-022-649-665,Patent Application,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,A61K39/395;;C07K16/28;;A61P35/00;;C07K16/30;;C07K16/40,,0,0,,,,PENDING
445,EP,B1,EP 3221363 B1,064-667-643-716-940,2020-05-06,2020,EP 15816276 A,2015-11-19,US 201462083056 P;;US 2015/0061639 W,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/064-667-643-716-940,Granted Patent,yes,3,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/395;;A61P35/00;;C07K16/30;;C07K16/40,,3,0,,,"STEVEN RUST ET AL: ""Combining phenotypic and proteomic approaches to identify membrane targets in a 'triple negative' breast cancer breast cancer cell type"", MOLECULAR CANCER, BIOMED CENTRAL, LONDON, GB, vol. 12, no. 1, 13 February 2013 (2013-02-13), page 11, XP021139556, ISSN: 1476-4598, DOI: 10.1186/1476-4598-12-11;;M. G. TERP ET AL: ""Anti-Human CD73 Monoclonal Antibody Inhibits Metastasis Formation in Human Breast Cancer by Inducing Clustering and Internalization of CD73 Expressed on the Surface of Cancer Cells"", THE JOURNAL OF IMMUNOLOGY, vol. 191, no. 8, 16 September 2013 (2013-09-16), pages 4165-4173, XP055245512, US ISSN: 0022-1767, DOI: 10.4049/jimmunol.1301274;;CANFIELD S M ET AL: ""THE BINDING AFFINITY OF HUMAN IGG FOR ITS HIGH AFFINITY FC RECEPTOR IS DETERMINED BY MULTIPLE AMINO ACIDS IN THE CH2 DOMAIN AND IS MODULATED BY THE HINGE REGION"", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 173, no. 6, 1 June 1991 (1991-06-01), pages 1483-1491, XP001181027, ISSN: 0022-1007, DOI: 10.1084/JEM.173.6.1483 cited in the application",ACTIVE
446,BR,B1,BR 112018011660 B1,110-798-034-102-798,2023-01-31,2023,BR 112018011660 A,2016-12-08,US 2016/0065570 W;;US 201562265611 P;;US 201662324428 P;;US 201662365543 P;;US 201615355836 A,2015-12-10,APARELHO COM ATUADOR DE EXTREMIDADE PARA INSTRUMENTO COM RECURSOS ULTRASSÔNICOS E ELETROCIRÚRGICOS,"ATUADOR DE EXTREMIDADE PARA INSTRUMENTO COM RECURSOS ULTRASSÔNICOS E ELETROCIRÚRGICOS. A presente invenção se refere a um aparelho que inclui um corpo, um conjunto de eixo de acionamento e um atuador de extremidade. O atuador de extremidade inclui uma lâmina ultrassônica e um conjunto de braço de aperto. A lâmina ultrassônica está em comunicação acústica com um guia de ondas acústicas do conjunto de eixo de acionamento. O conjunto de braço de aperto é pivotante em direção à, e na direção oposta à lâmina ultrassônica. O conjunto de braço de aperto inclui uma almofada de aperto e um eletrodo. O braço de aperto é configurado para comprimir o tecido contra a lâmina ultrassônica. A almofada de aperto tem uma extremidade proximal, uma extremidade distal e um par de paredes laterais que se estende entre a extremidade proximal e a extremidade distal. O eletrodo é operável para aplicar energia de RF ao tecido. O eletrodo se estende ao longo de ambos os lados laterais da almofada de aperto. O eletrodo se estende adicionalmente ao redor da extremidade distal da almofada de aperto.",ETHICON LLC,GREGORY W JOHNSON;;JASON R LESKO;;FREDERICK L ESTERA;;AMY M KRUMM (PORTER);;CATHERINE A CORBETT;;WILLIAM B WEISENBURGH II;;BARRY C WORRELL;;MARK A DAVISON;;CHAD P BOUDREAUX;;JOHN A HIBNER;;JOSEPH ISOSAKI;;SHAN WAN;;CANDICE OTREMBIAK;;EITAN T WIENER;;JEFFREY D MESSERLY;;MATTHEW C MILLER,,https://lens.org/110-798-034-102-798,Granted Patent,no,0,0,12,22,0,A61B18/1445;;A61B18/1492;;A61B2017/00389;;A61B2018/00404;;A61B2018/00595;;A61B2018/00607;;A61B2018/00619;;A61B2018/0063;;A61B2018/00791;;A61B2018/00922;;A61B2018/00994;;A61B2017/320094;;A61B2017/320095;;A61B17/320092;;A61B2017/2825;;A61B2017/320094;;A61B2017/320095;;A61B18/1445;;A61B2018/00595;;A61B2018/00607;;A61B2018/00404;;A61B2018/00619;;A61B18/1492;;A61B2017/00389;;A61B2018/00791;;A61B2018/00922;;A61B2018/0063;;A61B2018/00994;;A61B18/1206;;A61B2018/00077;;A61B2018/00083;;A61B2018/126;;A61B2018/142;;A61B2018/1455;;A61B17/320092,A61B18/14;;A61B17/00;;A61B17/29;;A61B17/32,,0,0,,,,ACTIVE
447,CL,A1,CL 2018001414 A1,152-646-413-951-221,2018-08-24,2018,CL 2018001414 A,2018-05-25,US 201462083056 P,2014-11-21,Anticuerpos contra cd73 y sus usos (divisional solicitud 201701296),"LA PRESENTE INVENCIÓN PROPORCIONA ANTICUERPOS MONOCLONALES AISLADOS, PARTICULARMENTE ANTICUERPOS HUMANOS, QUE SE UNEN AL CLUSTER DE DIFERENCIACIÓN 73 HUMANO (CD73) CON ALTA AFINIDAD, E INHIBEN LA ACTIVIDAD DE CD73, Y OPCIONALMENTE MEDIAN LA INTERNALIZACIÓN DE CD73 DEPENDIENTE DE ANTICUERPO. TAMBIÉN SE PROVEEN LAS MOLÉCULAS DE ÁCIDO NUCLEICO QUE CODIFICAN LOS ANTICUERPOS DE LA INVENCIÓN, VECTORES DE EXPRESIÓN, CÉLULAS HUÉSPED Y MÉTODOS PARA EXPRESAR LOS ANTICUERPOS DE LA INVENCIÓN. TAMBIÉN SE PROVEEN LOS INMUNOCONJUGADOS, MOLÉCULAS BIESPECIFICAS Y COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS ANTICUERPOS DE LA INVENCIÓN. LA INVENCIÓN TAMBIÉN PROPORCIONA MÉTODOS PARA INHIBIR EL CRECIMIENTO DE UNA CÉLULA TUMORAL QUE EXPRESA CD73 USANDO LOS ANTICUERPOS DE LA INVENCIÓN, INCLUYENDO MÉTODOS PARA TRATAR VARIOS TIPOS DE CÁNCER.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;SRINIVASAN MOHAN;;CORBETT MARTIN J;;KORMAN ALAN J;;CHEN GUODONG;;HUANG RICHARD;;HUANG HAICHUN;;BARNHART BRYAN C;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;SACK JOHN;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;ZHANG PINGPING;;YAMINIUK AARON P,,https://lens.org/152-646-413-951-221,Patent Application,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,A61K39/395;;A61P35/00;;C07K16/28;;C07K16/30;;C07K16/40,,0,0,,,,PENDING
448,US,A1,US 2022/0039858 A1,016-115-894-186-992,2022-02-10,2022,US 202117410349 A,2021-08-24,US 202117410349 A;;US 201615355836 A;;US 201562265611 P;;US 201662324428 P;;US 201662365543 P,2015-12-10,END EFFECTOR FOR INSTRUMENT WITH ULTRASONIC AND ELECTROSURGICAL FEATURES,"An apparatus includes a body, a shaft assembly, and an end effector. The end effector includes an ultrasonic blade and a clamp arm assembly. The ultrasonic blade is in acoustic communication with an acoustic waveguide of the shaft assembly. The clamp arm assembly is pivotable toward and away from the ultrasonic blade. The clamp arm assembly includes a clamp pad and an electrode. The clamp pad is configured to compress tissue against the ultrasonic blade. The clamp pad has a proximal end, a distal end, and a pair of lateral sides extending from the proximal end to the distal end. The electrode is operable to apply RF energy to tissue. The electrode extends along both lateral sides of the clamp pad. The electrode further extends around the distal end of the clamp pad.",CILAG GMBH INT,JOHNSON GREGORY W;;LESKO JASON R;;ESTERA FREDERICK L;;KRUMM AMY M;;CORBETT CATHERINE A;;WEISENBURGH II WILLIAM B;;WORRELL BARRY C;;DAVISON MARK A;;BOUDREAUX CHAD P;;HIBNER JOHN A;;ISOSAKI JOSEPH;;WAN SHAN;;OTREMBIAK CANDICE;;WIENER EITAN T;;MESSERLY JEFFREY D;;MILLER MATTHEW C,,https://lens.org/016-115-894-186-992,Patent Application,yes,0,0,12,22,0,A61B18/1445;;A61B18/1492;;A61B2017/00389;;A61B2018/00404;;A61B2018/00595;;A61B2018/00607;;A61B2018/00619;;A61B2018/0063;;A61B2018/00791;;A61B2018/00922;;A61B2018/00994;;A61B2017/320094;;A61B2017/320095;;A61B17/320092;;A61B2017/2825;;A61B2017/320094;;A61B2017/320095;;A61B18/1445;;A61B2018/00595;;A61B2018/00607;;A61B2018/00404;;A61B2018/00619;;A61B18/1492;;A61B2017/00389;;A61B2018/00791;;A61B2018/00922;;A61B2018/0063;;A61B2018/00994;;A61B18/1206;;A61B2018/00077;;A61B2018/00083;;A61B2018/126;;A61B2018/142;;A61B2018/1455;;A61B17/320092,A61B18/12;;A61B17/32;;A61B18/14,,0,0,,,,PENDING
449,CN,A,CN 108366827 A,119-056-909-022-374,2018-08-03,2018,CN 201680072340 A,2016-12-08,US 201562265611 P;;US 201662324428 P;;US 201662365543 P;;US 201615355836 A;;US 2016/0065570 W,2015-12-10,END EFFECTOR FOR INSTRUMENT WITH ULTRASONIC AND ELECTROSURGICAL FEATURES,"An apparatus includes a body, a shaft assembly, and an end effector. The end effector includes an ultrasonic blade and a clamp arm assembly. The ultrasonic blade is in acoustic communication with an acoustic waveguide of the shaft assembly. The clamp arm assembly is pivotable toward and away from the ultrasonic blade. The clamp arm assembly includes a clamp pad and an electrode. The clamp pad is configured to compress tissue against the ultrasonic blade. The clamp pad has a proximal end, a distal end, and a pair of lateral sides extending from the proximal end to the distal end. The electrodeis operable to apply RF energy to tissue. The electrode extends along both lateral sides of the clamp pad. The electrode further extends around the distal end of the clamp pad.",ETHICON ENDO SURGERY LLC,JOHNSON GREGORY W;;LESKO JASON R;;ESTERA FREDERICK L;;KRUMM (PORTER) AMY M;;CORBETT CATHERINE A;;WEISENBURGH II WILLIAM B;;WORRELL BARRY C;;DAVISON MARK A;;BOUDREAUX CHAD P;;HIBNER JOHN A;;ISOSAKI JOSEPH;;WAN SHAN;;OTREMBIAK CANDICE;;WIENER EITAN T;;MESSERLY JEFFREY D;;MILLER MATTHEW C,,https://lens.org/119-056-909-022-374,Patent Application,no,7,7,12,22,0,A61B18/1445;;A61B18/1492;;A61B2017/00389;;A61B2018/00404;;A61B2018/00595;;A61B2018/00607;;A61B2018/00619;;A61B2018/0063;;A61B2018/00791;;A61B2018/00922;;A61B2018/00994;;A61B2017/320094;;A61B2017/320095;;A61B17/320092;;A61B2017/2825;;A61B2017/320094;;A61B2017/320095;;A61B18/1445;;A61B2018/00595;;A61B2018/00607;;A61B2018/00404;;A61B2018/00619;;A61B18/1492;;A61B2017/00389;;A61B2018/00791;;A61B2018/00922;;A61B2018/0063;;A61B2018/00994;;A61B18/1206;;A61B2018/00077;;A61B2018/00083;;A61B2018/126;;A61B2018/142;;A61B2018/1455;;A61B17/320092,A61B18/14;;A61B17/00;;A61B17/29;;A61B17/32,,0,0,,,,ACTIVE
450,HK,A1,HK 1244817 A1,190-074-213-922-167,2018-08-17,2018,HK 18103196 A,2018-03-06,US 201462083056 P;;US 2015/0061639 W,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,NILS LONBERG;;ALAN J KORMAN;;BRYAN C BARNHART;;AARON P YAMNIUK;;MOHAN SRINIVASAN;;KARLA A HENNING;;MING LEI;;EMANUELA SEGA;;ANGELA GOODENOUGH;;MARIA N JURE-KUNKEL;;GUODONG CHEN;;JOHN SACK;;RICHARD HUANG;;MARTIN J CORBETT;;JOSEPH E MYERS;;LIANG SCHWEIZER;;SANDRA V HATCHER;;HAICHUN HUANG;;PINGPING ZHANG,,https://lens.org/190-074-213-922-167,Patent Application,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K/;;A61K/;;A61P/,,0,0,,,,PENDING
451,ME,B,ME 03806 B,020-460-214-552-402,2021-04-20,2021,ME P2020157 A,2015-11-19,US 201462083056 P;;EP 15816276 A;;US 2015/0061639 W,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,,BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/020-460-214-552-402,Granted Patent,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,A61K39/395;;A61P35/00;;C07K16/28;;C07K16/30;;C07K16/40,,0,0,,,,ACTIVE
452,KR,A,KR 20230125855 A,008-813-529-700-437,2023-08-29,2023,KR 20237028104 A,2015-11-19,US 201462083056 P;;KR 20177016541 A;;US 2015/0061639 W,2014-11-21,CD73 ANTIBODIES AGAINST CD73 AND USES THEREOF,"본 개시내용은 인간 분화 클러스터 73 (CD73)과 고 친화도로 결합하고; CD73의 활성을 억제하며; 임의로 항체 의존성 CD73 내재화를 매개하는, 단리된 모노클로날 항체, 특히 인간 항체를 제공한다. 본 개시내용의 항체를 코딩하는 핵산 분자, 본 개시내용의 항체를 발현하기 위한 발현 벡터, 숙주 세포 및 방법이 또한 제공된다. 본 개시내용의 항체를 포함하는 면역접합체, 이중특이적 분자 및 제약 조성물이 또한 제공된다. 본 개시내용은 또한, 본 개시내용의 항체를 사용하여 CD73을 발현하는 종양 세포의 성장을 억제하는 방법을 제공하는데, 이는 각종 암을 치료하는 방법을 포함한다.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/008-813-529-700-437,Patent Application,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/00;;A61P35/00,,0,0,,,,PENDING
453,AU,A1,AU 2015/349878 A1,053-326-848-503-16X,2017-05-25,2017,AU 2015/349878 A,2015-11-19,US 201462083056 P;;US 2015/0061639 W,2014-11-21,Antibodies against CD73 and uses thereof,"The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/053-326-848-503-16X,Patent Application,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/395;;A61P35/00;;C07K16/30;;C07K16/40,,0,0,,,,DISCONTINUED
454,US,A1,US 2017/0164972 A1,151-817-669-684-97X,2017-06-15,2017,US 201615355836 A,2016-11-18,US 201615355836 A;;US 201562265611 P;;US 201662324428 P;;US 201662365543 P,2015-12-10,END EFFECTOR FOR INSTRUMENT WITH ULTRASONIC AND ELECTROSURGICAL FEATURES,"An apparatus includes a body, a shaft assembly, and an end effector. The end effector includes an ultrasonic blade and a clamp arm assembly. The ultrasonic blade is in acoustic communication with an acoustic waveguide of the shaft assembly. The clamp arm assembly is pivotable toward and away from the ultrasonic blade. The clamp arm assembly includes a clamp pad and an electrode. The clamp pad is configured to compress tissue against the ultrasonic blade. The clamp pad has a proximal end, a distal end, and a pair of lateral sides extending from the proximal end to the distal end. The electrode is operable to apply RF energy to tissue. The electrode extends along both lateral sides of the clamp pad. The electrode further extends around the distal end of the clamp pad.",ETHICON ENDO SURGERY LLC,JOHNSON GREGORY W;;LESKO JASON R;;ESTERA FREDERICK L;;KRUMM AMY M;;CORBETT CATHERINE A;;WEISENBURGH II WILLIAM B;;WORRELL BARRY C;;DAVISON MARK A;;BOUDREAUX CHAD P;;HIBNER JOHN A;;ISOSAKI JOSEPH;;WAN SHAN;;OTREMBIAK CANDICE;;WIENER EITAN T;;MESSERLY JEFFREY D;;MILLER MATTHEW C,CILAG GMBH INTERNATIONAL (2021-04-05);;ETHICON LLC (2017-01-05),https://lens.org/151-817-669-684-97X,Patent Application,yes,6,109,12,22,0,A61B18/1445;;A61B18/1492;;A61B2017/00389;;A61B2018/00404;;A61B2018/00595;;A61B2018/00607;;A61B2018/00619;;A61B2018/0063;;A61B2018/00791;;A61B2018/00922;;A61B2018/00994;;A61B2017/320094;;A61B2017/320095;;A61B17/320092;;A61B2017/2825;;A61B2017/320094;;A61B2017/320095;;A61B18/1445;;A61B2018/00595;;A61B2018/00607;;A61B2018/00404;;A61B2018/00619;;A61B18/1492;;A61B2017/00389;;A61B2018/00791;;A61B2018/00922;;A61B2018/0063;;A61B2018/00994;;A61B18/1206;;A61B2018/00077;;A61B2018/00083;;A61B2018/126;;A61B2018/142;;A61B2018/1455;;A61B17/320092,A61B17/32;;A61B18/12;;A61B18/14,,0,0,,,,DISCONTINUED
455,CY,T1,CY 1123355 T1,042-870-242-573-999,2021-12-31,2021,CY 201100722 T,2020-08-04,US 201462083056 P;;US 2015/0061639 W,2014-11-21,ΑΝΤΙΣΩΜΑΤΑ ΕΝΑΝΤΙ CD73 ΚΑΙ ΧΡΗΣΕΙΣ ΕΞ ΑΥΤΩΝ,"Η παρούσα εφεύρεση παρέχει απομονωμένα μονοκλωνικά αντισώματα, ειδικότερα δε ανθρώπινα αντισώματα, που δεσμεύονται στην ανθρώπινη Συνάθροιση Διαφοροποίησης 73 (CD73) με υψηλή συγγένεια, και αναστέλλουν τη δραστηριότητα του CD73, και μεσολαβούν προαιρετικώς σε εξαρτώμενη από αντισώματα εσωτερικοποίηση CD73. Μόρια πυρηνικών οξέων που εγκωδικεύουν τα αντισώματα της αποκάλυψης, ανύσματα έκφρασης, κύτταρα ξενιστών και μέθοδοι για έκφραση των αντισωμάτων της αποκάλυψης παρέχονται επίσης. Ανοσοσυζεύγματα, δι-συγκεκριμένα μόρια και φαρμακευτικές συνθέσεις που περιλαμβάνουν τα αντισώματα της αποκάλυψης παρέχονται επίσης. Η αποκάλυψη παρέχει επίσης και μεθόδους για αναστολή της αύξησης ενός κυττάρου όγκου που εκφράζει CD73 χρησιμοποιώντας τα αντισώματα της αποκάλυψης, που συμπεριλαμβάνουν μεθόδους για αγωγή διαφόρων καρκίνων.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING;;JURE-KUNKEL MARIA N,,https://lens.org/042-870-242-573-999,Granted Patent,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/395;;A61P35/00;;C07K16/30;;C07K16/40,,0,0,,,,ACTIVE
456,WO,A3,WO 2016/081748 A3,102-320-787-913-277,2016-09-15,2016,US 2015/0061639 W,2015-11-19,US 201462083056 P,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,"The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/102-320-787-913-277,Search Report,yes,3,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/395;;A61P35/00;;C07K16/30;;C07K16/40,,3,3,094-218-297-204-09X;;048-700-652-556-098;;039-889-533-551-521,23406016;;10.1186/1476-4598-12-11;;pmc3582597;;24043904;;10.4049/jimmunol.1301274;;1827828;;10.1084/jem.173.6.1483;;pmc2190830,"STEVEN RUST ET AL: ""Combining phenotypic and proteomic approaches to identify membrane targets in a 'triple negative' breast cancer breast cancer cell type"", MOLECULAR CANCER, BIOMED CENTRAL, LONDON, GB, vol. 12, no. 1, 13 February 2013 (2013-02-13), pages 11, XP021139556, ISSN: 1476-4598, DOI: 10.1186/1476-4598-12-11;;M. G. TERP ET AL: ""Anti-Human CD73 Monoclonal Antibody Inhibits Metastasis Formation in Human Breast Cancer by Inducing Clustering and Internalization of CD73 Expressed on the Surface of Cancer Cells"", THE JOURNAL OF IMMUNOLOGY, vol. 191, no. 8, 16 September 2013 (2013-09-16), US, pages 4165 - 4173, XP055245512, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1301274;;CANFIELD S M ET AL: ""THE BINDING AFFINITY OF HUMAN IGG FOR ITS HIGH AFFINITY FC RECEPTOR IS DETERMINED BY MULTIPLE AMINO ACIDS IN THE CH2 DOMAIN AND IS MODULATED BY THE HINGE REGION"", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 173, no. 6, 1 June 1991 (1991-06-01), pages 1483 - 1491, XP001181027, ISSN: 0022-1007, DOI: 10.1084/JEM.173.6.1483",PENDING
457,CL,A1,CL 2017001296 A1,010-604-000-182-810,2018-02-16,2018,CL 2017001296 A,2017-05-19,US 201462083056 P,2014-11-21,Anticuerpos contra cd73 y sus usos,"<p>LA PRESENTE INVENCIÓN PROPORCIONA ANTICUERPOS MONOCLONALES AISLADOS, PARTICULARMENTE ANTICUERPOS HUMANOS, QUE SE UNEN AL CLUSTER DE DIFERENCIACIÓN 73 HUMANO (CD73) CON ALTA AFINIDAD, E INHIBEN LA ACTIVIDAD DE CD73, Y OPCIONALMENTE MEDIAN LA INTERNALIZACIÓN DE CD73 DEPENDIENTE DE ANTICUERPO. TAMBIÉN SE PROVEEN LAS MOLÉCULAS DE ÁCIDO NUCLÉICO QUE CODIFICAN LOS ANTICUERPOS DE LA INVENCIÓN, VECTORES DE EXPRESIÓN, CÉLULAS HUÉSPED Y MÉTODOS PARA EXPRESAR LOS ANTICUERPOS DE LA INVENCIÓN. TAMBIÉN SE PROVEEN LOS INMUNOCONJUGADOS, MOLÉCULAS BIESPECÍFICAS Y COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS ANTICUERPOS DE LA INVENCIÓN. LA INVENCIÓN TAMBIÉN PROPORCIONA MÉTODOS PARA INHIBIR EL CRECIMIENTO DE UNA CÉLULA TUMORAL QUE EXPRESA CD73 USANDO LOS ANTICUERPOS DE LA INVENCIÓN, INCLUYENDO MÉTODOS PARA TRATAR VARIOS TIPOS DE CÁNCER.</p>",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;CORBETT MARTIN J;;YAMNIUK AARON P;;KORMAN ALAN J;;CHEN GUODONG;;HUANG RICHARD;;HUANG HAICHUN;;BARNHART BRYAN C;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;SACK JOHN;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;ZHANG PINGPING;;SRINIVASAN MOHAN,,https://lens.org/010-604-000-182-810,Patent Application,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,A61K39/395;;A61P35/00;;C07K16/28;;C07K16/30;;C07K16/40,,0,0,,,,PENDING
458,KR,A,KR 20170080699 A,011-851-670-260-35X,2017-07-10,2017,KR 20177016541 A,2015-11-19,US 201462083056 P;;US 2015/0061639 W,2014-11-21,CD73 ANTIBODIES AGAINST CD73 AND USES THEREOF,"본 개시내용은 인간 분화 클러스터 73 (CD73)과 고 친화도로 결합하고; CD73의 활성을 억제하며; 임의로 항체 의존성 CD73 내재화를 매개하는, 단리된 모노클로날 항체, 특히 인간 항체를 제공한다. 본 개시내용의 항체를 코딩하는 핵산 분자, 본 개시내용의 항체를 발현하기 위한 발현 벡터, 숙주 세포 및 방법이 또한 제공된다. 본 개시내용의 항체를 포함하는 면역접합체, 이중특이적 분자 및 제약 조성물이 또한 제공된다. 본 개시내용은 또한, 본 개시내용의 항체를 사용하여 CD73을 발현하는 종양 세포의 성장을 억제하는 방법을 제공하는데, 이는 각종 암을 치료하는 방법을 포함한다.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/011-851-670-260-35X,Patent Application,no,1,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/28;;A61K39/00;;C07K16/30;;C07K16/40,,0,0,,,,ACTIVE
459,BR,A2,BR 112017010110 A2,116-763-252-778-006,2018-01-30,2018,BR 112017010110 A,2015-11-19,US 2015/0061639 W;;US 201462083056 P,2014-11-21,anticorpos contra cd73 e usos do mesmo,"a presente invenção refere-se a anticorpos monoclonais isolados, particularmente anticorpos humanos, que se ligam ao grupamento humano de diferenciação 73 (cd73) com alta afinidade, e inibem a atividade de cd73, e opcionalmente mediam a internalização de cd73 dependente de anticorpo. as moléculas de ácido nucleico que codificam os anticorpos da invenção, vetores de expressão, células hospedeiras e métodos para expressar os anticorpos da invenção também são providos. os imunoconjugados, moléculas biespecíficas e composições farmacêuticas compreendendo os anticorpos da invenção também são providos. a invenção também provê métodos para inibir o crescimento de uma célula tumoral expressando cd73 usando os anticorpos da invenção, incluindo métodos para tratar vários cânceres.",BRISTOL MYERS SQUIBB CO,AARON P YAMNIUK;;ALAN J KORMAN;;ANGELA GOODENOUGH;;BRYAN C BARNHART;;EMANUELA SEGA;;GUODONG CHEN;;HAICHUN HUANG;;JOHN SACK;;JOSEPH E MYERS;;KARLA A HENNING;;LIANG SCHWEIZER;;MARIA N JUREKUNKEL;;MARTIN J CORBETT;;MING LEI;;MOHAN SRINIVASAN;;NILS LONBERG;;PING-PING ZHANG;;RICHARD HUANG;;SANDRA V HATCHER,,https://lens.org/116-763-252-778-006,Patent Application,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,A61K39/395;;A61P35/00;;C07K16/28;;C07K16/30;;C07K16/40,,0,0,,,,PENDING
460,IL,A,IL 283965 A,131-552-547-824-536,2021-07-29,2021,IL 28396521 A,2021-06-14,US 201462083056 P;;US 2015/0061639 W,2014-11-21,Antibodies against cd73 and uses thereof,,BRISTOL MYERS SQUIBB PHARMA COMPANY;;LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,,https://lens.org/131-552-547-824-536,Patent Application,no,0,0,66,66,0,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,,,0,0,,,,PENDING
461,US,B2,US 9605080 B2,086-828-073-721-555,2017-03-28,2017,US 201614994828 A,2016-01-13,US 201614994828 A;;US 2015/0061639 W;;US 201462083056 P,2014-11-21,Antibodies against CD73,"The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN S;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JR JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,BRISTOL-MYERS SQUIBB COMPANY (2016-01-14),https://lens.org/086-828-073-721-555,Granted Patent,yes,112,25,66,66,380,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/30;;A61K39/00;;A61K39/395;;A61K45/06;;C07K16/40;;G01N33/573,,59,48,002-007-578-507-698;;048-700-652-556-098;;009-480-999-058-518;;094-218-297-204-09X;;035-262-880-872-181;;075-247-958-346-33X;;002-059-731-917-621;;013-552-326-036-140;;058-923-522-621-673;;042-598-633-420-113;;036-451-454-505-513;;016-465-232-588-036;;003-400-553-052-276;;093-145-147-210-709;;018-694-440-454-632;;039-889-533-551-521;;082-679-623-169-928;;030-827-478-377-311;;106-403-721-882-788;;056-584-393-786-220;;057-350-695-027-427;;010-583-084-540-282;;004-922-729-065-965;;077-937-964-199-621;;034-727-826-412-783;;153-181-187-821-793;;069-567-334-250-378;;046-940-559-099-224;;043-447-916-619-796;;000-513-978-398-020;;022-255-746-239-345;;001-056-624-840-550;;109-091-284-112-484;;004-458-031-333-650;;002-699-487-824-639;;140-815-540-810-121;;010-916-302-181-744;;026-126-853-260-259;;067-163-829-543-478;;048-700-652-556-098;;003-206-761-394-124;;030-419-208-989-964;;051-374-571-260-065;;020-301-454-048-952;;009-896-708-612-339;;087-153-613-664-816;;035-648-435-180-47X;;030-245-672-156-344,10458776;;10.1002/(sici)1521-4141(199908)29:08<2613::aid-immu2613>3.0.co;2-j;;24043904;;10.4049/jimmunol.1301274;;pmc5037986;;10.1080/19420862.2016.1143182;;26854859;;23406016;;10.1186/1476-4598-12-11;;pmc3582597;;10.4161/onci.26705;;pmc3926871;;24575377;;pmc52646;;10.1073/pnas.88.20.9036;;1833770;;10.1038/nbt1376;;18157117;;10.1177/1087057112443987;;22522649;;pmc2254484;;10.1007/s11302-006-9000-8;;18404474;;10.1158/2159-8290.cd-14-0341;;25035124;;10.1517/14728222.2014.915315;;24798880;;10.1158/1078-0432.ccr-13-0545;;23983257;;10.1021/bi8022174;;19254029;;10.1016/j.it.2012.02.009;;22487321;;10.1002/eji.1830241042;;7925582;;1827828;;10.1084/jem.173.6.1483;;pmc2190830;;15543996;;10.1016/j.chroma.2004.08.058;;10.1016/s0021-9673(04)01410-4;;10.1182/blood.v74.7.2486.2486;;2553165;;8477804;;10.1002/eji.1830230518;;10.3410/f.1001160.6701;;11520463;;10.1016/s1074-7613(01)00183-2;;10.1007/978-1-4684-1248-2_61;;3020912;;24489992;;pmc3902223;;pmc2883609;;10.1158/0008-5472.can-09-3109;;20179192;;10.1016/0006-291x(90)91601-n;;2173922;;6327507;;10.1016/s0171-2985(84)80038-8;;20120022;;pmc2867015;;10.1002/pro.352;;10.1021/bi800576c;;18549248;;10.1111/j.1432-1033.1990.tb19158.x;;2129526;;24986517;;10.1158/0008-5472.can-14-0957;;7490135;;pmc1384012;;10916148;;10.1016/s1461-5347(00)00280-7;;10.1016/0378-1119(93)90635-g;;8224905;;10.1016/s0898-6568(96)00132-5;;9113412;;11096108;;10.1074/jbc.m009483200;;10.1016/s0163-7258(00)00053-x;;11007998;;10.1073/pnas.0908801107;;20080644;;pmc2824381;;10.1038/onc.2010.292;;20661219;;8340761;;pmc2191116;;10.1084/jem.178.2.661;;pmc2190803;;2007852;;10.1084/jem.173.4.1025;;24043904;;10.4049/jimmunol.1301274;;3036115;;10.1016/0006-291x(87)91295-2;;10.1111/j.1399-0039.1990.tb01750.x;;2137649;;10.3410/f.725276419.793503869;;25500122;;pmc4297290;;10.1016/j.ccell.2014.11.001;;22146892;;10.1007/s00262-011-1171-7;;8106388;;10.1016/s0021-9258(17)41886-2;;10.1158/0008-5472.can-10-1544;;pmc2922475;;20682793;;23046227;;10.2217/imt.12.83;;17587186;;10.1007/s10585-007-9081-y,"Armour, K.L. et al. Recombinant human IgG molecules lacking Fc gamma receptor I binding and monocyte triggering activities. Eur. J. Immunol., vol. 29, p. 2613-2624 (1999).;;Terp, M.G. et al. Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells. J. Immunol., vol. 191(8):4165-4173 (2013).;;Barnhart, B. et al., “A Therapeutic Antibody that Inhibits CD73 Activity by Dual Mechanisms,” Bristol-Myers Squibb, AACR Annual Meeting 2016, Apr. 16-20, 2016, New Orleans, Louisiana, USA, Abstract No. 1476, 1 page.;;Barnhart, B., “Antibody Inhibition of CD73 Activity by Multiple Mechanisms for Tumor Therapy,” Bristol-Myers Squibb, Apr. 14, 2016, Presentation Slides, 19 pages.;;Geoghegan, JC et al., “Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action,” MAbs, vol. 8 (3): 454-467 (2016) doi: 10.1080/19420862.2016.1143182. Epub Feb. 8, 2016.;;International Search Report and Written Opinion, PCT/US2015/061639, dated Jul. 18, 2016, 31 pages.;;Rust, S. et al., “Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer cell type,” Molecular Cancer, vol. 12(11), pp. 1-11 (2013).;;Beavis, P. et al., “A2A blockade enhances anti-metastatic immune responses,” Oncolmmunology, vol. 2(12), e26705-1-e26705-3 (2013).;;Buisseret, L. et al., “CD73 Expression on Tumor-infiltrating Breast Cancer Leukocytes,” Proceedings of the 106th Annual Meeting of the American Association for Cancer Research? Apr. 18-22, 2015?Philadelphia, PA. Philadelphia (PA): AARC 2015, Poster Presentation, Abstract No. 3361, 1 page.;;Chappel, S. et al., “Identification of the Fcy receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies,” PNAS, vol. 88, pp. 9036-9040 (1991).;;Hay, C. et al., MEDI9447: enhancing anti-tumor immunity by targeting CD73 in the tumor microenvironment, Proceedings of the 106th Annual Meeting of the American Association for Cancer Research? Apr. 18-22, 2015? Philadelphia, PA. Philadelphia(PA): AARC 2015, Abstract No. 285, 2 pages.;;Huang, Q. et al., “Levels and enzyme activity of CD73 in primary samples from cancer patients,” Proceedings of the 106th Annual Meeting of the American Association for Cancer Research? Apr. 18-22, 2015?Philadelphia, PA. Philadelphia(PA): AARC 2015, Abstract No. 1538, 2 pages.;;Huang, Q. et al., “Levels and enzyme activity of CD73 in primary samples from cancer patients,” Proceedings of the 106th Annual Meeting of the American Association for Cancer Research? Apr. 18-22, 2015?Philadelphia, PA. Philadelphia(PA): AARC 2015,Poster Presentation, Abstract No. 1538, 2 pages.;;Kai, M. et al., “Switching Constant Domains Enhances Agonist Activities of Antibodies to a Thrombopoietin Receptor,” Nature Biotechnology, vol. 26(2), pp. 209-211 (2008).;;Sachsenmeier, K. et al., “Development of a Novel Ectonucleotidase Assay Suitable for High-Throughput Screening,” Journal of Biomolecular Screening, vol. 17(7), pp. 993-998 (2012).;;Strater, N. et al., “Ecto-5′-nucleotidase: Structure function Relationships,” Purinergic Signalling, vol. 2, pp. 343-350 (2006).;;Sult, E. et al., “Checkpoint inhibitor combinations in a human mixed leukocyte reaction,” Proceedings of the 106th Annual Meeting of the American Association for Cancer Research? Apr. 18-22, 2015?Philadelphia, PA. Philadelphia (PA): AARC 2015, Abstract No. 272, 2 pages.;;Young, A. et al., “Targeting Cancer-Derived Adenosine: New Therapeutic Approaches,” Cancer Discovery, vol. 4, pp. 879-888 (2014).;;Allard, B. et al., “Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer,” Expert Opinion Ther Targets, vol. 18 (Issue 7), pp. 1-19 (2014).;;Allard, B. et al., “Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs,” Clin Cancer Res, pp. 5626-5635 (Oct. 15, 2013 ).;;Allen, M. et al., “Interchain disulfide bonding in human IgG2 antibodies probed by site-directed mutagenesis,” Biochemistry, vol. 48 (17), pp. 3755-3766 (Mar. 2009).;;Beavis et al. “CD73: a potent suppressor of antitumor immune responses,” Trends in Immunol., vol. 33(5), pp. 231-237 (2012).;;Brekke, O. et al., “Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis,” Eur. J. Immunol, vol. 24, pp. 2542-2547 (1994).;;Canfield, S. et al., “The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region.,” J. Exp. Med., vol. 173, pp. 1483-1491 (1991).;;Dillon, T.et al, “Development of an analytical reversed-phase high-performance liquid chromatography-electrospray ionization mass spectrometry method for characterization of recombinant antibodies,” J. Chromatogr. A, vol. 1053, pp. 299-305 (2004).;;Fukunaga, Y. et al., “Increased density of ecto 5′ nucleotidase antigen on leukemic T cells from patients with cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma,” Blood, vol. 74(7), pp. 2486-2492 (1989).;;Greenwood, J. et al., “Structural motifs involved in human IgG antibody effector functions,” Eur J Immol, vol. 23 (5), pp. 1098-1104 (1993).;;Gross, J. et al., “TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS.,” Immunity, vol. 15, pp. 289-302 (2001).;;Gutensohn, W. et al., “Production and properties of monoclonal Abs against human ecto-5′-nucloeotidase,” Advances in Exp. Med. & Biol., vol. 195, pp. 385-389 (1986).;;Hausler, SF., et al., “Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion,” Am J Transl Res., vol. 6(2), pp. 129-139 (2014).;;Jin, D. et al., “CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression,” Cancer Res., vol. 70(6), 2245-2255 (2 page Supplement data) (2010).;;Klemens, M. et al., “Characterization of soluble vs membrane-bound human placental 5′-nucleotidase,” Biochem Biophys Res Commun.,vol. 172(3), pp. 1371-1377 (1990).;;Kummer, U. et al. “Development and properties of a monoclonal Ab specific for human Ecto-5′-nucleotidase,” Immunobiology, vol. 166, pp. 203-211 (1984).;;Lightl, S. et al., “Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding,” Protein Sci, vol. 19(4), pp. 753-762 (2010).;;Martinez, T. et al., “Disulfide connectivity of human immunoglobulin G2 structural isoforms,” Biochemistry, vol. 47(26), pp. 7496-7508 (May 2008).;;Misumi, Y., et al., “Primary structure of human placental 5′-nucleotidase and identification of the glycolipid anchor in the mature form,” (Fukuoka Univ., Jp), Eur J Biochem., vol. 191(3), pp. 563-569. (1990).;;Mittal, D. et al., “Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor,” vol. 74(14) Cancer Res, pp. 3652-3658 (Jul. 2014).;;Morgan, A. et al., “The N-terminal end of the CH2 domain of chimeric human IgG1 anti-FILA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding,” Immunology, vol. 86 (2), pp. 319-324 (1995).;;Morrison, S. et al., “Structural Determinants of Human IgG Function,” Immunologist,vol. 2, pp. 119-124 (1994).;;NCBI Reference Sequence NP—001191742.1, 4 pages (2012).;;Nielsen, UB et al., “Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries,” PSTT, vol. 3(8), pp. 282-291 (2000).;;Resta, R. et al., “Murine ecto-5′-nucleotidase (CD73): cDNA cloning and tissue distribution,” Gene, vol. 133(2), pp. 171-177 (1993) Abstract.;;Resta, R. et al., “T cell signalling through CD73,” Cell Signal, vol. 9(2), pp. 131-139 (1997).;;Shields, RL., “High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R,” J Biol Chem, vol. 276 (9), pp. 6591-6604 (2001).;;Spychala J., “Tumor-promoting functions of adenosine,” Pharmacology and Therapeutics, vol. 87 (2-3) pp. 161-173 (2000).;;Stagg, J. et al., “Anti-CD73 Antibody therapy inhibits breast tumor growth and metastasis,” PNAS, vol. 107(4), pp. 1547-1552 (2010).;;Stagg, J. et al., “Extracellular adenosine triphosphate and adenosine in cancer,” Oncogene , vol. 29 (39), pp. 5346-5358 (2010).;;Tao, MH et al., “Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation,” J Exp Med, vol. 178(2), pp. 661-667 (1993).;;Tao, MH., “The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain,” J Exp Med., vol. 173(4), pp. 1025-1028 (1991).;;Terp, M. et al., “Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells,” J. Immunol., vol. 191(8), pp. 4165-4173 (2013).;;Thomson, L. et al., “Purification of 5′-nucleotidase from human placenta after release from plasma membranes by phosphatidylinositol-specific phospholipase C,” Biochem Biophys Res Commun, vol. 145(1), pp. 118-125 (1987).;;Thomson, L.F. et al., “Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol-anchored lymphocyte differentiation antigen ecto-5′-nucleotidase (CD73),” Tissue Antigens, vol. 35(1), pp. 9-19 (1990).;;White, A. et al., “Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies,” Cancer Cell., vol. 27(1), pp. 138-148 (2015).;;Whiteside et al., “Disarming suppressor cells to improve immunotherapy,” Immunol. Immunother, vol. 61, pp. 283-288 (2012).;;Xu, Y. et al., “Residue at position 331 in the IgG1 and IgG4 CH2 domains contributes to their differential ability to bind and activate complement,” Journal of Biological Chemistry, vol. 269(5, pp. 3469-3474 (1994).;;Xu, Y. et al., The N-Terminal Sequence of the CH2 Domain Controls the Differential Ability of Human IgG 1 and IgG2 to Activate Complement, J. of Immunol., vol. 150, Abstract 862, p. 152A (1993).;;Zhang , B., “CD73: A novel target for cancer immunotherapy,” Cancer Res., vol. 70(16), pp. 6407-6411 (2010).;;Zhang, B., “Opportunities and challenges for anti-CD73 cancer therapy,” Immunotherapy, vol. 4(9), pp. 861-865 (2012).;;Zhi, X. et al., “RNA interference of ecto-5′-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion,” Clin. Exp. Metastasis, vol. 24, pp. 439-448 (2007).",ACTIVE
462,US,A1,US 2019/0055320 A1,028-546-459-876-315,2019-02-21,2019,US 201816113061 A,2018-08-27,US 201816113061 A;;US 201715520638 A;;US 2015/0061639 W;;US 201462083056 P,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,"The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA;;CHEN GUODONG;;SACK JOHN S;;HUANG RICHARD Y;;CORBETT MARTIN J;;MYERS JR JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,BRISTOL-MYERS SQUIBB COMPANY (2016-01-14),https://lens.org/028-546-459-876-315,Patent Application,yes,0,6,66,66,380,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/40;;A61K39/00;;A61K39/395;;A61K45/06;;A61K47/68;;C07K16/28;;C07K16/30;;G01N33/574,,0,0,,,,DISCONTINUED
463,US,A1,US 2019/0062456 A1,041-424-770-924-143,2019-02-28,2019,US 201816117183 A,2018-08-30,US 201816117183 A;;US 201715432180 A;;US 201614994828 A;;US 2015/0061639 W;;US 201462083056 P,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,"The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA;;CHEN GUODONG;;SACK JOHN S;;HUANG RICHARD Y;;CORBETT MARTIN J;;MYERS JR JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,BRISTOL-MYERS SQUIBB COMPANY (2016-01-14),https://lens.org/041-424-770-924-143,Patent Application,yes,0,4,66,66,380,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/40;;A61K39/00;;A61K39/395;;A61K45/06;;C07K16/28;;C07K16/30;;G01N33/573,,0,0,,,,ACTIVE
464,US,A1,US 2017/0253665 A1,019-530-844-773-23X,2017-09-07,2017,US 201715432180 A,2017-02-14,US 201715432180 A;;US 201614994828 A;;US 2015/0061639 W;;US 201462083056 P,2014-11-21,ANTIBODIES AGAINST CD73,"The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN S;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JR JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,BRISTOL-MYERS SQUIBB COMPANY (2016-01-14),https://lens.org/019-530-844-773-23X,Patent Application,yes,0,7,66,66,380,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,A61K39/395;;C07K16/40;;A61K45/06;;C07K16/30;;G01N33/573,,0,0,,,,ACTIVE
465,US,A1,US 2023/0051701 A1,041-233-867-011-525,2023-02-16,2023,US 202217737403 A,2022-05-05,US 202217737403 A;;US 201816117183 A;;US 201715432180 A;;US 201614994828 A;;US 2015/0061639 W;;US 201462083056 P,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,"The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN S;;HUANG RICHARD;;CORBETT MARTIN J;;MYERS JR JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,BRISTOL-MYERS SQUIBB COMPANY (2016-01-14),https://lens.org/041-233-867-011-525,Patent Application,yes,0,0,66,66,380,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/40;;A61K39/395;;A61K45/06;;A61K47/68;;C07K16/28;;C07K16/30;;G01N33/573;;G01N33/574,,0,0,,,,PENDING
466,US,B2,US 10100129 B2,028-777-394-385-598,2018-10-16,2018,US 201515520638 A,2015-11-19,US 201515520638 A;;US 201462083056 P;;US 2015/0061639 W,2014-11-21,Antibodies against CD73 and uses thereof,"The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA;;CHEN GUODONG;;SACK JOHN S;;HUANG RICHARD Y;;CORBETT MARTIN J;;MYERS JR JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,BRISTOL-MYERS SQUIBB COMPANY (2016-01-14),https://lens.org/028-777-394-385-598,Granted Patent,yes,124,13,66,66,380,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,A61K39/00;;A61K39/395;;A61K45/06;;A61K47/68;;C07K16/28;;C07K16/30;;C07K16/40;;G01N33/574,,76,53,140-815-540-810-121;;048-700-652-556-098;;051-374-571-260-065;;020-301-454-048-952;;009-896-708-612-339;;042-598-633-420-113;;087-153-613-664-816;;035-648-435-180-47X;;030-245-672-156-344;;089-077-605-701-286;;054-470-953-946-408;;019-381-122-709-352;;039-055-633-551-472;;036-451-454-505-513;;016-465-232-588-036;;003-400-553-052-276;;002-007-578-507-698;;093-145-147-210-709;;035-262-880-872-181;;018-694-440-454-632;;039-889-533-551-521;;075-247-958-346-33X;;082-679-623-169-928;;030-827-478-377-311;;009-480-999-058-518;;106-403-721-882-788;;056-584-393-786-220;;057-350-695-027-427;;010-583-084-540-282;;004-922-729-065-965;;002-059-731-917-621;;077-937-964-199-621;;034-727-826-412-783;;153-181-187-821-793;;069-567-334-250-378;;046-940-559-099-224;;043-447-916-619-796;;000-513-978-398-020;;022-255-746-239-345;;001-056-624-840-550;;109-091-284-112-484;;094-218-297-204-09X;;013-552-326-036-140;;004-458-031-333-650;;002-699-487-824-639;;140-815-540-810-121;;010-916-302-181-744;;058-923-522-621-673;;026-126-853-260-259;;067-163-829-543-478;;048-700-652-556-098;;003-206-761-394-124;;030-419-208-989-964,10.1073/pnas.0908801107;;20080644;;pmc2824381;;24043904;;10.4049/jimmunol.1301274;;10.3410/f.725276419.793503869;;25500122;;pmc4297290;;10.1016/j.ccell.2014.11.001;;22146892;;10.1007/s00262-011-1171-7;;8106388;;10.1016/s0021-9258(17)41886-2;;10.1158/2159-8290.cd-14-0341;;25035124;;10.1158/0008-5472.can-10-1544;;pmc2922475;;20682793;;23046227;;10.2217/imt.12.83;;17587186;;10.1007/s10585-007-9081-y;;pmc3804170;;10.4049/jimmunol.1301653;;24062486;;26332593;;10.1002/cyto.b.21320;;10.1038/nbt1344;;17989688;;10.1016/j.ymeth.2013.06.035;;23872058;;10.1517/14728222.2014.915315;;24798880;;10.1158/1078-0432.ccr-13-0545;;23983257;;10.1021/bi8022174;;19254029;;10458776;;10.1002/(sici)1521-4141(199908)29:08<2613::aid-immu2613>3.0.co;2-j;;10.1016/j.it.2012.02.009;;22487321;;10.4161/onci.26705;;pmc3926871;;24575377;;10.1002/eji.1830241042;;7925582;;1827828;;10.1084/jem.173.6.1483;;pmc2190830;;pmc52646;;10.1073/pnas.88.20.9036;;1833770;;15543996;;10.1016/j.chroma.2004.08.058;;10.1016/s0021-9673(04)01410-4;;10.1182/blood.v74.7.2486.2486;;2553165;;pmc5037986;;10.1080/19420862.2016.1143182;;26854859;;8477804;;10.1002/eji.1830230518;;10.3410/f.1001160.6701;;11520463;;10.1016/s1074-7613(01)00183-2;;10.1007/978-1-4684-1248-2_61;;3020912;;24489992;;pmc3902223;;pmc2883609;;10.1158/0008-5472.can-09-3109;;20179192;;10.1038/nbt1376;;18157117;;10.1016/0006-291x(90)91601-n;;2173922;;6327507;;10.1016/s0171-2985(84)80038-8;;20120022;;pmc2867015;;10.1002/pro.352;;10.1021/bi800576c;;18549248;;10.1111/j.1432-1033.1990.tb19158.x;;2129526;;24986517;;10.1158/0008-5472.can-14-0957;;7490135;;pmc1384012;;10916148;;10.1016/s1461-5347(00)00280-7;;10.1016/0378-1119(93)90635-g;;8224905;;10.1016/s0898-6568(96)00132-5;;9113412;;23406016;;10.1186/1476-4598-12-11;;pmc3582597;;10.1177/1087057112443987;;22522649;;11096108;;10.1074/jbc.m009483200;;10.1016/s0163-7258(00)00053-x;;11007998;;10.1073/pnas.0908801107;;20080644;;pmc2824381;;10.1038/onc.2010.292;;20661219;;pmc2254484;;10.1007/s11302-006-9000-8;;18404474;;8340761;;pmc2191116;;10.1084/jem.178.2.661;;pmc2190803;;2007852;;10.1084/jem.173.4.1025;;24043904;;10.4049/jimmunol.1301274;;3036115;;10.1016/0006-291x(87)91295-2;;10.1111/j.1399-0039.1990.tb01750.x;;2137649,"Stagg et al (PNAS, 2010, 107:1547-1552).;;Terp et al (Journal of Immunology, 2013, 191:4165-4173).;;White, A. et al., “Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies,” Cancer Cell., vol. 27(1), pp. 138-148 (2015).;;Whiteside et al., “Disarming suppressor cells to improve immunotherapy,” Cancer Immunol. Immunother , vol. 61, pp. 283-288 (2012).;;Xu, Y. et al., “Residue at position 331 in the IgG1 and IgG4 CH2 domains contributes to their differential ability to bind and activate complement,” Journal of Biological Chemistry, vol. 269(5): 3469-3474 (1994).;;Xu, Y. et al., The N-Terminal Sequence of the CH2 Domain Controls The Differential Ability of Human IgG 1 and IgG2 to Activate Complement, J. of Immunol., vol. 150, Abstract 862, p. 152A (1993).;;Young, A. et al., “Targeting Cancer-Derived Adenosine: New Therapeutic Approaches,” Cancer Discovery, vol. 4, pp. 879-888 (2014).;;Zhang , B., “CD73: A novel target for cancer immunotherapy,” Cancer Res., vol. 70(16), pp. 6407-6411 (2010).;;Zhang, B., “Opportunities and challenges for anti-CD73 cancer therapy,” Immunotherapy, vol. 4(9), pp. 861-865 (2012).;;Zhi, X. et al., “RNA interference of ecto-5′-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion,” Clin. Exp. Metastasis, vol. 24, pp. 439-448 (2007).;;International Preliminary Report on Patentability, PCT/US2015/061632, dated May 23, 2017, 17 pages.;;International Search Report and Written Opinion, PCT/US2015/061632, dated Jul. 7, 2016, 26 pages.;;International Search Report and Written Opinion, PCT/US2017/020714, dated Jul. 11, 2017, 21 pages.;;Lau, C. et al., “Chimeric Anti-CD14 IGG2/4 Hybrid Antibodies for Therapeutic Intervention in Pig and Human Models of Inflammation,” The Journal of Immunology, vol. 191(9):4769-4777 (2013).;;MAXIME MOULARD, MARIE-LAURE OZOUX: ""How validated receptor occupancy flow cytometry assays can impact decisions and support drug development : HOW VALIDATED RO FLOW CYTOMETRY ASSAYS CAN IMPACT DECISIONS AND SUPPORT DRUG DEVELOPMENT"", CYTOMETRY. PART B, CLINICAL CYTOMETRY, WILEY-LISS, HOBOKEN, NJ, US, vol. 90, no. 2, 1 March 2016 (2016-03-01), US, pages 150 - 158, XP055383541, ISSN: 1552-4949, DOI: 10.1002/cyto.b.21320;;Rother, R. et al., “Discovery and Development of the Complement Inhibitor Exulizmab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria,” Nature Biotechnology, vol. 25(11):1256-1264 (2007).;;Third Party Observation, PCT/US2015/061632, dated Mar. 21, 2017, 8 pages.;;Vafa, O. et al., “An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations,” METHODS, vol. 65(1):95-110 (2014).;;Allard, B. et al., “Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer,” Expert Opinion Ther Targets, vol. 18 (Issue 7), pp. 1-19 (2014).;;Allard, B. et al., “Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs,” Clin Cancer Res, pp. 5626-5635 (Oct. 15, 2013 ).;;Allen, M. et al., “Interchain disulfide bonding in human IgG2 antibodies probed by site-directed mutagenesis,” Biochemistry, vol. 48 (17), pp. 3755-3766 (Mar. 2009).;;Armour, K. et al., “Recombinant Human IgG Molecules lacking FCy receptor I binding and monocyte triggering activities,” Eur. J. Immunol., vol. 29, pp. 2613-2624 (2015).;;Barnhart, B. et al., “A Therapeutic Antibody that Inhibits CD73 Activity by Dual Mechanisms,” Bristol-Myers Squibb, AACR Annual Meeting 2016, Apr. 16-20, 2016, New Orleans, Louisiana, USA, Abstract No. 1476, 1 page.;;Barnhart, B., “Antibody Inhibition of CD73 Activity by Multiple Mechanisms for Tumor Therapy,” Bristol-Myers Squibb, Apr. 14, 2016, Presentation Slides, 19 pages.;;Beavis et al. “CD73: a potent suppressor of antitumor immune responses,” Trends in Immunol., vol. 33(5), pp. 231-237 (2012).;;Beavis, P. et al., “A2A blockade enhances anti-metastatic immune responses,” OncoImmunology, vol. 2(12), e26705-1-e26705-3(2013).;;Brekke, O. et al., “Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis,” Eur. J. Immunol, vol. 24, pp. 2542-2547 (1994).;;Buisseret, L. et al., “CD73 Expression on Tumor-infiltrating Breast Cancer Leukocytes,” Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, Apr. 18-22, 2015, Philadelphia, PA. Philadelphia (PA): AARC 2015, Poster Presentation, Abstract No. 3361, 1 page.;;Canfield, S. et al., “The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region.,” J. Exp. Med., vol. 173, pp. 1483-1491 (1991).;;Chappel, S. et al., “Identification of the Fcy receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies,” PNAS, vol. 88, pp. 9036-9040 (1991).;;Dillon, T.et al., “Development of an analytical reversed-phase high-performance liquid chromatography-electrospray ionization mass spectrometry method for characterization of recombinant antibodies,” J. Chromatogr. A, vol. 1053, pp. 299-305 (2004).;;Fukunaga, Y. et al., “Increased density of ecto 5′ nucleotidase antigen on leukemic T cells from patients with cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma,” Blood, vol. 74(7), pp. 2486-2492 (1989).;;Geoghegan, JC et al., “Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action,” MAbs, vol. 8 (3): 454-467 (2016) doi: 10.1080/19420862.2016.1143182. Epub Feb. 8, 2016.;;Greenwood, J. et al., “Structural motifs involved in human IgG antibody effector functions,” Eur J Immol, vol. 23 (5), pp. 1098-1104 (1993).;;Gross, J. et al., “TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS.,” Immunity, vol. 15, pp. 289-302 (2001).;;Gutensohn, W. et al., “Production and properties of monoclonal Abs against human ecto-5′-nucloeotidase,” Advances in Exp. Med. & Biol., vol. 195, pp. 385-389 (1986).;;Hausler, SF., et al., “Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion,” Am J Transl Res., vol. 6(2), pp. 129-139 (2014).;;Hay, C. et al., MEDI9447: enhancing anti-tumor immunity by targeting CD73 in the tumor microenvironment, Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, Apr. 18-22, 2015, Philadelphia, PA. Philadelphia(PA): AARC 2015, Abstract No. 285, 2 pages.;;Huang, Q. et al., “Levels and enzyme activity of CD73 in primary samples from cancer patients,” Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, Apr. 18-22, 2015, Philadelphia, PA. Philadelphia(PA): AARC 2015, Abstract No. 1538, 2 pages.;;International Preliminary Report on Patentability, PCT/US2015/061639, dated May 23, 2017, 18 pages.;;International Search Report, PCT/US2015/061639, dated Jul. 18, 2018, 31 pages.;;Jin, D. et al., “CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression,” Cancer Res., vol. 70(6), 2245-2255 (2 page Supplement data) (2010).;;Kai, M. et al., “Switching Constant Domains Enhances Agonist Activities of Antibodies to a Thrombopoietin Receptor,” Nature Biotechnology, vol. 26(2), pp. 209-211 (2008).;;Klemens, M. et al., “Characterization of soluble vs membrane-bound human placental 5′-nucleotidase,” Biochem Biophys Res Commun.,vol. 172(3), pp. 1371-1377 (1990).;;Kummer, U. et al. “Development and properties of a monoclonal Ab specific for human Ecto-5′-nucleotidase,” Immunobiology, vol. 166, pp. 203-211 (1984).;;Lightle, S. et al., “Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding,” Protein Sci, vol. 19(4), pp. 753-762 (2010).;;Martinez, T. et al., “Disulfide connectivity of human immunoglobulin G2 structural isoforms,” Biochemistry, vol. 47(26), pp. 7496-7508 (May 2008).;;Misumi, Y., et al., “Primary structure of human placental 5′-nucleotidase and identification of the glycolipid anchor in the mature form,” (Fukuoka Univ., Jp), Eur J Biochem., vol. 191(3), pp. 563-569. (1990).;;Mittal, D. et al., “Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor,” vol. 74(14) Cancer Res, pp. 3652-3658 (Jul. 2014).;;Morgan, A. et al., “The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding,” Immunology, vol. 86 (2), pp. 319-324 (1995).;;Morrison, S. et al., “Structural Determinants of Human IgG Function,” Immunologist,vol. 2, pp. 119-124 (1994).;;NCBI Reference Sequence NP_001191742.1, 4 pages (2012).;;Nielsen, UB et al., “Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries,” PSTT, vol. 3(8), pp. 282-291 (2000).;;Resta, R. et al., “Murine ecto-5′-nucleotidase (CD73): cDNA cloning and tissue distribution,” Gene, vol. 133(2), pp. 171-177 (1993) Abstract.;;Resta, R. et al., “T cell signalling through CD73,” Cell Signal, vol. 9(2), pp. 131-139 (1997).;;Rust, S. et al., “Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer cell type,” Molecular Cancer, vol. 12(11), pp. 1-11 (2013).;;Sachsenmeir, K. et al., “Development of A Novel Ectonucleotidase Assay Suitable for High-Throughput Screening,” Journal of Biomolecular Screening, vol. 17(7), pp. 993-998 (2012).;;Shields, RL., “High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R,” J Biol Chem, vol. 276 (9), pp. 3591-6604 (2001).;;Spychala J., “Tumor-promoting functions of adenosine,” Pharmacology and Therapeutics, vol. 87 (2-3) pp. 161-173 (2000).;;Stagg, J. et al., “Anti-CD73 Antibody therapy inhibits breast tumor growth and metastasis,” PNAS, vol. 107(4), pp. 1547-1552 (2010).;;Stagg, J. et al., “Extracellular adenosine triphosphate and adenosine in cancer,” Oncogene , vol. 29 (39), pp. 5346-5358 (2010).;;Strater, N. et al., “Ecto-5′-nucleotidase: Structure function Relationships,” Purinergic Signalling, vol. 2, pp. 343-350 (2006).;;Sult, E. et al., “Checkpoint inhibitor combinations in a human mixed leukocyte reaction,” Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, Apr. 18-22, 2015, Philadelphia, PA. Philadelphia (PA): AARC 2015, Abstract No. 272, 2 pages.;;Tao, MH et al., “Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation,” J Exp Med, vol. 178(2), pp. 661-667 (1993).;;Tao, MH., “The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain,” J Exp Med., vol. 173(4), pp. 1025-1028 (1991).;;Terp, M.G. et al.,“Anti-Human CD73 Monoclonal Antibody Inhibits Metastasis Formation in Human Breast Cancer by Inducing Clustering and Internalization of CD73 Expressed on the Surface of Cancer Cells,” The Journal of Immunology, vol. 191(8):4165-4173.;;Thomson, L. et al., “Purification of 5′-nucleotidase from human placenta after release from plasma membranes by phosphatidylinositol-specific phospholipase C,” Biochem Biophys Res Commun, vol. 145(1), pp. 118-125 (1987).;;Thomson, L.F. et al., “Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol-anchored lymphocyte differentiation antigen ecto-5′-nucleotidase (CD73),” Tissue Antigens, vol. 35(1), pp. 9-19 (1990).;;U.S. Appl. No. 15/432,180, dated Feb. 16, 2018, B. Hissong.;;U.S. Appl. No. 14/994,828, filed Jan. 13, 2016, Nils Lonberg.;;U.S. Appl. No. 15/432,180, filed Feb. 14, 2017, Nils Lonberg.;;U.S. Appl. No. 14/994,828, dated Jan. 27, 2017, B. Hissong.;;U.S. Appl. No. 14/994,828, dated Nov. 7, 2016, B. Hissong.;;U.S. Appl. No. 14/994,828, dated Jul. 14, 2016, B. Hissong.;;U.S. Appl. No. 14/994,828, dated May 23, 2016, B. Hissong.;;U.S. Appl. No. 15/520,954, filed Apr. 21, 2017, Nils Lonberg.",ACTIVE
467,US,A1,US 2018/0127513 A1,043-804-867-523-95X,2018-05-10,2018,US 201515520638 A,2015-11-19,US 201515520638 A;;US 201462083056 P;;US 2015/0061639 W,2014-11-21,ANTIBODIES AGAINST CD73 AND USES THEREOF,"The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA;;CHEN GUODONG;;SACK JOHN S;;HUANG RICHARD Y;;CORBETT MARTIN J;;MYERS JR JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,BRISTOL-MYERS SQUIBB COMPANY (2016-01-14),https://lens.org/043-804-867-523-95X,Patent Application,yes,0,6,66,66,380,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/40;;A61K39/00;;A61K39/395;;A61K45/06;;A61K47/68;;C07K16/28;;C07K16/30;;G01N33/574,,0,0,,,,ACTIVE
468,US,B2,US 10167343 B2,165-053-925-668-76X,2019-01-01,2019,US 201715432180 A,2017-02-14,US 201715432180 A;;US 201614994828 A;;US 2015/0061639 W;;US 201462083056 P,2014-11-21,Antibodies against CD73,"The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN S;;HUANG RICHARD Y;;CORBETT MARTIN J;;MYERS JR JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,BRISTOL-MYERS SQUIBB COMPANY (2016-01-14),https://lens.org/165-053-925-668-76X,Granted Patent,yes,123,3,66,66,380,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,C07K16/30;;A61K39/00;;A61K39/395;;A61K45/06;;C07K16/28;;C07K16/40;;G01N33/573,,66,51,089-077-605-701-286;;054-470-953-946-408;;019-381-122-709-352;;039-055-633-551-472;;020-301-454-048-952;;009-896-708-612-339;;042-598-633-420-113;;087-153-613-664-816;;035-648-435-180-47X;;030-245-672-156-344;;036-451-454-505-513;;016-465-232-588-036;;003-400-553-052-276;;002-007-578-507-698;;093-145-147-210-709;;035-262-880-872-181;;018-694-440-454-632;;039-889-533-551-521;;075-247-958-346-33X;;082-679-623-169-928;;030-827-478-377-311;;009-480-999-058-518;;106-403-721-882-788;;056-584-393-786-220;;057-350-695-027-427;;010-583-084-540-282;;004-922-729-065-965;;002-059-731-917-621;;077-937-964-199-621;;034-727-826-412-783;;153-181-187-821-793;;069-567-334-250-378;;046-940-559-099-224;;043-447-916-619-796;;000-513-978-398-020;;022-255-746-239-345;;001-056-624-840-550;;109-091-284-112-484;;094-218-297-204-09X;;013-552-326-036-140;;004-458-031-333-650;;002-699-487-824-639;;140-815-540-810-121;;010-916-302-181-744;;058-923-522-621-673;;026-126-853-260-259;;067-163-829-543-478;;048-700-652-556-098;;003-206-761-394-124;;030-419-208-989-964;;051-374-571-260-065,pmc3804170;;10.4049/jimmunol.1301653;;24062486;;26332593;;10.1002/cyto.b.21320;;10.1038/nbt1344;;17989688;;10.1016/j.ymeth.2013.06.035;;23872058;;22146892;;10.1007/s00262-011-1171-7;;8106388;;10.1016/s0021-9258(17)41886-2;;10.1158/2159-8290.cd-14-0341;;25035124;;10.1158/0008-5472.can-10-1544;;pmc2922475;;20682793;;23046227;;10.2217/imt.12.83;;17587186;;10.1007/s10585-007-9081-y;;10.1517/14728222.2014.915315;;24798880;;10.1158/1078-0432.ccr-13-0545;;23983257;;10.1021/bi8022174;;19254029;;10458776;;10.1002/(sici)1521-4141(199908)29:08<2613::aid-immu2613>3.0.co;2-j;;10.1016/j.it.2012.02.009;;22487321;;10.4161/onci.26705;;pmc3926871;;24575377;;10.1002/eji.1830241042;;7925582;;1827828;;10.1084/jem.173.6.1483;;pmc2190830;;pmc52646;;10.1073/pnas.88.20.9036;;1833770;;15543996;;10.1016/j.chroma.2004.08.058;;10.1016/s0021-9673(04)01410-4;;10.1182/blood.v74.7.2486.2486;;2553165;;pmc5037986;;10.1080/19420862.2016.1143182;;26854859;;8477804;;10.1002/eji.1830230518;;10.3410/f.1001160.6701;;11520463;;10.1016/s1074-7613(01)00183-2;;10.1007/978-1-4684-1248-2_61;;3020912;;24489992;;pmc3902223;;pmc2883609;;10.1158/0008-5472.can-09-3109;;20179192;;10.1038/nbt1376;;18157117;;10.1016/0006-291x(90)91601-n;;2173922;;6327507;;10.1016/s0171-2985(84)80038-8;;20120022;;pmc2867015;;10.1002/pro.352;;10.1021/bi800576c;;18549248;;10.1111/j.1432-1033.1990.tb19158.x;;2129526;;24986517;;10.1158/0008-5472.can-14-0957;;7490135;;pmc1384012;;10916148;;10.1016/s1461-5347(00)00280-7;;10.1016/0378-1119(93)90635-g;;8224905;;10.1016/s0898-6568(96)00132-5;;9113412;;23406016;;10.1186/1476-4598-12-11;;pmc3582597;;10.1177/1087057112443987;;22522649;;11096108;;10.1074/jbc.m009483200;;10.1016/s0163-7258(00)00053-x;;11007998;;10.1073/pnas.0908801107;;20080644;;pmc2824381;;10.1038/onc.2010.292;;20661219;;pmc2254484;;10.1007/s11302-006-9000-8;;18404474;;8340761;;pmc2191116;;10.1084/jem.178.2.661;;pmc2190803;;2007852;;10.1084/jem.173.4.1025;;24043904;;10.4049/jimmunol.1301274;;3036115;;10.1016/0006-291x(87)91295-2;;10.1111/j.1399-0039.1990.tb01750.x;;2137649;;10.3410/f.725276419.793503869;;25500122;;pmc4297290;;10.1016/j.ccell.2014.11.001,"International Preliminary Report on Patentability, PCT/US2015/061632, dated May 23, 2017, 17 pages.;;International Search Report and Written Opinion, PCT/US2015/061632, dated Jul. 7, 2016, 26 pages.;;International Search Report and Written Opinion, PCT/US2017/020714, dated Jul. 11, 2017, 21 pages.;;Lau, C. et al., “Chimeric Anti-CD14 IGG2/4 Hybrid Antibodies for Therapeutic Intervention in Pig and Human Models of Inflammation,” The Journal of Immunology, vol. 191(9):4769-4777 (2013).;;MAXIME MOULARD, MARIE-LAURE OZOUX: ""How validated receptor occupancy flow cytometry assays can impact decisions and support drug development : HOW VALIDATED RO FLOW CYTOMETRY ASSAYS CAN IMPACT DECISIONS AND SUPPORT DRUG DEVELOPMENT"", CYTOMETRY. PART B, CLINICAL CYTOMETRY, WILEY-LISS, HOBOKEN, NJ, US, vol. 90, no. 2, 1 March 2016 (2016-03-01), US, pages 150 - 158, XP055383541, ISSN: 1552-4949, DOI: 10.1002/cyto.b.21320;;Rother, R. et al., “Discovery and Development of the Complement Inhibitor Exulizmab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria,” Nature Biotechnology, vol. 25(11):1256-1264 (2007).;;Third Party Observation, PCT/US2015/061632, dated Mar. 21, 2017, 8 pages.;;Vafa, O. et al., “An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations,” Methods, vol. 65(1):95-110 (2014).;;International Preliminary Report on Patentability, PCT/US2015/061639, dated May 23, 2017, 18 pages.;;Whiteside et al., “Disarming suppressor cells to improve immunotherapy,” Immunol. Immunother, vol. 61, pp. 283-288 (2012).;;Xu, Y. et al., “Residue at position 331 in the IgG1 and IgG4 CH2 domains contributes to their differential ability to bind and activate complement,” Journal of Biological Chemistry, vol. 269(5, pp. 3469-3474 (1994).;;Xu, Y. et al., The N-Terminal Sequence of the CH2 Domain Controls the Differential Ability of Human IgG 1 and IgG2 to Activate Complement, J. of Immunol., vol. 150, Abstract 862, p. 152A (1993).;;Young, A. et al., “Targeting Cancer-Derived Adenosine: New Therapeutic Approaches,” Cancer Discovery, vol. 4, pp. 879-888 (2014).;;Zhang , B., “CD73: A novel target for cancer immunotherapy,” Cancer Res., vol. 70(16), pp. 6407-6411 (2010).;;Zhang, B., “Opportunities and challenges for anti-CD73 cancer therapy,” Immunotherapy, vol. 4(9), pp. 861-865 (2012).;;Zhi, X. et al., “RNA interference of ecto-5′-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion,” Clin. Exp. Metastasis, vol. 24, pp. 439-448 (2007).;;Allard, B. et al., “Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer,” Expert Opinion Ther Targets, vol. 18 (Issue 7), pp. 1-19 (2014).;;Allard, B. et al., “Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs,” Clin Cancer Res, pp. 5626-5635 (Oct. 15, 2013 ).;;Allen, M. et al., “Interchain disulfide bonding in human IgG2 antibodies probed by site-directed mutagenesis,” Biochemistry, vol. 48 (17), pp. 3755-3766 (Mar. 2009).;;Armour, K. et al., “Recombinant Human IgG Molecules lacking FCy receptor I binding and monocyte triggering activiites,” Eur. J. Immunol., vol. 29:2613-2624 (1999).;;Barnhart, B. et al., “A Therapeutic Antibody that Inhibits CD73 Activity by Dual Mechanisms,” Bristol-Myers Squibb, AACR Annual Meeting 2016, Apr. 16-20, 2016, New Orleans, Louisiana, USA, Abstract No. 1476, 1 page.;;Barnhart, B., “Antibody Inhibition of CD73 Activity by Multiple Mechanisms for Tumor Therapy,” Bristol-Myers Squibb, Apr. 14, 2016, Presentation Slides, 19 pages.;;Beavis et al. “CD73: a potent suppressor of antitumor immune responses,” Trends in Immunol., vol. 33(5), pp. 231-237 (2012).;;Beavis, P. et al., “A2A blockade enhances anti-metastatic immune responses,” Oncolmmunology, vol. 2(12), e26705-1-e26705-3 (2013).;;Brekke, O. et al., “Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis,” Eur. J. Immunol, vol. 24, pp. 2542-2547 (1994).;;Buisseret, L. et al., “CD73 Expression on Tumor-infiltrating Breast Cancer Leukocytes,” Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, Apr. 18-22, 2015, Philadelphia, PA. Philadelphia (PA): AARC 2015, Poster Presentation, Abstract No. 3361, 1 page.;;Canfield, S. et al., “The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region.,” J. Exp. Med., vol. 173, pp. 1483-1491 (1991).;;Chappel, S. et al., “Identification of the Fcy receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies,” PNAS, vol. 88, pp. 9036-9040 (1991).;;Dillon, T.et al., “Development of an analytical reversed-phase high-performance liquid chromatography-electrospray ionization mass spectrometry method for characterization of recombinant antibodies,” J. Chromatogr. A, vol. 1053, pp. 299-305 (2004).;;Fukunaga, Y. et al., “Increased density of ecto 5′ nucleotidase antigen on leukemic T cells from patients with cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma,” Blood, vol. 74(7), pp. 2486-2492 (1989).;;Geoghegan, JC et al., “Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action,” MAbs, vol. 8 (3): 454-467 (2016) doi: 10.1080/19420862.2016.1143182. Epub Feb. 8, 2016.;;Greenwood, J. et al., “Structural motifs involved in human IgG antibody effector functions,” Eur J Immol, vol. 23 (5), pp. 1098-1104 (1993).;;Gross, J. et al., “TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS.,” Immunity, vol. 15, pp. 289-302 (2001).;;Gutensohn, W. et al., “Production and properties of monoclonal Abs against human ecto-5′-nucloeotidase,” Advances in Exp. Med. & Biol., vol. 195, pp. 385-389 (1986).;;Hausler, SF., et al., “Anti-CD39 and anti-CD73 antibodies Al and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion,” Am J Transl Res., vol. 6(2), pp. 129-139 (2014).;;Hay, C. et al., MEDI9447: enhancing anti-tumor immunity by targeting CD73 In the tumor microenvironment, Proceedings of the 106th Annual Meeting of the American Association for Cancer Research? Apr. 18-22, 2015? Philadelphia, PA. Philadelphia(PA): AARC 2015, Abstract No. 285, 2 pages.;;Huang, Q. et al., “Levels and enzyme activity of CD73 in primary samples from cancer patients,” Proceedings of the 106th Annual Meeting of the American Association for Cancer Research? Apr. 18-22, 2015?Philadelphia, PA. Philadelphia(PA): AARC 2015,Poster Presentation, Abstract No. 1538, 2 pages.;;International Search Report, PCT/US2015/061639, dated Jul. 18, 2018, 31 pages.;;Jin, D. et al., “CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression,” Cancer Res., vol. 70(6), 2245-2255 (2 page Supplement data) (2010).;;Kai, M. et al., “Switching Constant Domains Enhances Agonist Activities of Antibodies to a Thrombopoietin Receptor,” Nature Biotechnology, vol. 26(2), pp. 209-211 (2008).;;Klemens, M. et al., “Characterization of soluble vs membrane-bound human placental 5′-nucleotidase,” Biochem Biophys Res Commun.,vol. 172(3), pp. 1371-1377 (1990).;;Kummer, U. et al. “Development and properties of a monoclonal Ab specific for human Ecto-5′-nucleotidase,” Immunobiology, vol. 166, pp. 203-211 (1984).;;Lightl, S. et al., “Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding,” Protein Sci, vol. 19(4), pp. 753-762 (2010).;;Martinez, T. et al., “Disulfide connectivity of human immunoglobulin G2 structural isoforms,” Biochemistry, vol. 47(26), pp. 7496-7508 (May 2008).;;Misumi, Y., et al., “Primary structure of human placental 5′-nucleotidase and identification of the glycolipid anchor in the mature form,” (Fukuoka Univ., Jp), Eur J Biochem., vol. 191(3), pp. 563-569. (1990).;;Mittal, D. et al., “Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor,” vol. 74(14) Cancer Res, pp. 3652-3658 (Jul. 2014).;;Morgan, A. et al., “The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding,” Immunology, vol. 86 (2), pp. 319-324 (1995).;;Morrison, S. et al., “Structural Determinants of Human IgG Function,” Immunologist,vol. 2, pp. 119-124 (1994).;;NCBI Reference Sequence NP_001191742.1, 4 pages (2012).;;Nielsen, UB et al., “Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries,” PSTT, vol. 3(8), pp. 282-291 (2000).;;Resta, R. et al., “Murine ecto-5′-nucleotidase (CD73): cDNA cloning and tissue distribution,” Gene, vol. 133(2), pp. 171-177 (1993) Abstract.;;Resta, R. et al., “T cell signalling through CD73,” Cell Signal, vol. 9(2), pp. 131-139 (1997).;;Rust, S. et al., “Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer cell type,” Molecula Cancer, vol. 12(11), pp. 1-11 (2013).;;Sachsenmeier, K. et al., “Development of a Novel Ectonucleotidase Assay Suitable for High-Throughput Screening,” Journal of Biomolecular Screening, vol. 17(7), pp. 993-998 (2012).;;Shields, RL., “High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R,” J Biol Chem, vol. 276 (9), pp. 6591-6604 (2001).;;Spychala J., “Tumor-promoting functions of adenosine,” Pharmacology and Therapeutics, vol. 87 (2-3) pp. 161-173 (2000).;;Stagg, J. et al., “Anti-CD73 Antibody therapy inhibits breast tumor growth and metastasis,” PNAS, vol. 107(4), pp. 1547-1552 (2010).;;Stagg, J. et al., “Extracellular adenosine triphosphate and adenosine in cancer,” Oncogene , vol. 29 (39), pp. 5346-5358 (2010).;;Strater, N. et al., “Ecto-5′-nucleotidase: Structure function Relationships,” Purinergic Signalling, vol. 2, pp. 343-350 (2006).;;Sult, E. et al., “Checkpoint inhibitor combinations in a human mixed leukocyte reaction,” Proceedings of the 106th Annual Meeting of the American Association for Cancer Research? Apr. 18-22, 2015?Philadelphia, PA. Philadelphia (PA): AARC 2015, Abstract No. 272, 2 pages.;;Tao, MH et al., “Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation,” J Exp Med, vol. 178(2), pp. 661-667 (1993).;;Tao, MH., “The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain,” J Exp Med., vol. 173(4), pp. 1025-1028 (1991).;;Terp, M. et al., “Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells,” J. Immunol., vol. 191(8), pp. 4165-4173 (2013).;;Thomson, L. et al., “Purification of 5′-nucleotidase from human placenta after release from plasma membranes by phosphatidylinositol-specific phospholipase C,” Biochem Biophys Res Commun, vol. 145(1), pp. 118-125 (1987).;;Thomson, L.F. et al., “Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol-anchored lymphocyte differentiation antigen ecto-5′-nucleotidase (CD73),” Tissue Antigens, vol. 35(1), pp. 9-19 (1990).;;White, A. et al., “Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies,” Cancer Cell., vol. 27(1), pp. 138-148 (2015).",ACTIVE
469,US,B2,US 11352440 B2,048-916-006-048-796,2022-06-07,2022,US 201816117183 A,2018-08-30,US 201816117183 A;;US 201715432180 A;;US 201614994828 A;;US 2015/0061639 W;;US 201462083056 P,2014-11-21,Antibodies against CD73 and uses thereof,"The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA N;;CHEN GUODONG;;SACK JOHN S;;HUANG RICHARD Y;;CORBETT MARTIN J;;MYERS JR JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;HUANG HAICHUN;;ZHANG PINGPING,BRISTOL-MYERS SQUIBB COMPANY (2016-01-14),https://lens.org/048-916-006-048-796,Granted Patent,yes,156,0,66,66,380,C07K16/2896;;C07K16/30;;C07K16/40;;A61K2039/505;;C07K2317/21;;C07K2317/567;;C07K2317/565;;C07K2317/34;;C07K2317/33;;C07K2317/52;;C07K2317/76;;C07K2317/77;;C07K2317/71;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61K2039/505;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/2896;;C07K16/30;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K16/40;;C07K2317/21;;C07K2317/24;;C07K2317/31;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/72;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;G01N33/573;;G01N33/57492;;G01N2333/916;;A61K39/395;;C07K16/28;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;C07K16/40;;A61P35/00;;A61P35/02;;A61P35/04;;A61K45/06;;C07K2317/522;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/72;;A61K2039/505;;C07K16/2896;;C07K16/30;;C07K16/40;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K47/6871;;A61P35/00;;A61P35/02;;A61P35/04;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/72;;G01N33/573;;G01N33/57492;;G01N2333/916;;C07K16/2896;;A61K2039/505;;C07K2317/34;;C07K2317/33;;C07K2317/94;;C07K2317/92;;C07K2317/76;;C07K2317/77;;A61P35/00;;C07K16/2896;;C07K16/30;;A61K2039/505;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/52;;C07K2317/565;;C07K2317/567;;C07K2317/71;;C07K2317/76;;C07K2317/77;;C07K2317/92;;C07K2317/94;;A61K39/3955;;C07K16/3015;;C07K16/3023;;C07K16/303;;C07K16/3038;;C07K16/3046;;C07K16/3053;;C07K16/3061;;C07K16/3069;;C07K2317/54;;C07K2317/55;;C07K2317/72;;G01N33/573;;C07K16/40;;A61K47/6871;;A61K39/39558;;A61K45/06;;C07K2317/24;;C07K2317/31;;C07K2317/522;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;G01N33/57492;;G01N2333/916,A61K39/395;;A61K39/00;;A61K45/06;;A61K47/68;;C07K16/28;;C07K16/30;;C07K16/40;;G01N33/573;;G01N33/574,,86,63,098-503-091-623-465;;037-087-863-393-493;;022-597-551-032-15X;;077-200-170-742-665;;035-056-717-503-258;;002-857-726-311-154;;048-328-032-768-200;;051-374-571-260-065;;036-451-454-505-513;;016-465-232-588-036;;003-400-553-052-276;;002-007-578-507-698;;093-145-147-210-709;;035-262-880-872-181;;018-694-440-454-632;;039-889-533-551-521;;075-247-958-346-33X;;082-679-623-169-928;;030-827-478-377-311;;009-480-999-058-518;;106-403-721-882-788;;056-584-393-786-220;;057-350-695-027-427;;010-583-084-540-282;;004-922-729-065-965;;002-059-731-917-621;;077-937-964-199-621;;034-727-826-412-783;;089-077-605-701-286;;153-181-187-821-793;;069-567-334-250-378;;046-940-559-099-224;;043-447-916-619-796;;000-513-978-398-020;;054-470-953-946-408;;022-255-746-239-345;;001-056-624-840-550;;109-091-284-112-484;;019-381-122-709-352;;094-218-297-204-09X;;013-552-326-036-140;;004-458-031-333-650;;014-210-778-023-187;;002-699-487-824-639;;140-815-540-810-121;;010-916-302-181-744;;058-923-522-621-673;;026-126-853-260-259;;067-163-829-543-478;;048-700-652-556-098;;003-206-761-394-124;;030-419-208-989-964;;039-055-633-551-472;;051-374-571-260-065;;020-301-454-048-952;;009-896-708-612-339;;042-598-633-420-113;;087-153-613-664-816;;035-648-435-180-47X;;030-245-672-156-344;;044-747-379-119-710;;021-494-060-474-852;;025-599-628-925-326,pmc4800751;;27014745;;10.1016/j.trecan.2016.01.003;;30556751;;10.1080/14728222.2019.1559829;;29914571;;10.1186/s40425-018-0360-8;;pmc6006764;;28258700;;pmc5338647;;10.1111/imr.12528;;10.1200/jco.2017.35.15_suppl.3004;;pmc5716054;;10.1186/s12967-017-1348-8;;29202855;;24590637;;10.1200/jco.2013.53.0105;;pmc4811023;;10.3410/f.725276419.793503869;;25500122;;pmc4297290;;10.1016/j.ccell.2014.11.001;;10.1517/14728222.2014.915315;;24798880;;10.1158/1078-0432.ccr-13-0545;;23983257;;10.1021/bi8022174;;19254029;;10458776;;10.1002/(sici)1521-4141(199908)29:08<2613::aid-immu2613>3.0.co;2-j;;10.1016/j.it.2012.02.009;;22487321;;10.4161/onci.26705;;pmc3926871;;24575377;;10.1002/eji.1830241042;;7925582;;1827828;;10.1084/jem.173.6.1483;;pmc2190830;;pmc52646;;10.1073/pnas.88.20.9036;;1833770;;15543996;;10.1016/j.chroma.2004.08.058;;10.1016/s0021-9673(04)01410-4;;10.1182/blood.v74.7.2486.2486;;2553165;;pmc5037986;;10.1080/19420862.2016.1143182;;26854859;;8477804;;10.1002/eji.1830230518;;10.3410/f.1001160.6701;;11520463;;10.1016/s1074-7613(01)00183-2;;10.1007/978-1-4684-1248-2_61;;3020912;;24489992;;pmc3902223;;pmc2883609;;10.1158/0008-5472.can-09-3109;;20179192;;10.1038/nbt1376;;18157117;;10.1016/0006-291x(90)91601-n;;2173922;;6327507;;10.1016/s0171-2985(84)80038-8;;pmc3804170;;10.4049/jimmunol.1301653;;24062486;;20120022;;pmc2867015;;10.1002/pro.352;;10.1021/bi800576c;;18549248;;10.1111/j.1432-1033.1990.tb19158.x;;2129526;;24986517;;10.1158/0008-5472.can-14-0957;;7490135;;pmc1384012;;26332593;;10.1002/cyto.b.21320;;10916148;;10.1016/s1461-5347(00)00280-7;;10.1016/0378-1119(93)90635-g;;8224905;;10.1016/s0898-6568(96)00132-5;;9113412;;10.1038/nbt1344;;17989688;;23406016;;10.1186/1476-4598-12-11;;pmc3582597;;10.1177/1087057112443987;;22522649;;11096108;;10.1074/jbc.m009483200;;10.1158/1538-7445.am2018-ct180;;10.1016/s0163-7258(00)00053-x;;11007998;;10.1073/pnas.0908801107;;20080644;;pmc2824381;;10.1038/onc.2010.292;;20661219;;pmc2254484;;10.1007/s11302-006-9000-8;;18404474;;8340761;;pmc2191116;;10.1084/jem.178.2.661;;pmc2190803;;2007852;;10.1084/jem.173.4.1025;;24043904;;10.4049/jimmunol.1301274;;3036115;;10.1016/0006-291x(87)91295-2;;10.1111/j.1399-0039.1990.tb01750.x;;2137649;;10.1016/j.ymeth.2013.06.035;;23872058;;10.3410/f.725276419.793503869;;25500122;;pmc4297290;;10.1016/j.ccell.2014.11.001;;22146892;;10.1007/s00262-011-1171-7;;8106388;;10.1016/s0021-9258(17)41886-2;;10.1158/2159-8290.cd-14-0341;;25035124;;10.1158/0008-5472.can-10-1544;;pmc2922475;;20682793;;23046227;;10.2217/imt.12.83;;17587186;;10.1007/s10585-007-9081-y;;29904196;;10.1038/nrd.2018.75;;10.1038/ncomms15373;;28497796;;pmc5437307;;24660106;;pmc3960454,"Antonioli, L., et al. Anti-CD73 in cancer immunotherapy: awakening new opportunities. Trends Cancer, 2016, 2(2):95-109.;;Ghalamfarsa, G., et al. CD73 is a potential opportunity for cancer immunotherapy. Expert Opinion on Therapeutic Targets, 2019, 23(2):127-142.;;Leone, R.D., et al. Targeting adenosine for cancer immunotherapy. Journal for ImmunoTherapy for Cancer, 2018, 6:57, p. 1-9.;;Allard B. et al., “The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor tar-gets,” HHS Public Access Author manuscript, pp. 1-47 (2017).;;Centene Corporation Clinical Policy for Nivolumab (Aug. 2015), 13 pages.;;Fong L. et al., “Safety and clinical activity of adenosine A2a receptor (A2aR) antago-nist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients,” ASCO Annual meetings 2017, 17 pages (2017) Retrieved from the Inter-net:URL:https://www.corvuspharma.com/file.cfm/23/docs/FongASC0173004.FINAL_6.05.2017.pdf.;;International Preliminary Report on Patentability, PCT/US2019/027219, dated Oct. 13, 2020, 9 pages.;;International Search Report and Written Opinion, PCT/US2019/027219, dated Sep. 2, 2019, 13 pages.;;International Search Report and Written Opinion, PCT/US2015/061639, dated Jul. 18, 2016, 31 pages.;;International Search Report and Written Opinion, PCT/US2018/034446, dated Oct. 15, 2018,27 pages.;;Morello S et al., “Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab,” Journal of Translation Medicine, vol. 15 (1):pp. 1-9 (2017).;;Topalian, S.L. et al., “Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab,” Journal of Clinical Oncology, vol. 32(10): 1020-1030 (2014).;;White, A. et al., “Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies,” Cancer Cell, vol. 27(1):138-148 (2015).;;Allard, B. et al., “Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer,” Expert Opinion Ther Targets, vol. 18 (Issue 7), pp. 1-19 (2014).;;Allard, B. et al., “Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs,” Clin Cancer Res, pp. 5626-5635 (Oct. 15, 2013).;;Allen, M. et al., “Interchain disulfide bonding in human IgG2 antibodies probed by site-directed mutagenesis,” Biochemistry, vol. 48 (17), pp. 3755-3766 (Mar. 2009).;;Armour, K. et al., “Recombinant Human IgG Molecules lacking FCy receptor I binding and monocyte triggering activiites,” Eur. J. Immunol., vol. 29, pp. 2613-2624 (1999).;;Barnhart, B. et al., “A Therapeutic Antibody that Inhibits CD73 Activity by Dual Mechanisms,” Bristol-Myers Squibb, AACR Annual Meeting 2016, Apr. 16-20, 2016, New Orleans, Louisiana, USA, Abstract No. 1476, 1 page.;;Barnhart, B., “Antibody Inhibition of CD73 Activity by Multiple Mechanisms for Tumor Therapy,” Bristol-Myers Squibb, Apr. 14, 2016, Presentation Slides, 19 pages.;;Beavis et al. “CD73: a potent suppressor of antitumor immune responses,” Trends in Immunol., vol. 33(5), pp. 231-237 (2012).;;Beavis, P. et al., “A2A blockade enhances anti-metastatic immune responses,” Oncolmmunology, vol. 2(12), e26705-1-e26705-3 (2013).;;Brekke, O. et al., “Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis,” Eur. J. Immunol, vol. 24, pp. 2542-2547 (1994).;;Buisseret, L. et al., “CD73 Expression on Tumor-infiltrating Breast Cancer Leukocytes,” Proceedings of the 106th Annual Meeting of the American Association for Cancer Research? Apr. 18-22, 2015?Philadelphia, PA. Philadelphia (PA): AARC 2015, Poster Presentation, Abstract No. 3361, 1 page.;;Canfield, S. et al., “The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region.,” J. Exp. Med., vol. 173, pp. 1483-1491 (1991).;;Chappel, S. et al., “Identification of the Fcy receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies,” PNAS, vol. 88, pp. 9036-9040 (1991).;;Dillon, T. et al., “Development of an analytical reversed-phase high-performance liquid chromatography-electrospray ionization mass spectrometry method for characterization of recombinant antibodies,” J. Chromatogr. A, vol. 1053, pp. 299-305 (2004).;;Fukunaga, Y. et al., “Increased density of ecto 5′ nucleotidase antigen on leukemic T cells from patients with cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma,” Blood, vol. 74(7), pp. 2486-2492 (1989).;;Geoghegan, JC et al., “Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action,” MAbs, vol. 8 (3): 454-467 (2016) doi: 10.1080/19420862.2016.1143182 Epub Feb. 8, 2016.;;Greenwood, J. et al., “Structural motifs involved in human IgG antibody effector functions,” Eur J Immol, vol. 23 (5), pp. 1098-1104 (1993).;;Gross, J. et al., “TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS.,” Immunity, vol. 15, pp. 289-302 (2001).;;Gutensohn, W. et al., “Production and properties of monoclonal Abs against human ecto-5′-nucloeotidase,” Advances in Exp. Med. & Biol., vol. 195, pp. 385-389 (1986).;;Hausler, SF., et al., “Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion,” Am J Transl Res., vol. 6(2), pp. 129-139 (2014).;;Hay, C. et al., MEDI9447: enhancing anti-tumor immunity by targeting CD73 In the tumor microenvironment, Proceedings of the 106th Annual Meeting of the American Association for Cancer Research? Apr. 18-22, 2015? Philadelphia, PA. Philadelphia(PA): AARC 2015, Abstract No. 285, 2 pages.;;Huang, Q. et al., “Levels and enzyme activity of CD73 in primary samples from cancer patients,” Proceedings of the 106th Annual Meeting of the American Association for Cancer Research? Apr. 18-22, 2015?Philadelphia, PA. Philadelphia(PA): AARC 2015,Poster Presentation, Abstract No. 1538, 2 pages.;;International Preliminary Report on Patentability, PCT/US2015/061632, dated May 23, 2017, 17 pages.;;International Preliminary Report on Patentability, PCT/US2015/061639, dated May 23, 2017, 18 pages.;;International Preliminary Report on Patentability, PCT/US2017/020714, dated Sep. 4, 2018, 11 pages.;;International Search Report and Written Opinion, PCT/US2015/061632, dated Jul. 7, 2016, 26 pages.;;International Search Report and Written Opinion, PCT/US2017/020714, dated Jul. 11, 2017, 21 pages.;;Invitation to Pay Applicable Fees, and, Where Applicable, Protest Fee, PCT/US2018/03446, dated Aug. 21, 2018, 24 pages.;;Jin, D. et al., “CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression,” Cancer Res., vol. 70(6), 2245-2255 (2 page Supplement data) (2010).;;Kai, M. et al., “Switching Constant Domains Enhances Agonist Activities of Antibodies to a Thrombopoietin Receptor,” Nature Biotechnology, vol. 26(2), pp. 209-211 (2008).;;Klemens, M. et al., “Characterization of soluble vs membrane-bound human placental 5′-nucleotidase,” Biochem Biophys Res Commun.,vol. 172(3), pp. 1371-1377 (1990).;;Kummer, U. et al. “Development and properties of a monoclonal Ab specific for human Ecto-5′-nucleotidase,” Immunobiology, vol. 166, pp. 203-211 (1984).;;Lau, C. et al., “Chimeric Anti-CD14 IGG2/4 Hybrid Antibodies for Therapeutic Intervention in Pig and Human Models of Inflammation,” The Journal of Immunology, vol. 191(9):4769-4777 (2013).;;Lightle, S. et al., “Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding,” Protein Sci, vol. 19(4), pp. 753-762 (2010).;;Martinez, T. et al., “Disulfide connectivity of human immunoglobulin G2 structural isoforms,” Biochemistry, vol. 47(26), pp. 7496-7508 (May 2008).;;Misumi, Y., et al., “Primary structure of human placental 5′-nucleotidase and identification of the glycolipid anchor in the mature form,” (Fukuoka Univ., Jp), Eur J Biochem., vol. 191(3), pp. 563-569. (1990).;;Mittal, D. et al., “Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor,” vol. 74(14) Cancer Res, pp. 3652-3658 (Jul. 2014).;;Morgan, A. et al., “The N-terminal end of the CH2 domain of chimeric human IgG 1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding,” Immunology, vol. 86 (2), pp. 319-324 (1995).;;Morrison, S. et al., “Structural Determinants of Human IgG Function,” Immunologist,vol. 2, pp. 119-124 (1994).;;MAXIME MOULARD, MARIE-LAURE OZOUX: ""How validated receptor occupancy flow cytometry assays can impact decisions and support drug development : HOW VALIDATED RO FLOW CYTOMETRY ASSAYS CAN IMPACT DECISIONS AND SUPPORT DRUG DEVELOPMENT"", CYTOMETRY PART B CLINICAL CYTOMETRY, WILEY-LISS, HOBOKEN, NJ, US, vol. 90, no. 2, 1 March 2016 (2016-03-01), US , pages 150 - 158, XP055383541, ISSN: 1552-4949, DOI: 10.1002/cyto.b.21320;;NCBI Reference Sequence NP_001 191742.1, 4 pages (2012).;;Nielsen, UB et al., “Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries,” PSTT, vol. 3(8), pp. 282-291 (2000).;;Resta, R. et al., “Murine ecto-5′-nucleotidase (CD73): cDNA cloning and tissue distribution,” Gene, vol. 133(2), pp. 171-177 (1993) Abstract.;;Resta, R. et al., “T cell signalling through CD73,” Cell Signal, vol. 9(2), pp. 131-139 (1997).;;Rother, R. et al., “Discovery and Development of the Complement Inhibitor Exulizmab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria,” Nature Biotechnology, vol. 25(11):1256-1264 (2007).;;Rust, S. et al., “Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer cell type,” Molecular Cancer, vol. 12(11), pp. 1-11 (2013).;;Sachsenmeier, K. et al., “Development of A Novel Ectonucleotidase Assay Suitable for High-Throughput Screening,” Journal of Biomolecular Screening, vol. 17(7), pp. 993-998 (2012).;;Shields, RL., “High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R,” J Biol Chem, vol. 276 (9), pp. 6591-6604 (2001).;;Siu, L. et al., “Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with Nivolumab in Patients with Advanced Solid Tumors,” AACR, (CT180), 17 pages (2018).;;Siu, L. et al., “Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with Nivolumab in Patients with Advanced Solid Tumors,” AACR: 2018—first disclosure, 2 pages.;;Spychala J., “Tumor-promoting functions of adenosine,” Pharmacology and Therapeutics, vol. 87 (2-3) pp. 161-173 (2000).;;Stagg, J. et al., “Anti-CD73 Antibody therapy inhibits breast tumor growth and metastasis,” PNAS, vol. 107(4), pp. 1547-1552 (2010).;;Stagg, J. et al., “Extracellular adenosine triphosphate and adenosine in cancer,” Oncogene , vol. 29 (39), pp. 5346-5358 (2010).;;Strater, N. et al., “Ecto-5′-nucleotidase: Structure function Relationships,” Purinergic Signalling, vol. 2, pp. 343-350 (2006).;;Sult, E. et al., “Checkpoint inhibitor combinations in a human mixed leukocyte reaction,” Proceedings of the 106th Annual Meeting of the American Association for Cancer Research? Apr. 18-22, 2015?Philadelphia, PA. Philadelphia (PA): AARC 2015, Abstract No. 272, 2 pages.;;Tao, MH et al., “Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation,” J Exp Med, vol. 178(2), pp. 661-667 (1993).;;Tao, MH., “The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain,” J Exp Med., vol. 173(4), pp. 1025-1028 (1991).;;Terp, M. et al., “Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells,” J. Immunol., vol. 191(8), pp. 4165-4173 (2013).;;Third Party Observation, PCT/US2015/061632, dated Mar. 21, 2017, 8 pages.;;Thomson, L. et al., “Purification of 5′-nucleotidase from human placenta after release from plasma membranes by phosphatidylinositol-specific phospholipase C,” Biochem Biophys Res Commun, vol. 145(1), pp. 118-125 (1987).;;Thomson, L.F. et al., “Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol-anchored lymphocyte differentiation antigen ecto-5′-nucleotidase (CD73),” Tissue Antigens, vol. 35(1), pp. 9-19 (1990).;;Vafa, O. et al., “An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations,” Methods, vol. 65(1):95-110 (2014).;;White, A. et al., “Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies,” Cancer Cell., vol. 27(1), pp. 138-148 (2015).;;Whiteside et al., “Disarming suppressor cells to improve immunotherapy,” Cancer Immunol. Immunother, vol. 61, pp. 283-288 (2012).;;Xu, Y. et al., “Residue at position 331 in the IgG1 and IgG4 CH2 domains contributes to their differential ability to bind and activate complement,” Journal of Biological Chemistry, vol. 269(5): 3469-3474 (1994).;;Xu, Y. et al., The N-Terminal Sequence of the CH2 Domain Controls The Differential Ability of Human IgG 1 and IgG2 to Activate Complement, J. of Immunol., vol. 150, Abstract 862, p. 152A (1993).;;Young, A. et al., “Targeting Cancer-Derived Adenosine: New Therapeutic Approaches,” Cancer Discovery, vol. 4, pp. 879-888 (2014).;;Zhang , B., “CD73: A novel target for cancer immunotherapy,” Cancer Res., vol. 70(16), pp. 6407-6411 (2010).;;Zhang, B., “Opportunities and challenges for anti-CD73 cancer therapy,” Immunotherapy, vol. 4(9), pp. 861-865 (2012).;;Zhi, X. et al., “RNA interference of ecto-5′-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion,” Clin. Exp. Metastasis, vol. 24, pp. 439-448 (2007).;;International Preliminary Report on Patentability, PCT/US2018/034446, dated Nov. 26, 2019, 14 pages.;;Mayes, P.A., et al., “The promise and challenges of immune agonist antibody development in cancer,” Nature reviews Drug Discovery , vol. 17(7): 509-527 ( 2018).;;Vazquez-Lombardi R.et al., “Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells,” Nature Communications, vol. 8: 12 pages (2017).;;Iannone, R., et al., “Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model,” American Journal of Cancer Research, vol. 4 (2): 172-181 (2014).",ACTIVE
470,KR,A,KR 20220033522 A,106-555-204-979-20X,2022-03-16,2022,KR 20227006534 A,2017-03-03,US 201662303985 P;;US 201662305378 P;;US 201662341220 P;;US 201662363703 P;;US 201662431987 P;;KR 20187028091 A;;US 2017/0020714 W,2016-03-04,-CD73 COMBINATION THERAPY WITH ANTI-CD73 ANTIBODIES,"항-CD73 항체를 면역-종양학 작용제, 예컨대 항-PD-1 항체와 조합하여 사용하여 종양 (예를 들어, 진행성 고형 종양)을 임상 치료하는 방법이 제공된다.",BRISTOL MYERS SQUIBB CO,BARNHART BRYAN C;;KORMAN ALAN J;;LONBERG NILS;;YAMNIUK AARON P;;SRIVISAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE KUNKEL MARIA;;CHEN GUODONG;;SACK JOHN S;;HUANG RICHARD Y;;CORBETT MARTIN J;;MYERS JOSEPH E JR;;SCHWEIZER LIANG;;HATCHER SANDRA V;;ALTURA RACHEL;;HUANG HAICHUN;;ZHANG PINGPING;;HILT EDWARD J;;HEDRICK MICHAEL NATHAN,,https://lens.org/106-555-204-979-20X,Patent Application,no,0,0,21,21,944,A61K9/0019;;A61K2039/507;;A61P1/04;;A61P1/18;;A61P5/00;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/2818;;C07K16/2896;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;C07K16/2818;;C07K16/2896;;A61K2039/507;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;A61P1/04;;A61P1/18;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;A61P5/00;;C07K16/2896;;C07K2317/52;;C07K2317/92;;C07K2317/94;;C07K2317/55;;C07K2317/34;;C07K2299/00;;C07K2317/21;;C07K2317/77;;C07K2317/76;;C07K2317/56;;A61P5/00;;C07K2317/54;;A61P43/00;;A61P1/18;;A61K9/0019;;C07K2317/90;;A61P1/04;;A61P35/00;;A61K2039/507;;C07K16/2818;;A61P15/00;;A61P11/00;;A61P35/00;;C07K16/2818;;C07K16/2896;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/56;;C07K2317/77;;C07K2317/76;;C07K2317/90;;C07K2317/94;;C07K2317/92;;A61K2039/507;;A61P35/00;;A61K9/0019;;C07K16/2818;;C07K16/2896;;C07K2317/76;;C07K2317/55;;C07K2299/00;;C07K2317/54;;C07K2317/34;;A61K2039/507;;C07K2317/92;;C07K2317/90;;C07K2317/52;;C07K2317/56;;C07K2317/21;;C07K2317/94;;C07K2317/77,C07K16/28;;A61K39/00;;A61P35/00,,0,0,,,,DISCONTINUED
471,IL,A,IL 295230 A,043-471-530-805-772,2022-10-01,2022,IL 29523022 A,2022-07-31,US 201662303985 P;;US 201662305378 P;;US 201662341220 P;;US 201662363703 P;;US 201662431987 P;;US 2017/0020714 W,2016-03-04,Combination therapy with anti-cd73 antibodies,,BRISTOL MYERS SQUIBB CO;;BARNHART BRYAN C;;KORMAN ALAN J;;LONBERG NILS;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE KUNKEL MARIA;;CHEN GUODONG;;SACK JOHN S;;HUANG RICHARD Y;;CORBETT MARTIN J;;MYERS JOSEPH E JR;;SCHWEIZER LIANG;;HATCHER SANDRA V;;ALTURA RACHEL;;HUANG HAICHUN;;ZHANG PINGPING;;HILT EDWARD J;;HEDRICK MICHAEL NATHAN,BARNHART BRYAN C;;KORMAN ALAN J;;LONBERG NILS;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA;;CHEN GUODONG;;SACK JOHN S;;HUANG RICHARD Y;;CORBETT MARTIN J;;MYERS JOSEPH E JR;;SCHWEIZER LIANG;;HATCHER SANDRA V;;ALTURA RACHEL;;HUANG HAICHUN;;ZHANG PINGPING;;HILT EDWARD J;;HEDRICK MICHAEL NATHAN,,https://lens.org/043-471-530-805-772,Patent Application,no,0,0,21,21,0,A61K9/0019;;A61K2039/507;;A61P1/04;;A61P1/18;;A61P5/00;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/2818;;C07K16/2896;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;C07K16/2818;;C07K16/2896;;A61K2039/507;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;A61P1/04;;A61P1/18;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;A61P5/00;;C07K16/2896;;C07K2317/52;;C07K2317/92;;C07K2317/94;;C07K2317/55;;C07K2317/34;;C07K2299/00;;C07K2317/21;;C07K2317/77;;C07K2317/76;;C07K2317/56;;A61P5/00;;C07K2317/54;;A61P43/00;;A61P1/18;;A61K9/0019;;C07K2317/90;;A61P1/04;;A61P35/00;;A61K2039/507;;C07K16/2818;;A61P15/00;;A61P11/00;;A61P35/00;;C07K16/2818;;C07K16/2896;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/56;;C07K2317/77;;C07K2317/76;;C07K2317/90;;C07K2317/94;;C07K2317/92;;A61K2039/507;;A61P35/00;;A61K9/0019;;C07K16/2818;;C07K16/2896;;C07K2317/76;;C07K2317/55;;C07K2299/00;;C07K2317/54;;C07K2317/34;;A61K2039/507;;C07K2317/92;;C07K2317/90;;C07K2317/52;;C07K2317/56;;C07K2317/21;;C07K2317/94;;C07K2317/77,A61K39/00;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/28,,0,0,,,,PENDING
472,US,A1,US 2019/0284293 A1,173-645-192-288-661,2019-09-19,2019,US 201716081115 A,2017-03-03,US 201716081115 A;;US 201662305378 P;;US 201662431987 P;;US 201662341220 P;;US 201662303985 P;;US 201662363703 P;;US 2017/0020714 W,2016-03-04,COMBINATION THERAPY WITH ANTI-CD73 ANTIBODIES,"Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-CD73 antibody in combination with an immuno-oncology agent, such as an anti-PD-1 antibody.",BRISTOL MYERS SQUIBB CO,LONBERG NILS;;KORMAN ALAN J;;BARNHART BRYAN C;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA;;CHEN GUODONG;;SACK JOHN S;;HUANG RICHARD Y;;CORBETT MARTIN J;;MYERS JR JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;ALTURA RACHEL A;;HUANG HAICHUN;;ZHANG PINGPING;;HILT EDWARD J;;HEDRICK MICHAEL NATHAN,,https://lens.org/173-645-192-288-661,Patent Application,yes,2,9,21,21,472,A61K9/0019;;A61K2039/507;;A61P1/04;;A61P1/18;;A61P5/00;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/2818;;C07K16/2896;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;C07K16/2818;;C07K16/2896;;A61K2039/507;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;A61P1/04;;A61P1/18;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;A61P5/00;;C07K16/2896;;C07K2317/52;;C07K2317/92;;C07K2317/94;;C07K2317/55;;C07K2317/34;;C07K2299/00;;C07K2317/21;;C07K2317/77;;C07K2317/76;;C07K2317/56;;A61P5/00;;C07K2317/54;;A61P43/00;;A61P1/18;;A61K9/0019;;C07K2317/90;;A61P1/04;;A61P35/00;;A61K2039/507;;C07K16/2818;;A61P15/00;;A61P11/00;;A61P35/00;;C07K16/2818;;C07K16/2896;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/56;;C07K2317/77;;C07K2317/76;;C07K2317/90;;C07K2317/94;;C07K2317/92;;A61K2039/507;;A61P35/00;;A61K9/0019;;C07K16/2818;;C07K16/2896;;C07K2317/76;;C07K2317/55;;C07K2299/00;;C07K2317/54;;C07K2317/34;;A61K2039/507;;C07K2317/92;;C07K2317/90;;C07K2317/52;;C07K2317/56;;C07K2317/21;;C07K2317/94;;C07K2317/77,C07K16/28;;A61K9/00,,2,1,016-465-232-588-036,10.1158/1078-0432.ccr-13-0545;;23983257,"Allard et al (Clinical Cancer Research, 2013, 19:5626-5635);;Centene Corporation Clinical Policy for Nivolumab (August 2015)",DISCONTINUED
473,KR,A,KR 20180118725 A,194-594-737-367-904,2018-10-31,2018,KR 20187028091 A,2017-03-03,US 201662303985 P;;US 201662305378 P;;US 201662341220 P;;US 201662363703 P;;US 201662431987 P;;US 2017/0020714 W,2016-03-04,항-CD73 항체와의 조합 요법,"항-CD73 항체를 면역-종양학 작용제, 예컨대 항-PD-1 항체와 조합하여 사용하여 종양 (예를 들어, 진행성 고형 종양)을 임상 치료하는 방법이 제공된다.",BRISTOL MYERS SQUIBB CO,BARNHART BRYAN C;;KORMAN ALAN J;;LONBERG NILS;;YAMNIUK AARON P;;SRIVISAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE KUNKEL MARIA;;CHEN GUODONG;;SACK JOHN S;;HUANG RICHARD Y;;CORBETT MARTIN J;;MYERS JOSEPH E JR;;SCHWEIZER LIANG;;HATCHER SANDRA V;;ALTURA RACHEL;;HUANG HAICHUN;;ZHANG PINGPING;;HILT EDWARD J;;HEDRICK MICHAEL NATHAN,,https://lens.org/194-594-737-367-904,Patent Application,no,0,0,21,21,944,A61K9/0019;;A61K2039/507;;A61P1/04;;A61P1/18;;A61P5/00;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/2818;;C07K16/2896;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;C07K16/2818;;C07K16/2896;;A61K2039/507;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;A61P1/04;;A61P1/18;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;A61P5/00;;C07K16/2896;;C07K2317/52;;C07K2317/92;;C07K2317/94;;C07K2317/55;;C07K2317/34;;C07K2299/00;;C07K2317/21;;C07K2317/77;;C07K2317/76;;C07K2317/56;;A61P5/00;;C07K2317/54;;A61P43/00;;A61P1/18;;A61K9/0019;;C07K2317/90;;A61P1/04;;A61P35/00;;A61K2039/507;;C07K16/2818;;A61P15/00;;A61P11/00;;A61P35/00;;C07K16/2818;;C07K16/2896;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/56;;C07K2317/77;;C07K2317/76;;C07K2317/90;;C07K2317/94;;C07K2317/92;;A61K2039/507;;A61P35/00;;A61K9/0019;;C07K16/2818;;C07K16/2896;;C07K2317/76;;C07K2317/55;;C07K2299/00;;C07K2317/54;;C07K2317/34;;A61K2039/507;;C07K2317/92;;C07K2317/90;;C07K2317/52;;C07K2317/56;;C07K2317/21;;C07K2317/94;;C07K2317/77,C07K16/28;;A61K39/00,,0,0,,,,DISCONTINUED
474,BR,A2,BR 112018067368 A2,156-724-759-904-269,2019-01-15,2019,BR 112018067368 A,2017-03-03,US 2017/0020714 W;;US 201662303985 P;;US 201662305378 P;;US 201662341220 P;;US 201662363703 P;;US 201662431987 P,2016-03-04,terapia de combinação com anticorpos anti-cd73,"são fornecidos métodos para o tratamento clínico de tumores (por exemplo, tumores sólidos avançados) utilizando um anticorpo anti-cd73 em combinação com um agente imuno-oncológico, tal como um anticorpo anti-pd-1.",BRISTOL MYERS SQUIBB CO,AARON P YAMNIUK;;ALAN J KORMAN;;ANGELA GOODENOUGH;;BRYAN C BARNHART;;EDWARD J HILT;;EMANUELA SEGA;;GUODONG CHEN;;HAICHUN HUANG;;JOHN S SACK;;JOSEPH E MYERS JR;;KARLA A HENNING;;LIANG SCHWEIZER;;MARIA JURE-KUNKEL;;MARTIN J CORBETT;;MICHAEL NATHAN HEDRICK;;MING LEI;;MOHAN SRIVISAN;;NILS LONBERG;;PINGPING ZHANG;;RACHEL A ALTURA;;RICHARD Y HUANG;;SANDRA V HATCHER,,https://lens.org/156-724-759-904-269,Patent Application,no,0,0,21,21,0,A61K9/0019;;A61K2039/507;;A61P1/04;;A61P1/18;;A61P5/00;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/2818;;C07K16/2896;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;C07K16/2818;;C07K16/2896;;A61K2039/507;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;A61P1/04;;A61P1/18;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;A61P5/00;;C07K16/2896;;C07K2317/52;;C07K2317/92;;C07K2317/94;;C07K2317/55;;C07K2317/34;;C07K2299/00;;C07K2317/21;;C07K2317/77;;C07K2317/76;;C07K2317/56;;A61P5/00;;C07K2317/54;;A61P43/00;;A61P1/18;;A61K9/0019;;C07K2317/90;;A61P1/04;;A61P35/00;;A61K2039/507;;C07K16/2818;;A61P15/00;;A61P11/00;;A61P35/00;;C07K16/2818;;C07K16/2896;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/56;;C07K2317/77;;C07K2317/76;;C07K2317/90;;C07K2317/94;;C07K2317/92;;A61K2039/507;;A61P35/00;;A61K9/0019;;C07K16/2818;;C07K16/2896;;C07K2317/76;;C07K2317/55;;C07K2299/00;;C07K2317/54;;C07K2317/34;;A61K2039/507;;C07K2317/92;;C07K2317/90;;C07K2317/52;;C07K2317/56;;C07K2317/21;;C07K2317/94;;C07K2317/77,C07K16/28;;A61K39/00,,0,0,,,,DISCONTINUED
475,AU,A8,AU 2017/228470 A8,164-737-701-492-495,2020-04-23,2020,AU 2017/228470 A,2017-03-03,US 201662305378 P;;US 201662431987 P;;US 201662341220 P;;US 201662363703 P;;US 201662303985 P;;US 2017/0020714 W,2016-03-04,Combination therapy with anti-CD73 antibodies,"Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-CD73 antibody in combination with an immuno-oncology agent, such as an anti-PD- 1 antibody.",BRISTOL MYERS SQUIBB CO,BARNHART BRYAN C;;KORMAN ALAN J;;LONBERG NILS;;YAMNIUK AARON P;;SRINIVASAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA;;CHEN GUODONG;;SACK JOHN S;;HUANG RICHARD Y;;CORBETT MARTIN J;;MYERS JR JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;ALTURA RACHEL;;HUANG HAICHUN;;ZHANG PINGPING;;HILT EDWARD J;;HEDRICK MICHAEL NATHAN,,https://lens.org/164-737-701-492-495,Patent Application,no,0,0,21,21,0,A61K9/0019;;A61K2039/507;;A61P1/04;;A61P1/18;;A61P5/00;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/2818;;C07K16/2896;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;C07K16/2818;;C07K16/2896;;A61K2039/507;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;A61P1/04;;A61P1/18;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;A61P5/00;;C07K16/2896;;C07K2317/52;;C07K2317/92;;C07K2317/94;;C07K2317/55;;C07K2317/34;;C07K2299/00;;C07K2317/21;;C07K2317/77;;C07K2317/76;;C07K2317/56;;A61P5/00;;C07K2317/54;;A61P43/00;;A61P1/18;;A61K9/0019;;C07K2317/90;;A61P1/04;;A61P35/00;;A61K2039/507;;C07K16/2818;;A61P15/00;;A61P11/00;;A61P35/00;;C07K16/2818;;C07K16/2896;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/56;;C07K2317/77;;C07K2317/76;;C07K2317/90;;C07K2317/94;;C07K2317/92;;A61K2039/507;;A61P35/00;;A61K9/0019;;C07K16/2818;;C07K16/2896;;C07K2317/76;;C07K2317/55;;C07K2299/00;;C07K2317/54;;C07K2317/34;;A61K2039/507;;C07K2317/92;;C07K2317/90;;C07K2317/52;;C07K2317/56;;C07K2317/21;;C07K2317/94;;C07K2317/77,C07K16/28;;A61K39/00,,0,0,,,,PENDING
476,CA,A1,CA 3016187 A1,160-851-946-664-025,2017-09-08,2017,CA 3016187 A,2017-03-03,US 201662303985 P;;US 201662305378 P;;US 201662341220 P;;US 201662363703 P;;US 201662431987 P;;US 2017/0020714 W,2016-03-04,COMBINATION THERAPY WITH ANTI-CD73 ANTIBODIES,"Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-CD73 antibody in combination with an immuno-oncology agent, such as an anti-PD- 1 antibody.",BRISTOL MYERS SQUIBB CO,BARNHART BRYAN C;;KORMAN ALAN J;;LONBERG NILS;;YAMNIUK AARON P;;SRIVISAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA;;CHEN GUODONG;;SACK JOHN S;;HUANG RICHARD Y;;CORBETT MARTIN J;;MYERS JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;ALTURA RACHEL;;HUANG HAICHUN;;ZHANG PINGPING;;HILT EDWARD J;;HEDRICK MICHAEL NATHAN,,https://lens.org/160-851-946-664-025,Patent Application,no,0,0,21,21,472,A61K9/0019;;A61K2039/507;;A61P1/04;;A61P1/18;;A61P5/00;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/2818;;C07K16/2896;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;C07K16/2818;;C07K16/2896;;A61K2039/507;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;A61P1/04;;A61P1/18;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;A61P5/00;;C07K16/2896;;C07K2317/52;;C07K2317/92;;C07K2317/94;;C07K2317/55;;C07K2317/34;;C07K2299/00;;C07K2317/21;;C07K2317/77;;C07K2317/76;;C07K2317/56;;A61P5/00;;C07K2317/54;;A61P43/00;;A61P1/18;;A61K9/0019;;C07K2317/90;;A61P1/04;;A61P35/00;;A61K2039/507;;C07K16/2818;;A61P15/00;;A61P11/00;;A61P35/00;;C07K16/2818;;C07K16/2896;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/56;;C07K2317/77;;C07K2317/76;;C07K2317/90;;C07K2317/94;;C07K2317/92;;A61K2039/507;;A61P35/00;;A61K9/0019;;C07K16/2818;;C07K16/2896;;C07K2317/76;;C07K2317/55;;C07K2299/00;;C07K2317/54;;C07K2317/34;;A61K2039/507;;C07K2317/92;;C07K2317/90;;C07K2317/52;;C07K2317/56;;C07K2317/21;;C07K2317/94;;C07K2317/77,C07K16/28;;A61K39/00,,0,0,,,,PENDING
477,WO,A1,WO 2017/152085 A1,010-631-128-078-119,2017-09-08,2017,US 2017/0020714 W,2017-03-03,US 201662363703 P;;US 201662431987 P;;US 201662303985 P;;US 201662305378 P;;US 201662341220 P,2016-03-04,COMBINATION THERAPY WITH ANTI-CD73 ANTIBODIES,"Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-CD73 antibody in combination with an immuno-oncology agent, such as an anti-PD- 1 antibody.",BRISTOL MYERS SQUIBB CO,BARNHART BRYAN C;;KORMAN ALAN J;;LONBERG NILS;;YAMNIUK AARON P;;SRIVISAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA;;CHEN GUODONG;;SACK JOHN S;;HUANG RICHARD Y;;CORBETT MARTIN J;;MYERS JOSEPH E JR;;SCHWEIZER LIANG;;HATCHER SANDRA V;;ALTURA RACHEL;;HUANG HAICHUN;;ZHANG PINGPING;;HILT EDWARD J;;HEDRICK MICHAEL NATHAN,,https://lens.org/010-631-128-078-119,Patent Application,yes,235,52,21,21,472,A61K9/0019;;A61K2039/507;;A61P1/04;;A61P1/18;;A61P5/00;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/2818;;C07K16/2896;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;C07K16/2818;;C07K16/2896;;A61K2039/507;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;A61P1/04;;A61P1/18;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;A61P5/00;;C07K16/2896;;C07K2317/52;;C07K2317/92;;C07K2317/94;;C07K2317/55;;C07K2317/34;;C07K2299/00;;C07K2317/21;;C07K2317/77;;C07K2317/76;;C07K2317/56;;A61P5/00;;C07K2317/54;;A61P43/00;;A61P1/18;;A61K9/0019;;C07K2317/90;;A61P1/04;;A61P35/00;;A61K2039/507;;C07K16/2818;;A61P15/00;;A61P11/00;;A61P35/00;;C07K16/2818;;C07K16/2896;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/56;;C07K2317/77;;C07K2317/76;;C07K2317/90;;C07K2317/94;;C07K2317/92;;A61K2039/507;;A61P35/00;;A61K9/0019;;C07K16/2818;;C07K16/2896;;C07K2317/76;;C07K2317/55;;C07K2299/00;;C07K2317/54;;C07K2317/34;;A61K2039/507;;C07K2317/92;;C07K2317/90;;C07K2317/52;;C07K2317/56;;C07K2317/21;;C07K2317/94;;C07K2317/77,C07K16/28;;A61K39/00,,251,197,016-465-232-588-036;;054-470-953-946-408;;048-700-652-556-098;;005-126-168-767-527;;087-153-613-664-816;;004-922-729-065-965;;140-815-540-810-121;;002-699-487-824-639;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;033-955-564-406-161;;040-577-067-037-463;;104-212-297-137-759;;010-953-281-569-514;;013-795-151-218-458;;092-334-939-903-42X;;018-694-084-068-187;;014-277-808-472-992;;061-754-151-573-898;;113-327-994-370-771;;006-553-734-546-212;;068-238-957-669-243;;105-316-874-895-908;;056-201-471-905-934;;028-862-168-091-90X;;006-063-411-401-033;;076-755-896-808-101;;003-856-837-394-337;;025-367-097-148-608;;061-044-805-382-614;;040-701-579-915-050;;018-694-084-068-187;;104-557-841-648-936;;034-441-292-442-799;;038-895-768-831-047;;132-281-029-747-299;;087-667-912-261-011;;001-835-514-097-551;;002-377-881-851-166;;038-595-729-934-153;;065-102-359-566-736;;042-204-626-457-327;;006-574-964-805-278;;030-323-674-660-051;;092-023-577-402-127;;022-179-293-052-569;;075-221-862-753-349;;059-687-023-079-503;;043-234-476-479-208;;054-706-628-377-190;;056-584-393-786-220;;054-717-629-774-351;;026-126-853-260-259;;039-889-533-551-521;;019-381-122-709-352;;009-326-889-091-346;;071-305-244-060-783;;075-247-958-346-33X;;040-833-896-641-924;;088-086-720-613-343;;002-007-578-507-698;;020-576-792-007-611;;120-925-618-376-989;;026-221-045-144-327;;007-454-016-910-916;;013-977-769-158-191;;066-149-708-871-507;;135-761-430-417-685;;004-473-514-471-578;;039-055-633-551-472;;005-537-680-968-965;;066-081-654-645-396;;004-458-031-333-650;;053-392-328-406-863;;004-458-031-333-650;;076-774-944-138-418;;053-665-670-663-452;;057-218-939-320-948;;094-082-569-858-098;;014-023-664-920-775;;130-038-918-195-153;;005-827-013-023-322;;025-344-156-370-62X;;059-062-592-770-898;;015-462-197-604-87X;;051-727-807-844-974;;019-159-298-022-100;;042-646-734-745-105;;010-488-381-022-259;;082-210-673-349-152;;004-458-031-333-650;;041-909-244-299-232;;078-432-639-041-575;;042-740-484-382-110;;040-307-220-582-194;;020-126-213-879-311;;078-432-639-041-575;;030-100-991-545-155;;042-740-484-382-110;;113-845-646-947-618;;060-497-589-543-959;;004-204-680-158-661;;081-343-876-706-909;;005-638-542-147-993;;043-239-734-190-347;;061-519-730-880-032;;057-945-343-734-358;;005-642-729-451-09X;;003-752-183-823-430;;002-348-443-531-16X;;048-438-498-956-024;;024-929-137-199-30X;;124-805-115-929-413;;008-328-268-697-591;;003-752-183-823-430;;015-466-204-116-873;;003-752-183-823-430;;070-318-112-524-781;;125-012-690-966-647;;071-163-081-597-04X;;035-135-729-507-737;;094-685-907-794-422;;062-029-719-290-327;;070-624-200-848-669;;012-746-915-512-650;;038-478-749-169-986;;035-554-935-107-802;;099-647-105-451-350;;009-621-637-014-514;;100-985-030-110-978;;030-630-100-818-462;;106-753-778-592-300;;032-820-729-763-323;;083-549-078-331-651;;043-108-278-056-872;;050-836-464-727-069;;071-707-020-428-907;;023-468-000-960-289;;033-754-369-798-314;;077-525-954-203-403;;028-969-172-280-017;;060-375-551-951-388;;020-753-772-581-741;;038-613-711-274-229;;047-951-914-695-080;;062-485-301-455-912;;038-613-711-274-229;;023-676-781-371-861;;026-744-100-669-883;;117-663-803-983-152;;051-940-176-386-905;;029-667-686-534-996;;071-441-220-740-553;;013-417-878-440-713;;028-742-425-129-686;;028-742-425-129-686;;012-300-595-074-789;;031-815-870-004-331;;040-841-912-862-912;;011-583-491-184-648;;126-659-091-098-052;;038-166-075-279-931;;083-079-509-375-354;;002-905-645-585-384;;067-078-099-297-810;;007-364-858-655-289;;056-942-841-068-650;;107-302-749-967-437;;039-238-464-990-600;;036-564-551-324-053;;020-123-860-433-320;;011-516-147-270-264;;020-986-423-793-233;;087-879-787-031-413;;027-326-505-837-755;;061-757-907-136-641;;030-049-949-326-687;;090-774-193-364-453;;029-750-154-523-855;;053-703-232-770-99X;;041-157-943-929-732;;007-470-431-271-066;;112-179-955-215-674;;007-709-585-201-038;;056-422-417-058-69X;;005-022-447-377-963;;127-416-339-660-812;;066-749-017-721-197;;001-467-559-709-949;;008-213-515-306-640;;053-703-232-770-99X;;033-109-855-318-388;;015-467-638-461-61X;;056-201-471-905-934;;015-821-816-269-604;;040-363-636-264-022,10.1158/1078-0432.ccr-13-0545;;23983257;;26332593;;10.1002/cyto.b.21320;;24043904;;10.4049/jimmunol.1301274;;10.1111/j.1600-065x.1998.tb01574.x;;9553767;;10.1158/0008-5472.can-10-1544;;pmc2922475;;20682793;;pmc2883609;;10.1158/0008-5472.can-09-3109;;20179192;;10.1073/pnas.0908801107;;20080644;;pmc2824381;;10.1016/s0163-7258(00)00053-x;;11007998;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;10.1038/nri2761;;20414204;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;10.4049/jimmunol.148.5.1547;;1531669;;10.1038/nbt1135;;16151405;;9780179;;10.4049/jimmunol.161.8.4083;;10.1385/0896033759;;10.1126/science.2471267;;2471267;;10.4049/jimmunol.137.11.3614;;2431039;;10.1016/0042-6822(90)90025-m;;1693247;;1697100;;10.1111/j.1365-3083.1990.tb02896.x;;8424945;;10.1021/bi00055a024;;10556249;;10.1093/protein/12.10.879;;pmc19525;;9012796;;10.1073/pnas.94.2.412;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;10.1016/j.metabol.2005.11.004;;16546483;;10.1056/nejm198710223171717;;3657876;;10.1016/s0022-3476(78)80601-5;;650346;;5527019;;10.1265/jjh.23.443;;5752712;;7521646;;10.1038/nbt0994-899;;10.1126/science.2471267;;2471267;;16263307;;10.1016/j.jasms.2005.09.008;;10.1021/bi00161a011;;1332755;;10.1021/bi00078a011;;7687462;;15299382;;10.1107/s0907444994001344;;2185018;;10.1111/j.1432-1033.1990.tb15454.x;;9351804;;10.1016/s0969-2126(97)00279-7;;977570;;10.1016/s0021-9258(20)81858-4;;15299544;;10.1107/s0907444992010400;;27799107;;10.1016/s0076-6879(97)76070-1;;3127726;;10.1038/332323a0;;10.1038/321522a0;;3713831;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;1404388;;10.1016/0022-2836(92)90223-7;;10.1002/eji.1830240409;;8149953;;18066027;;10.1038/nbt1207-1369;;19018092;;10.1182/blood-2008-09-179754;;10.4049/jimmunol.1003412;;21357255;;10.1016/j.molimm.2008.06.027;;18691763;;10.3410/f.1001160.6701;;11520463;;10.1016/s1074-7613(01)00183-2;;10.4049/jimmunol.164.8.4178;;10754313;;8340761;;pmc2191116;;10.1084/jem.178.2.661;;1827828;;10.1084/jem.173.6.1483;;pmc2190830;;10.1038/nbt1344;;17989688;;9307060;;10.1016/s0161-5890(97)00042-4;;2965792;;10.1038/332563a0;;pmc52646;;10.1073/pnas.88.20.9036;;1833770;;10917521;;10.1038/35018508;;19896358;;10.1016/j.copbio.2009.10.011;;10458776;;10.1002/(sici)1521-4141(199908)29:08<2613::aid-immu2613>3.0.co;2-j;;10.1097/00007890-199457110-00001;;10.1097/00007890-199406150-00001;;8009586;;9317161;;10.4049/jimmunol.159.7.3613;;10657642;;10.4049/jimmunol.164.4.1925;;pmc2467532;;10.2210/pdb3c2s/pdb;;18560159;;10.1107/s0907444908007877;;18577454;;10.1016/j.coi.2008.05.010;;20503261;;10.1002/dmrr.1080;;pmc40279;;10.1073/pnas.92.26.11980;;8618827;;10.1182/blood-2006-07-034017;;17038522;;10.1016/j.ymeth.2013.06.035;;23872058;;10.1158/1535-7163.mct-08-0201;;18723496;;10.4161/mabs.2.2.11158;;pmc2840237;;20150767;;11096108;;10.1074/jbc.m009483200;;11160318;;10.4049/jimmunol.166.4.2571;;11096108;;10.1074/jbc.m009483200;;pmc1389705;;10.1073/pnas.0508123103;;16537476;;pmc2826232;;19965644;;10.1182/blood-2009-06-229039;;10.1016/j.yexcr.2011.03.018;;21459085;;17875730;;10.1158/0008-5472.can-07-0696;;10.1186/bcr3069;;22129105;;pmc3326565;;3138110;;pmc454472;;10.1002/j.1460-2075.1988.tb03037.x;;10.1158/0008-5472.can-07-6297;;18483271;;10.1111/j.1365-3083.2009.02338.x;;19906198;;10.1046/j.1365-2567.1998.00472.x;;pmc1364140;;9659234;;16622479;;10.1038/nri1837;;21852502;;10.1126/science.1206954;;pmc3164589;;10.1073/pnas.1208698109;;pmc3390832;;22723355;;23744091;;10.1093/protein/gzt022;;pmc3785249;;14699147;;10.1074/jbc.c300470200;;10.4049/jimmunol.176.1.346;;16365427;;11096108;;10.1074/jbc.m009483200;;12391234;;10.4049/jimmunol.169.9.5171;;10.1074/jbc.m604292200;;16793771;;10.4049/jimmunol.0804182;;19494290;;10.1038/nbt.1601;;pmc2855492;;20081867;;17077181;;10.1093/intimm/dxl110;;10.1074/jbc.m604292200;;16793771;;10.1038/nbt1143;;16186811;;10.4049/jimmunol.0804182;;19494290;;10688122;;15695407;;10.1158/0008-5472.622.65.2;;pmc4154799;;10429243;;10.1038/11717;;pmc48562;;10.1073/pnas.89.5.1904;;1542690;;19915550;;10.1038/nbt.1588;;10.1038/nbt.1553;;19620983;;10.1002/eji.1830230216;;8436176;;2507634;;10.4049/jimmunol.143.8.2595;;10.1073/pnas.0908590107;;20080725;;pmc2818909;;11986321;;10.1074/jbc.m202069200;;16219319;;10.1016/j.jim.2005.08.009;;10.1158/1078-0432.ccr-08-3222;;19401346;;10.1002/bit.20151;;15352059;;10.1038/nbt1178;;16429149;;10.1182/blood-2009-06-225979;;10.3410/f.4252956.4109054;;pmc2881503;;20194898;;11986321;;10.1074/jbc.m202069200;;12427744;;10.1074/jbc.m210665200;;11986321;;10.1074/jbc.m202069200;;10.1038/6179;;10052355;;10.1146/annurev.immunol.26.021607.090232;;18370923;;10.1146/annurev.bi.41.070172.003325;;4563441;;10.4049/jimmunol.172.9.5489;;15100290;;2459288;;pmc2189025;;10.1084/jem.168.3.1099;;12042244;;10.1093/glycob/12.4.43r;;10.1038/316452a0;;3927174;;11275255;;10.1016/s0161-5890(00)00105-x;;10.2174/1389201023378229;;12463418;;10.1023/b:pham.0000008042.15988.c0;;14725359;;10397155;;10.1016/s0165-2478(99)00029-2;;10.1093/chromsci/40.6.343;;12137207;;8644915;;10.1021/ac00116a002;;10.1038/348552a0;;2247164;;1172191;;10.1038/256495a0;;8159246;;10.1038/368856a0;;10.1007/978-3-642-78432-3_3;;7494109;;10.3109/08830189509061738;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;10.1093/intimm/5.6.647;;8347558;;8475122;;10.1073/pnas.90.8.3720;;pmc46373;;8348148;;10.1038/ng0693-117;;8458340;;10.1002/j.1460-2075.1993.tb05722.x;;pmc413279;;8144892;;10.1093/intimm/6.4.579;;8018598;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;pmc15397;;10.1073/pnas.97.2.722;;10639146;;10.1038/nbt727;;12172556;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;10.1126/science.3929380;;3929380;;pmc363152;;10.1128/mcb.8.1.466-472.1988;;2827008;;10.1128/mcb.8.1.466;;25291200;;10.1016/0167-5699(85)90161-6;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;18553400;;10.1002/bit.21855;;17099914;;10.1002/bit.21260;;pmc3064176;;21282104;;10.1074/jbc.m110.185041;;pmc3064176;;21282104;;10.1074/jbc.m110.185041;;10.1016/j.cbpa.2009.03.023;;19414278;;10.1002/anie.200801313;;19072788;;10.1039/b908687k;;19675886;;10.1002/cbic.200800801;;19130455;;10.1016/j.chembiol.2008.01.007;;18291317;;19924746;;pmc4878437;;10.1002/anie.200903627;;10.1021/bc800294a;;19191567;;16424916;;10.1038/nrd1957;;10.1021/ja00245a050;;10.1002/jps.2600660104;;833720;;2674208;;10.1002/j.1552-4604.1989.tb03403.x;;3390170;;10.1016/s0006-291x(88)81333-0;;10.1128/aac.39.1.180;;pmc162506;;7695303;;7907597;;10.1016/s0021-9258(17)37081-3;;10.1016/0014-5793(94)00313-0;;8206150;;7820457;;10.1006/immu.1994.1029;;15470033;;10.4049/jimmunol.173.8.4919;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1126/science.7545313;;7545313;;9311915;;10.1126/science.278.5335.117;;9500607;;10.1038/nm0398-328;;10700237;;10.1038/73193;;9850053;;2871125;;pmc2188095;;10.1084/jem.163.5.1037;;10.1016/0167-5699(92)90153-x;;1385707;;8910274;;10.1126/science.274.5291.1363;;9624003;;10.1038/30989;;10657670;;10.4049/jimmunol.164.4.2160;;9176498;;10.1038/nm0697-682;;9930702;;10.1038/16717;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0969-2126(94)00113-8;;7704521;;9707601;;pmc21462;;10.1073/pnas.95.17.10067;;9850053;;10.1038/nm735;;12118245;;10.3410/f.1008846.113460;;27754618;;27799103;;10.1016/s0076-6879(97)76066-x;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;22997138;;10.1002/cbic.201200426;;10.2210/pdb4h1s/pdb;;19461840;;pmc2483472;;10.1107/s0021889807021206,"B. ALLARD ET AL: ""Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs"", CLINICAL CANCER RESEARCH, vol. 19, no. 20, 15 October 2013 (2013-10-15), pages 5626 - 5635, XP055216360, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-13-0545;;QIHUIHUANG ET AL: ""LevelsandEnzymeActivityofCD73inPrimarySamples FromCancerPatients"", 20 April 2015 (2015-04-20), XP055383479, Retrieved from the Internet <URL:https://www.researchgate.net/profile/Erin_Sult/publication/280532092_Levels_and_enzyme_activity_of_CD73_in_primary_samples_from_cancer_patients/links/55b9267a08ae092e965b2e33/Levels-and-enzyme-activity-of-CD73-in-primary-samples-from-cancer-patients.pdf> [retrieved on 20170621];;MAXIME MOULARD ET AL: ""How validated receptor occupancy flow cytometry assays can impact decisions and support drug development : HOW VALIDATED RO FLOW CYTOMETRY ASSAYS CAN IMPACT DECISIONS AND SUPPORT DRUG DEVELOPMENT"", CYTOMETRY. PART B, CLINICAL CYTOMETRY, vol. 90, no. 2, 11 December 2015 (2015-12-11), US, pages 150 - 158, XP055383541, ISSN: 1552-4949, DOI: 10.1002/cyto.b.21320;;BARNAHRT ET AL,: ""Abstract 1476: A therapeutic antibody that inhibits CD73 activity by dual mechanisms | Cancer Research"", 16 April 2016 (2016-04-16), XP055383567, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/76/14_Supplement/1476> [retrieved on 20170621];;M. G. TERP ET AL: ""Anti-Human CD73 Monoclonal Antibody Inhibits Metastasis Formation in Human Breast Cancer by Inducing Clustering and Internalization of CD73 Expressed on the Surface of Cancer Cells"", THE JOURNAL OF IMMUNOLOGY, vol. 191, no. 8, 16 September 2013 (2013-09-16), US, pages 4165 - 4173, XP055245512, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1301274;;RESTA ET AL., IMMUNOL REV, vol. 161, 1998, pages 95 - 109;;COLGAN ET AL., PRINERGIC SIGNAL, vol. 2, 2006, pages 351 - 60;;ZHANG ET AL., CANCER RES, vol. 70, 2010, pages 6407 - 11;;JIN ET AL., CANCER RES, vol. 70, 2010, pages 2245 - 55;;STAGG ET AL., PNAS, vol. 107, 2010, pages 1547 - 52;;SPYCHALA ET AL., PHARMACOL THER, vol. 87, pages 161 - 73;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;CHAN; CARTER, NAT. REV. IMMUNOL., vol. 10, 2010, pages 301;;SONGSIVILAI; LACHMANN, CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;LONBERG, NATURE BIOTECH., vol. 23, no. 9, 2005, pages 1117 - 1125;;JEFFERIS ET AL., MABS, vol. 1, 2009, pages 1;;KABAT, E. A. ET AL.: ""Sequences of Proteins of Immunological Interest, 5th ed."", 1991, NIH PUBLICATION NO. 91-3242;;ROUX ET AL., J. IMMUNOL., vol. 161, 1998, pages 4083;;ROUX ET AL., J IMMUNOL, vol. 161, 1998, pages 4083;;ALLEN ET AL., BIOCHEMISTRY, vol. 48, 2009, pages 3755;;G. E. MORRIS: ""Epitope Mapping Protocols in Methods in Molecular Biology"", vol. 66, 1996;;CUNNINGHAM; WELLS, SCIENCE, vol. 244, 1985, pages 1081;;ED HARLOW; DAVID LANE: ""Cold Spring Harb Protoc"", 2006;;ED HARLOW; DAVID LANE: ""Using Antibodies"", 1999, COLD SPRING HARBOR LABORATORY PRESS, article ""chapter 11"";;STAHLI ET AL., METHODS IN ENZYMOLOGY, vol. 9, 1983, pages 242;;KIRKLAND ET AL., J. IMMUNOL., vol. 137, 1986, pages 3614;;HARLOW; LANE: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR PRESS;;MOREL ET AL., MOL. IMMUNOL., vol. 25, no. 1, 1988, pages 7;;CHEUNG ET AL., VIROLOGY, vol. 176, 1990, pages 546;;MOLDENHAUER ET AL., SCAND. J. IMMUNOL., vol. 32, 1990, pages 77;;BRUMMELL ET AL., BIOCHEM., vol. 32, 1993, pages 1180 - 1187;;KOBAYASHI ET AL., PROTEIN ENG., vol. 12, no. 10, 1999, pages 879 - 884;;BURKS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 412 - 417;;E. MEYERS; W. MILLER, CABIOS, vol. 4, 1989, pages 11 - 17;;NEEDLEMAN; WUNSCH, J. MOL. BIOL., 1970, pages 444 - 453;;ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3389 - 3402;;F. AUSUBEL, ET AL.: ""Current Protocols in Molecular Biology"", 1987, GREENE PUBLISHING AND WILEY INTERSCIENCE;;DU BOIS D; DU BOIS EF, ARCHIVES OF INTERNAL MEDICINE, vol. 17, no. 6, June 1916 (1916-06-01), pages 863 - 71;;VERBRAECKEN, J. ET AL., METABOLISM - CLINICAL AND EXPERIMENTAL, vol. 55, no. 4, April 2006 (2006-04-01), pages 515 - 24;;MOSTELLER RD., N ENGL J MED., vol. 317, 1987, pages 1098;;HAYCOCK GB ET AL., J PEDIATR, vol. 93, 1978, pages 62 - 66;;GEHAN EA; GEORGE SL, CANCER CHEMOTHER REP, vol. 54, 1970, pages 225 - 235;;CURRENT, JD, THE INTERNET JOURNAL OF ANESTHESIOLOGY, vol. 2, no. 2, 1998;;FUJIMOTO S ET AL., NIPPON EISEIGAKU ZASSHI, vol. 5, 1968, pages 443 - 50;;SCHLICH E ET AL., ERNAHRUNGS UMSCHAU, vol. 57, 2010, pages 178 - 183;;JESPERS ET AL., BIOTECHNOLOGY, vol. 12, 1994, pages 899;;CUNNINGHAM; WELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085;;WEI ET AL., DRUG DISCOVERY TODAY, vol. 19, 2014, pages 95;;HAMBLEY; GROSS, J. AMERICAN SOC. MASS SPECTROMETRY, vol. 16, 2005, pages 2057;;ZINN-JUSTIN ET AL., BIOCHEMISTRY, vol. 31, 1992, pages 11335 - 11347;;ZINN-JUSTIN ET AL., BIOCHEMISTRY, vol. 32, 1993, pages 6884 - 6891;;GIEGE ET AL., ACTA CRYSTALLOGR, vol. D50, 1994, pages 339 - 350;;MCPHERSON, EUR. J. BIOCHEM., vol. 189, 1990, pages 1 - 23;;CHAYEN, STRUCTURE, vol. 5, 1997, pages 1269 - 1274;;MCPHERSON, J. BIOL. CHEM., vol. 251, 1976, pages 6300 - 6303;;SCOPES: ""Protein Purification: Principles and Practice, 3rd ed."", 1994, SPRINGER-VERLAG;;BLUNDELL; JOHNSON ET AL.: ""Meth. Enzymol."", 1985, ACADEMIC PRESS, pages: 114,115;;BRICOGNE, ACTA CRYST., vol. D49, 1993, pages 37 - 60;;BRICOGNE: ""Meth. Enzymol."", vol. 276A, 1997, pages: 361 - 423;;ROVERSI ET AL., ACTA CRYST., vol. D56, 2000, pages 1313 - 1323;;RIECHMANN, L. ET AL., NATURE, vol. 332, 1998, pages 323 - 327;;JONES, P. ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;QUEEN, C. ET AL., PROC. NATL. ACAD. SEE. U.S.A., vol. 86, 1989, pages 10029 - 10033;;TOMLINSON, I. M. ET AL.: ""The Repertoire of Human Germline V Sequences Reveals about Fifty Groups of V Segments with Different Hypervariable Loops"", J. MOL. BIOL., vol. 227, 1992, pages 776 - 798, XP024020607, DOI: doi:10.1016/0022-2836(92)90223-7;;COX, J. P. L. ET AL.: ""A Directory of Human Germ-line V Segments Reveals a Strong Bias in their Usage"", EUR. J. IMMUNOL., vol. 24, 1994, pages 827 - 836, XP003004702, DOI: doi:10.1002/eji.1830240409;;SALFELD, NAT. BIOTECHNOL., vol. 25, 2007, pages 1369;;BRUHNS ET AL., BLOOD, vol. 113, 2009, pages 3716;;SAFMAY ET AL., MOLEC. IMMUNOL., vol. 29, no. 5, 1992, pages 633 - 9;;HORTON ET AL., J. IMMUNOL., vol. 186, 2011, pages 4223;;CHU ET AL., MOL. IMMUNOL, vol. 45, 2008, pages 3926;;GROSS ET AL., IMMUNITY, vol. 15, 2001, pages 289;;IDUSOGIE ET AL., J. IMMUNOL., vol. 164, 2000, pages 4178;;TAO ET AL., J. EXP. MED., vol. 178, 1993, pages 661;;CANFIELD; MORRISON, J. EXP. MED., vol. 173, 1991, pages 1483;;ROTHER ET AL., NAT. BIOTECHNOL., vol. 25, 2007, pages 1256;;MUELLER ET AL., MOL. IMMUNOL., vol. 34, 1997, pages 441;;LABRIJN ET AL., CURR. OP. IMMUNOL., vol. 20, 2008, pages 479;;DUNCAN; WINTER, NATURE, vol. 332, 1988, pages 563;;CHAPPEL ET AL., PROC. NAT'L ACAD. SCI. (USA), vol. 88, 1991, pages 9036;;SONDERMANN ET AL., NATURE, vol. 406, 2000, pages 267;;STROHL, CURRENT OPINION IN BIOTECHNOLOGY, vol. 20, 2009, pages 685 - 691;;ARMOUR ET AL., EUR. J. IMMUNOL., vol. 29, 1999, pages 2613;;ALEGRE ET AL., TRANSPLANTATION, vol. 57, 1994, pages 1537;;COLE ET AL., J. IMMUNOL., vol. 159, 1997, pages 3613;;REDDY ET AL., J. IMMUNOL., vol. 164, 2000, pages 1925;;OGANESYAN ET AL., ACTA CRYSTALLOGR. D. BIOL. CRYSTALLOGR, 2008, pages 700;;LABRIJN, CURR. OP. IMMUNOL., vol. 20, 2008, pages 479;;DAVIS ET AL., J. IMMUNOL., vol. 34, 2007, pages 2204;;GLAESNER ET AL., DIABETES METAB. RES. REV., vol. 26, 2010, pages 287;;HUTCHINS ET AL., PROC. NAT'L ACAD. SCI. (USA), vol. 92, 1995, pages 11980;;AN ET AL., MABS, vol. 1, 2009, pages 572;;MCEARCHERN ET AL., BLOOD, vol. 109, 2007, pages 1185;;VAFA ET AL., METHODS, vol. 65, 2014, pages 114;;RICHARDS ET AL., MOL. CANCER THERAP., vol. 7, 2008, pages 2517;;MOORE ET AL., MABS, vol. 2, 2010, pages 181;;SHIELDS ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 6591;;IDUSOGIE ET AL., J. IMMUNOL., vol. 166, 2001, pages 2571;;SHIELDS ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604;;LAZAR ET AL., PROC. NAT'L ACAD SCI. (USA, vol. 103, 2006, pages 4005;;AWAN ET AL., BLOOD, vol. 115, 2010, pages 1204;;DESJARLAIS; LAZAR, EXP. CELL RES., vol. 317, 2011, pages 1278;;LAZAR ET AL., PROC. NAT'L ACAD SCI. (USA), vol. 103, 2006, pages 4005;;STAVENHAGEN ET AL., CANCER RES., vol. 67, 2007, pages 8882;;NORDSTROM ET AL., BREAST CANCER RES., vol. 13, 2011, pages R123;;DANGL ET AL., EMBO J., vol. 7, 1988, pages 1989;;NATSUME ET AL., CANCER RES., vol. 68, 2008, pages 3863;;MICHAELSEN ET AL., SCAND. J. IMMUNOL., vol. 70, 2009, pages 553;;REDPATH ET AL., IMMUNOLOGY, 1998, pages 595;;DALL'ACQUA ET AL., J. IMMUNOL., vol. 177, 2006, pages 1 129;;CARTER, NAT. REV. LMMUNOL., vol. 6, 2006, pages 343;;PRESTA, CURR. OP. IMMUNOL., vol. 20, 2008, pages 460;;LI; RAVETCH, SCIENCE, vol. 333, 2011, pages 1030;;LI; RAVETCH, PROC. NAT'L ACAD. SCI (USA), vol. 109, 2012, pages 10966;;CHU ET AL., MOL. IMMUNOL., vol. 45, 2008, pages 3926;;MIMOTO ET AL., PROTEIN. ENG. DES. & SELECTION, vol. 26, 2013, pages 589;;HINTON ET AL., J. BIOL. CHEM., vol. 279, no. 8, 2004, pages 6213 - 6216;;HINTON ET AL., JOURNAL OF IMMUNOLOGY, vol. 176, 2006, pages 346 - 356;;SHIELDS ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 9, 2001, pages 6591 - 6604;;DALL ACQUA ET AL., JOURNAL OF IMMUNOLOGY, vol. 169, 2002, pages 5171 - 5180;;DALL'ACQUA ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, 2006, pages 23514 - 23524;;YEUNG ET AL., J. IMMUNOL., vol. 182, 2009, pages 7663;;ZALEVSKY ET AL., NAT. BIOTECHNOL., vol. 28, 2010, pages 157;;PETKOVA ET AL., INT. IMMUNOL., vol. 18, 2006, pages 1759;;DALL' ACQUA ET AL., J. BIOL. CHEM., vol. 281, 2006, pages 23514;;VACCARO ET AL., NAT. BIOTECHNOL., vol. 23, 2005, pages 1283;;YEUNG ET AL., J. IMMUNOL., vol. 182, 2010, pages 7663 - 7671;;HORNICK ET AL., J. NUCL. MED., vol. 41, 2000, pages 355;;KIM ET AL., EUR. J. IMMUNOL., vol. 29, 2000, pages 2819;;KENANOVA ET AL., CANCER RES., vol. 65, 2005, pages 622;;CHAPMAN ET AL., NAT. BIOTECHNOL., vol. 17, 1999, pages 780;;YEH ET AL., PROC. NAT'L ACAD. SCI., vol. 89, 1992, pages 1904;;SCHELLENBERGER ET AL., NAT. BIOTECHNOL., vol. 27, 2009, pages 1186;;LABRIJN ET AL., NAT. BIOTECHNOL., vol. 27, 2009, pages 767;;PAUL, W. E.: ""Fundamental Immunology, 4th ed."", 1999, LIPPINCOTT-RAVEN;;BOLT ET AL., EUR. J. IMMUNOL., vol. 23, 1993, pages 403;;TAO; MORRISON, J. IMMUNOL., vol. 143, 1989, pages 2595;;JUNG ET AL., PROC. NAT'L ACAD. SCI (USA), vol. 107, 2010, pages 604;;SHIELDS ET AL., JBC, vol. 277, 2002, pages 26733;;NIWA ET AL., J. IMMUNOL. METHODS, vol. 306, 2005, pages 151;;CARDARELLI ET AL., CLIN. CANCER RES., vol. 15, 2009, pages 3376;;CARDARELLI ET AL., CANCER IMMUNOL. IMMUNOTHERAP., vol. 59, 2010, pages 257;;YAMANE-OHNUKI ET AL., BIOTECHNOL. BIOENG., vol. 87, 2004, pages 614;;ZHANG ET AL., MABS, vol. 3, 2011, pages 289;;LI ET AL., NAT. BIOTECHNOL., vol. 24, 2006, pages 210;;MOSSNER ET AL., BLOOD, vol. 115, 2010, pages 4393;;SHIELDS ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733;;SHINKAWA ET AL., J. BIOL. CHEM., vol. 278, 2003, pages 3466;;SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740;;UMANA ET AL., NAT. BIOTECH., vol. 17, 1999, pages 176 - 180;;NIMMERJAHN ET AL., ANN. REV. IMMUNOL., vol. 26, 2008, pages 513;;MARSHALL ET AL., ANNU REV BIOCHEM, vol. 41, 1972, pages 673 - 702;;GALA; MORRISON, J. IMMUNOL, vol. 172, 2004, pages 5489 - 94;;WALLICK ET AL., J EXP MED, vol. 168, 1988, pages 1099 - 109;;SPIRO, GLYCOBIOLOGY, vol. 12, 2002, pages 43R - 56R;;PAREKH ET AL., NATURE, vol. 316, 1985, pages 452 - 7;;MIMURA ET AL., MOL IMMUNOL, vol. 37, 2000, pages 697 - 706;;KRISHNAMURTHY R; MANNING M C, CURR PHARM BIOTECHNOL, vol. 3, 2002, pages 361 - 71;;CHEN ET AL., PHARM RES, vol. 20, 2003, pages 1952 - 60;;GHIRLANDO ET AL., IMMUNOL LETT, vol. 68, 1999, pages 47 - 52;;MURRAY ET AL., J. CHROMATOGR SCI, vol. 40, 2002, pages 343 - 9;;ALEXANDER A J; HUGHES D E, ANAL CHEM, vol. 67, 1995, pages 3626 - 32;;KABAT, E. A.: ""Sequences of Proteins of Immunological Interest, 5th ed."", 1991, NIH PUBLICATION NO. 91-3242;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495;;LONBERG ET AL., NATURE, vol. 368, no. 6474, 1994, pages 856 - 859;;LONBERG, N.: ""Handbook of Experimental Pharmacology"", vol. 113, 1994, pages: 49 - 101;;LONBERG, N.; HUSZAR, D., INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93;;HARDING, F.; LONBERG, N., ANN. N.Y. ACAD. SCI., vol. 764, 1995, pages 536 - 546;;TAYLOR, L. ET AL., NUCLEIC ACIDS RESEARCH, vol. 20, 1992, pages 6287 - 6295;;CHEN, J. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 5, 1993, pages 647 - 656;;TUAILLON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 3720 - 3724;;CHOI ET AL., NATURE GENETICS, vol. 4, 1993, pages 117 - 123;;CHEN, J. ET AL., EMBO J., vol. 12, 1993, pages 821 - 830;;TUAILLON ET AL., J. IMMUNOL., vol. 152, 1994, pages 2912 - 2920;;TAYLOR, L. ET AL., INTERNATIONAL IMMUNOLOGY, vol. 6, 1994, pages 579 - 591;;FISHWILD, D. ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;TOMIZUKA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 722 - 727;;KUROIWA ET AL., NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 889 - 894;;FISHWILD ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851;;MORRISON, S., SCIENCE, vol. 229, 1985, pages 1202;;GOEDDEL: ""Gene Expression Technology. Methods in Enzymology"", vol. 185, 1990, ACADEMIC PRESS;;TAKEBE, Y. ET AL., MOL. CELL. BIOL., vol. 8, 1988, pages 466 - 472;;BOSS, M. A.; WOOD, C. R., IMMUNOLOGY TODAY, vol. 6, 1985, pages 12 - 13;;URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R. J. KAUFMAN; P. A. SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621;;DICK ET AL., BIOTECHNOL. BIOENG., vol. 100, 2008, pages 1132;;DICK ET AL., BIOTECHNOL. BIOENG., vol. 97, 2007, pages 544;;LIU ET AL., JBC, vol. 286, 2011, pages 11211;;LIU ET AL., J. BIOL. CHEM., vol. 286, 2011, pages 11211;;SENTER, P. D., CURR. OPIN. CHEM. BIOL., vol. 13, 2009, pages 235 - 244;;HACKENBERGER, C. P. R.; SCHWARZER, D., ANGEW. CHEM. INT. ED. ENGL., vol. 47, 2008, pages 10030 - 10074;;SUNBUL, M.; YIN, J., ORG. BIOMOL. CHEM., vol. 7, 2009, pages 3361 - 3371;;FRESE, M. A.; DIERKS, T., CHEMBIOCHEM, vol. 10, 2009, pages 425 - 427;;TAKI, M. ET AL., PROT. ENG. DES. SEL., vol. 17, 2004, pages 119 - 126;;GAUTIER, A. ET AL., CHEM. BIOL., vol. 15, 2008, pages 128 - 136;;BORDUSA, F., HIGHLIGHTS IN BIOORGANIC CHEMISTRY, 2004, pages 389 - 403;;REN, H. ET AL., ANGEW. CHEM. INT. ED. ENGL., vol. 48, 2009, pages 9658 - 9662;;TAYLOR, E. VOGEL; IMPERIALI, B, NUCLEIC ACIDS AND MOLECULAR BIOLOGY, vol. 22, 2009, pages 65 - 96;;DE GRAAF, A. J. ET AL., BIOCONJUG. CHEM., vol. 20, 2009, pages 1281 - 1295;;SCHRAMA ET AL., NATURE REV. DRUG DISC., vol. 5, 2006, pages 147;;LEE ET AL., J. AM. CHEM. SOC., vol. 109, 1987, pages 3464,3466;;BERGE, S.M. ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;J.R. ROBINSON: ""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;V.V. RANADE, J. CLIN. PHARMACOL., vol. 29, 1989, pages 685;;UMEZAWA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 153, 1988, pages 1038;;P.G. BLOEMAN ET AL., FEBS LETT., vol. 357, 1995, pages 140;;M. OWAIS ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 39, 1995, pages 180;;BRISCOE ET AL., AM. J. PHYSIOL., vol. 1233, 1995, pages 134;;SCHREIER ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 9090;;M.L. LAUKKANEN, FEBS LETT., vol. 346, 1994, pages 123;;J.J. KILLION; I.J. FIDLER, IMMUNOMETHODS, vol. 4, 1994, pages 273;;HE ET AL., J. IMMUNOL., vol. 173, 2004, pages 4919 - 28;;ROSENBERG, S.: ""Development of Cancer Vaccines"", 2000, ASCO EDUCATIONAL BOOK SPRING, pages: 60 - 62;;LOGOTHETIS, C.: ""DEVELOPMENT OF CANCER VACCINES"", 2000, ASCO EDUCATIONAL BOOK SPRING, pages: 300 - 302;;KHAYAT, D.: ""DEVELOPMENT OF CANCER VACCINES"", 2000, ASCO EDUCATIONAL BOOK SPRING, pages: 414 - 428;;FOON, K.: ""DEVELOPMENT OF CANCER VACCINES"", 2000, ASCO EDUCATIONAL BOOK SPRING, pages: 730 - 738;;RESTIFO, N.; SZNOL, M.: ""Cancer Vaccines"", article ""Ch. 61"", pages: 3023 - 3043;;DEVITA ET AL.: ""Cancer: Principles and Practice of Oncology, 5th ed."", 1997;;DRANOFF ET AL., PROC. NATL. ACAD. SCI U.S.A., vol. 90, 1993, pages 3539 - 43;;ROSENBERG, S A, IMMUNITY, vol. 10, 1999, pages 281 - 7;;KIM ET AL., SCIENCE, vol. 266, 1994, pages 2011 - 2013;;SUOT; SRIVASTAVA, SCIENCE, vol. 269, 1995, pages 1585 - 1588;;TAMURA ET AL., SCIENCE, vol. 278, 1997, pages 117 - 120;;NESTLE ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 - 332;;KUGLER ET AL., NATURE MEDICINE, vol. 6, 2000, pages 332 - 336;;MOKYR ET AL., CANCER RESEARCH, vol. 58, 1998, pages 5301 - 5304;;KEHRL ET AL., J. EXP. MED., vol. 163, 1986, pages 1037 - 1050;;HOWARD; O'GARRA, IMMUNOLOGY TODAY, vol. 13, 1992, pages 198 - 200;;HAHNE ET AL., SCIENCE, vol. 274, 1996, pages 1363 - 1365;;RIDGE ET AL., NATURE, vol. 393, 1998, pages 474 - 478;;WEINBERG ET AL., IMMUNOL, vol. 164, 2000, pages 2160 - 2169;;MELERO ET AL., NATURE MEDICINE, vol. 3, 1997, pages 682 - 685;;HUTLOFF ET AL., NATURE, vol. 397, 1999, pages 262 - 266;;HOLLIGER, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;POLJAK, STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;ROSENBLATT ET AL., J. IMMUNOTHERAPY, vol. 34, 2011, pages 409;;HURWITZ ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, no. 17, 1998, pages 10067 - 10071;;CAMACHO ET AL., J. CLIN. ONCOLOGY, vol. 22, no. 145, 2004;;MOKYR ET AL., CANCER RES., vol. 58, 1998, pages 5301 - 5304;;FULDA ET AL., NAT MED, vol. 8, 2002, pages 808 - 15;;HYE ET AL., CANCER RESEARCH, vol. 65, 2005, pages 4799 - 808;;""Physicians' Desk Reference (PDR"", 1996, MEDICAL ECONOMICS COMPANY;;OTWINOWSKI Z.; MINOR W., METHODS IN ENZYMOLOGY, vol. 276, 1997, pages 307 - 326;;ALTSCHUL ET AL.: ""Basic local alignment search tool"", J. MOL. BIOL., vol. 215, 1990, pages 403 - 410, XP002949123, DOI: doi:10.1006/jmbi.1990.9999;;HEUTS ET AL., CHEMBIOCHEM, vol. 13, no. 16, 5 November 2012 (2012-11-05), pages 2384 - 91;;MCCOY ET AL., J. APPL. CRYST., vol. 40, 2007, pages 658 - 674;;BRICOGNE ET AL.: ""BUSTER version 2.11.6."", 2011, GLOBAL PHASING LTD",PENDING
478,KR,A,KR 20230038311 A,081-755-512-871-250,2023-03-17,2023,KR 20237007841 A,2017-03-03,US 201662303985 P;;US 201662305378 P;;US 201662341220 P;;US 201662363703 P;;US 201662431987 P;;KR 20227006534 A;;US 2017/0020714 W,2016-03-04,-CD73 COMBINATION THERAPY WITH ANTI-CD73 ANTIBODIES,"항-CD73 항체를 면역-종양학 작용제, 예컨대 항-PD-1 항체와 조합하여 사용하여 종양 (예를 들어, 진행성 고형 종양)을 임상 치료하는 방법이 제공된다.",BRISTOL MYERS SQUIBB CO,BARNHART BRYAN C;;KORMAN ALAN J;;LONBERG NILS;;YAMNIUK AARON P;;SRIVISAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE KUNKEL MARIA;;CHEN GUODONG;;SACK JOHN S;;HUANG RICHARD Y;;CORBETT MARTIN J;;MYERS JOSEPH E JR;;SCHWEIZER LIANG;;HATCHER SANDRA V;;ALTURA RACHEL;;HUANG HAICHUN;;ZHANG PINGPING;;HILT EDWARD J;;HEDRICK MICHAEL NATHAN,,https://lens.org/081-755-512-871-250,Patent Application,no,0,0,21,21,788,A61K9/0019;;A61K2039/507;;A61P1/04;;A61P1/18;;A61P5/00;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/2818;;C07K16/2896;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;C07K16/2818;;C07K16/2896;;A61K2039/507;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;A61P1/04;;A61P1/18;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;A61P5/00;;C07K16/2896;;C07K2317/52;;C07K2317/92;;C07K2317/94;;C07K2317/55;;C07K2317/34;;C07K2299/00;;C07K2317/21;;C07K2317/77;;C07K2317/76;;C07K2317/56;;A61P5/00;;C07K2317/54;;A61P43/00;;A61P1/18;;A61K9/0019;;C07K2317/90;;A61P1/04;;A61P35/00;;A61K2039/507;;C07K16/2818;;A61P15/00;;A61P11/00;;A61P35/00;;C07K16/2818;;C07K16/2896;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/56;;C07K2317/77;;C07K2317/76;;C07K2317/90;;C07K2317/94;;C07K2317/92;;A61K2039/507;;A61P35/00;;A61K9/0019;;C07K16/2818;;C07K16/2896;;C07K2317/76;;C07K2317/55;;C07K2299/00;;C07K2317/54;;C07K2317/34;;A61K2039/507;;C07K2317/92;;C07K2317/90;;C07K2317/52;;C07K2317/56;;C07K2317/21;;C07K2317/94;;C07K2317/77,C07K16/28;;A61K39/00;;A61P35/00,,0,0,,,,DISCONTINUED
479,EP,A1,EP 3423494 A1,068-433-134-920-568,2019-01-09,2019,EP 17712299 A,2017-03-03,US 201662303985 P;;US 201662305378 P;;US 201662341220 P;;US 201662363703 P;;US 201662431987 P;;US 2017/0020714 W,2016-03-04,COMBINATION THERAPY WITH ANTI-CD73 ANTIBODIES,,BRISTOL MYERS SQUIBB CO,BARNHART BRYAN C;;KORMAN ALAN J;;LONBERG NILS;;YAMNIUK AARON P;;SRIVISAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA;;CHEN GUODONG;;SACK JOHN S;;HUANG RICHARD Y;;CORBETT MARTIN J;;MYERS JOSEPH E JR;;SCHWEIZER LIANG;;HATCHER SANDRA V;;ALTURA RACHEL;;HUANG HAICHUN;;ZHANG PINGPING;;HILT EDWARD J;;HEDRICK MICHAEL NATHAN,,https://lens.org/068-433-134-920-568,Patent Application,yes,0,0,21,21,0,A61K9/0019;;A61K2039/507;;A61P1/04;;A61P1/18;;A61P5/00;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/2818;;C07K16/2896;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;C07K16/2818;;C07K16/2896;;A61K2039/507;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;A61P1/04;;A61P1/18;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;A61P5/00;;C07K16/2896;;C07K2317/52;;C07K2317/92;;C07K2317/94;;C07K2317/55;;C07K2317/34;;C07K2299/00;;C07K2317/21;;C07K2317/77;;C07K2317/76;;C07K2317/56;;A61P5/00;;C07K2317/54;;A61P43/00;;A61P1/18;;A61K9/0019;;C07K2317/90;;A61P1/04;;A61P35/00;;A61K2039/507;;C07K16/2818;;A61P15/00;;A61P11/00;;A61P35/00;;C07K16/2818;;C07K16/2896;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/56;;C07K2317/77;;C07K2317/76;;C07K2317/90;;C07K2317/94;;C07K2317/92;;A61K2039/507;;A61P35/00;;A61K9/0019;;C07K16/2818;;C07K16/2896;;C07K2317/76;;C07K2317/55;;C07K2299/00;;C07K2317/54;;C07K2317/34;;A61K2039/507;;C07K2317/92;;C07K2317/90;;C07K2317/52;;C07K2317/56;;C07K2317/21;;C07K2317/94;;C07K2317/77,C07K16/28;;A61K39/00,,0,0,,,,PENDING
480,MX,A,MX 2018010473 A,164-193-786-825-46X,2018-09-28,2018,MX 2018010473 A,2017-03-03,US 201662303985 P;;US 201662305378 P;;US 201662341220 P;;US 201662363703 P;;US 201662431987 P;;US 2017/0020714 W,2016-03-04,COMBINATION THERAPY WITH ANTI-CD73 ANTIBODIES.,"Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-CD73 antibody in combination with an immuno-oncology agent, such as an anti-PD- 1",BRISTOL MYERS SQUIBB CO,HAICHUN HUANG;;MARIA JURE-KUNKEL;;NILS LONBERG;;AARON P YAMNIUK;;MARTIN J CORBETT;;ALAN J KORMAN;;GUODONG CHEN;;BRYAN C BARNHART;;KARLA A HENNING;;MING LEI;;SANDRA V HATCHER;;ANGELA GOODENOUGH;;PINGPING ZHANG;;LIANG SCHWEIZER;;MOHAN SRIVISAN;;JOHN S SACK;;RICHARD Y HUANG;;JOSEPH E JR MYERS;;RACHEL ALTURA;;EDWARD J HILT;;MICHAEL NATHAN HEDRICK;;EMANUELA SEGA,,https://lens.org/164-193-786-825-46X,Patent Application,no,0,0,21,21,0,A61K9/0019;;A61K2039/507;;A61P1/04;;A61P1/18;;A61P5/00;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/2818;;C07K16/2896;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;C07K16/2818;;C07K16/2896;;A61K2039/507;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;A61P1/04;;A61P1/18;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;A61P5/00;;C07K16/2896;;C07K2317/52;;C07K2317/92;;C07K2317/94;;C07K2317/55;;C07K2317/34;;C07K2299/00;;C07K2317/21;;C07K2317/77;;C07K2317/76;;C07K2317/56;;A61P5/00;;C07K2317/54;;A61P43/00;;A61P1/18;;A61K9/0019;;C07K2317/90;;A61P1/04;;A61P35/00;;A61K2039/507;;C07K16/2818;;A61P15/00;;A61P11/00;;A61P35/00;;C07K16/2818;;C07K16/2896;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/56;;C07K2317/77;;C07K2317/76;;C07K2317/90;;C07K2317/94;;C07K2317/92;;A61K2039/507;;A61P35/00;;A61K9/0019;;C07K16/2818;;C07K16/2896;;C07K2317/76;;C07K2317/55;;C07K2299/00;;C07K2317/54;;C07K2317/34;;A61K2039/507;;C07K2317/92;;C07K2317/90;;C07K2317/52;;C07K2317/56;;C07K2317/21;;C07K2317/94;;C07K2317/77,C07K16/28;;A61K39/00,,0,0,,,,PENDING
481,CN,A,CN 109476740 A,196-934-769-140-553,2019-03-15,2019,CN 201780026552 A,2017-03-03,US 201662303985 P;;US 201662305378 P;;US 201662341220 P;;US 201662363703 P;;US 201662431987 P;;US 2017/0020714 W,2016-03-04,COMBINATION THERAPY WITH ANTI-CD73 ANTIBODIES,"Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-CD73 antibody in combination with an immuno-oncology agent (such as an anti-PD-1 antibody).",BRISTOL MYERS SQUIBB CO,BARNHART BRYAN C;;KORMAN ALAN J;;LONBERG NILS;;YAMNIUK AARON P;;SRIVISAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA;;CHEN GUODONG;;SACK JOHN S;;HUANG RICHARD Y;;CORBETT MARTIN J;;MYERS JOSEPH E JR;;SCHWEIZER LIANG;;HATCHER SANDRA V;;ALTURA RACHEL;;HUANG HAICHUN;;ZHANG PINGPING;;HILT EDWARD J;;HEDRICK MICHAEL NATHAN,,https://lens.org/196-934-769-140-553,Patent Application,no,0,6,21,21,0,A61K9/0019;;A61K2039/507;;A61P1/04;;A61P1/18;;A61P5/00;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/2818;;C07K16/2896;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;C07K16/2818;;C07K16/2896;;A61K2039/507;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;A61P1/04;;A61P1/18;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;A61P5/00;;C07K16/2896;;C07K2317/52;;C07K2317/92;;C07K2317/94;;C07K2317/55;;C07K2317/34;;C07K2299/00;;C07K2317/21;;C07K2317/77;;C07K2317/76;;C07K2317/56;;A61P5/00;;C07K2317/54;;A61P43/00;;A61P1/18;;A61K9/0019;;C07K2317/90;;A61P1/04;;A61P35/00;;A61K2039/507;;C07K16/2818;;A61P15/00;;A61P11/00;;A61P35/00;;C07K16/2818;;C07K16/2896;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/56;;C07K2317/77;;C07K2317/76;;C07K2317/90;;C07K2317/94;;C07K2317/92;;A61K2039/507;;A61P35/00;;A61K9/0019;;C07K16/2818;;C07K16/2896;;C07K2317/76;;C07K2317/55;;C07K2299/00;;C07K2317/54;;C07K2317/34;;A61K2039/507;;C07K2317/92;;C07K2317/90;;C07K2317/52;;C07K2317/56;;C07K2317/21;;C07K2317/94;;C07K2317/77,C07K16/28;;A61K39/00,,2,2,016-465-232-588-036;;048-700-652-556-098,10.1158/1078-0432.ccr-13-0545;;23983257;;24043904;;10.4049/jimmunol.1301274,"BERTRAND ALLARD: ""Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs"", 《CLINICAL CANCER RESEARCH》;;M. G. TERP ET AL: ""Anti-Human CD73 Monoclonal Antibody Inhibits Metastasis Formation in Human Breast Cancer by Inducing Clustering and Internalization of CD73 Expressed on the Surface of Cancer Cells"", 《THE JOURNAL OF IMMUNOLOGY》",PENDING
482,IL,A,IL 261395 A,005-449-684-130-908,2018-10-31,2018,IL 26139518 A,2018-08-27,US 201662303985 P;;US 201662305378 P;;US 201662341220 P;;US 201662363703 P;;US 201662431987 P;;US 2017/0020714 W,2016-03-04,Combination therapy with anti-cd73 antibodies,,BRISTOL MYERS SQUIBB CO;;KORMAN ALAN J;;JURE KUNKEL MARIA;;LONBERG NILS;;LEI MING;;SCHWEIZER LIANG;;BARNHART BRYAN C;;YAMNIUK AARON P;;HENNING KARLA A;;CHEN GUODONG;;HUANG HAICHUN;;HATCHER SANDRA V;;SRIVISAN MOHAN;;SEGA EMANUELA;;GOODENOUGH ANGELA;;SACK JOHN S;;HUANG RICHARD Y;;CORBETT MARTIN J;;MYERS JOSEPH E JR;;ALTURA RACHEL;;ZHANG PINGPING;;HILT EDWARD J;;HEDRICK MICHAEL NATHAN,KORMAN ALAN J;;JURE-KUNKEL MARIA;;LONBERG NILS;;LEI MING;;SCHWEIZER LIANG;;BARNHART BRYAN C;;YAMNIUK AARON P;;HENNING KARLA A;;CHEN GUODONG;;HUANG HAICHUN;;HATCHER SANDRA V;;SRIVISAN MOHAN;;SEGA EMANUELA;;GOODENOUGH ANGELA;;SACK JOHN S;;HUANG RICHARD Y;;CORBETT MARTIN J;;MYERS JOSEPH E JR;;ALTURA RACHEL;;ZHANG PINGPING;;HILT EDWARD J;;HEDRICK MICHAEL NATHAN,,https://lens.org/005-449-684-130-908,Patent Application,no,0,0,21,21,0,A61K9/0019;;A61K2039/507;;A61P1/04;;A61P1/18;;A61P5/00;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/2818;;C07K16/2896;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;C07K16/2818;;C07K16/2896;;A61K2039/507;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;A61P1/04;;A61P1/18;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;A61P5/00;;C07K16/2896;;C07K2317/52;;C07K2317/92;;C07K2317/94;;C07K2317/55;;C07K2317/34;;C07K2299/00;;C07K2317/21;;C07K2317/77;;C07K2317/76;;C07K2317/56;;A61P5/00;;C07K2317/54;;A61P43/00;;A61P1/18;;A61K9/0019;;C07K2317/90;;A61P1/04;;A61P35/00;;A61K2039/507;;C07K16/2818;;A61P15/00;;A61P11/00;;A61P35/00;;C07K16/2818;;C07K16/2896;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/56;;C07K2317/77;;C07K2317/76;;C07K2317/90;;C07K2317/94;;C07K2317/92;;A61K2039/507;;A61P35/00;;A61K9/0019;;C07K16/2818;;C07K16/2896;;C07K2317/76;;C07K2317/55;;C07K2299/00;;C07K2317/54;;C07K2317/34;;A61K2039/507;;C07K2317/92;;C07K2317/90;;C07K2317/52;;C07K2317/56;;C07K2317/21;;C07K2317/94;;C07K2317/77,,,0,0,,,,PENDING
483,AU,A1,AU 2017/228470 A1,126-342-496-609-695,2018-08-30,2018,AU 2017/228470 A,2017-03-03,US 201662305378 P;;US 201662431987 P;;US 201662341220 P;;US 201662363703 P;;US 201662303985 P;;US 2017/0020714 W,2016-03-04,Combination therapy with anti-CD73 antibodies,"Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-CD73 antibody in combination with an immuno-oncology agent, such as an anti-PD- 1 antibody.",BRISTOL MYERS SQUIBB CO,BARNHART BRYAN C;;KORMAN ALAN J;;LONBERG NILS;;YAMNIUK AARON P;;SRIVISAN MOHAN;;HENNING KARLA A;;LEI MING;;SEGA EMANUELA;;GOODENOUGH ANGELA;;JURE-KUNKEL MARIA;;CHEN GUODONG;;SACK JOHN S;;HUANG RICHARD Y;;CORBETT MARTIN J;;MYERS JR JOSEPH E;;SCHWEIZER LIANG;;HATCHER SANDRA V;;ALTURA RACHEL;;HUANG HAICHUN;;ZHANG PINGPING;;HILT EDWARD J;;HEDRICK MICHAEL NATHAN,,https://lens.org/126-342-496-609-695,Patent Application,no,0,0,21,21,0,A61K9/0019;;A61K2039/507;;A61P1/04;;A61P1/18;;A61P5/00;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;C07K16/2818;;C07K16/2896;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;C07K16/2818;;C07K16/2896;;A61K2039/507;;C07K2299/00;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/54;;C07K2317/55;;C07K2317/56;;C07K2317/76;;C07K2317/77;;C07K2317/90;;C07K2317/92;;C07K2317/94;;A61P1/04;;A61P1/18;;A61P11/00;;A61P15/00;;A61P35/00;;A61P43/00;;A61P5/00;;C07K16/2896;;C07K2317/52;;C07K2317/92;;C07K2317/94;;C07K2317/55;;C07K2317/34;;C07K2299/00;;C07K2317/21;;C07K2317/77;;C07K2317/76;;C07K2317/56;;A61P5/00;;C07K2317/54;;A61P43/00;;A61P1/18;;A61K9/0019;;C07K2317/90;;A61P1/04;;A61P35/00;;A61K2039/507;;C07K16/2818;;A61P15/00;;A61P11/00;;A61P35/00;;C07K16/2818;;C07K16/2896;;C07K2317/21;;C07K2317/34;;C07K2317/52;;C07K2317/55;;C07K2317/56;;C07K2317/77;;C07K2317/76;;C07K2317/90;;C07K2317/94;;C07K2317/92;;A61K2039/507;;A61P35/00;;A61K9/0019;;C07K16/2818;;C07K16/2896;;C07K2317/76;;C07K2317/55;;C07K2299/00;;C07K2317/54;;C07K2317/34;;A61K2039/507;;C07K2317/92;;C07K2317/90;;C07K2317/52;;C07K2317/56;;C07K2317/21;;C07K2317/94;;C07K2317/77,C07K16/28;;A61K39/00,,0,0,,,,PENDING
484,WO,A1,WO 2018/093536 A1,091-830-058-842-328,2018-05-24,2018,US 2017/0057871 W,2017-10-23,US 201615355892 A;;US 201562265611 P;;US 201662324428 P;;US 201662365543 P,2015-12-10,METHOD OF TREATING TISSUE USING END EFFECTOR WITH ULTRASONIC AND ELECTROSURGICAL FEATURES,An end effector of an instrument is positioned in a patient. An ultrasonic blade of the end effector is positioned against tissue in the patient. The ultrasonic blade is activated to vibrate ultrasonically while the ultrasonic blade is positioned against tissue. At least one electrode of the end effector is positioned against tissue in the patient. The at least one electrode is activated to apply RF electrosurgical energy to tissue against which the at least one electrode is positioned against tissue.,ETHICON LLC,JOHNSON GREGORY W;;LESKO JASON R;;ESTERA FREDERICK;;KRUMM AMY M;;CORBETT CATHERINE A;;WEISENBURGH II;;WORRELL BARRY C;;DAVISON MARK A;;BOUDREAUX CHAD P;;HIBNER JOHN A;;CUMMINGS NATHAN;;GENTRY ELLEN;;DANNAHER WILLIAM D;;HOUGH CHRISTINA M;;ISOSAKI JOSEPH;;FALLER CRAIG N;;WAN SHAN;;BROWN ADAM;;OTREMBIAK CANDICE;;WIENER EITAN T;;MESSERLY JEFFREY D;;CHEN KAI;;MILLER MATTHEW C;;CLEM WILLIAM E,,https://lens.org/091-830-058-842-328,Patent Application,yes,49,2,4,22,0,A61B2017/00389;;A61B2017/2825;;A61B2017/2945;;A61B2017/320078;;A61B2017/320073;;A61B2017/320095;;A61B18/1445;;A61B2018/00607;;A61B2018/00994;;A61B2018/126;;A61B2018/1452;;A61B2017/320094;;A61B17/320092;;A61B18/1445;;A61B2018/00607;;A61B2018/00994;;A61B2018/126;;A61B2018/1452;;A61B2017/320094;;A61B2017/320095;;A61B2017/320073;;A61B2017/2945;;A61B2017/00389;;A61B2017/2825;;A61B2017/320078,A61B18/14;;A61B17/32,,0,0,,,,PENDING
485,US,A1,US 2017/0164997 A1,087-371-554-439-576,2017-06-15,2017,US 201615355892 A,2016-11-18,US 201615355892 A;;US 201562265611 P;;US 201662324428 P;;US 201662365543 P,2015-12-10,METHOD OF TREATING TISSUE USING END EFFECTOR WITH ULTRASONIC AND ELECTROSURGICAL FEATURES,An end effector of an instrument is positioned in a patient. An ultrasonic blade of the end effector is positioned against tissue in the patient. The ultrasonic blade is activated to vibrate ultrasonically while the ultrasonic blade is positioned against tissue. At least one electrode of the end effector is positioned against tissue in the patient. The at least one electrode is activated to apply RF electrosurgical energy to tissue against which the at least one electrode is positioned against tissue.,ETHICON ENDO SURGERY LLC,JOHNSON GREGORY W;;LESKO JASON R;;ESTERA FREDERICK L;;KRUMM AMY M;;CORBETT CATHERINE A;;WEISENBURGH II WILLIAM B;;WORRELL BARRY C;;DAVISON MARK A;;BOUDREAUX CHAD P;;HIBNER JOHN A;;CUMMINGS NATHAN;;GENTRY ELLEN;;DANNAHER WILLIAM D;;HOUGH CHRISTINA M;;ISOSAKI JOSEPH;;FALLER CRAIG N;;WAN SHAN;;BROWN ADAM;;OTREMBIAK CANDICE;;WIENER EITAN T;;MESSERLY JEFFREY D;;CHEN KAI;;MILLER MATTHEW C;;CLEM WILLIAM E,STRATEGIXVISION INC (2016-12-02);;CILAG GMBH INTERNATIONAL (2021-04-05);;ETHICON LLC (2017-01-13),https://lens.org/087-371-554-439-576,Patent Application,yes,11,271,4,22,0,A61B2017/00389;;A61B2017/2825;;A61B2017/2945;;A61B2017/320078;;A61B2017/320073;;A61B2017/320095;;A61B18/1445;;A61B2018/00607;;A61B2018/00994;;A61B2018/126;;A61B2018/1452;;A61B2017/320094;;A61B17/320092;;A61B18/1445;;A61B2018/00607;;A61B2018/00994;;A61B2018/126;;A61B2018/1452;;A61B2017/320094;;A61B2017/320095;;A61B2017/320073;;A61B2017/2945;;A61B2017/00389;;A61B2017/2825;;A61B2017/320078,A61B18/14;;A61B17/32;;A61N7/02,,0,0,,,,DISCONTINUED
486,EP,A1,EP 3573558 A1,105-478-311-478-598,2019-12-04,2019,EP 17794564 A,2017-10-23,US 201615355892 A;;US 2017/0057871 W;;US 201562265611 P;;US 201662324428 P;;US 201662365543 P,2015-12-10,METHOD OF TREATING TISSUE USING END EFFECTOR WITH ULTRASONIC AND ELECTROSURGICAL FEATURES,,ETHICON LLC,JOHNSON GREGORY W;;LESKO JASON R;;ESTERA FREDERICK;;KRUMM AMY M;;CORBETT CATHERINE A;;WEISENBURGH II WILLIAM B;;WORRELL BARRY C;;DAVISON MARK A;;BOUDREAUX CHAD P;;HIBNER JOHN A;;CUMMINGS NATHAN;;GENTRY ELLEN;;DANNAHER WILLIAM D;;HOUGH CHRISTINA M;;ISOSAKI JOSEPH;;FALLER CRAIG N;;WAN SHAN;;BROWN ADAM;;OTREMBIAK CANDICE;;WIENER EITAN T;;MESSERLY JEFFREY D;;CHEN KAI;;MILLER MATTHEW C;;CLEM WILLIAM E,,https://lens.org/105-478-311-478-598,Patent Application,yes,0,0,4,22,0,A61B2017/00389;;A61B2017/2825;;A61B2017/2945;;A61B2017/320078;;A61B2017/320073;;A61B2017/320095;;A61B18/1445;;A61B2018/00607;;A61B2018/00994;;A61B2018/126;;A61B2018/1452;;A61B2017/320094;;A61B17/320092;;A61B18/1445;;A61B2018/00607;;A61B2018/00994;;A61B2018/126;;A61B2018/1452;;A61B2017/320094;;A61B2017/320095;;A61B2017/320073;;A61B2017/2945;;A61B2017/00389;;A61B2017/2825;;A61B2017/320078,A61B18/14;;A61B17/32,,0,0,,,,DISCONTINUED
487,US,A1,US 2022/0039861 A1,148-079-442-200-598,2022-02-10,2022,US 202117410361 A,2021-08-24,US 202117410361 A;;US 201615355892 A;;US 201562265611 P;;US 201662324428 P;;US 201662365543 P,2015-12-10,METHOD OF TREATING TISSUE USING END EFFECTOR WITH ULTRASONIC AND ELECTROSURGICAL FEATURES,An end effector of an instrument is positioned in a patient. An ultrasonic blade of the end effector is positioned against tissue in the patient. The ultrasonic blade is activated to vibrate ultrasonically while the ultrasonic blade is positioned against tissue. At least one electrode of the end effector is positioned against tissue in the patient. The at least one electrode is activated to apply RF electrosurgical energy to tissue against which the at least one electrode is positioned against tissue.,CILAG GMBH INT,JOHNSON GREGORY W;;LESKO JASON R;;ESTERA FREDERICK L;;KRUMM AMY M;;CORBETT CATHERINE A;;WEISENBURGH II WILLIAM B;;WORRELL BARRY C;;DAVISON MARK A;;BOUDREAUX CHAD P;;HIBNER JOHN A;;CUMMINGS NATHAN;;BURKART ELLEN;;DANNAHER WILLIAM D;;HOUGH CHRISTINA M;;ISOSAKI JOSEPH;;FALLER CRAIG N;;WAN SHAN;;BROWN ADAM N;;OTREMBIAK CANDICE;;WIENER EITAN T;;MESSERLY JEFFREY D;;CHEN KAI;;MILLER MATTHEW C;;CLEM WILLIAM E,,https://lens.org/148-079-442-200-598,Patent Application,yes,0,0,4,22,0,A61B2017/00389;;A61B2017/2825;;A61B2017/2945;;A61B2017/320078;;A61B2017/320073;;A61B2017/320095;;A61B18/1445;;A61B2018/00607;;A61B2018/00994;;A61B2018/126;;A61B2018/1452;;A61B2017/320094;;A61B17/320092;;A61B18/1445;;A61B2018/00607;;A61B2018/00994;;A61B2018/126;;A61B2018/1452;;A61B2017/320094;;A61B2017/320095;;A61B2017/320073;;A61B2017/2945;;A61B2017/00389;;A61B2017/2825;;A61B2017/320078,A61B18/14,,0,0,,,,PENDING
488,US,A1,US 2022/0004465 A1,078-494-335-968-359,2022-01-06,2022,US 202117367912 A,2021-07-06,US 202117367912 A;;US 202063048534 P,2020-07-06,CONSOLIDATED DATA RESTORATION FRAMEWORK,"Embodiments of the present invention provide a system for identifying occurrence of events and performing one or more actions to mitigate the impacts of the events. The system is configured for gathering data from one or more data sources of an entity, generating dataflows using the data gathered from the one or more data sources, identifying an anomaly based on one or more indicators and the dataflows, determining occurrence of an event and generating one or more propagation models associated with the event, performing event impact analysis based on the one or more propagation models, perform one or more actions to contain the event based on the one or more propagation models, identifying a last good copy of data based on the data gathered from the one or more data sources, retrieving the last good copy of data, and restoring the last good copy of data.",BANK OF AMERICA,HUNTLEY CHRISTOPHER EMMANUEL;;AJAKAIYE MUSA;;ANNADATA PRASAD V;;BALLIKAR DNYANESH P;;BAUER SINA;;BELLEW JASON KENNETH;;BENDEL TIMOTHY JOHN;;BEUMER DAVID ALAN;;BOSTON MICHELLE ANDREA;;BROWN LISA JULIA;;BUCK ROBIN J;;BUSCH BRIAN C;;CERTO SALVATORE MICHAEL;;CHATTA RAMESH NAIDU;;COOK LISA MICHELLE;;CORBETT JOSEPH;;CUSHING JOSEPH SETH;;DAVIDSON STEVEN PAUL;;DESHPANDE SHAILESH;;ERGASHEVA SEVARA;;ERVIN MARIA;;FOY JR JAMES WILSON;;FULLER NOEL MARY;;GAINES III BENJAMIN JUDSON;;GORDON CANDACE;;HERNANDEZ JESSE ANTONIO;;HOAGLAND CHRISTINE;;HOARD ROBERT CHARLES;;KARAFOTIS MICHAEL SPIRO;;KEVILLE WESLEY;;KUMAR SANDIP;;LAIL TERRI DORINDA;;MARAJ MUKESH;;MAXEY WYATT EDWARD;;MCKENZIE DARI ANN;;MEADOWS ASHLEY;;NEWELL HEATHER;;NODZAK CONOR MITCHELL LIAM;;OLLIE KENYELL JAVON;;PATEL JAYSHREE G;;PERRO DAVID JOHN;;RAGHAVAN NIVETHA;;RAM NIKHIL;;RAMIREZ TARA MICHEL;;READHEAD LAURIE;;RILEY MARY KATHLEEN;;ROCK ELIZABETH RACHEL;;ROOSE ANGELA DAWN;;SINGEETHAM SANJAY;;SORENSEN KYLE S;;SRINIVAS SHREYAS;;SUAREZ CONSTANCE JONES;;TASKAR VIRESH;;TRENT LINDA;;VARULE SACHIN;;WALTON BRADLEY;;WEEKLEY CHRISTIE M;;ALSTON YVETTE;;BANDARU RAVI K;;BARNHILL CARMEN R;;BENET JOSEPH;;GILCHRIST JAMIE;;KAUSHIK NAMRATA;;MAISONETT FERNANDO A,BANK OF AMERICA CORPORATION (2021-06-22),https://lens.org/078-494-335-968-359,Patent Application,yes,0,1,2,2,0,G06F11/1469;;G06F2201/84;;G06F11/3006;;G06F2201/86;;G06F11/0751;;G06F11/0793;;G06F2201/84;;G06F11/1469;;G06F2201/86;;G06F11/0751;;G06F11/0793,G06F11/14,,0,0,,,,ACTIVE
489,US,B2,US 11822435 B2,104-410-444-289-603,2023-11-21,2023,US 202117367912 A,2021-07-06,US 202117367912 A;;US 202063048534 P,2020-07-06,Consolidated data restoration framework,"Embodiments of the present invention provide a system for identifying occurrence of events and performing one or more actions to mitigate the impacts of the events. The system is configured for gathering data from one or more data sources of an entity, generating dataflows using the data gathered from the one or more data sources, identifying an anomaly based on one or more indicators and the dataflows, determining occurrence of an event and generating one or more propagation models associated with the event, performing event impact analysis based on the one or more propagation models, perform one or more actions to contain the event based on the one or more propagation models, identifying a last good copy of data based on the data gathered from the one or more data sources, retrieving the last good copy of data, and restoring the last good copy of data.",BANK OF AMERICA,HUNTLEY CHRISTOPHER EMMANUEL;;AJAKAIYE MUSA;;ANNADATA PRASAD V;;BALLIKAR DNYANESH P;;BAUER SINA;;BELLEW JASON KENNETH;;BENDEL TIMOTHY JOHN;;BEUMER DAVID ALAN;;BOSTON MICHELLE ANDREA;;BROWN LISA JULIA;;BUCK ROBIN J;;BUSCH BRIAN C;;CERTO SALVATORE MICHAEL;;CHATTA RAMESH NAIDU;;COOK LISA MICHELLE;;CORBETT JOSEPH;;CUSHING JOSEPH SETH;;DAVIDSON STEVEN PAUL;;DESHPANDE SHAILESH;;ERGASHEVA SEVARA;;ERVIN MARIA;;FOY JR JAMES WILSON;;FULLER NOEL MARY;;GAINES III BENJAMIN JUDSON;;GORDON CANDACE;;HERNANDEZ JESSE ANTONIO;;HOAGLAND CHRISTINE;;HOARD ROBERT CHARLES;;KARAFOTIS MICHAEL SPIRO;;KEVILLE WESLEY;;KUMAR SANDIP;;LAIL TERRI DORINDA;;MARAJ MUKESH;;MAXEY WYATT EDWARD;;MCKENZIE DARI ANN;;MEADOWS ASHLEY;;NEWELL HEATHER;;NODZAK CONOR MITCHELL LIAM;;OLLIE KENYELL JAVON;;PATEL JAYSHREE G;;PERRO DAVID JOHN;;RAGHAVAN NIVETHA;;RAM NIKHIL;;RAMIREZ TARA MICHEL;;READHEAD LAURIE;;RILEY MARY KATHLEEN;;ROCK ELIZABETH RACHEL;;ROOSE ANGELA DAWN;;SINGEETHAM SANJAY;;SORENSEN KYLE S;;SRINIVAS SHREYAS;;SUAREZ CONSTANCE JONES;;TASKAR VIRESH;;TRENT LINDA;;VARULE SACHIN;;WALTON BRADLEY;;WEEKLEY CHRISTIE M;;ALSTON YVETTE;;BANDARU RAVINDRA;;BARNHILL CARMEN R;;GILCHRIST JAMIE;;KAUSHIK NAMRATA;;MAISONETT FERNANDO A,BANK OF AMERICA CORPORATION (2021-06-22),https://lens.org/104-410-444-289-603,Granted Patent,yes,41,0,2,2,0,G06F11/1469;;G06F2201/84;;G06F11/3006;;G06F2201/86;;G06F11/0751;;G06F11/0793;;G06F2201/84;;G06F11/1469;;G06F2201/86;;G06F11/0751;;G06F11/0793,G06F11/14;;G06F11/07,,0,0,,,,ACTIVE
